WO2018175501A1

WO2018175501A1 - Genomic stability profiling

Info

Publication number: WO2018175501A1
Application number: PCT/US2018/023438
Authority: WO
Inventors: Nianqing Xiao; David Spetzler
Original assignee: Caris Mpi, Inc.
Priority date: 2017-03-20
Filing date: 2018-03-20
Publication date: 2018-09-27
Also published as: EP3601615A1; AU2018240195A1; EP3601615A4; US20200024669A1; CA3056896A1; IL269456A

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for the disease, such as treatments that provide potential benefit or potential lack of benefit for the disease. Molecular profiling can include biomarkers for immune checkpoint therapy, including microsatellite instability, tumor mutational burden, mismatch repair, and expression of checkpoint proteins such as PD-L1.

Description

GENOMIC STABILITY PROFILING

CROSS-REFERENCE

This application claims the benefit of priority to U.S. Provisional Patent Application Serial Nos.

62/474,035, filed March 20, 2017; 62/532,855, filed July 14, 2017; 62/622,679, filed January 26, 2018; and 62/631,381, filed February 15, 2018; which applications are incorporated by reference herein in their entirety.

BACKGROUND

[0001] Disease states in patients are typically treated with treatment regimens or therapies that are selected based on clinical based criteria; that is, a treatment therapy or regimen is selected for a patient based on the determination that the patient has been diagnosed with a particular disease (which diagnosis has been made from classical diagnostic assays). Although the molecular mechanisms behind various disease states have been the subject of studies for years, the specific application of a diseased individual's molecular profile in determining treatment regimens and therapies for that individual has been disease specific and not widely pursued.

[0002] Some treatment regimens have been determined using molecular profiling in combination with clinical characterization of a patient such as observations made by a physician (such as a code from the International Classification of Diseases, for example, and the dates such codes were determined), laboratory test results, x-rays, biopsy results, statements made by the patient, and any other medical information typically relied upon by a physician to make a diagnosis in a specific disease. However, using a combination of selection material based on molecular profiling and clinical characterizations (such as the diagnosis of a particular type of cancer) to determine a treatment regimen or therapy presents a risk that an effective treatment regimen may be overlooked for a particular individual since some treatment regimens may work well for different disease states even though they are associated with treating a particular type of disease state.

[0003] Patients with refractory or metastatic cancer are of particular concern for treating physicians. The majority of patients with metastatic or refractory cancer eventually run out of treatment options or may suffer a cancer type with no real treatment options. For example, some patients have very limited options after their tumor has progressed in spite of front line, second line and sometimes third line and beyond) therapies. For these patients, molecular profiling of their cancer may provide the only viable option for prolonging life.

[0004] More particularly, additional targets or specific therapeutic agents can be identified assessment of a comprehensive number of targets or molecular findings examining molecular mechanisms, genes, gene expressed proteins, and/or combinations of such in a patient's tumor. Identifying multiple agents that can treat multiple targets or underlying mechanisms would provide cancer patients with a viable therapeutic alternative on a personalized basis so as to avoid standard therapies, which may simply not work or identify therapies that would not otherwise be considered by the treating physician. [0005] There remains a need for better theranostic assessment of cancer victims, including molecular profiling analysis that provides more informed and effective personalized treatment options, resulting in improved patient care and enhanced treatment outcomes. The present invention provides methods and systems for identifying therapies of potential benefit and potential lack of benefit for these individuals by molecular profiling a sample from the individual. The molecular profiling can include analysis of genomic stability, including biomarkers that implicate immune checkpoint therapies. Such biomarkers include without limitation microsatellite instability (MSI), tumor mutational burden (TMB, also referred to as tumor mutation load or TML), mismatch repair proteins such as MLH1, MSH2, MSH6, and PMS2, immune modulating proteins such as PD-1, its ligand PD-L1, and CTLA-4.

SUMMARY OF THE INVENTION

[0006] In an aspect, the invention provides a method of determining microsatellite instability (MSI) in a biological sample, comprising: (a) obtaining a nucleic acid sequence of a plurality of microsatellite loci from the biological sample; (b) determining the number of altered microsatellite loci based on the nucleic acid sequences obtained in step (a); (c) comparing the number of altered microsatellite loci determined in step (b) to a threshold number; and (d) identifying the biological sample as MSI-high if the number of altered microsatellite loci is greater than or equal to the threshold number.

[0007] In embodiments of the method of determining MSI, the biological sample comprises formalin- fixed paraffin-embedded (FFPE) tissue, fixed tissue, a core needle biopsy, a fine needle aspirate, unstained slides, fresh frozen (FF) tissue, formalin samples, tissue comprised in a solution that preserves nucleic acid or protein molecules, a fresh sample, a malignant fluid, a bodily fluid, a tumor sample, a tissue sample, or any combination thereof. In preferred embodiments, the biological sample comprises cells from a tumor, e.g., a solid tumor. The biological sample may comprise a bodily fluid. In some embodiments, the bodily fluid comprises a malignant fluid, a pleural fluid, a peritoneal fluid, or any combination thereof. In some embodiments, the bodily fluid comprises peripheral blood, sera, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid, pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, tears, cyst fluid, pleural fluid, peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities,

bronchopulmonary aspirates, blastocyst cavity fluid, or umbilical cord blood.

[0008] In embodiments of the method of determining MSI, the nucleic acid sequence is obtained by sequencing DNA or RNA. In preferred embodiments, the DNA is genomic DNA. The sequencing can be high throughput sequencing (next generation sequencing (NGS)).

[0009] In embodiments of the method of determining MSI, the plurality of microsatellite loci comprises any useful number of loci, including without limitation at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 2000, 3000, 4000, 5000, 6000, or 7000 loci. The plurality of microsatellite loci can be filtered to exclude loci meeting certain desired criteria. In preferred embodiments, the plurality of microsatellite loci excludes: i) sex chromosome loci; ii) microsatellite loci in regions that typically have lower coverage depth relative to other genomic regions; iii) microsatellites with repeat unit lengths greater than 3, 4, 5, 6 or 7 nucleotides, preferably greater than 5 nucleotides; or iv) any combination of i)-iii). In some embodiments, the members of the plurality of microsatellite loci are selected from Table 16. For examples, the plurality of microsatellite loci may comprise all loci in Table 16, or the plurality of loci may consist of all loci in Table 16. The members of the plurality of microsatellite loci can be chosen based on certain desired criteria. In some embodiments, each member of the plurality of microsatellite loci is located within the vicinity of a gene. In preferred embodiments, each member of the plurality of microsatellite loci is located within the vicinity of a cancer gene. For example, each member of the plurality of microsatellite loci can be located within the vicinity of a cancer gene selected from Table 7, Table 8, Table 9, Table 10, or any combination thereof.

[0010] In embodiments of the method of determining MSI, determining the number of altered microsatellite loci in step (b) comprises comparing each nucleic acid sequence obtained in step (a) to a reference sequence for each microsatellite loci. For example, the reference sequence can be a human genomic reference sequence, including without limitation the UCSC Genome Browser database.

Determining the number of altered microsatellite loci may comprise identifying insertions or deletions that increased or decreased the number of repeats in each microsatellite loci. In some embodiments, the number of altered microsatellite loci only counts each altered loci once regardless of the number of insertions or deletions at that loci.

[0011] In embodiments of the method of determining MSI, the threshold number is calibrated based on comparison of the number of altered microsatellite loci per patient to MSI results obtained using a different laboratory technique on a same biological sample. The "same biological sample" can refer to any appropriate sample, such as the same physical sample or another portion of the same tumor. In some embodiments, the different laboratory technique comprises fragment analysis, immunohistochemistry of mismatch repair genes, immunohistochemistry of immunomodulators, or any combination thereof. In preferred embodiments, the different laboratory technique comprises the gold standard fragment analysis. The threshold number can be determined using any number of desired biological samples, including biological samples from at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, or 2000 different cancer patients. The samples can represent various cancers, e.g., from at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, or 25 distinct cancer lineages. In some embodiments, the distinct cancer lineages comprise cancers selected from colorectal adenocarcinoma, endometrial cancer, bladder cancer, breast carcinoma, cervical cancer, cholangiocarcinoma, esophageal and esophagogastric junction carcinoma, extrahepatic bile duct adenocarcinoma, gastric adenocarcinoma, gastrointestinal stromal tumors, glioblastoma, liver hepatocellular carcinoma, lymphoma, malignant solitary fibrous tumor of the pleura, melanoma, neuroendocrine tumors, NSCLC, female genital tract malignancy, ovarian surface epithelial carcinomas, pancreatic adenocarcinoma, prostatic adenocarcinoma, small intestinal

malignancies, soft tissue tumors, thyroid carcinoma, uterine sarcoma, uveal melanoma, and any combination thereof. In some embodiments, the threshold number is calibrated across at least 1, 2, 3, 4, 5,

6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, or 25 distinct cancer lineages using sensitivity, specificity, positive predictive value, negative predictive value, or any combination thereof. For example, the threshold can be tuned with high sensitivity to MSI-high to reduce false negatives, or high specificity to MSI-high to reduce false positives, or any desired balance between. In a preferred embodiment, the threshold number is set to provide high sensitivity to MSI-high as determined in colorectal cancer using the different laboratory technique, wherein optionally the different laboratory technique comprises fragment analysis.

[0012] The threshold number can be expressed as a number of loci or a percentage of loci or any appropriate measure. In some embodiments, the threshold number is less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the number of members of the plurality of microsatellite loci. On the other hand, the threshold number can be greater than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the number of members of the plurality of microsatellite loci. For example, the threshold number can be between about 10% and about 0.1% of the number of members of the plurality of microsatellite loci, or between about 5% and about 0.2% of the number of members of the plurality of microsatellite loci, or between about 3% and about 0.3% of the number of members of the plurality of microsatellite loci, or between about 1% and about 0.4% of the number of members of the plurality of microsatellite loci. As used herein, "about" may include a range of +/- 10% of the stated value.

[0013] In an embodiment of the method of determining MSI, the number of members of the plurality of microsatellite loci is greater than 7000 and the threshold number is > 40 and < 50, wherein optionally the threshold level is 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50. As a non-limiting example, the members of the plurality of microsatellite loci can be those in Table 16, which comprises 7317 members, and the threshold can be set to 46 loci. In this example, the threshold is 0.63% of the number of members of the plurality of microsatellite loci. The threshold can be recalibrated as described herein with changing members of the plurality of microsatellite loci.

[0014] In preferred embodiments of the method of determining MSI, MSI status, e.g., high, stable or low, is determined without assessing microsatellite loci in normal tissue.

[0015] In embodiments of the method of determining MSI, the method further comprises identifying the biological sample as microsatellite stable (MSS) if the number of altered microsatellite loci is below the threshold number.

[0016] In embodiments of the method of determining MSI, the method further comprises identifying the biological sample as MSI-low if the number of altered microsatellite loci in the sample is less than or equal to a lower threshold number. As further described herein, the MSI-low can be calibrated using similar methodology as MSI high. MSS can be the range between MSI-high and MSH-low.

[0017] The invention provides a method of determining a tumor mutation burden (TMB; also referred to as tumor mutation load or TML) for a biological sample. In embodiments of the method of determining MSI, the method further comprises determining a tumor mutation burden (TMB) for the biological sample. In preferred embodiments, TMB is determined using the same laboratory analysis as MSI. As a non-limiting illustration, a NGS panel is run on a biological sample and the sequencing results are used to calculate MSI, TMB, or both. In some embodiments, TMB is determined by sequence analysis of a plurality of genes, including without limitation cancer genes selected from Table 7, Table 8, Table 9, Table 10, or any combination thereof. In a preferred embodiment, TMB is determined using missense mutations that have not been previously identified as germline alterations in the art. Similar to MSI-high, TMB-High can be determined by comparing a mutation rate to a TMB-High threshold, wherein TMB- High is defined as the mutation rate greater than or equal to the TMB-High threshold. The mutation rate can be expressed in any appropriate units, including without limitation units of mutations / megabase. The TMB-High threshold can be determined by comparing TMB with MSI determined in colorectal cancer from a same sample. In various embodiments, the TMB-High threshold is greater than or equal to 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mutations / megabase of missense mutations. In a preferred embodiment, the TMB-High threshold is 17 mutations / megabase. Similarly, TMB-Low status can be determined by comparing a mutation rate to a TMB-Low threshold, wherein TMB-Low is defined as the mutation rate less than or equal to the TMB-Low threshold. The TMB-Low threshold can also be determined by comparing TMB with MSI determined in colorectal cancer from a same sample. In various embodiments, the TMB-Low threshold is less than or equal to 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutations / megabase of missense mutations. In a preferred embodiment, the TMB-Low threshold is 6 mutations / megabase.

[0018] In embodiments of the method of determining MSI, TMB, or both, the method further comprises profiling various additional biomarkers in the biological sample as desired, e.g., mismatch repair proteins such as MLH1, MSH2, MSH6, and PMS2, immune checkpoint protein such as PD-Ll, or any

combination thereof. The profiling can comprise any useful technique, including without limitation determining: i) a protein expression level, wherein optionally the protein expression level is determined using IHC, flow cytometry or an immunoassay; ii) a nucleic acid sequence, wherein optionally the sequence is determined using next generation sequencing; iii) a promoter hypermethylation, wherein optionally the hypermethylation is determined using pyrosequencing; and iv) any combination thereof.

[0019] In another aspect, the invention provides a method of identifying at least one therapy of potential benefit for an individual with cancer, the method comprising: (a) obtaining the biological sample from the individual, e.g., as described herein; (b) generating a molecular profile by performing the method of the invention for determining MSI, TMB, or both on the biological sample; and (c) identifying the therapy of potential benefit based on the molecular profile. Generating the molecular profile can also comprise performing additional analysis on the biological sample according to Table 5, Table 6, Table 7, Table 8, Table 9, Table 10, or any combination thereof. In some embodiments, generating the molecular profile comprises performing additional analysis on the biological sample to: i) determine a tumor mutation burden (TMB); ii) determine an expression level of MLH1; iii) determine an expression level of MSH2, determine an expression level of MSH6; iv) determine an expression level of PMS2; v) determine an expression level of PD-Ll; vi) or any combination thereof. The step of identifying can use drug-biomarker associations, such as those described herein. See, e.g., Table 11. In a preferred embodiment, the step of identifying comprises identifying potential benefit from an immune checkpoint inhibitor therapy when the biological sample is MSI-High. Similarly, the step of identifying may comprise identifying potential benefit from an immune checkpoint inhibitor therapy when the biological sample is MSI-High, TMB- High, MLH1-, MSH2-, MSH6-, PMS2-, PD-L1+, or any combination thereof. The step of identifying may comprise identifying potential benefit from an immune checkpoint inhibitor therapy when the biological sample is MSI-High, TMB-High, PD-L1+, or any combination thereof. See, e.g., Example 8 herein, which notes that each of these biomarkers can provide independent information; see also FIGs. 27A-BR and related text. The method can identify any useful immune checkpoint inhibitor therapy, including without limitation ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, pidilizumab, AMP-224, AMP-514, PDR001, BMS-936559, or any combination thereof. In addition, the method may comprise identifying at least one therapy of potential lack of benefit based on the molecular profile, at least one clinical trial for the subject based on the molecular profile, or any combination thereof. For examples, see FIGs. 27A-BR.

[0020] In embodiments of the method of identifying at least one therapy of potential benefit, the subject has not previously been treated with the at least one therapy of potential benefit. The cancer may comprise a metastatic cancer, a recurrent cancer, or any combination thereof. In some cases, the cancer is refractory to a prior therapy, including without limitation front-line or standard of care therapy for the cancer. In some embodiments, the cancer is refractory to all known standard of care therapies. In other

embodiments, the subject has not previously been treated for the cancer. The method may further comprise administering the at least one therapy of potential benefit to the individual. Progression free survival (PFS), disease free survival (DFS), or lifespan can be extended by the administration.

[0021] The method of identifying at least one therapy of potential benefit can be employed for any desired cancer. In various embodiments, the cancer comprises an acute lymphoblastic leukemia; acute myeloid leukemia; adrenocortical carcinoma; AIDS-related cancer; AIDS-related lymphoma; anal cancer; appendix cancer; astrocytomas; atypical teratoid/rhabdoid tumor; basal cell carcinoma; bladder cancer; brain stem glioma; brain tumor, brain stem glioma, central nervous system atypical teratoid/rhabdoid tumor, central nervous system embryonal tumors, astrocytomas, craniopharyngioma, ependymoblastoma, ependymoma, medulloblastoma, medulloepithelioma, pineal parenchymal tumors of intermediate differentiation, supratentorial primitive neuroectodermal tumors and pineoblastoma; breast cancer;

bronchial tumors; Burkitt lymphoma; cancer of unknown primary site (CUP); carcinoid tumor; carcinoma of unknown primary site; central nervous system atypical teratoid/rhabdoid tumor; central nervous system embryonal tumors; cervical cancer; childhood cancers; chordoma; chronic lymphocytic leukemia; chronic myelogenous leukemia; chronic myeloproliferative disorders; colon cancer; colorectal cancer;

craniopharyngioma; cutaneous T-cell lymphoma; endocrine pancreas islet cell tumors; endometrial cancer; ependymoblastoma; ependymoma; esophageal cancer; esthesioneuroblastoma; Ewing sarcoma; extracranial germ cell tumor; extragonadal germ cell tumor; extrahepatic bile duct cancer; gallbladder cancer; gastric (stomach) cancer; gastrointestinal carcinoid tumor; gastrointestinal stromal cell tumor; gastrointestinal stromal tumor (GIST); gestational trophoblastic tumor; glioma; hairy cell leukemia; head and neck cancer; heart cancer; Hodgkin lymphoma; hypopharyngeal cancer; intraocular melanoma; islet cell tumors; Kaposi sarcoma; kidney cancer; Langerhans cell histiocytosis; laryngeal cancer; lip cancer; liver cancer; malignant fibrous histiocytoma bone cancer; medulloblastoma; medulloepithelioma;

melanoma; Merkel cell carcinoma; Merkel cell skin carcinoma; mesothelioma; metastatic squamous neck cancer with occult primary; mouth cancer; multiple endocrine neoplasia syndromes; multiple myeloma; multiple myeloma/plasma cell neoplasm; mycosis fungoides; myelodysplastic syndromes;

myeloproliferative neoplasms; nasal cavity cancer; nasopharyngeal cancer; neuroblastoma; Non-Hodgkin lymphoma; nonmelanoma skin cancer; non-small cell lung cancer; oral cancer; oral cavity cancer;

oropharyngeal cancer; osteosarcoma; other brain and spinal cord tumors; ovarian cancer; ovarian epithelial cancer; ovarian germ cell tumor; ovarian low malignant potential tumor; pancreatic cancer; papillomatosis; paranasal sinus cancer; parathyroid cancer; pelvic cancer; penile cancer; pharyngeal cancer; pineal parenchymal tumors of intermediate differentiation; pineoblastoma; pituitary tumor; plasma cell neoplasm/multiple myeloma; pleuropulmonary blastoma; primary central nervous system (CNS) lymphoma; primary hepatocellular liver cancer; prostate cancer; rectal cancer; renal cancer; renal cell (kidney) cancer; renal cell cancer; respiratory tract cancer; retinoblastoma; rhabdomyosarcoma; salivary gland cancer; Sezary syndrome; small cell lung cancer; small intestine cancer; soft tissue sarcoma;

squamous cell carcinoma; squamous neck cancer; stomach (gastric) cancer; supratentorial primitive neuroectodermal tumors; T-cell lymphoma; testicular cancer; throat cancer; thymic carcinoma; thymoma; thyroid cancer; transitional cell cancer; transitional cell cancer of the renal pelvis and ureter; trophoblastic tumor; ureter cancer; urethral cancer; uterine cancer; uterine sarcoma; vaginal cancer; vulvar cancer; Waldenstrom macroglobulinemia; or Wilm's tumor. In various embodiments, the cancer comprises an acute myeloid leukemia (AML), breast carcinoma, cholangiocarcinoma, colorectal adenocarcinoma, extrahepatic bile duct adenocarcinoma, female genital tract malignancy, gastric adenocarcinoma, gastroesophageal adenocarcinoma, gastrointestinal stromal tumor (GIST), glioblastoma, head and neck squamous carcinoma, leukemia, liver hepatocellular carcinoma, low grade glioma, lung

bronchioloalveolar carcinoma (BAC), non-small cell lung cancer (NSCLC), lung small cell cancer (SCLC), lymphoma, male genital tract malignancy, malignant solitary fibrous tumor of the pleura (MSFT), melanoma, multiple myeloma, neuroendocrine tumor, nodal diffuse large B-cell lymphoma, non epithelial ovarian cancer (non-EOC), ovarian surface epithelial carcinoma, pancreatic adenocarcinoma, pituitary carcinomas, oligodendroglioma, prostatic adenocarcinoma, retroperitoneal or peritoneal carcinoma, retroperitoneal or peritoneal sarcoma, small intestinal malignancy, soft tissue tumor, thymic carcinoma, thyroid carcinoma, or uveal melanoma. The cancer can be of a lineage listed in Table 19.

[0022] In a related aspect, the invention provides a method of generating a molecular profiling report comprising preparing a report comprising the generated molecular profile using the methods of the invention above. In some embodiments, the report further comprises a list of the at least one therapy of potential benefit for the individual. In some embodiments, the report further comprises a list of at least one therapy of potential lack of benefit for the individual. In some embodiments, the report further comprises a list of at least one therapy of indeterminate benefit for the individual. The report may comprise identification of the at least one therapy as standard of care or not for the cancer lineage. The report can also comprise a listing of biomarkers tested when generating the molecular profile, the type of testing performed for each biomarker, and results of the testing for each biomarker. In some embodiments, the report further comprises a list of clinical trials for which the subject is indicated and/or eligible based on the molecular profile. In some embodiments, the report further comprises a list of evidence supporting the identification of therapies as of potential benefit, potential lack of benefit, or indeterminate benefit based on the molecular profile. The report can comprise any or all of these elements. For example, the report may comprise: 1) a list of biomarkers tested in the molecular profile; 2) a description of the molecular profile of the biomarkers as determined for the subject (e.g., type of testing and result for each biomarker); 3) a therapy associated with at least one of the biomarkers in the molecular profile; and 4) and an indication whether each therapy is of potential benefit, potential lack of benefit, or indeterminate benefit for treating the individual based on the molecular profile. The description of the molecular profile of the biomarkers can include the technique used to assess the biomarkers and the results of the assessment. The report can be computer generated, and can be a printed report, a computer file or both. The report can be made accessible via a secure web portal.

[0023] In an aspect, the invention provides the report generated by the methods of the invention. In a related aspect, the invention provides a computer system for generating the report. Exemplary reports generated according to the methods of the invention, and generated by a system of the invention, are found herein in FIGs. 27A-BR.

[0024] In an aspect, the invention provides use of a reagent in carrying out the methods of the invention as described above. In a related aspect, the invention provides of a reagent in the manufacture of a reagent or kit for carrying out the methods of the invention as described above. In still another related aspect, the invention provides a kit comprising a reagent for carrying out the methods of the invention as described above. The reagent can be any useful and desired reagent. In preferred embodiments, the reagent comprises at least one of a reagent for extracting nucleic acid from a sample, a reagent for performing ISH, a reagent for performing IHC, a reagent for performing PCR, a reagent for performing Sanger sequencing, a reagent for performing next generation sequencing, a probe set for performing next generation sequencing, a probe set for sequencing the plurality of microsatellite loci, a reagent for a DNA microarray, a reagent for performing pyrosequencing, a nucleic acid probe, a nucleic acid primer, an antibody, an aptamer, a reagent for performing bisulfite treatment of nucleic acid, and any combination thereof.

[0025] In an aspect, the invention provides a system for identifying at least one therapy associated with a cancer in an individual, comprising: (a) at least one host server; (b) at least one user interface for accessing the at least one host server to access and input data; (c) at least one processor for processing the inputted data; (d) at least one memory coupled to the processor for storing the processed data and instructions for: i) accessing an MSI status generated by the method of the invention above; and ii) identifying, based on the MSI status, at least one of: A) at least one therapy with potential benefit for treatment of the cancer; B) at least one therapy with potential lack of benefit for treatment of the cancer; and C) at least one therapy associated with a clinical trial; and (e) at least one display for displaying the identified at least one of: A) at least one therapy with potential benefit for treatment of the cancer; B) at least one therapy with potential lack of benefit for treatment of the cancer; and C) at least one therapy associated with a clinical trial. In some embodiments, the system further comprises at least one memory coupled to the processor for storing the processed data and instructions for identifying, based on the generated molecular profile according to the methods above, at least one of: A) at least one therapy with potential benefit for treatment of the cancer; B) at least one therapy with potential lack of benefit for treatment of the cancer; and C) at least one therapy associated with a clinical trial; and at least one display for display thereof. The system may further comprise at least one database comprising references for various biomarker states, data for drug/biomarker associations, or both.The at least one display can be a report provided by the invention.

INCORPORATION BY REFERENCE

[0026] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

[0027] A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are used, and the accompanying drawings of which:

[0028] FIG. 1 illustrates a block diagram of an exemplary embodiment of a system for determining individualized medical intervention for a particular disease state that utilizes molecular profiling of a patient's biological specimen that is non disease specific.

[0029] FIG. 2 is a flowchart of an exemplary embodiment of a method for determining individualized medical intervention for a particular disease state that utilizes molecular profiling of a patient's biological specimen that is non disease specific.

[0030] FIGs. 3A through 3D illustrate an exemplary patient profile report in accordance with step 80 of FIG. 2

[0031] FIG. 4 is a flowchart of an exemplary embodiment of a method for identifying a drug therapy /agent capable of interacting with a target.

[0032] FIGs. 5-14 are flowcharts and diagrams illustrating various parts of an information-based personalized medicine drug discovery system and method in accordance with the present invention.

[0033] FIGs. 15-25 are computer screen print outs associated with various parts of the information-based personalized medicine drug discovery system and method shown in FIGs. 5-14.

[0034] FIGs. 26A-F illustrate a molecular profiling service requisition using a molecular profiling approach as outlined in Tables 5-11, and accompanying text herein. [0035] FIGs. 27A-BR illustrate patient reports based on molecular profiling for individual patients having breast cancer (FIGs. 27A-Z), colorectal cancer (FIGs. 27AA-AV), or lung cancer (FIGs. 27AW-

BR)

[0036] FIG. 28 illustrates a molecular profiling system that performs analysis of a cancer sample using a variety of components that measure expression levels, chromosomal aberrations and mutations. The molecular "blueprint" of the cancer is used to generate a prioritized ranking of druggable targets and/or drug associated targets in tumor and their associated therapies.

[0037] FIG. 29 shows an example output of microarray profiling results and calls made using a cutoff value.

[0038] FIG. 30 illustrates results of molecular profiling of PD1 and PDL1 in HPV+ and HPV-/TP53 mutated head and neck squamous cell carcinomas.

[0039] FIGs. 31A-C illustrate microsatellite instability analysis by Next Generation Sequencing (NGS).

[0040] FIGs. 32A-J illustrate microsatellite instability analysis by fragment analysis (FA),

immunohistochemistry (IHC), and Next Generation Sequencing (NGS).

DETAILED DESCRIPTION OF THE INVENTION

[0041] The present invention provides methods and systems for identifying therapeutic agents for use in treatments on an individualized basis by using molecular profiling. The molecular profiling approach provides a method for selecting a candidate treatment for an individual that could favorably change the clinical course for the individual with a condition or disease, such as cancer. The molecular profiling approach provides clinical benefit for individuals, such as identifying drug target(s) that provide a longer progression free survival (PFS), longer disease free survival (DFS), longer overall survival (OS) or extended lifespan. Methods and systems of the invention are directed to molecular profiling of cancer on an individual basis that can provide alternatives for treatment that may be convention or alternative to conventional treatment regimens. For example, alternative treatment regimes can be selected through molecular profiling methods of the invention where, a disease is refractory to current therapies, e.g., after a cancer has developed resistance to a standard-of-care treatment. Illustrative schemes for using molecular profiling to identify a treatment regime are provided in Tables 2-3, Table 11, FIGs. 2, 26A-F, and 28, which are each described in further detail herein. Molecular profiling provides a personalized approach to selecting candidate treatments that are likely to benefit a cancer. In embodiments, the molecular profiling method is used to identify therapies for patients with poor prognosis, such as those with metastatic disease or those whose cancer has progressed on standard front line therapies, or whose cancer has progressed on previous chemotherapeutic or hormonal regimens. The molecular profiling of the invention can also be used to guide treatment in the front-line setting as desired.

[0042] Personalized medicine based on pharmacogenetic insights, such as those provided by molecular profiling according to the invention, is increasingly taken for granted by some practitioners and the lay press, but forms the basis of hope for improved cancer therapy. However, molecular profiling as taught herein represents a fundamental departure from the traditional approach to oncologic therapy where for the most part, patients are grouped together and treated with approaches that are based on findings from light microscopy and disease stage. Traditionally, differential response to a particular therapeutic strategy has only been determined after the treatment was given, i.e. a posteriori. The "standard" approach to disease treatment relies on what is generally true about a given cancer diagnosis and treatment response has been vetted by randomized phase III clinical trials and forms the "standard of care" in medical practice. The results of these trials have been codified in consensus statements by guidelines organizations such as the National Comprehensive Cancer Network and The American Society of Clinical Oncology. The NCCN Compendium™ contains authoritative, scientifically derived information designed to support decision-making about the appropriate use of drugs and biologies in patients with cancer. The NCCN Compendium™ is recognized by the Centers for Medicare and Medicaid Services (CMS) and United Healthcare as an authoritative reference for oncology coverage policy. On-compendium treatments are those recommended by such guides. The biostatistical methods used to validate the results of clinical trials rely on minimizing differences between patients, and are based on declaring the likelihood of error that one approach is better than another for a patient group defined only by light microscopy and stage, not by individual differences in tumors. The molecular profiling methods of the invention exploit such individual differences. The methods can provide candidate treatments that can be then selected by a physician for treating a patient.

[0043] Molecular profiling can be used to provide a comprehensive view of the biological state of a sample. In an embodiment, molecular profiling is used for whole tumor profiling. Accordingly, a number of molecular approaches are used to assess the state of a tumor. The whole tumor profiling can be used for selecting a candidate treatment for a tumor. Molecular profiling can be used to select candidate therapeutics on any sample for any stage of a disease. In embodiment, the methods of the invention are used to profile a newly diagnosed cancer. The candidate treatments indicated by the molecular profiling can be used to select a therapy for treating the newly diagnosed cancer. In other embodiments, the methods of the invention are used to profile a cancer that has already been treated, e.g., with one or more standard-of-care therapy. In embodiments, the cancer is refractory to the prior treatment/s. For example, the cancer may be refractory to the standard of care treatments for the cancer. The cancer can be a metastatic cancer or other recurrent cancer. The treatments can be on-compendium or off-compendium treatments.

[0044] Molecular profiling can be performed by any known means for detecting a molecule in a biological sample. Molecular profiling comprises methods that include but are not limited to, nucleic acid sequencing, such as a DNA sequencing or RNA sequencing; immunohistochemistry (IHC); in situ hybridization (ISH); fluorescent in situ hybridization (FISH); chromogenic in situ hybridization (CISH); PCR amplification (e.g., qPCR or RT-PCR); various types of microarray (mRNA expression arrays, low density arrays, protein arrays, etc); various types of sequencing (Sanger, pyrosequencing, etc); comparative genomic hybridization (CGH); high throughput or next generation sequencing (NGS); Northern blot; Southern blot; immunoassay; and any other appropriate technique to assay the presence or quantity of a biological molecule of interest. In various embodiments of the invention, any one or more of these methods can be used concurrently or subsequent to each other for assessing target genes disclosed herein. [0045] Molecular profiling of individual samples is used to select one or more candidate treatments for a disorder in a subject, e.g., by identifying targets for drugs that may be effective for a given cancer. For example, the candidate treatment can be a treatment known to have an effect on cells that differentially express genes as identified by molecular profiling techniques, an experimental drug, a government or regulatory approved drug or any combination of such drugs, which may have been studied and approved for a particular indication that is the same as or different from the indication of the subject from whom a biological sample is obtain and molecularly profiled.

[0046] When multiple biomarker targets are revealed by assessing target genes by molecular profiling, one or more decision rules can be put in place to prioritize the selection of certain therapeutic agent for treatment of an individual on a personalized basis. Rules of the invention aide prioritizing treatment, e.g., direct results of molecular profiling, anticipated efficacy of therapeutic agent, prior history with the same or other treatments, expected side effects, availability of therapeutic agent, cost of therapeutic agent, drug- drug interactions, and other factors considered by a treating physician. Based on the recommended and prioritized therapeutic agent targets, a physician can decide on the course of treatment for a particular individual. Accordingly, molecular profiling methods and systems of the invention can select candidate treatments based on individual characteristics of diseased cells, e.g., tumor cells, and other personalized factors in a subject in need of treatment, as opposed to relying on a traditional one-size fits all approach that is conventionally used to treat individuals suffering from a disease, especially cancer. In some cases, the recommended treatments are those not typically used to treat the disease or disorder inflicting the subject. In some cases, the recommended treatments are used after standard-of-care therapies are no longer providing adequate efficacy.

[0047] The treating physician can use the results of the molecular profiling methods to optimize a treatment regimen for a patient. The candidate treatment identified by the methods of the invention can be used to treat a patient; however, such treatment is not required of the methods. Indeed, the analysis of molecular profiling results and identification of candidate treatments based on those results can be automated and does not require physician involvement.

Biological Entities

[0048] Nucleic acids include deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, or complements thereof. Nucleic acids can contain known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non- naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-0- methyl ribonucleotides, peptide-nucleic acids (PNAs). Nucleic acid sequence can encompass

conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al, J. Biol. Chem. 260:2605-2608 (1985); Rossolini et al., Mol. Cell Probes 8:91-98

(1994)). The term nucleic acid can be used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide.

[0049] A particular nucleic acid sequence may implicitly encompass the particular sequence and "splice variants" and nucleic acid sequences encoding truncated forms. Similarly, a particular protein encoded by a nucleic acid can encompass any protein encoded by a splice variant or truncated form of that nucleic acid. "Splice variants," as the name suggests, are products of alternative splicing of a gene. After transcription, an initial nucleic acid transcript may be spliced such that different (alternate) nucleic acid splice products encode different polypeptides. Mechanisms for the production of splice variants vary, but include alternate splicing of exons. Alternate polypeptides derived from the same nucleic acid by read- through transcription are also encompassed by this definition. Any products of a splicing reaction, including recombinant forms of the splice products, are included in this definition. Nucleic acids can be truncated at the 5' end or at the 3' end. Polypeptides can be truncated at the N-terminal end or the C- terminal end. Truncated versions of nucleic acid or polypeptide sequences can be naturally occurring or created using recombinant techniques.

[0050] The terms "genetic variant" and "nucleotide variant" are used herein interchangeably to refer to changes or alterations to the reference human gene or cDNA sequence at a particular locus, including, but not limited to, nucleotide base deletions, insertions, inversions, and substitutions in the coding and non- coding regions. Deletions may be of a single nucleotide base, a portion or a region of the nucleotide sequence of the gene, or of the entire gene sequence. Insertions may be of one or more nucleotide bases. The genetic variant or nucleotide variant may occur in transcriptional regulatory regions, untranslated regions of mRNA, exons, introns, exon/intron junctions, etc. The genetic variant or nucleotide variant can potentially result in stop codons, frame shifts, deletions of amino acids, altered gene transcript splice forms or altered amino acid sequence.

[0051] An allele or gene allele comprises generally a naturally occurring gene having a reference sequence or a gene containing a specific nucleotide variant.

[0052] A haplotype refers to a combination of genetic (nucleotide) variants in a region of an mRNA or a genomic DNA on a chromosome found in an individual. Thus, a haplotype includes a number of genetically linked polymorphic variants which are typically inherited together as a unit.

[0053] As used herein, the term "amino acid variant" is used to refer to an amino acid change to a reference human protein sequence resulting from genetic variants or nucleotide variants to the reference human gene encoding the reference protein. The term "amino acid variant" is intended to encompass not only single amino acid substitutions, but also amino acid deletions, insertions, and other significant changes of amino acid sequence in the reference protein.

[0054] The term "genotype" as used herein means the nucleotide characters at a particular nucleotide variant marker (or locus) in either one allele or both alleles of a gene (or a particular chromosome region). With respect to a particular nucleotide position of a gene of interest, the nucleotide(s) at that locus or equivalent thereof in one or both alleles form the genotype of the gene at that locus. A genotype can be homozygous or heterozygous. Accordingly, "genotyping" means determining the genotype, that is, the nucleotide(s) at a particular gene locus. Genotyping can also be done by determining the amino acid variant at a particular position of a protein which can be used to deduce the corresponding nucleotide variant(s).

[0055] The term "locus" refers to a specific position or site in a gene sequence or protein. Thus, there may be one or more contiguous nucleotides in a particular gene locus, or one or more amino acids at a particular locus in a polypeptide. Moreover, a locus may refer to a particular position in a gene where one or more nucleotides have been deleted, inserted, or inverted.

[0056] Unless specified otherwise or understood by one of skill in art, the terms "polypeptide," "protein," and "peptide" are used interchangeably herein to refer to an amino acid chain in which the amino acid residues are linked by covalent peptide bonds. The amino acid chain can be of any length of at least two amino acids, including full-length proteins. Unless otherwise specified, polypeptide, protein, and peptide also encompass various modified forms thereof, including but not limited to glycosylated forms, phosphorylated forms, etc. A polypeptide, protein or peptide can also be referred to as a gene product.

[0057] Lists of gene and gene products that can be assayed by molecular profiling techniques are presented herein. Lists of genes may be presented in the context of molecular profiling techniques that detect a gene product (e.g., an mR A or protein). One of skill will understand that this implies detection of the gene product of the listed genes. Similarly, lists of gene products may be presented in the context of molecular profiling techniques that detect a gene sequence or copy number. One of skill will understand that this implies detection of the gene corresponding to the gene products, including as an example DNA encoding the gene products. As will be appreciated by those skilled in the art, a "biomarker" or "marker" comprises a gene and/or gene product depending on the context.

[0058] The terms "label" and "detectable label" can refer to any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical, chemical or similar methods. Such labels include biotin for staining with labeled streptavidin conjugate, magnetic beads (e.g.,

DYNABEADS™), fluorescent dyes (e.g., fluorescein, Texas red, rhodamine, green fluorescent protein,

3 125 35 14 32

and the like), radiolabels (e.g., H, I, S, C, or P), enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and calorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc) beads. Patents teaching the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275, 149; and 4,366,241. Means of detecting such labels are well known to those of skill in the art. Thus, for example, radiolabels may be detected using photographic film or scintillation counters, fluorescent markers may be detected using a photodetector to detect emitted light. Enzymatic labels are typically detected by providing the enzyme with a substrate and detecting the reaction product produced by the action of the enzyme on the substrate, and calorimetric labels are detected by simply visualizing the colored label. Labels can include, e.g., ligands that bind to labeled antibodies, fluorophores, chemiluminescent agents, enzymes, and antibodies which can serve as specific binding pair members for a labeled ligand. An introduction to labels, labeling procedures and detection of labels is found in Polak and Van Noorden Introduction to Immunocytochemistry, 2nd ed., Springer Verlag, NY (1997); and in Haugland Handbook of Fluorescent Probes and Research Chemicals, a combined handbook and catalogue Published by Molecular Probes, Inc. (1996).

[0059] Detectable labels include, but are not limited to, nucleotides (labeled or unlabelled), compomers, sugars, peptides, proteins, antibodies, chemical compounds, conducting polymers, binding moieties such as biotin, mass tags, calorimetric agents, light emitting agents, chemiluminescent agents, light scattering agents, fluorescent tags, radioactive tags, charge tags (electrical or magnetic charge), volatile tags and hydrophobic tags, biomolecules (e.g., members of a binding pair antibody /antigen, antibody/antibody, antibody/antibody fragment, antibody /antibody receptor, antibody /protein A or protein G, hapten/anti- hapten, biotin/avidin, biotin/streptavidin, folic acid/folate binding protein, vitamin B 12/intrinsic factor, chemical reactive group/complementary chemical reactive group (e.g., sulfhydryl/maleimide,

sulfhydryl/haloacetyl derivative, amine/isotriocyanate, amine/succinimidyl ester, and amine/sulfonyl halides) and the like.

[0060] The term "antibody" as used herein encompasses naturally occurring antibodies as well as non- naturally occurring antibodies, including, for example, single chain antibodies, chimeric, bifunctional and humanized antibodies, as well as antigen-binding fragments thereof, (e.g., Fab', F(ab')2, Fab, Fv and rlgG). See also, Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, 111.). See also, e.g., Kuby, J., Immunology, 3.sup.rd Ed., W. H. Freeman & Co., New York (1998). Such non-naturally occurring antibodies can be constructed using solid phase peptide synthesis, can be produced

recombinantly or can be obtained, for example, by screening combinatorial libraries consisting of variable heavy chains and variable light chains as described by Huse et al., Science 246: 1275-1281 (1989), which is incorporated herein by reference. These and other methods of making, for example, chimeric, humanized, CDR-grafted, single chain, and bifunctional antibodies are well known to those skilled in the art. See, e.g., Winter and Harris, Immunol. Today 14:243-246 (1993); Ward et al., Nature 341 :544-546 (1989); Harlow and Lane, Antibodies, 511-52, Cold Spring Harbor Laboratory publications, New York, 1988; Hilyard et al., Protein Engineering: A practical approach (IRL Press 1992); Borrebaeck, Antibody Engineering, 2d ed. (Oxford University Press 1995); each of which is incorporated herein by reference.

[0061] Unless otherwise specified, antibodies can include both polyclonal and monoclonal antibodies. Antibodies also include genetically engineered forms such as chimeric antibodies (e.g., humanized murine antibodies) and heteroconjugate antibodies (e.g., bispecific antibodies). The term also refers to recombinant single chain Fv fragments (scFv). The term antibody also includes bivalent or bispecific molecules, diabodies, triabodies, and tetrabodies. Bivalent and bispecific molecules are described in, e.g., Kostelny et al. (1992) J Immunol 148: 1547, Pack and Pluckthun (1992) Biochemistry 31 : 1579, Holliger et al. (1993) Proc Natl Acad Sci USA. 90:6444, Gruber et al. (1994) J Immunol:5368, Zhu et al. (1997) Protein Sci 6:781, Hu et al. (1997) Cancer Res. 56:3055, Adams et al. (1993) Cancer Res. 53:4026, and McCartney, et al. (1995) Protein Eng. 8:301.

[0062] Typically, an antibody has a heavy and light chain. Each heavy and light chain contains a constant region and a variable region, (the regions are also known as "domains"). Light and heavy chain variable regions contain four framework regions interrupted by three hyper-variable regions, also called complementarity-determining regions (CDRs). The extent of the framework regions and CDRs have been defined. The sequences of the framework regions of different light or heavy chains are relatively conserved within a species. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs in three dimensional spaces. The CDRs are primarily responsible for binding to an epitope of an antigen. The CDRs of each chain are typically referred to as CDR1, CDR2, and CDR3, numbered sequentially starting from the N- terminus, and are also typically identified by the chain in which the particular CDR is located. Thus, a VH CDR3 is located in the variable domain of the heavy chain of the antibody in which it is found, whereas a VL CDRl is the CDR1 from the variable domain of the light chain of the antibody in which it is found. References to VH refer to the variable region of an immunoglobulin heavy chain of an antibody, including the heavy chain of an Fv, scFv, or Fab. References to VL refer to the variable region of an

immunoglobulin light chain, including the light chain of an Fv, scFv, dsFv or Fab.

[0063] The phrase "single chain Fv" or "scFv" refers to an antibody in which the variable domains of the heavy chain and of the light chain of a traditional two chain antibody have been joined to form one chain. Typically, a linker peptide is inserted between the two chains to allow for proper folding and creation of an active binding site. A "chimeric antibody" is an immunoglobulin molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.

[0064] A "humanized antibody" is an immunoglobulin molecule that contains minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al, Nature 321 :522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992)). Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature 321 :522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science 239: 1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.

[0065] The terms "epitope" and "antigenic determinant" refer to a site on an antigen to which an antibody binds. Epitopes can be formed both from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation. Methods of determining spatial conformation of epitopes include, for example, x-ray crystallography and 2-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, Glenn E. Morris, Ed (1996).

[0066] The terms "primer", "probe," and "oligonucleotide" are used herein interchangeably to refer to a relatively short nucleic acid fragment or sequence. They can comprise DNA, RNA, or a hybrid thereof, or chemically modified analog or derivatives thereof. Typically, they are single -stranded. However, they can also be double-stranded having two complementing strands which can be separated by denaturation. Normally, primers, probes and oligonucleotides have a length of from about 8 nucleotides to about 200 nucleotides, preferably from about 12 nucleotides to about 100 nucleotides, and more preferably about 18 to about 50 nucleotides. They can be labeled with detectable markers or modified using conventional manners for various molecular biological applications.

[0067] The term "isolated" when used in reference to nucleic acids (e.g., genomic DNAs, cDNAs, mRNAs, or fragments thereof) is intended to mean that a nucleic acid molecule is present in a form that is substantially separated from other naturally occurring nucleic acids that are normally associated with the molecule. Because a naturally existing chromosome (or a viral equivalent thereof) includes a long nucleic acid sequence, an isolated nucleic acid can be a nucleic acid molecule having only a portion of the nucleic acid sequence in the chromosome but not one or more other portions present on the same chromosome. More specifically, an isolated nucleic acid can include naturally occurring nucleic acid sequences that flank the nucleic acid in the naturally existing chromosome (or a viral equivalent thereof). An isolated nucleic acid can be substantially separated from other naturally occurring nucleic acids that are on a different chromosome of the same organism. An isolated nucleic acid can also be a composition in which the specified nucleic acid molecule is significantly enriched so as to constitute at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or at least 99% of the total nucleic acids in the composition.

[0068] An isolated nucleic acid can be a hybrid nucleic acid having the specified nucleic acid molecule covalently linked to one or more nucleic acid molecules that are not the nucleic acids naturally flanking the specified nucleic acid. For example, an isolated nucleic acid can be in a vector. In addition, the specified nucleic acid may have a nucleotide sequence that is identical to a naturally occurring nucleic acid or a modified form or mutein thereof having one or more mutations such as nucleotide substitution, deletion/insertion, inversion, and the like. [0069] An isolated nucleic acid can be prepared from a recombinant host cell (in which the nucleic acids have been recombinantly amplified and/or expressed), or can be a chemically synthesized nucleic acid having a naturally occurring nucleotide sequence or an artificially modified form thereof.

[0070] The term "isolated polypeptide" as used herein is defined as a polypeptide molecule that is present in a form other than that found in nature. Thus, an isolated polypeptide can be a non-naturally occurring polypeptide. For example, an isolated polypeptide can be a "hybrid polypeptide." An isolated polypeptide can also be a polypeptide derived from a naturally occurring polypeptide by additions or deletions or substitutions of amino acids. An isolated polypeptide can also be a "purified polypeptide" which is used herein to mean a composition or preparation in which the specified polypeptide molecule is significantly enriched so as to constitute at least 10% of the total protein content in the composition. A "purified polypeptide" can be obtained from natural or recombinant host cells by standard purification techniques, or by chemically synthesis, as will be apparent to skilled artisans.

[0071] The terms "hybrid protein," "hybrid polypeptide," "hybrid peptide," "fusion protein," "fusion polypeptide," and "fusion peptide" are used herein interchangeably to mean a non-naturally occurring polypeptide or isolated polypeptide having a specified polypeptide molecule covalently linked to one or more other polypeptide molecules that do not link to the specified polypeptide in nature. Thus, a "hybrid protein" may be two naturally occurring proteins or fragments thereof linked together by a covalent linkage. A "hybrid protein" may also be a protein formed by covalently linking two artificial polypeptides together. Typically but not necessarily, the two or more polypeptide molecules are linked or "fused" together by a peptide bond forming a single non-branched polypeptide chain.

[0072] The term "high stringency hybridization conditions," when used in connection with nucleic acid hybridization, includes hybridization conducted overnight at 42 °C in a solution containing 50% formamide, 5 > SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate, pH 7.6,

5 > Denhardt's solution, 10% dextran sulfate, and 20 microgram/ml denatured and sheared salmon sperm DNA, with hybridization filters washed in O. l xSSC at about 65 °C. The term "moderate stringent hybridization conditions," when used in connection with nucleic acid hybridization, includes hybridization conducted overnight at 37 °C in a solution containing 50% formamide, 5> SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate, pH 7.6, 5 > Denhardt's solution, 10% dextran sulfate, and 20 microgram/ml denatured and sheared salmon sperm DNA, with hybridization filters washed in l xSSC at about 50 °C. It is noted that many other hybridization methods, solutions and temperatures can be used to achieve comparable stringent hybridization conditions as will be apparent to skilled artisans.

[0073] For the purpose of comparing two different nucleic acid or polypeptide sequences, one sequence (test sequence) may be described to be a specific percentage identical to another sequence (comparison sequence). The percentage identity can be determined by the algorithm of Karlin and Altschul, Proc. Natl. Acad. Sci. USA, 90:5873-5877 (1993), which is incorporated into various BLAST programs. The percentage identity can be determined by the "BLAST 2 Sequences" tool, which is available at the National Center for Biotechnology Information (NCBI) website. See Tatusova and Madden, FEMS Microbiol. Lett., 174(2):247-250 (1999). For pairwise DNA-DNA comparison, the BLASTN program is used with default parameters (e.g., Match: 1; Mismatch: -2; Open gap: 5 penalties; extension gap: 2 penalties; gap x_dropoff: 50; expect: 10; and word size: 11, with filter). For pairwise protein-protein sequence comparison, the BLASTP program can be employed using default parameters (e.g., Matrix: BLOSUM62; gap open: 11; gap extension: 1; x_dropoff: 15; expect: 10.0; and wordsize: 3, with filter). Percent identity of two sequences is calculated by aligning a test sequence with a comparison sequence using BLAST, determining the number of amino acids or nucleotides in the aligned test sequence that are identical to amino acids or nucleotides in the same position of the comparison sequence, and dividing the number of identical amino acids or nucleotides by the number of amino acids or nucleotides in the comparison sequence. When BLAST is used to compare two sequences, it aligns the sequences and yields the percent identity over defined, aligned regions. If the two sequences are aligned across their entire length, the percent identity yielded by the BLAST is the percent identity of the two sequences. If BLAST does not align the two sequences over their entire length, then the number of identical amino acids or nucleotides in the unaligned regions of the test sequence and comparison sequence is considered to be zero and the percent identity is calculated by adding the number of identical amino acids or nucleotides in the aligned regions and dividing that number by the length of the comparison sequence. Various versions of the BLAST programs can be used to compare sequences, e.g., BLAST 2.1.2 or BLAST+ 2.2.22.

[0074] A subject or individual can be any animal which may benefit from the methods of the invention, including, e.g., humans and non-human mammals, such as primates, rodents, horses, dogs and cats.

Subjects include without limitation a eukaryotic organisms, most preferably a mammal such as a primate, e.g., chimpanzee or human, cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish. Subjects specifically intended for treatment using the methods described herein include humans. A subject may be referred to as an individual or a patient.

[0075] Treatment of a disease or individual according to the invention is an approach for obtaining beneficial or desired medical results, including clinical results, but not necessarily a cure. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment or if receiving a different treatment. A treatment can include administration of a therapeutic agent, which can be an agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on diseased cells, e.g., cancer cells, or other cells that may promote a diseased state, e.g., activated immune cells. Therapeutic agents selected by the methods of the invention are not limited. Any therapeutic agent can be selected where a link can be made between molecular profiling and potential efficacy of the agent. Therapeutic agents include without limitation drugs, pharmaceuticals, small molecules, protein therapies, antibody therapies, viral therapies, gene therapies, and the like. Cancer treatments or therapies include apoptosis- mediated and non-apoptosis mediated cancer therapies including, without limitation, chemotherapy, hormonal therapy, radiotherapy, immunotherapy, and combinations thereof. Chemotherapeutic agents comprise therapeutic agents and combinations of therapeutic agents that treat, cancer cells, e.g., by killing those cells. Examples of different types of chemotherapeutic drugs include without limitation alkylating agents (e.g., nitrogen mustard derivatives, ethylenimines, alkylsulfonates, hydrazines and triazines, nitrosureas, and metal salts), plant alkaloids (e.g., vinca alkaloids, taxanes, podophyllotoxins, and camptothecan analogs), antitumor antibiotics (e.g., anthracyclines, chromomycins, and the like), antimetabolites (e.g., folic acid antagonists, pyrimidine antagonists, purine antagonists, and adenosine deaminase inhibitors), topoisomerase I inhibitors, topoisomerase II inhibitors, and miscellaneous antineoplastics (e.g., ribonucleotide reductase inhibitors, adrenocortical steroid inhibitors, enzymes, antimicrotubule agents, and retinoids).

[0076] A biomarker refers generally to a molecule, including without limitation a gene or product thereof, nucleic acids (e.g., DNA, R A), protein/peptide/polypeptide, carbohydrate structure, lipid, glycolipid, characteristics of which can be detected in a tissue or cell to provide information that is predictive, diagnostic, prognostic and/or theranostic for sensitivity or resistance to candidate treatment.

Biological Samples

[0077] A sample as used herein includes any relevant biological sample that can be used for molecular profiling, e.g., sections of tissues such as biopsy or tissue removed during surgical or other procedures, bodily fluids, autopsy samples, and frozen sections taken for histological purposes. Such samples include blood and blood fractions or products (e.g., serum, buffy coat, plasma, platelets, red blood cells, and the like), sputum, malignant effusion, cheek cells tissue, cultured cells (e.g., primary cultures, explants, and transformed cells), stool, urine, other biological or bodily fluids (e.g., prostatic fluid, gastric fluid, intestinal fluid, renal fluid, lung fluid, cerebrospinal fluid, and the like), etc. The sample can comprise biological material that is a fresh frozen & formalin fixed paraffin embedded (FFPE) block, formalin- fixed paraffin embedded, or is within an RNA preservative + formalin fixative. More than one sample of more than one type can be used for each patient. In a preferred embodiment, the sample comprises a fixed tumor sample.

[0078] The sample used in the methods described herein can be a formalin fixed paraffin embedded (FFPE) sample. The FFPE sample can be one or more of fixed tissue, unstained slides, bone marrow core or clot, core needle biopsy, malignant fluids and fine needle aspirate (FNA). In an embodiment, the fixed tissue comprises a tumor containing formalin fixed paraffin embedded (FFPE) block from a surgery or biopsy. In another embodiment, the unstained slides comprise unstained, charged, unbaked slides from a paraffin block. In another embodiment, bone marrow core or clot comprises a decalcified core. A formalin fixed core and/or clot can be paraffin-embedded. In still another embodiment, the core needle biopsy comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more, e.g., 3-4, paraffin embedded biopsy samples. An 18 gauge needle biopsy can be used. The malignant fluid can comprise a sufficient volume of fresh pleural/ascitic fluid to produce a 5x5x2mm cell pellet. The fluid can be formalin fixed in a paraffin block. In an embodiment, the core needle biopsy comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more, e.g., 4-6, paraffin embedded aspirates. [0079] A sample may be processed according to techniques understood by those in the art. A sample can be without limitation fresh, frozen or fixed cells or tissue. In some embodiments, a sample comprises formalin-fixed paraffin-embedded (FFPE) tissue, fresh tissue or fresh frozen (FF) tissue. A sample can comprise cultured cells, including primary or immortalized cell lines derived from a subject sample. A sample can also refer to an extract from a sample from a subject. For example, a sample can comprise

DNA, R A or protein extracted from a tissue or a bodily fluid. Many techniques and commercial kits are available for such purposes. The fresh sample from the individual can be treated with an agent to preserve

RNA prior to further processing, e.g., cell lysis and extraction. Samples can include frozen samples collected for other purposes. Samples can be associated with relevant information such as age, gender, and clinical symptoms present in the subject; source of the sample; and methods of collection and storage of the sample. A sample is typically obtained from a subject.

[0080] A biopsy comprises the process of removing a tissue sample for diagnostic or prognostic evaluation, and to the tissue specimen itself. Any biopsy technique known in the art can be applied to the molecular profiling methods of the present invention. The biopsy technique applied can depend on the tissue type to be evaluated (e.g., colon, prostate, kidney, bladder, lymph node, liver, bone marrow, blood cell, lung, breast, etc.), the size and type of the tumor (e.g., solid or suspended, blood or ascites), among other factors. Representative biopsy techniques include, but are not limited to, excisional biopsy, incisional biopsy, needle biopsy, surgical biopsy, and bone marrow biopsy. An "excisional biopsy" refers to the removal of an entire tumor mass with a small margin of normal tissue surrounding it. An "incisional biopsy" refers to the removal of a wedge of tissue that includes a cross-sectional diameter of the tumor. Molecular profiling can use a "core-needle biopsy" of the tumor mass, or a "fine-needle aspiration biopsy" which generally obtains a suspension of cells from within the tumor mass. Biopsy techniques are discussed, for example, in Harrison's Principles of Internal Medicine, Kasper, et al., eds., 16th ed., 2005, Chapter 70, and throughout Part V.

[0081] Standard molecular biology techniques known in the art and not specifically described are generally followed as in Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York (1989), and as in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1989) and as in Perbal, A Practical Guide to Molecular Cloning, John Wiley & Sons, New York (1988), and as in Watson et al., Recombinant DNA, Scientific American Books, New York and in Birren et al (eds) Genome Analysis: A Laboratory Manual Series, Vols. 1-4 Cold Spring Harbor Laboratory Press, New York (1998) and methodology as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057 and incorporated herein by reference.

Polymerase chain reaction (PCR) can be carried out generally as in PCR Protocols: A Guide to Methods and Applications, Academic Press, San Diego, Calif. (1990).

Vesicles

[0082] The sample can comprise vesicles. Methods of the invention can include assessing one or more vesicles, including assessing vesicle populations. A vesicle, as used herein, is a membrane vesicle that is shed from cells. Vesicles or membrane vesicles include without limitation: circulating microvesicles (cMVs), microvesicle, exosome, nanovesicle, dexosome, bleb, blebby, prostasome, microparticle, intralumenal vesicle, membrane fragment, intralumenal endosomal vesicle, endosomal-like vesicle, exocytosis vehicle, endosome vesicle, endosomal vesicle, apoptotic body, multivesicular body, secretory vesicle, phospholipid vesicle, liposomal vesicle, argosome, texasome, secresome, tolerosome, melanosome, oncosome, or exocytosed vehicle. Furthermore, although vesicles may be produced by different cellular processes, the methods of the invention are not limited to or reliant on any one mechanism, insofar as such vesicles are present in a biological sample and are capable of being characterized by the methods disclosed herein. Unless otherwise specified, methods that make use of a species of vesicle can be applied to other types of vesicles. Vesicles comprise spherical structures with a lipid bilayer similar to cell membranes which surrounds an inner compartment which can contain soluble components, sometimes referred to as the payload. In some embodiments, the methods of the invention make use of exosomes, which are small secreted vesicles of about 40-100 nm in diameter. For a review of membrane vesicles, including types and characterizations, see Thery et al, Nat Rev Immunol. 2009 Aug;9(8):581-93. Some properties of different types of vesicles include those in Table 1 :

Table 1 : Vesicle Properties

Abbreviations: phosphatidylserine (PPS); electron microscopy (EM)

[0083] Vesicles include shed membrane bound particles, or "microparticles," that are derived from either the plasma membrane or an internal membrane. Vesicles can be released into the extracellular environment from cells. Cells releasing vesicles include without limitation cells that originate from, or are derived from, the ectoderm, endoderm, or mesoderm. The cells mav have nHeronne genetic, environmental, and/or any other variations or alterations. For example, the cell can be tumor cells.

A vesicle can reflect any changes in the source cell, and thereby reflect changes in the originating cells, e.g., cells having various genetic mutations. In one mechanism, a vesicle is generated intracellularly when a segment of the cell membrane spontaneously invaginates and is ultimately exocytosed (see for example, Keller et al, Immunol. Lett. 107 (2): 102-8 (2006)). Vesicles also include cell-derived structures bounded by a lipid bilayer membrane arising from both herniated evagination (blebbing) separation and sealing of portions of the plasma membrane or from the export of any intracellular membrane -bounded vesicular structure containing various membrane-associated proteins of tumor origin, including surface-bound molecules derived from the host circulation that bind selectively to the tumor-derived proteins together with molecules contained in the vesicle lumen, including but not limited to tumor-derived microR As or intracellular proteins. Blebs and blebbing are further described in Charras et al, Nature Reviews

Molecular and Cell Biology, Vol. 9, No. 11, p. 730-736 (2008). A vesicle shed into circulation or bodily fluids from tumor cells may be referred to as a "circulating tumor-derived vesicle." When such vesicle is an exosome, it may be referred to as a circulating -tumor derived exosome (CTE). In some instances, a vesicle can be derived from a specific cell of origin. CTE, as with a cell-of-origin specific vesicle, typically have one or more unique biomarkers that permit isolation of the CTE or cell-of-origin specific vesicle, e.g., from a bodily fluid and sometimes in a specific manner. For example, a cell or tissue specific markers are used to identify the cell of origin. Examples of such cell or tissue specific markers are disclosed herein and can further be accessed in the Tissue-specific Gene Expression and Regulation (TiGER) Database, available at bioinfo.wilmer.jhu.edu/tiger/; Liu et al. (2008) TiGER: a database for tissue-specific gene expression and regulation. BMC Bioinformatics. 9:271; TissueDistributionDBs, available at genome.dkfz-heidelberg.de/menu/tissue_db/index.html.

[0084] A vesicle can have a diameter of greater than about 10 nm, 20 nm, or 30 nm. A vesicle can have a diameter of greater than 40 nm, 50 nm, 100 nm, 200 nm, 500 nm, 1000 nm or greater than 10,000 nm. A vesicle can have a diameter of about 30-1000 nm, about 30-800 nm, about 30-200 nm, or about 30-100 nm. In some embodiments, the vesicle has a diameter of less than 10,000 nm, 1000 nm, 800 nm, 500 nm, 200 nm, 100 nm, 50 nm, 40 nm, 30 nm, 20 nm or less than 10 nm. As used herein the term "about" in reference to a numerical value means that variations of 10% above or below the numerical value are within the range ascribed to the specified value. Typical sizes for various types of vesicles are shown in Table 1. Vesicles can be assessed to measure the diameter of a single vesicle or any number of vesicles. For example, the range of diameters of a vesicle population or an average diameter of a vesicle population can be determined. Vesicle diameter can be assessed using methods known in the art, e.g., imaging technologies such as electron microscopy. In an embodiment, a diameter of one or more vesicles is determined using optical particle detection. See, e.g., U.S. Patent 7,751,053, entitled "Optical Detection and Analysis of Particles" and issued July 6, 2010; and U.S. Patent 7,399,600, entitled "Optical Detection and Analysis of Particles" and issued July 15, 2010.

[0085] In some embodiments, vesicles are directly assayed from a biological sample without prior isolation, purification, or concentration from the biological sample. For example, the amount of vesicles in the sample can by itself provide a biosignature that provides a diagnostic, prognostic or theranostic determination. Alternatively, the vesicle in the sample may be isolated, captured, purified, or concentrated from a sample prior to analysis. As noted, isolation, capture or purification as used herein comprises partial isolation, partial capture or partial purification apart from other components in the sample. Vesicle isolation can be performed using various techniques as described herein or known in the art, including without limitation size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, affinity capture, immunoassay, immunoprecipitation, microfluidic separation, flow cytometry or combinations thereof.

[0086] Vesicles can be assessed to provide a phenotypic characterization by comparing vesicle characteristics to a reference. In some embodiments, surface antigens on a vesicle are assessed. A vesicle or vesicle population carrying a specific marker can be referred to as a positive (biomarker+) vesicle or vesicle population. For example, a DLL4+ population refers to a vesicle population associated with DLL4. Conversely, a DLL4- population would not be associated with DLL4. The surface antigens can provide an indication of the anatomical origin and/or cellular of the vesicles and other phenotypic information, e.g., tumor status. For example, vesicles found in a patient sample can be assessed for surface antigens indicative of colorectal origin and the presence of cancer, thereby identifying vesicles associated with colorectal cancer cells. The surface antigens may comprise any informative biological entity that can be detected on the vesicle membrane surface, including without limitation surface proteins, lipids, carbohydrates, and other membrane components. For example, positive detection of colon derived vesicles expressing tumor antigens can indicate that the patient has colorectal cancer. As such, methods of the invention can be used to characterize any disease or condition associated with an anatomical or cellular origin, by assessing, for example, disease-specific and cell-specific biomarkers of one or more vesicles obtained from a subject.

[0087] In embodiments, one or more vesicle payloads are assessed to provide a phenotypic

characterization. The payload with a vesicle comprises any informative biological entity that can be detected as encapsulated within the vesicle, including without limitation proteins and nucleic acids, e.g., genomic or cDNA, mR A, or functional fragments thereof, as well as microR As (miRs). In addition, methods of the invention are directed to detecting vesicle surface antigens (in addition or exclusive to vesicle payload) to provide a phenotypic characterization. For example, vesicles can be characterized by using binding agents (e.g., antibodies or aptamers) that are specific to vesicle surface antigens, and the bound vesicles can be further assessed to identify one or more payload components disclosed therein. As described herein, the levels of vesicles with surface antigens of interest or with payload of interest can be compared to a reference to characterize a phenotype. For example, overexpression in a sample of cancer- related surface antigens or vesicle payload, e.g., a tumor associated mRNA or microRNA, as compared to a reference, can indicate the presence of cancer in the sample. The biomarkers assessed can be present or absent, increased or reduced based on the selection of the desired target sample and comparison of the target sample to the desired reference sample. Non-limiting examples of target samples include: disease; treated/not-treated; different time points, such as a in a longitudinal study; and non-limiting examples of reference sample: non-disease; normal; different time points; and sensitive or resistant to candidate treatment(s).

[0088] In an embodiment, molecular profiling of the invention comprises analysis of microvesicles, such as circulating microvesicles.

MicroRNA

[0089] Various biomarker molecules can be assessed in biological samples or vesicles obtained from such biological samples. MicroRNAs comprise one class biomarkers assessed via methods of the invention. MicroRNAs, also referred to herein as miRNAs or miRs, are short RNA strands approximately 21-23 nucleotides in length. MiRNAs are encoded by genes that are transcribed from DNA but are not translated into protein and thus comprise non-coding RNA. The miRs are processed from primary transcripts known as pri-miRNA to short stem-loop structures called pre-miRNA and finally to the resulting single strand miRNA. The pre -miRNA typically forms a structure that folds back on itself in self-complementary regions. These structures are then processed by the nuclease Dicer in animals or DCL1 in plants. Mature miRNA molecules are partially complementary to one or more messenger RNA (mRNA) molecules and can function to regulate translation of proteins. Identified sequences of miRNA can be accessed at publicly available databases, such as www.microRNA.org, www.mirbase.org, or www.mirz.unibas.ch/cgi/miRNA.cgi.

[0090] miRNAs are generally assigned a number according to the naming convention " mir- [number]." The number of a miRNA is assigned according to its order of discovery relative to previously identified miRNA species. For example, if the last published miRNA was mir-121, the next discovered miRNA will be named mir-122, etc. When a miRNA is discovered that is homologous to a known miRNA from a different organism, the name can be given an optional organism identifier, of the form [organism identifier]- mir-[number]. Identifiers include hsa for Homo sapiens and mmu for Mus Musculus. For example, a human homolog to mir-121 might be referred to as hsa-mir-121 whereas the mouse homolog can be referred to as mmu-mir-121.

[0091] Mature microRNA is commonly designated with the prefix "miR" whereas the gene or precursor miRNA is designated with the prefix "mir." For example, mir-121 is a precursor for miR-121. When differing miRNA genes or precursors are processed into identical mature miRNAs, the genes/precursors can be delineated by a numbered suffix. For example, mir-121-1 and mir-121-2 can refer to distinct genes or precursors that are processed into miR-121. Lettered suffixes are used to indicate closely related mature sequences. For example, mir-121a and mir-121b can be processed to closely related miRNAs miR-121a and miR- 12 lb, respectively. In the context of the invention, any microRNA (miRNA or miR) designated herein with the prefix mir-* or miR-* is understood to encompass both the precursor and/or mature species, unless otherwise explicitly stated otherwise.

[0092] Sometimes it is observed that two mature miRNA sequences originate from the same precursor. When one of the sequences is more abundant that the other, a "*" suffix can be used to designate the less common variant. For example, miR-121 would be the predominant product whereas miR-121* is the less common variant found on the opposite arm of the precursor. If the predominant variant is not identified, the miRs can be distinguished by the suffix "5p" for the variant from the 5 ' arm of the precursor and the suffix "3p" for the variant from the 3 ' arm. For example, miR- 121-5p originates from the 5 ' arm of the precursor whereas miR-121-3p originates from the 3 ' arm. Less commonly, the 5p and 3p variants are referred to as the sense ("s") and anti-sense ("as") forms, respectively. For example, miR-121-5p may be referred to as miR- 121-s whereas miR-121-3p may be referred to as miR- 121-as.

[0093] The above naming conventions have evolved over time and are general guidelines rather than absolute rules. For example, the let- and lin- families of miRNAs continue to be referred to by these monikers. The mir/miR convention for precursor/mature forms is also a guideline and context should be taken into account to determine which form is referred to. Further details of miR naming can be found at www.mirbase.org or Ambros et al., A uniform system for microRNA annotation, RNA 9:277-279 (2003).

[0094] Plant miRNAs follow a different naming convention as described in Meyers et al., Plant Cell. 2008 20(12):3186-3190.

[0095] A number of miRNAs are involved in gene regulation, and miRNAs are part of a growing class of non-coding RNAs that is now recognized as a major tier of gene control. In some cases, miRNAs can interrupt translation by binding to regulatory sites embedded in the 3'-UTRs of their target mRNAs, leading to the repression of translation. Target recognition involves complementary base pairing of the target site with the miRNA's seed region (positions 2-8 at the miRNA's 5' end), although the exact extent of seed complementarity is not precisely determined and can be modified by 3' pairing. In other cases, miRNAs function like small interfering RNAs (siRNA) and bind to perfectly complementary mRNA sequences to destroy the target transcript.

[0096] Characterization of a number of miRNAs indicates that they influence a variety of processes, including early development, cell proliferation and cell death, apoptosis and fat metabolism. For example, some miRNAs, such as lin-4, let-7, mir- 14, mir-23, and bantam, have been shown to play critical roles in cell differentiation and tissue development. Others are believed to have similarly important roles because of their differential spatial and temporal expression patterns.

[0097] The miRNA database available at miRBase (www.mirbase.org) comprises a searchable database of published miRNA sequences and annotation. Further information about miRBase can be found in the following articles, each of which is incorporated by reference in its entirety herein: Griffiths-Jones et al., miRBase: tools for microRNA genomics. NAR 2008 36(Database Issue):D 154-D 158; Griffiths-Jones et al., miRBase: microRNA sequences, targets and gene nomenclature. NAR 2006 34(Database

Issue):D 140-D 144; and Griffiths- Jones, S. The microRNA Registry. NAR 2004 32(Database

Issue):D 109-D l 1 1. Representative miRNAs contained in Release 16 of miRBase, made available September 2010.

[0098] As described herein, microRNAs are known to be involved in cancer and other diseases and can be assessed in order to characterize a phenotype in a sample. See, e.g., Ferracin et al, Micromarkers: miRNAs in cancer diagnosis and prognosis, Exp Rev Mol Diag, Apr 2010, Vol. 10, No. 3, Pages 297-308; Fabbri, miRNAs as molecular biomarkers of cancer, Exp Rev Mol Diag, May 2010, Vol. 10, No. 4, Pages

435-444.

[0099] In an embodiment, molecular profiling of the invention comprises analysis of microRNA.

[00100] Techniques to isolate and characterize vesicles and miRs are known to those of skill in the art. In addition to the methodology presented herein, additional methods can be found in U.S. Patent Nos.

7,888,035, entitled "METHODS FOR ASSESSING RNA PATTERNS" and issued February 15, 2011; and 7,897,356, entitled "METHODS AND SYSTEMS OF USING EXOSOMES FOR DETERMINING PHENOTYPES" and issued March 1, 2011; and International Patent Publication Nos. WO/2011/066589, entitled "METHODS AND SYSTEMS FOR ISOLATING, STORING, AND ANALYZING VESICLES" and filed November 30, 2010; WO/2011/088226, entitled "DETECTION OF GASTROINTESTINAL DISORDERS" and filed January 13, 2011; WO/2011/109440, entitled "BIOMARKERS FOR

THERANOSTICS" and filed March 1, 2011; and WO/2011/127219, entitled "CIRCULATING

BIOMARKERS FOR DISEASE" and filed April 6, 2011, each of which applications are incorporated by reference herein in their entirety.

Circulating Biomarkers

[00101] Circulating biomarkers include biomarkers that are detectable in body fluids, such as blood, plasma, serum. Examples of circulating cancer biomarkers include cardiac troponin T (cTnT), prostate specific antigen (PSA) for prostate cancer and CA125 for ovarian cancer. Circulating biomarkers according to the invention include any appropriate biomarker that can be detected in bodily fluid, including without limitation protein, nucleic acids, e.g., DNA, mRNA and microRNA, lipids, carbohydrates and metabolites. Circulating biomarkers can include biomarkers that are not associated with cells, such as biomarkers that are membrane associated, embedded in membrane fragments, part of a biological complex, or free in solution. In one embodiment, circulating biomarkers are biomarkers that are associated with one or more vesicles present in the biological fluid of a subject.

[00102] Circulating biomarkers have been identified for use in characterization of various phenotypes, such as detection of a cancer. See, e.g., Ahmed N, et al., Proteomic-based identification of haptoglobin- 1 precursor as a novel circulating biomarker of ovarian cancer. Br. J. Cancer 2004; Mathelin et al., Circulating proteinic biomarkers and breast cancer, Gynecol Obstet Fertil. 2006 Jul-Aug;34(7-8):638-46. Epub 2006 Jul 28; Ye et al., Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Rev Proteomics. 2007 Feb;4(l): 121-31; Carney, Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Expert Rev Mol Diagn. 2007 May;7(3):309-19; Gagnon, Discovery and application of protein biomarkers for ovarian cancer, Curr Opin Obstet Gynecol. 2008 Feb;20(l):9-13; Pasterkamp et al, Immune regulatory cells: circulating biomarker factories in cardiovascular disease. Clin Sci (Lond). 2008 Aug; 115(4): 129-31; Fabbri, miRNAs as molecular biomarkers of cancer, Exp Rev Mol Diag, May 2010, Vol. 10, No. 4, Pages 435-444; PCT Patent Publication WO/2007/088537; U.S. Patents 7,745, 150 and 7,655,479; U.S. Patent Publications

20110008808, 20100330683, 20100248290, 20100222230, 20100203566, 20100173788, 20090291932, 20090239246, 20090226937, 20090111121, 20090004687, 20080261258, 20080213907, 20060003465, 20050124071, and 20040096915, each of which publication is incorporated herein by reference in its entirety. In an embodiment, molecular profiling of the invention comprises analysis of circulating biomarkers.

Gene Expression Profiling

[00103] The methods and systems of the invention comprise expression profiling, which includes assessing differential expression of one or more target genes disclosed herein. Differential expression can include overexpression and/or underexpression of a biological product, e.g., a gene, mRNA or protein, compared to a control (or a reference). The control can include similar cells to the sample but without the disease (e.g., expression profiles obtained from samples from healthy individuals). A control can be a previously determined level that is indicative of a drug target efficacy associated with the particular disease and the particular drug target. The control can be derived from the same patient, e.g., a normal adjacent portion of the same organ as the diseased cells, the control can be derived from healthy tissues from other patients, or previously determined thresholds that are indicative of a disease responding or not- responding to a particular drug target. The control can also be a control found in the same sample, e.g. a housekeeping gene or a product thereof (e.g., mRNA or protein). For example, a control nucleic acid can be one which is known not to differ depending on the cancerous or non-cancerous state of the cell. The expression level of a control nucleic acid can be used to normalize signal levels in the test and reference populations. Illustrative control genes include, but are not limited to, e.g., β-actin, glyceraldehyde 3- phosphate dehydrogenase and ribosomal protein PI . Multiple controls or types of controls can be used. The source of differential expression can vary. For example, a gene copy number may be increased in a cell, thereby resulting in increased expression of the gene. Alternately, transcription of the gene may be modified, e.g., by chromatin remodeling, differential methylation, differential expression or activity of transcription factors, etc. Translation may also be modified, e.g., by differential expression of factors that degrade mRNA, translate mRNA, or silence translation, e.g., microRNAs or siRNAs. In some embodiments, differential expression comprises differential activity. For example, a protein may carry a mutation that increases the activity of the protein, such as constitutive activation, thereby contributing to a diseased state. Molecular profiling that reveals changes in activity can be used to guide treatment selection.

Methods of gene expression profiling include methods based on hybridization analysis of polynucleotides, and methods based on sequencing of polynucleotides. Commonly used methods known in the art for the quantification of mRNA expression in a sample include northern blotting and in situ hybridization (Parker & Barnes (1999) Methods in Molecular Biology 106:247-283); RNAse protection assays (Hod (1992) Biotechniques 13:852-854); and reverse transcription polymerase chain reaction (RT-PCR) (Weis et al. (1992) Trends in Genetics 8:263-264). Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA- protein duplexes. Representative methods for sequencing -based gene expression analysis include Serial Analysis of Gene Expression (SAGE), gene expression analysis by massively parallel signature sequencing (MPSS) and/or next generation sequencing. [00104] RT-PCR

[00105] Reverse transcription polymerase chain reaction (RT-PCR) is a variant of polymerase chain reaction (PCR). According to this technique, a RNA strand is reverse transcribed into its DNA complement (i.e., complementary DNA, or cDNA) using the enzyme reverse transcriptase, and the resulting cDNA is amplified using PCR. Real-time polymerase chain reaction is another PCR variant, which is also referred to as quantitative PCR, Q-PCR, qRT-PCR, or sometimes as RT-PCR. Either the reverse transcription PCR method or the real-time PCR method can be used for molecular profiling according to the invention, and RT-PCR can refer to either unless otherwise specified or as understood by one of skill in the art.

[00106] RT-PCR can be used to determine RNA levels, e.g., mRNA or miRNA levels, of the biomarkers of the invention. RT-PCR can be used to compare such RNA levels of the biomarkers of the invention in different sample populations, in normal and tumor tissues, with or without drug treatment, to characterize patterns of gene expression, to discriminate between closely related RNAs, and to analyze RNA structure.

[00107] The first step is the isolation of RNA, e.g., mRNA, from a sample. The starting material can be total RNA isolated from human tumors or tumor cell lines, and corresponding normal tissues or cell lines, respectively. Thus RNA can be isolated from a sample, e.g., tumor cells or tumor cell lines, and compared with pooled DNA from healthy donors. If the source of mRNA is a primary tumor, mRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples.

[00108] General methods for mRNA extraction are well known in the art and are disclosed in standard textbooks of molecular biology, including Ausubel et al. (1997) Current Protocols of Molecular Biology, John Wiley and Sons. Methods for RNA extraction from paraffin embedded tissues are disclosed, for example, in Rupp & Locker (1987) Lab Invest. 56:A67, and De Andres et al., BioTechniques 18:42044 (1995). In particular, RNA isolation can be performed using purification kit, buffer set and protease from commercial manufacturers, such as Qiagen, according to the manufacturer's instructions (QIAGEN Inc., Valencia, CA). For example, total RNA from cells in culture can be isolated using Qiagen RNeasy mini- columns. Numerous RNA isolation kits are commercially available and can be used in the methods of the invention.

[00109] In the alternative, the first step is the isolation of miRNA from a target sample. The starting material is typically total RNA isolated from human tumors or tumor cell lines, and corresponding normal tissues or cell lines, respectively. Thus RNA can be isolated from a variety of primary tumors or tumor cell lines, with pooled DNA from healthy donors. If the source of miRNA is a primary tumor, miRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples.

[00110] General methods for miRNA extraction are well known in the art and are disclosed in standard textbooks of molecular biology, including Ausubel et al. (1997) Current Protocols of Molecular Biology, John Wiley and Sons. Methods for RNA extraction from paraffin embedded tissues are disclosed, for example, in Rupp & Locker (1987) Lab Invest. 56:A67, and De Andres et al., BioTechniques 18:42044 (1995). In particular, RNA isolation can be performed using purification kit, buffer set and protease from commercial manufacturers, such as Qiagen, according to the manufacturer's instructions. For example, total RNA from cells in culture can be isolated using Qiagen RNeasy mini -columns. Numerous miRNA isolation kits are commercially available and can be used in the methods of the invention.

[00111] Whether the RNA comprises mRNA, miRNA or other types of RNA, gene expression profiling by RT-PCR can include reverse transcription of the RNA template into cDNA, followed by amplification in a PCR reaction. Commonly used reverse transcriptases include, but are not limited to, avilo myeloblastosis virus reverse transcriptase (AMV-RT) and Moloney murine leukemia virus reverse transcriptase (MMLV-RT). The reverse transcription step is typically primed using specific primers, random hexamers, or oligo-dT primers, depending on the circumstances and the goal of expression profiling. For example, extracted RNA can be reverse-transcribed using a GeneAmp RNA PCR kit (Perkin Elmer, Calif, USA), following the manufacturer's instructions. The derived cDNA can then be used as a template in the subsequent PCR reaction.

[00112] Although the PCR step can use a variety of thermostable DNA-dependent DNA polymerases, it typically employs the Taq DNA polymerase, which has a 5'-3' nuclease activity but lacks a 3'-5' proofreading endonuclease activity. TaqMan PCR typically uses the 5'-nuclease activity of Taq or Tth polymerase to hydrolyze a hybridization probe bound to its target amplicon, but any enzyme with equivalent 5' nuclease activity can be used. Two oligonucleotide primers are used to generate an amplicon typical of a PCR reaction. A third oligonucleotide, or probe, is designed to detect nucleotide sequence located between the two PCR primers. The probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe. During the amplification reaction, the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner. The resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second fluorophore. One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative interpretation of the data.

[00113] TaqMan™ RT-PCR can be performed using commercially available equipment, such as, for example, ABI PRISM 7700™ Sequence Detection System™ (Perkin-Elmer-Applied Biosystems, Foster City, Calif, USA), or LightCycler (Roche Molecular Biochemicals, Mannheim, Germany). In one specific embodiment, the 5' nuclease procedure is run on a real-time quantitative PCR device such as the ABI PRISM 7700 Sequence Detection System. The system consists of a thermocycler, laser, charge- coupled device (CCD), camera and computer. The system amplifies samples in a 96-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fiber optic cables for all 96 wells, and detected at the CCD. The system includes software for running the instrument and for analyzing the data.

[00114] TaqMan data are initially expressed as Ct, or the threshold cycle. As discussed above, fluorescence values are recorded during every cycle and represent the amount of product amplified to that point in the amplification reaction. The point when the fluorescent signal is first recorded as statistically significant is the threshold cycle (Ct).

[00115] To minimize errors and the effect of sample-to-sample variation, RT-PCR is usually performed using an internal standard. The ideal internal standard is expressed at a constant level among different tissues, and is unaffected by the experimental treatment. RNAs most frequently used to normalize patterns of gene expression are mRNAs for the housekeeping genes glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and β-actin.

[00116] Real time quantitative PCR (also quantitative real time polymerase chain reaction, QRT-PCR or Q-PCR) is a more recent variation of the RT-PCR technique. Q-PCR can measure PCR product accumulation through a dual-labeled fluorigenic probe (i.e., TaqMan probe). Real time PCR is compatible both with quantitative competitive PCR, where internal competitor for each target sequence is used for normalization, and with quantitative comparative PCR using a normalization gene contained within the sample, or a housekeeping gene for RT-PCR. See, e.g. Held et al. (1996) Genome Research 6:986-994.

[00117] Protein-based detection techniques are also useful for molecular profiling, especially when the nucleotide variant causes amino acid substitutions or deletions or insertions or frame shift that affect the protein primary, secondary or tertiary structure. To detect the amino acid variations, protein sequencing techniques may be used. For example, a protein or fragment thereof corresponding to a gene can be synthesized by recombinant expression using a DNA fragment isolated from an individual to be tested. Preferably, a cDNA fragment of no more than 100 to 150 base pairs encompassing the polymorphic locus to be determined is used. The amino acid sequence of the peptide can then be determined by conventional protein sequencing methods. Alternatively, the HPLC-microscopy tandem mass spectrometry technique can be used for determining the amino acid sequence variations. In this technique, proteolytic digestion is performed on a protein, and the resulting peptide mixture is separated by reversed-phase chromatographic separation. Tandem mass spectrometry is then performed and the data collected is analyzed. See Gatlin et al., Anal. Chem., 72:757-763 (2000).

[00118] Microarray

[00119] The biomarkers of the invention can also be identified, confirmed, and/or measured using the microarray technique. Thus, the expression profile biomarkers can be measured in cancer samples using microarray technology. In this method, polynucleotide sequences of interest are plated, or arrayed, on a microchip substrate. The arrayed sequences are then hybridized with specific DNA probes from cells or tissues of interest. The source of mRNA can be total RNA isolated from a sample, e.g., human tumors or tumor cell lines and corresponding normal tissues or cell lines. Thus RNA can be isolated from a variety of primary tumors or tumor cell lines. If the source of mRNA is a primary tumor, mRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples, which are routinely prepared and preserved in everyday clinical practice.

[00120] The expression profile of biomarkers can be measured in either fresh or paraffin-embedded tumor tissue, or body fluids using microarray technology. In this method, polynucleotide sequences of interest are plated, or arrayed, on a microchip substrate. The arrayed sequences are then hybridized with specific DNA probes from cells or tissues of interest. As with the RT-PCR method, the source of miRNA typically is total RNA isolated from human tumors or tumor cell lines, including body fluids, such as serum, urine, tears, and exosomes and corresponding normal tissues or cell lines. Thus RNA can be isolated from a variety of sources. If the source of miRNA is a primary tumor, miRNA can be extracted, for example, from frozen tissue samples, which are routinely prepared and preserved in everyday clinical practice.

[00121] Also known as biochip, DNA chip, or gene array, cDNA microarray technology allows for identification of gene expression levels in a biologic sample. cDNAs or oligonucleotides, each representing a given gene, are immobilized on a substrate, e.g., a small chip, bead or nylon membrane, tagged, and serve as probes that will indicate whether they are expressed in biologic samples of interest. The simultaneous expression of thousands of genes can be monitored simultaneously.

[00122] In a specific embodiment of the microarray technique, PCR amplified inserts of cDNA clones are applied to a substrate in a dense array. In one aspect, at least 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,500, 2,000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10,000, 15,000, 20,000, 25,000, 30,000, 35,000, 40,000, 45,000 or at least 50,000 nucleotide sequences are applied to the substrate. Each sequence can correspond to a different gene, or multiple sequences can be arrayed per gene. The microarrayed genes, immobilized on the microchip, are suitable for hybridization under stringent conditions.

Fluorescently labeled cDNA probes may be generated through incorporation of fluorescent nucleotides by reverse transcription of RNA extracted from tissues of interest. Labeled cDNA probes applied to the chip hybridize with specificity to each spot of DNA on the array. After stringent washing to remove non- specifically bound probes, the chip is scanned by confocal laser microscopy or by another detection method, such as a CCD camera. Quantitation of hybridization of each arrayed element allows for assessment of corresponding mRNA abundance. With dual color fluorescence, separately labeled cDNA probes generated from two sources of RNA are hybridized pairwise to the array. The relative abundance of the transcripts from the two sources corresponding to each specified gene is thus determined simultaneously. The miniaturized scale of the hybridization affords a convenient and rapid evaluation of the expression pattern for large numbers of genes. Such methods have been shown to have the sensitivity required to detect rare transcripts, which are expressed at a few copies per cell, and to reproducibly detect at least approximately two-fold differences in the expression levels (Schena et al. (1996) Proc. Natl. Acad. Sci. USA 93(2): 106-149). Microarray analysis can be performed by commercially available equipment following manufacturer's protocols, including without limitation the Affymetrix GeneChip technology (Affymetrix, Santa Clara, CA), Agilent (Agilent Technologies, Inc., Santa Clara, CA), or Illumina (Illumina, Inc., San Diego, CA) microarray technology.

[00123] The development of microarray methods for large-scale analysis of gene expression makes it possible to search systematically for molecular markers of cancer classification and outcome prediction in a variety of tumor types.

[00124] In some embodiments, the Agilent Whole Human Genome Microarray Kit (Agilent Technologies, Inc., Santa Clara, CA). The system can analyze more than 41,000 unique human genes and transcripts represented, all with public domain annotations. The system is used according to the manufacturer's instructions.

[00125] In some embodiments, the Illumina Whole Genome DASL assay (Illumina Inc., San Diego, CA) is used. The system offers a method to simultaneously profile over 24,000 transcripts from minimal R A input, from both fresh frozen (FF) and formalin-fixed paraffin embedded (FFPE) tissue sources, in a high throughput fashion.

[00126] Microarray expression analysis comprises identifying whether a gene or gene product is up- regulated or down-regulated relative to a reference. The identification can be performed using a statistical test to determine statistical significance of any differential expression observed. In some embodiments, statistical significance is determined using a parametric statistical test. The parametric statistical test can comprise, for example, a fractional factorial design, analysis of variance (ANOVA), a t-test, least squares, a Pearson correlation, simple linear regression, nonlinear regression, multiple linear regression, or multiple nonlinear regression. Alternatively, the parametric statistical test can comprise a one-way analysis of variance, two-way analysis of variance, or repeated measures analysis of variance. In other embodiments, statistical significance is determined using a nonparametric statistical test. Examples include, but are not limited to, a Wilcoxon signed-rank test, a Mann-Whitney test, a Kruskal-Wallis test, a Friedman test, a Spearman ranked order correlation coefficient, a Kendall Tau analysis, and a

nonparametric regression test. In some embodiments, statistical significance is determined at a p-value of less than about 0.05, 0.01, 0.005, 0.001, 0.0005, or 0.0001. Although the microarray systems used in the methods of the invention may assay thousands of transcripts, data analysis need only be performed on the transcripts of interest, thereby reducing the problem of multiple comparisons inherent in performing multiple statistical tests. The p-values can also be corrected for multiple comparisons, e.g., using a Bonferroni correction, a modification thereof, or other technique known to those in the art, e.g., the Hochberg correction, Holm-Bonferroni correction, Sidak correction, or Dunnett's correction. The degree of differential expression can also be taken into account. For example, a gene can be considered as differentially expressed when the fold-change in expression compared to control level is at least 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.2, 2.5, 2.7, 3.0, 4, 5, 6, 7, 8, 9 or 10-fold different in the sample versus the control. The differential expression takes into account both overexpression and underexpression. A gene or gene product can be considered up or down-regulated if the differential expression meets a statistical threshold, a fold-change threshold, or both. For example, the criteria for identifying differential expression can comprise both a p-value of 0.001 and fold change of at least 1.5-fold (up or down). One of skill will understand that such statistical and threshold measures can be adapted to determine differential expression by any molecular profiling technique disclosed herein.

[00127] Various methods of the invention make use of many types of microarrays that detect the presence and potentially the amount of biological entities in a sample. Arrays typically contain addressable moieties that can detect the presence of the entity in the sample, e.g., via a binding event. Microarrays include without limitation DNA microarrays, such as cDNA microarrays, oligonucleotide microarrays and SNP microarrays, microRNA arrays, protein microarrays, antibody microarrays, tissue microarrays, cellular microarrays (also called transfection microarrays), chemical compound microarrays, and carbohydrate arrays (glycoarrays). DNA arrays typically comprise addressable nucleotide sequences that can bind to sequences present in a sample. MicroRNA arrays, e.g., the MMChips array from the

University of Louisville or commercial systems from Agilent, can be used to detect microRNAs. Protein microarrays can be used to identify protein-protein interactions, including without limitation identifying substrates of protein kinases, transcription factor protein-activation, or to identify the targets of biologically active small molecules. Protein arrays may comprise an array of different protein molecules, commonly antibodies, or nucleotide sequences that bind to proteins of interest. Antibody microarrays comprise antibodies spotted onto the protein chip that are used as capture molecules to detect proteins or other biological materials from a sample, e.g., from cell or tissue lysate solutions. For example, antibody arrays can be used to detect biomarkers from bodily fluids, e.g., serum or urine, for diagnostic applications. Tissue microarrays comprise separate tissue cores assembled in array fashion to allow multiplex histological analysis. Cellular microarrays, also called transfection microarrays, comprise various capture agents, such as antibodies, proteins, or lipids, which can interact with cells to facilitate their capture on addressable locations. Chemical compound microarrays comprise arrays of chemical compounds and can be used to detect protein or other biological materials that bind the compounds.

Carbohydrate arrays (glycoarrays) comprise arrays of carbohydrates and can detect, e.g., protein that bind sugar moieties. One of skill will appreciate that similar technologies or improvements can be used according to the methods of the invention.

[00128] Certain embodiments of the current methods comprise a multi-well reaction vessel, including without limitation, a multi-well plate or a multi -chambered microfluidic device, in which a multiplicity of amplification reactions and, in some embodiments, detection are performed, typically in parallel. In certain embodiments, one or more multiplex reactions for generating amplicons are performed in the same reaction vessel, including without limitation, a multi-well plate, such as a 96-well, a 384-well, a 1536-well plate, and so forth; or a microfluidic device, for example but not limited to, a TaqMan™ Low Density Array (Applied Biosystems, Foster City, CA). In some embodiments, a massively parallel amplifying step comprises a multi-well reaction vessel, including a plate comprising multiple reaction wells, for example but not limited to, a 24-well plate, a 96-well plate, a 384-well plate, or a 1536-well plate; or a multi- chamber microfluidics device, for example but not limited to a low density array wherein each chamber or well comprises an appropriate primer(s), primer set(s), and/or reporter probe(s), as appropriate. Typically such amplification steps occur in a series of parallel single-plex, two-plex, three-plex, four-plex, five-plex, or six-plex reactions, although higher levels of parallel multiplexing are also within the intended scope of the current teachings. These methods can comprise PCR methodology, such as RT-PCR, in each of the wells or chambers to amplify and/or detect nucleic acid molecules of interest.

[00129] Low density arrays can include arrays that detect 10s or 100s of molecules as opposed to 1000s of molecules. These arrays can be more sensitive than high density arrays. In embodiments, a low density array such as a TaqMan™ Low Density Array is used to detect one or more gene or gene product in any of Tables 5-12. For example, the low density array can be used to detect at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,

15, 20, 25, 30, 40, 50, 60, 70, 80, 90 or 100 genes or gene products selected from any of Tables 5-12.

[00130] In some embodiments, the disclosed methods comprise a microfluidics device, "lab on a chip," or micrototal analytical system (pTAS). In some embodiments, sample preparation is performed using a microfluidics device. In some embodiments, an amplification reaction is performed using a microfluidics device. In some embodiments, a sequencing or PCR reaction is performed using a microfluidic device. In some embodiments, the nucleotide sequence of at least a part of an amplified product is obtained using a microfluidics device. In some embodiments, detecting comprises a microfluidic device, including without limitation, a low density array, such as a TaqMan™ Low Density Array. Descriptions of exemplary microfluidic devices can be found in, among other places, Published PCT Application Nos. WO/0185341 and WO 04/011666; Kartalov and Quake, Nucl. Acids Res. 32:2873-79, 2004; and Fiorini and Chiu, Bio

Techniques 38:429-46, 2005.

Any appropriate microfluidic device can be used in the methods of the invention. Examples of microfluidic devices that may be used, or adapted for use with molecular profiling, include but are not limited to those described in U.S. Pat. Nos. 7,591,936, 7,581,429, 7,579,136, 7,575,722, 7,568,399, 7,552,741, 7,544,506, 7,541,578, 7,518,726, 7,488,596, 7,485,214, 7,467,928, 7,452,713, 7,452,509, 7,449,096, 7,431,887, 7,422,725, 7,422,669, 7,419,822, 7,419,639, 7,413,709, 7,411,184, 7,402,229, 7,390,463, 7,381,471, 7,357,864, 7,351,592, 7,351,380, 7,338,637, 7,329,391, 7,323,140, 7,261,824, 7,258,837, 7,253,003, 7,238,324, 7,238,255, 7,233,865, 7,229,538, 7,201,881, 7,195,986, 7,189,581, 7, 189,580, 7,189,368, 7, 141,978, 7, 138,062, 7, 135,147, 7,125,711, 7, 118,910, 7,118,661, 7,640,947, 7,666,361, 7,704,735; U.S. Patent Application Publication 20060035243; and International Patent Publication WO 2010/072410; each of which patents or applications are incorporated herein by reference in their entirety. Another example for use with methods disclosed herein is described in Chen et al, "Microfluidic isolation and trans criptome analysis of serum vesicles, " Lab on a Chip, Dec. 8, 2009 DOI: 10.1039/b916199f.

[00131] Gene Expression Analysis by Massively Parallel Signature Sequencing

(MPSS)

[00132] This method, described by Brenner et al. (2000) Nature Biotechnology 18:630-634, is a sequencing approach that combines non-gel-based signature sequencing with in vitro cloning of millions of templates on separate microbeads. First, a microbead library of DNA templates is constructed by in vitro cloning. This is followed by the assembly of a planar array of the template -containing microbeads in a flow cell at a high density. The free ends of the cloned templates on each microbead are analyzed simultaneously, using a fluorescence-based signature sequencing method that does not require DNA fragment separation. This method has been shown to simultaneously and accurately provide, in a single operation, hundreds of thousands of gene signature sequences from a cDNA library.

[00133] MPSS data has many uses. The expression levels of nearly all transcripts can be quantitatively determined; the abundance of signatures is representative of the expression level of the gene in the analyzed tissue. Quantitative methods for the analysis of tag frequencies and detection of differences among libraries have been published and incorporated into public databases for SAGE™ data and are applicable to MPSS data. The availability of complete genome sequences permits the direct comparison of signatures to genomic sequences and further extends the utility of MPSS data. Because the targets for MPSS analysis are not pre-selected (like on a microarray), MPSS data can characterize the full complexity of transcriptomes. This is analogous to sequencing millions of ESTs at once, and genomic sequence data can be used so that the source of the MPSS signature can be readily identified by computational means.

[00134] Serial Analysis of Gene Expression (SAGE)

[00135] Serial analysis of gene expression (SAGE) is a method that allows the simultaneous and quantitative analysis of a large number of gene transcripts, without the need of providing an individual hybridization probe for each transcript. First, a short sequence tag (e.g., about 10-14 bp) is generated that contains sufficient information to uniquely identify a transcript, provided that the tag is obtained from a unique position within each transcript. Then, many transcripts are linked together to form long serial molecules, that can be sequenced, revealing the identity of the multiple tags simultaneously. The expression pattern of any population of transcripts can be quantitatively evaluated by determining the abundance of individual tags, and identifying the gene corresponding to each tag. See, e.g. Velculescu et al. (1995) Science 270:484-487; and Velculescu et al. (1997) Cell 88:243-51.

DNA Copy Number Profiling

[00136] Any method capable of determining a DNA copy number profile of a particular sample can be used for molecular profiling according to the invention as long as the resolution is sufficient to identify the biomarkers of the invention. The skilled artisan is aware of and capable of using a number of different platforms for assessing whole genome copy number changes at a resolution sufficient to identify the copy number of the one or more biomarkers of the invention. Some of the platforms and techniques are described in the embodiments below. In some embodiments of the invention, ISH techniques as described herein are also used for determining copy number / gene amplification.

[00137] In some embodiments, the copy number profile analysis involves amplification of whole genome DNA by a whole genome amplification method. The whole genome amplification method can use a strand displacing polymerase and random primers.

[00138] In some aspects of these embodiments, the copy number profile analysis involves hybridization of whole genome amplified DNA with a high density array. In a more specific aspect, the high density array has 5,000 or more different probes. In another specific aspect, the high density array has 5,000, 10,000, 20,000, 50,000, 100,000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, or 1,000,000 or more different probes. In another specific aspect, each of the different probes on the array is an oligonucleotide having from about 15 to 200 bases in length. In another specific aspect, each of the different probes on the array is an oligonucleotide having from about 15 to 200, 15 to 150, 15 to 100, 15 to 75, 15 to 60, or 20 to 55 bases in length.

[00139] In some embodiments, a microarray is employed to aid in determining the copy number profile for a sample, e.g., cells from a tumor. Microarrays typically comprise a plurality of oligomers (e.g., DNA or RNA polynucleotides or oligonucleotides, or other polymers), synthesized or deposited on a substrate (e.g., glass support) in an array pattern. The support-bound oligomers are "probes", which function to hybridize or bind with a sample material (e.g., nucleic acids prepared or obtained from the tumor samples), in hybridization experiments. The reverse situation can also be applied: the sample can be bound to the microarray substrate and the oligomer probes are in solution for the hybridization. In use, the array surface is contacted with one or more targets under conditions that promote specific, high-affinity binding of the target to one or more of the probes. In some configurations, the sample nucleic acid is labeled with a detectable label, such as a fluorescent tag, so that the hybridized sample and probes are detectable with scanning equipment. DNA array technology offers the potential of using a multitude (e.g., hundreds of thousands) of different oligonucleotides to analyze DNA copy number profiles. In some embodiments, the substrates used for arrays are surface-derivatized glass or silica, or polymer membrane surfaces (see e.g., in Z. Guo, et al., Nucleic Acids Res, 22, 5456-65 (1994); U. Maskos, E. M. Southern, Nucleic Acids Res, 20, 1679-84 (1992), and E. M. Southern, et al., Nucleic Acids Res, 22, 1368-73 (1994), each incorporated by reference herein). Modification of surfaces of array substrates can be accomplished by many techniques. For example, siliceous or metal oxide surfaces can be derivatized with bifunctional silanes, i.e., silanes having a first functional group enabling covalent binding to the surface (e.g., Si-halogen or Si-alkoxy group, as in— S1CI3 or ~Si(OCH₃) ₃, respectively) and a second functional group that can impart the desired chemical and/or physical modifications to the surface to covalently or non-covalently attach ligands and/or the polymers or monomers for the biological probe array. Silylated derivatizations and other surface derivatizations that are known in the art (see for example U.S. Pat. No. 5,624,711 to Sundberg, U.S. Pat. No. 5,266,222 to Willis, and U.S. Pat. No. 5,137,765 to Farnsworth, each incorporated by reference herein). Other processes for preparing arrays are described in U.S. Pat. No. 6,649,348, to Bass et. al, assigned to Agilent Corp., which disclose DNA arrays created by in situ synthesis methods.

[00140] Polymer array synthesis is also described extensively in the literature including in the following: WO 00/58516, U.S. Pat. Nos. 5,143,854, 5,242,974, 5,252,743, 5,324,633, 5,384,261, 5,405,783, 5,424, 186, 5,451,683, 5,482,867, 5,491,074, 5,527,681, 5,550,215, 5,571,639, 5,578,832, 5,593,839, 5,599,695, 5,624,711, 5,631,734, 5,795,716, 5,831,070, 5,837,832, 5,856,101, 5,858,659, 5,936,324, 5,968,740, 5,974, 164, 5,981, 185, 5,981,956, 6,025,601, 6,033,860, 6,040,193, 6,090,555, 6,136,269, 6,269,846 and 6,428,752, 5,412,087, 6,147,205, 6,262,216, 6,310,189, 5,889,165, and 5,959,098 in PCT Applications Nos. PCT/US99/00730 (International Publication No. WO 99/36760) and PCT/USO 1/04285 (International Publication No. WO 01/58593), which are all incorporated herein by reference in their entirety for all purposes.

[00141] Nucleic acid arrays that are useful in the present invention include, but are not limited to, those that are commercially available from Affymetrix (Santa Clara, Calif.) under the brand name GeneChip™. Example arrays are shown on the website at affymetrix.com. Another microarray supplier is Illumina, Inc., of San Diego, Calif, with example arrays shown on their website at illumina.com.

[00142] In some embodiments, the inventive methods provide for sample preparation. Depending on the microarray and experiment to be performed, sample nucleic acid can be prepared in a number of ways by methods known to the skilled artisan. In some aspects of the invention, prior to or concurrent with genotyping (analysis of copy number profiles), the sample may be amplified any number of mechanisms. The most common amplification procedure used involves PCR. See, for example, PCR Technology: Principles and Applications for DNA Amplification (Ed. H. A. Erlich, Freeman Press, NY, N.Y., 1992); PCR Protocols: A Guide to Methods and Applications (Eds. Innis, et al., Academic Press, San Diego, Calif, 1990); Mattila et al, Nucleic Acids Res. 19, 4967 (1991); Eckert et al., PCR Methods and

Applications 1, 17 (1991); PCR (Eds. McPherson et al., IRL Press, Oxford); and U.S. Pat. Nos. 4,683,202, 4,683, 195, 4,800, 159 4,965,188, and 5,333,675, and each of which is incorporated herein by reference in their entireties for all purposes. In some embodiments, the sample may be amplified on the array (e.g., U.S. Pat. No. 6,300,070 which is incorporated herein by reference)

[00143] Other suitable amplification methods include the ligase chain reaction (LCR) (for example, Wu and Wallace, Genomics 4, 560 (1989), Landegren et al., Science 241, 1077 (1988) and Barringer et al. Gene 89: 117 (1990)), transcription amplification (Kwoh et al., Proc. Natl. Acad. Sci. USA 86, 1173 (1989) and WO88/10315), self-sustained sequence replication (Guatelli et al, Proc. Nat. Acad. Sci. USA, 87, 1874 (1990) and WO90/06995), selective amplification of target polynucleotide sequences (U.S. Pat. No. 6,410,276), consensus sequence primed polymerase chain reaction (CP-PCR) (U.S. Pat. No.

4,437,975), arbitrarily primed polymerase chain reaction (AP-PCR) (U.S. Pat. Nos. 5,413,909, 5,861,245) and nucleic acid based sequence amplification (NABSA). (See, U.S. Pat. Nos. 5,409,818, 5,554,517, and 6,063,603, each of which is incorporated herein by reference). Other amplification methods that may be used are described in, U.S. Pat. Nos. 5,242,794, 5,494,810, 4,988,617 and in U.S. Ser. No. 09/854,317, each of which is incorporated herein by reference.

[00144] Additional methods of sample preparation and techniques for reducing the complexity of a nucleic sample are described in Dong et al, Genome Research 11, 1418 (2001), in U.S. Pat. Nos.

6,361,947, 6,391,592 and U.S. Ser. Nos. 09/916,135, 09/920,491 (U.S. Patent Application Publication 20030096235), 09/910,292 (U.S. Patent Application Publication 20030082543), and 10/013,598.

[00145] Methods for conducting polynucleotide hybridization assays are well developed in the art.

Hybridization assay procedures and conditions used in the methods of the invention will vary depending on the application and are selected in accordance with the general binding methods known including those referred to in: Maniatis et al. Molecular Cloning: A Laboratory Manual (2.sup.nd Ed. Cold Spring Harbor, N.Y., 1989); Berger and Kimmel Methods in Enzymology, Vol. 152, Guide to Molecular Cloning Techniques (Academic Press, Inc., San Diego, Calif, 1987); Young and Davism, P.N.A.S, 80: 1194 (1983). Methods and apparatus for carrying out repeated and controlled hybridization reactions have been described in U.S. Pat. Nos. 5,871,928, 5,874,219, 6,045,996 and 6,386,749, 6,391,623 each of which are incorporated herein by reference.

[00146] The methods of the invention may also involve signal detection of hybridization between ligands in after (and/or during) hybridization. See U.S. Pat. Nos. 5,143,854, 5,578,832; 5,631,734; 5,834,758; 5,936,324; 5,981,956; 6,025,601; 6, 141,096; 6,185,030; 6,201,639; 6,218,803; and 6,225,625, in U.S. Ser. No. 10/389, 194 and in PCT Application PCT/US99/06097 (published as W099/47964), each of which also is hereby incorporated by reference in its entirety for all purposes.

[00147] Methods and apparatus for signal detection and processing of intensity data are disclosed in, for example, U.S. Pat. Nos. 5,143,854, 5,547,839, 5,578,832, 5,631,734, 5,800,992, 5,834,758; 5,856,092, 5,902,723, 5,936,324, 5,981,956, 6,025,601, 6,090,555, 6, 141,096, 6, 185,030, 6,201,639; 6,218,803; and 6,225,625, in U.S. Ser. Nos. 10/389,194, 60/493,495 and in PCT Application PCT/US99/06097

(published as W099/47964), each of which also is hereby incorporated by reference in its entirety for all purposes.

Immuno-based Assays

[00148] Protein-based detection molecular profiling techniques include immunoaffinity assays based on antibodies selectively immunoreactive with mutant gene encoded protein according to the present invention. These techniques include without limitation immunoprecipitation, Western blot analysis, molecular binding assays, enzyme-linked immunosorbent assay (ELISA), enzyme-linked

immunofiltration assay (ELIFA), fluorescence activated cell sorting (FACS) and the like. For example, an optional method of detecting the expression of a biomarker in a sample comprises contacting the sample with an antibody against the biomarker, or an immunoreactive fragment of the antibody thereof, or a recombinant protein containing an antigen binding region of an antibody against the biomarker; and then detecting the binding of the biomarker in the sample. Methods for producing such antibodies are known in the art. Antibodies can be used to immunoprecipitate specific proteins from solution samples or to immunoblot proteins separated by, e.g., polyacrylamide gels. Immunocytochemical methods can also be used in detecting specific protein polymorphisms in tissues or cells. Other well-known antibody-based techniques can also be used including, e.g., ELISA, radioimmunoassay (RIA), immunoradiometric assays (IRMA) and immunoenzymatic assays (IEMA), including sandwich assays using monoclonal or polyclonal antibodies. See, e.g., U.S. Pat. Nos. 4,376,110 and 4,486,530, both of which are incorporated herein by reference.

[00149] In alternative methods, the sample may be contacted with an antibody specific for a biomarker under conditions sufficient for an antibody-biomarker complex to form, and then detecting said complex. The presence of the biomarker may be detected in a number of ways, such as by Western blotting and ELISA procedures for assaying a wide variety of tissues and samples, including plasma or serum. A wide range of immunoassay techniques using such an assay format are available, see, e.g., U.S. Pat. Nos. 4,016,043, 4,424,279 and 4,018,653. These include both single-site and two-site or "sandwich" assays of the non-competitive types, as well as in the traditional competitive binding assays. These assays also include direct binding of a labelled antibody to a target biomarker.

[00150] A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, in a typical forward assay, an unlabelled antibody is immobilized on a solid substrate, and the sample to be tested brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody -antigen complex, a second antibody specific to the antigen, labelled with a reporter molecule capable of producing a detectable signal is then added and incubated, allowing time sufficient for the formation of another complex of antibody-antigen-labelled antibody. Any unreacted material is washed away, and the presence of the antigen is determined by observation of a signal produced by the reporter molecule. The results may either be qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of biomarker.

[00151] Variations on the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody. These techniques are well known to those skilled in the art, including any minor variations as will be readily apparent. In a typical forward sandwich assay, a first antibody having specificity for the biomarker is either covalently or passively bound to a solid surface. The solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs of microplates, or any other surface suitable for conducting an immunoassay. The binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing, the polymer-antibody complex is washed in preparation for the test sample. An aliquot of the sample to be tested is then added to the solid phase complex and incubated for a period of time sufficient (e.g. 2-40 minutes or overnight if more convenient) and under suitable conditions (e.g. from room temperature to 40°C such as between 25°C and 32°C inclusive) to allow binding of any subunit present in the antibody. Following the incubation period, the antibody subunit solid phase is washed and dried and incubated with a second antibody specific for a portion of the biomarker. The second antibody is linked to a reporter molecule which is used to indicate the binding of the second antibody to the molecular marker.

[00152] An alternative method involves immobilizing the target biomarkers in the sample and then exposing the immobilized target to specific antibody which may or may not be labelled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound target may be detectable by direct labelling with the antibody. Alternatively, a second labelled antibody, specific to the first antibody is exposed to the target-first antibody complex to form a target-first antibody- second antibody tertiary complex. The complex is detected by the signal emitted by the reporter molecule. By "reporter molecule", as used in the present specification, is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of antigen-bound antibody. The most commonly used reporter molecules in this type of assay are either enzymes, fluorophores or radionuclide containing molecules (i.e. radioisotopes) and chemiluminescent molecules.

[00153] In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognized, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan. Commonly used enzymes include horseradish peroxidase, glucose oxidase, β-galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable color change. Examples of suitable enzymes include alkaline phosphatase and peroxidase. It is also possible to employ fluorogenic substrates, which yield a fluorescent product rather than the chromogenic substrates noted above. In all cases, the enzyme-labelled antibody is added to the first antibody -molecular marker complex, allowed to bind, and then the excess reagent is washed away. A solution containing the appropriate substrate is then added to the complex of antibody-antigen-antibody. The substrate will react with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually

spectrophotometrically, to give an indication of the amount of biomarker which was present in the sample. Alternately, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state to excitability in the molecule, followed by emission of the light at a characteristic color visually detectable with a light microscope. As in the EIA, the fluorescent labelled antibody is allowed to bind to the first antibody -molecular marker complex. After washing off the unbound reagent, the remaining tertiary complex is then exposed to the light of the appropriate wavelength, the fluorescence observed indicates the presence of the molecular marker of interest. Immunofluorescence and EIA techniques are both very well established in the art. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed.

[00154] Immunohistochemistry (IHC)

[00155] IHC is a process of localizing antigens (e.g., proteins) in cells of a tissue binding antibodies specifically to antigens in the tissues. The antigen-binding antibody can be conjugated or fused to a tag that allows its detection, e.g., via visualization. In some embodiments, the tag is an enzyme that can catalyze a color-producing reaction, such as alkaline phosphatase or horseradish peroxidase. The enzyme can be fused to the antibody or non-covalently bound, e.g., using a biotin-avadin system. Alternatively, the antibody can be tagged with a fluorophore, such as fluorescein, rhodamine, DyLight Fluor or Alexa Fluor. The antigen-binding antibody can be directly tagged or it can itself be recognized by a detection antibody that carries the tag. Using IHC, one or more proteins may be detected. The expression of a gene product can be related to its staining intensity compared to control levels. In some embodiments, the gene product is considered differentially expressed if its staining varies at least 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.2, 2.5, 2.7, 3.0, 4, 5, 6, 7, 8, 9 or 10-fold in the sample versus the control.

[00156] IHC comprises the application of antigen-antibody interactions to histochemical techniques. In an illustrative example, a tissue section is mounted on a slide and is incubated with antibodies (polyclonal or monoclonal) specific to the antigen (primary reaction). The antigen-antibody signal is then amplified using a second antibody conjugated to a complex of peroxidase antiperoxidase (PAP), avidin-biotin- peroxidase (ABC) or avidin-biotin alkaline phosphatase. In the presence of substrate and chromogen, the enzyme forms a colored deposit at the sites of antibody-antigen binding. Immunofluorescence is an alternate approach to visualize antigens. In this technique, the primary antigen-antibody signal is amplified using a second antibody conjugated to a fluorochrome. On UV light absorption, the

fluorochrome emits its own light at a longer wavelength (fluorescence), thus allowing localization of antibody -antigen complexes. Epigenetic Status

[00157] Molecular profiling methods according to the invention also comprise measuring epigenetic change, i.e., modification in a gene caused by an epigenetic mechanism, such as a change in methylation status or histone acetylation. Frequently, the epigenetic change will result in an alteration in the levels of expression of the gene which may be detected (at the RNA or protein level as appropriate) as an indication of the epigenetic change. Often the epigenetic change results in silencing or down regulation of the gene, referred to as "epigenetic silencing." The most frequently investigated epigenetic change in the methods of the invention involves determining the DNA methylation status of a gene, where an increased level of methylation is typically associated with the relevant cancer (since it may cause down regulation of gene expression). Aberrant methylation, which may be referred to as hypermethylation, of the gene or genes can be detected. Typically, the methylation status is determined in suitable CpG islands which are often found in the promoter region of the gene(s). The term "methylation," "methylation state" or "methylation status" may refers to the presence or absence of 5-methylcytosine at one or a plurality of CpG

dinucleotides within a DNA sequence. CpG dinucleotides are typically concentrated in the promoter regions and exons of human genes.

[00158] Diminished gene expression can be assessed in terms of DNA methylation status or in terms of expression levels as determined by the methylation status of the gene. One method to detect epigenetic silencing is to determine that a gene which is expressed in normal cells is less expressed or not expressed in tumor cells. Accordingly, the invention provides for a method of molecular profiling comprising detecting epigenetic silencing.

[00159] Various assay procedures to directly detect methylation are known in the art, and can be used in conjunction with the present invention. These assays rely onto two distinct approaches: bisulphite conversion based approaches and non-bisulphite based approaches. Non-bisulphite based methods for analysis of DNA methylation rely on the inability of methylation-sensitive enzymes to cleave methylation cytosines in their restriction. The bisulphite conversion relies on treatment of DNA samples with sodium bisulphite which converts unmethylated cytosine to uracil, while methylated cytosines are maintained (Furuichi Y, Wataya Y, Hayatsu H, Ukita T. Biochem Biophys Res Commun. 1970 Dec 9;41(5): 1185- 91). This conversion results in a change in the sequence of the original DNA. Methods to detect such changes include MS AP-PCR (Methylation-Sensitive Arbitrarily-Primed Polymerase Chain Reaction), a technology that allows for a global scan of the genome using CG-rich primers to focus on the regions most likely to contain CpG dinucleotides, and described by Gonzalgo et al., Cancer Research 57:594-599, 1997; MethyLight™, which refers to the art-recognized fluorescence-based real-time PCR technique described by Eads et al., Cancer Res. 59:2302-2306, 1999; the HeavyMethyl™assay, in the embodiment thereof implemented herein, is an assay, wherein methylation specific blocking probes (also referred to herein as blockers) covering CpG positions between, or covered by the amplification primers enable methylation-specific selective amplification of a nucleic acid sample; Heavy Methyl™Methy Light™ is a variation of the MethyLight™ assay wherein the MethyLight™ assay is combined with methylation specific blocking probes covering CpG positions between the amplification primers; Ms-SNuPE (Methylation-sensitive Single Nucleotide Primer Extension) is an assay described by Gonzalgo & Jones,

Nucleic Acids Res. 25:2529-2531, 1997; MSP (Methylation-specific PCR) is a methylation assay described by Herman et al. Proc. Natl. Acad. Sci. USA 93:9821-9826, 1996, and by U.S. Pat. No.

5,786,146; COBRA (Combined Bisulfite Restriction Analysis) is a methylation assay described by Xiong & Laird, Nucleic Acids Res. 25:2532-2534, 1997; MCA (Methylated CpG Island Amplification) is a methylation assay described by Toyota et al, Cancer Res. 59:2307-12, 1999, and in WO 00/26401A1.

[00160] Other techniques for DNA methylation analysis include sequencing, methylation-specific PCR (MS-PCR), melting curve methylation-specific PCR (McMS-PCR), MLPA with or without bisulfite treatment, QAMA, MSRE-PCR, MethyLight, ConLight-MSP, bisulfite conversion-specific methylation- specific PCR (BS-MSP), COBRA (which relies upon use of restriction enzymes to reveal methylation dependent sequence differences in PCR products of sodium bisulfite-treated DNA), methylation-sensitive single -nucleotide primer extension conformation (MS-SNuPE), methylation-sensitive single-strand conformation analysis (MS-SSCA), Melting curve combined bisulfite restriction analysis (McCOBRA), PyroMethA, HeavyMethyl, MALDI-TOF, MassARRAY, Quantitative analysis of methylated alleles (QAMA), enzymatic regional methylation assay (ERMA), QBSUPT, Methyl Quant, Quantitative PCR sequencing and oligonucleotide-based microarray systems, Pyrosequencing, Meth-DOP-PCR. A review of some useful techniques is provided in Nucleic acids research, 1998, Vol. 26, No. 10, 2255-2264; Nature Reviews, 2003, Vol.3, 253-266; Oral Oncology, 2006, Vol. 42, 5-13, which references are incorporated herein in their entirety. Any of these techniques may be used in accordance with the present invention, as appropriate. Other techniques are described in U.S. Patent Publications 20100144836; and 20100184027, which applications are incorporated herein by reference in their entirety.

[00161] Through the activity of various acetylases and deacetylylases the DNA binding function of histone proteins is tightly regulated. Furthermore, histone acetylation and histone deactelyation have been linked with malignant progression. See Nature, 429: 457-63, 2004. Methods to analyze histone acetylation are described in U.S. Patent Publications 20100144543 and 20100151468, which applications are incorporated herein by reference in their entirety.

Sequence Analysis

[00162] Molecular profiling according to the present invention comprises methods for genotyping one or more biomarkers by determining whether an individual has one or more nucleotide variants (or amino acid variants) in one or more of the genes or gene products. Genotyping one or more genes according to the methods of the invention in some embodiments, can provide more evidence for selecting a treatment.

[00163] The biomarkers of the invention can be analyzed by any method useful for determining alterations in nucleic acids or the proteins they encode. According to one embodiment, the ordinary skilled artisan can analyze the one or more genes for mutations including deletion mutants, insertion mutants, frame shift mutants, nonsense mutants, missense mutant, and splice mutants.

[00164] Nucleic acid used for analysis of the one or more genes can be isolated from cells in the sample according to standard methodologies (Sambrook et al., 1989). The nucleic acid, for example, may be genomic DNA or fractionated or whole cell RNA, or miRNA acquired from exosomes or cell surfaces. Where RNA is used, it may be desired to convert the RNA to a complementary DNA. In one embodiment, the RNA is whole cell RNA; in another, it is poly-A RNA; in another, it is exosomal RNA. Normally, the nucleic acid is amplified. Depending on the format of the assay for analyzing the one or more genes, the specific nucleic acid of interest is identified in the sample directly using amplification or with a second, known nucleic acid following amplification. Next, the identified product is detected. In certain applications, the detection may be performed by visual means (e.g., ethidium bromide staining of a gel). Alternatively, the detection may involve indirect identification of the product via chemiluminescence, radioactive scintigraphy of radiolabel or fluorescent label or even via a system using electrical or thermal impulse signals (Affymax Technology; Bellus, 1994).

[00165] Various types of defects are known to occur in the biomarkers of the invention. Alterations include without limitation deletions, insertions, point mutations, and duplications. Point mutations can be silent or can result in stop codons, frame shift mutations or amino acid substitutions. Mutations in and outside the coding region of the one or more genes may occur and can be analyzed according to the methods of the invention. The target site of a nucleic acid of interest can include the region wherein the sequence varies. Examples include, but are not limited to, polymorphisms which exist in different forms such as single nucleotide variations, nucleotide repeats, multibase deletion (more than one nucleotide deleted from the consensus sequence), multibase insertion (more than one nucleotide inserted from the consensus sequence), microsatellite repeats (small numbers of nucleotide repeats with a typical 5- 1000 repeat units), di-nucleotide repeats, tri-nucleotide repeats, sequence rearrangements (including translocation and duplication), chimeric sequence (two sequences from different gene origins are fused together), and the like. Among sequence polymorphisms, the most frequent polymorphisms in the human genome are single-base variations, also called single -nucleotide polymorphisms (SNPs). SNPs are abundant, stable and widely distributed across the genome.

[00166] Molecular profiling includes methods for haplotyping one or more genes. The haplotype is a set of genetic determinants located on a single chromosome and it typically contains a particular combination of alleles (all the alternative sequences of a gene) in a region of a chromosome. In other words, the haplotype is phased sequence information on individual chromosomes. Very often, phased SNPs on a chromosome define a haplotype. A combination of haplotypes on chromosomes can determine a genetic profile of a cell. It is the haplotype that determines a linkage between a specific genetic marker and a disease mutation. Haplotyping can be done by any methods known in the art. Common methods of scoring SNPs include hybridization microarray or direct gel sequencing, reviewed in Landgren et al., Genome Research, 8:769-776, 1998. For example, only one copy of one or more genes can be isolated from an individual and the nucleotide at each of the variant positions is determined. Alternatively, an allele specific PCR or a similar method can be used to amplify only one copy of the one or more genes in an individual, and the SNPs at the variant positions of the present invention are determined. The Clark method known in the art can also be employed for haplotyping. A high throughput molecular haplotyping method is also disclosed in Tost et al., Nucleic Acids Res., 30(19):e96 (2002), which is incorporated herein by reference. [00167] Thus, additional variant(s) that are in linkage disequilibrium with the variants and/or haplotypes of the present invention can be identified by a haplotyping method known in the art, as will be apparent to a skilled artisan in the field of genetics and haplotyping. The additional variants that are in linkage disequilibrium with a variant or haplotype of the present invention can also be useful in the various applications as described below.

[00168] For purposes of genotyping and haplotyping, both genomic DNA and mRNA/cDNA can be used, and both are herein referred to generically as "gene."

[00169] Numerous techniques for detecting nucleotide variants are known in the art and can all be used for the method of this invention. The techniques can be protein-based or nucleic acid-based. In either case, the techniques used must be sufficiently sensitive so as to accurately detect the small nucleotide or amino acid variations. Very often, a probe is used which is labeled with a detectable marker. Unless otherwise specified in a particular technique described below, any suitable marker known in the art can be used, including but not limited to, radioactive isotopes, fluorescent compounds, biotin which is detectable using streptavidin, enzymes (e.g., alkaline phosphatase), substrates of an enzyme, ligands and antibodies, etc. See Jablonski et al., Nucleic Acids Res., 14:6115-6128 (1986); Nguyen et al., Biotechniques, 13: 116-123 (1992); Rigby et al., J. Mol. Biol, 113:237-251 (1977).

[00170] In a nucleic acid-based detection method, target DNA sample, i.e., a sample containing genomic DNA, cDNA, mRNA and/or miRNA, corresponding to the one or more genes must be obtained from the individual to be tested. Any tissue or cell sample containing the genomic DNA, miRNA, mRNA, and/or cDNA (or a portion thereof) corresponding to the one or more genes can be used. For this purpose, a tissue sample containing cell nucleus and thus genomic DNA can be obtained from the individual. Blood samples can also be useful except that only white blood cells and other lymphocytes have cell nucleus, while red blood cells are without a nucleus and contain only mRNA or miRNA. Nevertheless, miRNA and mRNA are also useful as either can be analyzed for the presence of nucleotide variants in its sequence or serve as template for cDNA synthesis. The tissue or cell samples can be analyzed directly without much processing. Alternatively, nucleic acids including the target sequence can be extracted, purified, and/or amplified before they are subject to the various detecting procedures discussed below. Other than tissue or cell samples, cDNAs or genomic DNAs from a cDNA or genomic DNA library constructed using a tissue or cell sample obtained from the individual to be tested are also useful.

[00171] To determine the presence or absence of a particular nucleotide variant, sequencing of the target genomic DNA or cDNA, particularly the region encompassing the nucleotide variant locus to be detected. Various sequencing techniques are generally known and widely used in the art including the Sanger method and Gilbert chemical method. The pyrosequencing method monitors DNA synthesis in real time using a luminometric detection system. Pyrosequencing has been shown to be effective in analyzing genetic polymorphisms such as single-nucleotide polymorphisms and can also be used in the present invention. See Nordstrom et al., Biotechnol. Appl. Biochem., 31(2): 107-112 (2000); Ahmadian et al., Anal. Biochem., 280: 103-110 (2000). [00172] Nucleic acid variants can be detected by a suitable detection process. Non limiting examples of methods of detection, quantification, sequencing and the like are; mass detection of mass modified amplicons (e.g., matrix-assisted laser desorption ionization (MALDI) mass spectrometry and electrospray

(ES) mass spectrometry), a primer extension method (e.g., iPLEX™; Sequenom, Inc.), microsequencing methods (e.g., a modification of primer extension methodology), ligase sequence determination methods

(e.g., U.S. Pat. Nos. 5,679,524 and 5,952, 174, and WO 01/27326), mismatch sequence determination methods (e.g., U.S. Pat. Nos. 5,851,770; 5,958,692; 6, 110,684; and 6, 183,958), direct DNA sequencing, fragment analysis (FA), restriction fragment length polymorphism (RFLP analysis), allele specific oligonucleotide (ASO) analysis, methylation-specific PCR (MSPCR), pyrosequencing analysis, acycloprime analysis, Reverse dot blot, GeneChip microarrays, Dynamic allele-specific hybridization

(DASH), Peptide nucleic acid (PNA) and locked nucleic acids (LNA) probes, TaqMan, Molecular

Beacons, Intercalating dye, FRET primers, AlphaScreen, SNPstream, genetic bit analysis (GBA),

Multiplex minisequencing, SNaPshot, GOOD assay, Microarray miniseq, arrayed primer extension

(APEX), Microarray primer extension (e.g., microarray sequence determination methods), Tag arrays,

Coded microspheres, Template-directed incorporation (TDI), fluorescence polarization, Colorimetric oligonucleotide ligation assay (OLA), Sequence-coded OLA, Microarray ligation, Ligase chain reaction,

Padlock probes, Invader assay, hybridization methods (e.g., hybridization using at least one probe, hybridization using at least one fluorescently labeled probe, and the like), conventional dot blot analyses, single strand conformational polymorphism analysis (SSCP, e.g., U.S. Pat. Nos. 5,891,625 and 6,013,499;

Orita et al, Proc. Natl. Acad. Sci. U.S.A. 86: 27776-2770 (1989)), denaturing gradient gel electrophoresis

(DGGE), heteroduplex analysis, mismatch cleavage detection, and techniques described in Sheffield et al.,

Proc. Natl. Acad. Sci. USA 49: 699-706 (1991), White et al., Genomics 12: 301-306 (1992), Grompe et al., Proc. Natl. Acad. Sci. USA 86: 5855-5892 (1989), and Grompe, Nature Genetics 5: 111-117 (1993), cloning and sequencing, electrophoresis, the use of hybridization probes and quantitative real time polymerase chain reaction (QRT-PCR), digital PCR, nanopore sequencing, chips and combinations thereof. The detection and quantification of alleles or paralogs can be carried out using the "closed-tube" methods described in U.S. patent application Ser. No. 11/950,395, filed on Dec. 4, 2007. In some embodiments the amount of a nucleic acid species is determined by mass spectrometry, primer extension, sequencing (e.g., any suitable method, for example nanopore or pyrosequencing), Quantitative PCR (Q-

PCR or QRT-PCR), digital PCR, combinations thereof, and the like.

[00173] The term "sequence analysis" as used herein refers to determining a nucleotide sequence, e.g., that of an amplification product. The entire sequence or a partial sequence of a polynucleotide, e.g., DNA or mRNA, can be determined, and the determined nucleotide sequence can be referred to as a "read" or "sequence read." For example, linear amplification products may be analyzed directly without further amplification in some embodiments (e.g., by using single -molecule sequencing methodology). In certain embodiments, linear amplification products may be subject to further amplification and then analyzed (e.g., using sequencing by ligation or pyrosequencing methodology). Reads may be subject to different types of sequence analysis. Any suitable sequencing method can be used to detect, and determine the amount of, nucleotide sequence species, amplified nucleic acid species, or detectable products generated from the foregoing. Examples of certain sequencing methods are described hereafter.

[00174] A sequence analysis apparatus or sequence analysis component(s) includes an apparatus, and one or more components used in conjunction with such apparatus, that can be used by a person of ordinary skill to determine a nucleotide sequence resulting from processes described herein (e.g., linear and/or exponential amplification products). Examples of sequencing platforms include, without limitation, the 454 platform (Roche) (Margulies, M. et al. 2005 Nature 437, 376-380), Illumina Genomic Analyzer (or Solexa platform) or SOLID System (Applied Biosystems; see PCT patent application publications WO 06/084132 entitled "Reagents, Methods, and Libraries For Bead-Based Sequencing" and WO07/121,489 entitled "Reagents, Methods, and Libraries for Gel-Free Bead-Based Sequencing"), the Helicos True Single Molecule DNA sequencing technology (Harris TD et al. 2008 Science, 320, 106-109), the single molecule, real-time (SMRT™) technology of Pacific Biosciences, and nanopore sequencing (Soni G V and Meller A. 2007 Clin Chem 53: 1996-2001), Ion semiconductor sequencing (Ion Torrent Systems, Inc, San Francisco, CA), or DNA nanoball sequencing (Complete Genomics, Mountain View, CA), VisiGen Biotechnologies approach (Invitrogen) and polony sequencing. Such platforms allow sequencing of many nucleic acid molecules isolated from a specimen at high orders of multiplexing in a parallel manner (Dear Brief Funct Genomic Proteomic 2003; 1: 397-416; Haimovich, Methods, challenges, and promise of next- generation sequencing in cancer biology. Yale J Biol Med. 2011 Dec;84(4):439-46). These non-Sanger- based sequencing technologies are sometimes referred to as NextGen sequencing, NGS, next-generation sequencing, next generation sequencing, and variations thereof. Typically they allow much higher throughput than the traditional Sanger approach. See Schuster, Next-generation sequencing transforms today's biology, Nature Methods 5: 16-18 (2008); Metzker, Sequencing technologies - the next generation. Nat Rev Genet. 2010 Jan; 11(1):31-46. These platforms can allow sequencing of clonally expanded or non-amplified single molecules of nucleic acid fragments. Certain platforms involve, for example, sequencing by ligation of dye-modified probes (including cyclic ligation and cleavage), pyrosequencing, and single-molecule sequencing. Nucleotide sequence species, amplification nucleic acid species and detectable products generated there from can be analyzed by such sequence analysis platforms. Next- generation sequencing can be used in the methods of the invention, e.g., to determine mutations, copy number, or expression levels, as appropriate. The methods can be used to perform whole genome sequencing or sequencing of specific sequences of interest, such as a gene of interest or a fragment thereof.

[00175] Sequencing by ligation is a nucleic acid sequencing method that relies on the sensitivity of DNA ligase to base-pairing mismatch. DNA ligase joins together ends of DNA that are correctly base paired. Combining the ability of DNA ligase to join together only correctly base paired DNA ends, with mixed pools of fluorescently labeled oligonucleotides or primers, enables sequence determination by fluorescence detection. Longer sequence reads may be obtained by including primers containing cleavable linkages that can be cleaved after label identification. Cleavage at the linker removes the label and regenerates the 5' phosphate on the end of the ligated primer, preparing the primer for another round of ligation. In some embodiments primers may be labeled with more than one fluorescent label, e.g., at least

1, 2, 3, 4, or 5 fluorescent labels.

[00176] Sequencing by ligation generally involves the following steps. Clonal bead populations can be prepared in emulsion microreactors containing target nucleic acid template sequences, amplification reaction components, beads and primers. After amplification, templates are denatured and bead enrichment is performed to separate beads with extended templates from undesired beads (e.g., beads with no extended templates). The template on the selected beads undergoes a 3' modification to allow covalent bonding to the slide, and modified beads can be deposited onto a glass slide. Deposition chambers offer the ability to segment a slide into one, four or eight chambers during the bead loading process. For sequence analysis, primers hybridize to the adapter sequence. A set of four color dye-labeled probes competes for ligation to the sequencing primer. Specificity of probe ligation is achieved by interrogating every 4th and 5th base during the ligation series. Five to seven rounds of ligation, detection and cleavage record the color at every 5th position with the number of rounds determined by the type of library used. Following each round of ligation, a new complimentary primer offset by one base in the 5' direction is laid down for another series of ligations. Primer reset and ligation rounds (5-7 ligation cycles per round) are repeated sequentially five times to generate 25-35 base pairs of sequence for a single tag. With mate- paired sequencing, this process is repeated for a second tag.

[00177] Pyrosequencing is a nucleic acid sequencing method based on sequencing by synthesis, which relies on detection of a pyrophosphate released on nucleotide incorporation. Generally, sequencing by synthesis involves synthesizing, one nucleotide at a time, a DNA strand complimentary to the strand whose sequence is being sought. Target nucleic acids may be immobilized to a solid support, hybridized with a sequencing primer, incubated with DNA polymerase, ATP sulfurylase, luciferase, apyrase, adenosine 5' phosphosulfate and luciferin. Nucleotide solutions are sequentially added and removed. Correct incorporation of a nucleotide releases a pyrophosphate, which interacts with ATP sulfurylase and produces ATP in the presence of adenosine 5' phosphosulfate, fueling the luciferin reaction, which produces a chemilumine scent signal allowing sequence determination. The amount of light generated is proportional to the number of bases added. Accordingly, the sequence downstream of the sequencing primer can be determined. An illustrative system for pyrosequencing involves the following steps: ligating an adaptor nucleic acid to a nucleic acid under investigation and hybridizing the resulting nucleic acid to a bead; amplifying a nucleotide sequence in an emulsion; sorting beads using a picoliter multiwell solid support; and sequencing amplified nucleotide sequences by pyrosequencing methodology (e.g., Nakano et al., "Single-molecule PCR using water-in-oil emulsion;" Journal of Biotechnology 102: 1 17-124 (2003)).

[00178] Certain single-molecule sequencing embodiments are based on the principal of sequencing by synthesis, and use single-pair Fluorescence Resonance Energy Transfer (single pair FRET) as a mechanism by which photons are emitted as a result of successful nucleotide incorporation. The emitted photons often are detected using intensified or high sensitivity cooled charge-couple-devices in conjunction with total internal reflection microscopy (TIRM). Photons are only emitted when the introduced reaction solution contains the correct nucleotide for incorporation into the growing nucleic acid chain that is synthesized as a result of the sequencing process. In FRET based single-molecule sequencing, energy is transferred between two fluorescent dyes, sometimes polymethine cyanine dyes Cy3 and Cy5, through long-range dipole interactions. The donor is excited at its specific excitation wavelength and the excited state energy is transferred, non-radiatively to the acceptor dye, which in turn becomes excited. The acceptor dye eventually returns to the ground state by radiative emission of a photon. The two dyes used in the energy transfer process represent the "single pair" in single pair FRET. Cy3 often is used as the donor fluorophore and often is incorporated as the first labeled nucleotide. Cy5 often is used as the acceptor fluorophore and is used as the nucleotide label for successive nucleotide additions after incorporation of a first Cy3 labeled nucleotide. The fluorophores generally are within 10 nanometers of each for energy transfer to occur successfully.

[00179] An example of a system that can be used based on single-molecule sequencing generally involves hybridizing a primer to a target nucleic acid sequence to generate a complex; associating the complex with a solid phase; iteratively extending the primer by a nucleotide tagged with a fluorescent molecule; and capturing an image of fluorescence resonance energy transfer signals after each iteration (e.g., U.S. Pat. No. 7,169,314; Braslavsky et al, PNAS 100(7): 3960-3964 (2003)). Such a system can be used to directly sequence amplification products (linearly or exponentially amplified products) generated by processes described herein. In some embodiments the amplification products can be hybridized to a primer that contains sequences complementary to immobilized capture sequences present on a solid support, a bead or glass slide for example. Hybridization of the primer-amplification product complexes with the immobilized capture sequences, immobilizes amplification products to solid supports for single pair FRET based sequencing by synthesis. The primer often is fluorescent, so that an initial reference image of the surface of the slide with immobilized nucleic acids can be generated. The initial reference image is useful for determining locations at which true nucleotide incorporation is occurring. Fluorescence signals detected in array locations not initially identified in the "primer only" reference image are discarded as non-specific fluorescence. Following immobilization of the primer-amplification product complexes, the bound nucleic acids often are sequenced in parallel by the iterative steps of, a) polymerase extension in the presence of one fluorescently labeled nucleotide, b) detection of fluorescence using appropriate microscopy, TIRM for example, c) removal of fluorescent nucleotide, and d) return to step a with a different fluorescently labeled nucleotide.

[00180] In some embodiments, nucleotide sequencing may be by solid phase single nucleotide sequencing methods and processes. Solid phase single nucleotide sequencing methods involve contacting target nucleic acid and solid support under conditions in which a single molecule of sample nucleic acid hybridizes to a single molecule of a solid support. Such conditions can include providing the solid support molecules and a single molecule of target nucleic acid in a "microreactor." Such conditions also can include providing a mixture in which the target nucleic acid molecule can hybridize to solid phase nucleic acid on the solid support. Single nucleotide sequencing methods useful in the embodiments described herein are described in U.S. Provisional Patent Application Ser. No. 61/021,871 filed Jan. 17, 2008. [00181] In certain embodiments, nanopore sequencing detection methods include (a) contacting a target nucleic acid for sequencing ("base nucleic acid," e.g., linked probe molecule) with sequence -specific detectors, under conditions in which the detectors specifically hybridize to substantially complementary subsequences of the base nucleic acid; (b) detecting signals from the detectors and (c) determining the sequence of the base nucleic acid according to the signals detected. In certain embodiments, the detectors hybridized to the base nucleic acid are disassociated from the base nucleic acid (e.g., sequentially dissociated) when the detectors interfere with a nanopore structure as the base nucleic acid passes through a pore, and the detectors disassociated from the base sequence are detected. In some embodiments, a detector disassociated from a base nucleic acid emits a detectable signal, and the detector hybridized to the base nucleic acid emits a different detectable signal or no detectable signal. In certain embodiments, nucleotides in a nucleic acid (e.g., linked probe molecule) are substituted with specific nucleotide sequences corresponding to specific nucleotides ("nucleotide representatives"), thereby giving rise to an expanded nucleic acid (e.g., U.S. Pat. No. 6,723,513), and the detectors hybridize to the nucleotide representatives in the expanded nucleic acid, which serves as a base nucleic acid. In such embodiments, nucleotide representatives may be arranged in a binary or higher order arrangement (e.g., Soni and Meller, Clinical Chemistry 53(1 1): 1996-2001 (2007)). In some embodiments, a nucleic acid is not expanded, does not give rise to an expanded nucleic acid, and directly serves a base nucleic acid (e.g., a linked probe molecule serves as a non-expanded base nucleic acid), and detectors are directly contacted with the base nucleic acid. For example, a first detector may hybridize to a first subsequence and a second detector may hybridize to a second subsequence, where the first detector and second detector each have detectable labels that can be distinguished from one another, and where the signals from the first detector and second detector can be distinguished from one another when the detectors are disassociated from the base nucleic acid. In certain embodiments, detectors include a region that hybridizes to the base nucleic acid (e.g., two regions), which can be about 3 to about 100 nucleotides in length (e.g., about 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95 nucleotides in length). A detector also may include one or more regions of nucleotides that do not hybridize to the base nucleic acid. In some embodiments, a detector is a molecular beacon. A detector often comprises one or more detectable labels independently selected from those described herein. Each detectable label can be detected by any convenient detection process capable of detecting a signal generated by each label (e.g., magnetic, electric, chemical, optical and the like). For example, a CD camera can be used to detect signals from one or more distinguishable quantum dots linked to a detector.

[00182] In certain sequence analysis embodiments, reads may be used to construct a larger nucleotide sequence, which can be facilitated by identifying overlapping sequences in different reads and by using identification sequences in the reads. Such sequence analysis methods and software for constructing larger sequences from reads are known to the person of ordinary skill (e.g., Venter et al., Science 291 : 1304- 1351 (2001)). Specific reads, partial nucleotide sequence constructs, and full nucleotide sequence constructs may be compared between nucleotide sequences within a sample nucleic acid (i.e., internal comparison) or may be compared with a reference sequence (i.e., reference comparison) in certain sequence analysis embodiments. Internal comparisons can be performed in situations where a sample nucleic acid is prepared from multiple samples or from a single sample source that contains sequence variations. Reference comparisons sometimes are performed when a reference nucleotide sequence is known and an objective is to determine whether a sample nucleic acid contains a nucleotide sequence that is substantially similar or the same, or different, than a reference nucleotide sequence. Sequence analysis can be facilitated by the use of sequence analysis apparatus and components described above.

[00183] Primer extension polymorphism detection methods, also referred to herein as "microsequencing" methods, typically are carried out by hybridizing a complementary oligonucleotide to a nucleic acid carrying the polymorphic site. In these methods, the oligonucleotide typically hybridizes adjacent to the polymorphic site. The term "adjacent" as used in reference to "microsequencing" methods, refers to the 3' end of the extension oligonucleotide being sometimes 1 nucleotide from the 5' end of the polymorphic site, often 2 or 3, and at times 4, 5, 6, 7, 8, 9, or 10 nucleotides from the 5' end of the polymorphic site, in the nucleic acid when the extension oligonucleotide is hybridized to the nucleic acid. The extension oligonucleotide then is extended by one or more nucleotides, often 1, 2, or 3 nucleotides, and the number and/or type of nucleotides that are added to the extension oligonucleotide determine which polymorphic variant or variants are present. Oligonucleotide extension methods are disclosed, for example, in U.S. Pat. Nos. 4,656, 127; 4,851,331; 5,679,524; 5,834, 189; 5,876,934; 5,908,755; 5,912, 118; 5,976,802; 5,981, 186; 6,004,744; 6,013,431; 6,017,702; 6,046,005; 6,087,095; 6,210,891; and WO 01/20039. The extension products can be detected in any manner, such as by fluorescence methods (see, e.g., Chen & Kwok, Nucleic Acids Research 25: 347-353 (1997) and Chen et al., Proc. Natl. Acad. Sci. USA 94/20: 10756- 10761 (1997)) or by mass spectrometric methods (e.g., MALDI-TOF mass spectrometry) and other methods described herein. Oligonucleotide extension methods using mass spectrometry are described, for example, in U.S. Pat. Nos. 5,547,835; 5,605,798; 5,691, 141; 5,849,542; 5,869,242; 5,928,906; 6,043,031; 6,194, 144; and 6,258,538.

Microsequencing detection methods often incorporate an amplification process that proceeds the extension step. The amplification process typically amplifies a region from a nucleic acid sample that comprises the polymorphic site. Amplification can be carried out using methods described above, or for example using a pair of oligonucleotide primers in a polymerase chain reaction (PCR), in which one oligonucleotide primer typically is complementary to a region 3' of the polymorphism and the other typically is complementary to a region 5' of the polymorphism. A PCR primer pair may be used in methods disclosed in U.S. Pat. Nos. 4,683, 195; 4,683,202, 4,965,188; 5,656,493; 5,998,143; 6,140,054; WO 01/27327; and WO 01/27329 for example. PCR primer pairs may also be used in any commercially available machines that perform PCR, such as any of the GeneAmp™ Systems available from Applied Biosystems.

[00184] Other appropriate sequencing methods include multiplex polony sequencing (as described in Shendure et al., Accurate Multiplex Polony Sequencing of an Evolved Bacterial Genome, Sciencexpress, Aug. 4, 2005, pg 1 available at www.sciencexpress.org/4 Aug. 2005/Pagel/10.1126/science.1117389, incorporated herein by reference), which employs immobilized microbeads, and sequencing in microfabricated picoliter reactors (as described in Margulies et al, Genome Sequencing in

Microfabricated High-Density Picolitre Reactors, Nature, August 2005, available at

www.nature.com/nature (published online 31 Jul. 2005, doi: 10.1038/nature03959, incorporated herein by reference).

[00185] Whole genome sequencing may also be used for discriminating alleles of RNA transcripts, in some embodiments. Examples of whole genome sequencing methods include, but are not limited to, nanopore -based sequencing methods, sequencing by synthesis and sequencing by ligation, as described above.

[00186] Nucleic acid variants can also be detected using standard electrophoretic techniques. Although the detection step can sometimes be preceded by an amplification step, amplification is not required in the embodiments described herein. Examples of methods for detection and quantification of a nucleic acid using electrophoretic techniques can be found in the art. A non-limiting example comprises running a sample (e.g., mixed nucleic acid sample isolated from maternal serum, or amplification nucleic acid species, for example) in an agarose or polyacrylamide gel. The gel may be labeled (e.g., stained) with ethidium bromide (see, Sambrook and Russell, Molecular Cloning: A Laboratory Manual 3d ed., 2001). The presence of a band of the same size as the standard control is an indication of the presence of a target nucleic acid sequence, the amount of which may then be compared to the control based on the intensity of the band, thus detecting and quantifying the target sequence of interest. In some embodiments, restriction enzymes capable of distinguishing between maternal and paternal alleles may be used to detect and quantify target nucleic acid species. In certain embodiments, oligonucleotide probes specific to a sequence of interest are used to detect the presence of the target sequence of interest. The oligonucleotides can also be used to indicate the amount of the target nucleic acid molecules in comparison to the standard control, based on the intensity of signal imparted by the probe.

[00187] Sequence-specific probe hybridization can be used to detect a particular nucleic acid in a mixture or mixed population comprising other species of nucleic acids. Under sufficiently stringent hybridization conditions, the probes hybridize specifically only to substantially complementary sequences. The stringency of the hybridization conditions can be relaxed to tolerate varying amounts of sequence mismatch. A number of hybridization formats are known in the art, which include but are not limited to, solution phase, solid phase, or mixed phase hybridization assays. The following articles provide an overview of the various hybridization assay formats: Singer et al., Biotechniques 4:230, 1986; Haase et al., Methods in Virology, pp. 189-226, 1984; Wilkinson, In situ Hybridization, Wilkinson ed., IRL Press, Oxford University Press, Oxford; and Hames and Higgins eds., Nucleic Acid Hybridization: A Practical Approach, IRL Press, 1987.

[00188] Hybridization complexes can be detected by techniques known in the art. Nucleic acid probes capable of specifically hybridizing to a target nucleic acid (e.g., mRNA or DNA) can be labeled by any suitable method, and the labeled probe used to detect the presence of hybridized nucleic acids. One commonly used method of detection is autoradiography, using probes labeled with 3 H, 125 I, 35 S, 14 C, 32 P, ³³P, or the like. The choice of radioactive isotope depends on research preferences due to ease of synthesis, stability, and half-lives of the selected isotopes. Other labels include compounds (e.g., biotin and digoxigenin), which bind to antiligands or antibodies labeled with fluorophores, chemiluminescent agents, and enzymes. In some embodiments, probes can be conjugated directly with labels such as fluorophores, chemiluminescent agents or enzymes. The choice of label depends on sensitivity required, ease of conjugation with the probe, stability requirements, and available instrumentation.

[00189] In embodiments, fragment analysis (referred to herein as "FA") methods are used for molecular profiling. Fragment analysis (FA) includes techniques such as restriction fragment length polymorphism (RFLP) and/or (amplified fragment length polymorphism). If a nucleotide variant in the target DNA corresponding to the one or more genes results in the elimination or creation of a restriction enzyme recognition site, then digestion of the target DNA with that particular restriction enzyme will generate an altered restriction fragment length pattern. Thus, a detected RFLP or AFLP will indicate the presence of a particular nucleotide variant.

[00190] Terminal restriction fragment length polymorphism (TRFLP) works by PCR amplification of DNA using primer pairs that have been labeled with fluorescent tags. The PCR products are digested using RFLP enzymes and the resulting patterns are visualized using a DNA sequencer. The results are analyzed either by counting and comparing bands or peaks in the TRFLP profile, or by comparing bands from one or more TRFLP runs in a database.

[00191] The sequence changes directly involved with an RFLP can also be analyzed more quickly by PCR. Amplification can be directed across the altered restriction site, and the products digested with the restriction enzyme. This method has been called Cleaved Amplified Polymorphic Sequence (CAPS). Alternatively, the amplified segment can be analyzed by Allele specific oligonucleotide (ASO) probes, a process that is sometimes assessed using a Dot blot.

[00192] A variation on AFLP is cDNA-AFLP, which can be used to quantify differences in gene expression levels.

[00193] Another useful approach is the single-stranded conformation polymorphism assay (SSCA), which is based on the altered mobility of a single -stranded target DNA spanning the nucleotide variant of interest. A single nucleotide change in the target sequence can result in different intramolecular base pairing pattern, and thus different secondary structure of the single-stranded DNA, which can be detected in a non-denaturing gel. See Orita et al., Proc. Natl. Acad. Sci. USA, 86:2776-2770 (1989). Denaturing gel-based techniques such as clamped denaturing gel electrophoresis (CDGE) and denaturing gradient gel electrophoresis (DGGE) detect differences in migration rates of mutant sequences as compared to wild- type sequences in denaturing gel. See Miller et al, Biotechniques, 5: 1016-24 (1999); Sheffield et al., Am. J. Hum, Genet., 49:699-706 (1991); Wartell et al., Nucleic Acids Res., 18:2699-2705 (1990); and Sheffield et al., Proc. Natl. Acad. Sci. USA, 86:232-236 (1989). In addition, the double-strand conformation analysis (DSCA) can also be useful in the present invention. See Arguello et al, Nat.

Genet, 18: 192-194 (1998).

[00194] The presence or absence of a nucleotide variant at a particular locus in the one or more genes of an individual can also be detected using the amplification refractory mutation system (ARMS) technique. See e.g., European Patent No. 0,332,435; Newton et al., Nucleic Acids Res., 17:2503-2515 (1989); Fox et al., Br. J. Cancer, 77: 1267-1274 (1998); Robertson et al., Eur. Respir. J., 12:477-482 (1998). In the ARMS method, a primer is synthesized matching the nucleotide sequence immediately 5' upstream from the locus being tested except that the 3 '-end nucleotide which corresponds to the nucleotide at the locus is a predetermined nucleotide. For example, the 3'-end nucleotide can be the same as that in the mutated locus. The primer can be of any suitable length so long as it hybridizes to the target DNA under stringent conditions only when its 3'-end nucleotide matches the nucleotide at the locus being tested. Preferably the primer has at least 12 nucleotides, more preferably from about 18 to 50 nucleotides. If the individual tested has a mutation at the locus and the nucleotide therein matches the 3 '-end nucleotide of the primer, then the primer can be further extended upon hybridizing to the target DNA template, and the primer can initiate a PCR amplification reaction in conjunction with another suitable PCR primer. In contrast, if the nucleotide at the locus is of wild type, then primer extension cannot be achieved. Various forms of ARMS techniques developed in the past few years can be used. See e.g., Gibson et al., Clin. Chem. 43: 1336-1341 (1997).

[00195] Similar to the ARMS technique is the mini sequencing or single nucleotide primer extension method, which is based on the incorporation of a single nucleotide. An oligonucleotide primer matching the nucleotide sequence immediately 5' to the locus being tested is hybridized to the target DNA, mRNA or miRNA in the presence of labeled dideoxyribonucleotides. A labeled nucleotide is incorporated or linked to the primer only when the dideoxyribonucleotides matches the nucleotide at the variant locus being detected. Thus, the identity of the nucleotide at the variant locus can be revealed based on the detection label attached to the incorporated dideoxyribonucleotides. See Syvanen et al, Genomics, 8:684- 692 (1990); Shumaker et al., Hum. Muta , 7:346-354 (1996); Chen et al., Genome Res., 10:549-547 (2000).

[00196] Another set of techniques useful in the present invention is the so-called "oligonucleotide ligation assay" (OLA) in which differentiation between a wild-type locus and a mutation is based on the ability of two oligonucleotides to anneal adjacent to each other on the target DNA molecule allowing the two oligonucleotides joined together by a DNA ligase. See Landergren et al., Science, 241 : 1077-1080 (1988); Chen et al, Genome Res., 8:549-556 (1998); Iannone et al., Cytometry, 39: 131-140 (2000). Thus, for example, to detect a single-nucleotide mutation at a particular locus in the one or more genes, two oligonucleotides can be synthesized, one having the sequence just 5' upstream from the locus with its 3' end nucleotide being identical to the nucleotide in the variant locus of the particular gene, the other having a nucleotide sequence matching the sequence immediately 3' downstream from the locus in the gene. The oligonucleotides can be labeled for the purpose of detection. Upon hybridizing to the target gene under a stringent condition, the two oligonucleotides are subject to ligation in the presence of a suitable ligase. The ligation of the two oligonucleotides would indicate that the target DNA has a nucleotide variant at the locus being detected.

[00197] Detection of small genetic variations can also be accomplished by a variety of hybridization- based approaches. Allele-specific oligonucleotides are most useful. See Conner et al., Proc. Natl. Acad. Sci. USA, 80:278-282 (1983); Saiki et al, Proc. Natl. Acad. Sci. USA, 86:6230-6234 (1989).

Oligonucleotide probes (allele-specific) hybridizing specifically to a gene allele having a particular gene variant at a particular locus but not to other alleles can be designed by methods known in the art. The probes can have a length of, e.g., from 10 to about 50 nucleotide bases. The target DNA and the oligonucleotide probe can be contacted with each other under conditions sufficiently stringent such that the nucleotide variant can be distinguished from the wild-type gene based on the presence or absence of hybridization. The probe can be labeled to provide detection signals. Alternatively, the allele-specific oligonucleotide probe can be used as a PCR amplification primer in an "allele-specific PCR" and the presence or absence of a PCR product of the expected length would indicate the presence or absence of a particular nucleotide variant.

[00198] Other useful hybridization-based techniques allow two single-stranded nucleic acids annealed together even in the presence of mismatch due to nucleotide substitution, insertion or deletion. The mismatch can then be detected using various techniques. For example, the annealed duplexes can be subject to electrophoresis. The mismatched duplexes can be detected based on their electrophoretic mobility that is different from the perfectly matched duplexes. See Cariello, Human Genetics, 42:726 (1988). Alternatively, in an RNase protection assay, a RNA probe can be prepared spanning the nucleotide variant site to be detected and having a detection marker. See Giunta et al., Diagn. Mol. Path., 5:265-270 (1996); Finkelstein et al., Genomics, 7: 167-172 (1990); Kinszler et al., Science 251 : 1366-1370 (1991). The RNA probe can be hybridized to the target DNA or mRNA forming a heteroduplex that is then subject to the ribonuclease RNase A digestion. RNase A digests the RNA probe in the heteroduplex only at the site of mismatch. The digestion can be determined on a denaturing electrophoresis gel based on size variations. In addition, mismatches can also be detected by chemical cleavage methods known in the art. See e.g., Roberts et al, Nucleic Acids Res., 25:3377-3378 (1997).

[00199] In the mutS assay, a probe can be prepared matching the gene sequence surrounding the locus at which the presence or absence of a mutation is to be detected, except that a predetermined nucleotide is used at the variant locus. Upon annealing the probe to the target DNA to form a duplex, the E. coli mutS protein is contacted with the duplex. Since the mutS protein binds only to heteroduplex sequences containing a nucleotide mismatch, the binding of the mutS protein will be indicative of the presence of a mutation. See Modrich et al., Ann. Rev. Genet., 25:229-253 (1991).

[00200] A great variety of improvements and variations have been developed in the art on the basis of the above-described basic techniques which can be useful in detecting mutations or nucleotide variants in the present invention. For example, the "sunrise probes" or "molecular beacons" use the fluorescence resonance energy transfer (FRET) property and give rise to high sensitivity. See Wolf et al, Proc. Nat. Acad. Sci. USA, 85:8790-8794 (1988). Typically, a probe spanning the nucleotide locus to be detected are designed into a hairpin-shaped structure and labeled with a quenching fluorophore at one end and a reporter fluorophore at the other end. In its natural state, the fluorescence from the reporter fluorophore is quenched by the quenching fluorophore due to the proximity of one fluorophore to the other. Upon hybridization of the probe to the target DNA, the 5' end is separated apart from the 3 '-end and thus fluorescence signal is regenerated. See Nazarenko et al., Nucleic Acids Res., 25:2516-2521 (1997);

Rychlik et al., Nucleic Acids Res., 17:8543-8551 (1989); Sharkey et al, Bio/Technology 12:506-509 (1994); Tyagi et al, Nat. Biotechnol., 14:303-308 (1996); Tyagi et al., Nat. Biotechnol., 16:49-53 (1998). The homo-tag assisted non-dimer system (HANDS) can be used in combination with the molecular beacon methods to suppress primer-dimer accumulation. See Brownie et al., Nucleic Acids Res., 25:3235- 3241 (1997).

[00201] Dye-labeled oligonucleotide ligation assay is a FRET-based method, which combines the OLA assay and PCR. See Chen et al., Genome Res. 8:549-556 (1998). TaqMan is another FRET-based method for detecting nucleotide variants. A TaqMan probe can be oligonucleotides designed to have the nucleotide sequence of the gene spanning the variant locus of interest and to differentially hybridize with different alleles. The two ends of the probe are labeled with a quenching fluorophore and a reporter fluorophore, respectively. The TaqMan probe is incorporated into a PCR reaction for the amplification of a target gene region containing the locus of interest using Taq polymerase. As Taq polymerase exhibits 5'- 3' exonuclease activity but has no 3 '-5' exonuclease activity, if the TaqMan probe is annealed to the target DNA template, the 5'-end of the TaqMan probe will be degraded by Taq polymerase during the PCR reaction thus separating the reporting fluorophore from the quenching fluorophore and releasing fluorescence signals. See Holland et al, Proc. Natl. Acad. Sci. USA, 88:7276-7280 (1991); Kalinina et al., Nucleic Acids Res., 25: 1999-2004 (1997); Whitcombe et al, Clin. Chem., 44:918-923 (1998).

[00202] In addition, the detection in the present invention can also employ a chemiluminescence-based technique. For example, an oligonucleotide probe can be designed to hybridize to either the wild-type or a variant gene locus but not both. The probe is labeled with a highly chemiluminescent acridinium ester. Hydrolysis of the acridinium ester destroys chemiluminescence. The hybridization of the probe to the target DNA prevents the hydrolysis of the acridinium ester. Therefore, the presence or absence of a particular mutation in the target DNA is determined by measuring chemiluminescence changes. See Nelson et al., Nucleic Acids Res., 24:4998-5003 (1996).

[00203] The detection of genetic variation in the gene in accordance with the present invention can also be based on the "base excision sequence scanning" (BESS) technique. The BESS method is a PCR-based mutation scanning method. BESS T-Scan and BESS G-Tracker are generated which are analogous to T and G ladders of dideoxy sequencing. Mutations are detected by comparing the sequence of normal and mutant DNA. See, e.g., Hawkins et al, Electrophoresis, 20: 1171-1176 (1999).

[00204] Mass spectrometry can be used for molecular profiling according to the invention. See Graber et al., Curr. Opin. Biotechnol., 9: 14-18 (1998). For example, in the primer oligo base extension (PROBE™) method, a target nucleic acid is immobilized to a solid-phase support. A primer is annealed to the target immediately 5' upstream from the locus to be analyzed. Primer extension is carried out in the presence of a selected mixture of deoxyribonucleotides and dideoxyribonucleotides. The resulting mixture of newly extended primers is then analyzed by MALDI-TOF. See e.g., Monforte et al, Nat. Med., 3:360-362 (1997). [00205] In addition, the microchip or microarray technologies are also applicable to the detection method of the present invention. Essentially, in microchips, a large number of different oligonucleotide probes are immobilized in an array on a substrate or carrier, e.g., a silicon chip or glass slide. Target nucleic acid sequences to be analyzed can be contacted with the immobilized oligonucleotide probes on the microchip. See Lipshutz et al, Biotechniques, 19:442-447 (1995); Chee et al., Science, 274:610-614 (1996); Kozal et al., Nat. Med. 2:753-759 (1996); Hacia et al., Nat. Genet., 14:441-447 (1996); Saiki et al., Proc. Natl. Acad. Sci. USA, 86:6230-6234 (1989); Gingeras et al., Genome Res., 8:435-448 (1998). Alternatively, the multiple target nucleic acid sequences to be studied are fixed onto a substrate and an array of probes is contacted with the immobilized target sequences. See Drmanac et al., Nat. Biotechnol., 16:54-58 (1998). Numerous microchip technologies have been developed incorporating one or more of the above described techniques for detecting mutations. The microchip technologies combined with computerized analysis tools allow fast screening in a large scale. The adaptation of the microchip technologies to the present invention will be apparent to a person of skill in the art apprised of the present disclosure. See, e.g., U.S. Pat. No. 5,925,525 to Fodor et al; Wilgenbus et al., J. Mol. Med., 77:761-786 (1999); Graber et al, Curr. Opin. Biotechnol., 9: 14-18 (1998); Hacia et al., Nat. Genet, 14:441-447 (1996); Shoemaker et al., Nat. Genet, 14:450-456 (1996); DeRisi et al., Nat. Genet., 14:457-460 (1996); Chee et al., Nat. Genet., 14:610-614 (1996); Lockhart et al, Nat. Genet., 14:675-680 (1996); Drobyshev et al, Gene, 188:45-52 (1997).

[00206] As is apparent from the above survey of the suitable detection techniques, it may or may not be necessary to amplify the target DNA, i.e., the gene, cDNA, mRNA, miRNA, or a portion thereof to increase the number of target DNA molecule, depending on the detection techniques used. For example, most PCR-based techniques combine the amplification of a portion of the target and the detection of the mutations. PCR amplification is well known in the art and is disclosed in U.S. Pat. Nos. 4,683, 195 and 4,800, 159, both which are incorporated herein by reference. For non-PCR-based detection techniques, if necessary, the amplification can be achieved by, e.g., in vivo plasmid multiplication, or by purifying the target DNA from a large amount of tissue or cell samples. See generally, Sambrook et al, Molecular Cloning: A Laboratory Manual, 2^nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989. However, even with scarce samples, many sensitive techniques have been developed in which small genetic variations such as single -nucleotide substitutions can be detected without having to amplify the target DNA in the sample. For example, techniques have been developed that amplify the signal as opposed to the target DNA by, e.g., employing branched DNA or dendrimers that can hybridize to the target DNA. The branched or dendrimer DNAs provide multiple hybridization sites for hybridization probes to attach thereto thus amplifying the detection signals. See Detmer et al., J. Clin. Microbiol., 34:901-907 (1996); Collins et al, Nucleic Acids Res., 25:2979-2984 (1997); Horn et al, Nucleic Acids Res., 25:4835-4841 (1997); Horn et al., Nucleic Acids Res., 25:4842-4849 (1997); Nilsen et al., J. Theor. Biol., 187:273-284 (1997).

[00207] The Invader™ assay is another technique for detecting single nucleotide variations that can be used for molecular profiling according to the invention. The Invader™ assay uses a novel linear signal amplification technology that improves upon the long turnaround times required of the typical PCR DNA sequenced-based analysis. See Cooksey et al., Antimicrobial Agents and Chemotherapy 44: 1296-1301 (2000). This assay is based on cleavage of a unique secondary structure formed between two overlapping oligonucleotides that hybridize to the target sequence of interest to form a "flap." Each "flap" then generates thousands of signals per hour. Thus, the results of this technique can be easily read, and the methods do not require exponential amplification of the DNA target. The Invader™ system uses two short DNA probes, which are hybridized to a DNA target. The structure formed by the hybridization event is recognized by a special cleavase enzyme that cuts one of the probes to release a short DNA "flap." Each released "flap" then binds to a fluorescently-labeled probe to form another cleavage structure. When the cleavase enzyme cuts the labeled probe, the probe emits a detectable fluorescence signal. See e.g.

Lyamichev et al, Nat. Biotechnol, 17:292-296 (1999).

[00208] The rolling circle method is another method that avoids exponential amplification. Lizardi et al., Nature Genetics, 19:225-232 (1998) (which is incorporated herein by reference). For example, Sniper™, a commercial embodiment of this method, is a sensitive, high-throughput SNP scoring system designed for the accurate fluorescent detection of specific variants. For each nucleotide variant, two linear, allele- specific probes are designed. The two allele-specific probes are identical with the exception of the 3'-base, which is varied to complement the variant site. In the first stage of the assay, target DNA is denatured and then hybridized with a pair of single, allele-specific, open-circle oligonucleotide probes. When the 3'-base exactly complements the target DNA, ligation of the probe will preferentially occur. Subsequent detection of the circularized oligonucleotide probes is by rolling circle amplification, whereupon the amplified probe products are detected by fluorescence. See Clark and Pickering, Life Science News 6, 2000, Amersham Pharmacia Biotech (2000).

[00209] A number of other techniques that avoid amplification all together include, e.g., surface -enhanced resonance Raman scattering (SERRS), fluorescence correlation spectroscopy, and single-molecule electrophoresis. In SERRS, a chromophore-nucleic acid conjugate is absorbed onto colloidal silver and is irradiated with laser light at a resonant frequency of the chromophore. See Graham et al., Anal. Chem., 69:4703-4707 (1997). The fluorescence correlation spectroscopy is based on the spatio-temporal correlations among fluctuating light signals and trapping single molecules in an electric field. See Eigen et al., Proc. Natl. Acad. Sci. USA, 91 :5740-5747 (1994). In single-molecule electrophoresis, the

electrophoretic velocity of a fluorescently tagged nucleic acid is determined by measuring the time required for the molecule to travel a predetermined distance between two laser beams. See Castro et al., Anal. Chem., 67:3181-3186 (1995).

[00210] In addition, the allele-specific oligonucleotides (ASO) can also be used in in situ hybridization using tissues or cells as samples. The oligonucleotide probes which can hybridize differentially with the wild-type gene sequence or the gene sequence harboring a mutation may be labeled with radioactive isotopes, fluorescence, or other detectable markers. In situ hybridization techniques are well known in the art and their adaptation to the present invention for detecting the presence or absence of a nucleotide variant in the one or more gene of a particular individual should be apparent to a skilled artisan apprised of this disclosure.

[00211] Accordingly, the presence or absence of one or more genes nucleotide variant or amino acid variant in an individual can be determined using any of the detection methods described above.

[00212] Typically, once the presence or absence of one or more gene nucleotide variants or amino acid variants is determined, physicians or genetic counselors or patients or other researchers may be informed of the result. Specifically the result can be cast in a transmittable form that can be communicated or transmitted to other researchers or physicians or genetic counselors or patients. Such a form can vary and can be tangible or intangible. The result with regard to the presence or absence of a nucleotide variant of the present invention in the individual tested can be embodied in descriptive statements, diagrams, photographs, charts, images or any other visual forms. For example, images of gel electrophoresis of PCR products can be used in explaining the results. Diagrams showing where a variant occurs in an individual's gene are also useful in indicating the testing results. The statements and visual forms can be recorded on a tangible media such as papers, computer readable media such as floppy disks, compact disks, etc., or on an intangible media, e.g., an electronic media in the form of email or website on internet or intranet. In addition, the result with regard to the presence or absence of a nucleotide variant or amino acid variant in the individual tested can also be recorded in a sound form and transmitted through any suitable media, e.g., analog or digital cable lines, fiber optic cables, etc., via telephone, facsimile, wireless mobile phone, internet phone and the like.

[00213] Thus, the information and data on a test result can be produced anywhere in the world and transmitted to a different location. For example, when a genotyping assay is conducted offshore, the information and data on a test result may be generated and cast in a transmittable form as described above. The test result in a transmittable form thus can be imported into the U.S. Accordingly, the present invention also encompasses a method for producing a transmittable form of information on the genotype of the two or more suspected cancer samples from an individual. The method comprises the steps of (1) determining the genotype of the DNA from the samples according to methods of the present invention; and (2) embodying the result of the determining step in a transmittable form. The transmittable form is the product of the production method.

In Situ Hybridization

[00214] In situ hybridization assays are well known and are generally described in Angerer et al., Methods Enzymol. 152:649-660 (1987). In an in situ hybridization assay, cells, e.g., from a biopsy, are fixed to a solid support, typically a glass slide. If DNA is to be probed, the cells are denatured with heat or alkali. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of specific probes that are labeled. The probes are preferably labeled, e.g., with radioisotopes or fluorescent reporters, or enzymatically. FISH (fluorescence in situ hybridization) uses fluorescent probes that bind to only those parts of a sequence with which they show a high degree of sequence similarity. CISH (chromogenic in situ hybridization) uses conventional peroxidase or alkaline phosphatase reactions visualized under a standard bright-field microscope. [00215] In situ hybridization can be used to detect specific gene sequences in tissue sections or cell preparations by hybridizing the complementary strand of a nucleotide probe to the sequence of interest. Fluorescent in situ hybridization (FISH) uses a fluorescent probe to increase the sensitivity of in situ hybridization.

[00216] FISH is a cytogenetic technique used to detect and localize specific polynucleotide sequences in cells. For example, FISH can be used to detect DNA sequences on chromosomes. FISH can also be used to detect and localize specific R As, e.g., mR As, within tissue samples. In FISH uses fluorescent probes that bind to specific nucleotide sequences to which they show a high degree of sequence similarity. Fluorescence microscopy can be used to find out whether and where the fluorescent probes are bound. In addition to detecting specific nucleotide sequences, e.g., translocations, fusion, breaks, duplications and other chromosomal abnormalities, FISH can help define the spatial-temporal patterns of specific gene copy number and/or gene expression within cells and tissues.

[00217] Various types of FISH probes can be used to detect chromosome translocations. Dual color, single fusion probes can be useful in detecting cells possessing a specific chromosomal translocation. The DNA probe hybridization targets are located on one side of each of the two genetic breakpoints. "Extra signal" probes can reduce the frequency of normal cells exhibiting an abnormal FISH pattern due to the random co-localization of probe signals in a normal nucleus. One large probe spans one breakpoint, while the other probe flanks the breakpoint on the other gene. Dual color, break apart probes are useful in cases where there may be multiple translocation partners associated with a known genetic breakpoint. This labeling scheme features two differently colored probes that hybridize to targets on opposite sides of a breakpoint in one gene. Dual color, dual fusion probes can reduce the number of normal nuclei exhibiting abnormal signal patterns. The probe offers advantages in detecting low levels of nuclei possessing a simple balanced translocation. Large probes span two breakpoints on different chromosomes. Such probes are available as Vysis probes from Abbott Laboratories, Abbott Park, IL.

[00218] CISH, or chromogenic in situ hybridization, is a process in which a labeled complementary DNA or RNA strand is used to localize a specific DNA or RNA sequence in a tissue specimen. CISH methodology can be used to evaluate gene amplification, gene deletion, chromosome translocation, and chromosome number. CISH can use conventional enzymatic detection methodology, e.g., horseradish peroxidase or alkaline phosphatase reactions, visualized under a standard bright-field microscope. In a common embodiment, a probe that recognizes the sequence of interest is contacted with a sample. An antibody or other binding agent that recognizes the probe, e.g., via a label carried by the probe, can be used to target an enzymatic detection system to the site of the probe. In some systems, the antibody can recognize the label of a FISH probe, thereby allowing a sample to be analyzed using both FISH and CISH detection. CISH can be used to evaluate nucleic acids in multiple settings, e.g., formalin-fixed, paraffin- embedded (FFPE) tissue, blood or bone marrow smear, metaphase chromosome spread, and/or fixed cells. In an embodiment, CISH is performed following the methodology in the SPoT-Light® HER2 CISH Kit available from Life Technologies (Carlsbad, CA) or similar CISH products available from Life

Technologies. The SPoT-Light® HER2 CISH Kit itself is FDA approved for in vitro diagnostics and can be used for molecular profiling of HER2. CISH can be used in similar applications as FISH. Thus, one of skill will appreciate that reference to molecular profiling using FISH herein can be performed using CISH, unless otherwise specified.

[00219] Silver-enhanced in situ hybridization (SISH) is similar to CISH, but with SISH the signal appears as a black coloration due to silver precipitation instead of the chromogen precipitates of CISH.

[00220] Modifications of the in situ hybridization techniques can be used for molecular profiling according to the invention. Such modifications comprise simultaneous detection of multiple targets, e.g., Dual ISH, Dual color CISH, bright field double in situ hybridization (BDISH). See e.g., the FDA approved INFORM HER2 Dual ISH DNA Probe Cocktail kit from Ventana Medical Systems, Inc.

(Tucson, AZ); DuoCISH™, a dual color CISH kit developed by Dako Denmark A/S (Denmark).

[00221] Comparative Genomic Hybridization (CGH) comprises a molecular cytogenetic method of screening tumor samples for genetic changes showing characteristic patterns for copy number changes at chromosomal and subchromosomal levels. Alterations in patterns can be classified as DNA gains and losses. CGH employs the kinetics of in situ hybridization to compare the copy numbers of different DNA or RNA sequences from a sample, or the copy numbers of different DNA or RNA sequences in one sample to the copy numbers of the substantially identical sequences in another sample. In many useful applications of CGH, the DNA or RNA is isolated from a subject cell or cell population. The comparisons can be qualitative or quantitative. Procedures are described that permit determination of the absolute copy numbers of DNA sequences throughout the genome of a cell or cell population if the absolute copy number is known or determined for one or several sequences. The different sequences are discriminated from each other by the different locations of their binding sites when hybridized to a reference genome, usually metaphase chromosomes but in certain cases interphase nuclei. The copy number information originates from comparisons of the intensities of the hybridization signals among the different locations on the reference genome. The methods, techniques and applications of CGH are known, such as described in U.S. Pat. No. 6,335,167, and in U.S. App. Ser. No. 60/804,818, the relevant parts of which are herein incorporated by reference.

[00222] In an embodiment, CGH used to compare nucleic acids between diseased and healthy tissues. The method comprises isolating DNA from disease tissues (e.g., tumors) and reference tissues (e.g., healthy tissue) and labeling each with a different "color" or fluor. The two samples are mixed and hybridized to normal metaphase chromosomes. In the case of array or matrix CGH, the hybridization mixing is done on a slide with thousands of DNA probes. A variety of detection system can be used that basically determine the color ratio along the chromosomes to determine DNA regions that might be gained or lost in the diseased samples as compared to the reference.

Molecular Profiling for Treatment Selection

[00223] The methods of the invention provide a candidate treatment selection for a subject in need thereof. Molecular profiling can be used to identify one or more candidate therapeutic agents for an individual suffering from a condition in which one or more of the biomarkers disclosed herein are targets for treatment. For example, the method can identify one or more chemotherapy treatments for a cancer. In an aspect, the invention provides a method comprising: performing at least one molecular profiling technique on at least one biomarker. Any relevant biomarker can be assessed using one or more of the molecular profiling techniques described herein or known in the art. The marker need only have some direct or indirect association with a treatment to be useful. Any relevant molecular profiling technique can be performed, such as those disclosed here. These can include without limitation, protein and nucleic acid analysis techniques. Protein analysis techniques include, by way of non-limiting examples,

immunoassays, immunohistochemistry, and mass spectrometry. Nucleic acid analysis techniques include, by way of non-limiting examples, amplification, polymerase chain amplification, hybridization, microarrays, in situ hybridization, sequencing, dye-terminator sequencing, next generation sequencing, pyrosequencing, and restriction fragment analysis.

[00224] Molecular profiling may comprise the profiling of at least one gene (or gene product) for each assay technique that is performed. Different numbers of genes can be assayed with different techniques. Any marker disclosed herein that is associated directly or indirectly with a target therapeutic can be assessed. For example, any "druggable target" comprising a target that can be modulated with a therapeutic agent such as a small molecule or binding agent such as an antibody, is a candidate for inclusion in the molecular profiling methods of the invention. The target can also be indirectly drug associated, such as a component of a biological pathway that is affected by the associated drug. The molecular profiling can be based on either the gene, e.g., DNA sequence, and/or gene product, e.g., mPvNA or protein. Such nucleic acid and/or polypeptide can be profiled as applicable as to presence or absence, level or amount, activity, mutation, sequence, haplotype, rearrangement, copy number, or other measurable characteristic. In some embodiments, a single gene and/or one or more corresponding gene products is assayed by more than one molecular profiling technique. A gene or gene product (also referred to herein as "marker" or "biomarker"), e.g., an mRNA or protein, is assessed using applicable techniques (e.g., to assess DNA, RNA, protein), including without limitation ISH, gene expression, IHC, sequencing or immunoassay. Therefore, any of the markers disclosed herein can be assayed by a single molecular profiling technique or by multiple methods disclosed herein (e.g., a single marker is profiled by one or more of IHC, ISH, sequencing, microarray, etc.). In some embodiments, at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or at least about 100 genes or gene products are profiled by at least one technique, a plurality of techniques, or using any desired combination of ISH, IHC, gene expression, gene copy, and sequencing. In some embodiments, at least about 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10,000, 1 1,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000, 30,000, 31,000, 32,000, 33,000, 34,000, 35,000, 36,000, 37,000, 38,000, 39,000, 40,000, 41,000, 42,000, 43,000, 44,000, 45,000, 46,000, 47,000, 48,000, 49,000, or at least 50,000 genes or gene products are profiled using various techniques. The number of markers assayed can depend on the technique used. For example, microarray and massively parallel sequencing lend themselves to high throughput analysis. Because molecular profiling queries molecular characteristics of the tumor itself, this approach provides information on therapies that might not otherwise be considered based on the lineage of the tumor.

[00225] In some embodiments, a sample from a subject in need thereof is profiled using methods which include but are not limited to IHC analysis, gene expression analysis, ISH analysis, and/or sequencing analysis (such as by PCR, RT-PCR, pyrosequencing, NGS) for one or more of the following: ABCC1, ABCG2, ACE2, ADA, ADH1C, ADH4, AGT, AR, AREG, ASNS, BCL2, BCRP, BDCA1, beta III tubulin, BIRC5, B-RAF, BRCAl, BRCA2, CA2, caveolin, CD20, CD25, CD33, CD52, CDA, CDKN2A, CDKN1A, CDKN1B, CDK2, CDW52, CES2, CK 14, CK 17, CK 5/6, c-KIT, c-Met, c-Myc, COX-2, Cyclin Dl, DCK, DHFR, DNMT1, DNMT3A, DNMT3B, E-Cadherin, ECGF1, EGFR, EML4-ALK fusion, EPHA2, Epiregulin, ER, ERBR2, ERCC1, ERCC3, EREG, ESR1, FLT1, folate receptor, FOLR1, FOLR2, FSHB, FSHPRHl, FSHR, FYN, GART, GNA11, GNAQ, GNRHl, GNRHRl, GSTP1, HCK, HDAC1, hENT-1, Her2/Neu, HGF, HIF1A, HIG1, HSP90, HSP90AA1, HSPCA, IGF-1R, IGFRBP, IGFRBP3, IGFRBP4, IGFRBP5, IL13RA1, IL2RA, KDR, Ki67, KIT, K-RAS, LCK, LTB, Lymphotoxin Beta Receptor, LYN, MET, MGMT, MLH1, MMR, MRP1, MS4A1, MSH2, MSH5, Myc, NFKB1, NFKB2, NFKBIA, NRAS, ODC1, OGFR, pl6, p21, p27, p53, p95, PARP-1, PDGFC, PDGFR,

PDGFRA, PDGFRB, PGP, PGR, PI3K, POLA, POLA1, PPARG, PPARGC1, PR, PTEN, PTGS2, PTPN12, RAF1, RARA, ROS1, RRM1, RRM2, RRM2B, RXRB, RXRG, SIK2, SPARC, SRC, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, Survivin, TK1, TLE3, TNF, TOPI, TOP2A, TOP2B, TS, TUBB3, TXN, TXNRD1, TYMS, VDR, VEGF, VEGFA, VEGFC, VHL, YES 1, ZAP70.

[00226] As understood by those of skill in the art, genes and proteins have developed a number of alternative names in the scientific literature. Listing of gene aliases and descriptions used herein can be found using a variety of online databases, including GeneCards® (www.genecards.org), HUGO Gene Nomenclature (www.genenames.org), Entrez Gene (www.ncbi.nlm.nih.gov/entrez/queiy .fcgi?db=gene), UniProtKB/Swiss-Prot (www.uniprot.org), UniProtKB/TrEMBL (www.uniprot.org), OMIM

(www .ncbi.nlm.nih.gov/entrez/query .fcgi?db=OMIM), GeneLoc (genecards.weizmann.ac.il/geneloc/), and Ensembl (www.ensembl.org). For example, gene symbols and names used herein can correspond to those approved by HUGO, and protein names can be those recommended by UniProtKB/Swiss-Prot. In the specification, where a protein name indicates a precursor, the mature protein is also implied.

Throughout the application, gene and protein symbols may be used interchangeably and the meaning can be derived from context, e.g., ISH or NGS can be used to analyze nucleic acids whereas IHC is used to analyze protein.

[00227] The choice of genes and gene products to be assessed to provide molecular profiles of the invention can be updated over time as new treatments and new drug targets are identified. For example, once the expression or mutation of a biomarker is correlated with a treatment option, it can be assessed by molecular profiling. One of skill will appreciate that such molecular profiling is not limited to those techniques disclosed herein but comprises any methodology conventional for assessing nucleic acid or protein levels, sequence information, or both. The methods of the invention can also take advantage of any improvements to current methods or new molecular profiling techniques developed in the future. In some embodiments, a gene or gene product is assessed by a single molecular profiling technique. In other embodiments, a gene and/or gene product is assessed by multiple molecular profiling techniques. In a non-limiting example, a gene sequence can be assayed by one or more of NGS, ISH and pyrosequencing analysis, the mRNA gene product can be assayed by one or more of NGS, RT-PCR and microarray, and the protein gene product can be assayed by one or more of IHC and immunoassay. One of skill will appreciate that any combination of biomarkers and molecular profiling techniques that will benefit disease treatment are contemplated by the invention.

Genes and gene products that are known to play a role in cancer and can be assayed by any of the molecular profiling techniques of the invention include without limitation those listed in any of

International Patent Publications WO/2007/137187 (Int'l Appl. No. PCT/US2007/069286), published November 29, 2007; WO/2010/045318 (Int'l Appl. No. PCT/US2009/060630), published April 22, 2010; WO/2010/093465 (Int'l Appl. No. PCT/US2010/000407), published August 19, 2010; WO/2012/170715 (Int'l Appl. No. PCT/US2012/041393), published December 13, 2012; WO/2014/089241 (Int'l Appl. No. PCT/US2013/073184), published June 12, 2014; WO/2011/056688 (Int'l Appl. No.

PCT/US2010/054366), published May 12, 2011; WO/2012/092336 (Int'l Appl. No.

PCT/US2011/067527), published July 5, 2012; WO/2015/116868 (Int'l Appl. No. PCT/US2015/013618), published August 6, 2015; WO/2017/053915 (Int'l Appl. No. PCT/US2016/053614), published March 30, 2017; and WO/2016/141169 (Int'l Appl. No. PCT/US2016/020657), published September 9, 2016; each of which publications is incorporated by reference herein in its entirety.

[00228] Mutation profiling can be determined by sequencing, including Sanger sequencing, array sequencing, pyrosequencing, NextGen sequencing, etc. Sequence analysis may reveal that genes harbor activating mutations so that drugs that inhibit activity are indicated for treatment. Alternately, sequence analysis may reveal that genes harbor mutations that inhibit or eliminate activity, thereby indicating treatment for compensating therapies. In some embodiments, sequence analysis comprises that of exon 9 and 11 of c-KIT. Sequencing may also be performed on EGFR-kinase domain exons 18, 19, 20, and 21. Mutations, amplifications or misregulations of EGFR or its family members are implicated in about 30% of all epithelial cancers. Sequencing can also be performed on PI3K, encoded by the PIK3CA gene. This gene is a found mutated in many cancers. Sequencing analysis can also comprise assessing mutations in one or more ABCC1, ABCG2, ADA, AR, ASNS, BCL2, BIRC5, BRCA1, BRCA2, CD33, CD52, CDA, CES2, DCK, DHFR, DNMTl, DNMT3A, DNMT3B, ECGFl, EGFR, EPHA2, ERBB2, ERCCl, ERCC3, ESR1, FLT1, FOLR2, FYN, GART, GNRH1, GSTP1, HCK, HDAC1, HIF1A, HSP90AA1, IGFBP3, IGFBP4, IGFBP5, IL2RA, KDR, KIT, LCK, LYN, MET, MGMT, MLH1, MS4A1, MSH2, NFKB1, NFKB2, NFKBIA, NRAS, OGFR, PARP1, PDGFC, PDGFRA, PDGFRB, PGP, PGR, POLA1, PTEN, PTGS2, PTPN12, RAF1, RARA, RRM1, RRM2, RRM2B, RXRB, RXRG, SIK2, SPARC, SRC, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, TK1, TNF, TOPI, TOP2A, TOP2B, TXNRD1, TYMS, VDR, VEGFA, VHL, YES 1, and ZAP70. One or more of the following genes can also be assessed by sequence analysis: ALK, EML4, hENT-1, IGF-1R, HSP90AA1, MMR, pl6, p21, p27, PARP-1, PI3K and TLE3. The genes and/or gene products used for mutation or sequence analysis can be at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500 or all of the genes and/or gene products listed in any of Tables 4-12, e.g., in any of Tables 5-10, or in any of Tables 7-10.

[00229] In embodiments, the methods of the invention are used detect gene fusions, such as those listed in any of International Patent Publications WO/2007/137187 (Int'l Appl. No. PCT/US2007/069286), published November 29, 2007; WO/2010/045318 (Int'l Appl. No. PCT/US2009/060630), published April 22, 2010; WO/2010/093465 (Int'l Appl. No. PCT/US2010/000407), published August 19, 2010;

WO/2012/170715 (Int'l Appl. No. PCT/US2012/041393), published December 13, 2012;

WO/2014/089241 (Int'l Appl. No. PCT/US2013/073184), published June 12, 2014; WO/2011/056688 (Int'l Appl. No. PCT/US2010/054366), published May 12, 2011; WO/2012/092336 (Int'l Appl. No. PCT/US2011/067527), published July 5, 2012; WO/2015/116868 (Int'l Appl. No. PCT/US2015/013618), published August 6, 2015; WO/2017/053915 (Int'l Appl. No. PCT/US2016/053614), published March 30, 2017; and WO/2016/141169 (Int'l Appl. No. PCT/US2016/020657), published September 9, 2016; each of which publications is incorporated by reference herein in its entirety. A fusion gene is a hybrid gene created by the juxtaposition of two previously separate genes. This can occur by chromosomal translocation or inversion, deletion or via trans-splicing. The resulting fusion gene can cause abnormal temporal and spatial expression of genes, leading to abnormal expression of cell growth factors, angiogenesis factors, tumor promoters or other factors contributing to the neoplastic transformation of the cell and the creation of a tumor. For example, such fusion genes can be oncogenic due to the juxtaposition of: 1) a strong promoter region of one gene next to the coding region of a cell growth factor, tumor promoter or other gene promoting oncogenesis leading to elevated gene expression, or 2) due to the fusion of coding regions of two different genes, giving rise to a chimeric gene and thus a chimeric protein with abnormal activity. Fusion genes are characteristic of many cancers. Once a therapeutic intervention is associated with a fusion, the presence of that fusion in any type of cancer identifies the therapeutic intervention as a candidate therapy for treating the cancer.

[00230] The presence of fusion genes can be used to guide therapeutic selection. For example, the BCR- ABL gene fusion is a characteristic molecular aberration in -90% of chronic myelogenous leukemia (CML) and in a subset of acute leukemias (Kurzrock et al, Annals of Internal Medicine 2003; 138:819- 830). The BCR-ABL results from a translocation between chromosomes 9 and 22, commonly referred to as the Philadelphia chromosome or Philadelphia translocation. The translocation brings together the 5' region of the BCR gene and the 3' region of ABL1, generating a chimeric BCR-ABL 1 gene, which encodes a protein with constitutively active tyrosine kinase activity (Mittleman et al., Nature Reviews Cancer 2007; 7:233-245). The aberrant tyrosine kinase activity leads to de-regulated cell signaling, cell growth and cell survival, apoptosis resistance and growth factor independence, all of which contribute to the pathophysiology of leukemia (Kurzrock et al., Annals of Internal Medicine 2003; 138:819-830). Patients with the Philadelphia chromosome are treated with imatinib and other targeted therapies. Imatinib binds to the site of the constitutive tyrosine kinase activity of the fusion protein and prevents its activity. Imatinib treatment has led to molecular responses (disappearance of BCR-ABL+ blood cells) and improved progression-free survival in BCR-ABL+ CML patients (Kantarjian et al, Clinical Cancer

Research 2007; 13: 1089-1097).

[00231] Another fusion gene, IGH-MYC, is a defining feature of -80% of Burkitt's lymphoma (Ferry et al. Oncologist 2006; 11:375-83). The causal event for this is a translocation between chromosomes 8 and 14, bringing the c-Myc oncogene adjacent to the strong promoter of the immunoglobulin heavy chain gene, causing c-myc overexpression (Mittleman et al., Nature Reviews Cancer 2007; 7:233-245). The c- myc rearrangement is a pivotal event in lymphomagenesis as it results in a perpetually proliferative state. It has wide ranging effects on progression through the cell cycle, cellular differentiation, apoptosis, and cell adhesion (Ferry et al. Oncologist 2006; 11 :375-83).

[00232] A number of recurrent fusion genes have been catalogued in the Mittleman database

(cgap.nci.nih.gov/Chromosomes/Mitelman). The gene fusions can be used to characterize neoplasms and cancers and guide therapy using the subject methods described herein. For example, TMPRSS2-ERG, TMPRSS2-ETV and SLC45A3-ELK4 fusions can be detected to characterize prostate cancer; and ETV6- NTRK3 and ODZ4-NRG1 can be used to characterize breast cancer. The EML4-ALK, RLF-MYCLl, TGF-ALK, or CD74-ROS1 fusions can be used to characterize a lung cancer. The ACSL3-ETV1, C150RF21-ETV1, FLJ35294-ETV1, HERV-ETV1, TMPRSS2-ERG, TMPRSS2-ETV 1/4/5, TMPRSS2- ETV4/5, SLC5A3-ERG, SLC5A3-ETV1, SLC5A3-ETV5 or KLK2-ETV4 fusions can be used to characterize a prostate cancer. The GOPC-ROS1 fusion can be used to characterize a brain cancer. The CHCHD7-PLAG1, CTN B 1 -PLAG 1 , FHIT-HMGA2, HMGA2-NFIB, LIFR-PLAG1, or TCEA1- PLAG1 fusions can be used to characterize a head and neck cancer. The ALPHA-TFEB, NONO-TFE3, PRCC-TFE3, SFPQ-TFE3, CLTC-TFE3, or MALAT1-TFEB fusions can be used to characterize a renal cell carcinoma (RCC). The AKAP9-BRAF, CCDC6-RET, ERCl-RETM, GOLGA5-RET, HOOK3-RET, HRH4-RET, KTN1-RET, NCOA4-RET, PCM1-RET, PRKARA 1 A-RET. RFG-RET, RFG9-RET, Ria- RET, TGF-NTRK1, TPM3-NTRK1, TPM3-TPR, TPR-MET, TPR-NTRK1, TRIM24-RET, TRIM27- RET or TRIM33-RET fusions can be used to characterize a thyroid cancer and/or papillary thyroid carcinoma; and the PAX8-PPARy fusion can be analyzed to characterize a follicular thyroid cancer. Fusions that are associated with hematological malignancies include without limitation TTL-ETV6, CDK6-MLL, CDK6-TLX3, ETV6-FLT3, ETV6-RU X1, ETV6-TTL, MLL-AFF1, MLL-AFF3, MLL- AFF4, MLL-GAS7, TCBA1-ETV6, TCF3-PBX1 or TCF3-TFPT, which are characteristic of acute lymphocytic leukemia (ALL); BCL11B-TLX3, IL2-TNFRFS17, NUP214-ABL1, NUP98-CCDC28A, TAL1-STIL, or ETV6-ABL2, which are characteristic of T-cell acute lymphocytic leukemia (T-ALL); ATIC-ALK, KIAA1618-ALK, MSN-ALK, MYH9-ALK, NPMl-ALK, TGF-ALK or TPM3-ALK, which are characteristic of anaplastic large cell lymphoma (ALCL); BCR-ABL1, BCR-JAK2, ETV6-EVI1, ETV6-MN1 or ETV6-TCBA1, characteristic of chronic myelogenous leukemia (CML); CBFB-MYH11, CHIC2-ETV6, ETV6-ABL1, ETV6-ABL2, ETV6-ARNT, ETV6-CDX2, ETV6-HLXB9, ETV6-PER1, MEF2D-D AZAP 1 , AML-AFFl, MLL-ARHGAP26, MLL-ARHGEF 12, MLL-CASC5, MLL-CBL,MLL- CREBBP, MLL-DAB21P, MLL-ELL, MLL-EP300, MLL-EPS15, MLL-FNBP1, MLL-FOX03A, MLL- GMPS, MLL-GPHN, MLL-MLLT1, MLL-MLLT11, MLL-MLLT3, MLL-MLLT6, MLL-MYOIF, MLL-PICALM, MLL-SEPT2, MLL-SEPT6, MLL-SORBS2, MYST3-SORBS2, MYST-CREBBP,

NPM1-MLF1, NUP98-HOXA13, PRDM16-EVI1, RABEP1-PDGFRB, RU X1-EVI1, RU X1-MDS1,

RU X1-RPL22, RUNX1-RU X1T1, RU X1-SH3D19, RU X1-USP42, RU X 1 -YTHDF2, RUNX1-

ZNF687, or TAF15-ZNF-384, which are characteristic of acute myeloid leukemia (AML); CCND1-

FSTL3, which is characteristic of chronic lymphocytic leukemia (CLL); BCL3-MYC, MYC-BTG1,

BCL7A-MYC, BRWD3 -ARHGAP20 or BTG1-MYC, which are characteristic of B-cell chronic lymphocytic leukemia (B-CLL); CITTA-BCL6, CLTC-ALK, IL21R-BCL6, PIM1-BCL6, TFCR-BCL6,

IKZF1-BCL6 or SEC31A-ALK, which are characteristic of diffuse large B-cell lymphomas (DLBCL);

FLIP1-PDGFRA, FLT3-ETV6, KIAA1509-PDGFRA, PDE4DIP-PDGFRB, NIN-PDGFRB, TP53BP1-

PDGFRB, or TPM3-PDGFRB, which are characteristic of hyper eosinophilia / chronic eosinophilia; and

IGH-MYC or LCP1-BCL6, which are characteristic of Burkitt's lymphoma. One of skill will understand that additional fusions, including those yet to be identified to date, can be used to guide treatment once their presence is associated with a therapeutic intervention.

[00233] The fusion genes and gene products can be detected using one or more techniques described herein. In some embodiments, the sequence of the gene or corresponding mRNA is determined, e.g., using Sanger sequencing, NGS, pyrosequencing, DNA microarrays, etc. Chromosomal abnormalities can be assessed using ISH, NGS or PCR techniques, among others. For example, a break apart probe can be used for ISH detection of ALK fusions such as EML4-ALK, KIF5B-ALK and/or TFG-ALK. As an alternate, PCR can be used to amplify the fusion product, wherein amplification or lack thereof indicates the presence or absence of the fusion, respectively. mRNA can be sequenced, e.g., using NGS to detect such fusions. See, e.g., Table 9 or Table 12 herein. In some embodiments, the fusion protein fusion is detected. Appropriate methods for protein analysis include without limitation mass spectroscopy, electrophoresis (e.g., 2D gel electrophoresis or SDS-PAGE) or antibody related techniques, including immunoassay, protein array or immunohistochemistry. The techniques can be combined. As a non-limiting example, indication of an ALK fusion by NGS can be confirmed by ISH or ALK expression using IHC, or vice versa.

Treatment Selection

[00234] The systems and methods allow identification of one or more therapeutic targets whose projected efficacy can be linked to therapeutic efficacy, ultimately based on the molecular profiling. Illustrative schemes for using molecular profiling to identify a treatment regime are provided throughout, e.g., in Tables 2-3, Table 11, FIGs. 2, 26A-F and 28, each of which is described in further detail herein.

Additional schemes are described in International Patent Publications WO/2007/137187 (Int'l Appl. No. PCT/US2007/069286), published November 29, 2007; WO/2010/045318 (Int'l Appl. No.

PCT/US2009/060630), published April 22, 2010; WO/2010/093465 (Int'l Appl. No.

PCT/US2010/000407), published August 19, 2010; WO/2012/170715 (Int'l Appl. No.

PCT/US2012/041393), published December 13, 2012; WO/2014/089241 (Int'l Appl. No.

PCT/US2013/073184), published June 12, 2014; WO/2011/056688 (Int'l Appl. No.

PCT/US2010/054366), published May 12, 2011; WO/2012/092336 (Int'l Appl. No. PCT/US2011/067527), published July 5, 2012; WO/2015/116868 (Int'l Appl. No. PCT/US2015/013618), published August 6, 2015; WO/2017/053915 (Int'l Appl. No. PCT/US2016/053614), published March 30, 2017; and WO/2016/141169 (Int'l Appl. No. PCT/US2016/020657), published September 9, 2016; each of which publications is incorporated by reference herein in its entirety. The invention comprises use of molecular profiling results to suggest associations with treatment responses. In an embodiment, the appropriate biomarkers for molecular profiling are selected on the basis of the subject's tumor type. These suggested biomarkers can be used to modify a default list of biomarkers. In other embodiments, the molecular profiling is independent of the source material. In some embodiments, rules are used to provide the suggested chemotherapy treatments based on the molecular profiling test results. In an embodiment, the rules are generated from abstracts of the peer reviewed clinical oncology literature. Expert opinion rules can be used but are optional. In an embodiment, clinical citations are assessed for their relevance to the methods of the invention using a hierarchy derived from the evidence grading system used by the United States Preventive Services Taskforce. The "best evidence" can be used as the basis for a rule. The simplest rules are constructed in the format of "if biomarker positive then treatment option one, else treatment option two." Treatment options comprise no treatment with a specific drug, treatment with a specific drug or treatment with a combination of drugs. In some embodiments, more complex rules are constructed that involve the interaction of two or more biomarkers. In such cases, the more complex interactions are typically supported by clinical studies that analyze the interaction between the biomarkers included in the rule. Finally, a report can be generated that describes the association of the chemotherapy response and the biomarker and a summary statement of the best evidence supporting the treatments selected. Ultimately, the treating physician will decide on the best course of treatment.

[00235] As a non-limiting example, molecular profiling might reveal that the EGFR gene is amplified or overexpressed, thus indicating selection of a treatment that can block EGFR activity, such as the monoclonal antibody inhibitors cetuximab and panitumumab, or small molecule kinase inhibitors effective in patients with activating mutations in EGFR such as gefitinib, erlotinib, and lapatinib. Other anti-EGFR monoclonal antibodies in clinical development include zalutumumab, nimotuzumab, and matuzumab. The candidate treatment selected can depend on the setting revealed by molecular profiling. For example, kinase inhibitors are often prescribed with EGFR is found to have activating mutations. Continuing with the illustrative embodiment, molecular profiling may also reveal that some or all of these treatments are likely to be less effective. For example, patients taking gefitinib or erlotinib eventually develop drug resistance mutations in EGFR. Accordingly, the presence of a drug resistance mutation would contraindicate selection of the small molecule kinase inhibitors. One of skill will appreciate that this example can be expanded to guide the selection of other candidate treatments that act against genes or gene products whose differential expression is revealed by molecular profiling. Similarly, candidate agents known to be effective against diseased cells carrying certain nucleic acid variants can be selected if molecular profiling reveals such variants.

[00236] As another example, consider the drug imatinib, currently marketed by Novartis as Gleevec in the US in the form of imatinib mesylate. Imatinib is a 2-phenylaminopyrimidine derivative that functions as a specific inhibitor of a number of tyrosine kinase enzymes. It occupies the tyrosine kinase active site, leading to a decrease in kinase activity. Imatinib has been shown to block the activity of Abelson cytoplasmic tyrosine kinase (ABL), c-Kit and the platelet-derived growth factor receptor (PDGFR). Thus, imatinib can be indicated as a candidate therapeutic for a cancer determined by molecular profiling to overexpress ABL, c-KIT or PDGFR. Imatinib can be indicated as a candidate therapeutic for a cancer determined by molecular profiling to have mutations in ABL, c-KIT or PDGFR that alter their activity, e.g., constitutive kinase activity of ABLs caused by the BCR-ABL mutation. As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases.

[00237] Cancer therapies that can be identified as candidate treatments by the methods of the invention include without limitation those listed in any of International Patent Publications WO/2007/137187 (Int'l Appl. No. PCT/US2007/069286), published November 29, 2007; WO/2010/045318 (Int'l Appl. No. PCT/US2009/060630), published April 22, 2010; WO/2010/093465 (Int'l Appl. No.

PCT/US2010/000407), published August 19, 2010; WO/2012/170715 (Int'l Appl. No.

PCT/US2013/073184), published June 12, 2014; WO/2011/056688 (Int'l Appl. No.

PCT/US2010/054366), published May 12, 2011; WO/2012/092336 (Int'l Appl. No.

PCT/US2011/067527), published July 5, 2012; WO/2015/116868 (Int'l Appl. No. PCT/US2015/013618), published August 6, 2015; WO/2017/053915 (Int'l Appl. No. PCT/US2016/053614), published March 30, 2017; and WO/2016/141169 (Int'l Appl. No. PCT/US2016/020657), published September 9, 2016; each of which publications is incorporated by reference herein in its entirety. The candidate treatments can be any of those in Table 11 herein.

Rules Engine

[00238] In some embodiments, a database is created that maps treatments and molecular profiling results. The treatment information can include the projected efficacy of a therapeutic agent against cells having certain attributes that can be measured by molecular profiling. The molecular profiling can include differential expression or mutations in certain genes, proteins, or other biological molecules of interest. Through the mapping, the results of the molecular profiling can be compared against the database to select treatments. The database can include both positive and negative mappings between treatments and molecular profiling results. In some embodiments, the mapping is created by reviewing the literature for links between biological agents and therapeutic agents. For example, a journal article, patent publication or patent application publication, scientific presentation, etc can be reviewed for potential mappings. The mapping can include results of in vivo, e.g., animal studies or clinical trials, or in vitro experiments, e.g., cell culture. Any mappings that are found can be entered into the database, e.g., cytotoxic effects of a therapeutic agent against cells expressing a gene or protein. In this manner, the database can be continuously updated. It will be appreciated that the methods of the invention are updated as well.

[00239] The rules can be generated by evidence -based literature review. Biomarker research continues to provide a better understanding of the clinical behavior and biology of cancer. This body of literature can be maintained in an up-to-date data repository incorporating recent clinical studies relevant to treatment options and potential clinical outcomes. The studies can be ranked so that only those with the strongest or most reliable evidence are selected for rules generation. For example, the rules generation can employ the grading system from the current methods of the U.S. Preventive Services Task Force. The literature evidence can be reviewed and evaluated based on the strength of clinical evidence supporting associations between biomarkers and treatments in the literature study. This process can be performed by a staff of scientists, physicians and other skilled reviewers. The process can also be automated in whole or in part by using language search and heuristics to identify relevant literature. The rules can be generated by a review of a plurality of literature references, e.g., tens, hundreds, thousands or more literature articles.

[00240] In another aspect, the invention provides a method of generating a set of evidence-based associations, comprising: (a) searching one or more literature database by a computer using an evidence- based medicine search filter to identify articles comprising a gene or gene product thereof, a disease, and one or more therapeutic agent; (b) filtering the articles identified in (a) to compile evidence-based associations comprising the expected benefit and/or the expected lack of benefit of the one or more therapeutic agent for treating the disease given the status of the gene or gene product; (c) adding the evidence -based associations compiled in (b) to the set of evidence-based associations; and (d) repeating steps (a)-(c) for an additional gene or gene product thereof. The status of the gene can include one or more assessments as described herein which relate to a biological state, e.g., one or more of an expression level, a copy number, and a mutation. The genes or gene products thereof can be one or more genes or gene products thereof selected from Table 2, Tables 6-9 or Tables 12-15. For example, the method can be repeated for at least 1, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600 or at least 700 of the genes or gene products thereof in Table 2, Tables 6-9 or Tables 12-15. The disease can be a disease described here, e.g., in embodiment the disease comprises a cancer. The one or more literature database can be selected from the group consisting of the National Library of Medicine's (NLM's) MEDLINE™ database of citations, a patent literature database, and a combination thereof.

[00241] Evidence-based medicine (EBM) or evidence-based practice (EBP) aims to apply the best available evidence gained from the scientific method to clinical decision making. This approach assesses the strength of evidence of the risks and benefits of treatments (including lack of treatment) and diagnostic tests. Evidence quality can be assessed based on the source type (from meta-analyses and systematic reviews of double-blind, placebo-controlled clinical trials at the top end, down to conventional wisdom at the bottom), as well as other factors including statistical validity, clinical relevance, currency, and peer- review acceptance. Evidence -based medicine filters are searches that have been developed to facilitate searches in specific areas of clinical medicine related to evidence-based medicine (diagnosis, etiology, meta-analysis, prognosis and therapy). They are designed to retrieve high quality evidence from published studies appropriate to decision-making. The evidence-based medicine filter used in the invention can be selected from the group consisting of a generic evidence-based medicine filter, a McMaster University optimal search strategy evidence-based medicine filter, a University of York statistically developed search evidence-based medicine filter, and a University of California San Francisco systemic review evidence- based medicine filter. See e.g., US Patent Publication 20080215570; Shojania and Bero. Taking advantage of the explosion of systematic reviews: an efficient MEDLINE search strategy. Eff Clin Pract. 2001 Jul- Aug;4(4): 157-62; Ingui and Rogers. Searching for clinical prediction rules in MEDLINE. J Am Med Inform Assoc. 2001 Jul-Aug;8(4):391-7; Haynes et al., Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey. BMJ. 2005 May

21;330(7501): 1179; Wilczynski and Haynes. Consistency and accuracy of indexing systematic review articles and meta-analyses in medline. Health Info Libr J. 2009 Sep;26(3):203-10; which references are incorporated by reference herein in their entirety. A generic filter can be a customized filter based on an algorithm to identify the desired references from the one or more literature database. For example, the method can use one or more approach as described in US Patent 5168533 to Kato et al, US Patent 6886010 to Kostoff, or US Patent Application Publication No. 20040064438 to Kostoff; which references are incorporated by reference herein in their entirety.

[00242] The further filtering of articles identified by the evidence-based medicine filter can be performed using a computer, by one or more expert user, or combination thereof. The one or more expert can be a trained scientist or physician. In embodiments, the set of evidence-based associations comprise one or more of the rules in Table 11 herein. The set of evidence-based associations include without limitation those listed in any of International Patent Publications WO/2007/137187 (Int'l Appl. No.

PCT/US2007/069286), published November 29, 2007; WO/2010/045318 (Int'l Appl. No.

PCT/US2009/060630), published April 22, 2010; WO/2010/093465 (Int'l Appl. No.

PCT/US2010/000407), published August 19, 2010; WO/2012/170715 (Int'l Appl. No.

PCT/US2013/073184), published June 12, 2014; WO/2011/056688 (Int'l Appl. No.

PCT/US2010/054366), published May 12, 2011; WO/2012/092336 (Int'l Appl. No.

[00243] The rules for the mappings can contain a variety of supplemental information. In some embodiments, the database contains prioritization criteria. For example, a treatment with more projected efficacy in a given setting can be preferred over a treatment projected to have lesser efficacy. A mapping derived from a certain setting, e.g., a clinical trial, may be prioritized over a mapping derived from another setting, e.g., cell culture experiments. A treatment with strong literature support may be prioritized over a treatment supported by more preliminary results. A treatment generally applied to the type of disease in question, e.g., cancer of a certain tissue origin, may be prioritized over a treatment that is not indicated for that particular disease. Mappings can include both positive and negative correlations between a treatment and a molecular profiling result. In a non-limiting example, one mapping might suggest use of a kinase inhibitor like erlotinib against a tumor having an activating mutation in EGFR, whereas another mapping might suggest against that treatment if the EGFR also has a drug resistance mutation. Similarly, a treatment might be indicated as effective in cells that overexpress a certain gene or protein but indicated as not effective if the gene or protein is underexpressed.

[00244] The selection of a candidate treatment for an individual can be based on molecular profiling results from any one or more of the methods described. In embodiments, selection of a candidate treatment for an individual is based on molecular profiling results from more than one of the methods described. For example, selection of treatment for an individual can be based on molecular profiling results from ISH alone, IHC alone, or NGS analysis alone. Alternately, selection can be based on results from multiple techniques, which results may be ranked according to a desired scheme, such by level of evidence. In some embodiments, sequencing reveals a drug resistance mutation so that the effected drug is not selected even if techniques such as IHC indicate differential expression of the target molecule. Any such contraindication, e.g., differential expression or mutation of another gene or gene product may override selection of a treatment.

[00245] An illustrative listing of microarray expression results versus predicted treatments is presented in Table 2. As disclosed herein, molecular profiling is performed to determine whether a gene or gene product is differentially expressed in a sample as compared to a control. The expression status of the gene or gene product is used to select agents that are predicted to be efficacious or not. For example, Table 2 shows that overexpression of the ADA gene or protein points to pentostatin as a possible treatment. On the other hand, underexpression of the ADA gene or protein implicates resistance to cytarabine, suggesting that cytarabine is not an optimal treatment.

Table 2: Molecular Profiling Results and Predicted Treatments

Gene Name Expression Status Candidate Agent(s) Possible Resistance

ADA Overexpressed pentostatin

ADA Underexpressed cytarabine

AR Overexpressed abarelix, bicalutamide,

flutamide, gonadorelin,

goserelin, leuprolide

ASNS Underexpressed asparaginase,

pegaspargase

BCRP (ABCG2) Overexpressed cisplatin, carboplatin, irinotecan, topotecan

BRCA1 Underexpressed mitomycin

BRCA2 Underexpressed mitomycin

CD52 Overexpressed alemtuzumab

CDA Overexpressed cytarabine

CES2 Overexpressed irinotecan

c-kit Overexpressed sorafenib, sunitinib,

imatinib

COX-2 Overexpressed celecoxib

DCK Overexpressed gemcitabine cytarabine

DHFR Underexpressed methotrexate,

pemetrexed

DHFR Overexpressed methotrexate

DNMT1 Overexpressed azacitidine, decitabine

DNMT3A Overexpressed azacitidine, decitabine

DNMT3B Overexpressed azacitidine, decitabine

EGFR Overexpressed erlotinib, gefitinib,

cetuximab, panitumumab EML4-ALK Overexpressed (present) crizotinib

EPHA2 Overexpressed dasatinib

ER Overexpressed anastrazole, exemestane,

fulvestrant, letrozole,

megestrol, tamoxifen,

medroxyprogesterone,

toremifene,

aminoglutethimide

ERCC 1 Overexpressed carboplatin, cisplatin

GART Underexpressed pemetrexed

HER-2 (ERBB2) Overexpressed trastuzumab, lapatinib

HIF-la Overexpressed sorafenib, sunitinib,

bevacizumab

ΙκΒ-α Overexpressed bortezomib

MGMT Underexpressed temozolomide

MGMT Overexpressed temozolomide

MRP 1 (ABCC1) Overexpressed etoposide, paclitaxel, docetaxel, vinblastine, vinorelbine, topotecan, teniposide

P-gp (ABCB l) Overexpressed doxorubicin,

etoposide, epirubicin, paclitaxel, docetaxel, vinblastine, vinorelbine, topotecan, teniposide, liposomal doxorubicin

PDGFR-a Overexpressed sorafenib, sunitinib,

imatinib

PDGFR-β Overexpressed sorafenib, sunitinib,

imatinib

PR Overexpressed exemestane, fulvestrant,

gonadorelin, goserelin,

medroxyprogesterone,

megestrol, tamoxifen,

toremifene

RARA Overexpressed ATRA

RRM1 Underexpressed gemcitabine,

hydroxyurea

RRM2 Underexpressed gemcitabine,

hydroxyurea

RRM2B Underexpressed gemcitabine,

hydroxyurea

RXR-a Overexpressed bexarotene

RXR-β Overexpressed bexarotene

SPARC Overexpressed nab-paclitaxel

SRC Overexpressed dasatinib

SSTR2 Overexpressed octreotide

SSTR5 Overexpressed octreotide

TOPO I Overexpressed irinotecan, topotecan

TOPO Ila Overexpressed doxorubicin, epirubicin,

liposomal- doxorubicin

TOPO Πβ Overexpressed doxorubicin, epirubicin,

liposomal- doxorubicin TS Underexpressed capecitabine, 5- fluorouracil, pemetrexed

TS Overexpressed capecitabine, 5- fluorouracil

VDR Overexpressed calcitriol, cholecalciferol

VEGFR1 (Fltl) Overexpressed sorafenib, sunitinib,

bevacizumab

VEGFR2 Overexpressed sorafenib, sunitinib,

bevacizumab

VHL Underexpressed sorafenib, sunitinib

[00246] Further drug associations and rules that can be used in embodiments of the invention are found in any of International Patent Publications WO/2007/137187 (Int'l Appl. No. PCT/US2007/069286), published November 29, 2007; WO/2010/045318 (Int'l Appl. No. PCT/US2009/060630), published April 22, 2010; WO/2010/093465 (Int'l Appl. No. PCT/US2010/000407), published August 19, 2010;

WO/2014/089241 (Int'l Appl. No. PCT/US2013/073184), published June 12, 2014; WO/2011/056688 (Int'l Appl. No. PCT/US2010/054366), published May 12, 2011; WO/2012/092336 (Int'l Appl. No. PCT/US2011/067527), published July 5, 2012; WO/2015/116868 (Int'l Appl. No. PCT/US2015/013618), published August 6, 2015; WO/2017/053915 (Int'l Appl. No. PCT/US2016/053614), published March 30, 2017; and WO/2016/141169 (Int'l Appl. No. PCT/US2016/020657), published September 9, 2016; each of which publications is incorporated by reference herein in its entirety. See e.g., "Table 4: Rules Summary for Treatment Selection" of WO/2011/056688.

[00247] The efficacy of various therapeutic agents given particular assay results, can be derived from reviewing, analyzing and rendering conclusions on empirical evidence, such as that is available the medical literature or other medical knowledge base. The results are used to guide the selection of certain therapeutic agents in a prioritized list for use in treatment of an individual. When molecular profiling results are obtained, e.g., differential expression or mutation of a gene or gene product, the results can be compared against the database to guide treatment selection. The set of rules in the database can be updated as new treatments and new treatment data become available. In some embodiments, the rules database is updated continuously. In some embodiments, the rules database is updated on a periodic basis. Any relevant correlative or comparative approach can be used to compare the molecular profiling results to the rules database. In one embodiment, a gene or gene product is identified as differentially expressed by molecular profiling. The rules database is queried to select entries for that gene or gene product.

Treatment selection information selected from the rules database is extracted and used to select a treatment. The information, e.g., to recommend or not recommend a particular treatment, can be dependent on whether the gene or gene product is over or underexpressed, or has other abnormalities at the genetic or protein levels as compared to a reference. In some cases, multiple rules and treatments may be pulled from a database comprising the comprehensive rules set depending on the results of the molecular profiling. In some embodiments, the treatment options are presented in a prioritized list. In some embodiments, the treatment options are presented without prioritization information. In either case, an individual, e.g., the treating physician or similar caregiver may choose from the available ontions. [00248] The methods described herein are used to prolong survival of a subject by providing personalized treatment. In some embodiments, the subject has been previously treated with one or more therapeutic agents to treat the disease, e.g., a cancer. The cancer may be refractory to one of these agents, e.g., by acquiring drug resistance mutations. In some embodiments, the cancer is metastatic. In some

embodiments, the subject has not previously been treated with one or more therapeutic agents identified by the method. Using molecular profiling, candidate treatments can be selected regardless of the stage, anatomical location, or anatomical origin of the cancer cells.

[00249] Progression-free survival (PFS) denotes the chances of staying free of disease progression for an individual or a group of individuals suffering from a disease, e.g., a cancer, after initiating a course of treatment. It can refer to the percentage of individuals in a group whose disease is likely to remain stable (e.g., not show signs of progression) after a specified duration of time. Progression-free survival rates are an indication of the effectiveness of a particular treatment. Similarly, disease-free survival (DFS) denotes the chances of staying free of disease after initiating a particular treatment for an individual or a group of individuals suffering from a cancer. It can refer to the percentage of individuals in a group who are likely to be free of disease after a specified duration of time. Disease-free survival rates are an indication of the effectiveness of a particular treatment. Treatment strategies can be compared on the basis of the PFS or DFS that is achieved in similar groups of patients. Disease-free survival is often used with the term overall survival when cancer survival is described.

[00250] The candidate treatment selected by molecular profiling according to the invention can be compared to a non-molecular profiling selected treatment by comparing the progression free survival (PFS) using therapy selected by molecular profiling (period B) with PFS for the most recent therapy on which the patient has just progressed (period A). In one setting, a PFS(B)/PFS(A) ratio > 1.3 was used to indicate that the molecular profiling selected therapy provides benefit for patient (Robert Temple, Clinical measurement in drug evaluation. Edited by Wu Ningano and G. T. Thicker John Wiley and Sons Ltd. 1995; Von Hoff, D.D. Clin Can Res. 4: 1079, 1999: Dhani et al. Clin Cancer Res. 15: 118-123, 2009). Other methods of comparing the treatment selected by molecular profiling to a non-molecular profiling selected treatment include determining response rate (RECIST) and percent of patients without progression or death at 4 months. The term "about" as used in the context of a numerical value for PFS means a variation of +/- ten percent (10%) relative to the numerical value. The PFS from a treatment selected by molecular profiling can be extended by at least 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or at least 90% as compared to a non-molecular profiling selected treatment. In some embodiments, the PFS from a treatment selected by molecular profiling can be extended by at least 100%, 150%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or at least about 1000% as compared to a non-molecular profiling selected treatment. In yet other embodiments, the PFS ratio (PFS on molecular profiling selected therapy or new treatment / PFS on prior therapy or treatment) is at least about 1.3. In yet other embodiments, the PFS ratio is at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2.0. In yet other embodiments, the PFS ratio is at least about 3, 4, 5, 6, 7, 8, 9 or 10. [00251] Similarly, the DFS can be compared in patients whose treatment is selected with or without molecular profiling. In embodiments, DFS from a treatment selected by molecular profiling is extended by at least 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or at least 90% as compared to a non- molecular profiling selected treatment. In some embodiments, the DFS from a treatment selected by molecular profiling can be extended by at least 100%, 150%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or at least about 1000% as compared to a non-molecular profiling selected treatment. In yet other embodiments, the DFS ratio (DFS on molecular profiling selected therapy or new treatment / DFS on prior therapy or treatment) is at least about 1.3. In yet other embodiments, the DFS ratio is at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2.0. In yet other embodiments, the DFS ratio is at least about 3, 4, 5, 6, 7, 8, 9 or 10.

[00252] In some embodiments, the candidate treatment of the invention will not increase the PFS ratio or the DFS ratio in the patient, nevertheless molecular profiling provides invaluable patient benefit. For example, in some instances no preferable treatment has been identified for the patient. In such cases, molecular profiling provides a method to identify a candidate treatment where none is currently identified. The molecular profiling may extend PFS, DFS or lifespan by at least 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 2 months, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months or 2 years. The molecular profiling may extend PFS, DFS or lifespan by at least 2 ½ years, 3 years, 4 years, 5 years, or more. In some embodiments, the methods of the invention improve outcome so that patient is in remission.

[00253] The effectiveness of a treatment can be monitored by other measures. A complete response (CR) comprises a complete disappearance of the disease: no disease is evident on examination, scans or other tests. A partial response (PR) refers to some disease remaining in the body, but there has been a decrease in size or number of the lesions by 30% or more. Stable disease (SD) refers to a disease that has remained relatively unchanged in size and number of lesions. Generally, less than a 50% decrease or a slight increase in size would be described as stable disease. Progressive disease (PD) means that the disease has increased in size or number on treatment. In some embodiments, molecular profiling according to the invention results in a complete response or partial response. In some embodiments, the methods of the invention result in stable disease. In some embodiments, the invention is able to achieve stable disease where non-molecular profiling results in progressive disease.

Computer Systems

[00254] The practice of the present invention may also employ conventional biology methods, software and systems. Computer software products of the invention typically include computer readable medium having computer-executable instructions for performing the logic steps of the method of the invention. Suitable computer readable medium include floppy disk, CD-ROM/DVD/DVD-ROM, hard-disk drive, flash memory, ROM/RAM, magnetic tapes and etc. The computer executable instructions may be written in a suitable computer language or combination of several languages. Basic computational biology methods are described in, for example Setubal and Meidanis et al., Introduction to Computational Biology

Methods (PWS Publishing Company, Boston, 1997); Salzberg, Searles, Kasif, (Ed.), Computational Methods in Molecular Biology, (Elsevier, Amsterdam, 1998); Rashidi and Buehler, Bioinformatics Basics: Application in Biological Science and Medicine (CRC Press, London, 2000) and Ouelette and Bzevanis Bioinformatics: A Practical Guide for Analysis of Gene and Proteins (Wiley & Sons, Inc., 2.sup.nd ed., 2001). See U.S. Pat. No. 6,420,108.

[00255] The present invention may also make use of various computer program products and software for a variety of purposes, such as probe design, management of data, analysis, and instrument operation. See, U.S. Pat. Nos. 5,593,839, 5,795,716, 5,733,729, 5,974,164, 6,066,454, 6,090,555, 6,185,561, 6,188,783, 6,223, 127, 6,229,911 and 6,308,170.

[00256] Additionally, the present invention relates to embodiments that include methods for providing genetic information over networks such as the Internet as shown in U.S. Ser. Nos. 10/197,621, 10/063,559 (U.S. Publication Number 20020183936), 10/065,856, 10/065,868, 10/328,818, 10/328,872, 10/423,403, and 60/482,389. For example, one or more molecular profiling techniques can be performed in one location, e.g., a city, state, country or continent, and the results can be transmitted to a different city, state, country or continent. Treatment selection can then be made in whole or in part in the second location. The methods of the invention comprise transmittal of information between different locations.

[00257] Conventional data networking, application development and other functional aspects of the systems (and components of the individual operating components of the systems) may not be described in detail herein but are part of the invention. Furthermore, the connecting lines shown in the various figures contained herein are intended to represent illustrative functional relationships and/or physical couplings between the various elements. It should be noted that many alternative or additional functional relationships or physical connections may be present in a practical system.

[00258] The various system components discussed herein may include one or more of the following: a host server or other computing systems including a processor for processing digital data; a memory coupled to the processor for storing digital data; an input digitizer coupled to the processor for inputting digital data; an application program stored in the memory and accessible by the processor for directing processing of digital data by the processor; a display device coupled to the processor and memory for displaying information derived from digital data processed by the processor; and a plurality of databases. Various databases used herein may include: patient data such as family history, demography and environmental data, biological sample data, prior treatment and protocol data, patient clinical data, molecular profiling data of biological samples, data on therapeutic drug agents and/or investigative drugs, a gene library, a disease library, a drug library, patient tracking data, file management data, financial management data, billing data and/or like data useful in the operation of the system. As those skilled in the art will appreciate, user computer may include an operating system (e.g., Windows NT, 95/98/2000, OS2, UNIX, Linux, Solaris, MacOS, etc.) as well as various conventional support software and drivers typically associated with computers. The computer may include any suitable personal computer, network computer, workstation, minicomputer, mainframe or the like. User computer can be in a home or medical/business environment with access to a network. In an illustrative embodiment, access is through a network or the Internet through a commercially -available web-browser software package.

[00259] As used herein, the term "network" shall include any electronic communications means which incorporates both hardware and software components of such. Communication among the parties may be accomplished through any suitable communication channels, such as, for example, a telephone network, an extranet, an intranet, Internet, point of interaction device, personal digital assistant (e.g., Palm Pilot®, Blackberry®), cellular phone, kiosk, etc.), online communications, satellite communications, off-line communications, wireless communications, transponder communications, local area network (LAN), wide area network (WAN), networked or linked devices, keyboard, mouse and/or any suitable communication or data input modality. Moreover, although the system is frequently described herein as being

implemented with TCP/IP communications protocols, the system may also be implemented using IPX, Appletalk, IP-6, NetBIOS, OSI or any number of existing or future protocols. If the network is in the nature of a public network, such as the Internet, it may be advantageous to presume the network to be insecure and open to eavesdroppers. Specific information related to the protocols, standards, and application software used in connection with the Internet is generally known to those skilled in the art and, as such, need not be detailed herein. See, for example, DrLiP ΝΑΓΚ, INTERNET STANDARDS AND

PROTOCOLS (1998); JAVA 2 COMPLETE, various authors, (Sybex 1999); DEBORAH RAY AND ERIC RAY, MASTERING HTML 4.0 (1997); and LOSHIN, TCP/IP CLEARLY EXPLAINED (1997) and DAVID GOURLEY AND BRIAN TOTTY, HTTP, THE DEFINITIVE GUIDE (2002), the contents of which are hereby incorporated by reference.

[00260] The various system components may be independently, separately or collectively suitably coupled to the network via data links which includes, for example, a connection to an Internet Service Provider (ISP) over the local loop as is typically used in connection with standard modem communication, cable modem, Dish networks, ISDN, Digital Subscriber Line (DSL), or various wireless communication methods, see, e.g., GILBERT HELD, UNDERSTANDING DATA COMMUNICATIONS (1996), which is hereby incorporated by reference. It is noted that the network may be implemented as other types of networks, such as an interactive television (ITV) network. Moreover, the system contemplates the use, sale or distribution of any goods, services or information over any network having similar functionality described herein.

[00261] As used herein, "transmit" may include sending electronic data from one system component to another over a network connection. Additionally, as used herein, "data" may include encompassing information such as commands, queries, files, data for storage, and the like in digital or any other form.

[00262] The system contemplates uses in association with web services, utility computing, pervasive and individualized computing, security and identity solutions, autonomic computing, commodity computing, mobility and wireless solutions, open source, biometrics, grid computing and/or mesh computing.

[00263] Any databases discussed herein may include relational, hierarchical, graphical, or object-oriented structure and/or any other database configurations. Common database products that may be used to implement the databases include DB2 by IBM (White Plains, NY), various database products available from Oracle Corporation (Redwood Shores, CA), Microsoft Access or Microsoft SQL Server by

Microsoft Corporation (Redmond, Washington), or any other suitable database product. Moreover, the databases may be organized in any suitable manner, for example, as data tables or lookup tables. Each record may be a single file, a series of files, a linked series of data fields or any other data structure. Association of certain data may be accomplished through any desired data association technique such as those known or practiced in the art. For example, the association may be accomplished either manually or automatically. Automatic association techniques may include, for example, a database search, a database merge, GREP, AGREP, SQL, using a key field in the tables to speed searches, sequential searches through all the tables and files, sorting records in the file according to a known order to simplify lookup, and/or the like. The association step may be accomplished by a database merge function, for example, using a "key field" in pre-selected databases or data sectors.

[00264] More particularly, a "key field" partitions the database according to the high-level class of objects defined by the key field. For example, certain types of data may be designated as a key field in a plurality of related data tables and the data tables may then be linked on the basis of the type of data in the key field. The data corresponding to the key field in each of the linked data tables is preferably the same or of the same type. However, data tables having similar, though not identical, data in the key fields may also be linked by using AGREP, for example. In accordance with one embodiment, any suitable data storage technique may be used to store data without a standard format. Data sets may be stored using any suitable technique, including, for example, storing individual files using an ISO/IEC 7816-4 file structure;

implementing a domain whereby a dedicated file is selected that exposes one or more elementary files containing one or more data sets; using data sets stored in individual files using a hierarchical filing system; data sets stored as records in a single file (including compression, SQL accessible, hashed vione or more keys, numeric, alphabetical by first tuple, etc.); Binary Large Object (BLOB); stored as ungrouped data elements encoded using ISO/IEC 7816-6 data elements; stored as ungrouped data elements encoded using ISO/IEC Abstract Syntax Notation (ASN.1) as in ISO/IEC 8824 and 8825; and/or other proprietary techniques that may include fractal compression methods, image compression methods, etc.

[00265] In one illustrative embodiment, the ability to store a wide variety of information in different formats is facilitated by storing the information as a BLOB. Thus, any binary information can be stored in a storage space associated with a data set. The BLOB method may store data sets as ungrouped data elements formatted as a block of binary via a fixed memory offset using either fixed storage allocation, circular queue techniques, or best practices with respect to memory management (e.g., paged memory, least recently used, etc.). By using BLOB methods, the ability to store various data sets that have different formats facilitates the storage of data by multiple and unrelated owners of the data sets. For example, a first data set which may be stored may be provided by a first party, a second data set which may be stored may be provided by an unrelated second party, and yet a third data set which may be stored, may be provided by a third party unrelated to the first and second party. Each of these three illustrative data sets may contain different information that is stored using different data storage formats and/or techniques.

Further, each data set may contain subsets of data that also may be distinct from other subsets.

[00266] As stated above, in various embodiments, the data can be stored without regard to a common format. However, in one illustrative embodiment, the data set (e.g., BLOB) may be annotated in a standard manner when provided for manipulating the data. The annotation may comprise a short header, trailer, or other appropriate indicator related to each data set that is configured to convey information useful in managing the various data sets. For example, the annotation may be called a "condition header", "header", "trailer", or "status", herein, and may comprise an indication of the status of the data set or may include an identifier correlated to a specific issuer or owner of the data. Subsequent bytes of data may be used to indicate for example, the identity of the issuer or owner of the data, user, transaction/membership account identifier or the like. Each of these condition annotations are further discussed herein.

[00267] The data set annotation may also be used for other types of status information as well as various other purposes. For example, the data set annotation may include security information establishing access levels. The access levels may, for example, be configured to permit only certain individuals, levels of employees, companies, or other entities to access data sets, or to permit access to specific data sets based on the transaction, issuer or owner of data, user or the like. Furthermore, the security information may restrict/permit only certain actions such as accessing, modifying, and/or deleting data sets. In one example, the data set annotation indicates that only the data set owner or the user are permitted to delete a data set, various identified users may be permitted to access the data set for reading, and others are altogether excluded from accessing the data set. However, other access restriction parameters may also be used allowing various entities to access a data set with various permission levels as appropriate. The data, including the header or trailer may be received by a standalone interaction device configured to add, delete, modify, or augment the data in accordance with the header or trailer.

[00268] One skilled in the art will also appreciate that, for security reasons, any databases, systems, devices, servers or other components of the system may consist of any combination thereof at a single location or at multiple locations, wherein each database or system includes any of various suitable security features, such as firewalls, access codes, encryption, decryption, compression, decompression, and/or the like.

[00269] The computing unit of the web client may be further equipped with an Internet browser connected to the Internet or an intranet using standard dial-up, cable, DSL or any other Internet protocol known in the art. Transactions originating at a web client may pass through a firewall in order to prevent unauthorized access from users of other networks. Further, additional firewalls may be deployed between the varying components of CMS to further enhance security.

[00270] Firewall may include any hardware and/or software suitably configured to protect CMS components and/or enterprise computing resources from users of other networks. Further, a firewall may be configured to limit or restrict access to various systems and components behind the firewall for web clients connecting through a web server. Firewall may reside in varying configurations including Stateful Inspection, Proxy based and Packet Filtering among others. Firewall may be integrated within an web server or any other CMS components or may further reside as a separate entity.

[00271] The computers discussed herein may provide a suitable website or other Internet-based graphical user interface which is accessible by users. In one embodiment, the Microsoft Internet Information Server (IIS), Microsoft Transaction Server (MTS), and Microsoft SQL Server, are used in conjunction with the Microsoft operating system, Microsoft NT web server software, a Microsoft SQL Server database system, and a Microsoft Commerce Server. Additionally, components such as Access or Microsoft SQL Server, Oracle, Sybase, Informix MySQL, Interbase, etc., may be used to provide an Active Data Object (ADO) compliant database management system.

[00272] Any of the communications, inputs, storage, databases or displays discussed herein may be facilitated through a website having web pages. The term "web page" as it is used herein is not meant to limit the type of documents and applications that might be used to interact with the user. For example, a typical website might include, in addition to standard HTML documents, various forms, Java applets, JavaScript, active server pages (ASP), common gateway interface scripts (CGI), extensible markup language (XML), dynamic HTML, cascading style sheets (CSS), helper applications, plug-ins, and the like. A server may include a web service that receives a request from a web server, the request including a URL (http://yahoo.com/stockquotes/ge) and an IP address (123.56.789.234). The web server retrieves the appropriate web pages and sends the data or applications for the web pages to the IP address. Web services are applications that are capable of interacting with other applications over a communications means, such as the internet. Web services are typically based on standards or protocols such as XML, XSLT, SOAP, WSDL and UDDI. Web services methods are well known in the art, and are covered in many standard texts. See, e.g., ALEX NGHIEM, IT WEB SERVICES: A ROADMAP FOR THE ENTERPRISE (2003), hereby incorporated by reference.

[00273] The web-based clinical database for the system and method of the present invention preferably has the ability to upload and store clinical data files in native formats and is searchable on any clinical parameter. The database is also scalable and may use an EAV data model (metadata) to enter clinical annotations from any study for easy integration with other studies. In addition, the web-based clinical database is flexible and may be XML and XSLT enabled to be able to add user customized questions dynamically. Further, the database includes exportability to CDISC ODM.

[00274] Practitioners will also appreciate that there are a number of methods for displaying data within a browser-based document. Data may be represented as standard text or within a fixed list, scrollable list, drop-down list, editable text field, fixed text field, pop-up window, and the like. Likewise, there are a number of methods available for modifying data in a web page such as, for example, free text entry using a keyboard, selection of menu items, check boxes, option boxes, and the like.

[00275] The system and method may be described herein in terms of functional block components, screen shots, optional selections and various processing steps. It should be appreciated that such functional blocks may be realized by any number of hardware and/or software components configured to perform the specified functions. For example, the system may employ various integrated circuit components, e.g., memory elements, processing elements, logic elements, look-up tables, and the like, which may carry out a variety of functions under the control of one or more microprocessors or other control devices.

Similarly, the software elements of the system may be implemented with any programming or scripting language such as C, C++, Macromedia Cold Fusion, Microsoft Active Server Pages, Java, COBOL, assembler, PERL, Visual Basic, SQL Stored Procedures, extensible markup language (XML), with the various algorithms being implemented with any combination of data structures, objects, processes, routines or other programming elements. Further, it should be noted that the system may employ any number of conventional techniques for data transmission, signaling, data processing, network control, and the like. Still further, the system could be used to detect or prevent security issues with a client-side scripting language, such as JavaScript, VBScript or the like. For a basic introduction of cryptography and network security, see any of the following references: (1) "Applied Cryptography: Protocols, Algorithms, And Source Code In C," by Bruce Schneier, published by John Wiley & Sons (second edition, 1995); (2) "Java Cryptography" by Jonathan Knudson, published by O'Reilly & Associates (1998); (3)

"Cryptography & Network Security: Principles & Practice" by William Stallings, published by Prentice Hall; all of which are hereby incorporated by reference.

[00276] As used herein, the term "end user", "consumer", "customer", "client", "treating physician", "hospital", or "business" may be used interchangeably with each other, and each shall mean any person, entity, machine, hardware, software or business. Each participant is equipped with a computing device in order to interact with the system and facilitate online data access and data input. The customer has a computing unit in the form of a personal computer, although other types of computing units may be used including laptops, notebooks, hand held computers, set-top boxes, cellular telephones, touch-tone telephones and the like. The owner/operator of the system and method of the present invention has a computing unit implemented in the form of a computer-server, although other implementations are contemplated by the system including a computing center shown as a main frame computer, a minicomputer, a PC server, a network of computers located in the same of different geographic locations, or the like. Moreover, the system contemplates the use, sale or distribution of any goods, services or information over any network having similar functionality described herein.

[00277] In one illustrative embodiment, each client customer may be issued an "account" or "account number". As used herein, the account or account number may include any device, code, number, letter, symbol, digital certificate, smart chip, digital signal, analog signal, biometric or other identifier/indicia suitably configured to allow the consumer to access, interact with or communicate with the system (e.g., one or more of an authorization/access code, personal identification number (PIN), Internet code, other identification code, and/or the like). The account number may optionally be located on or associated with a charge card, credit card, debit card, prepaid card, embossed card, smart card, magnetic stripe card, bar code card, transponder, radio frequency card or an associated account. The system may include or interface with any of the foregoing cards or devices, or a fob having a transponder and RFID reader in RF communication with the fob. Although the system may include a fob embodiment, the invention is not to be so limited. Indeed, system may include any device having a transponder which is configured to communicate with RFID reader via RF communication. Typical devices may include, for example, a key ring, tag, card, cell phone, wristwatch or any such form capable of being presented for interrogation. Moreover, the system, computing unit or device discussed herein may include a "pervasive computing device," which may include a traditionally non-computerized device that is embedded with a computing unit. The account number may be distributed and stored in any form of plastic, electronic, magnetic, radio frequency, wireless, audio and/or optical device capable of transmitting or downloading data from itself to a second device.

[00278] As will be appreciated by one of ordinary skill in the art, the system may be embodied as a customization of an existing system, an add-on product, upgraded software, a standalone system, a distributed system, a method, a data processing system, a device for data processing, and/or a computer program product. Accordingly, the system may take the form of an entirely software embodiment, an entirely hardware embodiment, or an embodiment combining aspects of both software and hardware. Furthermore, the system may take the form of a computer program product on a computer-readable storage medium having computer-readable program code means embodied in the storage medium. Any suitable computer-readable storage medium may be used, including hard disks, CD-ROM, optical storage devices, magnetic storage devices, and/or the like.

[00279] The system and method is described herein with reference to screen shots, block diagrams and flowchart illustrations of methods, apparatus (e.g., systems), and computer program products according to various embodiments. It will be understood that each functional block of the block diagrams and the flowchart illustrations, and combinations of functional blocks in the block diagrams and flowchart illustrations, respectively, can be implemented by computer program instructions.

[00280] These computer program instructions may be loaded onto a general purpose computer, special purpose computer, or other programmable data processing apparatus to produce a machine, such that the instructions that execute on the computer or other programmable data processing apparatus create means for implementing the functions specified in the flowchart block or blocks. These computer program instructions may also be stored in a computer-readable memory that can direct a computer or other programmable data processing apparatus to function in a particular manner, such that the instructions stored in the computer-readable memory produce an article of manufacture including instruction means which implement the function specified in the flowchart block or blocks. The computer program instructions may also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer-implemented process such that the instructions which execute on the computer or other programmable apparatus provide steps for implementing the functions specified in the flowchart block or blocks.

[00281] Accordingly, functional blocks of the block diagrams and flowchart illustrations support combinations of means for performing the specified functions, combinations of steps for performing the specified functions, and program instruction means for performing the specified functions. It will also be understood that each functional block of the block diagrams and flowchart illustrations, and combinations of functional blocks in the block diagrams and flowchart illustrations, can be implemented by either special purpose hardware-based computer systems which perform the specified functions or steps, or suitable combinations of special purpose hardware and computer instructions. Further, illustrations of the process flows and the descriptions thereof may make reference to user windows, web pages, websites, web forms, prompts, etc. Practitioners will appreciate that the illustrated steps described herein may comprise in any number of configurations including the use of windows, web pages, web forms, popup windows, prompts and the like. It should be further appreciated that the multiple steps as illustrated and described may be combined into single web pages and/or windows but have been expanded for the sake of simplicity. In other cases, steps illustrated and described as single process steps may be separated into multiple web pages and/or windows but have been combined for simplicity.

Molecular Profiling Methods

[00282] FIG. 1 illustrates a block diagram of an illustrative embodiment of a system 10 for determining individualized medical intervention for a particular disease state that uses molecular profiling of a patient's biological specimen. System 10 includes a user interface 12, a host server 14 including a processor 16 for processing data, a memory 18 coupled to the processor, an application program 20 stored in the memory 18 and accessible by the processor 16 for directing processing of the data by the processor 16, a plurality of internal databases 22 and external databases 24, and an interface with a wired or wireless communications network 26 (such as the Internet, for example). System 10 may also include an input digitizer 28 coupled to the processor 16 for inputting digital data from data that is received from user interface 12.

[00283] User interface 12 includes an input device 30 and a display 32 for inputting data into system 10 and for displaying information derived from the data processed by processor 16. User interface 12 may also include a printer 34 for printing the information derived from the data processed by the processor 16 such as patient reports that may include test results for targets and proposed drug therapies based on the test results.

[00284] Internal databases 22 may include, but are not limited to, patient biological sample/specimen information and tracking, clinical data, patient data, patient tracking, file management, study protocols, patient test results from molecular profiling, and billing information and tracking. External databases 24 nay include, but are not limited to, drug libraries, gene libraries, disease libraries, and public and private databases such as UniGene, OMIM, GO, TIGR, GenBank, KEGG and Biocarta.

[00285] Various methods may be used in accordance with system 10. FIG. 2 shows a flowchart of an illustrative embodiment of a method 50 for determining individualized medical intervention for a particular disease state that uses molecular profiling of a patient's biological specimen that is non disease specific. In order to determine a medical intervention for a particular disease state using molecular profiling that is independent of disease lineage diagnosis (i.e. not single disease restricted), at least one test is performed for at least one target from a biological sample of a diseased patient in step 52. A target is defined as any molecular finding that may be obtained from molecular testing. For example, a target may include one or more genes, one or more gene expressed proteins, one or more molecular mechanisms, and/or combinations of such. For example, the expression level of a target can be determined by the analysis of mR A levels or the target or gene, or protein levels of the gene. Tests for finding such targets may include, but are not limited, fluorescent in-situ hybridization (FISH), in-situ hybridization (ISH), and other molecular tests known to those skilled in the art. PCR-based methods, such as real-time PCR or quantitative PCR can be used. Furthermore, microarray analysis, such as a comparative genomic hybridization (CGH) micro array, a single nucleotide polymorphism (SNP) microarray, a proteomic array, or antibody array analysis can also be used in the methods disclosed herein. In some embodiments, microarray analysis comprises identifying whether a gene is up-regulated or down-regulated relative to a reference with a significance of p<0.001. Tests or analyses of targets can also comprise

immunohistochemical (IHC) analysis. In some embodiments, IHC analysis comprises determining whether 30% or more of a sample is stained, if the staining intensity is +2 or greater, or both.

[00286] Furthermore, the methods disclosed herein also including profiling more than one target. For example, the expression of a plurality of genes can be identified. Furthermore, identification of a plurality of targets in a sample can be by one method or by various means. For example, the expression of a first gene can be determined by one method and the expression level of a second gene determined by a different method. Alternatively, the same method can be used to detect the expression level of the first and second gene. For example, the first method can be IHC and the second by microarray analysis, such as detecting the gene expression of a gene.

[00287] In some embodiments, molecular profiling can also including identifying a genetic variant, such as a mutation, polymorphism (such as a SNP), deletion, or insertion of a target. For example, identifying a SNP in a gene can be determined by microarray analysis, real-time PCR, or sequencing. Other methods disclosed herein can also be used to identify variants of one or more targets.

[00288] Accordingly, one or more of the following may be performed: an IHC analysis in step 54, a microanalysis in step 56, and other molecular tests know to those skilled in the art in step 58.

[00289] Biological samples are obtained from diseased patients by taking a biopsy of a tumor, conducting minimally invasive surgery if no recent tumor is available, obtaining a sample of the patient's blood, or a sample of any other biological fluid including, but not limited to, cell extracts, nuclear extracts, cell lysates or biological products or substances of biological origin such as excretions, blood, sera, plasma, urine, sputum, tears, feces, saliva, membrane extracts, and the like.

[00290] In step 60, a determination is made as to whether one or more of the targets that were tested for in step 52 exhibit a change in expression compared to a normal reference for that particular target. In one illustrative method of the invention, an IHC analysis may be performed in step 54 and a determination as to whether any targets from the IHC analysis exhibit a change in expression is made in step 64 by determining whether 30% or more of the biological sample cells were +2 or greater staining for the particular target. It will be understood by those skilled in the art that there will be instances where +1 or greater staining will indicate a change in expression in that staining results may vary depending on the technician performing the test and type of target being tested. In another illustrative embodiment of the invention, a micro array analysis may be performed in step 56 and a determination as to whether any targets from the micro array analysis exhibit a change in expression is made in step 66 by identifying which targets are up-regulated or down-regulated by determining whether the fold change in expression for a particular target relative to a normal tissue of origin reference is significant at p< 0.001. A change in expression may also be evidenced by an absence of one or more genes, gene expressed proteins, molecular mechanisms, or other molecular findings.

[00291] After determining which targets exhibit a change in expression in step 60, at least one non-disease specific agent is identified that interacts with each target having a changed expression in step 70. An agent may be any drug or compound having a therapeutic effect. A non-disease specific agent is a therapeutic drug or compound not previously associated with treating the patient's diagnosed disease that is capable of interacting with the target from the patient's biological sample that has exhibited a change in expression. Some of the non-disease specific agents that have been found to interact with specific targets found in different cancer patients are shown in Table 3 below.

Table 3: Illustrative target-drug associations

[00292] Finally, in step 80, a patient profile report may be provided which includes the patient's test results for various targets and any proposed therapies based on those results. An illustrative patient profile report 100 is shown in FIGs. 3A-3D. Patient profile report 100 shown in FIG. 3A identifies the targets tested 102, those targets tested that exhibited significant changes in expression 104, and proposed non- disease specific agents for interacting with the targets 106. Patient profile report 100 shown in FIG. 3B identifies the results 108 of immunohistochemical analysis for certain gene expressed proteins 110 and whether a gene expressed protein is a molecular target 112 by determining whether 30% or more of the tumor cells were +2 or greater staining. Report 100 also identifies immunohistochemical tests that were not performed 114. Patient profile report 100 shown in FIG. 3C identifies the genes analyzed 116 with a micro array analysis and whether the genes were under expressed or over expressed 118 compared to a reference. Finally, patient profile report 100 shown in FIG. 3D identifies the clinical history 120 of the patient and the specimens that were submitted 122 from the patient. Molecular profiling techniques can be performed anywhere, e.g., a foreign country, and the results sent by network to an appropriate party, e.g., the patient, a physician, lab or other party located remotely.

[00293] FIG. 4 shows a flowchart of an illustrative embodiment of a method 200 for identifying a drug therapy /agent capable of interacting with a target. In step 202, a molecular target is identified which exhibits a change in expression in a number of diseased individuals. Next, in step 204, a drug

therapy/agent is administered to the diseased individuals. After drug therapy/agent administration, anv changes in the molecular target identified in step 202 are identified in step 206 in order to determine if the drug therapy/agent administered in step 204 interacts with the molecular targets identified in step 202. If it is determined that the drug therapy/agent administered in step 204 interacts with a molecular target identified in step 202, the drug therapy/agent may be approved for treating patients exhibiting a change in expression of the identified molecular target instead of approving the drug therapy/agent for a particular disease.

[00294] FIGs. 5-14 are flowcharts and diagrams illustrating various parts of an information-based personalized medicine drug discovery system and method in accordance with the present invention. FIG. 5 is a diagram showing an illustrative clinical decision support system of the information-based personalized medicine drug discovery system and method of the present invention. Data obtained through clinical research and clinical care such as clinical trial data, biomedical/molecular imaging data, genomics/proteomics/chemical library/literature/expert curation, biospecimen tracking/LIMS, family history/environmental records, and clinical data are collected and stored as databases and datamarts within a data warehouse. FIG. 6 is a diagram showing the flow of information through the clinical decision support system of the information-based personalized medicine drug discovery system and method of the present invention using web services. A user interacts with the system by entering data into the system via form-based entry/upload of data sets, formulating queries and executing data analysis jobs, and acquiring and evaluating representations of output data. The data warehouse in the web based system is where data is extracted, transformed, and loaded from various database systems. The data warehouse is also where common formats, mapping and transformation occurs. The web based system also includes datamarts which are created based on data views of interest.

[00295] A flow chart of an illustrative clinical decision support system of the information-based personalized medicine drug discovery system and method of the present invention is shown in FIG. 7. The clinical information management system includes the laboratory information management system and the medical information contained in the data warehouses and databases includes medical information libraries, such as drug libraries, gene libraries, and disease libraries, in addition to literature text mining. Both the information management systems relating to particular patients and the medical information databases and data warehouses come together at a data junction center where diagnostic information and therapeutic options can be obtained. A financial management system may also be incorporated in the clinical decision support system of the information-based personalized medicine drug discovery system and method of the present invention.

[00296] FIG. 8 is a diagram showing an illustrative biospecimen tracking and management system which may be used as part of the information-based personalized medicine drug discovery system and method of the present invention. FIG. 8 shows two host medical centers which forward specimens to a tissue/blood bank. The specimens may go through laboratory analysis prior to shipment. Research may also be conducted on the samples via micro array, genotyping, and proteomic analysis. This information can be redistributed to the tissue/blood bank. FIG. 9 depicts a flow chart of an illustrative biospecimen tracking and management system which may be used with the information-based personalized medicine drug discovery system and method of the present invention. The host medical center obtains samples from patients and then ships the patient samples to a molecular profiling laboratory which may also perform R A and DNA isolation and analysis.

[00297] A diagram showing a method for maintaining a clinical standardized vocabulary for use with the information-based personalized medicine drug discovery system and method of the present invention is shown in FIG. 10. FIG. 10 illustrates how physician observations and patient information associated with one physician's patient may be made accessible to another physician to enable the other physician to use the data in making diagnostic and therapeutic decisions for their patients.

[00298] FIG. 11 shows a schematic of an illustrative microarray gene expression database which may be used as part of the information-based personalized medicine drug discovery system and method of the present invention. The micro array gene expression database includes both external databases and internal databases which can be accessed via the web based system. External databases may include, but are not limited to, UniGene, GO, TIGR, GenBank, KEGG. The internal databases may include, but are not limited to, tissue tracking, LIMS, clinical data, and patient tracking. FIG. 12 shows a diagram of an illustrative micro array gene expression database data warehouse which may be used as part of the information-based personalized medicine drug discovery system and method of the present invention. Laboratory data, clinical data, and patient data may all be housed in the micro array gene expression database data warehouse and the data may in turn be accessed by public/private release and used by data analysis tools.

[00299] Another schematic showing the flow of information through an information-based personalized medicine drug discovery system and method of the present invention is shown in FIG. 13. Like FIG. 7, the schematic includes clinical information management, medical and literature information management, and financial management of the information-based personalized medicine drug discovery system and method of the present invention. FIG. 14 is a schematic showing an illustrative network of the information-based personalized medicine drug discovery system and method of the present invention. Patients, medical practitioners, host medical centers, and labs all share and exchange a variety of information in order to provide a patient with a proposed therapy or agent based on various identified targets.

[00300] FIGs. 15-25 are computer screen print outs associated with various parts of the information-based personalized medicine drug discovery system and method shown in FIGs. 5-14. FIG. 15 and FIG. 16 show computer screens where physician information and insurance company information is entered on behalf of a client. FIG. 17, FIG. 18 and FIG. 19 show computer screens in which information can be entered for ordering analysis and tests on patient samples.

[00301] FIG. 20 is a computer screen showing micro array analysis results of specific genes tested with patient samples. This information and computer screen is similar to the information detailed in the patient profile report shown in FIG. 3C. FIG. 22 is a computer screen that shows immunohistochemistry test results for a particular patient for various genes. This information is similar to the information contained in the patient profile report shown in FIG. 3B. [00302] FIG. 21 is a computer screen showing selection options for finding particular patients, ordering tests and/or results, issuing patient reports, and tracking current cases/patients.

[00303] FIG. 23 is a computer screen which outlines some of the steps for creating a patient profile report as shown in FIGS. 3A through 3D. FIG. 24 shows a computer screen for ordering an

immunohistochemistry test on a patient sample and FIG. 25 shows a computer screen for entering information regarding a primary tumor site for micro array analysis. It will be understood by those skilled in the art that any number and variety of computer screens may be used to enter the information necessary for using the information-based personalized medicine drug discovery system and method of the present invention and to obtain information resulting from using the information-based personalized medicine drug discovery system and method of the present invention.

[00304] The systems of the invention can be used to automate the steps of identifying a molecular profile to assess a cancer. In an aspect, the invention provides a method of generating a report comprising a molecular profile. The method comprises: performing a search on an electronic medium to obtain a data set, wherein the data set comprises a plurality of scientific publications corresponding to plurality of cancer biomarkers; and analyzing the data set to identify a rule set linking a characteristic of each of the plurality of cancer biomarkers with an expected benefit of a plurality of treatment options, thereby identifying the cancer biomarkers included within a molecular profile. The method can further comprise performing molecular profiling on a sample from a subject to assess the characteristic of each of the plurality of cancer biomarkers, and compiling a report comprising the assessed characteristics into a list, thereby generating a report that identifies a molecular profile for the sample. The report can further comprise a list describing the expected benefit of the plurality of treatment options based on the assessed characteristics, thereby identifying candidate treatment options for the subject. The sample from the subject may comprise cancer cells. The cancer can be any cancer disclosed herein or known in the art.

[00305] The characteristic of each of the plurality of cancer biomarkers can be any useful characteristic for molecular profiling as disclosed herein or known in the art. Such characteristics include without limitation mutations (point mutations, insertions, deletions, rearrangements, etc), epigenetic

modifications, copy number, nucleic acid or protein expression levels, post-translational modifications, and the like.

[00306] In an embodiment, the method further comprises identifying a priority list as amongst said plurality of cancer biomarkers. The priority list can be sorted according to any appropriate priority criteria. In an embodiment, the priority list is sorted according to strength of evidence in the plurality of scientific publications linking the cancer biomarkers to the expected benefit. In another embodiment, the priority list is sorted according to strength of the expected benefit. In still another embodiment, the priority list is sorted according to strength of the expected benefit. One of skill will appreciate that the priority list can be sorted according to a combination of these or other appropriate priority criteria. The candidate treatment options can be sorted according to the priority list, thereby identifying a ranked list of treatment options for the subject. [00307] The candidate treatment options can be categorized by expected benefit to the subject. For example, the candidate treatment options can categorized as those that are expected to provide benefit, those that are not expected to provide benefit, or those whose expected benefit cannot be determined.

[00308] The candidate treatment options can include regulatory approved and/or on-compendium treatments for the cancer. The candidate treatment options can include regulatory approved but off-label treatments for the cancer, such as a treatment that has been approved for a cancer of another lineage. The candidate treatment options can include treatments that are under development, such as in ongoing clinical trials. The report may identify treatments as approved, on- or off-compendium, in clinical trials, and the like.

[00309] In some embodiments, the method further comprises analyzing the data set to select a laboratory technique to assess the characteristics of the biomarkers, thereby designating a technique that can be used to assess the characteristic for each of the plurality of biomarkers. In other embodiments, the laboratory technique is chosen based on its applicability to assess the characteristic of each of the biomarkers. The laboratory techniques can be those disclosed herein, including without limitation FISH for gene copy number or mutation analysis, IHC for protein expression levels, RT-PCR for mutation or expression analysis, sequencing or fragment analysis for mutation analysis. Sequencing includes any useful sequencing method disclosed herein or known in the art, including without limitation Sanger sequencing, pyrosequencing, or next generation sequencing methods.

[00310] In a related aspect, the invention provides a method comprising: performing a search on an electronic medium to obtain a data set comprising a plurality of scientific publications corresponding to plurality of cancer biomarkers; analyzing the data set to select a method to assess a characteristic of each of the cancer biomarkers, thereby designating a method for characterizing each of the biomarkers; further analyzing the data set to select a rule set that identifies a priority list as amongst the biomarkers;

performing tumor profiling on a tumor sample from a subject comprising the selected methods to determine the status of the characteristic of each of the biomarkers; and compiling the status in a report according to said priority list; thereby generating a report that identifies a tumor profile.

Molecular Profiling Targets

[00311] The present invention provides methods and systems for analyzing diseased tissue using molecular profiling as previously described above. Because the methods rely on analysis of the characteristics of the tumor under analysis, the methods can be applied in for any tumor or any stage of disease, such an advanced stage of disease or a metastatic tumor of unknown origin. As described herein, a tumor or cancer sample is analyzed for molecular characteristics in order to predict or identify a candidate therapeutic treatment. The molecular characteristics can include the expression of genes or gene products, assessment of gene copy number, or mutational analysis. Any relevant determinable characteristic that can assist in prediction or identification of a candidate therapeutic can be included within the methods of the invention.

[00312] The biomarker patterns or biomarker signature sets can be determined for tumor types, diseased tissue types, or diseased cells including without limitation adipose, adrenal cortex, adrenal gland, adrenal gland - medulla, appendix, bladder, blood vessel, bone, bone cartilage, brain, breast, cartilage, cervix, colon, colon sigmoid, dendritic cells, skeletal muscle, endometrium, esophagus, fallopian tube, fibroblast, gallbladder, kidney, larynx, liver, lung, lymph node, melanocytes, mesothelial lining, myoepithelial cells, osteoblasts, ovary, pancreas, parotid, prostate, salivary gland, sinus tissue, skeletal muscle, skin, small intestine, smooth muscle, stomach, synovium, joint lining tissue, tendon, testis, thymus, thyroid, uterus, and uterus corpus.

[00313] The methods of the present invention can be used for selecting a treatment of any cancer or tumor type, including but not limited to breast cancer (including HER2+ breast cancer, HER2- breast cancer, ER/PR+, HER2- breast cancer, or triple negative breast cancer), pancreatic cancer, cancer of the colon and/or rectum, leukemia, skin cancer, bone cancer, prostate cancer, liver cancer, lung cancer, brain cancer, cancer of the larynx, gallbladder, parathyroid, thyroid, adrenal, neural tissue, head and neck, stomach, bronchi, kidneys, basal cell carcinoma, squamous cell carcinoma of both ulcerating and papillary type, metastatic skin carcinoma, osteo sarcoma, Ewing's sarcoma, veticulum cell sarcoma, myeloma, giant cell tumor, small-cell lung tumor, islet cell carcinoma, primary brain tumor, acute and chronic lymphocytic and granulocytic tumors, hairy -cell tumor, adenoma, hyperplasia, medullary carcinoma,

pheochromocytoma, mucosal neuroma, intestinal ganglioneuroma, hyperplastic corneal nerve tumor, marfanoid habitus tumor, Wilm's tumor, seminoma, ovarian tumor, leiomyoma, cervical dysplasia and in situ carcinoma, neuroblastoma, retinoblastoma, soft tissue sarcoma, malignant carcinoid, topical skin lesion, mycosis fungoides, rhabdomyosarcoma, Kaposi's sarcoma, osteogenic and other sarcoma, malignant hypercalcemia, renal cell tumor, polycythermia vera, adenocarcinoma, glioblastoma multiforma, leukemias, lymphomas, malignant melanomas, and epidermoid carcinomas. The cancer or tumor can comprise, without limitation, a carcinoma, a sarcoma, a lymphoma or leukemia, a germ cell tumor, a blastoma, or other cancers. Carcinomas that can be assessed using the subject methods include without limitation epithelial neoplasms, squamous cell neoplasms, squamous cell carcinoma, basal cell neoplasms basal cell carcinoma, transitional cell papillomas and carcinomas, adenomas and

adenocarcinomas (glands), adenoma, adenocarcinoma, linitis plastica insulinoma, glucagonoma, gastrinoma, vipoma, cholangiocarcinoma, hepatocellular carcinoma, adenoid cystic carcinoma, carcinoid tumor of appendix, prolactinoma, oncocytoma, hurthle cell adenoma, renal cell carcinoma, grawitz tumor, multiple endocrine adenomas, endometrioid adenoma, adnexal and skin appendage neoplasms, mucoepidermoid neoplasms, cystic, mucinous and serous neoplasms, cystadenoma, pseudomyxoma peritonei, ductal, lobular and medullary neoplasms, acinar cell neoplasms, complex epithelial neoplasms, warthin's tumor, thymoma, specialized gonadal neoplasms, sex cord stromal tumor, thecoma, granulosa cell tumor, arrhenoblastoma, Sertoli leydig cell tumor, glomus tumors, paraganglioma,

pheochromocytoma, glomus tumor, nevi and melanomas, melanocyte nevus, malignant melanoma, melanoma, nodular melanoma, dysplastic nevus, lentigo maligna melanoma, superficial spreading melanoma, and malignant acral lentiginous melanoma. Sarcoma that can be assessed using the subject methods include without limitation Askin's tumor, botryodies, chondrosarcoma, Ewing's sarcoma, malignant hemangio endothelioma, malignant schwannoma, osteosarcoma, soft tissue sarcomas including: alveolar soft part sarcoma, angiosarcoma, cystosarcoma phyllodes, dermatofibrosarcoma, desmoid tumor, desmoplastic small round cell tumor, epithelioid sarcoma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, fibrosarcoma, hemangiopericytoma, hemangiosarcoma, kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, malignant fibrous histiocytoma, neurofibrosarcoma, rhabdomyosarcoma, and synovialsarcoma. Lymphoma and leukemia that can be assessed using the subject methods include without limitation chronic lymphocytic leukemia/small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma (such as Waldenstrom

macroglobulinemia), splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, monoclonal immunoglobulin deposition diseases, heavy chain diseases, extranodal marginal zone B cell lymphoma, also called malt lymphoma, nodal marginal zone B cell lymphoma (nmzl), follicular lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, burkitt lymphoma/leukemia, T cell prolymphocytic leukemia, T cell large granular lymphocytic leukemia, aggressive NK cell leukemia, adult T cell leukemia/lymphoma, extranodal NK/T cell lymphoma, nasal type, enteropathy -type T cell lymphoma, hepatosplenic T cell lymphoma, blastic NK cell lymphoma, mycosis fungoides / sezary syndrome, primary cutaneous CD30-positive T cell lymphoproliferative disorders, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papulosis, angioimmunoblastic T cell lymphoma, peripheral T cell lymphoma, unspecified, anaplastic large cell lymphoma, classical Hodgkin lymphomas (nodular sclerosis, mixed cellularity, lymphocyte -rich, lymphocyte depleted or not depleted), and nodular lymphocyte- predominant Hodgkin lymphoma. Germ cell tumors that can be assessed using the subject methods include without limitation germinoma, dysgerminoma, seminoma, nongerminomatous germ cell tumor, embryonal carcinoma, endodermal sinus turmor, choriocarcinoma, teratoma, polyembryoma, and gonadoblastoma. Blastoma includes without limitation nephroblastoma, medulloblastoma, and retinoblastoma. Other cancers include without limitation labial carcinoma, larynx carcinoma,

hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric carcinoma,

adenocarcinoma, thyroid cancer (medullary and papillary thyroid carcinoma), renal carcinoma, kidney parenchyma carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, testis carcinoma, urinary carcinoma, melanoma, brain tumors such as glioblastoma, astrocytoma, meningioma, medulloblastoma and peripheral neuroectodermal tumors, gall bladder carcinoma, bronchial carcinoma, multiple myeloma, basalioma, teratoma, retinoblastoma, choroidea melanoma, seminoma, rhabdomyosarcoma, craniopharyngeoma, osteosarcoma, chondrosarcoma, myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma, and plasmocytoma.

[00314] In an embodiment, the cancer may be a acute myeloid leukemia (AML), breast carcinoma, cholangiocarcinoma, colorectal adenocarcinoma, extrahepatic bile duct adenocarcinoma, female genital tract malignancy, gastric adenocarcinoma, gastroesophageal adenocarcinoma, gastrointestinal stromal tumors (GIST), glioblastoma, head and neck squamous carcinoma, leukemia, liver hepatocellular carcinoma, low grade glioma, lung bronchioloalveolar carcinoma (BAC), lung non-small cell lung cancer (NSCLC), lung small cell cancer (SCLC), lymphoma, male genital tract malignancy, malignant solitary fibrous tumor of the pleura (MSFT), melanoma, multiple myeloma, neuroendocrine tumor, nodal diffuse large B-cell lymphoma, non epithelial ovarian cancer (non-EOC), ovarian surface epithelial carcinoma, pancreatic adenocarcinoma, pituitary carcinomas, oligodendroglioma, prostatic adenocarcinoma, retroperitoneal or peritoneal carcinoma, retroperitoneal or peritoneal sarcoma, small intestinal malignancy, soft tissue tumor, thymic carcinoma, thyroid carcinoma, or uveal melanoma.

[00315] In a further embodiment, the cancer may be a lung cancer including non-small cell lung cancer and small cell lung cancer (including small cell carcinoma (oat cell cancer), mixed small cell/large cell carcinoma, and combined small cell carcinoma), colon cancer, breast cancer, prostate cancer, liver cancer, pancreas cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, gastric cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, hepatocellular carcinoma, papillary renal carcinoma, head and neck squamous cell carcinoma, leukemia, lymphoma, myeloma, or a solid tumor.

[00316] In embodiments, the cancer comprises an acute lymphoblastic leukemia; acute myeloid leukemia; adrenocortical carcinoma; AIDS-related cancers; AIDS-related lymphoma; anal cancer; appendix cancer; astrocytomas; atypical teratoid/rhabdoid tumor; basal cell carcinoma; bladder cancer; brain stem glioma; brain tumor (including brain stem glioma, central nervous system atypical teratoid/rhabdoid tumor, central nervous system embryonal tumors, astrocytomas, craniopharyngioma, ependymoblastoma, ependymoma, medulloblastoma, medulloepithelioma, pineal parenchymal tumors of intermediate differentiation, supratentorial primitive neuroectodermal tumors and pineoblastoma); breast cancer; bronchial tumors; Burkitt lymphoma; cancer of unknown primary site; carcinoid tumor; carcinoma of unknown primary site; central nervous system atypical teratoid/rhabdoid tumor; central nervous system embryonal tumors;

cervical cancer; childhood cancers; chordoma; chronic lymphocytic leukemia; chronic myelogenous leukemia; chronic myeloproliferative disorders; colon cancer; colorectal cancer; craniopharyngioma; cutaneous T-cell lymphoma; endocrine pancreas islet cell tumors; endometrial cancer;

ependymoblastoma; ependymoma; esophageal cancer; esthesioneuroblastoma; Ewing sarcoma;

extracranial germ cell tumor; extragonadal germ cell tumor; extrahepatic bile duct cancer; gallbladder cancer; gastric (stomach) cancer; gastrointestinal carcinoid tumor; gastrointestinal stromal cell tumor; gastrointestinal stromal tumor (GIST); gestational trophoblastic tumor; glioma; hairy cell leukemia; head and neck cancer; heart cancer; Hodgkin lymphoma; hypopharyngeal cancer; intraocular melanoma; islet cell tumors; Kaposi sarcoma; kidney cancer; Langerhans cell histiocytosis; laryngeal cancer; lip cancer; liver cancer; malignant fibrous histiocytoma bone cancer; medulloblastoma; medulloepithelioma;

melanoma; Merkel cell carcinoma; Merkel cell skin carcinoma; mesothelioma; metastatic squamous neck cancer with occult primary; micropapillary urothelial carcinoma; mouth cancer; multiple endocrine neoplasia syndromes; multiple myeloma; multiple myeloma/plasma cell neoplasm; mycosis fungoides; myelodysplastic syndromes; myeloproliferative neoplasms; nasal cavity cancer; nasopharyngeal cancer; neuroblastoma; Non-Hodgkin lymphoma; nonmelanoma skin cancer; non-small cell lung cancer; oral cancer; oral cavity cancer; oropharyngeal cancer; osteosarcoma; other brain and spinal cord tumors;

ovarian cancer; ovarian epithelial cancer; ovarian germ cell tumor; ovarian low malignant potential tumor; pancreatic cancer; papillomatosis; paranasal sinus cancer; parathyroid cancer; pelvic cancer; penile cancer; pharyngeal cancer; pineal parenchymal tumors of intermediate differentiation; pineoblastoma; pituitary tumor; plasma cell neoplasm/multiple myeloma; pleuropulmonary blastoma; primary central nervous system (CNS) lymphoma; primary hepatocellular liver cancer; prostate cancer; rectal cancer; renal cancer; renal cell (kidney) cancer; renal cell cancer; respiratory tract cancer; retinoblastoma;

rhabdomyosarcoma; salivary gland cancer; Sezary syndrome; small cell lung cancer; small intestine cancer; soft tissue sarcoma; squamous cell carcinoma; squamous neck cancer; stomach (gastric) cancer; supratentorial primitive neuroectodermal tumors; T-cell lymphoma; testicular cancer; throat cancer; thymic carcinoma; thymoma; thyroid cancer; transitional cell cancer; transitional cell cancer of the renal pelvis and ureter; trophoblastic tumor; ureter cancer; urethral cancer; uterine cancer; uterine sarcoma; vaginal cancer; vulvar cancer; Waldenstrom macroglobulinemia; or Wilm's tumor.

[00317] The methods of the invention can be used to determine biomarker patterns or biomarker signature sets in a number of tumor types, diseased tissue types, or diseased cells including accessory, sinuses, middle and inner ear, adrenal glands, appendix, hematopoietic system, bones and joints, spinal cord, breast, cerebellum, cervix uteri, connective and soft tissue, corpus uteri, esophagus, eye, nose, eyeball, fallopian tube, extrahepatic bile ducts, other mouth, intrahepatic bile ducts, kidney, appendix-colon, larynx, lip, liver, lung and bronchus, lymph nodes, cerebral, spinal, nasal cartilage, excl. retina, eye, nos, oropharynx, other endocrine glands, other female genital, ovary, pancreas, penis and scrotum, pituitary gland, pleura, prostate gland, rectum renal pelvis, ureter, peritonem, salivary gland, skin, small intestine, stomach, testis, thymus, thyroid gland, tongue, unknown, urinary bladder, uterus, nos, vagina & labia, and vulva,nos.

[00318] In some embodiments, the molecular profiling methods are used to identify a treatment for a cancer of unknown primary (CUP). Approximately 40,000 CUP cases are reported annually in the US. Most of these are metastatic and/or poorly differentiated tumors. Because molecular profiling can identify a candidate treatment depending only upon the diseased sample, the methods of the invention can be used in the CUP setting. Moreover, molecular profiling can be used to create signatures of known tumors, which can then be used to classify a CUP and identify its origin. In an aspect, the invention provides a method of identifying the origin of a CUP, the method comprising performing molecular profiling on a panel of diseased samples to determine a panel of molecular profiles that correlate with the origin of each diseased sample, performing molecular profiling on a CUP sample, and correlating the molecular profile of the CUP sample with the molecular profiling of the panel of diseased samples, thereby identifying the origin of the CUP sample. The identification of the origin of the CUP sample can be made by matching the molecular profile of the CUP sample with the molecular profiles that correlate most closely from the panel of disease samples.

[00319] The biomarker patterns or biomarker signature sets of the cancer or tumor can be used to determine a therapeutic agent or therapeutic protocol that is capable of interacting with the biomarker pattern or signature set. For example, with advanced breast cancer, immunohistochemistry analysis can be used to determine one or more proteins that are overexpressed. Accordingly, a biomarker pattern or biomarker signature set can be identified for advanced stage breast cancer and a therapeutic agent or therapeutic protocol can be identified with predicted benefit (or lack thereof) for the patient.

[00320] The biomarker patterns and/or biomarker signature sets can comprise pluralities of biomarkers. In yet other embodiments, the biomarker patterns or signature sets can comprise at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 biomarkers. In some embodiments, the biomarker signature sets or biomarker patterns can comprise at least 15, 20, 30, 40, 50, or 60 biomarkers. In some embodiments, the biomarker signature sets or biomarker patterns can comprise at least 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10,000, 15,000, 20,000, 25,000, 30,000, 35,000, 40,000, 45,000 or 50,000 biomarkers. Analysis of the one or more biomarkers can be by one or more methods. For example, analysis of 2 biomarkers can be performed using sequence analysis. Alternatively, one biomarker may be analyzed by IHC and another by sequencing. Any such combinations of useful methods and biomarkers are contemplated herein.

[00321] As described herein, the molecular profiling of one or more targets can be used to determine or identify a therapeutic for an individual. For example, the expression level of one or more biomarkers can be used to determine or identify a therapeutic for an individual. The one or more biomarkers, such as those disclosed herein, can be used to form a biomarker pattern or biomarker signature set, which is used to identify a therapeutic for an individual. In some embodiments, the therapeutic identified is one that the individual has not previously been treated with. For example, a reference biomarker pattern has been established for a particular therapeutic, such that individuals with the reference biomarker pattern will be responsive to that therapeutic. An individual with a biomarker pattern that differs from the reference, for example the expression of a gene in the biomarker pattern is changed or different from that of the reference, would not be administered that therapeutic. In another example, an individual exhibiting a biomarker pattern that is the same or substantially the same as the reference is advised to be treated with that therapeutic. In some embodiments, the individual has not previously been treated with that therapeutic and thus a new therapeutic has been identified for the individual.

[00322] Molecular profiling according to the invention can take on a biomarker-centric or a therapeutic- centric point of view. Although the approaches are not mutually exclusive, the biomarker-centric approach focuses on sets of biomarkers that are expected to be informative for a tumor of a given tumor lineage, whereas the therapeutic -centric point approach identifies candidate therapeutics using biomarker panels that are lineage independent. In a biomarker-centric view, panels of specific biomarkers are run on different tumor types. This approach provides a method of identifying a candidate therapeutic by collecting a sample from a subject with a cancer of known origin, and performing molecular profiling on the cancer for specific biomarkers depending on the origin of the cancer. The molecular profiling can be performed using any of the various techniques disclosed herein. As an example, biomarker panels may include those for breast cancer, ovarian cancer, colorectal cancer, lung cancer, and a profile to run on any cancer. See e.g., Table 5 for marker profiles that can be assessed for various cancer lineages. Markers can be assessed using various techniques such as sequencing approaches (NGS, pyrosequencing, etc), ISH (e.g., FISH/CISH), and for protein expression, e.g., using IHC. The candidate therapeutic can be selected based on the molecular profiling results according to the subject methods. A potential advantage to the bio-marker centric approach is only performing assays that are most likely to yield informative results in a given lineage. Another potential advantage is that this approach can focus on identifying therapeutics conventionally used to treat cancers of the specific lineage. In a therapeutic-centric approach, the biomarkers assessed are not dependent on the origin of the tumor. Rather, this approach provides a method of identifying a candidate therapeutic by collecting a sample from a subject with any given cancer, and performing molecular profiling on the cancer for a panel of biomarkers without regards to the origin of the cancer. The molecular profiling can be performed using any of the various techniques disclosed herein, e.g., such as described above. The candidate therapeutic is selected based on the molecular profiling results according to the subject methods. A potential advantage to the therapeutic- marker centric approach is that the most promising therapeutics are identified only taking into account the molecular characteristics of the tumor itself. Another advantage is that the method can be preferred for a cancer of unidentified primary origin (CUP). In some embodiments, a hybrid of biomarker-centric and therapeutic -centric points of view is used to identify a candidate therapeutic. This method comprises identifying a candidate therapeutic by collecting a sample from a subject with a cancer of known origin, and performing molecular profiling on the cancer for a comprehensive panel of biomarkers, wherein a portion of the markers assessed depend on the origin of the cancer. For example, consider a breast cancer. A comprehensive biomarker panel may be run on the breast cancer, e.g., that for any solid tumor as described herein, but additional sequencing analysis is performed on one or more additional markers, e.g., BRCA1 or any other marker with mutations informative for theranosis or prognosis of the breast cancer. Theranosis can be used to refer to the likely efficacy of a therapeutic treatment. Prognosis refers to the likely outcome of an illness. One of skill will apprecitate that the hybrid approach can be used to identify a candidate therapeutic for any cancer having additional biomarkers that provide theranostic or prognostic information, including the cancers disclosed herein.

[00323] The genes and gene products used for molecular profiling, e.g., by IHC, ISH, sequencing (e.g., NGS), and/or PCR (e.g., qPCR), can be selected from those listed in any of Tables 4-12, e.g, any of Tables 5-10, or according to Table 5. Assessing one or more biomarkers disclosed herein can be used for characterizing any of the cancers disclosed herein. Characterizing includes the diagnosis of a disease or condition, the prognosis of a disease or condition, the determination of a disease stage or a condition stage, a drug efficacy, a physiological condition, organ distress or organ rejection, disease or condition progression, therapy-related association to a disease or condition, or a specific physiological or biological state.

[00324] A cancer in a subject can be characterized by obtaining a biological sample from a subject and analyzing one or more biomarkers from the sample. For example, characterizing a cancer for a subject or individual may include detecting a disease or condition (including pre-symptomatic early stage detecting), determining the prognosis, diagnosis, or theranosis of a disease or condition, or determining the stage or progression of a disease or condition. Characterizing a cancer can also include identifying appropriate treatments or treatment efficacy for specific diseases, conditions, disease stages and condition stages, predictions and likelihood analysis of disease progression, particularly disease recurrence, metastatic spread or disease relapse. Characterizing can also be identifying a distinct type or subtype of a cancer. The products and processes described herein allow assessment of a subject on an individual basis, which can provide benefits of more efficient and economical decisions in treatment.

[00325] In an aspect, characterizing a cancer includes predicting whether a subject is likely to respond to a treatment for the cancer. As used herein, a "responder" responds to or is predicted to respond to a treatment and a "non-responder" does not respond or is predicted to not respond to the treatment. Biomarkers can be analyzed in the subject and compared to biomarker profiles of previous subjects that were known to respond or not to a treatment. If the biomarker profile in a subject more closely aligns with that of previous subjects that were known to respond to the treatment, the subject can be characterized, or predicted, as a responder to the treatment. Similarly, if the biomarker profile in the subject more closely aligns with that of previous subjects that did not respond to the treatment, the subject can be characterized, or predicted as a non-responder to the treatment.

[00326] The sample used for characterizing a cancer can be any disclosed herein, including without limitation a tissue sample, tumor sample, or a bodily fluid. Bodily fluids that can be used included without limitation peripheral blood, sera, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen (including prostatic fluid), Cowper's fluid or pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, malignant effusion, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates or other lavage fluids. In an embodiment, the sample comprises vesicles. The biomarkers can be associated with the vesicles. In some embodiments, vesicles are isolated from the sample and the biomarkers associated with the vesicles are assessed.

[00327] Molecular profiling according to the invention can be used to guide treatment selection for cancers at any stage of disease or prior treatment. Molecular profiling comprises assessment of various biological characteristics including without limitation DNA mutations, gene rearrangements, gene copy number variation, R A expression, gene fusions, protein expression, as well as assessment of other biological entities and phenomena that can inform clinical decision making. In some embodiments, the methods herein are used to guide selection of candidate treatments using the standard of care treatments for a particular type or lineage of cancer. Profiling of biomarkers that implicate standard-of-care treatments may be used to assist in treatment selection for a newly diagnosed cancer having multiple treatment options. Standard-of-care treatments may comprise NCCN on-compendium treatments or other standard treatments used for a cancer of a given lineage. One of skill will appreciate that such profiles can be updated as the standard of care and/or availability of experimental agents for a given disease lineage change. In other embodiments, molecular profiling is performed for additional biomarkers to identify treatments as beneficial or not beyond that go beyond the standard-of-care for a particular lineage or stage of the cancer. Such comprehensive profiling can be performed to assess a wide panel of druggable or drug-associated biomarker targets for any biological sample or specimen of interest. The comprehensive profile can also be used to guide selection of candidate treatments for any cancer at any point of care. The comprehensive profile may also be preferable when standard-of-care treatments not expected to provide further benefit, such as in the salvage treatment setting for recurrent cancer or wherein all standard treatments have been exhausted. For example, the comprehensive profile may be used to assist in treatment selection when standard therapies are not an option for any reason including, without limitation, when standard treatments have been exhausted for the patient. The comprehensive profile may be used to assist in treatment selection for highly aggressive or rare tumors with uncertain treatment regimens. For example, a comprehensive profile can be used to identify a candidate treatment for a newly diagnosed case or when the patient has exhausted standard of care therapies or has an aggressive disease. In practice, molecular profiling according to the invention has indeed identified beneficial therapies for a cancer patient when all standard-of-care treatments were exhausted the treating physician was unsure ofwhat treatment to select next. See the Examples herein. One of skill in the art will appreciate that by its very nature a comprehensive molecular profiling can be used to select a therapy for any appropriate indication independent of the nature of the indication (e.g., source, stage, prior treatment, etc). However, in some embodiments, a comprehensive molecular profile is tailored for a particular indication. For example, biomarkers associated with treatments that are known to be ineffective for a cancer from a particular lineage or anatomical origin may not be assessed as part of a comprehensive molecular profile for that particular cancer. Similarly, biomarkers associated with treatments that have been previously used and failed for a particular patient may not be assessed as part of a comprehensive molecular profile for that particular patient. In yet another non-limiting example, biomarkers associated with treatments that are only known to be effective for a cancer from a particular anatomical origin may only be assessed as part of a comprehensive molecular profile for that particular cancer. One of skill will further appreciate that the comprehensive molecular profile can be updated to reflect advancements, e.g., new treatments, new biomarker-drug associations, and the like, as available.

Molecular Intelligence Profiles

[00328] The invention provides molecular intelligence (MI) molecular profiles using a variety of techniques to assess panels of biomarkers in order to identity candidate therapeutics as potentially beneficial or potentially of lack of benefit for treating a cancer. Such techniques comprise IHC for protein expression profiling, CISH/FISH for DNA copy number and rearrangement, and Sanger sequencing, pyrosequencing, PCR, RFLP, fragment analysis and Next Generation sequencing for aspects such as mutations (including insertions and deletions), fusions, copy number and expression. Exemplary profiles are described in Tables 5-10 herein. The profiling can be performed using the biomarker - drug associations and related rules for the various cancer lineages as described herein. In some embodiments, the associations are according to any one of Tables 2-3 or Table 11. Additional biomarker - drug associations can be found in any of International Patent Publications WO/2007/137187 (Int'l Appl. No. PCT/US2007/069286), published November 29, 2007; WO/2010/045318 (Int'l Appl. No.

PCT/US2009/060630), published April 22, 2010; WO/2010/093465 (Int'l Appl. No. PCT/US2010/000407), published August 19, 2010; WO/2012/170715 (Int'l Appl. No.

PCT/US2013/073184), published June 12, 2014; WO/2011/056688 (Int'l Appl. No.

PCT/US2010/054366), published May 12, 2011; WO/2012/092336 (Int'l Appl. No.

PCT/US2011/067527), published July 5, 2012; WO/2015/116868 (Int'l Appl. No. PCT/US2015/013618), published August 6, 2015; WO/2017/053915 (Int'l Appl. No. PCT/US2016/053614), published March 30, 2017; and WO/2016/141169 (Int'l Appl. No. PCT/US2016/020657), published September 9, 2016; each of which publications is incorporated by reference herein in its entirety. Molecular intelligence profiles may include analysis of a panel of genes linked to known therapies and clinical trials, as well as genes that are known to be involved in cancer and have alternative clinical utilities including predictive, prognostic or diagnostic uses, genes provided in Tables 5-10 without a drug association denoted in Table 11. The panel may be assessed using Next Generation sequencing analysis, e.g., according to the panel of genes and characteristics in Tables 6-10.

[00329] The biomarkers which comprise the molecular intelligence molecular profiles can include genes or gene products that are known to be associated directly with a particular drug or class of drugs. The biomarkers can also be genes or gene products that interact with such drug associated targets, e.g., as members of a common pathway. The biomarkers can be selected from any of International Patent Publications WO/2007/137187 (Int'l Appl. No. PCT/US2007/069286), published November 29, 2007; WO/2010/045318 (Int'l Appl. No. PCT/US2009/060630), published April 22, 2010; WO/2010/093465 (Int'l Appl. No. PCT/US2010/000407), published August 19, 2010; WO/2012/170715 (Int'l Appl. No. PCT/US2012/041393), published December 13, 2012; WO/2014/089241 (Int'l Appl. No.

PCT/US2013/073184), published June 12, 2014; WO/2011/056688 (Int'l Appl. No.

PCT/US2010/054366), published May 12, 2011; WO/2012/092336 (Int'l Appl. No.

PCT/US2011/067527), published July 5, 2012; WO/2015/116868 (Int'l Appl. No. PCT/US2015/013618), published August 6, 2015; WO/2017/053915 (Int'l Appl. No. PCT/US2016/053614), published March 30, 2017; and WO/2016/141169 (Int'l Appl. No. PCT/US2016/020657), published September 9, 2016; each of which publications is incorporated by reference herein in its entirety. In some embodiments, the genes and/or gene products included in the molecular intelligence (MI) molecular profiles are selected from

Table 4. For example, the molecular profiles can be performed for at least one, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 or 76 of lpl9q, ABL1, AKT1, ALK, APC, AR, AREG, ATM, BRAF, BRCA1, BRCA2, CDH1, CSF1R, CTNNB 1, EGFR, EGFRvIII, ER, ERBB2, ERBB3, ERBB4, ERCC1, EREG, FBXW7, FGFR1, FGFR2, FLT3, GNA11, GNAQ, GNAS, H3K36me3, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT (cKit), KRAS, MET (cMET), MGMT, MLH1, MPL, MSH2, MSH6, MSI, NOTCH1, NPM1, NRAS, PBRM1, PDGFRA, PD-1, PD-L1, PGP, PIK3CA (PI3K), PMS2, PR, PTEN, PTPN11, RBI, RET, ROS 1, RRM1, SMAD4, SMARCB1, SMO, SPARC, STK11, TLE3, TOP2A, TOPOl, TP53, TS, TUBB3, VHL, and VEGFR2. The biomarkers can be assessed using the laboratory methods as listed in Tables 5-11, or using similar analysis methodology such as disclosed herein.

Table 4: Exemplary Genes and Gene Products and Related Therapies lpl9q lpl9q codeletions result from an unbalanced translocation between the p and q arms in chromosomes 1 and 19, respectively. Along with IDH mutations, lpl9q deletions are associated with oligodendroglioma tumorigenesis. Rates of lpl9q codeletion are especially high in low-grade and anaplastic oligodendroglioma. By contrast, lpl9q codeletions are lower in high grade gliomas like anaplastic astrocytoma and glioblastoma multiforme. NCCN Central Nervous System Guidelines mention lpl9q codeletions are indicative of a better prognosis in oligodendroglioma. Prospective studies indicate lpl9q codeletions are associated with potential benefit to PCV (procarbazine, CCNU [lomustine], vincristine) chemotherapy in anaplastic oligodendroglial tumors.

ABLl ABLl also known as Abelson murine leukemia homolog 1. Most CML patients have a chromosomal abnormality due to a fusion between Abelson (Abl) tyrosine kinase gene at chromosome 9 and break point cluster (Bcr) gene at chromosome 22 resulting in constitutive activation of the Bcr- Abl fusion gene. Imatinib is a Bcr- Abl tyrosine kinase inhibitor commonly used in treating CML patients. Mutations in the ABLl gene are common in imatinib resistant CML patients which occur in 30-90% of patients. However, more than 50 different point mutations in the ABLl kinase domain may be inhibited by the second generation kinase inhibitors, dasatinib, bosutinib and nilotinib. The gatekeeper mutation, T315I that causes resistance to all currently approved TKIs accounts for about 15% of the mutations found in patients with imatinib resistance. BCR- ABLl mutation analysis is recommended to help facilitate selection of appropriate therapy for patients with CML after treatment with imatinib fails.

AKT1 AKT1 gene (v-akt murine thymoma viral oncogene homologue 1) encodes a serine/threonine kinase which is a pivotal mediator of the PI3K-related signaling pathway, affecting cell survival, proliferation and invasion. Dysregulated AKT activity is a frequent genetic defect implicated in tumorigenesis and has been indicated to be detrimental to hematopoiesis. Activating mutation E17K has been described in breast (2-4%), endometrial (2-4%), bladder cancers (3%), NSCLC (1%), squamous cell carcinoma of the lung (5%) and ovarian cancer (2%). This mutation in the pleckstrin homology domain facilitates the recruitment of AKT to the plasma membrane and subsequent activation by altering phosphoinositide binding. A mosaic activating mutation E17K has also been suggested to be the cause of Proteus syndrome. Mutation E49K has been found in bladder cancer, which enhances AKT activation and shows transforming activity in cell lines.

ALK ALK or anaplastic lymphoma receptor tyrosine kinase belongs to the insulin receptor superfamily. It has been found to be rearranged or mutated in tumors including anaplastic large cell lymphomas, neuroblastoma, anaplastic thyroid cancer and non- small cell lung cancer. EML4-ALK fusion or point mutations of ALK result in the constitutively active ALK kinase, causing aberrant activation of downstream signaling pathways including RAS-ERK, JAK3-STAT3 and PI3K-AKT. Patients with an EML4- ALK rearrangement are likely to respond to the ALK-targeted agent crizotinib and ceritinib. ALK secondary mutations found in NSCLC have been associated with acquired resistance to ALK inhibitor, crizotinib and ceritinib.

AR The androgen receptor (AR) gene encodes for the androgen receptor protein, a member of the steroid receptor family. Like other members of the nuclear steroid receptor family, AR is a DNA-binding transcription factor activated by specific hormones, in this case testosterone or DHT. Mutations of this gene are not often found in untreated, localized prostate cancer. Instead, they occur more frequently in hormone-refractory, androgen-ablated, and metastatic tumors. Recent findings indicate that specific mutations in AR (e.g. F876L, AR-V7) are associated with resistance to newer- generation, AR-targeted therapies such as enzalutamide.

APC APC or adenomatous polyposis coli is a key tumor suppressor gene that encodes for a large multi-domain protein. This protein exerts its tumor suppressor function in the Wnt/B-catenin cascade mainly by controlling the degradation of β-catenin, the central activator of transcription in the Wnt signaling pathway. The Wnt signaling pathway mediates important cellular functions including intercellular adhesion, stabilization of the cytoskeleton, and cell cycle regulation and apoptosis, and it is important in embryonic development and oncogenesis. Mutation in APC results in a truncated protein product with abnormal function, lacking the domains involved in β-catenin degradation. Somatic mutation in the APC gene can be detected in the majority of colorectal tumors (80%) and it is an early event in colorectal tumorigenesis. APC wild type patients have shown better disease control rate in the metastatic setting when treated with oxaliplatin, while when treated with fluoropyrimidine regimens, APC wild type patients experience more hematological toxicities. APC mutation has also been identified in oral squamous cell carcinoma, gastric cancer as well as hepatoblastoma and may contribute to cancer formation. Germline mutation in APC causes familial adenomatous polyposis, which is an autosomal dominant inherited disease that will inevitably develop to colorectal cancer if left untreated. COX-2 inhibitors including celecoxib may reduce the recurrence of adenomas and incidence of advanced adenomas in individuals with an increased risk of CRC. Turcot syndrome and Gardner's syndrome have also been associated with germline APC defects. Germline mutations of the APC have also been associated with an increased risk of developing desmoid disease, papillary thyroid carcinoma and hepatoblastoma.

A REG AREG, also known as amphiregulin, is a ligand of the epidermal growth factor receptor. Overexpression of AREG in primary colorectal cancer patients has been associated with increased clinical benefit from cetuximab in KRAS wildtype patients.

ATM ATM or ataxia telangiectasia mutated is activated by DNA double-strand breaks and

DNA replication stress. It encodes a protein kinase that acts as a tumor suppressor and regulates various biomarkers involved in DNA repair, which include p53, BRCA1, CHK2, RAD 17, RAD9, and NBS1. Although ATM is associated with hematologic malignancies, somatic mutations have been found in colon (18%), head and neck (14%), and prostate (12%) cancers. Inactivating ATM mutations make patients potentially more susceptible to PARP inhibitors. Germline mutations in ATM are associated with ataxia-telangiectasia (also known as Louis-Bar syndrome) and a predisposition to malignancy.

BRAF BRAF encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway initiated by EGFR activation, which affects cell division, differentiation, and secretion. BRAF somatic mutations have been found in melanoma (43%), thyroid (39%), biliary tree (14%), colon (12%), and ovarian tumors (12%). A BRAF enzyme inhibitor, vemurafenib, was approved by FDA to treat unresectable or metastatic melanoma patients harboring BRAF V600E mutations. BRAF inherited mutations are associated with Noonan/Cardio-Facio-Cutaneous (CFC) syndrome, syndromes associated with short stature, distinct facial features, and potential heart/skeletal abnormalities.

BRCA1 BRCA1 or breast cancer type 1 susceptibility gene encodes a protein involved in cell growth, cell division, and DNA-damage repair. It is a tumor suppressor gene which plays an important role in mediating double-strand DNA breaks by homologous recombination (HR). Tumors with BRCA1 mutation may be more sensitive to platinum agents and PARP inhibitors.

BRCA2 BRCA2 or breast cancer type 2 susceptibility gene encodes a protein involved in cell growth, cell division, and DNA-damage repair. It is a tumor suppressor gene which plays an important role in mediating double-strand DNA breaks by homologous recombination (HR). Tumors with BRCA2 mutation may be more sensitive to platinum agents and PARP inhibitors.

CDH1 This gene is a classical cadherin from the cadherin superfamily. The encoded protein is a calcium dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. The protein plays a major role in epithelial architecture, cell adhesion and cell invasion. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid and ovarian cancer. Loss of function is thought to contribute to progression in cancer by increasing proliferation, invasion, and/or metastasis. The ectodomain of this protein mediates bacterial adhesion to mammalian cells and the cytoplasmic domain is required for internalization.

CSF1R CSF1R or colony stimulating factor 1 receptor gene encodes a transmembrane tyrosine kinase, a member of the CSF1/PDGF receptor family. CSF1R mediates the cytokine (CSF-1) responsible for macrophage production, differentiation, and function. Although associated with hematologic malignancies, mutations of this gene are associated with cancers of the liver (21%), colon (13%), prostate (3%), endometrium (2%), and ovary (2%). It is suggested that patients with CSF1R mutations could respond to imatinib.Germline mutations in CSF1R are associated with diffuse leukoencephalopathy, a rapidly progressive neurodegenerative disorder.

CTN B1 CTNNB 1 or cadherin-associated protein, beta 1, encodes for β-catenin, a central mediator of the Wnt signaling pathway which regulates cell growth, migration, differentiation and apoptosis. Mutations in CTNNB1 (often occurring in exon 3) prevent the breakdown of β-catenin, which allows the protein to accumulate resulting in persistent transactivation of target genes, including c-myc and cyclin-D 1. Somatic CTNNB1 mutations occur in 1-4% of colorectal cancers, 2-3% of melanomas, 25-38% of endometrioid ovarian cancers, 84-87% of sporadic desmoid tumors, as well as the pediatric cancers, hepatoblastoma, medulloblastoma and Wilms' tumors.

EGFR EGFR or epidermal growth factor receptor, is a transmembrane receptor tyrosine kinase belonging to the ErbB family of receptors. Upon ligand binding, the activated receptor triggers a series of intracellular pathways (Ras/MAPK, PI3K Akt, JAK-STAT) that result in cell proliferation, migration and adhesion. EGFR mutations have been observed in 20-25% of non-small cell lung cancer (NSCLC), 10% of endometrial and peritoneal cancers. Somatic gain-of-function EGFR mutations, including in-frame deletions in exon 19 or point mutations in exon 21, confer sensitivity to first- and second-generation tyrosine kinase inhibitors (TKIs, e.g., erlotinib, gefitinib and afatinib), whereas the secondary mutation, T790M in exon 20, confers reduced response. Non-small cell lung cancer cancer patients overexpressing EGFR protein have been found to respond to the EGFR monoclonal antibody, cetuximab. Germline mutations and polymorphisms of EGFR have been associated with familial lung adenocarcinomas .

EGFRvIII EGFRvIII is a mutated form of EGFR with deletion of exon 2 to 7 on the extracellular ligand-binding domain. This genetic alteration has been found in about 30% of glioblastoma, 30% of head and neck squamous cell cancer, 30% of breast cancer and 15% of NSCLC, and has not been found in normal tissue. EGFRvIII can form homo- dimers or heterodimers with EGFR or ERBB2, resulting in constitutive activation in the absence of ligand binding, activating various downstream signaling pathways including the PI3K and MAPK pathways, leading to increased cell proliferation and motility as well as inhibition of apoptosis. Preliminary studies have shown that EGFRvIII expression may associate with higher sensitivity to erlotinib and gefitinib, as well as to pan-Her inhibitors including neratinib and dacomitinib. EGFRvIII peptide vaccine rindopepimut (CDX-110) and monoclonal antibodies specific to EGFRvIII including ABT-806 and AMG595 are being investigated in clinical trials.

ER The estrogen receptor (ER) is a member of the nuclear hormone family of intracellular receptors which is activated by the hormone estrogen. It functions as a DNA binding transcription factor to regulate estrogen-mediated gene expression. Estrogen receptors overexpressing breast cancers are referred to as 'ER positive.' Estrogen binding to ER on cancer cells leads to cancer cell proliferation. Breast tumors over-expressing ER are treated with hormone-based anti-estrogen therapy. For example, everolimus combined with exemestane may improve survival in ER positive Her2 negative breast cancer patients who are resistant to aromatase inhibitors.

ERBB2 ERBB2 (HER2 (human epidermal growth factor receptor 2)) or v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This gene binds to other ligand- bound EGF receptor family members to form a heterodimer and enhances kinase- mediated activation of downstream signaling pathways, leading to cell proliferation. Most common mechanism for activation of HER2 are gene amplification and over- expression with somatic mutations being rare. Her2 is overexpressed in 15-30% of newly diagnosed breast cancers. Clinically, Her2 is a target for the monoclonal antibodies trastuzumab and pertuzumab which bind to the receptor extracellularly; the kinase inhibitor lapatinib binds and blocks the receptor intracellularly.

ERBB3 ERBB3 encodes a protein (HER3 (human epidermal growth factor receptor 3)) that is a member of the EGFR family of protein tyrosine kinases. ERBB3 protein does not actually contain a kinase domain itself, but it can activate other members of the EGFR kinase family by forming heterodimers. Heterodimerization with other kinases triggers an intracellular cascade increasing cell proliferation. Mutations in ERBB3 have been observed primarily in gastric cancer and cancer of the gall bladder. Other tissue types known to harbor ERBB3 mutations include hormone-positive breast cancer, glioblastoma, ovarian, colon, head and neck and lung.

ERBB4 ERBB4 (HER4) is a member of the Erbb receptor family known to play a pivotal role in cell-cell signaling and signal transduction regulating cell growth and development. The most commonly affected signaling pathways are the PI3K-Akt and MAP kinase pathways. Erbb4 was found to be somatically mutated in 19% of melanomas and Erbb4 mutations may confer "oncogene addiction" on melanoma cells. Erbb4 mutations have also been observed in various other cancer types, including, gastric carcinomas (2%), colorectal carcinomas (1-3%), non-small cell lung cancer (2-5%) and breast carcinomas

(i%).

ERCC1 ERCC1, or excision repair cross-complementation group 1, is a key component of the nucleotide excision repair (NER) pathway. NER is a DNA repair mechanism necessary for the repair of DNA damage from a variety of sources including platinum agents. Tumors with low expression of ERCC1 have impaired NER capacity and may be more sensitive to platinum agents.

EREG EREG, also known as epiregulin, is a ligand of the epidermal growth factor receptor.

Overexpression of EREG in primary colorectal cancer patients has been related to clinical outcome in KRAS wildtype patients treated with cetuximab indicating ligand driven autocrine oncogenic EGFR signaling.

FBXW7 FBXW7 or E3 ligase F-box and WD repeat domain containing 7, also known as Cdc4, encodes three protein isoforms which constitute a component of the ubiquitin- proteasome complex. Mutation of FBXW7 occurs in hotspots and disrupts the recognition of and binding with substrates which inhibits the proper targeting of proteins for degradation (e.g. Cyclin E, c-Myc, SREBP1, c-Jun, Notch-1, mTOR and MCL1). Mutation frequencies identified in cholangiocarcinomas, acute T- lymphoblastic leukemia/lymphoma, and carcinomas of endometrium, colon and stomach are 35%, 31%, 9%, 9%, and 6%, respectively. Targeting an oncoprotein downstream of FBXW7, such as mTOR or c-Myc, may provide a therapeutic strategy. Tumor cells with mutated FBXW7 may be sensitive to rapamycin treatment, suggesting FBXW7 loss (mutation) may be a predictive biomarker for treatment with inhibitors of the mTOR pathway. In addition, it has been proposed that loss of FBXW7 confers resistance to tubulin-targeting agents like paclitaxel or vinorelbine, by interfering with the degradation of MCL1, a regulator of apoptosis.

FGFR1 FGFR1 or fibroblast growth factor receptor 1, encodes for FGFR1 which is important for cell division, regulation of cell maturation, formation of blood vessels, wound healing and embryonic development. Somatic activating mutations are rare, but have been documented in melanoma, glioblastoma, and lung tumors. Germline, gain-of- function mutations in FGFR1 result in developmental disorders including Kallmann syndrome and Pfeiffer syndrome. Preclinical studies suggest that FGFR1 amplification may be associated with endocrine resistance in breast cancer. FGFR1 amplification has been observed in various cancer types including breast cancer, squamous cell lung cancer, head and neck squamous cell cancer and esophageal cancer and may indicate sensitivity to FGFR-targeted therapies.

FGFR2 FGFR2 is a receptor for fibroblast growth factor. Activation of FGFR2 through mutation and amplification has been noted in a number of cancers. Somatic mutations of the fibroblast growth factor receptor 2 (FGFR2) tyrosine kinase are present in endometrial carcinoma, lung squamous cell carcinoma, cervical carcinoma, and melanoma. In the endometrioid histology of endometrial cancer, the frequency of FGFR2 mutation is 16% and the mutation is associated with shorter disease free survival in patients diagnosed with early stage disease. Loss of function FGFR2 mutations occur in about 8% melanomas and contribute to melanoma pathogenesis. Germline mutations in FGFR2 are associated with numerous medical conditions that include congenital craniofacial malformation disorders, Apert syndrome and the related Pfeiffer and Crouzon syndromes. Amplification of FGFR2 has been shown in 5-10% of gastric cancer and breast cancer and may indicate sensitivity to FGFR-targeted therapies.

FLT3 FLT3 or Fms-like tyrosine kinase 3 receptor is a member of class III receptor tyrosine kinase family, which includes PDGFRA/B and KIT. Signaling through FLT3 ligand- receptor complex regulates hematopoiesis, specifically lymphocyte development. The FLT3 internal tandem duplication (FLT3-ITD) is the most common genetic lesion in acute myeloid leukemia (AML), occurring in 25% of cases. FLT3 mutations are uncommon in solid tumors; however they have been documented in breast cancer.

GNA11 GNA11 is a proto-oncogene that belongs to the Gq family of the G alpha family of G protein coupled receptors. Known downstream signaling partners of GNA11 are phospholipase C beta and RhoA and activation of GNA11 induces MAPK activity. Over half of uveal melanoma patients lacking a mutation in GNAQ exhibit somatic mutations in GNA11. Activating mutations of GNA11 have not been found in other malignancies. GNAQ This gene encodes the Gq alpha subunit of G proteins. G proteins are a family of heterotrimeric proteins coupling seven-transmembrane domain receptors. Oncogenic mutations in GNAQ result in a loss of intrinsic GTPase activity, resulting in a constitutively active Galpha subunit. This results in increased signaling through the MAPK pathway. Somatic mutations in GNAQ have been found in 50% of primary uveal melanoma patients and up to 28% of uveal melanoma metastases.

GNAS GNAS (or GNAS complex locus) encodes a stimulatory G protein alpha-subunit. These guanine nucleotide binding proteins (G proteins) are a family of heterotrimeric proteins which couple seven-transmembrane domain receptors to intracellular cascades. Stimulatory G-protein alpha-subunit transmits hormonal and growth factor signals to effector proteins and is involved in the activation of adenylate cyclases. Mutations of GNAS gene at codons 201 or 227 lead to constitutive cAMP signaling. GNAS somatic mutations have been found in pituitary (28%), pancreatic (20%), ovarian (11%), adrenal gland (6%), and colon (6%) cancers. Patients with somatic GNAS mutations may derive benefit from clinical trials with MEK inhibitors. Germline mutations of GNAS have been shown to be the cause of McCune -Albright syndrome (MAS), a disorder marked by endocrine, dermatologic, and bone abnormalities. GNAS is usually found as a mosaic mutation in patients. Loss of function mutations are associated with pseudohypoparathyroidism and pseudopseudohypoparathyroidism.

H3K36me3 Trimethylated histone H3 lysine 36 (H3K36me3) is a chromatin regulatory protein that regulates gene expression. A loss of H3K36me3 protein correlates with loss of expression or mutation of SETD2 which is a member of the SET domain family of histone methyltransferases. Loss of SETD2 as well as H3K36m3 protein has been detected in various solid tumors including renal cell carcinoma and breast cancer and leads to poor prognosis.

HRAS HRAS (homologous to the oncogene of the Harvey rat sarcoma virus), together with

KRAS and NRAS, belong to the superfamily of RAS GTPase. RAS protein activates RAS-MEK-ERK/MAPK kinase cascade and controls intracellular signaling pathways involved in fundamental cellular processes such as proliferation, differentiation, and apoptosis. Mutant Ras proteins are persistently GTP -bound and active, causing severe dysregulation of the effector signaling. HRAS mutations have been identified in cancers from the urinary tract (10%-40%), skin (6%) and thyroid (4%) and they account for 3% of all RAS mutations identified in cancer. RAS mutations (especially HRAS mutations) occur (5%) in cutaneous squamous cell carcinomas and keratoacanthomas that develop in patients treated with BRAF inhibitor vemurafenib, likely due to the paradoxical activation of the MAPK pathway. Germline mutation in HRAS has been associated with Costello syndrome, a genetic disorder that is characterized by delayed development and mental retardation and distinctive facial features and heart abnormalities.

IDH1 IDH1 encodes for isocitrate dehydrogenase in cytoplasm and is found to be mutated in

60-90% of secondary gliomas, 75% of cartilaginous tumors, 17% of thyroid tumors, 15% of cholangiocarcinoma, 12-18% of patients with acute myeloid leukemia, 5% of primary gliomas, 3% of prostate cancer, as well as in less than 2% in paragangliomas, colorectal cancer and melanoma. Mutated IDH1 results in impaired catalytic function of the enzyme, thus altering normal physiology of cellular respiration and metabolism.

IDH2 IDH2 encodes for the mitochondrial form of isocitrate dehydrogenase, a key enzyme in the citric acid cycle, which is essential for cell respiration. Mutation in IDH2 not only results in impaired catalytic function of the enzyme, but also causes the overproduction of an onco-metabolite, 2-hydroxy-glutarate, which can extensively alter the methylation profile in cancer. IDH2 mutation is mutually exclusive of IDH1 mutation, and has been found in 2% of gliomas and 10% of AML, as well as in cartilaginous tumors and cholangiocarcinoma. In gliomas, IDH2 mutations are associated with lower grade astrocytomas, oligodendrogliomas (grade II/III), as well as secondary glioblastoma (transformed from a lower grade glioma), and are associated with a better prognosis. In secondary glioblastoma, preliminary evidence suggests that IDH2 mutation may associate with a better response to alkylating agent temozolomide. IDH mutations have also been suggested to associate with a benefit from using hypomethylating agents in cancers including AML. Germline IDH2 mutation has been indicated to associate with a rare inherited neurometabolic disorder D-2- hydroxyglutaric aciduria.

JAK2 JAK2 or Janus kinase 2 is a part of the JAK/STAT pathway which mediates multiple cellular responses to cytokines and growth factors including proliferation and cell survival. It is also essential for numerous developmental and homeostatic processes, including hematopoiesis and immune cell development. Mutations in the JAK2 kinase domain result in constitutive activation of the kinase and the development of chronic myeloproliferative neoplasms such as polycythemia vera (95%), essential thrombocythemia (50%) and myelofibrosis (50%). JAK2 mutations were also found in BCR-ABL1 -negative acute lymphoblastic leukemia patients and the mutated patients show a poor outcome. Germline mutations in JAK2 have been associated with myeloproliferative neoplasms and thrombocythemia.

JAK3 JAK3 or Janus activated kinase 3 is an intracellular tyrosine kinase involved in cytokine signaling, while interacting with members of the STAT family. Like JAK1, JAK2, and TYK2, JAK3 is a member of the JAK family of kinases. When activated, kinase enzymes phosphorylate one or more signal transducer and activator of transcription (STAT) factors, which translocate to the cell nucleus and regulate the expression of genes associated with survival and proliferation. JAK3 signaling is related to T cell development and proliferation. This biomarker is found in malignancies including without limitation head and neck (21%) colon (7%), prostate (5%), ovary (4%), breast (2%), lung (1%), and stomach (1%) cancer. Its prognostic and predictive utility is under investigation. Germline mutations of JAK3 are associated with severe, combined immunodeficiency disease (SCID).

KDR KDR (kinase insert domain receptor), also known as VEGFR2 (vascular endothelial growth factor 2), is one of three main subtypes of VEGFR and is expressed on almost all endothelial cells. This protein is an important signaling protein in angiogenesis. VEGFR2 copy number changes are frequently observed in lung, glioma and triple negative breast cancer. Evidence suggests that increased levels of VEGFR2 may be predictive of response to anti-angiogenic drugs and multi-targeted kinase inhibitors. Several VEGFR antagonists are either FDA-approved or in clinical trials (i.e. bevacizumab, cabozantinib, regorafenib, pazopanib, and vandetanib).

KIT (cKit) c-KIT is a receptor tyrosine kinase expressed by hematopoietic stem cells, interstitial cells of cajal (pacemaker cells of the gut) and other cell types. Upon binding of c-KIT to stem cell factor (SCF), receptor dimerization initiates a phosphorylation cascade resulting in proliferation, apoptosis, chemotaxis and adhesion. C-KIT mutation has been identified in various cancer types including gastrointestinal stromal tumors (GIST) (up to 85%) and melanoma (chronic sun damage type, acral or mucosal) (20- 40%). C-KIT is inhibited by multi -targeted agents including imatinib and sunitinib.

KRAS KRAS or V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog encodes a signaling intermediate involved in many signaling cascades including the EGFR pathway. KRAS somatic mutations have been found in pancreatic (57%), colon (35%), lung (16%), biliary tract (28%), and endometrial (15%) cancers. Mutations at activating hotspots are associated with resistance to EGFR tyrosine kinase inhibitors (erlotinib, gefitinib) in NSCLC and monoclonal antibodies (cetuximab, panitumumab) in CRC patients. Patients with KRAS G13D mutation have been shown to derive benefit from anti- EGFR monoclonal antibody therapy in CRC patients. Several germline mutations of KRAS (VI 41, T58I, and D153V amino acid substitutions) are associated with Noonan syndrome.

MET (cMET) MET is a proto-oncogene that encodes the tyrosine kinase receptor, cMET, of hepatocyte growth factor (HGF) or scatter factor (SF). cMet mutations cause aberrant MET signaling in various cancer types including renal papillary, hepatocellular, head and neck squamous, gastric carcinomas and non-small cell lung cancer. Specifically, mutations in the juxtamembrane domain (exon 14, 15) results in the constitutive activation and show enhanced tumorigenicity. Germline mutations in cMET have been associated with hereditary papillary renal cell carcinoma.

MGMT O-6-methylguanine-DNA methyltransferase (MGMT) encodes a DNA repair enzyme.

MGMT expression is mainly regulated at the epigenetic level through CpG island promoter methylation which in turn causes functional silencing of the gene. MGMT methylation and/or low expression has been correlated with response to alkylating agents like temozolomide and dacarbazine.

MLH1 MLH1 or mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) gene encodes a mismatch repair (MMR) protein which repairs DNA mismatches that occur during replication. Although the frequency is higher in colon cancer (10%), MLH1 somatic mutations have been found in esophageal (6%), ovarian (5%), urinary tract (5%), pancreatic (5%), and prostate (5%) cancers. Germline mutations of MLH1 are associated with Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC). Patients with Lynch syndrome are at increased risk for various malignancies, including intestinal, gynecologic, and upper urinary tract cancers and in its variant, Muir-Torre syndrome, with sebaceous tumors.

MPL MPL or myeloproliferative leukemia gene encodes the thrombopoietin receptor, which is the main humoral regulator of thrombopoiesis in humans. MPL mutations cause constitutive activation of JAK-STAT signaling and have been detected in 5-7% of patients with primary myelofibrosis (PMF) and 1% of those with essential thrombocythemia (ET).

MSH2 This locus is frequently mutated in hereditary nonpolyposis colon cancer (HNPCC).

When cloned, it was discovered to be a human homolog of the E. coli mismatch repair gene mutS, consistent with the characteristic alterations in microsatellite sequences found in HNPCC. The protein product is a component of the DNA mismatch repair system (MMR), and forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair. After mismatch binding, MutS alpha or beta forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events. MutS alpha may also play a role in DNA homologous recombination repair.

MSH6 This gene encodes a member of the DNA mismatch repair MutS family. Mutations in this gene may be associated with hereditary nonpolyposis colon cancer, colorectal cancer, and endometrial cancer. The protein product is a component of the DNA mismatch repair system (MMR), and heterodimerizes with MSH2 to form MutS alpha, which binds to DNA mismatches thereby initiating DNA repair. MutS alpha may also play a role in DNA homologous recombination repair. Recruited on chromatin in Gl and early S phase via its PWWP domain that specifically binds trimethylated 'Lys-36' of histone H3 (H3K36me3): early recruitment to chromatin to be replicated allowing a quick identification of mismatch repair to initiate the DNA mismatch repair reaction.

MSI Microsatellites are short, tandem repeated DNA sequences from 1-6 base pairs in length. These repeats are distributed throughout the genome and often vary in length from one individual to another due to differences in the number of tandem repeats at each locus. They can be used to detect a form of genomic instability called microsatellite instability. MSI is a change in length of a microsatellite allele due to insertion or deletion of repeat units during DNA replication and failure of the DNA mis-match repair system to correct these errors. Therefore, the presence of MSI is indicative of a loss of mismatch repair (MMR) activity.

NOTCH 1 NOTCH 1 or notch homolog 1, translocation-associated, encodes a member of the

Notch signaling network, an evolutionary conserved pathway that regulates developmental processes by regulating interactions between physically adjacent cells. Mutations in NOTCH 1 play a central role in disruption of micro environmental communication, potentially leading to cancer progression. Due to the dual, bidirectional signaling of NOTCH 1, activating mutations have been found in acute lymphoblastic leukemia and chronic lymphocytic leukemia, however loss of function mutations in NOTCH 1 are prevalent in 11-15% of head and neck squamous cell carcinoma. NOTCH 1 mutations have also been found in 2% of glioblastomas, 1% of ovarian cancers, 10% lung adenocarcinomas, 8% of squamous cell lung cancers and 5% of breast cancers. Notch pathway-directed therapy approaches differ depending on whether the tumor harbors gain or loss of function mutations, thus are classified as Notch pathway inhibitors or activators, respectively.

NPMl NPMl or nucleophosmin is a nucleolar phosphoprotein belonging to a family of nuclear chaperones with proliferative and growth-suppressive roles. In several hematological malignancies, the NPM locus is lost or translocated, leading to expression of oncogenic proteins. NPMl is mutated in one-third of patients with adult acute myeloid leukemia (AML) leading to activation of downstream pathways including JAK/STAT, RAS/ERK, and PI3K. Although there are few NPM-directed therapies currently being investigated, research shows AML tumor cells with mutant NPM are more sensitive to chemotherapeutic agents, including daunorubicin and camptothecin.

NPvAS NRAS is an oncogene and a member of the (GTPase) ras family, which includes KRAS

and HRAS. This biomarker has been detected in multiple cancers including melanoma (15%)), colorectal cancer (4%), AML (10%) and bladder cancer (2%). Evidence suggests that an acquired mutation in NRAS may be associated with resistance to vemurafenib in melanoma patients. In colorectal cancer patients NRAS mutation is associated with resistance to EGFR-targeted monoclonal antibodies. Germline mutations in NRAS have been associated with Noonan syndrome, autoimmune lymphoproliferative syndrome and juvenile myelomonocytic leukemia.

PBRM1 This locus encodes a subunit of ATP -dependent chromatin-remodeling complexes. The encoded protein has been identified as in integral component of complexes necessary for ligand-dependent transcriptional activation by nuclear hormone receptors. Mutations at this locus have been associated with primary clear cell renal cell carcinoma.

PD-1 PD-1 (programmed death 1) is a co-inhibitory receptor expressed on activated T, B and

NK cells, and tumor infiltrating lymphocytes (TIL). PD-1 is a negative regulator of the immune system and inhibits the proliferation and effector function of the lymphocytes after binding with its ligands including PD-L1. PD-1/PD-L1 signaling pathway functions to attenuate or escape antitumor immunity by maintaining an immunosuppressive tumor microenvironment. Studies show that the presence of PD-1+ TIL is associated with a poor prognosis in various cancer types including lymphoma and breast cancer.

PD-L1 PD-L1 (programmed cell death ligand 1; also known as cluster of differentiation 274

(CD274) or B7 homolog 1 (B7-H1)) is a glycoprotein expressed in various tumor types and is associated with poor outcome. Upon binding to its receptor, PD-1, the PD-l/PD- Ll interaction functions to negatively regulate the immune system, attenuating antitumor immunity by maintaining an immunosuppressive tumor microenvironment. PD-L1 expression is upregulated in tumor cells through activation of common oncogenic pathways or exposure to inflammatory cytokines. Assessment of PD-L1 offers information on patient prognosis and also represents a target for immune manipulation in treatment of solid tumors. Clinical trials are currently recruiting patients with various tumor types testing immunomodulatory agents.

PDGFRA PDGFRA is the alpha-type platelet-derived growth factor receptor, a surface tyrosine kinase receptor structurally homologous to c-KIT, which activates PIK3CA/AKT, RAS/MAPK and JAK/STAT signaling pathways. PDGFRA mutations are found in 5- 8% of patients with gastrointestinal stromal tumors (GIST) and increases to 30% in KIT wildtype GIST. Germline mutations in PDGFRA have been associated with Familial gastrointestinal stromal tumors and Hypereosinophillic Syndrome (HES).

PGP P-glycoprotein (MDRl, ABCB l) is an ATP -dependent, transmembrane drug efflux pump with broad substrate specificity, which pumps antitumor drugs out of cells. Its expression is often induced by chemotherapy drugs and is thought to be a major mechanism of chemotherapy resistance. Overexpression of p-gp is associated with resistance to anthracylines (doxorubicin, epirubicin). P-gp remains the most important and dominant representative of Multi-Drug Resistance phenotype and is correlated with disease state and resistant phenotype.

PIK3CA (PI3K) PIK3CA (phosphoinositide-3 -kinase catalytic alpha polypeptide) encodes a protein in the PI3 kinase pathway. This pathway is an active target for drug development. PIK3CA somatic mutations have been found in breast (26%), endometrial (23%), urinary tract (19%), colon (13%), and ovarian (11%) cancers. PIK3CA exon 20 mutations have been associated with benefit from mTOR inhibitors (everolimus, temsirolimus). Evidence suggests that breast cancer patients with activation of the PI3K pathway due to PTEN loss or PIK3CA mutation/amplification have a significantly shorter survival following trastuzumab treatment. PIK3CA mutated colorectal cancer patients are less likely to respond to EGFR targeted monoclonal antibody therapy. Somatic mosaic activating mutations in PIK3CA are said to cause CLOVES syndrome.

PMS2 This gene encodes the postmeiotic segregation increased 2 (PMS2) protein involved in

DNA mismatch repair. PMS2 forms a heterodimer with MLH1 and, together, this complex interacts with other complexes bound to mismatched bases. Loss of PMS2 leads to mismatch repair deficiency and microsatellite instability. Inactivating mutations in this gene are associated with protein loss and hereditary Lynch syndrome, the latter being linked with a lifetime risk for various malignancies, especially colorectal and endometrial cancer.

PR The progesterone receptor (PR or PGR) is an intracellular steroid receptor that specifically binds progesterone, an important hormone that fuels breast cancer growth. PR positivity in a tumor indicates that the tumor is more likely to be responsive to hormone therapy by anti -estrogens, aromatase inhibitors and progestogens.

PTEN PTEN or phosphatase and tensin homolog is a tumor suppressor gene that prevents cells from proliferating. PTEN is an important mediator in signaling downstream of EGFR, and loss of PTEN gene function/expression due to gene mutations or allele loss is associated with reduced benefit to EGFR-targeted monoclonal antibodies. Mutation in PTEN is found in 5-14% of colorectal cancer and 7% of breast cancer. PTEN mutation leads to loss of function of the encoded phosphatase, and an upregulation of the PIK3CA/AKT pathway. Germline PTEN mutations associate with Cowden disease and Bannayan-Riley-Ruvalcaba syndrome. These dominantly inherited disorders belong to a family of hamartomatous polyposis syndromes which feature multiple tumor-like growths (hamartomas) accompanied by an increased risk of breast carcinoma, follicular carcinoma of the thyroid, glioma, prostate and endometrial cancer. Trichilemmoma, a benign, multifocal neoplasm of the skin is also associated with PTEN germline mutations.

PTPN11 PTPNl 1 or tyrosine-protein phosphatase non-receptor type 11 is a proto-oncogene that encodes a signaling molecule, Shp-2, which regulates various cell functions like mitogenic activation and transcription regulation. PTPNl 1 gain-of-function somatic mutations have been found to induce hyperactivation of the Akt and MAPK networks. Because of this hyperactivation, Ras effectors, such as Mek and PI3K, are potential targets for novel therapeutics in those with PTPN11 gain-of-function mutations. PTPNl 1 somatic mutations are found in hematologic and lymphoid malignancies (8%), gastric (2%), colon (2%), ovarian (2%), and soft tissue (2%) cancers. Germline mutations of PTPNl 1 are associated with Noonan syndrome, which itself is associated with juvenile myelomonocytic leukemia (JMML). PTPNl 1 is also associated with LEOPARD syndrome, which is associated with neuroblastoma and myeloid leukemia.

RBI RBI or retinoblastoma- 1 is a tumor suppressor gene whose protein regulates the cell cycle by interacting with various transcription factors, including the E2F family (which controls the expression of genes involved in the transition of cell cycle checkpoints). Besides ocular cancer, RB 1 mutations have also been detected in other malignancies, such as ovarian (10%), bladder (41%), prostate (8%), breast (6%), brain (6%), colon (5%), and renal (2%) cancers. RB I status, along with other mitotic checkpoints, has been associated with the prognosis of GIST patients. Germline mutations of RBI are associated with the pediatric tumor, retinoblastoma. Inherited retinoblastoma is usually bilateral. Studies indicate patients with a history of retinoblastoma are at increased risk for secondary malignancies.

RET RET or rearranged during transfection gene, located on chromosome 10, activates cell signaling pathways involved in proliferation and cell survival. RET mutations are found in 23-69% of sporadic medullary thyroid cancers (MTC), but RET fusions are common in papillary thyroid cancer, and more recently have been found in 1-2% of lung adenocarcinoma. Germline activating mutations of RET are associated with multiple endocrine neoplasia type 2 (MEN2), which is characterized by the presence of medullary thyroid carcinoma, bilateral pheochromocytoma, and primary hyperparathyroidism. Germline inactivating mutations of RET are associated with Hirschsprung's disease.

ROS1 The proto-oncogene ROS 1 is a receptor tyrosine kinase of the insulin receptor family.

The ligand and function of ROS 1 are unknown. Dimerization of ROS1 -fused proteins results in constitutive activation of the receptor kinase, leading to cell proliferation and survival. Clinical data show that ROS-rearranged NSCLC patients have increased sensitivity and improved response to the MET/ALK/ROS inhibitor, crizotinib.

RRM1 Ribonucleotide reductase subunit Ml (RRMl) is a component of the ribonucleotide reductase holoenzyme consisting of Ml and M2 subunits. The ribonucleotide reductase is a rate-limiting enzyme involved in the production of nucleotides required for DNA synthesis. Gemcitabine is a deoxycitidine analogue which inhibits ribonucleotide reductase activity. High RRMl level is associated with resistance to gemcitabine. SMAD4 SMAD4 or mothers against decapentaplegic homolog 4, is one of eight proteins in the SMAD family, involved in multiple signaling pathways and are key modulators of the transcriptional responses to the transforming growth factor-β (TGFB) receptor kinase complex. SMAD4 resides on chromosome 18q21, one of the most frequently deleted chromosomal regions in colorectal cancer. Smad4 stabilizes Smad DNA-binding complexes and also recruits transcriptional coactivators such as histone acetyltransferases to regulatory elements. Dysregulation of SMAD4 occurs late in tumor development, and occurs through mutations of the MHl domain which inhibits the DNA-binding function, thus dysregulating TGFBR signaling. Mutated (inactivated) SMAD4 is found in 50% of pancreatic cancers and 10-35% of colorectal cancers. Germline mutations in SMAD4 are associated with juvenile polyposis (JP) and combined syndrome of JP and hereditary hemorrhagic teleangiectasia (JP-HHT).

SMARCB 1 SMARCB 1 also known as SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1, is a tumor suppressor gene implicated in cell growth and development. Loss of expression of SMARCB 1 has been observed in tumors including epithelioid sarcoma, renal medullary carcinoma, undifferentiated pediatric sarcomas, and a subset of hepatoblastomas. Germline mutation in SMARCB 1 causes about 20% of all rhabdoid tumors which makes it important for clinicians to facilitate genetic testing and refer families for genetic counseling. Germline SMARCB 1 mutations have also been identified as the pathogenic cause of a subset of schwannomas and meningiomas.

SMO SMO (smoothened) is a G protein-coupled receptor which plays an important role in the Hedgehog signaling pathway. It is a key regulator of cell growth and differentiation during development, and is important in epithelial and mesenchymal interaction in many tissues during embryogenesis. Dysregulation of the Hedgehog pathway is found in cancers including basal cell carcinomas (12%) and medulloblastoma (1%). A gain- of-function mutation in SMO results in constitutive activation of hedgehog pathway signaling, contributing to the genesis of basal cell carcinoma. SMO mutations have been associated with the resistance to SMO antagonist GDC-0449 in medulloblastoma patients by blocking the binding to SMO. SMO mutation may also contribute partially to resistance to SMO antagonist LDE225 in BCC. Various clinical trials (on www.clinicaltrials.gov) investigating SMO antagonists may be available for SMO mutated patients.

SPARC SPARC (secreted protein acidic and rich in cysteine) is a calcium-binding matricellular glycoprotein secreted by many types of cells. Studies indicate SPARC over-expression improves the response to the anticancer drug, nab-paclitaxel. The improved response is thought to be related to SPARC'S role in accumulating albumin and albumin-targeted agents within tumor tissue.

STK11 STK11 also known as LKB1, is a serine/threonine kinase. It is thought to be a tumor suppressor gene which acts by interacting with p53 and CDC42. It modulates the activity of AMP-activated protein kinase, causes inhibition of mTOR, regulates cell polarity, inhibits the cell cycle, and activates p53. Somatic mutations in this gene are associated with a history of smoking and KRAS mutation in NSCLC patients. The frequency of STK11 mutation in lung adenocarcinomas ranges from 7%-30%. STK11 loss may play a role in development of metastatic disease in lung cancer patients. Mutations of this gene also drive progression of HPV-induced dysplasia to invasive, cervical cancer and hence STK11 status may be exploited clinically to predict the likelihood of disease recurrence. Germline mutations in STK11 are associated with Peutz-Jeghers syndrome which is characterized by early onset hamartomatous gastrointestinal polyps and increased risk of breast, colon, gastric and ovarian cancer.

-I l l- TLE3 TLE3 is a member of the transducin-like enhancer of split (TLE) family of proteins that have been implicated in tumorigenesis. It acts downstream of APC and beta-catenin to repress transcription of a number of oncogenes, which influence growth and microtubule stability. Studies indicate that TLE3 expression is associated with response to taxane therapy.

TOP2A TOPOIIA is an enzyme that alters the supercoiling of double-stranded DNA and allows chromosomal segregation into daughter cells. Due to its essential role in DNA synthesis and repair, and frequent overexpression in tumors, TOPOIIA is an ideal target for antineoplastic agents. Amplification of TOPOIIA with or without HER2 co- amplification, as well as high protein expression of TOPOIIA, have been associated with benefit from anthracycline based therapy.

TOPOI Topoisomerase I is an enzyme that alters the supercoiling of double -stranded DNA.

TOPOI acts by transiently cutting one strand of the DNA to relax the coil and extend the DNA molecule. Expression of TOPOI has been associated with response to TOPOI inhibitors including irinotecan and topotecan.

TP53 TP53, or p53, plays a central role in modulating response to cellular stress through transcriptional regulation of genes involved in cell-cycle arrest, DNA repair, apoptosis, and senescence. Inactivation of the p53 pathway is essential for the formation of the majority of human tumors. Mutation in p53 (TP53) remains one of the most commonly described genetic events in human neoplasia, estimated to occur in 30-50% of all cancers. Generally, presence of a disruptive p53 mutation is associated with a poor prognosis in all types of cancers, and diminished sensitivity to radiation and chemotherapy. In addition, various clinical trials (on www.clinicaltrials.gov) investigating agents which target p53's downstream or upstream effectors may have clinical utility depending on the p53 status. For example, for p53 mutated patients, Chkl inhibitors in advanced cancer and Weel inhibitors in ovarian cancer have been investigated. For p53 wildtype patients with sarcoma, mdm2 inhibitors have been investigated. Germline p53 mutations are associated with the Li-Fraumeni syndrome (LFS) which may lead to early-onset of several forms of cancer currently known to occur in the syndrome, including sarcomas of the bone and soft tissues, carcinomas of the breast and adrenal cortex (hereditary adrenocortical carcinoma), brain tumors and acute leukemias.

TS Thymidylate synthase (TS) is an enzyme involved in DNA synthesis that generates thymidine monophosphate (dTMP), which is subsequently phosphorylated to thymidine triphosphate for use in DNA synthesis and repair. Low levels of TS are predictive of response to fluoropyrimidines and other folate analogues.

TUBB3 Class III β-Tubulin (TUBB3) is part of a class of proteins that provide the framework for microtubules, major structural components of the cytoskeleton. Due to their importance in maintaining structural integrity of the cell, microtubules are ideal targets for anti-cancer agents. Low expression of TUBB3 is associated with potential clinical benefit to taxane therapy.

VHL VHL or von Hippel-Lindau gene encodes for tumor suppressor protein pVHL, which polyubiquitylates hypoxia-inducible factor. Absence of pVHL causes stabilization of HIF and expression of its target genes, many of which are important in regulating angiogenesis, cell growth and cell survival. VHL somatic mutation has been seen in 20- 70% of patients with sporadic clear cell renal cell carcinoma (ccRCC) and the mutation may imply a poor prognosis, adverse pathological features, and increased tumor grade or lymph-node involvement. Renal cell cancer patients with a 'loss of function' mutation in VHL show a higher response rate to therapy (bevacizumab or sorafenib) than is seen in patients with wild type VHL. Germline mutations in VHL cause von Hippel-Lindau syndrome, associated with clear-cell renal-cell carcinomas, central nervous system hemangioblastomas, pheochromocytomas and pancreatic tumors.

[00330] Table 5 shows exemplary MI molecular profiles for various tumor lineages. In the table, the lineage is shown in the column "Tumor Type." The remaining columns show various biomarkers that can be assessed using the indicated methodology (i.e., immunohistochemistry (IHC), ISH or other techniques). One of skill will appreciate that similar methodology can be employed as desired. For example, other suitable protein analysis methods can be used instead of IHC, other suitable nucleic acid analysis methods can be used instead of ISH (e.g., that assess copy number and/or rearrangements, translocations and the like), and other suitable nucleic acid analysis methods can be used instead of fragment analysis. Similarly, FISH and CISH are generally interchangeable and the choice may be made based upon probe availability, resources, and the like. Tables 6-10 present panels of genes that can be assessed as part of the MI molecular profiles using Next Generation Sequencing (NGS) analysis. One of skill will appreciate that other nucleic acid analysis methods can be used instead of NGS analysis, e.g., other sequencing, hybridization (e.g., microarray, Nanostring) and/or amplification (e.g., PCR based) methods.

[00331] Nucleic acid analysis may be performed to assess various aspects of a gene. For example, nucleic acid analysis can include, but is not limited to, mutational analysis, fusion analysis, variant analysis, splice variants, SNP analysis and gene copy number/amplification. Such analysis can be performed using any number of techniques described herein or known in the art, including without limitation sequencing (e.g., Sanger, Next Generation, pyrosequencing), PCR, variants of PCR such as RT-PCR, fragment analysis, and the like. NGS techniques may be used to detect mutations, fusions, variants and copy number of multiple genes in a single assay. Table 4 describes a number of biomarkers including genes bearing mutations that have been identified in various cancer lineages. Unless otherwise stated or obvious in context, a "mutation" as used herein may comprise any change in a gene as compared to its wild type, including without limitation a mutation, polymorphism, deletion, insertion, indels (i.e., insertions or deletions), substitution, translocation, fusion, break, duplication, amplification, repeat, or copy number variation. In an aspect, the invention provides a molecular profile comprising mutational analysis of one or more genes in any of Tables 7-10. In one embodiment, the genes are assessed using Next Generation sequencing methods, e.g., using a TruSeq/MiSeq/HiSeq/NexSeq system offered by Illumina Corporation or an Ion Torrent system from Life Technologies.

[00332] In preferred embodiments, the MI molecular profiles of the invention comprise high-throughput sequencing analysis. Exemplary analyses are listed in Tables 6-10. As desired, different analyses may be performed for different sets of genes. For example, Table 6 lists various genes that may be assessed for genomic stability (e.g., MSI and TMB), Table 7 lists various genes that may be assessed for point mutations and indels, Table 8 lists various genes that may be assessed for point mutations, indels and copy number variations, Table 9 lists various genes that may be assessed for gene fusions, and Table 10 lists genes that can be assessed for transcript variants. Gene fusion and transcript analysis may be performed by analysis of RNA transcripts as desired. [00333] Table 5 provides various biomarker panels that can be assessed for the indicated tumor lineages.

In preferred embodiments, the panels can comprise the NGS analyses in Tables 6-10. For example, in the

NGS column in Table 5, the Mutation analysis can be performed on DNA using the panels in Tables 6-8, and Table 10 as desired, the CNA analysis can be performed on DNA using the panel in Table 8, and the

Fusion analysis can be performed on RNA using the panels in Table 9. Table 11 presents a view of associations between the biomarkers assessed and various therapeutic agents. Such associations can be determined by correlating the biomarker assessment results with drug associations from sources such as the NCCN, literature reports and clinical trials. The columns headed "Agent" provide candidate agents

(e.g., drugs) or biomarker status to be included in the report. In some cases, the agent comprises clinical trials that can be matched to a biomarker status. Where agents are indicated, the association of the agent with the indicated biomarker can included in the MI report. In certain cases, multiple biomarkers are associated with a given agent or agents. For example, carboplatin, cisplatin, oxaliplatin are associated with

BRCA1, BRCA2 and ERCC1. Platform abbreviations are as used throughout the application, e.g., IHC: immunohistochemistry; CISH: colorimetric in situ hybridization; NGS: next generation sequencing; PCR: polymerase chain reaction; CNA: copy number alteration. The candidate agents may comprise those undergoing clinical trials, as indicated.

[00334] As described herein, the invention further provides a report comprising results of the molecular profiling and corresponding candidate treatments that are identified as likely beneficial or likely not beneficial.

Table 5 - Molecular Profile and Report Parameters

TUBB3 Analysis (DNA)

Table 6 - Genomic Stability Testing (DNA)

Microsatellite Instability (MSI) Tumor Mutational Burden (TMB)

Table 7 - Point Mutations and Indels

ABL1 DDB2 HOXC13 MUTYH RNF213

ACKR3 DDIT3 HOXD11 MYCL (MYCLl) RPL10

AKT1 DNM2 HOXD13 NBN SEPT5

AMER1 DNMT3A HRAS NDRG1 SEPT6 (FAM123B)

AR EIF4A2 IKBKE NKX2-1 SFPQ

ARAF ELF4 INHBA NONO SLC45A3

ATP2B3 ELN IRS2 NOTCH 1 SMARCA4

ATRX ERCC1 JUN NRAS SOCS 1

BCL11B ETV4 KAT6A NUMA1 SOX2

(MYST3)

BCL2 FAM46C KAT6B NUTM2B SPOP

BCL2L2 FANCF KCNJ5 OLIG2 SRC

BCOR FEV KDM5C OMD SSX1

BCORL1 FOXL2 KDM6A P2RY8 STAG2

BRD3 FOX03 KDSR PAFAH1B2 TALI

BRD4 FOX04 KLF4 PAK3 TAL2

BTG1 FSTL3 KLK2 PATZ1 TBL1XR1

BTK GATA1 LASP1 PAX8 TCEA1

C15orf65 GATA2 LMOl PDE4DIP TCL1A

CBLC GNA11 LM02 PHF6 TERT

CD79B GPC3 MAFB PHOX2B TFE3

CDH1 HEY1 MAX PIK3CG TFPT

CDK12 HIST1H3B MECOM PLAG1 THRAP3

CDKN2B HIST1H4I MED 12 PMS1 TLX3

CDKN2C HLF MKL1 POU5F1 TMPRSS2

CEBPA HMGN2P46 MLLT11 PPP2R1A UBR5

CHCHD7 HNF1A MM PRF1 VHL

CNOT3 HOXA11 MPL PRKDC WAS

COL1A1 HOXA13 MSN RAD21 ZBTB16

COX6C HOXA9 MTCP1 RECQL4 ZRSR2

Table 8 - Point Mutations, Indels and Copy Number Variations

AFDN CRKL GMPS MYH9 SDHAF2

AFF1 CRTC1 GNA13 NACA SDHB

AFF3 CRTC3 GNAQ NCKIPSD SDHC

AFF4 CSF1R GNAS NCOA1 SDHD

AKAP9 CSF3R GOLGA5 NCOA2 SEPT9

AKT2 CTCF GOPC NCOA4 SET

AKT3 CTLA4 GPHN NF1 SETBP1

ALDH2 CTN A1 GRIN2A NF2 SETD2

ALK CTN B 1 GSK3B NFE2L2 SF3B 1

APC CYLD H3F3A NFIB SH2B3

ARFRP1 CYP2D6 H3F3B NFKB2 SH3GL1

ARHGAP26 DAXX HERPUD 1 NFKBIA SLC34A2

ARHGEF12 DDR2 HGF NIN SMAD2

ARID 1 A DDX10 HIP1 NOTCH2 SMAD4

ARID2 DDX5 HMGA1 NPM1 SMARCB l

ARNT DDX6 HMGA2 NSD1 SMARCE1

ASPSCR1 DEK HNRNPA2B1 NSD2 SMO

ASXL1 DICERl HOOK3 NSD3 SNX29

ATF1 D0T1L HSP90AA1 NT5C2 SOX10

ATIC EBF1 HSP90AB 1 NTRK1 SPECC1

ATM ECT2L IDH1 NTRK2 SPEN

ATP1A1 EGFR IDH2 NTRK3 SRGAP3

ATR ELK4 IGF1R NUP214 SRSF2

AURKA ELL IKZF1 NUP93 SRSF3

AURKB EML4 IL2 NUP98 SS18

AXIN1 EMSY IL21R NUTM1 SS18L1

AXL EP300 IL6ST PALB2 STAT3

BAP1 EPHA3 IL7R PAX3 STAT4

BARD1 EPHA5 IRF4 PAX5 STAT5B

BCL10 EPHB1 ITK PAX7 STIL

BCL11A EPS 15 JAK1 PBRM1 STK11

ERBB2

BCL2L11 JAK2 PBX1 SUFU

(HER2/NEU)

BCL3 ERBB3 (HER3) JAK3 PCM1 SUZ12

BCL6 ERBB4 (HER4) JAZF1 PCSK7 SYK

BCL7A ERC1 KDM5A PDCD1 (PD1) TAF15

BCL9 ERCC2 KDR (VEGFR2) PDCD1LG2 TCF12 (PDL2)

BCR ERCC3 KEAP1 PDGFB TCF3

BIRC3 ERCC4 KIAA1549 PDGFRA TCF7L2

BLM ERCC5 KIF5B PDGFRB TET1

BMPR1A ERG KIT PDK1 TET2

BRCA1 ESR1 KLHL6 PERI TFEB

BRCA2 ETVl KMT2A (MLL) PICALM TFG

BRIP1 ETV5 KMT2C (MLL3) PIK3CA TFRC

BUB IB ETV6 KMT2D (MLL2) PIK3R1 TGFBR2

CACNA1D EWSR1 KNL1 PIK3R2 TLX1

CALR EXT1 KRAS PIM1 TNFAIP3

CAMTA1 EXT2 KTN1 PML TNFRSF14

CANT1 EZH2 LCK PMS2 TNFRSF17

CARD 11 EZR LCP1 POLE TOPI

CARS FANCA LGR5 POT1 TP53

CASP8 FANCC LHFPL6 POU2AF1 TPM3

CBFA2T3 FANCD2 LIFR PPARG TPM4

CBFB FANCE LPP PRCC TPR

CBL FANCG LRIG3 PRDM1 TRAF7

CBLB FANCL LRP1B PRDM16 TRIM26

CCDC6 FAS LYL1 PRKAR1A TRIM27

CCNB1IP1 FBXOl l MAF PRRX1 TRIM33

CCND1 FBXW7 MALT1 PSIP1 TRIP 11

CCND2 FCRL4 MAML2 PTCH1 TRRAP

MAP2K1

CCND3 FGF10 PTEN TSC1

(MEK1)

MAP2K2

CCNE1 FGF14 PTPN11 TSC2

(MEK2)

CD274 (PDL1) FGF19 MAP2K4 PTPRC TSHR

CD74 FGF23 MAP3K1 RABEP1 TTL

CD79A FGF3 MCL1 RAC1 U2AF1

CDC73 FGF4 MDM2 RAD50 USP6

CDH11 FGF6 MDM4 RAD51 VEGFA

CDK4 FGFR1 MDS2 RAD51B VEGFB

CDK6 FGFR10P MEF2B RAF1 VTI1A

CDK8 FGFR2 MEN1 RALGDS WDCP

CDKN1B FGFR3 MET RANBP17 WIF1 CDKN2A FGFR4 MITF RAP1GDS 1 WISP3

CDX2 FH MLF1 RARA WRN

CHEK1 FHIT MLH1 RBI WT1

CHEK2 FIP1L1 MLLT1 RBM15 WWTR1

CHIC2 FLCN MLLT10 REL XPA

CHN1 FLU MLLT3 RET XPC

CIC FLT1 MLLT6 RICTOR XPOl

CIITA FLT3 MNX1 RMI2 YWHAE

CLP1 FLT4 MRE11 RNF43 ZMYM2

CLTC FNBP1 MSH2 ROS 1 ZNF217

CLTCL1 FOXA1 MSH6 RPL22 ZNF331

CNBP FOXOl MSI2 RPL5 ZNF384

CNTRL FOXP1 MTOR RPN1 ZNF521

FUBP1 MYB RPTOR ZNF703

Table 9 - Gene Fusions

Table 10 - Variant Transcripts

I EGFR vIII I

Table 11 - Therapeutic Agent - Biomarker Associations

Agent Biomarker Platform afatinib (assoc. in NSCLC only) EGFR NGS Mutation

ERBB2 (Her2) NGS Mutation afatinib + cetuximab (combination assoc. in EGFR T790M NGS Mutation

NSCLC only)

alectinib, brigatinib, ceritinib ALK IHC; NGS Fusion Analysis

(RNA)

mitomycin-c BRCA1 NGS Mutation

BRCA2

atezolizumab, nivolumab, pembrolizumab PD-L1 IHC

(assoc. in Bladder, CUP, Gastric, Kidney,

Melanoma, NSCLC only)

nivolumab, pembrolizumab MSI NGS Mutation

niraparib, olaparib, rucaparib ATM (assoc. in NGS Mutation

Prostate only)

BRCA1

BRCA2

osimertinib (assoc. in NSCLC only) EGFR T790M NGS Mutation

palbociclib, abemaciclib, ribociclib (assoc. in ER IHC

Breast only) ERBB2 (Her2) IHC

sunitinib (assoc. in GIST only) KIT NGS

trametinib (assoc. in Melanoma and Lung) BRAF NGS

trastuzumab CISH, IHC, NGS Mutation

ERBB2 (HER2) (NSCLC only), CNA (DNA)

PTEN (assoc. in IHC

Breast only)

PIK3CA (assoc. in NGS Mutation

Breast only)

vandetanib NGS Mutation (DNA) &

RET Fusion Analysis (RNA)

[00335] With regard to Table 11, cetuximab/panitumumab, vemurafenib/dabrafenib, and trametinib may be reported in combination for CRC. Hormone therapies may include: tamoxifen, toremifene, fulvestrant, letrozole, anastrozole, exemestane, megestrol acetate, leuprolide, goserelin, bicalutamide, flutamide, abiraterone, enzalutamide, triptorelin, abarelix, degarelix.

[00336] The biomarker - treatment associations can follow certain rules. The rules comprise a predicted likelihood of benefit or lack of benefit of a certain treatment for the cancer given an assessment of one or more biomarker. Exemplary biomarker - treatment association rules that can be used in the systems and methods of the invention are presented in any of International Patent Publications WO/2007/137187 (Int'l Appl. No. PCT/US2007/069286), published November 29, 2007; WO/2010/045318 (Int'l Appl. No. PCT/US2009/060630), published April 22, 2010; WO/2010/093465 (Int'l Appl. No.

PCT/US2010/000407), published August 19, 2010; WO/2012/170715 (Int'l Appl. No.

PCT/US2013/073184), published June 12, 2014; WO/2011/056688 (Int'l Appl. No.

PCT/US2010/054366), published May 12, 2011; WO/2012/092336 (Int'l Appl. No.

PCT/US2011/067527), published July 5, 2012; WO/2015/116868 (Int'l Appl. No. PCT/US2015/013618), published August 6, 2015; WO/2017/053915 (Int'l Appl. No. PCT/US2016/053614), published March 30, 2017; and WO/2016/141169 (Int'l Appl. No. PCT/US2016/020657), published September 9, 2016; each of which publications is incorporated by reference herein in its entirety. Based on the molecular profiling results, the rules may provide a predicted benefit level and an evidence level, and list of references for each biomarker-drug association rule. In embodiments of the invention, the benefit level is ranked from 1-

5, wherein the levels indicate the predicted strength of the biomarker-drug association based on the indicated evidence. Relevant published studies can be evaluated using the U.S. Preventive Services Task Force ("USPSTF") grading scheme for study design and validity. See, e.g.,

www.uspreventiveservicestaskforce.org/uspstf/grades.htm. In some embodiments, the benefit level predicted for the agent corresponds to the following:

[00337] 1 : Expected benefit.

[00338] 2: Expected reduced benefit.

[00339] 3: Expected lack of benefit.

[00340] 4: No data is available.

[00341] 5: Data is available but no expected benefit or lack of benefit reported because the biomarker in this case is the not principal driver of that specific rule.

[00342] The evidence level may correspond to the following:

[00343] J_: Very high level of evidence. For example, the treatment comprises the standard of care.

[00344] 2: High level of evidence but perhaps insufficient to be considered for standard of care.

[00345] 3 : Weaker evidence - fewer publications or clinical studies, or perhaps some controversial evidence.

[00346] Any of the biomarker assays herein, including without limitation those listed in any of Tables 2-

12, e.g., Table 4, Table 5, Table 6, Table 7, Table 8, Table 9, Table 10, Table 11, Table 12, or any useful combination thereof, can be performed individually as desired. Additional biomarkers can also be made available for individual testing, e.g., selected from any of International Patent Publications

WO/2007/137187 (Int'l Appl. No. PCT/US2007/069286), published November 29, 2007;

WO/2010/045318 (Int'l Appl. No. PCT/US2009/060630), published April 22, 2010; WO/2010/093465 (Int'l Appl. No. PCT/US2010/000407), published August 19, 2010; WO/2012/170715 (Int'l Appl. No. PCT/US2012/041393), published December 13, 2012; WO/2014/089241 (Int'l Appl. No.

PCT/US2013/073184), published June 12, 2014; WO/2011/056688 (Int'l Appl. No.

PCT/US2010/054366), published May 12, 2011; WO/2012/092336 (Int'l Appl. No.

PCT/US2011/067527), published July 5, 2012; WO/2015/116868 (Int'l Appl. No. PCT/US2015/013618), published August 6, 2015; WO/2017/053915 (Int'l Appl. No. PCT/US2016/053614), published March 30, 2017; and WO/2016/141169 (Int'l Appl. No. PCT/US2016/020657), published September 9, 2016; each of which publications is incorporated by reference herein in its entirety. One of skill will appreciate that any combination of the individual biomarker assays could be performed. In some embodiments, a selection of individual tests is made when insufficient tumor sample is available for performing all molecular profiling tests in Table 5.

[00347] As non-limiting examples, ERCC 1 is assessed according to the profiles of the invention, such as described in any of Table 5 or Table 11. Lack of ERCC1 expression, e.g., as determined by IHC, can indicate positive benefit for platinum compounds (cisplatin, carboplatin, oxaliplatin), and conversely positive expression of ERCC1 can indicate lack of benefit of these drugs. The presence of EGFRvIII may be assessed using expression analysis at the protein or mRNA level, e.g., by either IHC or PCR, respectively. Expression of EGFRvIII can suggest treatment with EGFR inhibitors. Mutational analysis can be performed for IDH2, e.g., by Sanger sequencing, pyrosequencing or by next generation sequencing approaches. IDH2 mutations suggest the same therapy indications as IDH1 mutations, e.g., for decarbazine and temozolomide. In some cases, the analysis performed for each biomarker can depend on the lineage as desired. For example, EGFR IHC results may be assessed using H-SCORE for NSCLC but not other lineages.

[00348] Additional biomarkers that may be assessed according to the molecular profiling of the invention include BAP1 (BRCA1 Associated Protein- 1 (Ubiquitin Carboxy -Terminal Hydrolase)), SETD2 (SET Domain Containing 2). In some embodiments of the invention, their expression is assessed at the protein and/or mRNA level. For example, IHC can be used to assess the protein expression of one or more of these biomarkers. PBRMl and H3K36me3 may be assessed in kidney cancer, e.g., at the protein level such as by IHC. Molecular profiling of the invention can include at least one of TOP2A by CISH, Chromosome 17 by CISH, PBRMl (PB1/BAF180) by IHC, BAP1 by IHC, SETD2 (ANTI-HI STONE H3) by IHC, MDM2 by CISH, Chromosome 12 by CISH, ALK by IHC, CTLA4 by IHC, CD3 by IHC, NY-ESO-1 by IHC, MAGE-A by IHC, TP by IHC, and EGFR by CISH. Nucleic Acid Sequence Analysis

[00349] The invention provides molecular profile for a cancer which comprises sequence analysis of panels of genes and other desired genetic loci. Sequence analysis can be used to detect any change in a gene as compared to its wild type, including without limitation a mutation, polymorphism, deletion, insertion, indels (i.e., insertions or deletions), substitution, translocation, fusion, break, duplication, amplification, repeat, or copy number variation. In some embodiments, the panel of genes is selected from any one of Tables 6-10 as described herein. For example, the molecular profile may comprise sequence analysis of at least one, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 or 46, of ABL1, AKT1, ALK, APC, ATM, BRAF, BRCA1, BRCA2, CDH1, CSF1R, CTNNB 1, EGFR, ERBB2 (HER2), ERBB4 (HER4), FBXW7, FGFR1, FGFR2, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, JAK2, JAK3, KDR (VEGFR2), KIT (cKIT), KRAS, MET (cMET), MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RBI, RET, SMAD4, SMARCB 1, SMO, STK11, TP53, and VHL. The status of the genes can be linked to drug efficacy (e.g., predicted benefit or lack of benefit) or clinical trial enrollment as desired. See, e.g., Table 11.

[00350] The molecular profile may comprise analysis of at least one, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, or all of ABI1, ABL1, ACKR3, AKT1, AMER1 (FAM123B), AR, ARAF, ATP2B3, ATRX, BCL1 IB, BCL2, BCL2L2, BCOR, BCORL1, BRD3, BRD4, BTG1, BTK, C15orf65, CBLC, CD79B, CDH1, CDK12, CDKN2B, CDKN2C, CEBPA, CHCHD7, CNOT3, COL1A1, COX6C, CRLF2, DDB2, DDIT3, DNM2, DNMT3A, EIF4A2, ELF4, ELN, ERCC1, ETV4, FAM46C, FANCF, FEV, FOXL2, FOX03, FOX04, FSTL3, GATA1, GATA2, GNA11, GPC3, HEY1, HIST1H3B, HIST1H4I, HLF, HMGN2P46, HNF1A, HOXA11, HOXA13, HOXA9, HOXC11, HOXC13, HOXD11, HOXD13, HRAS, IKBKE, INHBA, IRS2, JUN, KAT6A (MYST3), KAT6B, KCNJ5, KDM5C, KDM6A, KDSR, KLF4, KLK2, LASP1, LMOl, LM02, MAFB, MAX, MECOM, MED 12, MKLl, MLLTl l, MNl, MPL, MSN, MTCPl, MUCl, MUTYH, MYCL (MYCL1), NBN, NDRG1, NKX2-1, NONO, NOTCH1, NRAS, NUMA1, NUTM2B, OLIG2, OMD, P2RY8, PAFAH1B2, PAK3, PATZ1, PAX8, PDE4DIP, PHF6, PHOX2B, PIK3CG, PLAG1, PMS1, POU5F1, PPP2R1A, PRF1, PRKDC, RAD21, RECQL4, RHOH, RNF213, RPL10, SEPT5, SEPT6, SFPQ, SLC45A3, SMARCA4, SOCS1, SOX2, SPOP, SRC, SSX1, STAG2, TALI, TAL2, TBL1XR1, TCEA1, TCL1A, TERT, TFE3, TFPT, THRAP3, TLX3, TMPRSS2, UBR5, VHL, WAS, ZBTB 16 and ZRSR2. Such genes can be assessed, e.g., for point mutations and indels, or other characteristics as desired. The molecular profile may comprise analysis of at least one, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400 or all, of ABL2, ACSL3, ACSL6, AFF1, AFF3, AFF4, AKAP9, AKT2, AKT3, ALDH2, ALK, APC, ARFRP1, ARHGAP26, ARHGEF12, ARID 1 A, ARID2, ARNT, ASPSCR1, ASXL1, ATF1, ATIC, ATM, ATP1A1, ATR, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BCL10, BCL11A, BCL2L11, BCL3, BCL6, BCL7A, BCL9, BCR,

BIRC3, BLM, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, BUB IB, Cl lorBO (EMSY), C2orf44, CACNA1D, CALR, CAMTA1, CANT1, CARD 11, CARS, CASC5, CASP8, CBFA2T3, CBFB, CBL, CBLB, CCDC6, CCNB 1IP1, CCND1, CCND2, CCND3, CCNE1, CD274 (PDL1), CD74, CD79A, CDC73, CDHl l, CDK4, CDK6, CDK8, CDKNIB, CDKN2A, CDX2, CHEKl, CHEK2, CHIC2, CHNl, CIC, CIITA, CLP1, CLTC, CLTCL1, CNBP, CNTRL, COPB 1, CREB 1, CREB3L1, CREB3L2, CREBBP, CRKL, CRTC1, CRTC3, CSF1R, CSF3R, CTCF, CTLA4, CTNNA1, CTNNB 1, CYLD, CYP2D6, DAXX, DDR2, DDX10, DDX5, DDX6, DEK, DICERl, DOT1L, EBF1, ECT2L, EGFR, ELK4, ELL, EML4, EP300, EPHA3, EPHA5, EPHB1, EPS15, ERBB2 (HER2), ERBB3 (HER3), ERBB4 (HER4), ERCl, ERCC2, ERCC3, ERCC4, ERCC5, ERG, ESRl, ETVl, ETV5, ETV6, EWSRl, EXT1, EXT2, EZH2, EZR, FANCA, FANCC, FANCD2, FANCE, FANCG, FANCL, FAS, FBXOl 1, FBXW7, FCRL4, FGF10, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR10P, FGFR2, FGFR3, FGFR4, FH, FHIT, FIP1L1, FLCN, FLU, FLT1, FLT3, FLT4, FNBP1, FOXA1, FOXOl, FOXP1, FUBP1, FUS, GAS7, GATA3, GID4 (C17orf39), GMPS, GNA13, GNAQ, GNAS, GOLGA5, GOPC, GPHN, GPR124, GRIN2A, GSK3B, H3F3A, H3F3B, HERPUD1, HGF, HIP1, HMGA1, HMGA2, HNRNPA2B 1, HOOK3, HSP90AA1, HSP90AB1, IDH1, IDH2, IGF1R, IKZF1, IL2, IL21R, IL6ST, IL7R, IRF4, ITK, JAK1, JAK2, JAK3, JAZF1, KDM5A, KDR (VEGFR2), KEAP1, KIAA1549, KIF5B, KIT, KLHL6, KMT2A (MLL), KMT2C (MLL3), KMT2D (MLL2), KRAS, KTNl, LCK, LCPl, LGR5, LHFP, LIFR, LPP, LRIG3, LRP1B, LYL1, MAF, MALTl, MAML2, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MCL1, MDM2, MDM4, MDS2, MEF2B, MEN1, MET (cMET), MITF, MLF1, MLHl, MLLTl, MLLTIO, MLLT3, MLLT4, MLLT6, MNXl, MREl 1A, MSH2, MSH6, MSI2, MTOR, MYB, MYC, MYCN, MYD88, MYH11, MYH9, NACA, NCKIPSD, NCOA1, NCOA2, NCOA4, NF1, NF2, NFE2L2, NFIB, NFKB2, NFKBIA, NIN, NOTCH2, NPM1, NR4A3, NSD1, NT5C2, NTRK1, NTRK2, NTRK3, NUP214, NUP93, NUP98, NUTM1, PALB2, PAX3, PAX5, PAX7, PBRM1, PBX1, PCM1, PCSK7, PDCD1 (PD 1), PDCD1LG2 (PDL2), PDGFB, PDGFRA, PDGFRB, PDK1, PERI, PICALM, PIK3CA, PIK3R1, PIK3R2, PIM1, PML, PMS2, POLE, POT1, POU2AF1, PPARG, PRCC, PRDM1, PRDM16, PRKAR1A, PRRX1, PSIP1, PTCH1, PTEN, PTPN11, PTPRC, RABEP1, RAC1, RAD50, RAD51, RAD51B, RAF1, RALGDS, RANBP17, RAP1GDS 1, RARA, RB I, RBM15, REL, RET, RICTOR, RMI2, RNF43, ROS 1, RPL22, RPL5, RPN1, RPTOR, RUNX1, RUNX1T1, SBDS, SDC4, SDHAF2, SDHB, SDHC, SDHD, SEPT9, SET, SETBP1, SETD2, SF3B1, SH2B3, SH3GL1, SLC34A2, SMAD2, SMAD4, SMARCB1, SMARCE1, SMO, SNX29, SOX 10, SPECC1, SPEN, SRGAP3, SRSF2, SRSF3, SS18, SS18L1, STAT3, STAT4, STAT5B, STIL, STK11, SUFU, SUZ12, SYK, TAF15, TCF12, TCF3, TCF7L2, TET1, TET2, TFEB, TFG, TFRC, TGFBR2, TLX1, TNFAIP3, TNFRSF14, TNFRSF17, TOPI, TP53, TPM3, TPM4, TPR, TRAF7, TRIM26, TRIM27, TRIM33, TRIP11, TRRAP, TSC1, TSC2, TSHR, TTL, U2AF1, USP6, VEGFA, VEGFB, VTI1A, WHSC1, WHSC1L1, WIF1, WISP3, WRN, WT1, WWTR1, XPA, XPC, XPOl, YWHAE, ZMYM2, ZNF217, ZNF331, ZNF384, ZNF521 and ZNF703. Such genes can be assessed, e.g., for point mutations, indels and copy number, or other characteristics as desired. The molecular profile may comprise analysis of at least one, e.g., 1, 2, 3, 4, 5, 6, 7 or 8 of ALK, BRAF, NTRKl, NTRK2, NTRK3, RET, ROS 1 and RSP03.

Such genes can be assessed for gene fusions or other characteristics as desired. The molecular profile may comprise analysis of EGFR vIII and/or MET Exon 14 Skipping. Such analysis may include identification of variant transcripts. In some embodiments, all genes listed in Tables 6-10 are analyzed as indicated in the table headers. The analysis can be used to determine MSI, TMB, or both for the tumor. NGS sequencing may be used to perform such analysis in a high throughput manner. Any useful combinations such as those listed in this paragraph may be assessed by sequence analysis.

[00351] In an embodiment, the plurality of genes and/or gene products comprises sequence analysis of at least one, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57 or 58, of ABL1, AKT1, ALK, APC, AR, ARAF, ATM, BAP1, BRAF, BRCA1, BRCA2, CDK4, CDKN2A, CHEK1, CHEK2, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, JAK2, KDR, KIT, KRAS, MAP2K1 (MEKl), MAP2K2 (MEK2), MET, MLHl, MPL, NFl, NOTCHl, NRAS, NTRKl, PDGFRA, PDGFRB, PIK3CA, PTCH1, PTEN, RAF1, RET, ROS1, SMO, SRC, TP53, VHL, WT1. The genes assessed by sequence analysis may further comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 450, 500, or all genes, selected from the group consisting of ABIl, ABL2, ACSL3, ACSL6, AFFl, AFF3, AFF4, AKAP9, AKT2, AKT3, ALDH2, AMER1, AR, ARFRP1, ARHGAP26, ARHGEF12, ARID 1 A, ARID2, ARNT, ASPSCR1, ASXL1, ATF1, ATIC, ATP1A1, ATP2B3, ATR, ATRX, AURKA, AURKB, AXINl, AXL, BARDl, BCLIO, BCLl 1A, BCLl IB, BCL2, BCL2L11, BCL2L2, BCL3, BCL6, BCL7A, BCL9, BCOR, BCORL1, BCR, BIRC3, BLM, BMPR1A, BRD3, BRD4, BRIP1, BTG1, BTK, BUB1B, Cl lorf30, C15orf21, C15orf55, C15orf65, C16orf75, C2orf44, CACNA1D, CALR, CAMTA1, CANT1, CARD11, CARS, CASC5, CASP8, CBFA2T3, CBFB, CBL, CBLB, CBLC, CCDC6, CCNB1IP1, CCND1, CCND2, CCND3, CCNE1, CD274, CD74, CD79A, CD79B, CDC73, CDH11, CDK12, CDK4, CDK6, CDK8, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CDX2, CEBPA, CHCHD7, CHIC2, CHN1, CIC, CIITA, CLP1, CLTC, CLTCL1, CNBP, CNOT3, CNTRL, COL1A1, COPB 1, COX6C, CREB1, CREB3L1, CREB3L2, CREBBP, CRKL, CRLF2, CRTC1, CRTC3, CSF3R, CTCF, CTLA4, CTNNA1, CXCR7, CYLD, CYP2D6, DAXX, DDB2, DDIT3, DDX10, DDX5, DDX6, DEK, DICERl, DNM2, DNMT3A, DOT1L, DUX4, EBF1, ECT2L, EIF4A2, ELF4, ELK4, ELL, ELN, EML4, EP300, EPHA3, EPHA5, EPHB 1, EPS15, ERC1, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERG, ESR1, ETV1, ETV4, ETV5, ETV6, EWSR1, EXT1, EXT2, EZH2, EZR, FAM123B, FAM22A, FAM22B, FAM46C, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, FAS, FBXOl 1, FCGR2B, FCRL4, FEV, FGF10, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFRIOP, FGFR3, FGFR4, FH, FHIT, FIP1L1, FLCN, FLU, FLT1, FLT4, FNBP1, FOXA1, FOXL2, FOXOl, FOX03, FOX04, FOXP1, FSTL3, FUBP1, FUS, GAS7, GATA1, GATA2, GATA3, GID4, GMPS, GNA13, GOLGA5, GOPC, GPC3, GPHN, GPR124, GRIN2A, GSK3B, H3F3A, H3F3B, HERPUD1, HEY1, HGF, HIP1, HIST1H3B, HIST1H4I, HLF, HMGAl, HMGA2, HNRNPA2B 1, HOOK3, HOXAl 1, HOXA13, HOXA9, HOXCl 1,

HOXC13, HOXD11, HOXD13, HSP90AA1, HSP90AB1, IGF1R, IKBKE, IKZF1, IL2, IL21R, IL6ST, IL7R, INHBA, IRF4, IRS2, ITK, JAK1, JAZF1, JU , KAT6A, KCNJ5, KDM5A, KDM5C, KDM6A, KDSR, KEAP1, KIAA1549, KIF5B, KLF4, KLHL6, KLK2, KTN1, LASP1, LCK, LCP1, LGR5, LHFP, LIFR, LMOl, LM02, LPP, LRIG3, LRP1B, LYL1, MAF, MAFB, MALT1, MAML2, MAP2K1 (MEK1), MAP2K2 (MEK2), MAP2K4, MAP3K1, MAX, MCL1, MDM2, MDM4, MDS2, MECOM, MED 12, MEF2B, MEN1, MITF, MKL1, MLF1, MLL, MLL2, MLL3, MLLT1, MLLT10, MLLT11, MLLT3, MLLT4, MLLT6, MN1, MNX1, MRE11A, MSH2, MSH6, MSI2, MSN, MTCP1, MTOR, MUC1, MUTYH, MYB, MYC, MYCL1, MYCN, MYD88, MYH11, MYH9, MYST4, NACA, NBN, NCKIPSD, NCOA1, NCOA2, NCOA4, NDRG1, NF2, NFE2L2, NFIB, NFKB2, NFKBIA, NIN, NKX2- 1, NONO, NOTCH2, NR4A3, NSD1, NT5C2, NTRK2, NTRK3, NUMA1, NUP214, NUP93, NUP98, OLIG2, OMD, P2RY8, PAFAH1B2, PAK3, PALB2, PATZ1, PAX3, PAX5, PAX7, PAX8, PBRM1, PBX1, PCM1, PCSK7, PDCD1, PDCD1LG2, PDE4DIP, PDGFB, PDGFRB, PDK1, PERI, PHF6, PHOX2B, PICALM, PIK3CG, PIK3R1, PIK3R2, PIM1, PLAG1, PML, PMS 1, PMS2, POLE, POT1, POU2AF1, POU5F1, PPARG, PPP2R1A, PRCC, PRDM1, PRDM16, PRF1, PRKAR1A, PRKDC, PRRX1, PSIP1, PTCH1, PTPRC, RABEP1, RAC1, RAD21, RAD50, RAD51, RAD51L1, RALGDS, RANBP17, RAP1GDS1, RARA, RBM15, RECQL4, REL, RHOH, RICTOR, RNF213, RNF43, RPL10, RPL22, RPL5, RPN1, RPTOR, RUNDC2A, RUNX1, RUNxlTl, SBDS, SDC4, SDHAF2, SDHB, SDHC, SDHD, SEPT5, SEPT6, SEPT9, SET, SETBP1, SETD2, SF3B 1, SFPQ, SFRS3, SH2B3, SH3GL1, SLC34A2, SLC45A3, SMAD2, SMARCA4, SMARCE1, SOCS 1, SOX10, SOX2, SPECC1, SPEN, SPOP, SRC, SRGAP3, SRSF2, SS18, SS18L1, SSX1, SSX2, SSX4, STAG2, STAT3, STAT4, STAT5B, STIL, SUFU, SUZ12, SYK, TAF15, TALI, TAL2, TBL1XR1, TCEA1, TCF12, TCF3, TCF7L2, TCL1A, TERT, TET1, TET2, TFE3, TFEB, TFG, TFPT, TFRC, TGFBR2, THRAP3, TLX1, TLX3, TMPRSS2, TNFAIP3, TNFRSF14, TNFRSF17, TOPI, TPM3, TPM4, TPR, TRAF7, TRIM26, TRIM27, TRIM33, TRIP11, TRRAP, TSC1, TSC2, TSHR, TTL, U2AF1, UBR5, USP6, VEGFA, VEGFB, VTI1A, WAS, WHSC1, WHSC1L1, WIF1, WISP3, WRN, WWTR1, XPA, XPC, XPOl, YWHAE, ZBTB 16, ZMYM2, ZNF217, ZNF331, ZNF384, ZNF521, ZNF703 and ZRSR2. Any useful combinations such as those listed in this paragraph may be assessed by sequence analysis.

[00352] The genes assessed by sequence analysis may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, or all genes, selected from the group consisting of ABLl, ACVRIB, AKTl, AKT2, AKT3, ALK, ALK, ALOX12B, AMER1, APC, AR, ARAF, ARFRP1, ARID 1 A, ASXL1, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BCL2, BCL2, BCL2L1, BCL2L2, BCL6, BCOR, BCORLl, BCR, BRAF, BRAF, BRCAl, BRCAl, BRCA2, BRCA2, BRD4, BRIPl, BTGl, BTG2, BTK, Cl lorf30, CALR, CARD11, CASP8, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD22, CD274, CD70, CD74, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CHEK1, CHEK2, CIC, CREBBP, CRKL, CSF1R, CSF3R, CTCF, CTNNAl, CTNNB l, CUL3, CUL4A, CXCR4, CYP17A1, DAXX, DDR1, DDR2, DIS3,

DNMT3A, DOT1L, EED, EGFR, EGFR, EP300, EPHA3, EPHB 1, EPHB4, ERBB2, ERBB3, ERBB4, ERCC4, ERG, ERRFIl, ESRl, ETV4, ETV5, ETV6, EWSRl, EZH2, EZR, FAM46C, FANCA, FANCC, FANCG, FANCL, FAS, FBXW7, FGF10, FGF12, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFRl, FGFRl, FGFR2, FGFR2, FGFR3, FGFR3, FGFR4, FH, FLCN, FLT1, FLT3, FOXL2, FUBP1,

GABRA6, GATA3, GATA4, GATA6, GID4 (C17orf39), GNA11, GNA13, GNAQ, GNAS, GRM3, GSK3B, H3F3A, HDAC1, HGF, HNF1A, HRAS, HSD3B1, ID3, IDH1, IDH2, IGFIR, IKBKE, IKZFl, INPP4B, IRF2, IRF4, IRS2, JAK1, JAK2, JAK3, JUN, KDM5A, KDM5C, KDM6A, KDR, KEAP1, KEL, KIT, KIT, KLHL6, KMT2A (MLL), KMT2A (MLL), KMT2D (MLL2), KRAS, LTK, LYN, MAF, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K13, MAPK1, MCL1, MDM2, MDM4, MED 12, MEF2B, MEN1, MERTK, MET, MITF, MKNK1, MLH1, MPL, MRE11A, MSH2, MSH2, MSH3, MSH6, MST1R, MTAP, MTOR, MUTYH, MYB, MYC, MYC, MYCL, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NFKBIA, NKX2-1, NOTCH1, NOTCH2, NOTCH2, NOTCH3, NPM1, NRAS, NT5C2, NTRK1, NTRK1, NTRK2, NTRK2, NTRK3, NUTM1, P2RY8, PALB2, PARK2, PARP1, PARP2, PARP3, PAX5, PBRM1, PDCD1, PDCD1LG2, PDGFRA, PDGFRA, PDGFRB, PDK1, PIK3C2B, PIK3C2G, PIK3CA, PIK3CB, PIK3R1, PIM1, PMS2, POLD1, POLE, PPARG, PPP2R1A, PPP2R2A, PRDM1, PRKAR1A, PRKCI, PTCH1, PTEN, PTPN11, PTPRO, QKI, RAC1, RAD21, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAF1, RAF1, RARA, RARA, RBI, RBM10, REL, RET, RET, RICTOR, RNF43, ROS 1, ROS 1, RPTOR, RSP02, SDC4, SDHA, SDHB, SDHC, SDHD, SETD2, SF3B 1, SGKl, SLC34A2, SMAD2, SMAD4, SMARCA4, SMARCB l, SMO, SNCAIP, SOCS l, SOX2, SOX9, SPEN, SPOP, SRC, STAG2, STAT3, STK11, SUFU, SYK, TBX3, TEK, TERC, TERT, TET2, TGFBR2, TIPARP, TMPRSS2, TNFAIP3, TNFRSF14, TP53, TSC1, TSC2, TYR03, U2AF1, VEGFA, VHL, WHSC1, WHSC1L1, WT1, XPOl, XRCC2, ZNF217, and ZNF703.

[00353] As noted, various cancers are characterized by chromosomal translocations and gene fusions. For example, acute lymphoblastic leukemia has been characterized by a number of kinase fusions. See, e.g, Table 12; G. Roberts et al., Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371, 1005-1015 (2014), which reference is incorporated herein in its entirety. Crizotinib and imatinib target specific tyrosine kinases that form chimeric fusions. Crizotinib is FDA approved for ALK positive fusions in NSCLC and imatinib induces remission in leukemia patients that are positive for BCR-ABL fusions. In an embodiment, the molecular profile of the invention comprises sequence analysis to assess a gene fusion in at least one, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, of ABL1, ABL2, CSF1R, PDGFRB, CRLF2, JAK2, EPOR, IL2RB, NTRK3, PTK2B, TSLP and TYK2. Kinase fusions and other gene fusions have been observed in a number of carcinomas. See, e.g., N. Stransky, E. Cerami, S. Schalm, J. L. Kim, C. Lengauer, The landscape of kinase fusions in cancer. Nat Commun 5, 4846 (2014), which reference is incorporated herein in its entirety. In another embodiment, sequence analysis is used to assess a gene fusion in at least one , e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 or 53, of AKT3, ALK, ARHGAP26, AXL, BRAF, BRD3, BRD4, EGFR, ERG, ESR1, ETVl, ETV4, ETV5, ETV6, EWSR1, FGFR1, FGFR2, FGFR3, FGR, INSR, MAML2,

MAST1, MAST2, MET, MSMB, MUSK, MYB, NOTCH 1, NOTCH2, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUTM1, PDGFRA, PDGFRB, PIK3CA, PKN1, PPARG, PRKCA, PRKCB, RAF1, RELA, RET, ROS1, RSP02, RSP03, TERT, TFE3, TFEB, THADA and TMPRSS2. Fusions with any desired number of these genes can be detected in carcinomas of various lineages. Similarly, a number of gene fusions have been detected in a variety of sarcomas. In an embodiment, sequence analysis is used to assess a gene fusion in at least one, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26, of ALK, CAMTA1, CCNB3, CIC, EPC, EWSR1, FKHR, FUS, GLI1, HMGA2, JAZF1, MEAF6, MKL2, NCOA2, NTRK3, PDGFB, PLAG1, ROS 1, SS18, STAT6, TAF15, TCF12, TFE3, TFG, USP6 and YWHAE. Any desired number of fusions in these genes can be detected in various sarcomas. Additional gene fusions that can be detected as part of the molecular profiling of the invention are described in M. J. Annala, B. C. Parker, W. Zhang, M. Nykter, Fusion genes and their discovery using high throughput sequencing. Cancer Lett. 340, 192-200 (2013), which reference is incorporated herein in its entirety. Gene fusions can be detected by various technologies, including without limitation IHC (e.g., to detect mutant proteins produced by gene fusions), ISH, PCR (e.g., RT- PCR), microarrays and sequencing analysis. In an embodiment, the fusions are detected using Next Generation Sequencing technology.

Table 12 - Kinase gene fusions

[00354] Various cancer genes disclosed in the COSMIC (Catalogue Of Somatic Mutations In Cancer) database (available at cancer.sanger.ac.uk/cancergenome/projects/cosmic/) can be assessed as well.

Clinical Trial Connector

[00355] Thousands of clinical trials for therapies are underway in the United States, with several hundred of these tied to biomarker status. In an embodiment, the molecular intelligence molecular profiles of the invention include molecular profiling of markers that are associated with ongoing clinical trials. Thus, the molecular profile can be linked to clinical trials of therapies that are correlated to a subject's biomarker profile. The method can further comprise identifying trial location(s) to facilitate patient enrollment. The database of ongoing clinical trials can be obtained from www.clinicaltrials.gov in the United States, or similar source in other locations. The molecular profiles generated by the methods of the invention can be linked to ongoing clinical trials and updated on a regular basis, e.g., daily, bi-weekly, weekly, monthly, or other appropriate time period.

[00356] Although significant advances in cancer treatment have been made in recent years, not all patients can be effectively treated within the standard of care paradigm. Many patients are eligible for clinical trials participation, yet less than 3 percent are actually enrolled in a trial, according to recent National Cancer Institute (NCI) statistics. The Clinical Trials Connector allows caregivers such as physicians to quickly identify and review global clinical trial opportunities in real-time that are molecularly targeted to each patient. In embodiments, the Clinical Trials Connector has one or more of the following features: Examines thousands of open and enrolling clinical trials; Individualizes clinical trials based on molecular profiling as described herein; Includes interactive and customizable trial search filters by: Biomarker, Mechanism of action, Therapy, Phase of study, and other clinical factors (age, sex, etc.). The Clinical Trials Connector can be a computer database that is accessed once molecular profiling results are available. In some embodiments, the database comprises the EmergingMed database (EmergingMed, New York, NY). One of skill can identify appropriate clinical trials, e.g., by searching www.clinicaltrials.gov by the various biomarkers of interest and determining whether the molecular profiling results indicated the patient meets eligibility criteria for the identified trials.

[00357] In an aspect, the invention provides a set of rules for matching of clinical trials to biomarker status as determined by the molecular profiling described herein. In some embodiments, the matching of clinical trials to biomarker status is performed using one or more pre-specified criteria: 1) Trials are matched based on the OFF NCCN Compendia drug/drug class associated with potential benefit by the molecular profiling rules; 2) Trials are matched based on biomarker driven eligibility requirement of the trial; and 3) Trials are matched based on the molecular profile of the patient, the biology of the disease and the associated signaling pathways. In the latter case, i.e. item 3, clinical trial matching may comprise further criteria as follows. First, for directly targetable markers, match trials with agents directly targeting the gene (e.g., FGFR results map to anti-FGFR therapy trials; ERBB2 results map to anti-HER2 agents, etc). In addition, for directly targetable markers, trial matching considers downstream markers under the following scenarios: a) a known resistance mechanism is available (e.g., cMET inhibitors for EGFR gene); b) clinical evidence associates the (mutated) biomarker with drugs targeting downstream pathways (e.g., mTOR inhibitors when PIK3CA is mutated); and c) active clinical trials are enrolling patients (with the biomarker aberration in the inclusion criteria) with drugs targeting the downstream pathways (e.g.,

SMO inhibitors for BCR-ABL mutation T3151). In the case of markers that are not directly targetable by a known therapeutic agent, trial matching may consider alternative, downstream markers (e.g., platinum agents for ATM gene; MEK inhibitors for GNAS/GNAQ/GNA11 mutation). The clinical trials that are matched may be identified based on results of "pathogenic," "presumed pathogenic," or variant of uncertain (or unknown) significance ("VUS"). In some embodiments, the decision to

incorporate/associate a drug class with a biomarker mutation can further depend on one or more of the following: 1) Clinical evidence; 2) Preclinical evidence; 3) Understanding of the biological pathway affected by the biomarker; and 4) expert analysis. In some embodiments, the status of various biomarkers provided herein, e.g., in any of Tables 4-10 is linked to clinical trials using one or more of these criteria.

[00358] The guiding principle above can be used to identify classes of drugs that are linked to certain biomarkers. The biomarkers can be linked to various clinical trials that are studying these biomarkers, including without limitation requiring a certain biomarker status for clinical trial inclusion. Clinical trials studying the drug classes and/or specific agents listed can be matched to the biomarker. In an aspect, the invention provides a method of selecting a clinical trial for enrollment of a patient, comprising performing molecular profiling of one or more biomarker on a sample from the patient using the methods described herein. For example, the profiling can be performed for one on more biomarker in any of Tables 2-12 using the technique indicated in the table. The results of the profiling are matched to classes of drugs using the above criteria. Clinical trials studying members of the classes of drugs are identified. The patient is a potential candidate for the so-identified clinical trials.

Report

[00359] In an embodiment, the methods of the invention comprise generating a molecular profile report. The report can be delivered to the treating physician or other caregiver of the subject whose cancer has been profiled. The report can comprise multiple sections of relevant information, including without limitation: 1) a list of the genes and/or gene products in the molecular profile; 2) a description of the molecular profile of the genes and/or gene products as determined for the subject; 3) a treatment associated with one or more of the genes and/or gene products in the molecular profile; and 4) and an indication whether each treatment is likely to benefit the patient, not benefit the patient, or has indeterminate benefit. The list of the genes and/or gene products in the molecular profile can be those presented herein for the molecular intelligence profiles of the invention. The description of the molecular profile of the genes and/or gene products as determined for the subject may include such information as the laboratory technique used to assess each biomarker (e.g., RT-PCR, FISH/CISH, IHC, PCR, FA/RFLP, NGS, etc) as well as the result and criteria used to score each technique. By way of example, the criteria for scoring a protein as positive or negative for IHC may comprise the amount of staining and/or percentage of positive cells, or criteria for scoring a mutation may be a presence or absence. The treatment associated with one or more of the genes and/or gene products in the molecular profile can be determined using a biomarker-drug association rule set such as in any of International Patent Publications WO/2007/137187 (Int'l Appl. No. PCT/US2007/069286), published November 29, 2007;

PCT/US2013/073184), published June 12, 2014; WO/2011/056688 (Int'l Appl. No.

PCT/US2010/054366), published May 12, 2011; WO/2012/092336 (Int'l Appl. No.

PCT/US2011/067527), published July 5, 2012; WO/2015/116868 (Int'l Appl. No. PCT/US2015/013618), published August 6, 2015; WO/2017/053915 (Int'l Appl. No. PCT/US2016/053614), published March 30, 2017; and WO/2016/141169 (Int'l Appl. No. PCT/US2016/020657), published September 9, 2016; each of which publications is incorporated by reference herein in its entirety. The indication whether each treatment is likely to benefit the patient, not benefit the patient, or has indeterminate benefit may be weighted. For example, a potential benefit may be a strong potential benefit or a lesser potential benefit. Such weighting can be based on any appropriate criteria, e.g., the strength of the evidence of the biomarker-treatment association, or the results of the profiling, e.g., a degree of over- or underexpression.

[00360] Various additional components can be added to the report as desired. In an embodiment, the report comprises a list having an indication of whether one or more of the genes and/or gene products in the molecular profile are associated with an ongoing clinical trial. The report may include identifiers for any such trials, e.g., to facilitate the treating physician's investigation of potential enrollment of the subject in the trial. In some embodiments, the report provides a list of evidence supporting the association of the genes and/or gene products in the molecular profile with the reported treatment. The list can contain citations to the evidentiary literature and/or an indication of the strength of the evidence for the particular biomarker-treatment association. In still another embodiment, the report comprises a description of the genes and/or gene products in the molecular profile. The description of the genes and/or gene products in the molecular profile may comprise without limitation the biological function and/or various treatment associations.

[00361] FIGs. 27A-BR herein present three illustrative patient reports according to the invention. FIGs. 27A-27Z provide an illustrative molecular profiling report derived from molecular profiling of a breast cancer. FIGs. 27AA-AV provide an illustrative molecular profiling report derived from molecular profiling of a colorectal cancer. FIGs. 27AW-BR provide an illustrative molecular profiling report derived from molecular profiling of a lung cancer (NSCLC). In all cases, the reports are for actual patients and are de-identified.

[00362] As noted herein, the same biomarker may be assessed by one or more technique. In such cases, the results of the different analysis may be prioritized in case of inconsistent results. For example, the different methods may detect different aspects of a single biomarker (e.g., expression level versus mutation), or one method may be more sensitive than another. In one example, consider that molecular profiling esults obtained using the FDA approved cobas PCR (Roche Diagnostics) can be prioritized over Next Generation sequencing results. However, if the sequencing detects a mutation, e.g., V600E, V600E2 or V600K, when PCR either detects wild type or is not determinable, the report may contain a note describing both sets of results including any therapy that may be implicated. In the case of melanoma, when the result of BRAF cobas PCR is "Wild type" or "no data" whereas BRAF sequencing is "V600E" or "V600E2", the report may comprise a note that BRAF mutation was not detected by the FDA-approved Cobas PCR test, however, a V600E/E2 mutation was detected by alternative methods (next generation/ Sanger sequencing) and that evidence suggests that the presence of a V600E mutation associates with potential clinical benefit from vemurafenib, dabrafenib or trametinib therapy. Similarly, when the result of BRAF cobas PCR is "Wild type" or "no data" and BRAF sequencing is "V600K", the report may comprise a note that BRAF mutation was not detected by the FDA-approved Cobas PCR test, however, a V600K mutation was detected by alternative methods (next generation/ Sanger sequencing) and that evidence suggests that the presence of a V600K mutation associates with potential clinical benefit from trametinib therapy.

[00363] The molecular profiling report can be delivered to the caregiver for the subject, e.g., the oncologist or other treating physician. The caregiver can use the results of the report to guide a treatment regimen for the subject. For example, the caregiver may use one or more treatments indicated as likely benefit in the report to treat the patient. Similarly, the caregiver may avoid treating the patient with one or more treatments indicated as likely lack of benefit in the report.

Immune Modulators

[00364] PD 1 (programmed death- 1, PD-1) is a transmembrane glycoprotein receptor that is expressed on CD4-/CD8-thymocytes in transition to CD4+/CD8+ stage and on mature T and B cells upon activation. It is also present on activated myeloid lineage cells such as monocytes, dendritic cells and NK cells. In normal tissues, PD-1 signaling in T cells regulates immune responses to diminish damage, and counteracts the development of autoimmunity by promoting tolerance to self-antigens. PD-Ll (programmed cell death 1 ligand 1, PDL1, cluster of differentiation 274, CD274, B7 homolog 1, B7-H1, B7H1) and PD-L2 (programmed cell death 1 ligand 2, PDL2, B7-DC, B7DC, CD273, cluster of differentiation 273) are PD1 ligands. PD-Ll is constitutively expressed in many human cancers including without limitation melanoma, ovarian cancer, lung cancer, clear cell renal cell carcinoma (CRCC), urothelial carcinoma, HNSCC, and esophageal cancer. Blockade of PD-1 which is expressed in tumor-infiltrating T cells (TILs) has created an important rationale for development to monoclonal antibody therapy to target blockade of PD l/PDL-1 pathway. Tumor cell expression of PD-Ll is used as a mechanism to evade

recognition/destruction by the immune system as in normal cells the PD1/PDL1 interplay is an immune checkpoint. Monoclonal antibodies targeting PD-1/PD-L1 that boost the immune system are being developed for the treatment of cancer. See, e.g., Flies et al, Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med. 2011 Dec;84(4):409-21; Sznol and Chen, Antagonist Antibodies to PD-1 and B7-H1 (PD-Ll) in the Treatment of Advanced Human Cancer, Clin Cancer Res; 19(5) March 1, 2013; Momtaz and Postow, Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med. 2014 Nov 15;7:357-65; Shin and Ribas, The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?, Curr Opin Immunol. 2015 Jan 23;33C:23-35; which references are incorporated by reference herein in their entirety. Several drugs are in clinical development that affect the PDL1/PD1 pathway include: 1) Nivolumab

(BMS936558/MDX-1106), an anti-PD l drug from Bristol Myers Squib drug which was approved by the U.S. FDA in late 2014 under the brand name OPDIVO for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor; 2) Pembrolizumab (formerly lambrolizumab, MK-3475, trade name

Keytruda), an anti-PDl drug from Merck approved in late 2014 for use following treatment with ipilimumab, or after treatment with ipilimumab and a BRAF inhibitor in patients who carry a BRAF mutation; 3) BMS-936559/MDX-1105, an anti-PDLl drug from Bristol Myers Squib with initial evidence in advanced solid tumors; and 4) MPDL3280A, an anti-PDLl drug from Roche with initial evidence in NSCLC.

[00365] Expression of PD 1 , PD-L 1 and/or PD-L2 expression can be assessed at the protein and/or mRNA level according to the methods of the invention. For example, IHC can be used to assess their protein expression. Expression may indicate likely benefit of inhibitors of the B7-H1/PD-1 pathway, whereas lack of expression may indicate lack of benefit thereof. In some embodiments, expression of both PD-1 and PD-L1 is assessed and likely benefit of inhibitors of the B7-H1/PD-1 pathway is determined only upon co-expression of both of these immunosuppressive components. Certain cells express PD-L1 mRNA, but not the protein, due to translational suppression by microRNA miR-513. Therefore, analysis of PD-L 1 protein may be desirable for molecular profiling. Molecular profiling may also include that of miR-513. Expression of miR-513 above a certain threshold may indicate lack of benefit of immune modulation therapy.

[00366] In an aspect, the invention provides a method of identifying at least one treatment associated with a cancer in a subject, comprising: a) determining a molecular profile for at least one sample from the subject by assessing a plurality of gene or gene products, wherein the plurality of genes and/or gene products comprises at least one of PD-1 and PD-L1; and b) identifying, based on the molecular profile, at least one of: i) at least one treatment that is associated with benefit for treatment of the cancer; ii) at least one treatment that is associated with lack of benefit for treatment of the cancer; and iii) at least one treatment associated with a clinical trial. Expression of PD-1 and/or PD-L1 may be performed along with that of additional biomarkers that guide treatment selection according to the invention. Such additional biomarkers can be additional immune modulators including without limitation CTL4A, IDOl, COX2, CD80, CD86, CD8A, Granzyme A, Granzyme B, CD19, CCR7, CD276, LAG-3, TIM-3, and a combination thereof. The additional biomarkers could also comprise other useful biomarkers disclosed herein, such any of Tables 2-12. For example, the additional biomarkers may comprise at least one of lpl9q, ABL1, AKT1, ALK, APC, AR, ATM, BRAF, BRCA1, BRCA2, cKIT, cMET, CSF1R, CTNNB1, EGFR, EGFRvIII, ER, ERBB2 (HER2), FGFRl, FGFR2, FLT3, GNAl 1, GNAQ, GNAS, HER2, HRAS, IDH1, IDH2, JAK2, KDR (VEGFR2), KRAS, MGMT, MGMT-Me, MLH1, MPL, NOTCH 1, NRAS, PDGFRA, Pgp, PIK3CA, PR, PTEN, RET, RRM1, SMO, SPARC, TLE3, TOP2A, TOPOl, TP53, TS, TUBB3, VHL, CDH1, ERBB4, FBXW7, HNF1A, JAK3, NPM1, PTPN11, RBI, SMAD4, SMARCB 1, STK1, MLH1, MSH2, MSH6, PMS2, microsatellite instability (MSI), ROS1 and ERCC1. These additional analyses may suggest combinations of therapies likely to benefit the patient, such as a PD-

1/PD-Ll pathway inhibitor and another therapy suggested by the molecular profiling. See, e.g., additional biomarker-drug associations in any of Tables 2-3, Table 11. In some embodiments, anti-CTLA-4 therapy, including without limitation ipilimumab, is administered with PD-1/PD-L1 pathway therapy.

[00367] The invention further provides association of immune modulation therapy, including without limitation PD-1/PD-L1 pathway inhibitor treatments, with molecular profiling of biomarkers in addition to PD-1/PD-L1 themselves. In an embodiment of the invention, beneficial treatment of the cancer with immunotherapy targeting at least one of PD-1, PD-L1, CTLA-4, IDO-1, and CD276, is associated with a molecular profile indicating that the cancer is AR-/HER2-/ER-/PR- (quadruple negative) and/or carries a mutation in BRCA1. In some embodiments, the invention provides associating beneficial treatment of the cancer with immunotherapy targeting immune modulating therapy wherein the molecular profile indicates that the cancer carries a mutation in at least one cancer-related gene. The cancer-related gene can include at least one, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46 or 47, of ABL1, AKT1, ALK, APC, ATM, BRAF, BRCA1, BRCA2, cKIT, cMET, CSF1R, CTN B 1, EGFR, ERBB2, FGFR1, FGFR2, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, JAK2, KDR (VEGFR2), KRAS, MLH1, MPL, NOTCH1, NRAS, PDGFRA, PIK3CA, PTEN, RET, SMO, TP53, VHL, CDH1, ERBB4, FBXW7, HNFIA, JAK3, NPMl, PTPNl 1, RB I, SMAD4, SMARCBl and STKl . Other cancer related genes, such as those disclosed herein or in the COSMIC (Catalogue Of Somatic Mutations In Cancer) database (available at cancer.sanger.ac.uk/cancergenome/projects/cosmic/), can be assessed as well. See Tables 7- 10 for additional genes that can be assessed. It will be apparent to one of skill that such profiling may be performed independently of direct assessment of immune modulators themselves. As an illustrative example, a tumor determined to carry a mutation in BRCA1 may be a candidate for anti-PD-1 and/or anti- PD-L1 therapy. Thus, in a related aspect, the invention provides a method of identifying at least one treatment associated with a cancer in a subject, comprising: a) determining a molecular profile for at least one sample from the subject by assessing a plurality of genes and/or gene products other than PD-1 and/or PD-L1; and b) identifying, based on the molecular profile, that the cancer is likely to benefit from anti- PD-1 or anti-PD-Ll therapy.

[00368] Expression of PD-1 is generally assessed in tumor infiltrating lymphocytes (TILs). PD-L1 may be expressed in various cells in the tumor microenvironment. In addition to tumor cells, PD-L1 can be expressed by T cells, natural killer (NK) cells, macrophages, myeloid dendritic cells (DCs), B cells, epithelial cells, and vascular endothelial cells. In some cases, the response to anti-PD-l/PD-Ll therapy may be dependent on which cells in the tumor microenvironment express PD-L1. Thus, in some embodiments of the invention, the tumor microenvionment is assessed to determine the expression patterns of PD-L1 and the likely benefit or lack thereof is dependent on the cells determined to express PD-L1. Such PD-L1 expression can be determined in various cells, including without limitation one or more of T cells, natural killer (NK) cells, macrophages, myeloid dendritic cells (DCs), B cells, epithelial cells, and endothelial cells. [00369] Certain tumor cells may also more susceptible to immune modulating therapy and thus more likely associated with likely treatment benefit. An "immune modulating therapy" can include antagonists such as antibodies to PD-1, PD-L1, PD-L2, CTL4A, IDOl, COX2, CD80, CD86, CD8A, Granzyme A,

Granzyme B, CD19, CCR7, CD276, LAG-3 or TIM-3. The antagonist could also be a soluble ligand or small molecule inhibitor. As a non-limiting example, a soluble PD-L1 construct may bind PD-1 and thus block its immunosuppressive activity. In an embodiment, the invention provides for determining the apoptotic or necrotic environment of the tumor. Apoptotic or necrotic cells may be associated with likely treatment benefit from immune modulating therapy. Thus, the invention provides a method of identifying at least one treatment associated with a cancer in a subject, comprising: a) determining a molecular profile for at least one sample from the subject by assessing tumor necrosis or apoptosis; and b) associating the cancer with likely to benefit from immune modulating therapy, including without limitation anti-PD-1 or anti-PD-Ll therapy, if apoptotic or necrotic tumor cells are identified.

Genomic Stability Profiling

[00370] Microsatellites are repeated sequences of DNA. These sequences can be made of repeating units of one to six base pairs in length. Although the length of these microsatellites is highly variable from person to person and contributes to the individual DNA fingerprint, each individual has microsatellites of a set length.

[00371] Microsatellite instability (MSI) is the condition of genetic hypermutability that results from impaired DNA mismatch repair (MMR). Deficient MMR may be referred to as dMMR. MSI may be caused by hypermutation of the MLH1 gene, or by mutations in MMR genes such as MLH1, MSH2, MSH6, and PMS2. The presence of MSI represents phenotypic evidence that MMR is not functioning normally. Microsatellite instability may be found in any variety of cancer, including without limitation colon cancer, gastric cancer, endometrium cancer, ovarian cancer, hepatobiliary tract cancer, urinary tract cancer, brain cancer, and skin cancers. MSI is most prevalent as the cause of colon cancers.

[00372] The NCI has agreed on five microsatellite markers as the godl standard to determine MSI presence: two mononucelotides, BAT25 and BAT26, and three dinucelotide repeats, D2S 123, D5S346, and D17S250. MSI-High (MSI-H) tumors result from MSI of greater than 30% of unstable MSI biomarkers. MSI-Low (MSI-L) tumors result from less than 30% of unstable MSI biomarkers. MSI-L tumors are classified as tumors of alternative etiologies. Several studies demonstrate that MSI-H patients respond best to surgery alone, rather than chemotherapy and surgery, thus preventing patients from needlessly experiencing chemotherapy. Recently it has been found that MSI status can affect response to immune therapy. For example, PD-1 blockade was more effective against MSI-high tumors than against microsatellite-stable tumors. See Le et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015 Jun 25; 372:2509; Int'l Patent Publication WO2016077553A1 to Diaz et al entitled "Checkpoint blockade and microsatellite instability"; which references are incorporated by reference herein in their entirety.

[00373] High tumor mutational load (TML; or tumor mutation burden, TMB) is another recently identified biomarker that is a potential indicator of immunotherapy response. See, e.g., Le et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N Engl J Med 2015; 372:2509-2520; Rizvi et al., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015 Apr 3; 348(6230): 124-128; Rosenberg et al, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial. Lancet. 2016 May 7; 387(10031): 1909-1920; Snyder et al., Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. N Engl J Med. 2014 Dec 4; 371(23): 2189-2199; Int'l Patent Publication WO2016081947A2 to Chan et al entitled "Determinants of Cancer Response to Immunotherapy by PD-1 Blockade"; Int'l Patent Publication WO2017151524A1 to Frampton et al. entitled "Methods and Systems for Evaluating Tumor Mutational Burden"; all of which references are incorporated by reference herein in their entirety.

[00374] Immune checkpoints are regulators of the immune system. These pathways are crucial for self- tolerance, which prevents the immune system from attacking cells indiscriminately. Programmed death- 1 (PD-1, CD279) is an immune suppressive molecule that is upregulated on activated T cells and other immune cells. It is activated by binding to its ligand PD-Ll (B7-H1, CD274), which results in intracellular responses that reduce T-cell activation. The PD1/PDL1 interplay is an immune checkpoint. Tumor cell expression of PD-Ll is used as a mechanism to evade recognition/destruction by the immune system. Aberrant PD-Ll expression had been observed on cancer cells, leading to the development of PD- 1/PD-Ll -directed cancer therapies. Checkpoint therapy includes agents that block PD-l/PD-Ll immune suppression. Blockade of the PD-1 and PD-Ll interaction has led to clinical responses in several cancer types. Clinically available examples of PD-Ll inhibitors include durvalumab, atezolizumab and avelumab. Cancer immunotherapy agents that target the PD-1 receptor include nivolumab,

pembrolizumab, pidilizumab and BMS-936559.

[00375] The invention provides advantages over previous methods in determining biomarkers of genomic stability and immune checkpoint response. The systems and methods provided herein can be used to assess multiple biomarkers which provide complementary indications that checkpoint therapy may be of potential benefit to a cancer victim. See, e.g., Examples 7 and 8 herein. The systems and methods can be integrated into comprehensive molecular profiling to identify multiple potential therapies of benefit or potential lack of benefit for the cancer victim. See, e.g., Examples 1-6 herein.

[00376] In an aspect, the invention provides a method of determining microsatellite instability (MSI) in a biological sample, comprising: (a) obtaining a nucleic acid sequence of a plurality of microsatellite loci from the biological sample; (b) determining the number of altered microsatellite loci based on the nucleic acid sequences obtained in step (a); (c) comparing the number of altered microsatellite loci determined in step (b) to a threshold number; and (d) identifying the biological sample as MSI-high if the number of altered microsatellite loci is greater than or equal to the threshold number.

[00377] The biological sample can be any useful biological sample. In embodiments of the method of determining MSI, the biological sample comprises formalin-fixed paraffin-embedded (FFPE) tissue, fixed tissue, a core needle biopsy, a fine needle aspirate, unstained slides, fresh frozen (FF) tissue, formalin samples, tissue comprised in a solution that preserves nucleic acid or protein molecules, a fresh sample, a malignant fluid, a bodily fluid, a tumor sample, a tissue sample, or any combination thereof. In preferred embodiments, the biological sample comprises cells from a tumor, e.g., a solid tumor. The biological sample may comprise a bodily fluid. In some embodiments, the bodily fluid comprises a malignant fluid, a pleural fluid, a peritoneal fluid, or any combination thereof. In some embodiments, the bodily fluid comprises peripheral blood, sera, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid, pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, tears, cyst fluid, pleural fluid, peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocyst cavity fluid, or umbilical cord blood. The sample may comprise microvesicles.

[00378] In embodiments of the method of determining MSI, the nucleic acid sequence is obtained by sequencing DNA or R A. In preferred embodiments, the DNA is genomic DNA. For example, genomic DNA from the biological sample can be sequenced. The sequencing can be any useful sequencing method, preferably high throughput sequencing, also referred to as next generation sequencing (NGS), in order to efficiently assess multiple loci.

[00379] In embodiments of the method of determining MSI, the plurality of microsatellite loci comprises any useful number of loci, including without limitation at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000 or 10000 loci. The plurality of microsatellite loci can be filtered to exclude loci meeting certain criteria. In preferred embodiments, the plurality of microsatellite loci excludes: i) sex chromosome loci; ii) microsatellite loci in regions that typically have lower coverage depth relative to other genomic regions; iii) microsatellites with repeat unit lengths greater than 3, 4, 5, 6 or 7 nucleotides, preferably greater than 5 nucleotides; or iv) any combination of i)-iii). In regards to ii), the coverage depth (also known as sequencing depth or read depth) describes the number of times that a given nucleotide in the genome has been read in an experiment. Greater number of reads can lead to better sequencing results. Thus, the method may favor analysis of higher quality sequences with greater sequencing depth.

[00380] In some embodiments, the members of the plurality of microsatellite loci are selected from Table 16. For example, the plurality of microsatellite loci may comprise all loci in Table 16, or the plurality of loci may consist of all loci in Table 16. In other embodiments, the plurality of microsatellite loci comprise certain loci from Table 16 and other additional loci that meet desired criteria. The members of the plurality of microsatellite loci can be chosen based on certain desired criteria. In some embodiments, the members of the plurality of microsatellite loci are located within the vicinity of a gene. In preferred embodiments, each member of the plurality of microsatellite loci is located within the vicinity of a cancer gene. For example, each member of the plurality of microsatellite loci can be located within the vicinity of a cancer gene selected from Table 7, Table 8, Table 9, Table 10, or any combination thereof. Accordingly, mutations, indels, CNV, fusions, and the like can be detected in a panel of cancer genes, and the same sequencing runs can be used to assess MSI.

[00381] In embodiments of the method of determining MSI, determining the number of altered microsatellite loci in step (b) comprises comparing each nucleic acid sequence obtained in step (a) to a reference sequence for each microsatellite loci. For example, the reference sequence can be a human genomic reference sequence, including without limitation those provided by the UCSC Genome Browser or Ensembl genome browser projects. Determining the number of altered microsatellite loci may comprise identifying microsatellites with insertions or deletions that increased or decreased the number of repeats in the microsatellite as compared to the reference sequence. In some embodiments, the number of altered microsatellite loci only counts each altered loci once regardless of the number of insertions or deletions at that loci. For example, a microsatellite with two inserted repeats as compared to the reference sequence would only be counted once in determining the number of altered microsatellite loci.

[00382] In embodiments of the method of determining MSI, the threshold number is calibrated based on comparison of the number of altered microsatellite loci per patient to MSI results obtained using a different laboratory technique on a same biological sample. The "same biological sample" can refer to any appropriate sample, such as the same physical sample, another portion of the same tumor, or less preferred a related tumor from the same individual. In some embodiments, the different laboratory technique comprises fragment analysis, immunohistochemistry of mismatch repair genes, immunohistochemistry of immunomodulators, or any combination thereof. In preferred embodiments, the different laboratory technique comprises the gold standard fragment analysis as described herein. The threshold number can be determined using any number of desired biological samples, including biological samples from at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, or 2000 different cancer patients. The samples can represent various cancers, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 distinct cancer lineages. In some embodiments, the distinct cancer lineages comprise cancers selected from colorectal adenocarcinoma, endometrial cancer, bladder cancer, breast carcinoma, cervical cancer, cholangiocarcinoma, esophageal and esophagogastric junction carcinoma, extrahepatic bile duct adenocarcinoma, gastric adenocarcinoma, gastrointestinal stromal tumors, glioblastoma, liver hepatocellular carcinoma, lymphoma, malignant solitary fibrous tumor of the pleura, melanoma, neuroendocrine tumors, NSCLC, female genital tract malignancy, ovarian surface epithelial carcinomas, pancreatic adenocarcinoma, prostatic adenocarcinoma, small intestinal malignancies, soft tissue tumors, thyroid carcinoma, uterine sarcoma, uveal melanoma, and any combination thereof. In some

embodiments, the threshold number is calibrated across at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, or 25 distinct cancer lineages using sensitivity, specificity, positive predictive value, negative predictive value, or any combination thereof. For example, the threshold can be tuned with high sensitivity to MSI-high to reduce false negatives, or high specificity to MSI-high to reduce false positives, or any desired balance between. [00383] In a preferred embodiment, the threshold number is set to provide high sensitivity to MSI-high as determined in colorectal cancer using the different laboratory technique, which different laboratory technique can be fragment analysis.

[00384] The threshold number will be related to the number and characteristics of the interrogated microsatellite loci. The threshold can be recalibrated, e.g., if a different set of loci are chosen. If relevant data is available, the threshold can be calibrated for different settings, such as different clinical criteria. For example, a different threshold may be calculated for different cancer lineages. In other embodiments, the threshold may be calibrated for different patient characteristics such as sex, age, clinical history including prior disease and treatments. Calibrating the threshold for different settings may rely on having sufficient data available to tune sensitivity, specificity, positive predictive value, negative predictive value, or other criteria in a statistically significant manner.

[00385] The threshold number can be expressed using any appropriate measure, including without limitation as a number of loci or as a percentage of loci. In some embodiments, the threshold number is less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the number of members of the plurality of microsatellite loci. On the other hand, the threshold number can be greater than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the number of members of the plurality of microsatellite loci. For example, the threshold number can be between about 10% and about 0.1% of the number of members of the plurality of microsatellite loci, or between about 5% and about 0.2% of the number of members of the plurality of microsatellite loci, or between about 3% and about 0.3% of the number of members of the plurality of microsatellite loci, or between about 1% and about 0.4% of the number of members of the plurality of microsatellite loci. As used herein, "about" may include a range of +/- 10% of the stated value.

[00386] As an example of the method of determining MSI, the number of members of the plurality of microsatellite loci is greater than 7000 and the threshold number is > 40 and < 50, wherein optionally the threshold level is 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50. Example 8 herein presents one illustration of the method of determining MSI. In the Example the members of the plurality of microsatellite loci are those in Table 16, which comprises 7317 members. Using the methods described herein, the threshold was set to 46 loci. Accordingly, the threshold was 0.63% of the number of members of the plurality of microsatellite loci. The threshold can be recalibrated as described herein with changing members of the plurality of microsatellite loci.

[00387] In preferred embodiments of the method of determining MSI, MSI status, e.g., high, stable or low, is determined without assessing microsatellite loci in normal tissue. Thus, the invention can avoid taking additional tissue from an individual.

[00388] In embodiments of the method of determining MSI, the method further comprises identifying the biological sample as microsatellite stable (MSS) if the number of altered microsatellite loci is below the threshold number. Relatedly, the method may also comprise identifying the biological sample as MSI-low if the number of altered microsatellite loci in the sample is less than or equal to a lower threshold number. As further described herein, the MSI-low can be calibrated using similar methodology as MSI high described above. MSS can be the range between MSI-high and MSH-low.

[00389] The invention also provides a method of determining a tumor mutation burden (TMB; also referred to as tumor mutation load or TML) for a biological sample. In embodiments of the method of determining MSI, the method further comprises determining a tumor mutation burden (TMB) for the biological sample. In preferred embodiments, TMB is determined using the same laboratory analysis as MSI. As a non-limiting illustration, a NGS panel is run on a biological sample and the sequencing results are used to calculate MSI, TMB, or both. In some embodiments, TMB is determined by sequence analysis of a plurality of genes, including without limitation cancer genes selected from Table 7, Table 8, Table 9, Table 10, or any combination thereof. In a preferred embodiment, TMB is determined using missense mutations that have not been previously identified as germline alterations in the art. Similar to MSI-high, TMB-High can be determined by comparing a mutation rate to a TMB-High threshold, wherein TMB- High is defined as the mutation rate greater than or equal to the TMB-High threshold. The mutation rate can be expressed in any appropriate units, including without limitation units of mutations / megabase. The TMB-High threshold can be determined by comparing TMB with MSI determined in colorectal cancer from a same sample. This is because TMB and MSI may be more strongly correlated in CRC than in other types of cancer. In various embodiments, the TMB-High threshold is greater than or equal to 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 mutations / megabase of missense mutations. In a preferred embodiment, the TMB-High threshold is 17 mutations / megabase. Similarly, TMB-Low status can be determined by comparing a mutation rate to a TMB-Low threshold, wherein TMB-Low is defined as the mutation rate less than or equal to the TMB-Low threshold. The TMB-Low threshold can also be determined by comparing TMB with MSI determined in colorectal cancer from a same sample. In various embodiments, the TMB-Low threshold is less than or equal to 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutations / megabase of missense mutations. In a preferred embodiment, the TMB-Low threshold is 6 mutations / megabase.

[00390] As with MSI described above, the TMB thresholds can be recalibrated when sequencing results are obtained for different genes or different regions of the same genes. The TMB thresholds can also be recalibrated for different settings wherein sufficient data is available to tune sensitivity, specificity, positive predictive value, negative predictive value, or other criteria in a robust manner.

[00391] In embodiments of the method of determining MSI, TMB, or both, the method further comprises profiling various additional biomarkers in the biological sample as desired, e.g., mismatch repair proteins such as MLH1, MSH2, MSH6, and PMS2, immune checkpoint proteins such as PD-L1, or any combination thereof. The profiling can comprise any useful technique, including without limitation determining: i) a protein expression level, wherein optionally the protein expression level is determined using IHC, flow cytometry or an immunoassay; ii) a nucleic acid sequence, wherein optionally the sequence is determined using next generation sequencing; iii) a promoter hypermethylation, wherein optionally the hypermethylation is determined using pyrosequencing; and iv) any combination thereof. For example, it may be desired to profile promoter hypermethylation of MLH1; mutations in MLH1, MSH2, MSH6, and PMS2; protein expression of MLH1, MSH2, MSH6, PMS2 and PD-L1; and any combination thereof. Checkpoint proteins of interest can include PD-1, PD-L1, PD-L2, CTL4A, IDO l, COX2, CD80, CD86, CD8A, Granzyme A, Granzyme B, CD19, CCR7, CD276, LAG-3, TIM-3, or any useful combination thereof.

[00392] In another aspect, the invention provides a method of identifying at least one therapy of potential benefit for an individual with cancer, the method comprising: (a) obtaining a biological sample from the individual, e.g., as described herein; (b) generating a molecular profile by performing the method of the invention for determining MSI, TMB, or both on the biological sample (e.g., as described above); and (c) identifying the therapy of potential benefit based on the molecular profile. Generating the molecular profile can also comprise performing additional analysis on the biological sample according to Table 5, Table 6, Table 7, Table 8, Table 9, Table 10, or any combination thereof. In some embodiments, generating the molecular profile comprises performing additional analysis on the biological sample to: i) determine a tumor mutation burden (TMB); ii) determine an expression level of MLH1 ; iii) determine an expression level of MSH2, determine an expression level of MSH6; iv) determine an expression level of PMS2; v) determine an expression level of PD-L1; vi) or any combination thereof. Additional analysis maybe be useful, e.g., promoter hypermethylation of MLH1; mutations in MLH1, MSH2, MSH6, and PMS2; protein expression of MLH1, MSH2, MSH6, PMS2 and PD-L1; and any combination thereof

[00393] The step of identifying can use drug-biomarker associations, such as those described herein. See, e.g., Table 11. The step of identifying can use drug-biomarker association rule sets such as in any of International Patent Publications WO/2007/137187 (Int'l Appl. No. PCT/US2007/069286), published November 29, 2007; WO/2010/045318 (Int'l Appl. No. PCT/US2009/060630), published April 22, 2010; WO/2010/093465 (Int'l Appl. No. PCT/US2010/000407), published August 19, 2010; WO/2012/170715 (Int'l Appl. No. PCT/US2012/041393), published December 13, 2012; WO/2014/089241 (Int'l Appl. No. PCT/US2013/073184), published June 12, 2014; WO/2011/056688 (Int'l Appl. No.

PCT/US2010/054366), published May 12, 2011; WO/2012/092336 (Int'l Appl. No.

PCT/US2011/067527), published July 5, 2012; WO/2015/116868 (Int'l Appl. No. PCT/US2015/013618), published August 6, 2015; WO/2017/053915 (Int'l Appl. No. PCT/US2016/053614), published March 30, 2017; and WO/2016/141169 (Int'l Appl. No. PCT/US2016/020657), published September 9, 2016; each of which publications is incorporated by reference herein in its entirety. In a preferred embodiment, the step of identifying comprises identifying potential benefit from an immune checkpoint inhibitor therapy when the biological sample is MSI-High. Similarly, the step of identifying may comprise identifying potential benefit from an immune checkpoint inhibitor therapy when the biological sample is MSI-High, TMB-High, MLH1-, MSH2-, MSH6-, PMS2-, PD-L1+, or any combination thereof. The step of identifying may comprise identifying potential benefit from an immune checkpoint inhibitor therapy when the biological sample is MSI-High, TMB-High, PD-L1+, or any combination thereof. See, e.g., Example 8 herein, which notes that each of these biomarkers can provide independent information; see also FIGs. 27A-BR and related text. The method can identify any useful immune checkpoint inhibitor therapy, including without limitation ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, pidilizumab, AMP-224, AMP-514, PDR001, BMS-936559, or any combination thereof. In addition, the method may comprise identifying at least one therapy of potential lack of benefit based on the molecular profile, at least one clinical trial for the subject based on the molecular profile, or any combination thereof. For examples, see FIGs. 27A-BR.

[00394] In embodiments of the method of identifying at least one therapy of potential benefit, the subject has not previously been treated with the at least one therapy of potential benefit. The cancer may comprise a metastatic cancer, a recurrent cancer, or any combination thereof. In some cases, the cancer is refractory to a prior therapy, including without limitation front-line or standard of care therapy for the cancer. In some embodiments, the cancer is refractory to all known standard of care therapies. In other

[00395] The method of identifying at least one therapy of potential benefit can be employed for any desired cancer, such as those disclosed herein. In some embodiments, the cancer is of a lineage listed in Table 19.

[00396] In a related aspect, the invention provides a method of generating a molecular profiling report comprising preparing a report comprising the generated molecular profile using the methods of the invention above. In some embodiments, the report further comprises a list of the at least one therapy of potential benefit for the individual. In some embodiments, the report further comprises a list of at least one therapy of potential lack of benefit for the individual. In some embodiments, the report further comprises a list of at least one therapy of indeterminate benefit for the individual. The report may comprise identification of the at least one therapy as standard of care or not for the cancer lineage. The report can also comprise a listing of biomarkers tested when generating the molecular profile, the type of testing performed for each biomarker, and results of the testing for each biomarker. In some embodiments, the report further comprises a list of clinical trials for which the subject is indicated and/or eligible based on the molecular profile. In some embodiments, the report further comprises a list of evidence supporting the identification of therapies as of potential benefit, potential lack of benefit, or indeterminate benefit based on the molecular profile. The report can comprise any or all of these elements. For example, the report may comprise: 1) a list of biomarkers tested in the molecular profile; 2) a description of the molecular profile of the biomarkers as determined for the subject (e.g., type of testing and result for each biomarker); 3) a therapy associated with at least one of the biomarkers in the molecular profile; and 4) and an indication whether each therapy is of potential benefit, potential lack of benefit, or indeterminate benefit for treating the individual based on the molecular profile. The description of the molecular profile of the biomarkers can include the technique used to assess the biomarkers and the results of the assessment. The report can be computer generated, and can be a printed report, a computer file or both. The report can be made accessible via a secure web portal.

[00397] In an aspect, the invention provides the report generated by the methods of the invention. In a related aspect, the invention provides a computer system for generating the report. Exemplary reports generated according to the methods of the invention, and generated by a system of the invention, are found herein in FIGs. 27A-BR. See also Example 3.

[00398] In an aspect, the invention provides use of a reagent in carrying out the methods of the invention as described above. In a related aspect, the invention provides of a reagent in the manufacture of a reagent or kit for carrying out the methods of the invention as described above. In still another related aspect, the invention provides a kit comprising a reagent for carrying out the methods of the invention as described above. The reagent can be any useful and desired reagent. In preferred embodiments, the reagent comprises at least one of a reagent for extracting nucleic acid from a sample, a reagent for performing ISH, a reagent for performing IHC, a reagent for performing PCR, a reagent for performing Sanger sequencing, a reagent for performing next generation sequencing, a probe set for performing next generation sequencing, a probe set for sequencing the plurality of microsatellite loci, a reagent for a DNA microarray, a reagent for performing pyrosequencing, a nucleic acid probe, a nucleic acid primer, an antibody, an aptamer, a reagent for performing bisulfite treatment of nucleic acid, and any combination thereof.

[00399] In an aspect, the invention provides a system for identifying at least one therapy associated with a cancer in an individual, comprising: (a) at least one host server; (b) at least one user interface for accessing the at least one host server to access and input data; (c) at least one processor for processing the inputted data; (d) at least one memory coupled to the processor for storing the processed data and instructions for: i) accessing an MSI status generated by the method of the invention above; and ii) identifying, based on the MSI status, at least one of: A) at least one therapy with potential benefit for treatment of the cancer; B) at least one therapy with potential lack of benefit for treatment of the cancer; and C) at least one therapy associated with a clinical trial; and (e) at least one display for displaying the identified at least one of: A) at least one therapy with potential benefit for treatment of the cancer; B) at least one therapy with potential lack of benefit for treatment of the cancer; and C) at least one therapy associated with a clinical trial. In some embodiments, the system further comprises at least one memory coupled to the processor for storing the processed data and instructions for identifying, based on the generated molecular profile according to the methods above, at least one of: A) at least one therapy with potential benefit for treatment of the cancer; B) at least one therapy with potential lack of benefit for treatment of the cancer; and C) at least one therapy associated with a clinical trial; and at least one display for display thereof. The system may further comprise at least one database comprising references for various biomarker states, data for drug/biomarker associations, or both.The at least one display can be a report provided by the invention. See, e.g., the report herein in FIGs. 27A-BR. See also Example 3.

EXAMPLES

Example 1: Molecular Profiling System

[00400] Molecular profiling is performed to determine a treatment for a disease, typically a cancer. Using a molecular profiling approach, molecular characteristics of the disease itself are assessed to determine a candidate treatment. Thus, this approach provides the ability to select treatments without regard to the anatomical origin of the diseased tissue, or other "one-size-fits-all" approaches that do not take into account personalized characteristics of a particular patient's affliction. The profiling comprises determining gene and gene product expression levels, gene copy number and mutation analysis.

Treatments are identified that are indicated to be effective against diseased cells that overexpress certain genes or gene products, underexpress certain genes or gene products, carry certain chromosomal aberrations or mutations in certain genes, or any other measureable cellular alterations as compared to non-diseased cells. Because molecular profiling is not limited to choosing amongst therapeutics intended to treat specific diseases, the system has the power to take advantage of any useful technique to measure any biological characteristic that can be linked to a therapeutic efficacy. The end result allows caregivers to expand the range of therapies available to treat patients, thereby providing the potential for longer life span and/or quality of life than traditional "one-size-fits-all" approaches to selecting treatment regimens.

[00401] FIG. 28 illustrates a molecular profiling system that performs analysis of a cancer sample using a variety of components that measure various biological aspects including without limitation expression levels, chromosomal aberrations and mutations. The molecular "blueprint" of the cancer is used to generate a prioritized ranking of druggable targets and/or drug associated targets in tumor and their associated therapies.

[00402] A system for carrying out molecular profiling according to the invention comprises the components used to perform molecular profiling on a patient sample, identify potentially beneficial and non-beneficial treatment options based on the molecular profiling, and return a report comprising the results of the analysis to the treating physician or other appropriate caregiver.

[00403] Formalin-fixed paraffin-embedded (FFPE) can be reviewed by a pathologist for quality control before subsequent analysis. Nucleic acids (DNA and RNA) can be extracted from FFPE tissues after microdissection of the fixed slides. Nucleic acids can be extracted using methods such as phenol- chlorform extraction or kits such as the QIAamp DNA FFPE Tissue kit according to the manufacturer's instructions (QIAGEN Inc., Valencia, CA).

[00404] Gene expression analysis can be performed using an expression microarray or qPCR (RT-PCR). The qPCR can be performed using a low density microarray. In addition to gene expression analysis, the system can perform a set of immunohistochemistry assays on the input sample. Gene copy number is determined for a number of genes via ISH (in situ hybridization) and mutational analysis can be performed by DNA sequencing (including sequence sensitive PCR assays and fragment analysis such as RFLP, as desired) for specific mutations. Comprehensive sequencing analysis with high throughput techniques (also known as next generation sequencing, NGS) can be performed to assess numerous genes, including whole exome analysis, and numerous types of alterations in high throughput fashion. For example, NGS can be used to assess mutations, including point mutations, insertions, deletions, and copy number in DNA, and gene fusions and copy number in RNA. Molecular profiling data can be stored for each patient case. Data is reported from any desired combination of analysis performed. All laboratory experiments are performed according to Standard Operating Procedures (SOPs). [00405] Expression can be measured using real-time PCR (qPCR, RT-PCR). The analysis can employ a low density microarray. The low density microarray can be a PCR-based microarray, such as a Taqman™ Low Density Microarray (Applied Biosystems, Foster City, CA).

[00406] Expression can be measured using a microarray. The expression microarray can be an Agilent 44K chip (Agilent Technologies, Inc., Santa Clara, CA). This system is capable of determining the relative expression level of roughly 44,000 different sequences through RT-PCR from RNA extracted from fresh frozen tissue. Alternately, the system uses the Illumina Whole Genome DASL assay (Illumina Inc., San Diego, CA), which offers a method to simultaneously profile over 24,000 transcripts from minimal RNA input, from both fresh frozen (FF) and formalin-fixed paraffin embedded (FFPE) tissue sources, in a high throughput fashion. The analysis makes use of the Whole-Genome DASL Assay with UDG (Illumina, cat#DA-903-1024/DA-903-1096), the Illumina Hybridization Oven, and the Illumina iScan System according to the manufacturer's protocols. FIG. 29 shows example results obtained from microarray profiling of an FFPE sample. Total RNA was extracted from tumor tissue and was converted to cDNA. The cDNA sample was then subjected to a whole genome (24K) microarray analysis using the Illumina Whole Genome DASL process. The expression of a subset of 80 genes was then compared to a tissue specific normal control and the relative expression ratios of these 80 target genes indicated in the figure was determined as well as the statistical significance of the differential expression.

[00407] Polymerase chain reaction (PCR) amplification is performed using the ABI Veriti Thermal Cycler (Applied Biosystems, cat#9902). PCR is performed using the Platinum Taq Polymerase High Fidelity Kit (Invitrogen, cat#l 1304-029). Amplified products can be purified prior to further analysis with Sanger sequencing, pyrosequencing or the like. Purification is performed using CleanSEQ reagent, (Beckman Coulter, cat#000121), AMPure XP reagent (Beckman Coulter, cat#A63881) or similar. Sequencing of amplified DNA is performed using Applied Biosystem's ABI Prism 3730x1 DNA Analyzer and BigDye® Terminator V 1.1 chemistry (Life Technologies Corporation, Carlsbad, CA). The BRAF V600E mutation is assessed using the FDA approved cobas® 4800 BRAF V600 Mutation Test from Roche Molecular Diagnostics (Roche Diagnostics, Indianapolis, IN). NextGeneration sequencing is performed using the MiSeq platform from Illumina Corporation (San Diego, California, USA) according to the manufacturer's recommended protocols.

[00408] For RFLP, fragment analysis can performed on reverse transcribed mRNA isolated from a formalin-fixed paraffin-embedded tumor sample using FAM-linked primers designed to flank and amplify desired locations.

[00409] IHC is performed according to standard protocols. IHC detection systems vary by marker and include Dako's Autostainer Plus (Dako North America, Inc., Carpinteria, CA), Ventana Medical Systems Benchmark® XT (Ventana Medical Systems, Tucson, AZ), and the Leica/Vision Biosystems Bond System (Leica Microsystems Inc., Bannockburn, IL). All systems are operated according to the manufacturers' instructions.

[00410] ISH is performed on formalin-fixed paraffin-embedded (FFPE) tissue. FFPE tissue slides for FISH must be Hematoxylin and Eosion (H & E) stained and given to a pathologist for evaluation. Pathologists will mark areas of tumor to be ISHed for analysis. The pathologist report must show tumor is present and sufficient enough to perform a complete analysis. FISH or CISH are performed using the Abbott Molecular VP2000 according to the manufacturer's instructions (Abbott Laboratories, Des Plaines, IA). ALK can be assessed using the Vysis ALK Break Apart FISH Probe Kit from Abbott Molecular, Inc. (Des Plaines, IL). HER2 can be assessed using the INFORM HER2 Dual ISH DNA Probe Cocktail kit from Ventana Medical Systems, Inc. (Tucson, AZ) and/or SPoT-Light® HER2 CISH Kit available from Life Technologies (Carlsbad, CA).

[00411] DNA for mutation analysis is extracted from formalin-fixed paraffin-embedded (FFPE) tissues after macrodissection of the fixed slides in an area that % tumor nuclei > 10% as determined by a pathologist. Extracted DNA is only used for mutation analysis if % tumor nuclei > 10%. DNA is extracted using the QIAamp DNA FFPE Tissue kit according to the manufacturer's instructions (QIAGEN Inc., Valencia, CA). DNA can also be extracted using the QuickExtract™ FFPE DNA Extraction Kit according to the manufacturer's instructions (Epicentre Biotechnologies, Madison, WI). The BRAF Mutector I BRAF Kit (TrimGen, cat#MH 1001-04) is used to detect BRAF mutations (TrimGen Corporation, Sparks, MD). Roche's Cobas PCR kit can be used to assess the BRAF V600E mutation. The DxS KRAS

Mutation Test Kit (DxS, #KR-03) is used to detect KRAS mutations (QIAGEN Inc., Valencia, CA). BRAF and KRAS sequencing of amplified DNA is performed using Applied Biosystems' BigDye® Terminator V 1.1 chemistry (Life Technologies Corporation, Carlsbad, CA).

[00412] Next generation sequencing is performed using a TruSeq/MiSeq/HiSeq/NexSeq system offered by Illumina Corporation (San Diego, CA) or an Ion Torrent system from Life Technologies (Carlsbad, CA, a division of Thermo Fisher Scientific Inc.) according to the manufacturer's instructions.

Example 2: Molecular Profiling Service

[00413] FIGs. 26A-C illustrate a molecular profiling service requisition using a molecular profiling approach as outlined in Tables 5-11, and accompanying text herein. Such requisition presents choices for molecular profiling that can be presented to a caregiver, e.g., a medical oncologist who may prescribe a therapeutic regimen to a cancer patient. FIG. 26A shows a choice of MI Profile™ panel that is assessed using multiple technologies, e.g., according to Table 5 (which, as noted, preferably comprises Tables 6- 10 for NGS), or a MI Tumor Seek™ panel, e.g., with the gene analysis presented in Tables 6-10. FIG. 26B amd FIG. 26C illustrate sample requirements that can be used to perform molecular profiling on a patient tumor sample according to the biomarker choices in FIG. 26A. FIG. 26B provides requirements for formalin fixed paraffin embedded (FFPE) and FIG. 26C provides requirements for fresh samples or insufficient sample to perform all testing. In the event that insufficient quantity or tissue, bodily fluid or percent tumor is available to perform all tests desired to be performed, certain tests can be prioritized, e.g., according to physician preference or experience with the various biomarkers in similar tumor types.

[00414] FIGs. 26D-E illustrate sample requirements and corresponding test performance. FIG. 26D shows expected technical sensitivity and specificity of ISH, CISH and FISH. FIG. 26E shows expected technical criteria inclusing positive predictive value (PPV), sensitivity and specificity of Next Generation Sequencing (NGS). [00415] Using the comprehensive genomic profiling approach provided herein to assess DNA, RNA and proteins reveals a reliable molecular blueprint to guide more precise and individualized treatment decisions from among 60+ FDA-approved therapies (at present).

Example 3: Molecular Profiling Reports

[00416] FIGs. 27A-BR present molecular profiling reports of the invention which are de-identified but from molecular profiling of actual patients according to the systems and methods of the invention.

[00417] FIGs. 27A-Z illustrate an exemplary patient report based on molecular profiling the tumor of an individual having breast cancer. FIG. 27A illustrates a cover page of a report indicating patient and specimen information for the patient. Note that the molecular profiling results indicate ER/PR positive and HER2 negative under the header "Lineage Relevant Biomarkers." Under the header "Other Notable Biomarker Results," note that the patient is considered both TMB ("Tumor Mutation Load") high (49 Mutations/Mb) and MSI high. FIG. 27A also displays a summary of therapies associated with potential benefit, therapies associated with uncertain benefit, and therapies associated with potential lack of benefit. These sections indicate the relevant biomarkers for the therapeutic associations. Agents associated with potential benefit are highlighted in bold if the drug/biomarker association(s) are supported by the highest level of clinical evidence. For this patient, the MSI results suggested potential benefit of the anti PD-1 antibody pembrolizumab. The lack of HER2 suggested potential lack of benefit from anti-HER2 therapies. FIG. 27B continues from FIG. 27A. FIGs. 27C-D provide a summary of biomarker results from the indicated assays. The biomarkers comprise those most commonly associated with cancer. Further results for additional biomarkers are described in the appendix. FIG. 27E provides a number of significant notes for the ordering physician, e.g., a note concerning clinical trials in the appendix, and details about the patient sample and analyses performed on the sample. FIGs. 27F-I provide additional information about drug recommendations shown on the first pages. These sections indicate whether the associations are FDA-approved or ON-NCCN COMPENDIUM®, or OFF-NCCN COMPENDIUM®. FIGs. 27F-G provide more detailed information for biomarker profiling used to associate agents with potential benefit. As noted on the front page, agents associated with potential benefit are highlighted in bold if the drug/biomarker association(s) are supported by the highest level of clinical evidence. For example, the OFF-NCCN COMPENDIUM® section notes that nivolumab and pembrolizumab are associated with potential benefit for treating the patient's breast cancer because the sample was determined to be MSI high based on analysis with NGS. FIG. 27H illustrates more detailed information for biomarker profiling used to associate agents with uncertain benefit. The report notes that therapies are placed in the uncertain benefit category when a result suggests only a decreased likelihood of response (vs. little to no likelihood of response) or if there is insufficient evidence to associate the drug with either benefit or lack of benefit. The appendix to the report will provide further information about the results and why the association was made. FIG. 271 illustrates more detailed information for biomarker profiling used to associate agents with lack of potential benefit. FIG. 27J provides information for biomarker profiling matched to potential clinical trials for which the patient might be enrolled. The page notes that additional information pertaining to clinical trials relevant to the patient are made available to the ordering physician over a web portal ("MI Portal"). As noted, the patient may be matched to multiple trials for a given biomarker result. FIG. 27K presents a disclaimer, noting, inter alia, that "[t]he decision to select any, all, or none of the listed therapies resides within the discretion of the treating physician." The remainder of the report comprises an appendix with additional details about the molecular profiling that was performed and evidence used to make drug -treatment associations. FIGs. 27L-27T provide more details about results obtained through NGS analysis. FIG. 27L provides information about the TMB analysis and results. The report notes that high mutational load is a potential indicator of immunotherapy response (Le et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N Engl J Med 2015; 372:2509-2520; Rizvi et al., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015 Apr 3; 348(6230): 124-128; Rosenberg et al., Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial. Lancet. 2016 May 7; 387(10031): 1909-1920; Snyder et al, Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. N Engl J Med. 2014 Dec 4; 371(23): 2189-2199; all of which references are incorporated by reference herein in their entirety). FIGs. 27L- 270 list details concerning the genes found to harbor alterations. As shown, this patient had a high TMB and alterations were found in a number of genes. FIG. 27P notes genes that were tested by NGS with no detected alterations. FIG. 27Q summarizes genes tested that were found to have unclassified mutations, e.g., these mutations have not previously been identified as pathogenic, and also lists genes with indeterminate results, e.g., due to low coverage for some or all exons during the NGS runs. FIG. 27R provides more information about how Next Generation Sequencing was performed. FIG. 27S provides information about gene amplification ("CNV" or copy number variation) detected by NGS analysis and corresponding methodology. FIG. 27T provides information about MSI detected by NGS analysis and corresponding methodology. As noted, this patient was considered MSI high based on the NGS results. FIG. 27U provides more information about the IHC analysis performed on the patient sample, e.g., the staining threshold and results for each marker. FIG. 27V provides more information about the ISH analysis performed on the patient sample, which comprised CISH for TOP2A. FIG. 27W, FIG. 27X, and FIG. 27Y provide a listing of published references used to provide evidence of the biomarker - agent association rules used to construct the therapy recommendations. FIG. 27Z provides the framework used for the literature level of evidence as included in the report.

[00418] FIGs. 27AA-AV illustrate an molecular patient report based on molecular profiling the tumor of an individual having colorectal cancer, specifically adenocarcinoma of the cecum. The report follows the same general format as the report above but is tailored to molecular profiling results obtained for this specific patient. FIG. 27AA is the cover page for this report. Under the "Lineage Relevant Biomarkers" section, note that the patient is considered MSI high by NGS. In addition, this patient was found to be negative for expression of the mismatch repair proteins MLHl and PMS2. These MSI, MLHl and PMS2 results all point to potential clinical benefit of the anti-PD-1 monoclonal antibodies nivolumab and pembrolizumab based on the highest level of clinical evidence. As shown in the section "Other Notable Biomarker Results," the tumor was also TMB high (34 Mutations/Mb) and PD-Ll positive as determined by IHC. Unlike the breast cancer patient above, molecular profiling of this patient did not identify any therapies with potential lack of benefit. FIGs. 27AB-AC provide a summary of biomarker results from the indicated assays for the biomarkers most commonly associated with cancer. FIG. 27AD provides a number of significant notes for the ordering physician, e.g., a note concerning clinical trials in the appendix, and details about the patient sample and analyses performed on the sample. For this case, the notes also explain that the tumor displays evidence of MMR protein deficiency and recommends testing for Lynch Syndrome. FIG. 27AE provides more detailed information for biomarker profiling used to associate agents with potential benefit. FIG. 27AF illustrates more detailed information for biomarker profiling used to associate agents with uncertain benefit. FIGs. 27AG-AH provide information for biomarker profiling matched to potential clinical trials for which the patient might be enrolled. FIG. 27AI presents a disclaimer, noting, inter alia, that "[t]he decision to select any, all, or none of the listed therapies resides within the discretion of the treating physician." The remainder of the report comprises an appendix with additional details about the molecular profiling that was performed and evidence used to make drug-treatment associations. FIGs. 27AJ-27AR provide more details about results obtained through

NGS analysis. FIG. 27AJ provides information about the TMB analysis and results. FIGs. 27AJ- 27AN list details concerning the genes found to harbor alterations. FIG. 27AN also notes genes that were tested by NGS with no mutations detected. FIG. 27AO summarizes genes tested that were found to have unclassified mutations, e.g., these mutations have not previously been identified as pathogenic, and also lists genes with indeterminate results, e.g., due to low coverage for some or all exons during the NGS runs. FIG. 27AP provides more information about how Next Generation Sequencing was performed.

FIG. 27AQ provides information about gene amplification ("CNV" or copy number variation) detected by NGS analysis and corresponding methodology. Unlike the breast cancer case in the report above, no

CNSs were detected for this CRC patient. FIG. 27AR provides information about MSI detected by NGS analysis and corresponding methodology. As noted, this patient was considered MSI high based on the

NGS results. FIG. 27AS provides more information about the IHC analysis performed on the patient sample, e.g., the staining threshold and results for each marker. FIG. 27AT and FIG. 27AU provide a listing of published references used to provide evidence of the biomarker - agent association rules used to construct the therapy recommendations. FIG. 27AV provides the framework used for the literature level of evidence as included in the report.

[00419] FIGs. 27AW-BR illustrate an exemplary patient report based on molecular profiling the tumor of an individual having a non-small cell carcinoma of the lung (NSCLC). The report follows the same general format as the reports above but is tailored to molecular profiling results obtained for this specific patient. FIG. 27AW and FIG. 27AX are the cover page for this report. Under the "Lineage Relevant Biomarkers" section, note that fusions were not detected via RNA sequencing in the ROS1 or RET genes. The patient's tumor was found to have high expression of PD-L1 by IHC, suggesting potential benefit of the anti-PD-1 monoclonal antibodies nivolumab and pembrolizumab and the anti-PD-Ll monoclonal antibody atezolizumab, each based on the highest level of clinical evidence. As shown in the section "Other Notable Biomarker Results," the tumor was also TMB high (36 Mutations/Mb) but MSI stable. Thus, PD-Ll and TMB but not MSI would suggest immune checkpoint therapies for this patient. The cover page lists several therapies with potential benefit for treating the patient and several therapies with potential lack of benefit for treating the patient. The molecular profiling did not identify therapies with uncertain benefit. FIG. 27AX continues from FIG. 27AW. This section notes that the PD-Ll result is sufficient to guide pembrolizumab use for front-line, metastatic & pretreated, metastatic NSCLC, but that nivolumab & atezolizumab are not FDA -approved in the front-line, metastatic setting. FIGs. 27AY-AZ provide a summary of biomarker results from the indicated assays. The biomarkers comprise those most commonly associated with cancer. On FIG. 27AZ, the report lists a number of genes tested for R A alterations by NGS. No fusions or variant transcripts were detected. FIG. 27BA provides a number of significant notes for the ordering physician, e.g., a note concerning clinical trials in the appendix, and details about the patient sample and analyses performed on the sample. FIG. 27BB provides more detailed information for biomarker profiling used to associate agents with potential benefit. For example, the FDA-APPRO VED/ON-NCCN COMPENDIUM® section notes that atezolizumab, nivolumab and pembrolizumab are associated with potential benefit for treating the patient's lung cancer because the sample was determined to have high expression of PD-Ll protein by IHC even though the tumor was MSI stable based on analysis with NGS. Again the report points to different approvals for these therapies in this setting. FIG. 27BC and FIG. 27BD illustrate more detailed information for biomarker profiling used to associate agents with lack of potential benefit. FIG. 27BE provides information for biomarker profiling matched to potential clinical trials for which the patient might be enrolled. FIG. 27BF presents a disclaimer, noting, inter alia, that "[t]he decision to select any, all, or none of the listed therapies resides within the discretion of the treating physician." The remainder of the report comprises an appendix with additional details about the molecular profiling that was performed and evidence used to make drug- treatment associations. FIGs. 27BG-27BM provide more details about results obtained through NGS analysis. FIG. 27BG provides information about the TMB analysis and results. FIG. 27BG also lists details concerning the genes found to harbor alterations. As shown, this patient had a high TMB and pathogenic alterations were found in three genes (KRAS, PBRMl and TP53). FIG. 27BH notes genes that were tested by NGS with no detected alterations. FIG. 27BI summarizes genes tested that were found to have unclassified mutations, e.g., these mutations have not previously been identified as pathogenic, and also lists genes with indeterminate results, e.g., due to low coverage for some or all exons during the NGS runs. FIG. 27BJ provides more information about how Next Generation Sequencing was performed. FIG. 27BK provides information about gene amplification ("CNV" or copy number variation) detected by NGS analysis and corresponding methodology. In this case, amplification of the FLCN gene was observed but was not evalutated for clinical significance. FIG. 27BL provides information about gene fusion and variant transcript testing that was performed by NGS analysis of RNA. FIG. 27BM provides information about MSI detected by NGS analysis and corresponding methodology. As noted, no MSI was observed based on the NGS results. FIG. 27BN provides more information about the IHC analysis performed on the patient sample, e.g., the staining threshold and results for each marker. FIG. 27BO, FIG. 27BP, and FIG. 27BQ provide a listing of published references used to provide evidence of the biomarker - agent association rules used to construct the therapy recommendations. FIG. 27BR provides the framework used for the literature level of evidence as included in the report.

Example 4: Molecular Profiling of Immune checkpoint related genes

[00420] Clinical response to immune checkpoint inhibitor therapy ranges from 18% to 28% by tumor type. There is unmet clinical need for laboratory tests that can identify patients likely to respond to such therapy. Reports indicate that 36% of transgenic tumors with PD-1 expression responded to anti-PDl therapy while no PD-1 negative cases responded. Estimated objective responses for tumors expressing FoxP3 and IDO by IHC were 10.38 and 8.72 respectively. This Example used microarray expression data to characterize the presence of immune response modulators in human tumors and possibly identify a subset of cases as the candidates for immune checkpoint inhibitor therapy.

[00421] A retrospective analysis of gene expression microarray data for immune related genes was performed on 9,025 qualifying paraffin embedded human tumor specimens (HumanHT-12 v4 beadChip Illumina Inc., San Diego, CA). Samples from LN metastases were excluded from analysis. Immune checkpoint-related genes examined included CTLA4, its binding partners CD80 and CD86, PD-L1, CD276 (B7-H3), Granzymes A and B, CD8a, CD19 and the chemokine receptor CCR7. The normalized expression values for these genes were plotted by tumor types to compare relative expression levels and Principal Component Analysis was performed.

[00422] The results of this analysis showed that PD-L1 expression was above the 90th percentile of normal control tissue in 4% of breast cancers, 3% of renal cancers, 7% of NSCLC, 3% ovarian cancer and 5% of colon cancer tumors. Principal component analysis of the immune checkpoint-related genes showed the greatest percentage of "distinct" cases within ovarian, melanoma, colon, gastric and pancreatic cancers.

[00423] Microarray analysis can identify tumors with unique immune components that are more likely to respond to immune checkpoint therapy.

Example 5: PD1 and PDL1 in HPV+ and HPV-/TP53 mutated head and neck squamous cell carcinomas

[00424] This Example investigated the role of the programmed death 1 (PD1) and programmed death ligand 1 (PDL1) immunomodulatory axis in head and neck squamous cell carcinoma (HNSCC), a cancer with viral and non-viral etiologies. Determination of the impact of this testing in human papilloma virus (HPV)-positive and HPV-negative/TP53 -mutated HNSCC carries great importance due to the development of new immunomodulatory agents.

[00425] Thirty-four HNSCC cases, including 16 HPV+ and 18 HPV-/TP53 mutant, were analyzed for the PD 1/PDL1 immunomodulatory axis by immunohistochemical methods. HNSCC arising in the following anatomic sites were assessed: pharynx, larynx, mouth, parotid gland, paranasal sinuses, tongue and metastatic SCC consistent with head and neck primary.

[00426] Results are summarized in FIG. 30. 8/34 (24%) HNSCC were positive for cancer cells expression of PDL1, and 13/34 (38%) HNSCC were positive for PD1+ tumor infiltrating lymphocytes (TILs). 3/34 (8.8%) were positive for both components of the PD1/PDL1 axis. Comparison of PD1 and PDLl expression in HPV + and HPV-/TP53mutant HNSCC showed PD1 + TILs were more frequent in HPV+ vs. HPV- HNSCC (56% vs. 22%; p=0.07), whereas PDL1+ tumor cells more frequent in HPV- vs. HPV+ HNSCC (38% vs. 13%; p=0.14). PD1 and PDLl were expressed in both oropharyngeal and non- oropharyngeal HNSCC: 33% vs. 39% for PD1 + TILs, respectively, and 11% and 33% for PDL-1, respectively. To examine the role of PD1 and PDLl in progression of disease, expression was compared between metastatic and non-metastatic HNSCC. PD1 + TILs were detected in 45% of metastatic vs. 25% non-metastatic HNSCC (p=0.29), and PDLl was detected in 27% vs. 17% of metastatic vs. non-metastatic HNSCC. Interestingly, the three cases that were positive for both PD1 and PDLl were metastatic HNSCC, including a tumor of the mandible which had metastasized to the bone of the arm, and two unknown primary consistent with head and neck primary, one metastatasized to the lymph nodes and the other metastasized to the lung.

[00427] Immune evasion through the PD1/PDL1 axis is relevant to both viral (HPV) and non-viral (TP53) etiologies of HNSCC. Expression of both axis components was less frequently observed across HNSCC tumor sites, and elevated expression of both PD1 and PLD1 was seen at a higher frequency in metastatic HNSCC. In summary, we observed that: 1) PDLl + TILs were more frequent (56%) in HPV + HNSCC; 2) PD1 expression was more frequent (38%) in HPV-/TP53 mutated HNSCC; 3) elevation of both components of the axis (PD1 and PDLl), occurs at low frequency (8%); 4) expression of PDLl and PD1 occurs in head and neck cancers that occur in oropharyngeal and non-oropharyngeal sites; and 5) the PD 1/PDL1 pathway is more frequently expressed in metastatic cases vs. non-metastatic HNSCC.

Example 6: Mutations on the homologous recombination (HR) pathway in 13 cancer types

[00428] Background: HR pathway is important in DNA double strand break repair. Defects of HR promote carcinogenesis and are associated with selective sensitivity to PARPi and DNA-damaging agents including platinum. We used next-generation sequencing (NGS) to survey genes on the HR pathway in 1029 tumors in 13 cancer types.

[00429] Method: NGS on -600 whole genes (see Tables 6-10) was performed using formalin-fixed paraffin-embedded samples on the Illumina NextSeq platform. All variants were detected with > 99 % confidence and with the sensitivity of 10%. Variants that are pathogenic or presumed pathogenic are counted as mutations.

[00430] Results: Table 13 summarizes mutation rates of 7 key genes (ATM, BRCA1, BRCA2, CHEK1, CHEK2, PALB2 and PTEN) included in this study. PTEN mutations were seen in 6.3% of tumors, ATM in 5%, BRCA1 in 2%, BRCA2 in 2%, PALB2 in 1%, CHEK2 in 1% and CHEK1 mutation is not seen in the cohort studied. Overall, 15% of tumors carry at least one mutation in any of the 7 genes, and the highest mutation rates were seen in endometrial (43%), GBM (34%) and gastric cancers (23%). The highest rates of ATM (9.7%), BRCA2 (6.5%) and PALB2 (6.5%) were seen in gastric cancer while the highest CHEK2 (5.6%), BRCA1 (7.3%) and PTEN (44%) mutations were seen in cholangiocarcinoma, ovarian and endometrial tumors, respectively. [00431] Exceptional response was seen in a 53-year old patient with metastatic poorly-differentiated adenocarcinoma of the stomach after 4 cycles of FOLFOX without surgery, which included ongoing radiographic partial response and dramatic relief of symptoms. A nonsense mutation on PALB2 (S326*) was found while the other 23 HRD genes were wild type; ERCC1 IHC showed intact expression.

Table 13 - Mutation rates of 7 key genes

[00432] Conclusion: Mutation rates of at least 8 to 43% on the HR pathway are reported from 13 cancer types. This method can potentially identify responders to DNA-damaging agents including platinum.

Example 7: Calculating Microsatellite Instability from Next Generation Sequencing Results

[00433] Microsatellite instability status by Next Generation Sequencing (MSI-NGS) is measured by the direct analysis of known microsatellite regions sequenced in the NGS panel of the invention, presented in Tables 6-10 and accompanying text. This approach allows us to combine NGS analysis to assess multiple characteristics, including without limitation mutations, indels, copy number, fusions, and MSI.

[00434] To establish clinical thresholds, MSI-NGS results were compared with results from over 2,000 matching clinical cases analyzed with traditional, PCR-based methods. Genomic variants in the microsatellite loci are detected using the same depth and frequency criteria as used for mutation detection. Only insertions and deletions resulting in a change in the number of tandem repeats are considered in this assay. Some microsatellite regions with known polymorphisms or technical sequencing issues are excluded from the analysis. The total number of microsatellite alterations in each sample are counted and grouped into two categories: MSI-High and MSI-Stable. MSI-Low results are reported in the Stable category.

[00435] Each sample was identified as follows:

[00436] MSI-H - Defined as > 65 incidents of difference from the expected nucleotide at any given region in the approximately 720 surveyed regions of the genome concerning microsatellite instability.

[00437] MS Stable (MSS) - Defined as <65 incidents of difference from the expected nucleotide at any given region in the approximately 720 surveyed regions of the genome concerning microsatellite instability.

[00438] Any ambiguous result that is less than the 99% confidence interval cutoff is considered as "MS Stable (MSS)." Any ambiguous result where there was an insufficient number of reads to be analyzed is considered as "Quantity not Sufficient (QNS)."

[00439] Comparison of MSI calculated by the gold standard fragment analysis (FA) compared to the MSI- NGS approach of the invention is shown in Table 15. Statistical analysis of the testing for all lineages is shown in Table 14. In the table, the statistics are calculated using fragment analysis as the gold standard.

Table 14: Statistical analysis of MSI-NGS

None Of Others Apply 21 100.0%

Ovarian Surface Epithelial 15 100.0%

Carcinomas

Pancreatic Adenocarcinoma 44 97.7%

Prostatic Adenocarcinoma 1 100.0%

Small Intestinal Malignancies 7 100.0%

Soft Tissue Tumors 1 100.0%

Thyroid Carcinoma 1 100.0%

Uveal Melanoma 1 100.0%

Table 15: MSI FA vs. NGS Accuracy Summary

[00440] Frequency of MSI-H determined by NGS across multiple tumor lineages is shown in FIG. 31 A. A box plot showing frequency within specified tumor types (female genital tract, colorectal, or all) is shown in FIG. 31B. A scatter plot showing the same is shown in FIG. 31C.

[00441] We also determined tumor mutation load (TML; also referred to as tumor mutation burden or TMB) using the same Next Generation Sequencing (NGS) analysis. TML was performed based on NGS analysis from genomic DNA isolated from a formalin-fixed paraffin-embedded tumor sample using the Illumina NextSeq platform.

[00442] Total mutational load was calculated using only missense mutations that have not been previously reported as germline alterations. Like MSI-H, high mutational load is a potential indicator of

immunotherapy response. We defined threshold levels for Total Mutational Load and establish cutoff points:

[00443] · High: greater than or equal to 17 mutations/Megabase (>17 mutations/Mb). Approximately 7% of our molecular profiling cases reported a High result.

[00444] · Intermediate: greater than or equal to 7 but fewer than 17 mutations/ Megabase (>7 and <17 mutations/Mb). Approximately 34% of our molecular profiling cases reported an Intermediate result.

[00445] · Low: less than or equal to 6 mutations/Megabase (<6 mutations/Mb). Approximately 59% of our molecular profiling cases reported a Low result. Example 8: Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients

[00446] This Example is related to the Example above and presents additional assessment of microsatellite instability, PD-L1 and tumor mutational load in 11,251 patients across 31 tumor types.

[004471 Summary

[00448] Microsatellite instability (MSI) testing identifies patients who may benefit from immune checkpoint inhibitors. In this Example, we developed an MSI assay that uses data from a next-generation sequencing (NGS) panel to determine MSI status. The assay is applicable across cancer types and does not require matched samples from normal tissue. This Example describes the MSI-NGS method and explores the relationship of MSI with tumor mutational burden (TMB, also referred to as tumor mutational load or TML) and PD-L1. MSI examined by PCR fragment analysis and NGS was compared for 2,189 matched cases. Mismatch repair status by immunohistochemistry was compared to MSI-NGS for 1,986 matched cases. TMB was examined by NGS and PD-L1 was determined by

immunohistochemistry (IHC). Among 2, 189 matched cases that spanned 26 cancer types, MSI-NGS, as compared to MSI by PCR fragment analysis, had sensitivity of 95.8% (95% confidence interval [CI] 92.24, 98.08), specificity of 99.4% (95% CI 98.94, 99.69), positive predictive value of 94.5% (95% CI 90.62, 97.14), and negative predictive value of 99.2% (95% CI, 98.75, 99.57). High MSI (MSI-H) status was identified in 23 of 26 cancer types. Among 11,348 cases examined (including the 2,189 matched cases), the overall rates of MSI-H, TMB-high and PD-L1 positivity were 3.0%, 7.7%, and 25.4%, respectively. Thirty percent of MSI-H cases were TMB-low and only 26% of MSI-H cases were PD-L1 positive. The overlap between TMB, MSI, and PD-L1 differed among cancer types. Only 0.6% of the cases were positive for all three markers. This Example shows that MSI-H status can be determined by NGS across cancer types, and that MSI-H offers distinct data for treatment decisions regarding immune checkpoint inhibitors, in addition to the data available from TMB and PD-L1. Thus, the techniques are complementary.

[00449] Introduction

[00450] Microsatellite instability (MSI) involves the gain or loss of nucleotides from microsatellite tracts, which are DNA elements composed of repeating motifs that occur as alleles of variable lengths. [1] MSI can result from inherited mutations or originate somatically. Lynch syndrome results from inherited mutations of known mismatch repair (MMR) genes. Tumors are classified as MMR-deficient (dMMR) if they have somatic or germline mutations. MSI can also occur due to epigenetic changes or altered microRNA pathways affecting MMR proteins, or without a loss of a known underlying protein. [2] MSI is most commonly found in colon and endometrial cancers (the most common Lynch syndrome cancer types). However, recent analyses have found MSI in at least 24 cancer types, demonstrating that MSI is a generalized cancer phenotype. [3-6]

[00451] MSI has been associated with improved prognosis, but until the recent advent of immune checkpoint inhibitors, the predictive use of MSI has been limited. A proof-of-concept study including 87 patients with 12 different cancer types demoednstrat the predictive value of MSI status to predict response of solid tumors to the anti-PD-1 agent pembrolizumab. [5,7] This ability of MSI to predict pembrolizumab response has led to the first tumor-agnostic drug approval by the FDA in May 2017. Additional evidence showed an improved response for MSI-high (MSI-H) patients to the anti-PD-1 agents nivolumab and MEDI0680, the anti-PD-Ll agent durvalumab, and the anti-CTLA-4 agent ipilimumab. [7-10]

[00452] These results elevate MSI status as a third, possibly independent, predictive biomarker for immune checkpoint inhibitors, along with PD-L1 and tumor mutational burden (TMB). [11-17] Given that patient responses to these drugs can be highly durable, [5,7, 18] it is critical to identify as many potential responders as possible. Therefore, a method to efficiently determine MSI status for every cancer patient is needed.

[00453] Currently, MSI is most commonly detected through polymerase chain reaction (PCR) by fragment analysis (FA) of five conserved satellite regions, which is considered the gold standard method for MSI detection. [1, 19] However, FA is not ideal in the clinic as it requires samples of both tumor and normal tissue. As a result, FA is not always feasible for cases with limited amounts of tissue, including the analysis of cancer metastases, which are commonly submitted as biopsies and may contain few normal cells. Additionally, determining MSI by FA and MMR analysis from immunohistochemistry (IHC) are performed as stand-alone tests and would be inefficient to perform on every cancer patient because the incidence of MSI is only about 5% across cancer types. [5]

[00454] As broad tumor profiling becomes a common part of care for cancer patients, it is preferable to determine MSI status from sequencing panel results. Next-generation sequencing (NGS) was recently found to be feasible to determine MSI status, but the published techniques also require the use of paired tumor and normal tissue. [3,6] We have access to a large database of samples with both broad NGS results and matching MSI status by FA and dMMR status by IHC. These data were obtained using the molecular profiling systems and methods of the invention. See, e.g., Tables 5-11 and related discussion. We used this database to develope and validate an NGS-based MSI assay without the need for matched samples from normal tissue. In this Example, we describe our process for developing such a method and explore the relationship of MSI with other immunotherapy markers, specifically TMB and PD-L1.

[004551 Methods

[00456] Patient Cohort

[00457] For development of the NGS assay, 2, 189 cases were retrospectively selected based on having data available for both the 592-gene sequencing panel (see Tables 7-10) and MSI testing by PCR FA (assay details below). For the TMB, PD-L1, and MSI-NGS comparison, 11,348 patients were

retrospectively selected based on available data from commercial comprehensive sequencing profiles performed on their tumors by our commercial laboratory (Caris Life Sciences, Phoenix, Arizona) that included PD-L1 by immunohistochemistry (IHC) and the 592-NGS gene sequencing panel. This research used a collection of existing data that were de-identified prior to analysis. As this research was compliant with 45 CFR 46.101(b), the project was deemed exempt from IRB oversight and consent requirements were waived.

[00458] Fragment analysis by PCR [00459] MSI-FA was tested by the fluorescent multiplex PCR-based method (MSI Analysis; Promega,

Life Sciences, Madison, WI, USA).

[00460] Next-generation sequencing

[00461] NGS was performed on genomic DNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor samples using the NextSeq platform (Illumina, Inc., San Diego, CA). A custom-designed

SureSelect XT assay (Agilent Technologies, Santa Clara, CA) was used to enrich the 592 whole-gene targets that a 592-gene NGS panel. All variants were detected with >99% confidence based on allele frequency and baited-capture pull-down coverage with an average sequencing depth of over 500X and with analytic sensitivity of 5% variant frequency.

[00462]Microsatellite instability by NGS

[00463] Microsatellite loci in the target regions of a 592-gene NGS panel were first identified using the MISA algorithm (pgrc.ipk-gatersleben.de/misa/), which revealed 8,921 microsatellite locations.

Subsequent analyses excluded sex chromosome loci, microsatellite loci in regions that typically have lower coverage depth relative to other genomic regions, and microsatellites with repeat unit lengths greater than 5 nucleotides. These exclusions resulted in 7,317 target microsatellite loci. See Table 16 for positions of the loci. In the table, column "Chr" is the chromosome, "Start" and "End" are the position of the loci, and "MS" is information about the microsatellite.

Table 16: Microsatellite Loci analyzed by NGS

Chr Start End MS Chr Start End MS

1 2488123 2488127 pl.(G)5 1 6257812 6257816 pl.(T)5

1 2488147 2488151 pl.(C)5 1 7309621 7309625 pl.(A)5

1 2488178 2488182 pl.(C)5 1 7723490 7723495 pl.(G)6

1 2489156 2489160 pl.(C)5 1 7723845 7723849 pl.(C)5

1 2489190 2489194 pl.(C)5 1 7724102 7724106 pl.(G)5

1 2492097 2492102 pl.(C)6 1 7724422 7724426 pl.(C)5

1 3102806 3102810 pl.(C)5 1 7724439 7724443 pl.(C)5

1 3102833 3102837 pl.(C)5 1 7724522 7724526 pl.(G)5

1 3102939 3102943 pl.(G)5 1 7724959 7724964 pl.(G)6

1 3301766 3301770 pl.(G)5 1 7724998 7725002 pl.(G)5

1 3313126 3313130 pl.(C)5 1 7725042 7725046 pl.(C)5

1 3319446 3319450 pl.(G)5 1 7725082 7725086 pl.(C)5

1 3328152 3328156 pl.(C)5 1 7796391 7796396 pl.(T)6

1 3328185 3328189 pl.(C)5 1 7798090 7798094 pl.(A)5

1 3328293 3328297 pl.(C)5 1 7798545 7798549 pl.(A)5

1 3328330 3328334 pl.(C)5 1 7811271 7811275 pl.(A)5

1 3328372 3328376 pl.(C)5 1 7811329 7811336 pl.(A)8

1 3328709 3328713 pl.(G)5 1 7815698 7815702 pl.(C)5

1 3328724 3328733 pl.(C)5(G)5 1 7826532 7826536 pl.(A)5

1 3328960 3328964 pl.(C)5 1 7826612 7826616 pl.(T)5

1 3329142 3329146 pl.(C)5 1 11166625 11166629 pl.(A)5

1 3329312 3329316 pl.(C)5 1 11167510 11167515 pl.(A)6

1 3331205 3331209 pl.(C)5 1 11182071 11182082 p3.(TCT)4

1 3334475 3334479 pl.(C)5 1 11184561 11184565 pl.(T)5

1 3334506 3334510 pl.(C)5 1 11187710 11187714 pl.(G)5

1 3350287 3350291 pl.(C)5 1 11188191 11188195 pl.(A)5

1 3350390 3350394 pl.(G)5 1 11188513 11188517 pl.(G)5

1 6253104 6253108 pl.(A)5 1 11188944 11188948 pl.(C)5

1 6257785 6257792 pl.(T)8 1 11189012 11189016 pl.(A)5

1 6257794 6257799 pl.(C)6 1 11199383 11199387 ni Chr Start End MS Chr Start End MS

1 11199496 11199500 pl.(A)5 1 16258889 16258899 pl.(A)5(C)6

1 11206726 11206730 pl.(T)5 1 16258928 16258933 pl.(A)6

1 11206853 11206862 p2.(AC)5 1 16258944 16258950 pl.(A)7

1 11217213 11217217 pl.(C)5 1 16259015 16259019 pl.(A)5

1 11259454 11259458 pl.(G)5 1 16259043 16259048 pl.(G)6

1 11272384 11272388 pl.(A)5 1 16259480 16259485 pl.(C)6

1 11273547 11273551 pl.(C)5 1 16260017 16260021 pl.(C)5

1 11276287 11276291 pl.(A)5 1 16260029 16260033 pl.(C)5

1 11290970 11290974 pl.(C)5 1 16260194 16260199 pl.(G)6

1 11292544 11292548 pl.(A)5 1 16260214 16260219 pl.(C)6

1 11294235 11294240 pl.(G)6 1 16260290 16260294 pl.(C)5

1 11303189 11303193 pl.(G)5 1 16260452 16260456 pl.(C)5

1 11307945 11307949 pl.(G)5 1 16260470 16260474 pl.(A)5

1 11308047 11308051 pl.(G)5 1 16260486 16260491 pl.(A)6

1 11316169 11316173 pl.(A)5 1 16261246 16261251 pl.(C)6

1 11316256 11316261 pl.(A)6 1 16261550 16261554 pl.(C)5

1 11318597 11318601 pl.(A)5 1 16262460 16262464 pl.(C)5

1 16174523 16174527 pl.(G)5 1 16262466 16262470 pl.(C)5

1 16199301 16199306 pl.(T)6 1 16262478 16262482 pl.(C)5

1 16199579 16199583 pl.(C)5 1 16262497 16262501 pl.(C)5

1 16202753 16202757 pl.(G)5 1 16262553 16262557 pl.(C)5

1 16202886 16202890 pl.(C)5 1 16262680 16262685 pl.(C)6

1 16203144 16203155 p3.(CAG)4 1 16264073 16264077 pl.(C)5

1 16235807 16235811 pl.(T)5 1 16264430 16264434 pl.(C)5

1 16235914 16235918 pl.(A)5 1 16265971 16265975 pl.(A)5

1 16237722 16237726 pl.(A)5 1 17355139 17355143 pl.(T)5

1 16242716 16242721 pl.(A)6 1 17371390 17371395 pl.(T)6

1 16245412 16245417 pl.(T)6 1 18958059 18958063 pl.(T)5

1 16247345 16247356 p4.(TTTG)3 1 18958157 18958161 pl.(C)5

1 16248729 16248739 pl.(T)l l 1 18961629 18961633 pl.(A)5

1 16248776 16248780 pl.(T)5 1 19027261 19027266 pl.(C)6

1 16254575 16254580 pl.(T)6 1 19027292 19027303 p3.(CCA)4

1 16255093 16255098 pl.(A)6 1 19029590 19029594 pl.(G)5

1 16255142 16255153 p2.(GA)6 1 19062159 19062163 pl.(C)5

1 16255170 16255174 pl.(A)5 1 19062397 19062401 pl.(C)5

1 16255340 16255344 pl.(A)5 1 19062421 19062425 pl.(C)5

1 16255728 16255732 pl.(A)5 1 19062496 19062500 pl.(A)5

1 16255783 16255788 pl.(A)6 1 27023290 27023294 pl.(G)5

1 16255883 16255889 pl.(A)7 1 27023327 27023331 pl.(C)5

1 16256044 16256049 pl.(A)6 1 27023377 27023388 p3.(CGC)4

1 16256126 16256130 pl.(A)5 1 27023451 27023462 p3.(GCG)4

1 16256205 16256210 pl.(A)6 1 27023462 27023466 pl.(G)5

1 16256321 16256326 pl.(A)6 1 27023560 27023565 pl.(C)6

1 16256375 16256379 pl.(C)5 1 27023716 27023721 pl.(G)6

1 16256411 16256415 pl.(A)5 1 27023744 27023748 pl.(G)5

1 16256610 16256614 pl.(A)5 1 27023769 27023773 pl.(C)5

1 16256833 16256837 pl.(A)5 1 27023831 27023835 pl.(G)5

1 16256950 16256955 pl.(T)6 1 27023861 27023865 pl.(G)5

1 16257221 16257225 pl.(A)5 1 27023904 27023909 pl.(G)6

1 16257322 16257327 pl.(T)6 1 27024002 27024007 pl.(G)6

1 16257525 16257529 pl.(A)5 1 27057727 27057738 p3.(CAG)4

1 16257531 16257535 pl.(A)5 1 27057924 27057928 pl.(C)5

1 16257842 16257846 pl.(C)5 1 27057937 27057942 pl.(C)6

1 16258130 16258134 pl.(C)5 1 27059207 27059211 pl.(C)5

1 16258181 16258185 pl.(A)5 1 27088659 27088663 pl.(C)5

1 16258284 16258288 pl.(A)5 1 27088682 27088687 pl.(C)6

1 16258376 16258380 pl.(A)5 1 27088788 27088793 pl.(G)6

1 16258727 16258731 pl.(A)5 1 27089697 27089701 pl.(C)5

1 16258735 16258740 pl.(A)6 1 27089706 27089710 pl.(G)5

1 16258789 16258793 pl.(C)5 1 27092740 27092744 nl ίΠ« Chr Start End MS Chr Start End MS

1 27092815 27092819 pl.(C)5 1 36767233 36767238 pl.(A)6

1 27093065 27093069 pl.(T)5 1 36931673 36931677 pl.(A)5

1 27097622 27097627 pl.(A)6 1 36931687 36931691 pl.(A)5

1 27097688 27097692 pl.(A)5 1 36932008 36932012 pl.(G)5

1 27097751 27097755 pl.(C)5 1 36932123 36932127 pl.(G)5

1 27099103 27099108 pl.(C)6 1 36932275 36932279 pl.(C)5

1 27100176 27100181 pl.(C)6 1 36932921 36932925 pl.(G)5

1 27100182 27100205 p3.(GCA)8 1 36933724 36933728 pl.(G)5

1 27100919 27100930 p3.(CAG)4 1 36933744 36933748 pl.(G)5

1 27100934 27100938 pl.(C)5 1 36935323 36935329 pl.(G)7

1 27101068 27101072 pl.(C)5 1 36935371 36935376 pl.(G)6

1 27101117 27101121 pl.(C)5 1 36937024 36937028 pl.(C)5

1 27101268 27101273 pl.(C)6 1 36937736 36937740 pl.(G)5

1 27101375 27101379 pl.(C)5 1 36937983 36937987 pl.(G)5

1 27101402 27101407 pl.(C)6 1 36938271 36938276 pl.(G)6

1 27101417 27101421 pl.(C)5 1 36941121 36941125 pl.(C)5

1 27101438 27101442 pl.(C)5 1 36941221 36941225 pl.(C)5

1 27101570 27101574 pl.(C)5 1 36941237 36941241 pl.(G)5

1 27101612 27101617 pl.(C)6 1 40363033 40363037 pl.(T)5

1 27105507 27105511 pl.(T)5 1 40363133 40363137 pl.(C)5

1 27105676 27105690 p3.(GAA)5 1 40363185 40363189 pl.(G)5

1 27105931 27105937 pl.(G)7 1 40363366 40363370 pl.(G)5

1 27106078 27106082 pl.(C)5 1 40363553 40363557 pl.(G)5

1 27106100 27106104 pl.(A)5 1 40366672 40366676 pl.(G)5

1 27106804 27106809 pl.(C)6 1 40366747 40366751 pl.(C)5

1 27106917 27106921 pl.(G)5 1 40366925 40366929 pl.(G)5

1 27107227 27107231 pl.(T)5 1 40366939 40366943 pl.(G)5

1 32740658 32740662 pl.(G)5 1 40366987 40366992 pl.(G)6

1 32741500 32741511 p4.(CATT)3 1 40367129 40367134 pl.(G)6

1 32742059 32742063 pl.(G)5 1 43804231 43804235 pl.(C)5

1 35650015 35650021 pl.(A)7 1 43804953 43804958 pl.(C)6

1 35650069 35650074 pl.(T)6 1 43814993 43815004 p3.(CTG)4

1 35652860 35652866 pl.(A)7 1 43815037 43815041 pl.(C)5

1 35654780 35654784 pl.(T)5 1 43817880 43817884 pl.(C)5

1 35654867 35654873 pl.(T)7 1 45794921 45794925 pl.(A)5

1 35654893 35654897 pl.(T)5 1 45794961 45794965 pl.(G)5

1 35656128 35656132 pl.(T)5 1 45795066 45795070 pl.(T)5

1 35656203 35656207 pl.(A)5 1 45795115 45795120 pl.(A)6

1 35656978 35656982 pl.(A)5 1 45796855 45796859 pl.(T)5

1 35657137 35657141 pl.(A)5 1 45797418 45797423 pl.(G)6

1 35657872 35657876 pl.(G)5 1 45798340 45798344 pl.(C)5

1 35657920 35657924 pl.(C)5 1 45798845 45798849 pl.(G)5

1 35658230 35658234 pl.(C)5 1 45800191 45800195 pl.(A)5

1 36748170 36748174 pl.(A)5 1 47685527 47685531 pl.(G)5

1 36748270 36748279 p2.(TC)5 1 47685558 47685562 pl.(G)5

1 36748306 36748310 pl.(G)5 1 47685570 47685574 pl.(C)5

1 36752369 36752373 pl.(A)5 1 47685576 47685580 pl.(C)5

1 36752590 36752594 pl.(C)5 1 47685588 47685592 pl.(C)5

1 36752768 36752772 pl.(A)5 1 47685598 47685602 pl.(C)5

1 36754648 36754652 pl.(T)5 1 47685640 47685651 p3.(CCT)4

1 36754729 36754734 pl.(A)6 1 47685732 47685736 pl.(G)5

1 36754778 36754782 pl.(A)5 1 47691412 47691416 pl.(G)5

1 36755001 36755005 pl.(A)5 1 47691475 47691481 pl.(G)7

1 36755075 36755079 pl.(A)5 1 47691518 47691522 pl.(G)5

1 36755118 36755122 pl.(A)5 1 47691569 47691580 p4.(CAGA)3

1 36755229 36755233 pl.(C)5 1 47716916 47716920 pl.(A)5

1 36756967 36756971 pl.(T)5 1 47717309 47717314 pl.(T)6

1 36757033 36757037 pl.(A)5 1 47725985 47725989 pl.(T)5

1 36758282 36758286 pl.(A)5 1 47726013 47726017 pl.(T)5

1 36759466 36759470 pl.(C)5 1 47726091 47726097 nl ΓΠ7 Chr Start End MS Chr Start End MS

1 47726217 47726221 pl.(A)5 1 78429978 78429984 pl.(T)7

1 47728643 47728647 pl.(T)5 1 78430049 78430054 pl.(A)6

1 47728681 47728685 pl.(C)5 1 78430320 78430324 pl.(T)5

1 47735440 47735444 pl.(A)5 1 78430775 78430779 pl.(C)5

1 47746352 47746356 pl.(G)5 1 78430879 78430883 pl.(T)5

1 47746401 47746406 pl.(A)6 1 78444659 78444664 pl.(G)6

1 47746581 47746585 pl.(G)5 1 78444746 78444757 p4.(AAGA)3

1 47753233 47753237 pl.(A)5 1 85733287 85733291 pl.(A)5

1 47753256 47753260 pl.(A)5 1 85733513 85733519 pl.(A)7

1 47753310 47753314 pl.(T)5 1 85733574 85733578 pl.(T)5

1 47755250 47755255 pl.(A)6 1 85736376 85736381 pl.(T)6

1 47755264 47755270 pl.(A)7 1 85736457 85736461 pl.(T)5

1 47767318 47767322 pl.(A)5 1 85736511 85736518 pl.(T)8

1 47767932 47767936 pl.(A)5 1 93297607 93297611 pl.(C)5

1 47767947 47767954 pl.(T)8 1 93298933 93298938 pl.(T)6

1 47768022 47768026 pl.(A)5 1 93299088 93299094 pl.(T)7

1 47770675 47770680 pl.(A)6 1 93299149 93299153 pl.(A)5

1 51436054 51436058 pl.(G)5 1 93300356 93300360 pl.(G)5

1 51436084 51436089 pl.(G)6 1 93301898 93301902 pl.(T)5

1 51439843 51439847 pl.(G)5 1 93306186 93306190 pl.(A)5

1 51439919 51439923 pl.(G)5 1 110882250 110882254 pl.(G)5

1 51826933 51826937 pl.(T)5 1 110882373 110882377 pl.(G)5

1 51829591 51829595 pl.(G)5 1 110882421 110882425 pl.(A)5

1 51829633 51829638 pl.(T)6 1 110882436 110882440 pl.(G)5

1 51829709 51829713 pl.(A)5 1 110882873 110882878 pl.(C)6

1 51864840 51864846 pl.(A)7 1 110882973 110882977 pl.(C)5

1 51869083 51869088 pl.(T)6 1 110883792 110883796 pl.(C)5

1 51869130 51869134 pl.(T)5 1 110883798 110883802 pl.(C)5

1 51875324 51875328 pl.(T)5 1 110884185 110884189 pl.(A)5

1 51912754 51912758 pl.(T)5 1 110884244 110884248 pl.(A)5

1 51913720 51913724 pl.(T)5 1 110884257 110884262 pl.(A)6

1 51913797 51913801 pl.(A)5 1 110884341 110884346 pl.(G)6

1 51926826 51926830 pl.(A)5 1 110884751 110884756 pl.(G)6

1 59247730 59247734 pl.(C)5 1 110888908 110888921 pl.(T)7(C)7

1 59247894 59247898 pl.(T)5 1 110888983 110888987 pl.(T)5

1 59247929 59247933 pl.(T)5 1 114942160 114942165 pl.(T)6

1 59248011 59248015 pl.(G)5 1 114942176 114942180 pl.(T)5

1 59248124 59248138 p3.(GCT)5 1 114948088 114948092 pl.(T)5

1 59248285 59248289 pl.(C)5 1 114949592 114949597 pl.(T)6

1 59248461 59248465 pl.(G)5 1 114952868 114952872 pl.(G)5

1 65303790 65303799 p2.(GA)5 1 114967382 114967386 pl.(A)5

1 65304140 65304145 pl.(T)6 1 114968116 114968130 p3.(TGT)5

1 65304281 65304286 pl.(A)6 1 114968349 114968353 pl.(A)5

1 65305357 65305361 pl.(T)5 1 115006901 115006905 pl.(T)5

1 65306997 65307004 pl.(T)8 1 115053195 115053200 pl.(C)6

1 65310532 65310536 pl.(T)5 1 115053423 115053427 pl.(C)5

1 65311293 65311297 pl.(C)5 1 115053499 115053505 pl.(C)7

1 65325833 65325839 pl.(G)7 1 115053552 115053569 p3.(TCC)6

1 65330547 65330551 pl.(A)5 1 115053651 115053655 pl.(C)5

1 65330576 65330580 pl.(T)5 1 115251216 115251221 pl.(T)6

1 65330611 65330616 pl.(T)6 1 115251257 115251261 pl.(A)5

1 65330630 65330636 pl.(T)7 1 115252352 115252356 pl.(A)5

1 65339111 65339118 pl.(T)8 1 115256602 115256606 pl.(G)5

1 65339129 65339133 pl.(T)5 1 116916142 116916146 pl.(G)5

1 78414403 78414414 pl.(T)7(C)5 1 116926684 116926688 pl.(A)5

1 78414991 78414998 pl.(A)8 1 116926693 116926697 pl.(A)5

1 78425957 78425961 pl.(A)5 1 116926702 116926707 pl.(A)6

1 78426120 78426124 pl.(G)5 1 116929970 116929974 pl.(C)5

1 78426185 78426192 pl.(A)8 1 116930018 116930023 pl.(G)6

1 78428598 78428602 pl.(T)5 1 116930849 116930853 nl (A\ Chr Start End MS Chr Start End MS

1 116931592 116931596 pl.(C)5 1 147086319 147086323 pl.(C)5

1 116931650 116931654 pl.(T)5 1 147090673 147090677 pl.(C)5

1 116932053 116932057 pl.(T)5 1 147090769 147090773 pl.(C)5

1 116932151 116932155 pl.(C)5 1 147090856 147090860 pl.(C)5

1 116932827 116932832 pl.(T)6 1 147090982 147090987 pl.(C)6

1 116932871 116932875 pl.(A)5 1 147091079 147091083 pl.(T)5

1 116936320 116936325 pl.(G)6 1 147091117 147091121 pl.(G)5

1 116947067 116947072 pl.(C)6 1 147091159 147091164 pl.(A)6

1 116947123 116947127 pl.(C)5 1 147091501 147091508 pl.(C)8

1 118166214 118166218 pl.(G)5 1 147091546 147091550 pl.(G)5

1 120458005 120458009 pl.(C)5 1 147091594 147091598 pl.(C)5

1 120458185 120458189 pl.(G)5 1 147091752 147091756 pl.(A)5

1 120458339 120458343 pl.(G)5 1 147091830 147091834 pl.(C)5

1 120458384 120458388 pl.(C)5 1 147091890 147091895 pl.(C)6

1 120458436 120458441 pl.(G)6 1 147092053 147092057 pl.(C)5

1 120458741 120458745 pl.(A)5 1 147092277 147092281 pl.(C)5

1 120460319 120460323 pl.(T)5 1 147092615 147092620 pl.(C)6

1 120464983 120464987 pl.(C)5 1 147092659 147092670 p3.(GCT)4

1 120466363 120466367 pl.(C)5 1 147092681 147092687 pl.(C)7

1 120468081 120468085 pl.(C)5 1 147094076 147094081 pl.(C)6

1 120468185 120468190 pl.(G)6 1 147094090 147094101 p4.(CAGC)3

1 120468279 120468283 pl.(C)5 1 147095634 147095638 pl.(T)5

1 120468376 120468380 pl.(C)5 1 147095890 147095894 pl.(C)5

1 120469123 120469127 pl.(G)5 1 147095918 147095922 pl.(C)5

1 120480012 120480016 pl.(G)5 1 147095957 147095962 pl.(G)6

1 120480571 120480576 pl.(T)6 1 147096004 147096008 pl.(C)5

1 120480596 120480600 pl.(T)5 1 147096074 147096078 pl.(G)5

1 120483185 120483189 pl.(T)5 1 147096321 147096325 pl.(C)5

1 120483204 120483208 pl.(G)5 1 147096567 147096571 pl.(G)5

1 120496255 120496259 pl.(T)5 1 147096667 147096672 pl.(C)6

1 120508193 120508197 pl.(A)5 1 150549801 150549815 p3.(TGG)5

1 120510781 120510785 pl.(G)5 1 150550940 150550944 pl.(T)5

1 120510802 120510806 pl.(C)5 1 150551310 150551314 pl.(C)5

1 120512304 120512308 pl.(C)5 1 150551492 150551503 p3.(TCC)4

1 120512374 120512378 pl.(G)5 1 150551728 150551732 pl.(G)5

1 120529594 120529598 pl.(G)5 1 150551810 150551815 pl.(G)6

1 144873902 144873906 pl.(G)5 1 150551858 150551862 pl.(C)5

1 144873958 144873962 pl.(C)5 1 150551940 150551944 pl.(C)5

1 144877213 144877218 pl.(T)6 1 150551952 150551958 pl.(C)7

1 144879086 144879091 pl.(T)6 1 150552014 150552025 p3.(CGC)4

1 144879143 144879147 pl.(T)5 1 150789283 150789288 pl.(G)6

1 144886269 144886273 pl.(A)5 1 150790388 150790393 pl.(T)6

1 144906113 144906117 pl.(T)5 1 150795825 150795829 pl.(A)5

1 144909858 144909863 pl.(A)6 1 150807080 150807084 pl.(T)5

1 144909884 144909889 pl.(T)6 1 150825241 150825245 pl.(A)5

1 144909929 144909933 pl.(T)5 1 151039875 151039879 pl.(A)5

1 144911966 144911971 pl.(A)6 1 154130203 154130207 pl.(G)5

1 144912160 144912164 pl.(G)5 1 154142948 154142952 pl.(G)5

1 144917592 144917596 pl.(T)5 1 154148611 154148615 pl.(T)5

1 144917619 144917623 pl.(T)5 1 155159732 155159736 pl.(G)5

1 144917941 144917945 pl.(A)5 1 155160736 155160740 pl.(A)5

1 144923716 144923721 pl.(T)6 1 156737669 156737673 pl.(G)5

1 144994767 144994771 pl.(C)5 1 156737723 156737727 pl.(C)5

1 144994948 144994953 pl.(T)6 1 156737750 156737754 pl.(C)5

1 147084716 147084720 pl.(C)5 1 156737768 156737772 pl.(C)5

1 147084745 147084749 pl.(C)5 1 156737804 156737809 pl.(C)6

1 147084784 147084789 pl.(G)6 1 156737833 156737838 pl.(C)6

1 147084813 147084817 pl.(C)5 1 156737930 156737934 pl.(C)5

1 147084833 147084837 pl.(G)5 1 156737954 156737958 pl.(C)5

1 147086304 147086308 pl.(C)5 1 156752062 156752066 ni ms Chr Start End MS Chr Start End MS

1 156756445 156756449 pl.(A)5 1 186287740 186287744 pl.(A)5

1 156756698 156756702 pl.(C)5 1 186291530 186291536 pl.(A)7

1 156756709 156756713 pl.(T)5 1 186292867 186292871 pl.(G)5

1 156756839 156756844 pl.(C)6 1 186292967 186292971 pl.(A)5

1 156761536 156761543 pl.(C)8 1 186294885 186294889 pl.(A)5

1 156770304 156770308 pl.(C)5 1 186294989 186294993 pl.(A)5

1 156830849 156830853 pl.(C)5 1 186296797 186296801 pl.(A)5

1 156834203 156834207 pl.(G)5 1 186300619 186300623 pl.(T)5

1 156836777 156836781 pl.(G)5 1 186301462 186301466 pl.(G)5

1 156837888 156837893 pl.(C)6 1 186302486 186302490 pl.(A)5

1 156838343 156838347 pl.(G)5 1 186302530 186302534 pl.(A)5

1 156841421 156841425 pl.(G)5 1 186305643 186305647 pl.(T)5

1 156844688 156844692 pl.(C)5 1 186305676 186305681 pl.(T)6

1 156845387 156845391 pl.(C)5 1 186305812 186305816 pl.(T)5

1 156845863 156845867 pl.(C)5 1 186307246 186307250 pl.(T)5

1 156845918 156845922 pl.(G)5 1 186307380 186307385 pl.(A)6

1 156846308 156846312 pl.(C)5 1 186310509 186310513 pl.(T)5

1 156848968 156848972 pl.(C)5 1 186312587 186312591 pl.(T)5

1 156851434 156851438 pl.(G)5 1 186312610 186312614 pl.(A)5

1 157548320 157548324 pl.(T)5 1 186313145 186313149 pl.(T)5

1 157556026 157556030 pl.(C)5 1 186313608 186313612 pl.(T)5

1 157556200 157556204 pl.(C)5 1 186315318 186315322 pl.(T)5

1 162724572 162724576 pl.(C)5 1 186316427 186316431 pl.(T)5

1 162731105 162731109 pl.(C)5 1 186319434 186319438 pl.(T)5

1 162741857 162741861 pl.(G)5 1 186319444 186319449 pl.(T)6

1 162743287 162743291 pl.(A)5 1 186320543 186320547 pl.(T)5

1 162745596 162745600 pl.(C)5 1 186321144 186321148 pl.(C)5

1 164529037 164529041 pl.(G)5 1 186322991 186322996 pl.(A)6

1 164529161 164529165 pl.(G)5 1 186324639 186324644 pl.(T)6

1 164532540 164532545 pl.(A)6 1 186324655 186324659 pl.(T)5

1 164761720 164761724 pl.(T)5 1 186324661 186324666 pl.(T)6

1 164761771 164761775 pl.(C)5 1 186324676 186324680 pl.(A)5

1 164781392 164781397 pl.(T)6 1 186325408 186325412 pl.(A)5

1 164818582 164818586 pl.(C)5 1 186325588 186325592 pl.(A)5

1 164818591 164818595 pl.(C)5 1 186326758 186326762 pl.(A)5

1 170633350 170633354 pl.(G)5 1 186327661 186327667 pl.(A)7

1 170633450 170633454 pl.(A)5 1 186329976 186329980 pl.(T)5

1 170688888 170688894 pl.(A)7 1 186330040 186330045 pl.(A)6

1 170695421 170695425 pl.(A)5 1 186331005 186331011 pl.(A)7

1 170695521 170695525 pl.(G)5 1 186331975 186331980 pl.(T)6

1 170699410 170699414 pl.(A)5 1 186332020 186332024 pl.(T)5

1 170705330 170705337 pl.(A)8 1 186332122 186332126 pl.(T)5

1 170705364 170705368 pl.(A)5 1 186332552 186332556 pl.(T)5

1 179077188 179077192 pl.(T)5 1 186344286 186344297 p4.(CGCC)3

1 179077445 179077449 pl.(G)5 1 193091320 193091327 pl.(G)8

1 179077639 179077643 pl.(G)5 1 193091458 193091462 pl.(G)5

1 179077738 179077742 pl.(G)5 1 193099382 193099386 pl.(T)5

1 179077894 179077900 pl.(T)7 1 193111006 193111011 pl.(A)6

1 179078126 179078130 pl.(T)5 1 193111146 193111155 p2.(AG)5

1 179078174 179078178 pl.(C)5 1 193116999 193117003 pl.(T)5

1 179078192 179078196 pl.(C)5 1 193117013 193117017 pl.(T)5

1 179078198 179078202 pl.(C)5 1 193119423 193119429 pl.(T)7

1 179078242 179078247 pl.(C)6 1 193121497 193121504 pl.(T)8

1 179078404 179078409 pl.(G)6 1 193202112 193202117 pl.(T)6

1 179078450 179078455 pl.(C)6 1 193202211 193202215 pl.(G)5

1 179089414 179089418 pl.(A)5 1 193205403 193205407 pl.(T)5

1 179090803 179090807 pl.(C)5 1 198675866 198675870 pl.(A)5

1 179090862 179090866 pl.(G)5 1 198676006 198676010 pl.(A)5

1 179095689 179095693 pl.(T)5 1 198677301 198677305 pl.(A)5

1 186283862 186283866 pl.(A)5 1 198677333 198677337 nl (A\ Chr Start End MS Chr Start End MS

1 198682103 198682108 pl.(T)6 1 243675627 243675631 pl.(T)5

1 198682150 198682154 pl.(C)5 1 243675733 243675737 pl.(A)5

1 198685800 198685804 pl.(T)5 1 243708813 243708817 pl.(T)5

1 198685811 198685815 pl.(A)5 1 243716129 243716133 pl.(A)5

1 198685834 198685838 pl.(A)5 1 243727111 243727115 pl.(T)5

1 198687311 198687315 pl.(C)5 1 243778402 243778406 pl.(A)5

1 198700752 198700756 pl.(A)5 1 243801048 243801052 pl.(A)5

1 198700836 198700840 pl.(T)5 1 243809344 243809348 pl.(A)5

1 198710998 198711003 pl.(A)6 1 243859003 243859008 pl.(T)6

1 198711005 198711009 pl.(A)5 1 244006490 244006494 pl.(C)5

1 198711161 198711165 pl.(A)5 2 16082314 16082325 pl.(C)7(G)5

1 198719615 198719619 pl.(A)5 2 16082361 16082365 pl.(C)5

1 198721829 198721833 pl.(A)5 2 16082406 16082410 pl.(C)5

1 198723478 198723482 pl.(T)5 2 16082483 16082488 pl.(G)6

1 198725101 198725105 pl.(A)5 2 16082503 16082507 pl.(C)5

1 204494595 204494603 pl.(T)9 2 16082849 16082853 pl.(G)5

1 204499948 204499952 pl.(A)5 2 16082882 16082886 pl.(G)5

1 204507366 204507370 pl.(A)5 2 16085825 16085829 pl.(C)5

1 204512004 204512008 pl.(T)5 2 16085857 16085861 pl.(C)5

1 204513648 204513655 pl.(T)8 2 16085913 16085918 pl.(C)6

1 204513708 204513712 pl.(T)5 2 16085937 16085941 pl.(C)5

1 204513807 204513811 pl.(A)5 2 16086094 16086098 pl.(A)5

1 204515939 204515944 pl.(A)6 2 16086158 16086162 pl.(A)5

1 204518491 204518495 pl.(T)5 2 24253851 24253855 pl.(G)5

1 204518797 204518801 pl.(T)5 2 24253907 24253911 pl.(A)5

1 205589099 205589105 pl.(A)7 2 24254041 24254045 pl.(A)5

1 205589395 205589399 pl.(G)5 2 24255783 24255788 pl.(T)6

1 205589581 205589585 pl.(T)5 2 24255825 24255830 pl.(A)6

1 205589637 205589642 pl.(T)6 2 24260951 24260955 pl.(A)5

1 205589952 205589957 pl.(T)6 2 24260980 24260985 pl.(T)6

1 205592873 205592877 pl.(C)5 2 24261144 24261148 pl.(T)5

1 205601104 205601109 pl.(C)6 2 24261448 24261453 pl.(T)6

1 205601160 205601164 pl.(G)5 2 24881538 24881542 pl.(T)5

1 205632214 205632218 pl.(G)5 2 24888787 24888792 pl.(A)6

1 205632349 205632353 pl.(G)5 2 24905832 24905836 pl.(T)5

1 205632404 205632408 pl.(C)5 2 24905951 24905955 pl.(G)5

1 205633643 205633647 pl.(C)5 2 24920612 24920617 pl.(T)6

1 205633809 205633813 pl.(G)5 2 24929424 24929433 pl.(T)5(C)5

1 206646621 206646625 pl.(G)5 2 24929917 24929928 p3.(TAA)4

1 206650064 206650068 pl.(A)5 2 24930470 24930474 pl.(A)5

1 206651502 206651506 pl.(G)5 2 24930557 24930562 pl.(A)6

1 206651689 206651693 pl.(G)5 2 24952369 24952374 pl.(G)6

1 206652330 206652335 pl.(C)6 2 24952524 24952528 pl.(A)5

1 206652424 206652428 pl.(C)5 2 24952576 24952580 pl.(T)5

1 206653438 206653442 pl.(G)5 2 24962290 24962294 pl.(T)5

1 206666428 206666432 pl.(G)5 2 24964778 24964789 p4.(CCTC)3

1 206666643 206666647 pl.(G)5 2 24964817 24964821 pl.(C)5

1 226252006 226252010 pl.(T)5 2 24975030 24975034 pl.(G)5

1 226252013 226252017 pl.(T)5 2 24991211 24991216 pl.(C)6

1 226252186 226252191 pl.(A)6 2 25457093 25457098 pl.(T)6

1 241661228 241661232 pl.(T)5 2 25457096 25457107 p4.(TTTG)3

1 241661277 241661282 pl.(A)6 2 25457136 25457140 pl.(C)5

1 241663854 241663858 pl.(C)5 2 25457292 25457296 pl.(G)5

1 241663883 241663887 pl.(T)5 2 25463562 25463566 pl.(C)5

1 241663894 241663905 p4.(TGAG)3 2 25467164 25467168 pl.(C)5

1 241667416 241667420 pl.(A)5 2 25467448 25467452 pl.(C)5

1 241669471 241669485 p5.(GAAAA)3 2 25467482 25467493 p3.(CGT)4

1 241675450 241675455 pl.(A)6 2 25468154 25468158 pl.(G)5

1 243663039 243663043 pl.(T)5 2 25469091 25469095 pl.(T)5

1 243663048 243663053 pl.(T)6 2 25469530 25469535 nl ϊΓ ή Chr Start End MS Chr Start End MS

2 25470030 25470035 pl.(G)6 2 48026824 48026828 pl.(T)5

2 25470580 25470584 pl.(C)5 2 48026890 48026894 pl.(C)5

2 25470993 25470997 pl.(G)5 2 48026912 48026916 pl.(A)5

2 25497869 25497873 pl.(C)5 2 48027196 48027201 pl.(A)6

2 25505341 25505345 pl.(G)5 2 48027356 48027360 pl.(T)5

2 25505431 25505436 pl.(C)6 2 48027807 48027812 pl.(A)6

2 25523009 25523014 pl.(G)6 2 48028031 48028035 pl.(G)5

2 29416296 29416300 pl.(C)5 2 48028246 48028250 pl.(A)5

2 29416400 29416404 pl.(T)5 2 48030591 48030595 pl.(G)5

2 29416532 29416536 pl.(C)5 2 48030640 48030647 pl.(C)8

2 29416692 29416696 pl.(C)5 2 48030692 48030698 pl.(T)7

2 29430082 29430086 pl.(G)5 2 48030797 48030802 pl.(G)6

2 29443612 29443617 pl.(C)6 2 48032172 48032177 pl.(T)6

2 29445400 29445404 pl.(G)5 2 48032741 48032753 pl.(T)13

2 29446223 29446227 pl.(T)5 2 48032768 48032773 pl.(T)6

2 29449779 29449783 pl.(C)5 2 48033792 48033803 p4.(TAAC)3

2 29451784 29451789 pl.(C)6 2 48034961 48034965 pl.(A)5

2 29451794 29451798 pl.(C)5 2 48035098 48035102 pl.(T)5

2 29451806 29451810 pl.(C)5 2 48035198 48035203 pl.(A)6

2 29451823 29451827 pl.(C)5 2 48035237 48035241 pl.(T)5

2 29451843 29451847 pl.(G)5 2 48035381 48035385 pl.(A)5

2 29456453 29456457 pl.(C)5 2 48035569 48035573 pl.(A)5

2 29474017 29474021 pl.(G)5 2 48036768 48036772 pl.(A)5

2 29497981 29497985 pl.(G)5 2 48036794 48036798 pl.(A)5

2 29543728 29543732 pl.(A)5 2 48040378 48040382 pl.(C)5

2 29940572 29940576 pl.(A)5 2 48045988 48045992 pl.(A)5

2 30143052 30143057 pl.(G)6 2 48047602 48047606 pl.(A)5

2 30143204 30143208 pl.(C)5 2 48050368 48050372 pl.(T)5

2 42472625 42472639 p5.(TATTT)3 2 48050503 48050507 pl.(A)5

2 42472806 42472811 pl.(A)6 2 48059567 48059571 pl.(T)5

2 42509950 42509954 pl.(T)5 2 48059702 48059707 pl.(A)6

2 42511767 42511771 pl.(T)5 2 48059824 48059828 pl.(A)5

2 42513400 42513404 pl.(T)5 2 48060148 48060152 pl.(A)5

2 42513507 42513511 pl.(T)5 2 48065987 48065991 pl.(T)5

2 42522392 42522396 pl.(T)5 2 48066086 48066090 pl.(T)5

2 42528484 42528488 pl.(A)5 2 48066828 48066832 pl.(T)5

2 42530232 42530239 pl.(T)8 2 58392896 58392900 pl.(T)5

2 42530298 42530302 pl.(T)5 2 58392978 58392982 pl.(A)5

2 42557052 42557056 pl.(C)5 2 58393015 58393021 pl.(A)7

2 47630513 47630517 pl.(G)5 2 58425803 58425808 pl.(A)6

2 47635524 47635536 pl.(T)13 2 58456936 58456940 pl.(A)5

2 47637222 47637226 pl.(T)5 2 58468409 58468413 pl.(G)5

2 47641441 47641445 pl.(T)5 2 60687547 60687551 pl.(T)5

2 47641550 47641554 pl.(T)5 2 60687584 60687589 pl.(T)6

2 47641560 47641586 pl.(A)27 2 60688110 60688114 pl.(G)5

2 47657069 47657073 pl.(A)5 2 60688188 60688192 pl.(T)5

2 47672714 47672718 pl.(T)5 2 60688200 60688205 pl.(C)6

2 47693875 47693879 pl.(A)5 2 60688535 60688549 p3.(CTC)5

2 47693895 47693899 pl.(A)5 2 60688748 60688752 pl.(G)5

2 47702153 47702157 pl.(T)5 2 60688929 60688933 pl.(G)5

2 47702377 47702381 pl.(A)5 2 60688969 60688975 pl.(G)7

2 47702412 47702417 pl.(A)6 2 60689197 60689201 pl.(C)5

2 47705528 47705532 pl.(T)5 2 60689218 60689222 pl.(G)5

2 48010482 48010486 pl.(C)5 2 60689254 60689260 pl.(G)7

2 48010623 48010627 pl.(C)5 2 60773209 60773214 pl.(T)6

2 48018202 48018207 pl.(T)6 2 60773254 60773258 pl.(T)5

2 48023067 48023071 pl.(T)5 2 60773302 60773306 pl.(A)5

2 48025857 48025863 pl.(A)7 2 60773316 60773320 pl.(C)5

2 48025968 48025972 pl.(G)5 2 61108902 61108913 p4.(CTGA)3

2 48026753 48026757 pl.(A)5 2 61118800 61118809 ni rr Ai Chr Start End MS Chr Start End MS

2 61121518 61121528 pl.(C)5(T)6 2 113977718 113977722 pl.(G)5

2 61128112 61128118 pl.(T)7 2 113984838 113984842 pl.(A)5

2 61128158 61128163 pl.(A)6 2 113993069 113993073 pl.(A)5

2 61143988 61144003 pl.(A)6(T)10 2 113993122 113993126 pl.(G)5

2 61144018 61144022 pl.(A)5 2 113993165 113993176 p4.(GGAG)3

2 61144078 61144082 pl.(T)5 2 113999149 113999153 pl.(G)5

2 61145665 61145669 pl.(A)5 2 113999254 113999265 p3.(GCT)4

2 61145736 61145740 pl.(A)5 2 113999310 113999315 pl.(C)6

2 61149057 61149071 p5.(CCCAC)3 2 113999683 113999687 pl.(G)5

2 61149100 61149104 pl.(T)5 2 113999715 113999719 pl.(G)5

2 61149471 61149475 pl.(T)5 2 114002135 114002139 pl.(G)5

2 61149656 61149661 pl.(T)6 2 114002160 114002164 pl.(C)5

2 61705930 61705937 pl.(A)8 2 128018892 128018896 pl.(A)5

2 61706067 61706071 pl.(A)5 2 128018930 128018935 pl.(A)6

2 61709615 61709619 pl.(T)5 2 128028913 128028918 pl.(T)6

2 61711203 61711207 pl.(A)5 2 128030506 128030510 pl.(C)5

2 61711243 61711247 pl.(A)5 2 128046254 128046258 pl.(C)5

2 61712930 61712934 pl.(A)5 2 128046944 128046958 p3.(TCT)5

2 61712973 61712977 pl.(C)5 2 140992437 140992441 pl.(C)5

2 61713075 61713079 pl.(G)5 2 140995858 140995862 pl.(T)5

2 61715356 61715360 pl.(T)5 2 140997015 140997019 pl.(T)5

2 61715915 61715921 pl.(A)7 2 141004734 141004738 pl.(A)5

2 61717919 61717923 pl.(A)5 2 141032034 141032039 pl.(C)6

2 61719275 61719279 pl.(T)5 2 141032173 141032179 pl.(A)7

2 61719519 61719524 pl.(A)6 2 141055467 141055471 pl.(A)5

2 61719726 61719730 pl.(T)5 2 141081550 141081554 pl.(T)5

2 61719790 61719794 pl.(T)5 2 141081572 141081576 pl.(T)5

2 61719892 61719896 pl.(A)5 2 141108389 141108394 pl.(T)6

2 61722619 61722624 pl.(T)6 2 141110564 141110573 p2.(CA)5

2 61725841 61725845 pl.(A)5 2 141113925 141113929 pl.(T)5

2 61729435 61729441 pl.(T)7 2 141113974 141113978 pl.(T)5

2 61729451 61729457 pl.(A)7 2 141115624 141115629 pl.(T)6

2 61749782 61749786 pl.(T)5 2 141115652 141115656 pl.(T)5

2 61760967 61760971 pl.(T)5 2 141116522 141116526 pl.(A)5

2 100167879 100167883 pl.(A)5 2 141128266 141128270 pl.(A)5

2 100168061 100168065 pl.(G)5 2 141128365 141128369 pl.(T)5

2 100170975 100170979 pl.(G)5 2 141130712 141130716 pl.(A)5

2 100171155 100171160 pl.(C)6 2 141135864 141135870 pl.(A)7

2 100176879 100176883 pl.(T)5 2 141143539 141143543 pl.(T)5

2 100176904 100176908 pl.(A)5 2 141143572 141143576 pl.(T)5

2 100199306 100199310 pl.(T)5 2 141208234 141208239 pl.(A)6

2 100199430 100199435 pl.(T)6 2 141214104 141214108 pl.(T)5

2 100199438 100199442 pl.(T)5 2 141242901 141242905 pl.(T)5

2 100199465 100199469 pl.(A)5 2 141243012 141243017 pl.(T)6

2 100209976 100209980 pl.(C)5 2 141243038 141243043 pl.(T)6

2 100210161 100210165 pl.(C)5 2 141259407 141259411 pl.(T)5

2 100210258 100210263 pl.(G)6 2 141259418 141259423 pl.(A)6

2 100217914 100217920 pl.(G)7 2 141259448 141259455 pl.(A)8

2 100218011 100218031 p3.(GCT)7 2 141272298 141272302 pl.(T)5

2 100623096 100623100 pl.(C)5 2 141283924 141283928 pl.(A)5

2 100623488 100623499 p3.(GAA)4 2 141294163 141294167 pl.(T)5

2 100623849 100623853 pl.(A)5 2 141294272 141294276 pl.(T)5

2 100623910 100623914 pl.(C)5 2 141294286 141294298 pl.(A)13

2 100721972 100721976 pl.(G)5 2 141299414 141299418 pl.(T)5

2 111881310 111881316 pl.(A)7 2 141356235 141356239 pl.(T)5

2 111881487 111881491 pl.(C)5 2 141356336 141356340 pl.(T)5

2 111921713 111921717 pl.(T)5 2 141359214 141359218 pl.(G)5

2 113260620 113260624 pl.(A)5 2 141458023 141458027 pl.(T)5

2 113286319 113286323 pl.(C)5 2 141459420 141459424 pl.(A)5

2 113286398 113286402 pl.(A)5 2 141459696 141459701 nl (A Chr Start End MS Chr Start End MS

2 141597545 141597552 pl.(A)8 2 178098895 178098899 pl.(T)5

2 141598486 141598490 pl.(C)5 2 190660590 190660594 pl.(A)5

2 141607888 141607893 pl.(T)6 2 190670364 190670375 pl.(T)7(C)5

2 141607901 141607906 pl.(A)6 2 190708677 190708681 pl.(T)5

2 141609260 141609264 pl.(G)5 2 190717487 190717491 pl.(A)5

2 141660739 141660749 pl.(A)5(G)6 2 190718958 190718962 pl.(T)5

2 141665484 141665488 pl.(T)5 2 190719104 190719108 pl.(T)5

2 141680595 141680599 pl.(T)5 2 190719198 190719203 pl.(A)6

2 141680622 141680626 pl.(T)5 2 190719286 190719290 pl.(A)5

2 141751647 141751651 pl.(T)5 2 190719511 190719515 pl.(A)5

2 141751713 141751719 pl.(A)7 2 190719560 190719565 pl.(A)6

2 141762996 141763000 pl.(C)5 2 190719640 190719645 pl.(A)6

2 141771114 141771119 pl.(T)6 2 190719737 190719741 pl.(T)5

2 141771219 141771223 pl.(A)5 2 190719845 190719849 pl.(A)5

2 141773284 141773288 pl.(A)5 2 190732517 190732521 pl.(T)5

2 141773292 141773296 pl.(T)5 2 190732527 190732531 pl.(T)5

2 141773388 141773392 pl.(A)5 2 190738207 190738214 pl.(T)8

2 141773405 141773416 p4.(ATCC)3 2 190742124 190742129 pl.(T)6

2 141812783 141812787 pl.(C)5 2 191897673 191897677 pl.(A)5

2 141816467 141816472 pl.(T)6 2 191897880 191897884 pl.(A)5

2 141819648 141819653 pl.(T)6 2 191898281 191898285 pl.(A)5

2 142004926 142004930 pl.(A)5 2 191898355 191898359 pl.(A)5

2 142012219 142012224 pl.(A)6 2 191904031 191904042 pl.(G)6(A)6

2 142888355 142888372 p3.(CGG)6 2 191926444 191926448 pl.(T)5

2 173429358 173429362 pl.(T)5 2 191929569 191929573 pl.(C)5

2 173429695 173429699 pl.(T)5 2 191929687 191929691 pl.(A)5

2 173435501 173435506 pl.(C)6 2 191937834 191937838 pl.(T)5

2 173460549 173460553 pl.(T)5 2 191937921 191937925 pl.(A)5

2 175664838 175664842 pl.(A)5 2 192011359 192011363 pl.(T)5

2 175664863 175664867 pl.(T)5 2 192011385 192011389 pl.(T)5

2 175665019 175665023 pl.(A)5 2 192011486 192011496 pl.(A)l l

2 175676229 175676233 pl.(A)5 2 192012886 192012890 pl.(A)5

2 175676320 175676324 pl.(A)5 2 198261056 198261062 pl.(A)7

2 175677132 175677136 pl.(T)5 2 198262763 198262767 pl.(T)5

2 175689250 175689260 pl.(A)ll 2 198262848 198262853 pl.(A)6

2 175742640 175742645 pl.(T)6 2 198263229 198263233 pl.(T)5

2 176957811 176957825 p3.(GCG)5 2 198263253 198263257 pl.(G)5

2 176957922 176957926 pl.(C)5 2 198265161 198265166 pl.(A)6

2 176957973 176957977 pl.(C)5 2 198265558 198265562 pl.(T)5

2 176972310 176972327 p3.(GCG)6 2 198265663 198265667 pl.(A)5

2 176972335 176972340 pl.(G)6 2 198266175 198266180 pl.(A)6

2 176972351 176972355 pl.(G)5 2 198268494 198268498 pl.(A)5

2 176972366 176972370 pl.(G)5 2 198269829 198269833 pl.(T)5

2 176972369 176972380 p3.(GGC)4 2 198269850 198269854 pl.(T)5

2 176972383 176972388 pl.(G)6 2 198269860 198269864 pl.(T)5

2 176972405 176972422 p3.(GCG)6 2 198269909 198269913 pl.(A)5

2 176973638 176973643 pl.(C)6 2 198270036 198270040 pl.(A)5

2 176973655 176973659 pl.(A)5 2 198274507 198274511 pl.(G)5

2 176973706 176973710 pl.(T)5 2 198274526 198274530 pl.(T)5

2 178095517 178095521 pl.(T)5 2 198274641 198274645 pl.(T)5

2 178095666 178095671 pl.(T)6 2 198274735 198274740 pl.(A)6

2 178095702 178095706 pl.(T)5 2 198281452 198281456 pl.(A)5

2 178095717 178095721 pl.(T)5 2 198281489 198281494 pl.(T)6

2 178095723 178095727 pl.(T)5 2 198281606 198281610 pl.(T)5

2 178095782 178095786 pl.(T)5 2 198281639 198281645 pl.(A)7

2 178095914 178095919 pl.(T)6 2 198285205 198285209 pl.(T)5

2 178096620 178096624 pl.(T)5 2 198288703 198288707 pl.(A)5

2 178096646 178096650 pl.(A)5 2 202131204 202131208 pl.(A)5

2 178098833 178098837 pl.(A)5 2 202149728 202149732 pl.(C)5

2 178098886 178098891 pl.(T)6 2 202149799 202149804 nl mfi Chr Start End MS Chr Start End MS

2 202149819 202149823 pl.(G)5 2 216191536 216191540 pl.(T)5

2 202151246 202151250 pl.(A)5 2 216197092 216197096 pl.(T)5

2 202151290 202151296 pl.(A)7 2 216199709 216199713 pl.(A)5

2 202151331 202151350 p5.(TTTGT)4 2 216203619 216203623 pl.(A)5

2 204732741 204732746 pl.(T)6 2 216214252 216214256 pl.(C)5

2 204736166 204736172 pl.(T)7 2 216214394 216214399 pl.(T)6

2 204737476 204737480 pl.(C)5 2 219846402 219846407 pl.(C)6

2 204737596 204737601 pl.(T)6 2 219846447 219846451 pl.(G)5

2 208442219 208442225 pl.(T)7 2 219848978 219848982 pl.(C)5

2 209101739 209101743 pl.(A)5 2 223066018 223066025 pl.(C)8

2 209103947 209103951 pl.(A)5 2 223066830 223066834 pl.(C)5

2 209106756 209106760 pl.(T)5 2 223066912 223066918 pl.(A)7

2 209108211 209108215 pl.(T)5 2 223085082 223085086 pl.(A)5

2 209113152 209113156 pl.(G)5 2 223086020 223086025 pl.(C)6

2 209113160 209113164 pl.(T)5 2 223159023 223159027 pl.(G)5

2 209116180 209116184 pl.(A)5 2 223161883 223161887 pl.(A)5

2 209116263 209116269 pl.(T)7 2 223163338 223163342 pl.(G)5

2 209116294 209116298 pl.(A)5 2 223787801 223787805 pl.(A)5

2 209116300 209116309 pl.(A)10 2 223787808 223787813 pl.(A)6

2 212248322 212248327 pl.(A)6 2 223789195 223789199 pl.(A)5

2 212248465 212248469 pl.(A)5 2 223791722 223791728 pl.(T)7

2 212248737 212248742 pl.(T)6 2 223791766 223791770 pl.(G)5

2 212251753 212251757 pl.(A)5 2 223793638 223793643 pl.(A)6

2 212295694 212295698 pl.(T)5 2 223795389 223795393 pl.(G)5

2 212295829 212295833 pl.(A)5 2 223795419 223795423 pl.(A)5

2 212426821 212426827 pl.(A)7 2 223795430 223795434 pl.(A)5

2 212484009 212484015 pl.(A)7 2 223797889 223797893 pl.(A)5

2 212488635 212488640 pl.(T)6 2 223806243 223806247 pl.(A)5

2 212495221 212495225 pl.(T)5 2 237489563 237489567 pl.(C)5

2 212530121 212530125 pl.(C)5 2 242793291 242793295 pl.(G)5

2 212530143 212530147 pl.(T)5 2 242793363 242793368 pl.(G)6

2 212537933 212537937 pl.(G)5 2 242794819 242794823 pl.(G)5

2 212566899 212566903 pl.(G)5 2 242795104 242795110 pl.(G)7

2 212568866 212568871 pl.(A)6 3 9027284 9027298 p3.(GCT)5

2 212570033 212570038 pl.(A)6 3 9027335 9027340 pl.(G)6

2 212578380 212578393 pl.(A)14 3 9032370 9032374 pl.(C)5

2 212652892 212652897 pl.(A)6 3 9032381 9032385 pl.(G)5

2 212812214 212812218 pl.(A)5 3 9032393 9032397 pl.(G)5

2 212989591 212989600 p2.(AG)5 3 9032473 9032477 pl.(C)5

2 213403254 213403259 pl.(T)6 3 9034600 9034606 pl.(C)7

2 213403307 213403311 pl.(C)5 3 9034634 9034638 pl.(G)5

2 215593635 215593639 pl.(C)5 3 9034650 9034654 pl.(T)5

2 215595127 215595131 pl.(A)5 3 9036052 9036056 pl.(G)5

2 215595238 215595242 pl.(A)5 3 9036130 9036134 pl.(C)5

2 215610468 215610473 pl.(T)6 3 9051979 9051983 pl.(C)5

2 215634041 215634045 pl.(A)5 3 9055018 9055022 pl.(T)5

2 215645459 215645463 pl.(T)5 3 9055047 9055051 pl.(G)5

2 215645681 215645685 pl.(T)5 3 9057404 9057408 pl.(G)5

2 215645926 215645930 pl.(T)5 3 9066959 9066963 pl.(T)5

2 215645947 215645951 pl.(T)5 3 9067025 9067030 pl.(A)6

2 215645975 215645981 pl.(T)7 3 9074419 9074423 pl.(G)5

2 215645984 215645989 pl.(T)6 3 9074430 9074435 pl.(G)6

2 215646008 215646012 pl.(T)5 3 9099940 9099944 pl.(C)5

2 215646085 215646091 pl.(T)7 3 9106069 9106073 pl.(C)5

2 215646241 215646247 pl.(A)7 3 9106268 9106272 pl.(G)5

2 216182872 216182876 pl.(T)5 3 9146365 9146369 pl.(T)5

2 216182916 216182921 pl.(G)6 3 9166511 9166515 pl.(A)5

2 216184375 216184380 pl.(T)6 3 10074539 10074543 pl.(A)5

2 216184457 216184461 pl.(A)5 3 10076843 10076852 pl.(T)10

2 216190739 216190743 pl.(A)5 3 10077963 10077968 nl mfi Chr Start End MS Chr Start End MS

3 10078012 10078018 pi. (T)7 3 47061320 47061324 pi. (T)5

3 10084236 10084240 pi. (T)5 3 47061333 47061337 pi. (A)5

3 10089712 10089717 pi. (T)6 3 47084127 47084131 pi. (T)5

3 10094059 10094064 pi. (T)6 3 47084146 47084151 pi. (G)6

3 10106400 10106404 pi. (T)5 3 47098488 47098492 pi. (G)5

3 10114640 10114644 pi. (A)5 3 47098957 47098961 pi. (T)5

3 10114658 10114662 pi. (A)5 3 47103666 47103670 pi. (T)5

3 10116267 10116272 pi. (T)6 3 47103755 47103764 p2. (TC)5

3 10119789 10119793 pi. (C)5 3 47125832 47125836 pi. (T)5

3 10122854 10122858 pi. (T)5 3 47127812 47127816 pi. (G)5

3 10123017 10123021 pi. (T)5 3 47129682 47129686 pi. (T)5

3 10123023 10123027 pi. (T)5 3 47143010 47143015 pi. (A)6

3 10123127 10123131 pi. (T)5 3 47144836 47144840 pi. (T)5

3 10123139 10123143 pi. (T)5 3 47144893 47144897 pi. (T)5

3 10128940 10128945 pi. (A)6 3 47147524 47147528 pi. (T)5

3 10138052 10138056 pi. (A)5 3 47155352 47155357 pi. (A)6

3 10138138 10138143 pi. (A)6 3 47161807 47161811 pi. (G)5

3 10140655 10140659 pi. (T)5 3 47161907 47161913 pi. (T)7

3 10188297 10188301 pi. (T)5 3 47161939 47161945 pi. (T)7

3 12421190 12421194 pi. (T)5 3 47161951 47161956 pi. (T)6

3 12458270 12458275 pi. (C)6 3 47161958 47161962 pi. (A)5

3 12626352 12626356 pi. (A)5 3 47162078 47162082 pi. (A)5

3 12626656 12626660 pi. (C)5 3 47162414 47162418 pi. (A)5

3 12632476 12632490 p5. (GGGGA)3 3 47162429 47162433 pi. (T)5

3 12641658 12641662 pi. (T)5 3 47162731 47162735 pi. (A)5

3 12641708 12641712 pi. (G)5 3 47162778 47162782 pi. (T)5

3 14188875 14188879 pi. (T)5 3 47163364 47163368 pi. (A)5

3 14188888 14188892 pi. (A)5 3 47163377 47163383 pi. (T)7

3 14190333 14190337 pi. (G)5 3 47163936 47163940 pi. (T)5

3 14199816 14199821 pi. (T)6 3 47164127 47164131 pi. (A)5

3 14199970 14199974 pi. (G)5 3 47164218 47164222 pi. (A)5

3 14214448 14214453 pi. (T)6 3 47164240 47164245 pi. (T)6

3 14214472 14214476 pi. (C)5 3 47164309 47164313 pi. (T)5

3 14214538 14214542 pi. (G)5 3 47164414 47164418 pi. (T)5

3 14219966 14219980 p3. (CCT)5 3 47164525 47164529 pi. (G)5

3 30648341 30648345 pi. (G)5 3 47165048 47165052 pi. (T)5

3 30648383 30648387 pi. (G)5 3 47165068 47165072 pi. (T)5

3 30713742 30713746 pi. (G)5 3 47165213 47165219 pi. (T)7

3 30715585 30715589 pi. (T)5 3 47165283 47165289 pi. (T)7

3 37035101 37035105 pi. (G)5 3 47165962 47165966 pi. (A)5

3 37050315 37050320 pi. (T)6 3 47205375 47205379 pi. (C)5

3 37050349 37050354 pi. (A)6 3 47205443 47205447 pi. (C)5

3 37053348 37053353 pi. (A)6 3 47205468 47205472 pi. (G)5

3 37056043 37056047 pi. (A)5 3 47205469 47205483 p5. (GGGGA)3

3 37059062 37059066 pi. (A)5 3 48711991 48711995 pi. (C)5

3 37067100 37067120 pi. (T)21 3 48716309 48716313 pi. (C)5

3 37067416 37067420 pi. (A)5 3 48716893 48716899 pi. (G)7

3 37067433 37067437 pi. (G)5 3 48719000 48719004 pi. (G)5

3 37070349 37070354 pi. (C)6 3 48719030 48719034 pi. (G)5

3 37083746 37083750 pi. (T)5 3 48719081 48719085 pi. (G)5

3 37090053 37090057 pi. (C)5 3 48719186 48719190 pi. (C)5

3 38181482 38181486 pi. (C)5 3 48719525 48719529 pi. (G)5

3 38182798 38182807 p2. (GT)5 3 48720448 48720455 pi. (G)8

3 41265503 41265509 pi. (T)7 3 52437565 52437569 pi. (A)5

3 41266867 41266871 pi. (A)5 3 52437697 52437701 pi. (G)5

3 41268677 41268690 p2. (AT)7 3 52439132 52439136 pi. (G)5

3 41268763 41268767 pi. (A)5 3 52439770 52439775 pi. (C)6

3 41275622 41275626 pi. (T)5 3 52440912 52440917 pi. (C)6

3 41277217 41277221 pi. (G)5 3 52441339 52441343 pi. (A)5

3 41277997 41278001 pi. (A)5 3 52442625 52442629 nl Chr Start End MS Chr Start End MS

3 52443613 52443617 pi. (C)5 3 53783488 53783492 pl.(A)5

3 52443950 52443954 pi. (C)5 3 53785830 53785834 pl.(A)5

3 52584541 52584545 pi. (G)5 3 53785937 53785941 pl.(A)5

3 52584583 52584587 pi. (G)5 3 53804484 53804488 pl.(T)5

3 52588798 52588803 pi. (C)6 3 53804530 53804535 pl.(G)6

3 52597513 52597518 pi. (A)6 3 53809907 53809911 pl.(A)5

3 52610609 52610614 pi. (T)6 3 53810048 53810052 pl.(T)5

3 52610623 52610627 pi. (T)5 3 53810622 53810626 pl.(T)5

3 52610674 52610678 pi. (A)5 3 53810766 53810770 pl.(A)5

3 52610705 52610709 pi. (T)5 3 53815579 53815584 pl.(T)6

3 52613210 52613214 pi. (T)5 3 53834368 53834379 p3.(AGA)4

3 52620657 52620661 pi. (A)5 3 53837522 53837526 pl.(C)5

3 52620707 52620712 pi. (G)6 3 53837534 53837538 pl.(G)5

3 52621438 52621442 pi. (A)5 3 53842755 53842759 pl.(C)5

3 52621447 52621451 pi. (T)5 3 53844126 53844131 pl.(C)6

3 52623187 52623191 pi. (T)5 3 53844281 53844285 pl.(A)5

3 52623279 52623285 pi. (A)7 3 53845307 53845311 pl.(C)5

3 52637540 52637545 pi. (T)6 3 53845434 53845438 pl.(C)5

3 52637589 52637593 pi. (T)5 3 59999769 59999773 pl.(T)5

3 52637671 52637675 pi. (T)5 3 69987193 69987197 pl.(A)5

3 52637700 52637705 pi. (A)6 3 69988240 69988244 pl.(T)5

3 52643538 52643542 pi. (A)5 3 69990375 69990379 pl.(T)5

3 52643771 52643776 pi. (T)6 3 69998250 69998254 pl.(C)5

3 52643791 52643795 pi. (T)5 3 69998303 69998307 pl.(A)5

3 52643943 52643948 pi. (T)6 3 70000969 70000973 pl.(T)5

3 52649393 52649404 p3. (TCA)4 3 70001016 70001020 pl.(A)5

3 52651438 52651442 pi. (T)5 3 70014243 70014247 pl.(A)5

3 52651549 52651553 pi. (T)5 3 70014329 70014333 pl.(C)5

3 52651562 52651566 pi. (G)5 3 71007357 71007371 p5.(AAAAG)3

3 52661290 52661294 pi. (T)5 3 71007372 71007378 pl.(A)7

3 52668671 52668676 pi. (T)6 3 71007398 71007402 pl.(C)5

3 52668694 52668698 pi. (A)5 3 71007409 71007413 pl.(C)5

3 52668760 52668764 pi. (A)5 3 71007463 71007472 pl.(T)10

3 52677254 52677258 pi. (T)5 3 71008342 71008354 pl.(T)13

3 52682400 52682405 pi. (T)6 3 71008357 71008361 pl.(T)5

3 52692236 52692240 pi. (A)5 3 71008547 71008552 pl.(A)6

3 52702538 52702542 pi. (A)5 3 71019936 71019940 pl.(T)5

3 52702591 52702595 pi. (T)5 3 71021729 71021733 pl.(T)5

3 53529193 53529213 p3. (GAT)7 3 71027087 71027092 pl.(G)6

3 53529215 53529221 pi. (A)7 3 71027189 71027195 pl.(A)7

3 53531331 53531335 pi. (C)5 3 71064782 71064786 pl.(G)5

3 53531385 53531390 pi. (A)6 3 71101710 71101721 p3.(TGT)4

3 53531495 53531506 pi. (T)7(G)5 3 71101751 71101756 pl.(T)6

3 53535633 53535638 pi. (T)6 3 71102805 71102816 p3.(CTG)4

3 53535671 53535675 pi. (T)5 3 71161797 71161801 pl.(A)5

3 53684793 53684797 pi. (T)5 3 71247357 71247368 p3.(TGC)4

3 53684807 53684811 pi. (A)5 3 71247502 71247506 pl.(T)5

3 53684834 53684838 pi. (T)5 3 71247538 71247542 pl.(A)5

3 53684851 53684855 pi. (T)5 3 89259454 89259458 pl.(A)5

3 53699795 53699799 pi. (T)5 3 89391024 89391029 pl.(A)6

3 53699805 53699809 pi. (A)5 3 89457252 89457257 pl.(A)6

3 53699823 53699829 pi. (T)7 3 89499363 89499368 pl.(C)6

3 53707806 53707810 pi. (T)5 3 89521599 89521606 pl.(T)8

3 53757510 53757514 pi. (A)5 3 89521775 89521783 pl.(A)9

3 53757896 53757900 pi. (T)5 3 89528536 89528542 pl.(T)7

3 53760960 53760964 pi. (G)5 3 89528554 89528558 pl.(A)5

3 53764570 53764574 pi. (A)5 3 100447544 100447548 pl.(T)5

3 53766932 53766937 pi. (A)6 3 100451343 100451347 pl.(T)5

3 53766941 53766945 pi. (C)5 3 100451449 100451454 pl.(A)6

3 53783459 53783463 pi. (A)5 3 100451471 100451475 nl (A\ Chr Start End MS Chr Start End MS

3 100463652 100463669 p2.(TG)9 - 142185320 142185324 pl.(T)5

3 105377957 105377961 pl.(T)5 3 142185379 142185384 pl.(A)6

3 105378046 105378050 pl.(G)5 3 142186845 142186850 pl.(T)6

3 105389200 105389204 pl.(A)5 3 142186918 142186923 pl.(A)6

3 105397288 105397292 pl.(A)5 3 142188260 142188264 pl.(A)5

3 105397370 105397374 pl.(G)5 3 142188304 142188308 pl.(A)5

105400444 105400448 pl.(A)5 3 142188315 142188319 pl.(A)5

105470321 105470325 pl.(A)5 3 142188414 142188418 pl.(G)5

105470336 105470340 pl.(A)5 3 142188929 142188933 pl.(T)5

105495229 105495233 pl.(T)5 3 142204082 142204086 pl.(A)5

3 105495248 105495253 pl.(A)6 3 142204129 142204134 pl.(A)6

3 105572327 105572331 pl.(T)5 3 142211980 142211985 pl (T)6

3 105572471 105572475 pl.(T)5 - 142212118 142212122 pl.(T)5

3 105572511 105572515 pl.(A)5 3 142212161 142212166 pl.(A)6

3 105586315 105586319 pl.(G)5 3 142217539 142217543 pl.(A)5

3 119545603 119545607 pl.(T)5 3 142217557 142217563 pl.(T)7

3 119562124 119562128 pl.(G)5 3 142217620 142217624 pl.(A)5

3 119582342 119582347 pl.(A)6 3 142226777 142226781 pl.(A)5

119812307 119812318 p4.(TTCC)3 3 142242900 142242904 pl.(C)5

128199894 128199898 pl.(G)5 3 142243036 142243040 pl.(T)5

128200024 128200028 pl.(G)5 3 142253926 142253930 pl.(T)5

128204623 128204628 pl.(C)6 3 142254937 142254941 pl.(A)5

3 128204842 128204847 pl.(C)6 3 142254981 142254986 pl.(T)6

3 128204873 128204877 pl.(C)5 3 142255005 142255010 pl.(A)6

3 128204992 128204996 pl.(C)5 - 142266651 142266655 pl.(A)5

3 128205004 128205008 pl.(C)5 j - 142269140 142269144 pl.(A)5

3 128205139 128205143 pl.(C)5 3 142269152 142269156 pl.(A)5

3 128205878 128205889 p3.(CGG)4 3 142272097 142272102 pl.(A)6

3 128339230 128339234 pl.(C)5 3 142272249 142272253 pl.(A)5

3 128344748 128344752 pl.(T)5 3 142272577 142272581 pl.(A)5 j 128351003 128351014 p4.(GGAA)3 3 142272654 142272658 pl.(A)5 j 128889268 128889272 pl.(A)5 3 142274740 142274749 pl.(T)10 j 128889416 128889421 pl.(A)6 3 142274988 142274995 pl.(A)8 j 128889948 128889952 pl.(T)5 3 142275275 142275280 pl.(A)6

J 134670328 134670333 pl.(G)6 3 142275421 142275426 pl.(A)6

3 134670484 134670488 pl.(C)5 3 142278207 142278211 pl.(A)5

3 134670543 134670547 pl.(G)5 - 142281061 142281065 pl.(A)5

3 134670605 134670609 pl.(T)5 - 142281272 142281276 pl.(T)5

3 134670669 134670673 pl.(A)5 3 142281423 142281427 pl.(A)5

3 134851675 134851679 pl.(A)5 3 142281435 142281440 pl.(A)6

3 134851793 134851797 pl.(C)5 3 142281476 142281480 pl.(A)5

3 134851848 134851853 pl.(C)6 3 142281489 142281493 pl.(A)5 j 134872994 134872998 pl.(C)5 3 142281514 142281518 pl.(T)5 j 134885771 134885775 pl.(T)5 3 142281578 142281583 pl.(A)6 j 134967191 134967195 pl.(C)5 3 142281708 142281712 pl.(A)5 j 134978012 134978016 pl.(G)5 3 142281785 142281789 pl.(A)5

J 138664567 138664571 pl.(G)5 3 142281818 142281822 pl.(A)5

3 138664694 138664698 pl.(G)5 3 142281842 142281846 pl.(A)5

3 138664711 138664715 pl.(G)5 - 142297540 142297544 pl.(C)5

3 138664761 138664766 pl.(G)6 - 149238651 149238655 pl.(G)5

3 138664989 138664994 pl.(G)6 3 149260194 149260211 p3.(CTG)6

3 138665121 138665132 p3.(GCG)4 3 149260290 149260294 pl.(G)5

3 138665398 138665402 pl.(G)5 3 149290774 149290779 pl.(T)6

3 138665446 138665450 pl.(C)5 3 149374711 149374715 pl.(G)5

3 138665525 138665529 pl.(C)5 3 149374852 149374856 pl.(C)5

142168447 142168451 pl.(A)5 3 149375071 149375075 pl.(G)5

142176505 142176509 pl.(A)5 3 149375101 149375105 pl.(A)5

142178110 142178114 pl.(A)5 3 155588695 155588699 pl.(G)5

142178158 142178162 pl.(T)5 3 155621685 155621691 pl.(A)7

3 142180938 142180943 pl.(A)6 3 155621758 155621762 ni Chr Start End MS Chr Start End MS

3 155628498 155628502 pi. (A)5 3 183210422 183210426 pi. (C)5

3 155629044 155629048 pi. (A)5 3 183217395 183217399 pi. (T)5

3 155632332 155632336 pi. (A)5 3 183217498 183217502 pi. (G)5

3 155637130 155637134 pi. (A)5 3 185774991 185774995 pi. (G)5

3 155640070 155640074 pi. (T)5 3 185775264 185775268 pi. (T)5

3 155640086 155640090 pi. (A)5 3 185775275 185775279 pi. (A)5

3 155643020 155643024 pi. (T)5 3 185782229 185782233 pi. (C)5

3 155649541 155649545 pi. (T)5 3 185783667 185783671 pi. (G)5

3 155649624 155649628 pi. (T)5 3 185783736 185783740 pi. (G)5

3 158289044 158289048 pi. (T)5 3 185783742 185783746 pi. (G)5

3 158310271 158310275 pi. (T)5 3 185797673 185797677 pi. (G)5

3 158310379 158310386 pi. (T)8 3 185797721 185797726 pi. (G)6

3 158315957 158315961 pi. (T)5 3 185797728 185797732 pi. (G)5

3 158322940 158322944 pi. (G)5 3 185797801 185797805 pi. (G)5

3 158322983 158322988 pi. (A)6 3 185797835 185797840 pi. (G)6

3 168802839 168802843 pi. (A)5 3 185823443 185823447 pi. (A)5

3 168807891 168807895 pi. (T)5 3 185823714 185823718 pi. (G)5

3 168813037 168813041 pi. (A)5 3 186501339 186501344 pi. (A)6

3 168833257 168833268 pi. (T)7(C)5 3 186501389 186501393 pi. (T)5

3 168833279 168833284 pi. (T)6 3 186502742 186502748 pi. (T)7

3 168833437 168833441 pi. (G)5 3 186502865 186502869 pi. (C)5

3 168833560 168833565 pi. (A)6 3 186503760 186503764 pi. (A)5

3 168833605 168833610 pi. (T)6 3 186504283 186504287 pi. (T)5

3 168833647 168833651 pi. (T)5 3 186504339 186504344 pi. (A)6

3 168834343 168834348 pi. (A)6 3 186504375 186504379 pi. (A)5

3 168845646 168845650 pi. (A)5 3 186504977 186504981 pi. (T)5

3 168845715 168845719 pi. (T)5 3 186506924 186506928 pi. (G)5

3 176750928 176750932 pi. (A)5 3 187446270 187446275 pi. (G)6

3 176755963 176755967 pi. (A)5 3 187447190 187447194 pi. (G)5

3 176768307 176768311 pi. (A)5 3 187447236 187447241 pi. (G)6

3 176769342 176769347 pi. (T)6 3 187447317 187447321 pi. (G)5

3 176771709 176771713 pi. (A)5 3 187447335 187447339 pi. (G)5

3 178916662 178916666 pi. (C)5 3 187447440 187447444 pi. (G)5

3 178916781 178916785 pi. (C)5 3 187447647 187447651 pi. (G)5

3 178916857 178916862 pi. (T)6 3 187451496 187451501 pi. (A)6

3 178916894 178916898 pi. (T)5 3 188123887 188123891 pi. (T)5

3 178916905 178916909 pi. (T)5 3 188124035 188124039 pi. (A)5

3 178919194 178919200 pi. (A)7 3 188202394 188202398 pi. (C)5

3 178919303 178919307 pi. (A)5 3 188242550 188242554 pi. (C)5

3 178921526 178921530 pi. (A)5 3 188326942 188326946 pi. (T)5

3 178922278 178922283 pi. (T)6 3 188327027 188327031 pi. (C)5

3 178927965 178927970 pi. (T)6 3 188327199 188327213 p5. (CAGCC)3

3 178928039 178928043 pi. (A)5 3 188327388 188327392 pi. (C)5

3 178928133 178928137 pi. (T)5 3 188327441 188327445 pi. (G)5

3 178937471 178937475 pi. (A)5 3 188327604 188327608 pi. (C)5

3 178941854 178941862 pi. (T)9 3 188426133 188426137 pi. (A)5

3 178941881 178941885 pi. (T)5 3 188477889 188477896 pi. (T)8

3 178942518 178942522 pi. (A)5 3 188592312 188592316 pi. (A)5

3 178942597 178942601 pi. (A)5 3 195785160 195785164 pi. (A)5

3 178948003 178948007 pi. (T)5 3 195792356 195792360 pi. (T)5

3 178948037 178948041 pi. (T)5 3 195794379 195794383 pi. (A)5

3 178948055 178948060 pi. (A)6 3 195798301 195798305 pi. (C)5

3 178952104 178952108 pi. (A)5 3 195798375 195798379 pi. (A)5

3 181430202 181430207 pi. (G)6 3 195798975 195798979 pi. (T)5

3 181430206 181430217 p3. (GGC)4 3 195800949 195800953 pi. (T)5

3 181430251 181430255 pi. (A)5 3 195802038 195802042 pi. (A)5

3 181430546 181430550 pi. (C)5 3 195802087 195802091 pi. (T)5

3 181430901 181430906 pi. (C)6 4 1795648 1795652 pi. (C)5

3 181431011 181431015 pi. (C)5 4 1795654 1795658 pi. (C)5

3 183209685 183209691 pi. (G)7 4 1801055 1801059 nl Chr Start End MS Chr Start End MS

4 1801064 1801068 pl.(G)5 4 25678148 25678162 p3.(GCT)5

4 1803553 1803557 pl.(C)5 4 25678396 25678401 pl.(G)6

4 1806181 1806187 pl.(C)7 4 41747792 41747812 p3.(CGC)7

4 1806204 1806208 pl.(C)5 4 41747903 41747907 pl.(C)5

4 1807211 1807215 pl.(G)5 4 41747966 41747970 pl.(C)5

4 1807357 1807361 pl.(A)5 4 41748008 41748019 p3.(GCC)4

4 1807545 1807549 pl.(C)5 4 41748077 41748081 pl.(C)5

4 1808312 1808317 pl.(G)6 4 41748093 41748097 pl.(C)5

4 1808898 1808902 pl.(C)5 4 41748119 41748130 p3.(CCG)4

4 1808951 1808955 pl.(C)5 4 41748151 41748155 pl.(G)5

4 1808972 1808976 pl.(G)5 4 41748179 41748183 pl.(C)5

4 1809111 1809126 p2.(TG)8 4 41748245 41748249 pl.(T)5

4 1809128 1809145 p2.(GT)9 4 54243963 54243967 pl.(G)5

4 1809269 1809274 pl.(G)6 4 54250052 54250057 pl.(T)6

4 1809312 1809316 pl.(C)5 4 54255957 54255968 p4.(TTTG)3

4 1902558 1902562 pl.(G)5 4 54255969 54255973 pl.(T)5

4 1902712 1902716 pl.(C)5 4 54256016 54256020 pl.(G)5

4 1902733 1902737 pl.(A)5 4 54265884 54265893 pl.(T)10

4 1902857 1902861 pl.(A)5 4 54294251 54294255 pl.(T)5

4 1902973 1902977 pl.(A)5 4 54319075 54319080 pl.(T)6

4 1918589 1918593 pl.(A)5 4 54319188 54319197 p2.(AG)5

4 1918603 1918607 pl.(A)5 4 54319248 54319261 p2.(AG)7

4 1918709 1918713 pl.(A)5 4 54324888 54324892 pl.(A)5

4 1919853 1919862 pl.(T)10 4 55127451 55127455 pl.(T)5

4 1919987 1919991 pl.(G)5 4 55129961 55129965 pl.(G)5

4 1920318 1920322 pl.(T)5 4 55131076 55131081 pl.(T)6

4 1920334 1920338 pl.(A)5 4 55131167 55131171 pl.(T)5

4 1936885 1936891 pl.(A)7 4 55133838 55133842 pl.(A)5

4 1941386 1941390 pl.(A)5 4 55136788 55136794 pl.(T)7

4 1941510 1941521 p3.(AAT)4 4 55138608 55138612 pl.(G)5

4 1952883 1952887 pl.(A)5 4 55139691 55139695 pl.(T)5

4 1952910 1952914 pl.(A)5 4 55144081 55144085 pl.(A)5

4 1953826 1953830 pl.(C)5 4 55146474 55146478 pl.(T)5

4 1955041 1955045 pl.(T)5 4 55151549 55151553 pl.(A)5

4 1955146 1955151 pl.(A)6 4 55151636 55151640 pl.(T)5

4 1955190 1955194 pl.(C)5 4 55151647 55151652 pl.(A)6

4 1957419 1957424 pl.(G)6 4 55152055 55152059 pl.(A)5

4 1957738 1957742 pl.(A)5 4 55155276 55155280 pl.(A)5

4 1957747 1957751 pl.(C)5 4 55156487 55156492 pl.(A)6

4 1957795 1957799 pl.(T)5 4 55156579 55156583 pl.(A)5

4 1957857 1957861 pl.(G)5 4 55156730 55156734 pl.(G)5

4 1957881 1957885 pl.(G)5 4 55561665 55561669 pl.(T)5

4 1957909 1957913 pl.(A)5 4 55561719 55561730 p4.(CCAT)3

4 1959653 1959657 pl.(T)5 4 55564705 55564709 pl.(A)5

4 1959740 1959744 pl.(C)5 4 55589841 55589845 pl.(T)5

4 1977066 1977071 pl.(A)6 4 55595550 55595555 pl.(T)6

4 1978235 1978239 pl.(A)5 4 55602749 55602753 pl.(T)5

4 1980559 1980566 pl.(C)8 4 55603380 55603384 pl.(A)5

4 25665813 25665818 pl.(C)6 4 55946088 55946092 pl.(G)5

4 25665901 25665905 pl.(T)5 4 55948210 55948214 pl.(T)5

4 25667740 25667744 pl.(T)5 4 55948753 55948757 pl.(T)5

4 25667751 25667755 pl.(A)5 4 55953819 55953830 p3.(TCC)4

4 25669536 25669540 pl.(G)5 4 55955928 55955932 pl.(A)5

4 25672366 25672371 pl.(A)6 4 55961127 55961132 pl.(A)6

4 25672400 25672404 pl.(A)5 4 55964855 55964861 pl.(T)7

4 25672408 25672412 pl.(A)5 4 55968075 55968079 pl.(A)5

4 25676023 25676028 pl.(C)6 4 55968579 55968583 pl.(G)5

4 25676120 25676124 pl.(C)5 4 55971148 55971152 pl.(C)5

4 25676185 25676196 p3.(CAC)4 4 55972858 55972863 pl.(T)6

4 25677772 25677776 pl.(T)5 4 55972885 55972889 ni ms Chr Start End MS Chr Start End MS

4 55973958 55973962 pl.(G)5 4 99337959 99337963 pl.(A)5

4 55976725 55976729 pl.(T)5 4 99341159 99341163 pl.(T)5

4 55976739 55976746 pl.(A)8 4 99342494 99342498 pl.(G)5

4 55976833 55976837 pl.(G)5 4 106155594 106155598 pl.(T)5

4 55976876 55976880 pl.(C)5 4 106155700 106155704 pl.(A)5

4 55976931 55976935 pl.(T)5 4 106155779 106155784 pl.(A)6

4 55979581 55979585 pl.(A)5 4 106156073 106156077 pl.(A)5

4 55979612 55979616 pl.(T)5 4 106156082 106156086 pl.(T)5

4 55979652 55979658 pl.(A)7 4 106156289 106156300 p3.(CAC)4

4 55981089 55981093 pl.(T)5 4 106156321 106156325 pl.(C)5

4 55981509 55981513 pl.(T)5 4 106156365 106156369 pl.(A)5

4 55984971 55984975 pl.(A)5 4 106156652 106156656 pl.(T)5

4 55987311 55987315 pl.(T)5 4 106156759 106156763 pl.(C)5

4 66197678 66197682 pl.(A)5 4 106156936 106156941 pl.(G)6

4 66213912 66213916 pl.(T)5 4 106157060 106157064 pl.(A)5

4 66218764 66218768 pl.(A)5 4 106157174 106157178 pl.(A)5

4 66230873 66230877 pl.(T)5 4 106157336 106157340 pl.(A)5

4 66286238 66286243 pl.(T)6 4 106157385 106157389 pl.(C)5

4 66286255 66286260 pl.(T)6 4 106157657 106157661 pl.(T)5

4 66356229 66356233 pl.(T)5 4 106157797 106157801 pl.(A)5

4 66356423 66356428 pl.(G)6 4 106157879 106157883 pl.(T)5

4 66467373 66467377 pl.(T)5 4 106158109 106158113 pl.(A)5

4 66467573 66467578 pl.(T)6 4 106158447 106158452 pl.(A)6

4 66467646 66467650 pl.(T)5 4 106162508 106162512 pl.(A)5

4 66535395 66535399 pl.(G)5 4 106162524 106162528 pl.(T)5

4 66535403 66535414 p3.(CGC)4 4 106180768 106180772 pl.(T)5

4 66535417 66535421 pl.(G)5 4 106190759 106190763 pl.(T)5

4 66535558 66535563 pl.(C)6 4 106193850 106193855 pl.(A)6

4 87967419 87967423 pl.(T)5 4 106194000 106194004 pl.(A)5

4 87967836 87967843 pl.(T)8 4 106196282 106196293 p3.(CAG)4

4 87968333 87968337 pl.(C)5 4 106196300 106196311 p3.(CAG)4

4 87968534 87968545 p4.(CCTC)3 4 106196921 106196925 pl.(A)5

4 87968551 87968555 pl.(A)5 4 106197245 106197249 pl.(G)5

4 87968676 87968681 pl.(A)6 4 106197435 106197439 pl.(A)5

4 88016058 88016062 pl.(C)5 4 106197506 106197511 pl.(A)6

4 88016086 88016090 pl.(A)5 4 106197682 106197686 pl.(C)5

4 88035512 88035516 pl.(T)5 4 123374926 123374930 pl.(T)5

4 88035572 88035583 p4.(CAGC)3 4 153244148 153244152 pl.(C)5

4 88035615 88035619 pl.(C)5 4 153244156 153244161 pl.(C)6

4 88035693 88035697 pl.(C)5 4 153244308 153244312 pl.(A)5

4 88035715 88035720 pl.(C)6 4 153249361 153249366 pl.(T)6

4 88035736 88035741 pl.(C)6 4 153249546 153249550 pl.(A)5

4 88035786 88035790 pl.(C)5 4 153253877 153253883 pl.(A)7

4 88035822 88035827 pl.(A)6 4 153268090 153268094 pl.(T)5

4 88035872 88035876 pl.(G)5 4 153268228 153268241 pl.(A)14

4 88035996 88036001 pl.(C)6 4 153332463 153332467 pl.(T)5

4 88036039 88036043 pl.(C)5 4 153332605 153332619 p3.(CTC)5

4 88036275 88036279 pl.(C)5 5 1254606 1254610 pl.(C)5

4 88036440 88036444 pl.(A)5 5 1254623 1254627 pl.(G)5

4 88047293 88047298 pl.(C)6 5 1255464 1255468 pl.(A)5

4 88048164 88048173 pl.(T)10 5 1278878 1278882 pl.(G)5

4 88048787 88048791 pl.(T)5 5 1282589 1282593 pl.(A)5

4 88048825 88048830 pl.(A)6 5 1293577 1293581 pl.(G)5

4 88053466 88053471 pl.(A)6 5 1293665 1293669 pl.(G)5

4 88056720 88056727 pl.(T)8 5 1293687 1293691 pl.(G)5

4 88056889 88056893 pl.(T)5 5 1294033 1294037 pl.(G)5

4 88056910 88056914 pl.(A)5 5 1294078 1294083 pl.(G)6

4 99264305 99264310 pl.(A)6 5 1294324 1294328 pl.(C)5

4 99264406 99264410 pl.(A)5 5 1294361 1294365 pl.(G)5

4 99313094 99313098 pl.(T)5 5 1294441 1294445 nl ίΠ« Chr Start End MS Chr Start End MS

5 1294587 1294591 pl.(C)5 5 55247858 55247862 pl.(T)5

5 1294602 1294606 pl.(C)5 5 55247869 55247875 pl.(T)7

5 1294665 1294676 pl.(G)7(C)5 5 55252033 55252037 pl.(T)5

5 1294786 1294790 pl.(G)5 5 55259338 55259342 pl.(A)5

5 35857056 35857067 p2.(CT)6 5 55264203 55264207 pl.(T)5

5 35857111 35857116 pl.(T)6 5 55264211 55264215 pl.(T)5

5 35874591 35874596 pl.(T)6 5 55265589 55265593 pl.(T)5

5 35874637 35874643 pl.(A)7 5 55265686 55265690 pl.(A)5

5 35875697 35875701 pl.(T)5 5 56155721 56155725 pl.(A)5

5 35876072 35876076 pl.(T)5 5 56161262 56161266 pl.(A)5

5 35876454 35876458 pl.(C)5 5 56161288 56161292 pl.(T)5

5 38481718 38481723 pl.(A)6 5 56161813 56161817 pl.(T)5

5 38481785 38481789 pl.(A)5 5 56168460 56168464 pl.(T)5

5 38486086 38486090 pl.(T)5 5 56168639 56168643 pl.(T)5

5 38489248 38489252 pl.(A)5 5 56170991 56170995 pl.(G)5

5 38490360 38490365 pl.(A)6 5 56171018 56171022 pl.(G)5

5 38496537 38496541 pl.(T)5 5 56174794 56174800 pl.(T)7

5 38496667 38496671 pl.(T)5 5 56176901 56176905 pl.(T)5

5 38496703 38496707 pl.(A)5 5 56177104 56177108 pl.(T)5

5 38499634 38499639 pl.(T)6 5 56177383 56177389 pl.(T)7

5 38499688 38499692 pl.(A)5 5 56177849 56177872 p3.(CAA)8

5 38502761 38502766 pl.(T)6 5 56178258 56178263 pl.(A)6

5 38506008 38506012 pl.(T)5 5 56178577 56178588 p3.(GAA)4

5 38506172 38506176 pl.(A)5 5 56181758 56181762 pl.(G)5

5 38506742 38506749 pl.(A)8 5 56189345 56189349 pl.(T)5

5 38510573 38510577 pl.(A)5 5 56189555 56189562 pl.(A)8

5 38510609 38510613 pl.(A)5 5 67522546 67522550 pl.(A)5

5 38510729 38510733 pl.(T)5 5 67522700 67522705 pl.(G)6

5 38510792 38510796 pl.(A)5 5 67522741 67522747 pl.(A)7

5 38510829 38510833 pl.(A)5 5 67575567 67575572 pl.(T)6

5 38511940 38511944 pl.(A)5 5 67588943 67588947 pl.(A)5

5 38512069 38512073 pl.(A)5 5 67588972 67588976 pl.(T)5

5 38523590 38523594 pl.(A)5 5 67590411 67590415 pl.(A)5

5 38523689 38523693 pl.(A)5 5 67591240 67591244 pl.(T)5

5 38530610 38530614 pl.(T)5 5 67591259 67591263 pl.(A)5

5 38942487 38942492 pl.(A)6 5 112102013 112102017 pl.(T)5

5 38945177 38945183 pl.(A)7 5 112102932 112102936 pl.(A)5

5 38945715 38945719 pl.(A)5 5 112116587 112116591 pl.(A)5

5 38945793 38945798 pl.(T)6 5 112151185 112151189 pl.(T)5

5 38947421 38947425 pl.(C)5 5 112155032 112155036 pl.(A)5

5 38950626 38950631 pl.(T)6 5 112157585 112157589 pl.(T)5

5 38950702 38950706 pl.(T)5 5 112157696 112157700 pl.(A)5

5 38950768 38950772 pl.(A)5 5 112162793 112162797 pl.(T)5

5 38954869 38954873 pl.(T)5 5 112162804 112162808 pl.(G)5

5 38958824 38958828 pl.(T)5 5 112162950 112162954 pl.(T)5

5 38959898 38959902 pl.(T)5 5 112164604 112164608 pl.(A)5

5 38959950 38959954 pl.(A)5 5 112164664 112164668 pl.(A)5

5 38960610 38960614 pl.(A)5 5 112170747 112170751 pl.(T)5

5 38963152 38963156 pl.(A)5 5 112173394 112173398 pl.(G)5

5 38967334 38967339 pl.(A)6 5 112173561 112173565 pl.(A)5

5 38967467 38967471 pl.(T)5 5 112173690 112173694 pl.(T)5

5 38975712 38975716 pl.(G)5 5 112173831 112173835 pl.(A)5

5 44305137 44305141 pl.(T)5 5 112175101 112175105 pl.(T)5

5 44388711 44388715 pl.(A)5 5 112175651 112175655 pl.(A)5

5 44388715 44388732 p3.(AGC)6 5 112175676 112175685 p2.(AG)5

5 55237477 55237482 pl.(C)6 5 112175952 112175957 pl.(A)6

5 55237512 55237517 pl.(T)6 5 112175993 112176004 p3.(GAT)4

5 55237520 55237524 pl.(T)5 5 112176064 112176069 pl.(A)6

5 55237562 55237566 pl.(T)5 5 112176193 112176197 pl.(G)5

5 55243421 55243445 pl.(A)25 5 112176345 112176349 nl (A\ Chr Start End MS Chr Start End MS

5 112176400 112176404 pl.(A)5 5 131977876 131977880 pl.(A)5

5 112176521 112176525 pl.(A)5 5 131977985 131977989 pl.(A)5

5 112176575 112176579 pl.(A)5 5 131978055 131978059 pl.(A)5

5 112176596 112176600 pl.(A)5 5 132219022 132219033 p4.(ACCT)3

5 112176661 112176666 pl.(A)6 5 132219033 132219037 pl.(T)5

5 112176676 112176681 pl.(A)6 5 132223525 132223529 pl.(T)5

5 112176740 112176744 pl.(A)5 5 132224872 132224878 pl.(A)7

5 112176856 112176860 pl.(T)5 5 132227923 132227927 pl.(T)5

5 112176892 112176903 p3.(TGA)4 5 132228017 132228021 pl.(T)5

5 112177265 112177269 pl.(C)5 5 132228818 132228822 pl.(A)5

5 112177435 112177440 pl.(A)6 5 132232045 132232049 pl.(T)5

5 112177442 112177446 pl.(A)5 5 132232094 132232098 pl.(T)5

5 112177473 112177477 pl.(A)5 5 132232104 132232108 pl.(C)5

5 112177643 112177654 p3.(GCT)4 5 132232258 132232263 pl.(A)6

5 112177758 112177762 pl.(A)5 5 132232439 132232443 pl.(T)5

5 112177826 112177830 pl.(A)5 5 132232616 132232620 pl.(T)5

5 112177864 112177870 pl.(A)7 5 132232627 132232632 pl.(T)6

5 112178033 112178038 pl.(A)6 5 132232811 132232815 pl.(T)5

5 112178377 112178381 pl.(A)5 5 132232922 132232926 pl.(G)5

5 112178525 112178529 pl.(A)5 5 132232936 132232940 pl.(A)5

5 112179036 112179040 pl.(A)5 5 132262874 132262878 pl.(G)5

5 112179043 112179047 pl.(A)5 5 132270072 132270076 pl.(A)5

5 112179057 112179061 pl.(A)5 5 132270259 132270264 pl.(T)6

5 112179130 112179134 pl.(A)5 5 132270490 132270494 pl.(T)5

5 112179329 112179333 pl.(C)5 5 132270638 132270644 pl.(A)7

5 112179489 112179493 pl.(A)5 5 132270641 132270660 p5.(AAAAT)4

5 131289960 131289965 pl.(T)6 5 138118985 138118989 pl.(G)5

5 131290067 131290071 pl.(A)5 5 138160447 138160458 p3.(GGA)4

5 131296307 131296311 pl.(A)5 5 138253498 138253502 pl.(T)5

5 131298340 131298344 pl.(T)5 5 138253516 138253520 pl.(A)5

5 131310536 131310541 pl.(A)6 5 138266190 138266194 pl.(A)5

5 131312419 131312423 pl.(A)5 5 138266535 138266539 pl.(A)5

5 131321147 131321151 pl.(G)5 5 138269653 138269657 pl.(A)5

5 131323925 131323929 pl.(G)5 5 142150301 142150306 pl.(C)6

5 131325118 131325122 pl.(A)5 5 142252952 142252956 pl.(T)5

5 131329854 131329858 pl.(A)5 5 142264851 142264857 pl.(T)7

5 131347218 131347223 pl.(C)6 5 142264869 142264873 pl.(A)5

5 131347259 131347278 p5.(GGCCC)4 5 142264915 142264919 pl.(A)5

5 131893103 131893107 pl.(C)5 5 142264938 142264942 pl.(A)5

5 131915179 131915184 pl.(T)6 5 142283153 142283157 pl.(A)5

5 131923617 131923621 pl.(T)5 5 142435659 142435664 pl.(T)6

5 131923719 131923723 pl.(A)5 5 142437269 142437273 pl.(A)5

5 131923755 131923759 pl.(A)5 5 142513610 142513614 pl.(C)5

5 131926940 131926944 pl.(A)5 5 142526787 142526793 pl.(C)7

5 131926963 131926967 pl.(A)5 5 142586763 142586768 pl.(C)6

5 131926992 131926996 pl.(A)5 5 142586864 142586868 pl.(C)5

5 131927105 131927109 pl.(T)5 5 142586999 142587003 pl.(T)5

5 131930589 131930593 pl.(A)5 5 149433732 149433743 p3.(CTG)4

5 131930612 131930616 pl.(A)5 5 149441304 149441308 pl.(G)5

5 131930716 131930720 pl.(A)5 5 149447806 149447820 p3.(AGC)5

5 131931355 131931359 pl.(T)5 5 149447875 149447879 pl.(G)5

5 131931452 131931460 pl.(A)9 5 149449788 149449792 pl.(G)5

5 131939635 131939639 pl.(A)5 5 149449859 149449864 pl.(G)6

5 131940487 131940491 pl.(T)5 5 149452997 149453001 pl.(C)5

5 131940562 131940566 pl.(A)5 5 149456951 149456955 pl.(T)5

5 131944965 131944970 pl.(T)6 5 149457796 149457800 pl.(G)5

5 131944976 131944980 pl.(A)5 5 149457820 149457824 pl.(G)5

5 131953752 131953757 pl.(T)6 5 149460366 149460370 pl.(G)5

5 131953798 131953802 pl.(A)5 5 149460476 149460481 pl.(G)6

5 131976354 131976359 pl.(T)6 5 149495286 149495292 nl (CM

-111- Chr Start End MS Chr Start End MS

5 149495322 149495326 pl.(C)5 5 176562218 176562222 pl.(T)5

5 149495457 149495461 pl.(G)5 5 176562406 176562411 pl.(A)6

5 149497192 149497196 pl.(G)5 5 176562813 176562817 pl.(A)5

5 149497245 149497249 pl.(G)5 5 176562850 176562854 pl.(A)5

5 149498311 149498315 pl.(T)5 5 176562871 176562875 pl.(C)5

5 149498364 149498369 pl.(G)6 5 176563040 176563044 pl.(T)5

5 149499679 149499683 pl.(A)5 5 176618897 176618901 pl.(A)5

5 149501606 149501610 pl.(G)5 5 176619010 176619014 pl.(A)5

5 149502612 149502616 pl.(G)5 5 176631274 176631278 pl.(A)5

5 149503828 149503832 pl.(C)5 5 176636918 176636922 pl.(A)5

5 149513452 149513456 pl.(G)5 5 176636934 176636938 pl.(A)5

5 149514303 149514307 pl.(G)5 5 176637122 176637127 pl.(A)6

5 149515273 149515277 pl.(G)5 5 176637438 176637442 pl.(A)5

5 149515369 149515373 pl.(G)5 5 176637807 176637811 pl.(C)5

5 149786443 149786447 pl.(C)5 5 176638299 176638303 pl.(A)5

5 149792325 149792330 pl.(C)6 5 176638344 176638348 pl.(G)5

5 156638281 156638290 p2.(TG)5 5 176638499 176638503 pl.(T)5

5 156655341 156655345 pl.(A)5 5 176638712 176638716 pl.(T)5

5 156670614 156670627 p2.(CT)7 5 176638771 176638775 pl.(A)5

5 156671260 156671264 pl.(T)5 5 176638869 176638873 pl.(A)5

5 156671325 156671329 pl.(C)5 5 176665224 176665229 pl.(T)6

5 156671397 156671401 pl.(T)5 5 176665367 176665371 pl.(T)5

5 158139169 158139173 pl.(G)5 5 176671279 176671283 pl.(T)5

5 158139202 158139206 pl.(G)5 5 176673750 176673755 pl.(A)6

5 158267101 158267105 pl.(A)5 5 176673759 176673763 pl.(A)5

5 158523982 158523986 pl.(T)5 5 176675269 176675275 pl.(A)7

5 158526518 158526522 pl.(C)5 5 176678738 176678742 pl.(A)5

5 158526526 158526532 pl.(A)7 5 176694670 176694674 pl.(A)5

5 158526535 158526549 pl.(A)15 5 176696691 176696696 pl.(T)6

5 170305084 170305092 pl.(T)9 5 176696802 176696807 pl.(A)6

5 170337964 170337969 pl.(T)6 5 176700715 176700719 pl.(A)5

5 170338144 170338149 pl.(A)6 5 176707817 176707821 pl.(A)5

5 170341158 170341165 pl.(T)8 5 176707830 176707834 pl.(A)5

5 170343461 170343466 pl.(T)6 5 176707841 176707845 pl.(A)5

5 170343564 170343568 pl.(A)5 5 176710903 176710907 pl.(T)5

5 170345756 170345760 pl.(T)5 5 176721039 176721043 pl.(C)5

5 170345870 170345874 pl.(A)5 5 176721165 176721170 pl.(A)6

5 170346624 170346628 pl.(A)5 5 176721676 176721680 pl.(A)5

5 170351501 170351505 pl.(A)5 5 176721713 176721718 pl.(A)6

5 170736336 170736350 p5.(GCCCA)3 5 176722008 176722012 pl.(T)5

5 170736508 170736518 pl.(C)6(G)5 5 180039532 180039536 pl.(C)5

5 170738381 170738385 pl.(C)5 5 180043887 180043891 pl.(G)5

5 170814982 170814986 pl.(C)5 5 180046104 180046108 pl.(G)5

5 170818291 170818300 pl.(T)10 5 180047191 180047195 pl.(G)5

5 170818719 170818723 pl.(G)5 5 180047630 180047641 p3.(GAG)4

5 170818812 170818816 pl.(T)5 5 180048013 180048017 pl.(G)5

5 170819918 170819923 pl.(A)6 5 180048255 180048259 pl.(G)5

5 170827864 170827868 pl.(A)5 5 180048638 180048642 pl.(G)5

5 176516627 176516631 pl.(G)5 5 180052994 180052998 pl.(G)5

5 176517816 176517820 pl.(C)5 5 180053023 180053029 pl.(G)7

5 176517955 176517959 pl.(C)5 5 180055897 180055902 pl.(G)6

5 176519635 176519639 pl.(C)5 5 180057717 180057721 pl.(C)5

5 176520346 176520350 pl.(C)5 5 180057786 180057790 pl.(G)5

5 176520541 176520545 pl.(C)5 5 180058748 180058754 pl.(G)7

5 176522601 176522606 pl.(C)6 6 395001 395006 pl.(A)6

5 176523645 176523649 pl.(G)5 6 401582 401586 pl.(A)5

5 176523720 176523724 pl.(C)5 6 401637 401641 pl.(C)5

5 176523731 176523736 pl.(C)6 6 407598 407602 pl.(A)5

5 176524562 176524566 pl.(C)5 6 407623 407627 pl.(T)5

5 176524623 176524627 pl.(C)5 6 407630 407648 nl mi Q Chr Start End MS Chr Start End MS

6 18236684 18236688 pl.(T)5 6 33288181 33288185 pl.(G)5

6 18236771 18236775 pl.(G)5 6 33288230 33288235 pl.(T)6

6 18236786 18236790 pl.(T)5 6 33288505 33288509 pl.(C)5

6 18237613 18237618 pl.(T)6 6 33288636 33288640 pl.(G)5

6 18237685 18237690 pl.(T)6 6 33289130 33289134 pl.(T)5

6 18237718 18237722 pl.(T)5 6 33289253 33289257 pl.(A)5

6 18237737 18237742 pl.(T)6 6 33289715 33289719 pl.(C)5

6 18249928 18249932 pl.(T)5 6 33290632 33290636 pl.(C)5

6 18250027 18250031 pl.(T)5 6 34211287 34211292 pl.(A)6

6 18250049 18250055 pl.(T)7 6 34212738 34212742 pl.(C)5

6 18250077 18250081 pl.(A)5 6 34212786 34212790 pl.(C)5

6 18256579 18256583 pl.(A)5 6 34212897 34212902 pl.(C)6

6 18256592 18256596 pl.(T)5 6 34213026 34213030 pl.(G)5

6 18256613 18256617 pl.(T)5 6 34213286 34213290 pl.(C)5

6 18256633 18256637 pl.(T)5 6 34213350 34213354 pl.(C)5

6 18258171 18258175 pl.(A)5 6 35423683 35423687 pl.(G)5

6 18258250 18258256 pl.(A)7 6 35423707 35423711 pl.(G)5

6 18258300 18258310 pl.(A)ll 6 35423781 35423785 pl.(G)5

6 18258596 18258601 pl.(T)6 6 35423794 35423799 pl.(G)6

6 18264066 18264071 pl.(C)6 6 35423814 35423819 pl.(C)6

6 18264075 18264079 pl.(T)5 6 35425715 35425721 pl.(C)7

6 18264079 18264096 p3.(TCC)6 6 35430614 35430618 pl.(A)5

6 18264177 18264181 pl.(G)5 6 36564525 36564529 pl.(T)5

6 18264188 18264192 pl.(C)5 6 36566617 36566621 pl.(C)5

6 26031861 26031865 pl.(A)5 6 36566670 36566675 pl.(A)6

6 26032176 26032180 pl.(T)5 6 37138536 37138540 pl.(C)5

6 27107127 27107131 pl.(G)5 6 37139227 37139231 pl.(G)5

6 28872182 28872187 pl.(G)6 6 41652400 41652404 pl.(G)5

6 28876787 28876791 pl.(T)5 6 41652536 41652540 pl.(G)5

6 28876796 28876800 pl.(A)5 6 41652557 41652561 pl.(C)5

6 28876874 28876879 pl.(A)6 6 41652638 41652642 pl.(G)5

6 28887809 28887820 p3.(GCT)4 6 41652678 41652682 pl.(C)5

6 28889692 28889696 pl.(C)5 6 41655721 41655725 pl.(G)5

6 28889731 28889735 pl.(T)5 6 41658516 41658520 pl.(G)5

6 30153635 30153639 pl.(G)5 6 41658662 41658666 pl.(G)5

6 30153780 30153784 pl.(C)5 6 41658784 41658788 pl.(G)5

6 30153952 30153956 pl.(C)5 6 41658830 41658850 p3.(TGC)7

6 30154080 30154091 p3.(TCC)4 6 41903746 41903751 pl.(G)6

6 30154114 30154118 pl.(C)5 6 41904990 41904994 pl.(A)5

6 30154228 30154232 pl.(G)5 6 41905008 41905012 pl.(T)5

6 30156985 30156990 pl.(A)6 6 41905136 41905140 pl.(A)5

6 30157254 30157261 pl.(T)8 6 41908153 41908157 pl.(T)5

6 30164529 30164533 pl.(G)5 6 41908284 41908288 pl.(G)5

6 30166295 30166300 pl.(T)6 6 41908326 41908330 pl.(G)5

6 30166308 30166312 pl.(A)5 6 41909318 41909322 pl.(C)5

6 31133481 31133485 pl.(G)5 6 43738412 43738416 pl.(C)5

6 31133713 31133717 pl.(C)5 6 43738450 43738465 p4.(GACA)4

6 31138182 31138187 pl.(C)6 6 43738469 43738473 pl.(C)5

6 31138204 31138209 pl.(G)6 6 43738572 43738576 pl.(G)5

6 31138213 31138217 pl.(G)5 6 43738656 43738660 pl.(G)5

6 31138221 31138225 pl.(C)5 6 43738725 43738729 pl.(G)5

6 31138247 31138251 pl.(C)5 6 43738757 43738761 pl.(G)5

6 31138326 31138331 pl.(C)6 6 43742136 43742140 pl.(C)5

6 31138357 31138361 pl.(G)5 6 43745337 43745341 pl.(G)5

6 33286806 33286811 pl.(G)6 6 43748498 43748502 pl.(A)5

6 33286921 33286925 pl.(G)5 6 43748586 43748590 pl.(C)5

6 33286952 33286956 pl.(T)5 6 43749684 43749688 pl.(T)5

6 33287204 33287209 pl.(T)6 6 43749766 43749770 pl.(A)5

6 33287213 33287218 pl.(G)6 6 44216355 44216359 pl.(T)5

6 33287477 33287481 pl.(G)5 6 44218116 44218120 nl (A^ Chr Start End MS Chr Start End MS

6 44218855 44218859 pl.(T)5 6 117923411 117923415 pl.(C)5

6 44218872 44218876 pl.(A)5 6 135513546 135513557 p4.(AGCC)3

6 44219348 44219352 pl.(A)5 6 135516873 135516877 pl.(C)5

6 44219919 44219930 p3.(AGA)4 6 135520107 135520112 pl.(C)6

6 44220917 44220921 pl.(A)5 6 135521214 135521218 pl.(T)5

6 44221284 44221289 pl.(C)6 6 135524433 135524437 pl.(A)5

6 44221427 44221431 pl.(C)5 6 138192450 138192454 pl.(T)5

6 44221447 44221453 pl.(T)7 6 138196178 138196187 pl.(T)5(C)5

6 44221611 44221615 pl.(T)5 6 138198200 138198206 pl.(T)7

6 106534376 106534380 pl.(G)5 6 138198275 138198279 pl.(T)5

6 106534448 106534452 pl.(A)5 6 138199945 138199950 pl.(G)6

6 106536080 106536084 pl.(C)5 6 138202341 138202345 pl.(C)5

6 106543600 106543604 pl.(T)5 6 138202351 138202357 pl.(C)7

6 106552738 106552742 pl.(A)5 6 138202374 138202378 pl.(C)5

6 106552960 106552964 pl.(T)5 6 139135617 139135621 pl.(C)5

6 106553015 106553019 pl.(C)5 6 139135710 139135716 pl.(T)7

6 106553281 106553286 pl.(C)6 6 139159482 139159486 pl.(T)5

6 106553392 106553396 pl.(G)5 6 139159583 139159587 pl.(T)5

6 106553654 106553658 pl.(C)5 6 139159637 139159641 pl.(T)5

6 106553686 106553690 pl.(A)5 6 139165541 139165545 pl.(T)5

6 108985249 108985253 pl.(G)5 6 139165569 139165573 pl.(C)5

6 112390553 112390557 pl.(A)5 6 139167719 139167723 pl.(A)5

6 112390591 112390595 pl.(A)5 6 139167740 139167744 pl.(A)5

6 112390640 112390644 pl.(T)5 6 139170491 139170495 pl.(A)5

6 112390836 112390840 pl.(G)5 6 139175149 139175156 pl.(T)8

6 117609742 117609746 pl.(T)5 6 139175180 139175184 pl.(A)5

6 117609971 117609977 pl.(A)7 6 139175252 139175256 pl.(G)5

6 117622205 117622210 pl.(A)6 6 139183821 139183825 pl.(C)5

6 117641139 117641143 pl.(T)5 6 139206941 139206946 pl.(A)6

6 117642528 117642533 pl.(T)6 6 139207980 139207986 pl.(T)7

6 117647482 117647486 pl.(T)5 6 139222184 139222188 pl.(A)5

6 117647582 117647587 pl.(A)6 6 152129146 152129150 pl.(C)5

6 117650558 117650562 pl.(T)5 6 152129329 152129334 pl.(G)6

6 117650618 117650624 pl.(A)7 6 152129338 152129343 pl.(C)6

6 117658508 117658512 pl.(A)5 6 152163717 152163729 pl.(T)7(C)6

6 117662483 117662488 pl.(A)6 6 152201837 152201841 pl.(A)5

6 117665251 117665255 pl.(T)5 6 152265517 152265521 pl.(C)5

6 117674324 117674328 pl.(T)5 6 152415641 152415652 p3.(GCA)4

6 117674338 117674342 pl.(A)5 6 152420068 152420072 pl.(G)5

6 117678986 117678990 pl.(A)5 6 159188461 159188466 pl.(G)6

6 117679149 117679153 pl.(A)5 6 159188471 159188475 pl.(G)5

6 117681120 117681126 pl.(A)7 6 159188477 159188481 pl.(G)5

6 117681183 117681189 pl.(A)7 6 159191877 159191886 p2.(TC)5

6 117686799 117686803 pl.(G)5 6 159197474 159197478 pl.(T)5

6 117704481 117704485 pl.(T)5 6 159197545 159197549 pl.(A)5

6 117704674 117704679 pl.(A)6 6 159204621 159204626 pl.(T)6

6 117706969 117706973 pl.(A)5 6 159206452 159206457 pl.(G)6

6 117717435 117717439 pl.(A)5 6 159208242 159208253 p2.(GA)6

6 117718143 117718147 pl.(T)5 6 159210326 159210330 pl.(A)5

6 117718150 117718154 pl.(T)5 6 159210407 159210411 pl.(A)5

6 117725598 117725603 pl.(A)6 6 167417867 167417871 pl.(A)5

6 117746838 117746842 pl.(T)5 6 167424351 167424355 pl.(A)5

6 117884426 117884431 pl.(T)6 6 167435989 167435993 pl.(A)5

6 117888010 117888014 pl.(T)5 6 167438322 167438327 pl.(C)6

6 117896328 117896333 pl.(T)6 6 167438330 167438334 pl.(A)5

6 117896482 117896487 pl.(T)6 6 167446136 167446140 pl.(A)5

6 117896489 117896494 pl.(T)6 6 167453520 167453531 pl.(T)12

6 117896524 117896528 pl.(T)5 6 167453584 167453588 pl.(A)5

6 117923382 117923386 pl.(C)5 6 167453600 167453605 pl.(T)6

6 117923402 117923406 pl.(C)5 6 168227739 168227743 nl ίΓ« Chr Start End MS Chr Start End MS

6 168275999 168276007 pl.(T)9 7 27204573 27204577 pl.(T)5

6 168276119 168276123 pl.(A)5 7 27204771 27204782 p3.(CGC)4

6 168281031 168281036 pl.(T)6 7 27204794 27204798 pl.(G)5

6 168281163 168281167 pl.(A)5 7 27222386 27222391 pl.(C)6

6 168289886 168289892 pl.(T)7 7 27222462 27222470 pl.(T)9

6 168289954 168289965 p3.(TGA)4 7 27222626 27222630 pl.(T)5

6 168299094 168299098 pl.(A)5 7 27224255 27224259 pl.(G)5

6 168311975 168311979 pl.(T)5 7 27224333 27224337 pl.(A)5

6 168315411 168315415 pl.(A)5 7 27224404 27224408 pl.(G)5

6 168319589 168319593 pl.(T)5 7 27224538 27224542 pl.(G)5

6 168325729 168325734 pl.(A)6 7 27237806 27237810 pl.(T)5

6 168343797 168343801 pl.(T)5 7 27237847 27237852 pl.(T)6

6 168344722 168344726 pl.(C)5 7 27238018 27238022 pl.(C)5

6 168347542 168347546 pl.(A)5 7 27238918 27238922 pl.(C)5

6 168348628 168348639 p4.(TGAT)3 7 27239082 27239099 p3.(GGC)6

6 168351857 168351861 pl.(T)5 7 27239299 27239316 p3.(GCG)6

6 168352157 168352161 pl.(C)5 7 27239356 27239360 pl.(G)5

6 168352226 168352230 pl.(C)5 7 27239370 27239374 pl.(G)5

6 168352576 168352580 pl.(G)5 7 27239470 27239481 p3.(GCC)4

6 168352590 168352594 pl.(C)5 7 27239494 27239498 pl.(C)5

6 168352796 168352807 p3.(GAG)4 7 27239519 27239523 pl.(G)5

6 168352873 168352878 pl.(G)6 7 27239527 27239531 pl.(C)5

7 2956939 2956943 pl.(A)5 7 27239533 27239537 pl.(C)5

7 2956965 2956969 pl.(G)5 7 27239575 27239586 p3.(GCC)4

7 2956977 2956981 pl.(G)5 7 27239669 27239673 pl.(G)5

7 2959196 2959200 pl.(C)5 7 27872456 27872460 pl.(G)5

7 2962854 2962859 pl.(C)6 7 27880327 27880331 pl.(T)5

7 2963941 2963955 p3.(GGA)5 7 27934870 27934874 pl.(G)5

7 2968283 2968287 pl.(G)5 7 27934891 27934896 pl.(G)6

7 2968323 2968329 pl.(G)7 7 27934922 27934926 pl.(G)5

7 2972200 2972204 pl.(G)5 7 28031575 28031579 pl.(T)5

7 2979408 2979412 pl.(T)5 7 28031608 28031612 pl.(A)5

7 6029421 6029425 pl.(T)5 7 28220144 28220148 pl.(C)5

7 6029594 6029599 pl.(A)6 7 28220213 28220218 pl.(C)6

7 6035199 6035203 pl.(A)5 7 28220249 28220264 p4.(GAGG)4

7 6035204 6035215 p4.(CTGT)3 7 41729229 41729233 pl.(C)5

7 6038913 6038918 pl.(A)6 7 41729291 41729295 pl.(T)5

7 6042170 6042174 pl.(G)5 7 41729717 41729721 pl.(T)5

7 6042177 6042181 pl.(G)5 7 41729727 41729731 pl.(C)5

7 6043349 6043354 pl.(C)6 7 41729741 41729752 p3.(TTC)4

7 6431651 6431655 pl.(C)5 7 41729902 41729906 pl.(T)5

7 6439748 6439752 pl.(T)5 7 41729931 41729935 pl.(C)5

7 13935462 13935466 pl.(A)5 7 41739874 41739878 pl.(G)5

7 13935520 13935524 pl.(G)5 7 41739907 41739911 pl.(G)5

7 13935534 13935538 pl.(C)5 7 50367244 50367249 pl.(C)6

7 13940436 13940440 pl.(T)5 7 50467731 50467735 pl.(G)5

7 13946143 13946147 pl.(A)5 7 50467765 50467769 pl.(C)5

7 13971174 13971178 pl.(G)5 7 50468338 50468342 pl.(C)5

7 13975473 13975479 pl.(G)7 7 55086911 55086915 pl.(C)5

7 13978876 13978881 pl.(A)6 7 55209967 55209971 pl.(T)5

7 26232161 26232165 pl.(C)5 7 55220231 55220235 pl.(T)5

7 26232885 26232890 pl.(C)6 7 55220290 55220294 pl.(C)5

7 26232999 26233004 pl.(A)6 7 55220336 55220340 pl.(C)5

7 26233227 26233231 pl.(C)5 7 55221748 55221753 pl.(C)6

7 26236287 26236291 pl.(A)5 7 55224297 55224301 pl.(A)5

7 26236526 26236530 pl.(T)5 7 55224349 55224353 pl.(G)5

7 26237027 26237031 pl.(A)5 7 55225358 55225362 pl.(T)5

7 27203196 27203201 pl.(T)6 7 55227932 55227936 pl.(A)5

7 27203415 27203419 pl.(T)5 7 55227965 55227970 pl.(A)6

7 27204507 27204512 pl.(G)6 7 55229225 55229229 nl ίΓ« Chr Start End MS Chr Start End MS

7 55233014 55233018 pl.(C)5 7 91603014 91603019 pl.(T)6

7 55240709 55240713 pl.(G)5 7 91603085 91603092 pl.(A)8

7 55241605 55241611 pl.(C)7 7 91603096 91603100 pl.(A)5

7 55241689 55241693 pl.(A)5 7 91621461 91621465 pl.(T)5

7 55248972 55248983 p4.(CTCC)3 7 91625049 91625053 pl.(A)5

7 55249015 55249019 pl.(C)5 7 91643633 91643638 pl.(T)6

7 55268082 55268086 pl.(C)5 7 91651624 91651628 pl.(T)5

7 55268880 55268884 pl.(G)5 7 91652170 91652175 pl.(A)6

7 55269420 55269424 pl.(T)5 7 91659279 91659283 pl.(A)5

7 55273058 55273062 pl.(C)5 7 91659314 91659318 pl.(T)5

7 66453434 66453439 pl.(T)6 7 91667790 91667794 pl.(G)5

7 66458407 66458413 pl.(A)7 7 91671392 91671403 p2.(AG)6

7 66459254 66459258 pl.(T)5 7 91682235 91682239 pl.(A)5

7 66460264 66460268 pl.(G)5 7 91691612 91691617 pl.(A)6

7 66460304 66460308 pl.(T)5 7 91691621 91691625 pl.(T)5

7 66460387 66460391 pl.(G)5 7 91691642 91691647 pl.(A)6

7 73450875 73450880 pl.(C)6 7 91699372 91699377 pl.(A)6

7 73456975 73456979 pl.(G)5 7 91706997 91707001 pl.(T)5

7 73459542 73459546 pl.(C)5 7 91707110 91707114 pl.(A)5

7 73459571 73459575 pl.(G)5 7 91708403 91708409 pl.(A)7

7 73461040 73461044 pl.(G)5 7 91708517 91708521 pl.(A)5

7 73461083 73461087 pl.(C)5 7 91708684 91708688 pl.(A)5

7 73462826 73462830 pl.(C)5 7 91709093 91709097 pl.(A)5

7 73462840 73462844 pl.(C)5 7 91709321 91709325 pl.(A)5

7 73462847 73462858 p3.(GCA)4 7 91709345 91709351 pl.(A)7

7 73470654 73470658 pl.(G)5 7 91709360 91709364 pl.(A)5

7 73472033 73472037 pl.(C)5 7 91709410 91709415 pl.(A)6

7 73477649 73477660 p3.(CCG)4 7 91709425 91709439 p5.(AAAGA)3

7 73478013 73478017 pl.(G)5 7 91711875 91711880 pl.(T)6

7 73480300 73480304 pl.(G)5 7 91711954 91711958 pl.(A)5

7 75167499 75167503 pl.(T)5 7 91712575 91712579 pl.(A)5

7 75168684 75168688 pl.(T)5 7 91712607 91712611 pl.(A)5

7 75168704 75168708 pl.(T)5 7 91712721 91712725 pl.(A)5

7 75177117 75177121 pl.(A)5 7 91712800 91712805 pl.(A)6

7 75178254 75178258 pl.(C)5 7 91712978 91712982 pl.(T)5

7 75184819 75184823 pl.(T)5 7 91724401 91724406 pl.(A)6

7 75184858 75184862 pl.(A)5 7 91726097 91726102 pl.(A)6

7 75187006 75187011 pl.(T)6 7 91726334 91726338 pl.(A)5

7 75189224 75189229 pl.(G)6 7 91726373 91726377 pl.(A)5

7 75192296 75192300 pl.(G)5 7 91726415 91726419 pl.(A)5

7 75192503 75192507 pl.(G)5 7 91726480 91726486 pl.(A)7

7 75221837 75221843 pl.(G)7 7 91726628 91726632 pl.(A)5

7 75228512 75228516 pl.(T)5 7 91727411 91727415 pl.(T)5

7 75228569 75228573 pl.(A)5 7 91727536 91727540 pl.(T)5

7 75368106 75368110 pl.(C)5 7 91728992 91728996 pl.(T)5

7 81331966 81331970 pl.(A)5 7 91732039 91732045 pl.(G)7

7 81332070 81332074 pl.(C)5 7 91734984 91734989 pl.(T)6

7 81334699 81334703 pl.(T)5 7 91734999 91735003 pl.(T)5

7 81336593 81336597 pl.(A)5 7 92244391 92244395 pl.(G)5

7 81336686 81336690 pl.(A)5 7 92247376 92247380 pl.(A)5

7 81350139 81350143 pl.(T)5 7 92300790 92300794 pl.(G)5

7 81359104 81359109 pl.(A)6 7 92404153 92404158 pl.(A)6

7 81381504 81381508 pl.(C)5 7 98478770 98478774 pl.(A)5

7 81381573 81381577 pl.(A)5 7 98478794 98478798 pl.(G)5

7 81388045 81388050 pl.(T)6 7 98478828 98478832 pl.(A)5

7 81388108 81388112 pl.(A)5 7 98488076 98488082 pl.(A)7

7 81388124 81388130 pl.(A)7 7 98490033 98490038 pl.(T)6

7 81392088 81392093 pl.(T)6 7 98490115 98490120 pl.(A)6

7 81392096 81392100 pl.(T)5 7 98490143 98490147 pl.(T)5

7 81392145 81392150 pl.(T)6 7 98491411 98491418 ni mx Chr Start End MS Chr Start End MS

7 98493378 98493384 pl.(T)7 7 116340050 116340055 pl.(A)6

7 98493449 98493453 pl.(T)5 7 116340276 116340280 pl.(A)5

7 98495412 98495416 pl.(C)5 7 116340302 116340306 pl.(T)5

7 98498314 98498318 pl.(T)5 7 116397479 116397486 pl.(T)8

7 98507728 98507732 pl.(T)5 7 116397808 116397812 pl.(A)5

7 98507853 98507857 pl.(C)5 7 116397823 116397827 pl.(A)5

7 98507859 98507863 pl.(C)5 7 116398499 116398506 pl.(T)8

7 98507865 98507869 pl.(C)5 7 116399473 116399477 pl.(A)5

7 98507893 98507897 pl.(C)5 7 116403178 116403182 pl.(C)5

7 98508876 98508881 pl.(A)6 7 116403197 116403201 pl.(T)5

7 98515033 98515037 pl.(C)5 7 116409676 116409690 pl.(T)15

7 98524998 98525002 pl.(G)5 7 116411545 116411549 pl.(T)5

7 98528336 98528341 pl.(G)6 7 116411672 116411676 pl.(T)5

7 98530881 98530886 pl.(C)6 7 116411687 116411691 pl.(A)5

7 98531029 98531034 pl.(G)6 7 116411714 116411718 pl.(T)5

7 98535262 98535267 pl.(T)6 7 116415001 116415005 pl.(C)5

7 98535273 98535277 pl.(T)5 7 116422111 116422115 pl.(A)5

7 98540560 98540564 pl.(T)5 7 116423366 116423370 pl.(A)5

7 98540617 98540621 pl.(G)5 7 116435929 116435933 pl.(T)5

7 98545875 98545879 pl.(T)5 7 124462469 124462473 pl.(A)5

7 98547042 98547047 pl.(T)6 7 124462616 124462621 pl.(A)6

7 98547123 98547128 pl.(G)6 7 124475297 124475326 p5.(AAACA)6

7 98547301 98547305 pl.(A)5 7 124481074 124481078 pl.(T)5

7 98547796 98547800 pl.(A)5 7 124481106 124481110 pl.(T)5

7 98548487 98548494 pl.(T)8 7 124481113 124481117 pl.(T)5

7 98548546 98548550 pl.(G)5 7 124481129 124481133 pl.(T)5

7 98550875 98550880 pl.(C)6 7 124481193 124481197 pl.(A)5

7 98552722 98552726 pl.(T)5 7 124482959 124482963 pl.(T)5

7 98554014 98554018 pl.(T)5 7 124493026 124493030 pl.(T)5

7 98563430 98563434 pl.(A)5 7 124493195 124493200 pl.(A)6

7 98564719 98564723 pl.(A)5 7 124503391 124503396 pl.(A)6

7 98564757 98564761 pl.(T)5 7 124503678 124503682 pl.(T)5

7 98565202 98565206 pl.(T)5 7 124510996 124511000 pl.(T)5

7 98565212 98565216 pl.(T)5 7 124532340 124532344 pl.(G)5

7 98567763 98567767 pl.(C)5 7 124532410 124532419 p2.(TA)5

7 98575825 98575831 pl.(T)7 7 128828933 128828938 pl.(G)6

7 98575870 98575875 pl.(A)6 7 128828954 128828958 pl.(G)5

7 98581816 98581820 pl.(A)5 7 128829015 128829019 pl.(G)5

7 98581964 98581968 pl.(A)5 7 128829040 128829060 p3.(GCT)7

7 98582553 98582560 pl.(T)8 7 128829061 128829065 pl.(G)5

7 98588108 98588112 pl.(A)5 7 128829075 128829080 pl.(G)6

7 98592295 98592300 pl.(C)6 7 128829195 128829199 pl.(C)5

7 98601805 98601809 pl.(T)5 7 128843218 128843222 pl.(C)5

7 98601869 98601873 pl.(A)5 7 128843237 128843242 pl.(C)6

7 98602962 98602966 pl.(T)5 7 128845540 128845551 p4.(TGGC)3

7 98609745 98609751 pl.(A)7 7 128849133 128849137 pl.(T)5

7 106508725 106508729 pl.(C)5 7 128851867 128851871 pl.(C)5

7 106508868 106508872 pl.(A)5 7 128851990 128851994 pl.(C)5

7 106509148 106509152 pl.(T)5 7 128852004 128852009 pl.(C)6

7 106509352 106509356 pl.(C)5 7 128852018 128852022 pl.(C)5

7 106513176 106513180 pl.(T)5 7 128852155 128852159 pl.(C)5

7 106513324 106513328 pl.(A)5 7 128852189 128852193 pl.(C)5

7 106519968 106519972 pl.(A)5 7 137565203 137565207 pl.(G)5

7 106519994 106519999 pl.(A)6 7 137567290 137567295 pl.(C)6

7 106523586 106523590 pl.(A)5 7 137567332 137567336 pl.(G)5

7 106545698 106545702 pl.(A)5 7 137588705 137588709 pl.(T)5

7 106545716 106545720 pl.(A)5 7 137593037 137593041 pl.(G)5

7 106545850 106545854 pl.(A)5 7 137593187 137593192 pl.(A)6

7 116339146 116339150 pl.(C)5 7 137600671 137600675 pl.(G)5

7 116339820 116339824 pl.(T)5 7 137600766 137600771 nl (A Chr Start End MS Chr Start End MS

7 138522806 138522810 pl.(G)5 7 148515090 148515094 pl.(G)5

7 138522909 138522913 pl.(A)5 7 148523667 148523671 pl.(G)5

7 138524926 138524931 pl.(C)6 7 148524312 148524316 pl.(A)5

7 138529070 138529074 pl.(C)5 7 148525889 148525900 p3.(CAT)4

7 138529172 138529176 pl.(G)5 7 148525944 148525948 pl.(A)5

7 138545927 138545931 pl.(C)5 7 148526849 148526854 pl.(T)6

7 138546032 138546036 pl.(G)5 7 148526948 148526954 pl.(A)7

7 138552754 138552759 pl.(G)6 7 148543694 148543704 pl.(A)l l

7 138552883 138552887 pl.(A)5 7 151836879 151836886 pl.(A)8

7 138556027 138556032 pl.(G)6 7 151843775 151843780 pl.(T)6

7 138591757 138591761 pl.(A)5 7 151845524 151845529 pl.(A)6

7 138601643 138601648 pl.(G)6 7 151845959 151845964 pl (T)6

7 138601804 138601808 pl.(G)5 7 151846107 151846111 pl (G)5

7 138602056 138602061 pl.(G)6 7 151846132 151846136 pl.(G)5

7 138602382 138602386 pl.(A)5 7 151847998 151848002 pl.(T)5

7 138602401 138602405 pl.(G)5 7 151851236 151851240 pl.(A)5

7 138602480 138602484 pl.(G)5 7 151851386 151851390 pl.(G)5

7 138602492 138602496 pl.(A)5 7 151851534 151851539 pl.(A)6

7 138602538 138602542 pl.(A)5 7 151853400 151853404 pl.(G)5

7 138602605 138602609 pl.(A)5 7 151856009 151856013 pl.(T)5

7 138602642 138602646 pl.(T)5 7 151856100 151856104 pl.(T)5

7 138602699 138602703 pl.(A)5 7 151856145 151856149 pl.(C)5

7 138602804 138602808 pl.(G)5 7 151859283 151859287 pl.(T)5

7 138603456 138603460 pl.(C)5 7 151859308 151859312 pl (T)5

7 138603524 138603530 pl.(A)7 7 151859314 151859318 pl (T)5

7 138604003 138604008 pl.(A)6 7 151859851 151859855 pl.(T)5

7 140434422 140434426 pl.(C)5 7 151859859 151859863 pl.(T)5

7 140434441 140434445 pl.(T)5 7 151860074 151860078 pl.(A)5

7 140434528 140434532 pl.(T)5 7 151860578 151860582 pl.(T)5

7 140434575 140434585 pl.(A)ll 7 151860601 151860605 pl.(G)5

7 140439643 140439647 pl.(T)5 7 151864470 151864474 pl.(A)5

7 140439738 140439742 pl.(A)5 7 151873588 151873593 pl.(A)6

7 140449187 140449191 pl.(T)5 7 151873715 151873726 p3.(TGG)4

7 140453161 140453165 pl.(T)5 7 151874013 151874019 pl.(T)7

7 140454037 140454041 pl.(A)5 7 151874068 151874072 pl (T)5

7 140477809 140477813 pl.(T)5 7 151874093 151874098 pl (T)6

7 140481500 140481504 pl.(A)5 7 151874148 151874156 pl.(T)9

7 140482927 140482933 pl.(G)7 7 151874419 151874423 pl.(C)5

7 140494272 140494276 pl.(A)5 7 151874474 151874478 pl.(T)5

7 140501344 140501348 pl.(A)5 7 151874914 151874918 pl.(A)5

7 140501351 140501355 pl.(T)5 7 151875101 151875127 pl.(A)27

7 140507866 140507870 pl.(A)5 7 151877054 151877058 pl.(G)5

7 140534451 140534455 pl.(T)5 7 151878109 151878113 pl.(G)5

7 140534499 140534503 pl.(A)5 7 151878541 151878545 pl.(G)5

7 140534585 140534589 pl.(A)5 7 151878596 151878600 pl.(A)5

7 140550015 140550020 pl.(A)6 7 151878689 151878693 pl.(A)5

7 140624550 140624554 pl.(G)5 7 151879202 151879206 pl.(A)5

7 148504717 148504722 pl.(G)6 7 151879244 151879248 pl (T)5

7 148506171 148506176 pl.(A)6 7 151879594 151879608 p3.(TGC)5

7 148506210 148506214 pl.(A)5 7 151879612 151879616 pl.(T)5

7 148507509 148507513 pl.(A)5 7 151880046 151880050 pl.(A)5

7 148508745 148508749 pl.(T)5 7 151880116 151880120 pl.(A)5

7 148508768 148508772 pl.(A)5 7 151880236 151880240 pl.(T)5

7 148508774 148508778 pl.(C)5 7 151884553 151884557 pl.(T)5

7 148511052 148511056 pl.(T)5 7 151884567 151884572 pl.(A)6

7 148511094 148511098 pl.(T)5 7 151884924 151884928 pl.(A)5

7 148512036 148512040 pl.(A)5 7 151884941 151884947 pl.(A)7

7 148513791 148513795 pl.(T)5 7 151891126 151891130 pl.(G)5

7 148514998 148515009 p3.(TCT)4 7 151900053 151900057 pl (T)5

7 148515025 148515030 pl.(C)6 7 151900060 151900064 ni ms Chr Start End MS Chr Start End MS

7 151900081 151900086 pl.(T)6 8 37553556 37553567 p3.(GCG)4

7 151902317 151902322 pl.(A)6 8 37553617 37553621 pl.(C)5

7 151945668 151945672 pl.(T)5 8 37554758 37554769 p3.(GGC)4

7 151948058 151948063 pl.(A)6 8 37554848 37554852 pl.(G)5

7 152009035 152009049 p5.(AAAAT)3 8 37555026 37555030 pl.(C)5

7 152012386 152012391 pl.(T)6 8 37555283 37555287 pl.(G)5

7 152012404 152012408 pl.(A)5 8 37555461 37555465 pl.(G)5

7 152012429 152012433 pl.(A)5 8 37555488 37555493 pl.(C)6

7 152132815 152132820 pl.(G)6 8 37555652 37555657 pl.(G)6

7 152132914 152132919 pl.(G)6 8 37556087 37556092 pl.(G)6

7 156798245 156798249 pl.(G)5 8 37654927 37654931 pl.(G)5

7 156798464 156798468 pl.(C)5 8 37686460 37686464 pl.(G)5

7 156798518 156798522 pl.(T)5 8 37688229 37688233 pl.(G)5

7 156802527 156802541 p3.(GCC)5 8 37688289 37688293 pl.(G)5

7 156802899 156802913 p3.(CCG)5 8 37690520 37690525 pl.(C)6

7 156802932 156802943 p3.(GCG)4 8 37690604 37690608 pl.(G)5

7 156802992 156802997 pl.(G)6 8 37691326 37691330 pl.(T)5

7 156803028 156803032 pl.(T)5 8 37691477 37691482 pl.(C)6

7 156803036 156803040 pl.(T)5 8 37691605 37691611 pl.(G)7

7 156803134 156803138 pl.(G)5 8 37691622 37691626 pl.(C)5

8 17796333 17796337 pl.(T)5 8 37691652 37691656 pl.(G)5

8 17796383 17796388 pl.(C)6 8 37692771 37692782 p4.(GGAG)3

8 17813153 17813157 pl.(A)5 8 37692820 37692825 pl.(C)6

8 17815108 17815119 p3.(GAG)4 8 37692839 37692843 pl.(C)5

8 17817883 17817894 p4.(AAGA)3 8 37693064 37693069 pl.(C)6

8 17819536 17819540 pl.(T)5 8 37693102 37693106 pl.(C)5

8 17819576 17819581 pl.(A)6 8 37693141 37693145 pl.(C)5

8 17819646 17819650 pl.(T)5 8 37693150 37693154 pl.(C)5

8 17820599 17820606 pl.(A)8 8 37693265 37693269 pl.(C)5

8 17822270 17822274 pl.(A)5 8 37695362 37695366 pl.(G)5

8 17823526 17823530 pl.(T)5 8 37696500 37696505 pl.(G)6

8 17824539 17824543 pl.(A)5 8 37697098 37697103 pl.(G)6

8 17827126 17827130 pl.(T)5 8 37697732 37697736 pl.(C)5

8 17827189 17827193 pl.(A)5 8 37698805 37698809 pl.(C)5

8 17842969 17842973 pl.(T)5 8 37698869 37698873 pl.(C)5

8 17849217 17849221 pl.(T)5 8 37699108 37699113 pl.(C)6

8 17868733 17868737 pl.(T)5 8 37699128 37699133 pl.(C)6

8 17868806 17868810 pl.(A)5 8 37699472 37699476 pl.(G)5

8 30916688 30916692 pl.(T)5 8 37699483 37699487 pl.(G)5

8 30938371 30938380 pl.(T)10 8 37699770 37699774 pl.(C)5

8 30938519 30938523 pl.(G)5 8 37699777 37699782 pl.(G)6

8 30958354 30958360 pl.(T)7 8 38178597 38178601 pl.(T)5

8 30958410 30958414 pl.(G)5 8 38184339 38184343 pl.(C)5

8 30969265 30969269 pl.(A)5 8 38186882 38186887 pl.(A)6

8 30973859 30973863 pl.(T)5 8 38187222 38187228 pl.(T)7

8 30973918 30973922 pl.(A)5 8 38187254 38187259 pl.(T)6

8 30982106 30982110 pl.(A)5 8 38187416 38187421 pl.(A)6

8 30989870 30989874 pl.(T)5 8 38189039 38189043 pl.(T)5

8 30989979 30989983 pl.(A)5 8 38189075 38189080 pl.(A)6

8 30999029 30999033 pl.(T)5 8 38189112 38189116 pl.(A)5

8 30999111 30999115 pl.(A)5 8 38196090 38196094 pl.(T)5

8 30999297 30999301 pl.(T)5 8 38205092 38205098 pl.(T)7

8 31001132 31001138 pl.(A)7 8 38205221 38205225 pl.(T)5

8 31004868 31004873 pl.(T)6 8 38205309 38205313 pl.(T)5

8 31004940 31004944 pl.(C)5 8 38271281 38271285 pl.(G)5

8 31007878 31007882 pl.(A)5 8 38272307 38272311 pl.(T)5

8 31014961 31014965 pl.(C)5 8 38273506 38273510 pl.(G)5

8 31030608 31030612 pl.(T)5 8 38274839 38274843 pl.(C)5

8 37553456 37553460 pl.(C)5 8 38275515 38275519 pl.(G)5

8 37553471 37553477 pl.(C)7 8 38285482 38285486 ni ms Chr Start End MS Chr Start End MS

8 38285914 38285931 p3.(TCA)6 8 48743276 48743280 pl.(T)5

8 41789699 41789703 pl.(T)5 8 48744384 48744388 pl.(T)5

8 41790037 41790041 pl.(C)5 8 48746799 48746805 pl.(T)7

8 41790297 41790301 pl.(G)5 8 48749870 48749874 pl.(A)5

8 41790636 41790640 pl.(G)5 8 48752732 48752736 pl.(T)5

8 41790654 41790658 pl.(G)5 8 48762068 48762072 pl.(A)5

8 41790660 41790664 pl.(G)5 8 48765235 48765240 pl.(T)6

8 41790747 41790758 p3.(GGC)4 8 48767862 48767866 pl.(T)5

8 41790787 41790798 p3.(GCT)4 8 48767931 48767935 pl.(C)5

8 41791683 41791688 pl.(A)6 8 48773510 48773514 pl.(T)5

8 41791749 41791753 pl.(T)5 8 48773512 48773523 p4.(TTTC)3

8 41792054 41792065 p3.(CTC)4 8 48774943 48774947 pl.(T)5

8 41792289 41792293 pl.(T)5 8 48776024 48776028 pl.(T)5

8 41792295 41792299 pl.(T)5 8 48776143 48776147 pl.(A)5

8 41798420 41798434 p3.(CTC)5 8 48777257 48777261 pl.(G)5

8 41798569 41798573 pl.(C)5 8 48790417 48790422 pl.(A)6

8 41798776 41798780 pl.(T)5 8 48792053 48792057 pl.(T)5

8 41798792 41798796 pl.(C)5 8 48794481 48794485 pl.(T)5

8 41800494 41800498 pl.(T)5 8 48798560 48798564 pl.(T)5

8 41805325 41805330 pl.(A)6 8 48798714 48798718 pl.(A)5

8 41812907 41812911 pl.(G)5 8 48800098 48800102 pl.(T)5

8 41832291 41832295 pl.(A)5 8 48805809 48805813 pl.(C)5

8 41832349 41832355 pl.(A)7 8 48805866 48805871 pl.(C)6

8 41834604 41834609 pl.(C)6 8 48805952 48805956 pl.(A)5

8 41834638 41834643 pl.(A)6 8 48815313 48815317 pl.(A)5

8 41834752 41834763 p3.(TGA)4 8 48825049 48825053 pl.(C)5

8 41834787 41834791 pl.(T)5 8 48827899 48827903 pl.(T)5

8 41836184 41836189 pl.(T)6 8 48839881 48839885 pl.(G)5

8 41836258 41836263 pl.(T)6 8 48841643 48841647 pl.(A)5

8 41836300 41836306 pl.(A)7 8 48842539 48842544 pl.(A)6

8 41838453 41838458 pl.(A)6 8 48842577 48842581 pl.(A)5

8 41839361 41839365 pl.(T)5 8 48843263 48843267 pl.(A)5

8 41845090 41845094 pl.(A)5 8 48845567 48845571 pl.(A)5

8 41906122 41906127 pl.(A)6 8 48845704 48845708 pl.(A)5

8 41906431 41906435 pl.(T)5 8 48848382 48848386 pl.(T)5

8 41906439 41906444 pl.(T)6 8 48852117 48852121 pl.(A)5

8 42752338 42752342 pl.(G)5 8 48852217 48852221 pl.(T)5

8 42761301 42761307 pl.(T)7 8 48852235 48852239 pl.(T)5

8 42780781 42780785 pl.(T)5 8 48855805 48855810 pl.(T)6

8 42821759 42821763 pl.(A)5 8 54900673 54900677 pl.(C)5

8 42823205 42823209 pl.(A)5 8 54912512 54912517 pl.(T)6

8 42829340 42829344 pl.(A)5 8 57078932 57078937 pl.(G)6

8 42841866 42841871 pl.(A)6 8 57079050 57079054 pl.(A)5

8 42873516 42873520 pl.(A)5 8 57079074 57079078 pl.(G)5

8 48686943 48686950 pl.(A)8 8 57079242 57079246 pl.(C)5

8 48689394 48689398 pl.(A)5 8 57079261 57079265 pl.(T)5

8 48689466 48689470 pl.(G)5 8 57079754 57079760 pl.(T)7

8 48689477 48689483 pl.(T)7 8 57080731 57080736 pl.(T)6

8 48689518 48689523 pl.(T)6 8 57129070 57129074 pl.(A)5

8 48691608 48691612 pl.(T)5 8 71036967 71036971 pl.(G)5

8 48695164 48695168 pl.(A)5 8 71037104 71037114 pl.(A)l l

8 48697751 48697755 pl.(G)5 8 71050537 71050542 pl.(C)6

8 48697773 48697777 pl.(T)5 8 71068308 71068312 pl.(G)5

8 48713514 48713518 pl.(T)5 8 71068744 71068748 pl.(G)5

8 48715987 48715991 pl.(T)5 8 71068882 71068886 pl.(G)5

8 48730125 48730129 pl.(A)5 8 71068925 71068929 pl.(T)5

8 48734202 48734207 pl.(G)6 8 71069263 71069267 pl.(C)5

8 48734296 48734300 pl.(A)5 8 71069457 71069466 p2.(CA)5

8 48736512 48736516 pl.(A)5 8 71071846 71071850 pl.(A)5

8 48743156 48743160 pl.(A)5 8 71078980 71078984 nl ίΓ« Chr Start End MS Chr Start End MS

8 71082457 71082461 pl.(T)5 8 103291370 103291374 pl.(A)5

8 71126235 71126239 pl.(A)5 8 103291445 103291449 pl.(A)5

8 71126289 71126293 pl.(T)5 8 103292700 103292704 pl.(A)5

8 80677425 80677429 pl.(A)5 8 103293591 103293595 pl.(A)5

8 80677444 80677448 pl.(C)5 8 103298018 103298022 pl.(A)5

8 80677640 80677644 pl.(G)5 8 103298852 103298856 pl.(T)5

8 80677795 80677799 pl.(C)5 8 103299795 103299800 pl.(A)6

8 80678947 80678951 pl.(T)5 8 103306080 103306084 pl.(A)5

8 80679465 80679469 pl.(T)5 8 103306183 103306187 pl.(T)5

8 80679910 80679914 pl.(G)5 8 103306189 103306193 pl.(T)5

8 90947779 90947783 pl.(T)5 8 103306224 103306228 pl.(A)5

8 90947794 90947798 pl.(T)5 8 103306348 103306353 pl.(A)6

8 90947821 90947825 pl.(T)5 8 103307567 103307571 pl.(A)5

8 90958369 90958373 pl.(T)5 8 103307657 103307661 pl.(T)5

8 90958387 90958392 pl.(T)6 8 103309812 103309816 pl.(T)5

8 90958441 90958445 pl.(T)5 8 103309837 103309842 pl.(A)6

8 90958480 90958485 pl.(T)6 8 103311747 103311751 pl.(G)5

8 90965543 90965547 pl.(T)5 8 103312263 103312267 pl.(G)5

8 90965571 90965575 pl.(T)5 8 103312274 103312279 pl.(G)6

8 90965666 90965672 pl.(T)7 8 103323558 103323562 pl.(T)5

8 90965716 90965720 pl.(T)5 8 103324395 103324400 pl.(T)6

8 90965809 90965813 pl.(T)5 8 103324415 103324419 pl.(T)5

8 90967501 90967505 pl.(A)5 8 103326065 103326069 pl.(A)5

8 90967512 90967518 pl.(T)7 8 103335562 103335566 pl.(T)5

8 90967555 90967566 p3.(CTG)4 8 103335572 103335576 pl.(T)5

8 90967732 90967736 pl.(T)5 8 103338829 103338833 pl.(T)5

8 90967790 90967794 pl.(A)5 8 103338835 103338840 pl.(T)6

8 90971024 90971028 pl.(T)5 8 103338900 103338905 pl.(A)6

8 90982697 90982701 pl.(A)5 8 103341394 103341398 pl.(A)5

8 90982788 90982792 pl.(A)5 8 103354687 103354692 pl.(T)6

8 90983414 90983418 pl.(A)5 8 103358631 103358636 pl.(A)6

8 90983477 90983481 pl.(T)5 8 103372393 103372397 pl.(C)5

8 90983514 90983518 pl.(A)5 8 103372421 103372425 pl.(G)5

8 90983523 90983527 pl.(A)5 8 103424497 103424501 pl.(C)5

8 90995032 90995036 pl.(T)5 8 103424517 103424522 pl.(C)6

8 92998419 92998425 pl.(T)7 8 117859821 117859825 pl.(T)5

8 92998520 92998525 pl.(T)6 8 117861249 117861253 pl.(C)5

8 92999205 92999209 pl.(A)5 8 117861275 117861279 pl.(A)5

8 93004123 93004133 pl.(G)5(A)6 8 117862878 117862882 pl.(T)5

8 93026928 93026932 pl.(G)5 8 117862902 117862906 pl.(T)5

8 93027002 93027006 pl.(G)5 8 117862960 117862964 pl.(G)5

8 93029501 93029505 pl.(G)5 8 117864899 117864903 pl.(T)5

8 100899849 100899853 pl.(A)5 8 117864953 117864966 pl.(A)14

8 100904153 100904157 pl.(C)5 8 117866532 117866536 pl.(T)5

8 103266520 103266524 pl.(T)5 8 117868962 117868966 pl.(G)5

8 103271320 103271325 pl.(T)6 8 118811931 118811935 pl.(C)5

8 103273493 103273497 pl.(A)5 8 118817137 118817141 pl.(A)5

8 103274272 103274278 pl.(A)7 8 118831983 118831988 pl.(G)6

8 103274301 103274306 pl.(A)6 8 118832020 118832025 pl.(G)6

8 103276789 103276793 pl.(A)5 8 118832041 118832045 pl.(A)5

8 103283437 103283446 p2.(TC)5 8 118842504 118842508 pl.(A)5

8 103284806 103284810 pl.(T)5 8 118847797 118847802 pl.(A)6

8 103284819 103284823 pl.(A)5 8 119122534 119122543 pl.(A)5(C)5

8 103284844 103284848 pl.(A)5 8 119122707 119122711 pl.(A)5

8 103289261 103289265 pl.(T)5 8 119122917 119122921 pl.(T)5

8 103289349 103289356 pl.(T)8 8 119122951 119122955 pl.(T)5

8 103289380 103289384 pl.(T)5 8 119123039 119123044 pl.(G)6

8 103289405 103289409 pl.(T)5 8 119123271 119123276 pl.(T)6

8 103291141 103291145 pl.(A)5 8 128750605 128750619 p3.(CAG)5

8 103291328 103291332 pl.(G)5 8 128750632 128750636 nl ίΓ« Chr Start End MS Chr Start End MS

8 128750884 128750888 pl.(A)5 9 14307419 14307423 pl.(T)5

8 128753004 128753009 pl.(T)6 9 15472612 15472622 pl.(A)l l

8 128753053 128753057 pl.(C)5 9 15474077 15474081 pl.(T)5

8 128753073 128753078 pl.(A)6 9 15474084 15474088 pl.(T)5

8 134251178 134251182 pl.(G)5 9 15474112 15474117 pl.(T)6

8 134251198 134251202 pl.(C)5 9 15474179 15474183 pl.(T)5

8 134266788 134266792 pl.(A)5 9 15474190 15474194 pl.(T)5

8 134269008 134269012 pl.(C)5 9 15474206 15474210 pl.(T)5

8 134270678 134270682 pl.(A)5 9 15479677 15479681 pl.(T)5

8 134274390 134274394 pl.(G)5 9 15486837 15486841 pl.(T)5

8 145736797 145736801 pl.(C)5 9 15490114 15490119 pl.(A)6

8 145737639 145737643 pl.(C)5 9 15490125 15490130 pl.(A)6

8 145737936 145737940 pl.(G)5 9 15510192 15510196 pl.(G)5

8 145738055 145738059 pl.(C)5 9 15510204 15510208 pl.(G)5

8 145738157 145738161 pl.(G)5 9 20346378 20346391 pl.(A)14

8 145738349 145738354 pl.(G)6 9 20346394 20346405 pl.(A)12

8 145738582 145738593 pl.(G)12 9 20360754 20360758 pl.(T)5

8 145738686 145738690 pl.(G)5 9 20413869 20413874 pl.(T)6

8 145738854 145738858 pl.(G)5 9 20413913 20413917 pl.(A)5

8 145739692 145739696 pl.(C)5 9 20413945 20413949 pl.(T)5

8 145739819 145739823 pl.(C)5 9 20413952 20413958 pl.(T)7

8 145741231 145741235 pl.(C)5 9 20414226 20414230 pl.(T)5

8 145741277 145741282 pl.(G)6 9 20414264 20414268 pl.(A)5

8 145741488 145741493 pl.(G)6 9 20414278 20414295 p3.(CTG)6

8 145741638 145741642 pl.(C)5 9 20414311 20414340 p3.(CTG)10

8 145741649 145741653 pl.(G)5 9 20414344 20414373 p3.(CTG)10

8 145741746 145741750 pl.(G)5 9 20620656 20620660 pl.(T)5

8 145741888 145741897 pl.(G)5(C)5 9 20620780 20620785 pl.(T)6

8 145742041 145742045 pl.(T)5 9 20622260 20622264 pl.(G)5

8 145742075 145742079 pl.(G)5 9 20622295 20622302 pl.(C)8

8 145742551 145742555 pl.(C)5 9 20622310 20622316 pl.(C)7

8 145743170 145743179 p2.(GC)5 9 21970951 21970956 pl.(C)6

9 5021975 5021979 pl.(A)5 9 21971164 21971175 p3.(AGC)4

9 5050673 5050677 pl.(T)5 9 21974721 21974725 pl.(C)5

9 5054549 5054554 pl.(T)6 9 22005991 22005995 pl.(C)5

9 5054799 5054803 pl.(T)5 9 22006203 22006214 p3.(AGC)4

9 5055780 5055784 pl.(A)5 9 22008918 22008922 pl.(C)5

9 5066768 5066773 pl.(T)6 9 22008960 22008964 pl.(C)5

9 5069060 5069065 pl.(A)6 9 35074203 35074207 pl.(G)5

9 5069193 5069197 pl.(C)5 9 35075283 35075287 pl.(T)5

9 5069916 5069921 pl.(T)6 9 35075485 35075489 pl.(T)5

9 5072526 5072530 pl.(T)5 9 35075702 35075706 pl.(A)5

9 5073682 5073691 pl.(T)10 9 35075737 35075742 pl.(G)6

9 5078342 5078346 pl.(A)5 9 35076762 35076766 pl.(C)5

9 5080279 5080283 pl.(A)5 9 35077347 35077351 pl.(G)5

9 5089745 5089750 pl.(A)6 9 36840626 36840630 pl.(G)5

9 5090509 5090513 pl.(A)5 9 36882050 36882056 pl.(G)7

9 5090759 5090763 pl.(A)5 9 37002679 37002683 pl.(G)5

9 5126454 5126462 pl.(T)9 9 37015109 37015114 pl.(T)6

9 5457072 5457076 pl.(T)5 9 37020764 37020775 pl.(A)5(C)7

9 5457160 5457164 pl.(A)5 9 80343588 80343601 pl.(A)14

9 5462974 5462985 p3.(ACC)4 9 80409491 80409495 pl.(C)5

9 5465480 5465494 p5.(GTTTT)3 9 87317312 87317316 pl.(A)5

9 5465491 5465495 pl.(T)5 9 87325715 87325719 pl.(T)5

9 5549526 5549530 pl.(C)5 9 87342556 87342560 pl.(T)5

9 5563169 5563173 pl.(A)5 9 87563493 87563497 pl.(C)5

9 14120432 14120436 pl.(T)5 9 87635213 87635217 pl.(G)5

9 14125670 14125674 pl.(G)5 9 87636217 87636221 pl.(C)5

9 14150181 14150185 pl.(C)5 9 93606226 93606230 pl.(T)5

9 14307011 14307015 pl.(A)5 9 93606273 93606278 ni n½ Chr Start End MS Chr Start End MS

9 93607789 93607794 pl.(A)6 9 102594983 102594987 pl.(A)5

9 93607811 93607815 pl.(A)5 9 102595013 102595017 pl.(A)5

9 93626932 93626937 pl.(A)6 9 102607096 102607100 pl.(T)5

9 93636955 93636959 pl.(C)5 9 108424883 108424887 pl.(A)5

9 93637106 93637110 pl.(A)5 9 108424895 108424899 pl.(A)5

9 93637127 93637131 pl.(A)5 9 108424951 108424955 pl.(G)5

9 93639884 93639888 pl.(A)5 9 110247979 110247984 pl.(A)6

9 95177534 95177545 p3.(TCA)4 9 110248034 110248038 pl.(A)5

9 95179010 95179014 pl.(A)5 9 110248092 110248096 pl.(T)5

9 95179088 95179092 pl.(T)5 9 110249301 110249305 pl.(C)5

9 95179202 95179206 pl.(T)5 9 110249756 110249760 pl.(G)5

9 95179799 95179804 pl.(A)6 9 110249797 110249801 pl.(G)5

9 95179830 95179835 pl.(A)6 9 110250136 110250140 pl.(G)5

9 95179845 95179855 pl.(T)l l 9 110250508 110250512 pl.(G)5

9 97864031 97864035 pl.(T)5 9 110251460 110251464 pl.(G)5

9 97873777 97873781 pl.(G)5 9 123850624 123850629 pl.(A)6

9 97873817 97873822 pl.(G)6 9 123850829 123850833 pl.(T)5

9 97887369 97887380 p4.(TGCT)3 9 123852600 123852605 pl.(A)6

9 97897697 97897701 pl.(A)5 9 123857182 123857186 pl.(A)5

9 97897715 97897719 pl.(T)5 9 123875985 123875993 pl.(A)9

9 97912296 97912300 pl.(G)5 9 123876006 123876012 pl.(A)7

9 98011579 98011583 pl.(A)5 9 123886191 123886201 pl.(T)l l

9 98209301 98209305 pl.(G)5 9 123888221 123888227 pl.(T)7

9 98209351 98209355 pl.(C)5 9 123898238 123898242 pl.(A)5

9 98209358 98209362 pl.(G)5 9 123902907 123902911 pl.(C)5

9 98209593 98209598 pl.(G)6 9 123903071 123903075 pl.(A)5

9 98209617 98209623 pl.(G)7 9 123904446 123904450 pl.(A)5

9 98211549 98211554 pl.(G)6 9 123904543 123904547 pl.(A)5

9 98220484 98220488 pl.(T)5 9 123907228 123907232 pl.(G)5

9 98222070 98222074 pl.(A)5 9 123907509 123907515 pl.(T)7

9 98229671 98229675 pl.(C)5 9 123908514 123908525 p3.(CCA)4

9 98229687 98229691 pl.(A)5 9 123911070 123911074 pl.(C)5

9 98231105 98231110 pl.(G)6 9 123912504 123912508 pl.(C)5

9 98231272 98231276 pl.(G)5 9 123912667 123912671 pl.(C)5

9 98231358 98231363 pl.(G)6 9 123912690 123912695 pl.(C)6

9 98232166 98232170 pl.(A)5 9 123916991 123916996 pl.(T)6

9 98238450 98238456 pl.(A)7 9 123917049 123917053 pl.(A)5

9 98239029 98239033 pl.(T)5 9 123919750 123919755 pl.(A)6

9 98239095 98239099 pl.(A)5 9 123920143 123920147 pl.(A)5

9 98239147 98239151 pl.(A)5 9 123921184 123921188 pl.(A)5

9 98242380 98242384 pl.(A)5 9 123921303 123921308 pl.(T)6

9 98242682 98242686 pl.(T)5 9 123924525 123924531 pl.(A)7

9 98242690 98242694 pl.(G)5 9 123928385 123928389 pl.(A)5

9 98268793 98268799 pl.(T)7 9 123929885 123929896 p3.(AAC)4

9 98270530 98270536 pl.(C)7 9 123932010 123932021 p4.(AGAA)3

9 98270593 98270604 p3.(GCC)4 9 123932083 123932087 pl.(A)5

9 98270647 98270667 p3.(GCC)7 9 123933690 123933694 pl.(A)5

9 100437715 100437720 pl.(A)6 9 123935531 123935535 pl.(A)5

9 100437726 100437731 pl.(T)6 9 123935756 123935760 pl.(A)5

9 100437873 100437881 pl.(A)9 9 131454204 131454209 pl.(T)6

9 100447212 100447217 pl.(T)6 9 131454245 131454249 pl.(T)5

9 100447238 100447243 pl.(T)6 9 132658125 132658129 pl.(T)5

9 100449461 100449466 pl.(T)6 9 132658279 132658283 pl.(A)5

9 100455962 100455976 p3.(TTC)5 9 132665264 132665268 pl.(T)5

9 102590616 102590642 p3.(CAC)9 9 132671226 132671230 pl.(T)5

9 102590749 102590753 pl.(C)5 9 132686221 132686225 pl.(G)5

9 102590768 102590773 pl.(C)6 9 132687243 132687250 pl.(T)8

9 102590780 102590784 pl.(G)5 9 132689475 132689479 pl.(T)5

9 102590922 102590927 pl.(C)6 9 132691983 132691987 pl.(A)5

9 102591267 102591271 pl.(T)5 9 132757214 132757218 ni ms Chr Start End MS Chr Start End MS

9 133730247 133730251 pl.(A)5 9 134103591 134103595 pl.(G)5

9 133738286 133738290 pl.(C)5 9 134103724 134103728 pl.(C)5

9 133738348 133738352 pl.(G)5 9 134106070 134106074 pl.(C)5

9 133748264 133748268 pl.(C)5 9 134107704 134107713 pl.(C)5(T)5

9 133748408 133748412 pl.(A)5 9 135771689 135771693 pl.(G)5

9 133756058 133756062 pl.(C)5 9 135771861 135771865 pl.(T)5

9 133759412 133759416 pl.(C)5 9 135771962 135771966 pl.(G)5

9 133759460 133759464 pl.(A)5 9 135771988 135772005 p3.(GCT)6

9 133759490 133759504 p3.(AAG)5 9 135772054 135772058 pl.(G)5

9 133759623 133759627 pl.(C)5 9 135772600 135772604 pl.(T)5

9 133759706 133759710 pl.(G)5 9 135772615 135772620 pl.(T)6

9 133760024 133760029 pl.(C)6 9 135772902 135772906 pl.(T)5

9 133760039 133760043 pl.(A)5 9 135772951 135772957 pl.(T)7

9 133760167 133760171 pl.(C)5 9 135773001 135773018 pl.(A)18

9 133760232 133760236 pl.(C)5 9 135776231 135776236 pl.(A)6

9 133760264 133760268 pl.(G)5 9 135781141 135781145 pl.(A)5

9 133760378 133760382 pl.(C)5 9 135781157 135781161 pl.(G)5

9 133760543 133760547 pl.(A)5 9 135782131 135782135 pl.(T)5

9 133760598 133760602 pl.(C)5 9 135782168 135782172 pl.(A)5

9 133760613 133760617 pl.(C)5 9 135785964 135785969 pl.(G)6

9 133760858 133760862 pl.(A)5 9 135785984 135785988 pl.(G)5

9 134003047 134003051 pl.(T)5 9 135787662 135787666 pl.(T)5

9 134003058 134003062 pl.(A)5 9 135797261 135797265 pl.(A)5

9 134003840 134003846 pl.(T)7 9 135798769 135798773 pl.(A)5

9 134004676 134004680 pl.(A)5 9 135804209 135804213 pl.(G)5

9 134007993 134008000 pl.(A)8 9 135973945 135973956 p4.(CCAG)3

9 134010285 134010290 pl.(A)6 9 135975698 135975709 p3.(CTC)4

9 134015925 134015930 pl.(T)6 9 135977929 135977933 pl.(G)5

9 134019779 134019783 pl.(T)5 9 135985013 135985017 pl.(T)5

9 134019805 134019809 pl.(C)5 9 136898775 136898786 p3.(GCT)4

9 134019867 134019871 pl.(C)5 9 136898800 136898804 pl.(C)5

9 134019942 134019946 pl.(C)5 9 136901171 136901175 pl.(T)5

9 134019964 134019968 pl.(C)5 9 136905293 136905304 p3.(CTT)4

9 134021508 134021512 pl.(T)5 9 136906996 136907000 pl.(G)5

9 134021565 134021569 pl.(C)5 9 136907005 136907009 pl.(G)5

9 134022865 134022869 pl.(T)5 9 136910452 136910456 pl.(G)5

9 134027114 134027118 pl.(T)5 9 136913497 136913501 pl.(G)5

9 134034756 134034762 pl.(T)7 9 136913572 136913576 pl.(T)5

9 134034863 134034868 pl.(A)6 9 136915566 136915571 pl.(G)6

9 134039457 134039461 pl.(C)5 9 136915646 136915651 pl.(G)6

9 134049595 134049599 pl.(C)5 9 136915664 136915668 pl.(G)5

9 134062668 134062672 pl.(T)5 9 136916734 136916738 pl.(G)5

9 134072590 134072594 pl.(T)5 9 136916775 136916779 pl.(T)5

9 134072656 134072660 pl.(G)5 9 136916784 136916788 pl.(A)5

9 134072880 134072884 pl.(T)5 9 136917543 136917547 pl.(T)5

9 134073008 134073014 pl.(C)7 9 136918529 136918536 pl.(G)8

9 134073037 134073041 pl.(C)5 9 136918573 136918577 pl.(G)5

9 134073110 134073114 pl.(T)5 9 139390697 139390701 pl.(G)5

9 134073195 134073199 pl.(T)5 9 139390736 139390741 pl.(G)6

9 134073232 134073236 pl.(C)5 9 139390945 139390959 p3.(GTG)5

9 134073326 134073330 pl.(C)5 9 139391171 139391175 pl.(G)5

9 134073493 134073498 pl.(A)6 9 139391188 139391192 pl.(G)5

9 134073597 134073601 pl.(G)5 9 139391207 139391211 pl.(C)5

9 134073722 134073726 pl.(C)5 9 139391409 139391413 pl.(C)5

9 134073881 134073885 pl.(C)5 9 139391778 139391782 pl.(G)5

9 134074264 134074269 pl.(G)6 9 139391799 139391804 pl.(C)6

9 134090591 134090596 pl.(T)6 9 139392013 139392017 pl.(G)5

9 134090650 134090654 pl.(G)5 9 139395260 139395264 pl.(C)5

9 134090704 134090708 pl.(A)5 9 139396258 139396262 pl.(G)5

9 134090728 134090732 pl.(G)5 9 139396482 139396487 nl ϊΓ ή Chr Start End MS Chr Start End MS

9 139396543 139396548 pl.(G)6 10 32304596 32304600 pl.(A)5

9 139396919 139396923 pl.(G)5 10 32307245 32307249 pl.(T)5

9 139399409 139399420 p3.(CAC)4 10 32307420 32307424 pl.(T)5

9 139399552 139399556 pl.(G)5 10 32310012 32310016 pl.(T)5

9 139399561 139399566 pl.(G)6 10 32311193 32311198 pl.(A)6

9 139400023 139400028 pl.(G)6 10 32311826 32311832 pl.(T)7

9 139400047 139400051 pl.(C)5 10 32311883 32311887 pl.(T)5

9 139401034 139401038 pl.(C)5 10 32311973 32311977 pl.(A)5

9 139401270 139401274 pl.(C)5 10 32317434 32317439 pl.(T)6

9 139401385 139401390 pl.(G)6 10 32323677 32323683 pl.(T)7

9 139401813 139401817 pl.(C)5 10 32323685 32323689 pl.(T)5

9 139402400 139402404 pl.(C)5 10 32323691 32323695 pl.(T)5

9 139402596 139402600 pl.(G)5 10 32323704 32323708 pl.(T)5

9 139403348 139403352 pl.(G)5 10 32324604 32324608 pl.(A)5

9 139403530 139403534 pl.(G)5 10 32324876 32324880 pl.(T)5

9 139404395 139404399 pl.(C)5 10 32344763 32344767 pl.(G)5

9 139405686 139405690 pl.(G)5 10 43597993 43597997 pl.(C)5

9 139407996 139408000 pl.(G)5 10 43606646 43606651 pl.(C)6

9 139409097 139409101 pl.(C)5 10 43607569 43607573 pl.(C)5

9 139409991 139409995 pl.(C)5 10 43609003 43609007 pl.(G)5

9 139410494 139410498 pl.(G)5 10 43609018 43609022 pl.(G)5

9 139410555 139410569 p5.(GGGGA)3 10 43609043 43609047 pl.(G)5

9 139412303 139412307 pl.(G)5 10 43609915 43609919 pl.(C)5

9 139413951 139413955 pl.(C)5 10 43612076 43612080 pl.(A)5

9 139417304 139417315 p4.(GGCA)3 10 43614972 43614976 pl.(C)5

9 139417352 139417356 pl.(C)5 10 43615516 43615520 pl.(T)5

9 139418228 139418232 pl.(C)5 10 43617431 43617435 pl.(T)5

9 139418371 139418375 pl.(G)5 10 43619159 43619163 pl.(G)5

10 8097767 8097771 pl.(T)5 10 43622120 43622125 pl.(C)6

10 8100355 8100359 pl.(C)5 10 43623553 43623557 pl.(T)5

10 8100425 8100430 pl.(C)6 10 51580868 51580872 pl.(T)5

10 8100452 8100457 pl.(G)6 10 51581255 51581263 pl.(T)9

10 8100728 8100734 pl.(C)7 10 51582894 51582898 pl.(C)5

10 8100754 8100758 pl.(C)5 10 51584605 51584609 pl.(T)5

10 8115752 8115756 pl.(A)5 10 51584652 51584656 pl.(G)5

10 8115771 8115775 pl.(A)5 10 51584695 51584699 pl.(A)5

10 8115780 8115785 pl.(A)6 10 51585043 51585047 pl.(C)5

10 21827751 21827755 pl.(T)5 10 51585146 51585155 p2.(GT)5

10 21884240 21884255 p4.(ATTT)4 10 51585216 51585220 pl.(A)5

10 21884253 21884257 pl.(T)5 10 51585402 51585406 pl.(C)5

10 21962283 21962287 pl.(T)5 10 51586312 51586317 pl.(C)6

10 21962452 21962458 pl.(G)7 10 61592325 61592330 pl.(T)6

10 21962680 21962684 pl.(A)5 10 61665867 61665872 pl.(G)6

10 22002690 22002696 pl.(T)7 10 61666040 61666045 pl.(C)6

10 22015159 22015164 pl.(T)6 10 61666067 61666071 pl.(C)5

10 22019953 22019957 pl.(T)5 10 61666139 61666144 pl.(C)6

10 22021893 22021897 pl.(A)5 10 70332076 70332081 pl.(T)6

10 22021908 22021912 pl.(A)5 10 70332153 70332160 pl.(A)8

10 22022825 22022829 pl.(G)5 10 70332162 70332166 pl.(A)5

10 22024060 22024064 pl.(T)5 10 70332201 70332205 pl.(A)5

10 22029094 22029098 pl.(C)5 10 70332273 70332279 pl.(A)7

10 27037488 27037498 pl.(A)ll 10 70332364 70332368 pl.(T)5

10 27037681 27037686 pl.(A)6 10 70332447 70332451 pl.(C)5

10 27040546 27040550 pl.(G)5 10 70332471 70332475 pl.(A)5

10 27040624 27040638 p3.(TGG)5 10 70332815 70332819 pl.(A)5

10 27040637 27040641 pl.(G)5 10 70332865 70332869 pl.(C)5

10 27040715 27040719 pl.(A)5 10 70333548 70333552 pl.(A)5

10 27044646 27044650 pl.(G)5 10 70333977 70333981 pl.(A)5

10 27044652 27044656 pl.(G)5 10 70404534 70404538 pl.(A)5

10 27057880 27057884 pl.(G)5 10 70404575 70404579 nl (A\ Chr Start End MS Chr Start End MS

10 70404687 70404691 pl.(A)5 10 76788645 76788659 p3.(GAG)5

10 70404695 70404699 pl.(A)5 10 76788690 76788701 p3.(GAA)4

10 70404809 70404814 pl.(A)6 10 76788718 76788722 pl.(A)5

10 70404887 70404891 pl.(A)5 10 76788748 76788752 pl.(A)5

10 70405054 70405058 pl.(A)5 10 76788775 76788779 pl.(A)5

10 70405365 70405369 pl.(A)5 10 76788956 76788961 pl.(T)6

10 70405500 70405504 pl.(T)5 10 76789101 76789105 pl.(C)5

10 70405652 70405657 pl.(A)6 10 76790190 76790194 pl.(G)5

10 70405778 70405783 pl.(A)6 10 76790223 76790228 pl.(C)6

10 70405827 70405831 pl.(A)5 10 76790731 76790735 pl.(C)5

10 70405928 70405932 pl.(A)5 10 88649875 88649879 pl.(A)5

10 70405964 70405968 pl.(A)5 10 88649922 88649927 pl.(T)6

10 70406663 70406667 pl.(A)5 10 88659632 88659636 pl.(C)5

10 70406707 70406712 pl.(A)6 10 88659789 88659794 pl.(T)6

10 70411615 70411619 pl.(A)5 10 88671986 88671991 pl.(T)6

10 70412266 70412270 pl.(A)5 10 88676877 88676882 pl.(T)6

10 70426793 70426798 pl.(T)6 10 88681365 88681369 pl.(A)5

10 70426827 70426831 pl.(A)5 10 89624200 89624204 pl.(T)5

10 70446284 70446290 pl.(A)7 10 89692758 89692762 pl.(T)5

10 70446420 70446431 p3.(CAA)4 10 89692949 89692953 pl.(T)5

10 70450596 70450600 pl.(A)5 10 89693003 89693007 pl.(A)5

10 70450626 70450630 pl.(A)5 10 89693017 89693022 pl.(T)6

10 70451094 70451098 pl.(C)5 10 89717770 89717775 pl.(A)6

10 70451161 70451165 pl.(T)5 10 90767548 90767552 pl.(T)5

10 70451314 70451318 pl.(A)5 10 90768708 90768714 pl.(T)7

10 70451408 70451412 pl.(A)5 10 90770283 90770291 pl.(T)9

10 70451582 70451586 pl.(C)5 10 90770365 90770371 pl.(T)7

10 72357844 72357848 pl.(C)5 10 90773868 90773872 pl.(T)5

10 72357859 72357863 pl.(G)5 10 90774094 90774099 pl.(A)6

10 72358049 72358054 pl.(C)6 10 90774212 90774216 pl.(A)5

10 72358189 72358194 pl.(C)6 10 102891275 102891280 pl.(C)6

10 72358309 72358313 pl.(G)5 10 102891476 102891480 pl.(G)5

10 72358622 72358633 p3.(CTT)4 10 102891496 102891500 pl.(G)5

10 72358914 72358918 pl.(G)5 10 102891511 102891515 pl.(G)5

10 76602675 76602680 pl.(A)6 10 102891557 102891568 p3.(GGC)4

10 76603077 76603081 pl.(G)5 10 102891638 102891652 p3.(GGC)5

10 76729788 76729793 pl.(T)6 10 102891685 102891689 pl.(G)5

10 76735201 76735205 pl.(G)5 10 102891736 102891740 pl.(C)5

10 76735416 76735421 pl.(T)6 10 102893955 102893960 pl.(C)6

10 76735491 76735495 pl.(A)5 10 102893961 102893972 p3.(AAG)4

10 76735581 76735585 pl.(C)5 10 104157118 104157122 pl.(A)5

10 76735588 76735592 pl.(C)5 10 104157745 104157749 pl.(G)5

10 76735770 76735774 pl.(A)5 10 104158134 104158139 pl.(C)6

10 76735895 76735906 p3.(CTC)4 10 104158163 104158168 pl.(C)6

10 76735912 76735916 pl.(G)5 10 104158489 104158493 pl.(C)5

10 76735933 76735937 pl.(T)5 10 104158555 104158559 pl.(G)5

10 76735974 76735978 pl.(A)5 10 104158585 104158589 pl.(G)5

10 76736029 76736033 pl.(C)5 10 104158597 104158601 pl.(G)5

10 76737084 76737088 pl.(A)5 10 104158626 104158630 pl.(G)5

10 76737164 76737168 pl.(T)5 10 104159413 104159422 p2.(CG)5

10 76741594 76741598 pl.(A)5 10 104159830 104159834 pl.(C)5

10 76744828 76744832 pl.(T)5 10 104159956 104159960 pl.(G)5

10 76744938 76744943 pl.(T)6 10 104160509 104160514 pl.(G)6

10 76744954 76744959 pl.(A)6 10 104160697 104160701 pl.(C)5

10 76781741 76781745 pl.(A)5 10 104160987 104160991 pl.(C)5

10 76781834 76781845 p3.(GAG)4 10 104161493 104161497 pl.(C)5

10 76781906 76781929 p3.(GAA)8 10 104162002 104162006 pl.(C)5

10 76781945 76781949 pl.(C)5 10 104162077 104162081 pl.(C)5

10 76788476 76788480 pl.(A)5 10 104162112 104162116 pl.(C)5

10 76788604 76788608 pl.(A)5 10 104162145 104162149 nl ίΓ« Chr Start End MS Chr Start End MS

10 104162152 104162156 pl.(C)5 11 3720389 3720395 pl.(T)7

10 104162165 104162169 pl.(C)5 11 3722033 3722037 pl.(T)5

10 104263800 104263804 pl.(C)5 11 3726589 3726593 pl.(A)5

10 104263883 104263887 pl.(C)5 11 3740668 3740672 pl.(T)5

10 104263935 104263939 pl.(C)5 11 3744609 3744613 pl.(A)5

10 104263952 104263956 pl.(C)5 11 3752812 3752816 pl.(A)5

10 104263974 104263980 pl.(C)7 11 3765751 3765756 pl.(G)6

10 104264000 104264004 pl.(C)5 11 3784225 3784229 pl.(A)5

10 104268916 104268921 pl.(T)6 11 3789983 3789987 pl.(A)5

10 104356981 104356986 pl.(C)6 11 3800491 3800495 pl.(A)5

10 104849327 104849331 pl.(C)5 11 8246089 8246100 p4.(TGGC)3

10 104849337 104849341 pl.(C)5 11 14480238 14480243 pl.(A)6

10 104849436 104849450 p3.(TCC)5 11 14496048 14496052 pl.(T)5

10 104849491 104849496 pl.(G)6 11 14501268 14501281 pl.(A)14

10 104849674 104849679 pl.(A)6 11 14502418 14502422 pl.(T)5

10 104850467 104850471 pl.(A)5 11 14502646 14502651 pl.(A)6

10 104852946 104852951 pl.(A)6 11 32410683 32410687 pl.(T)5

10 104852993 104852997 pl.(A)5 11 32439208 32439212 pl.(A)5

10 104854138 104854143 pl.(A)6 11 32449555 32449559 pl.(G)5

10 104865462 104865466 pl.(C)5 11 32449577 32449581 pl.(G)5

10 104866337 104866341 pl.(A)5 11 32456485 32456496 p3.(GGC)4

10 104934639 104934643 pl.(T)5 11 32456497 32456501 pl.(G)5

10 114286893 114286897 pl.(G)5 11 32456560 32456564 pl.(G)5

10 114297997 114298001 pl.(T)5 11 32456619 32456630 p3.(GCC)4

10 114428722 114428726 pl.(A)5 11 33881115 33881119 pl.(A)5

10 114575121 114575125 pl.(T)5 11 33886331 33886336 pl.(G)6

10 114710508 114710516 pl.(A)9 11 33891192 33891196 pl.(G)5

10 114900984 114900988 pl.(C)5 11 33891230 33891244 p3.(GCT)5

10 114903755 114903759 pl.(C)5 11 44129501 44129506 pl.(G)6

10 114911500 114911504 pl.(A)5 11 44129596 44129600 pl.(A)5

10 114925317 114925325 pl.(A)9 11 44130793 44130797 pl.(C)5

10 114925402 114925407 pl.(C)6 11 44151655 44151659 pl.(C)5

10 114925494 114925498 pl.(C)5 11 44219553 44219557 pl.(A)5

10 114925597 114925601 pl.(C)5 11 44228334 44228338 pl.(T)5

10 114925622 114925626 pl.(C)5 11 44254034 44254038 pl.(T)5

10 123239442 123239447 pl.(A)6 11 44254051 44254055 pl.(G)5

10 123243323 123243327 pl.(A)5 11 46299640 46299644 pl.(G)5

10 123244965 123244969 pl.(A)5 11 46299728 46299732 pl.(G)5

10 123245002 123245006 pl.(C)5 11 46321677 46321681 pl.(C)5

10 123247515 123247519 pl.(T)5 11 46329463 46329467 pl.(C)5

10 123256046 123256050 pl.(T)5 11 46329542 46329546 pl.(C)5

10 123263369 123263373 pl.(G)5 11 46332609 46332614 pl.(C)6

10 123274648 123274652 pl.(G)5 11 46332663 46332668 pl.(C)6

10 123310847 123310851 pl.(T)5 11 46333965 46333969 pl.(C)5

10 123310879 123310884 pl.(C)6 11 46339001 46339005 pl.(C)5

11 532622 532626 pl.(C)5 11 46341895 46341899 pl.(C)5

11 534295 534306 p3.(CCA)4 11 46341922 46341927 pl.(G)6

11 3022322 3022326 pl.(A)5 11 47238032 47238037 pl.(T)6

11 3022339 3022343 pl.(C)5 11 47238424 47238428 pl.(T)5

11 3023251 3023256 pl.(G)6 11 47238467 47238471 pl.(C)5

11 3033426 3033430 pl.(T)5 11 47238541 47238545 pl.(G)5

11 3039177 3039181 pl.(A)5 11 47254486 47254490 pl.(T)5

11 3039746 3039751 pl.(G)6 11 47256329 47256333 pl.(A)5

11 3039858 3039862 pl.(T)5 11 47256906 47256910 pl.(C)5

11 3039888 3039893 pl.(T)6 11 57427437 57427441 pl.(G)5

11 3040398 3040402 pl.(G)5 11 57428440 57428444 pl.(C)5

11 3050562 3050566 pl.(C)5 11 57428477 57428481 pl.(G)5

11 3059386 3059390 pl.(T)5 11 57428542 57428546 pl.(T)5

11 3062186 3062190 pl.(T)5 11 61205469 61205473 pl.(T)5

11 3697615 3697619 pl.(A)5 11 61205478 61205482 ni ms Chr Start End MS Chr Start End MS

11 61213475 61213479 pl.(A)5 11 85722158 85722162 pl.(T)5

11 61213481 61213485 pl.(A)5 11 85722175 85722179 pl.(T)5

11 61213566 61213570 pl.(G)5 11 85723442 85723446 pl.(A)5

11 64003758 64003762 pl.(G)5 11 85742661 85742671 pl.(A)6(T)5

11 64004663 64004670 pl.(A)8 11 85779704 85779708 pl.(T)5

11 64004948 64004952 pl.(C)5 11 85779875 85779879 pl.(C)5

11 64005041 64005045 pl.(C)5 11 94189473 94189479 pl.(T)7

11 64005904 64005908 pl.(G)5 11 94192633 94192638 pl.(T)6

11 64572093 64572099 pl.(G)7 11 94197282 94197287 pl.(T)6

11 64572161 64572165 pl.(G)5 11 94197308 94197313 pl.(A)6

11 64572679 64572683 pl.(G)5 11 94203625 94203629 pl.(A)5

11 64573118 64573122 pl.(C)5 11 94203691 94203695 pl.(A)5

11 64573691 64573695 pl.(G)5 11 94203731 94203735 pl.(A)5

11 64574476 64574480 pl.(C)5 11 94204818 94204822 pl.(T)5

11 64575157 64575163 pl.(G)7 11 94204884 94204888 pl.(A)5

11 64575580 64575584 pl.(G)5 11 94209523 94209528 pl.(T)6

11 64577250 64577254 pl.(C)5 11 94211932 94211936 pl.(T)5

11 64577375 64577379 pl.(G)5 11 94219083 94219094 p4.(TACT)3

11 69465873 69465882 p2.(CT)5 11 94219218 94219222 pl.(A)5

11 69465988 69466002 p3.(GAG)5 11 95713133 95713137 pl.(A)5

11 69518488 69518492 pl.(G)5 11 95825204 95825221 p3.(TGC)6

11 69518572 69518576 pl.(G)5 11 95825240 95825254 p3.(TGC)5

11 69588898 69588902 pl.(G)5 11 95825261 95825275 p3.(TGC)5

11 69589770 69589774 pl.(C)5 11 95825357 95825371 p3.(TGC)5

11 69625177 69625181 pl.(C)5 11 95825375 95825413 p3.(TGC)13

11 69625188 69625192 pl.(G)5 11 95825707 95825711 pl.(G)5

11 71715035 71715039 pl.(G)5 11 95826041 95826045 pl.(G)5

11 71715808 71715812 pl.(G)5 11 95826328 95826332 pl.(A)5

11 71716313 71716318 pl.(G)6 11 96074680 96074684 pl.(G)5

11 71718342 71718347 pl.(G)6 11 96074734 96074738 pl.(G)5

11 71718403 71718408 pl.(G)6 11 96074804 96074808 pl.(C)5

11 71723497 71723501 pl.(G)5 11 96074983 96074987 pl.(C)5

11 71724190 71724194 pl.(C)5 11 96075011 96075017 pl.(C)7

11 71724368 71724372 pl.(C)5 11 96075030 96075034 pl.(G)5

11 71724810 71724814 pl.(C)5 11 96075040 96075044 pl.(G)5

11 71724878 71724882 pl.(T)5 11 96075053 96075057 pl.(C)5

11 71726491 71726495 pl.(T)5 11 102195499 102195503 pl.(A)5

11 71730666 71730670 pl.(G)5 11 102195699 102195703 pl.(T)5

11 71735404 71735408 pl.(A)5 11 102196080 102196084 pl.(T)5

11 76164345 76164349 pl.(T)5 11 102206685 102206690 pl.(T)6

11 76169215 76169220 pl.(T)6 11 102206733 102206737 pl.(T)5

11 76169411 76169415 pl.(A)5 11 108098310 108098317 pl.(T)8

11 76174889 76174893 pl.(A)5 11 108098490 108098494 pl.(T)5

11 76175070 76175074 pl.(A)5 11 108098609 108098613 pl.(T)5

11 76207304 76207308 pl.(C)5 11 108099906 108099910 pl.(T)5

11 76227322 76227327 pl.(G)6 11 108099993 108099997 pl.(A)5

11 76234303 76234307 pl.(A)5 11 108114662 108114676 pl.(T)15

11 76237646 76237650 pl.(A)5 11 108114808 108114812 pl.(T)5

11 76248827 76248832 pl.(T)6 11 108114817 108114823 pl.(T)7

11 76248845 76248849 pl.(A)5 11 108115748 108115752 pl.(A)5

11 76255291 76255296 pl.(T)6 11 108119661 108119665 pl.(T)5

11 76255462 76255466 pl.(C)5 11 108121411 108121425 pl.(T)15

11 76255598 76255602 pl.(A)5 11 108122621 108122625 pl.(A)5

11 76255708 76255712 pl.(C)5 11 108123531 108123535 pl.(T)5

11 76255788 76255792 pl.(A)5 11 108123593 108123597 pl.(A)5

11 76255811 76255816 pl.(C)6 11 108123616 108123621 pl.(T)6

11 76257075 76257079 pl.(C)5 11 108124552 108124556 pl.(A)5

11 85685858 85685863 pl.(A)6 11 108124626 108124630 pl.(T)5

11 85692159 85692163 pl.(T)5 11 108124773 108124785 pl.(T)6(A)7

11 85692227 85692231 pl.(C)5 11 108128247 108128251 nl (A^ Chr Start End MS Chr Start End MS

11 108129740 108129744 pl.(T)5 11 108577510 108577514 pl.(A)5

11 108137910 108137914 pl.(A)5 11 108586617 108586621 pl.(A)5

11 108139124 108139128 pl.(T)5 11 108586637 108586642 pl.(A)6

11 108139130 108139134 pl.(T)5 11 108586702 108586706 pl.(T)5

11 108141956 108141970 pl.(T)15 11 108593903 108593907 pl.(A)5

11 108142051 108142055 pl.(A)5 11 108593913 108593917 pl.(A)5

11 108143340 108143344 pl.(T)5 11 108593971 108593982 p3.(GAA)4

11 108151714 108151718 pl.(T)5 11 111225266 111225270 pl.(G)5

11 108151825 108151829 pl.(A)5 11 111249888 111249892 pl.(T)5

11 108151890 108151894 pl.(A)5 11 111959582 111959586 pl.(T)5

11 108154947 108154951 pl.(T)5 11 111965518 111965522 pl.(T)5

11 108159797 108159801 pl.(A)5 11 113934034 113934038 pl.(A)5

11 108160451 108160455 pl.(A)5 11 113934713 113934717 pl.(G)5

11 108164137 108164141 pl.(T)5 11 113934826 113934830 pl.(G)5

11 108164164 108164169 pl.(A)6 11 113934944 113934948 pl.(C)5

11 108164210 108164214 pl.(A)5 11 113934966 113934970 pl.(C)5

11 108168095 108168099 pl.(A)5 11 113934995 113934999 pl.(C)5

11 108172365 108172371 pl.(T)7 11 113935136 113935141 pl.(G)6

11 108172409 108172413 pl.(A)5 11 113935186 113935190 pl.(G)5

11 108172510 108172515 pl.(A)6 11 117023146 117023151 pl.(T)6

11 108173580 108173584 pl.(T)5 11 117031852 117031858 pl.(T)7

11 108173696 108173701 pl.(T)6 11 117031874 117031879 pl.(T)6

11 108175510 108175514 pl.(T)5 11 117031909 117031913 pl.(G)5

11 108178635 108178639 pl.(T)5 11 117038254 117038258 pl.(G)5

11 108178656 108178661 pl.(A)6 11 117038323 117038327 pl.(G)5

11 108180876 108180880 pl.(T)5 11 117079626 117079631 pl.(G)6

11 108180904 108180908 pl.(T)5 11 117089206 117089211 pl.(G)6

11 108186846 108186851 pl.(T)6 11 117100408 117100413 pl.(C)6

11 108192014 108192019 pl.(T)6 11 117100518 117100523 pl.(G)6

11 108196880 108196885 pl.(A)6 11 118307276 118307280 pl.(G)5

11 108196958 108196965 pl.(T)8 11 118307279 118307290 p3.(GGC)4

11 108198492 108198496 pl.(T)5 11 118307291 118307296 pl.(G)6

11 108199804 108199808 pl.(A)5 11 118307453 118307457 pl.(G)5

11 108202155 108202162 pl.(T)8 11 118307639 118307643 pl.(G)5

11 108202201 108202205 pl.(T)5 11 118307664 118307668 pl.(G)5

11 108202632 108202636 pl.(C)5 11 118342567 118342571 pl.(A)5

11 108202729 108202733 pl.(A)5 11 118342634 118342640 pl.(A)7

11 108203475 108203480 pl.(T)6 11 118342685 118342690 pl.(A)6

11 108203633 108203640 pl.(T)8 11 118342759 118342763 pl.(G)5

11 108205782 108205786 pl.(A)5 11 118342966 118342970 pl.(A)5

11 108216477 108216483 pl.(A)7 11 118343011 118343021 pl.(A)6(G)5

11 108216561 108216565 pl.(A)5 11 118343037 118343041 pl.(A)5

11 108217994 108217999 pl.(T)6 11 118343084 118343088 pl.(A)5

11 108236039 108236043 pl.(T)5 11 118343253 118343257 pl.(A)5

11 108236191 108236195 pl.(A)5 11 118343504 118343509 pl.(A)6

11 108236294 108236298 pl.(T)5 11 118343529 118343534 pl.(C)6

11 108535865 108535879 p3.(CGC)5 11 118343660 118343664 pl.(T)5

11 108535953 108535958 pl.(A)6 11 118343831 118343835 pl.(C)5

11 108535977 108535981 pl.(A)5 11 118343872 118343876 pl.(T)5

11 108544183 108544189 pl.(T)7 11 118344076 118344080 pl.(A)5

11 108544239 108544245 pl.(A)7 11 118344186 118344192 pl.(C)7

11 108547804 108547808 pl.(T)5 11 118344308 118344312 pl.(A)5

11 108547859 108547863 pl.(G)5 11 118344435 118344439 pl.(C)5

11 108550090 108550094 pl.(T)5 11 118344494 118344503 p2.(AG)5

11 108550244 108550248 pl.(A)5 11 118344554 118344558 pl.(A)5

11 108550272 108550276 pl.(A)5 11 118344656 118344661 pl.(A)6

11 108559710 108559715 pl.(A)6 11 118344783 118344788 pl.(A)6

11 108559733 108559737 pl.(T)5 11 118344955 118344960 pl.(A)6

11 108559769 108559775 pl.(T)7 11 118352418 118352422 pl.(T)5

11 108577455 108577459 pl.(T)5 11 118352435 118352439 nl (A^ Chr Start End MS Chr Start End MS

11 118352447 118352451 pl.(A)5 11 119144566 119144570 pl.(C)5

11 118352780 118352784 pl.(A)5 11 119144700 119144704 pl.(T)5

11 118354899 118354903 pl.(A)5 11 119145604 119145609 pl.(T)6

11 118354983 118354988 pl.(A)6 11 119148860 119148867 pl.(T)8

11 118360971 118360976 pl.(A)6 11 119149356 119149373 p3.(ATG)6

11 118361941 118361952 p3.(ATG)4 11 119155727 119155731 pl.(C)5

11 118362558 118362562 pl.(A)5 11 119156070 119156074 pl.(C)5

11 118363830 118363834 pl.(C)5 11 119169057 119169061 pl.(T)5

11 118364990 118364994 pl.(T)5 11 119170435 119170439 pl.(A)5

11 118365075 118365080 pl.(A)6 11 120276837 120276842 pl.(A)6

11 118365422 118365426 pl.(T)5 11 120298953 120298957 pl.(G)5

11 118365442 118365446 pl.(A)5 11 120310939 120310944 pl.(T)6

11 118367017 118367021 pl.(C)5 11 120319849 120319853 pl.(A)5

11 118369078 118369082 pl.(T)5 11 120319887 120319891 pl.(C)5

11 118369199 118369204 pl.(A)6 11 120322399 120322403 pl.(T)5

11 118373442 118373446 pl.(A)5 11 120328775 120328780 pl.(T)6

11 118373904 118373909 pl.(A)6 11 120329994 120329999 pl.(T)6

11 118373951 118373956 pl.(T)6 11 120331368 120331372 pl.(T)5

11 118374197 118374201 pl.(A)5 11 120336039 120336043 pl.(A)5

11 118374222 118374226 pl.(A)5 11 120340100 120340105 pl.(A)6

11 118374498 118374503 pl.(T)6 11 120345283 120345287 pl.(A)5

11 118374752 118374756 pl.(A)5 11 120347360 120347365 pl.(T)6

11 118374839 118374843 pl.(A)5 11 120351016 120351020 pl.(G)5

11 118374939 118374943 pl.(A)5 11 120351043 120351048 pl.(T)6

11 118375010 118375024 p5.(AGCTC)3 11 120352143 120352147 pl.(C)5

11 118375057 118375061 pl.(C)5 11 125505317 125505321 pl.(T)5

11 118375068 118375072 pl.(A)5 11 125505378 125505386 pl.(A)9

11 118375279 118375283 pl.(A)5 11 125505404 125505410 pl.(A)7

11 118375294 118375298 pl.(T)5 11 125513679 125513684 pl.(T)6

11 118375507 118375511 pl.(A)5 11 125513691 125513695 pl.(A)5

11 118375915 118375920 pl.(A)6 11 125523746 125523750 pl.(T)5

11 118376310 118376315 pl.(A)6 11 128564127 128564132 pl.(G)6

11 118376474 118376478 pl.(A)5 11 128628138 128628142 pl.(C)5

11 118376857 118376861 pl.(C)5 11 128638115 128638120 pl.(C)6

11 118377153 118377157 pl.(G)5 11 128642763 128642767 pl.(T)5

11 118377230 118377234 pl.(A)5 11 128680557 128680561 pl.(A)5

11 118379840 118379844 pl.(T)5 11 128680798 128680802 pl.(C)5

11 118380758 118380763 pl.(A)6 11 128680805 128680810 pl.(G)6

11 118380780 118380784 pl.(T)5 11 128680832 128680836 pl.(C)5

11 118390461 118390466 pl.(C)6 11 128781906 128781910 pl.(G)5

11 118391565 118391570 pl.(A)6 11 128781918 128781922 pl.(C)5

11 118392900 118392904 pl.(C)5 11 128786512 128786517 pl.(C)6

11 118622560 118622570 pl.(T)6(A)5 11 128786524 128786529 pl.(G)6

11 118622625 118622630 pl.(A)6 12 402031 402035 pl.(T)5

11 118622653 118622657 pl.(T)5 12 402100 402104 pl.(T)5

11 118622671 118622677 pl.(A)7 12 402240 402244 pl.(A)5

11 118625599 118625604 pl.(A)6 12 402340 402344 pl.(A)5

11 118626099 118626104 pl.(T)6 12 404967 404972 pl.(A)6

11 118626216 118626226 pl.(A)ll 12 416644 416648 pl.(T)5

11 118629513 118629517 pl.(T)5 12 416676 416681 pl.(T)6

11 118629614 118629621 pl.(G)8 12 416953 416960 pl.(T)8

11 118630686 118630690 pl.(T)5 12 417142 417146 pl.(T)5

11 118639005 118639010 pl.(T)6 12 419044 419048 pl.(T)5

11 118650374 118650378 pl.(A)5 12 419050 419054 pl.(T)5

11 118651873 118651877 pl.(T)5 12 419071 419076 pl.(T)6

11 118656821 118656825 pl.(T)5 12 419084 419088 pl.(T)5

11 118656857 118656861 pl.(C)5 12 419118 419122 pl.(G)5

11 119077161 119077165 pl.(G)5 12 419135 419139 pl.(A)5

11 119077179 119077183 pl.(G)5 12 420234 420238 pl.(A)5

11 119077233 119077253 p3.(CAC)7 12 430200 430204 nl (A\ Chr Start End MS Chr Start End MS

12 431595 431599 pl.(T)5 12 12874095 12874099 pl.(A)5

12 431738 431742 pl.(A)5 12 12874183 12874187 pl.(T)5

12 442737 442741 pl.(G)5 12 25362678 25362682 pl.(A)5

12 442811 442816 pl.(C)6 12 25362710 25362715 pl.(A)6

12 443456 443460 pl.(A)5 12 25362760 25362764 pl.(T)5

12 461499 461504 pl.(A)6 12 25362769 25362773 pl.(T)5

12 463406 463415 pl.(A)10 12 25398338 25398342 pl.(A)5

12 464424 464428 pl.(A)5 12 46123563 46123568 pl.(G)6

12 465650 465654 pl.(A)5 12 46123592 46123602 pl.(T)6(A)5

12 465706 465711 pl.(A)6 12 46123612 46123617 pl.(A)6

12 472228 472232 pl.(T)5 12 46123837 46123843 pl.(A)7

12 493223 493227 pl.(T)5 12 46211615 46211619 pl.(A)5

12 498235 498240 pl.(C)6 12 46231095 46231099 pl.(T)5

12 498268 498282 pl.(G)15 12 46231185 46231189 pl.(T)5

12 1137352 1137356 pl.(G)5 12 46231273 46231277 pl.(T)5

12 1192721 1192725 pl.(A)5 12 46231462 46231466 pl.(A)5

12 1219363 1219367 pl.(A)5 12 46243567 46243571 pl.(T)5

12 1219505 1219509 pl.(A)5 12 46244454 46244458 pl.(C)5

12 1221435 1221439 pl.(A)5 12 46244967 46244971 pl.(C)5

12 1250834 1250838 pl.(A)5 12 46245162 46245166 pl.(C)5

12 1291166 1291171 pl.(A)6 12 46245318 46245322 pl.(G)5

12 1291191 1291195 pl.(A)5 12 46245609 46245613 pl.(C)5

12 1292501 1292505 pl.(A)5 12 46246026 46246030 pl.(A)5

12 1292582 1292586 pl.(A)5 12 46254574 46254578 pl.(T)5

12 1292595 1292600 pl.(A)6 12 46254728 46254732 pl.(A)5

12 1299088 1299097 p2.(GA)5 12 46285553 46285558 pl.(T)6

12 1345991 1345997 pl.(A)7 12 46285708 46285712 pl.(T)5

12 1372324 1372328 pl.(A)5 12 46285788 46285792 pl.(A)5

12 1481028 1481032 pl.(A)5 12 46287216 46287220 pl.(G)5

12 1553714 1553720 pl.(T)7 12 46298706 46298712 pl.(T)7

12 1553817 1553821 pl.(C)5 12 46298836 46298840 pl.(A)5

12 1553909 1553913 pl.(G)5 12 46298861 46298865 pl.(A)5

12 4383409 4383414 pl.(G)6 12 46298884 46298888 pl.(G)5

12 4479552 4479556 pl.(C)5 12 49415529 49415533 pl.(G)5

12 4479697 4479701 pl.(G)5 12 49415856 49415867 p3.(GAT)4

12 4479749 4479753 pl.(G)5 12 49416586 49416590 pl.(G)5

12 4479769 4479773 pl.(G)5 12 49418437 49418441 pl.(G)5

12 4479807 4479811 pl.(G)5 12 49420204 49420209 pl.(C)6

12 4481766 4481770 pl.(A)5 12 49420846 49420850 pl.(G)5

12 4481872 4481876 pl.(A)5 12 49420963 49420967 pl.(G)5

12 4488739 4488743 pl.(C)5 12 49420989 49420993 pl.(G)5

12 6777019 6777023 pl.(C)5 12 49420996 49421000 pl.(G)5

12 6777029 6777034 pl.(G)6 12 49421573 49421577 pl.(C)5

12 6777070 6777111 p3.(TGC)14 12 49421807 49421811 pl.(C)5

12 6777205 6777216 p3.(GCT)4 12 49422868 49422872 pl.(G)5

12 6787521 6787525 pl.(G)5 12 49422946 49422950 pl.(C)5

12 6787601 6787605 pl.(G)5 12 49424114 49424118 pl.(C)5

12 6788698 6788703 pl.(A)6 12 49424167 49424171 pl.(G)5

12 11803022 11803027 pl.(A)6 12 49424178 49424183 pl.(G)6

12 11803097 11803101 pl.(A)5 12 49424374 49424378 pl.(T)5

12 11905374 11905378 pl.(T)5 12 49424443 49424448 pl.(C)6

12 12006348 12006352 pl.(T)5 12 49424489 49424493 pl.(G)5

12 12006418 12006423 pl.(T)6 12 49424666 49424671 pl.(G)6

12 12022376 12022380 pl.(C)5 12 49424970 49424974 pl.(G)5

12 12022502 12022507 pl.(C)6 12 49425051 49425055 pl.(C)5

12 12022665 12022669 pl.(C)5 12 49425349 49425353 pl.(G)5

12 12022734 12022738 pl.(C)5 12 49425456 49425460 pl.(G)5

12 12871044 12871048 pl.(C)5 12 49425510 49425514 pl.(G)5

12 12871053 12871058 pl.(C)6 12 49425668 49425672 pl.(G)5

12 12874045 12874049 pl.(A)5 12 49425694 49425698 nl ίΓ« Chr Start End MS Chr Start End MS

12 49425824 49425838 p3.(GCT)5 12 49436102 49436106 pl.(C)5

12 49425865 49425869 pl.(T)5 12 49436666 49436670 pl.(G)5

12 49426022 49426026 pl.(G)5 12 49436954 49436958 pl.(C)5

12 49426670 49426681 p3.(GCT)4 12 49437515 49437519 pl.(A)5

12 49426730 49426750 p3.(GCT)7 12 49438036 49438040 pl.(T)5

12 49426906 49426920 p3.(TGC)5 12 49438211 49438216 pl.(T)6

12 49426973 49426978 pl.(G)6 12 49440431 49440436 pl.(G)6

12 49427027 49427031 pl.(G)5 12 49441816 49441821 pl.(C)6

12 49427047 49427058 p3.(TGC)4 12 49442512 49442523 p3.(TCC)4

12 49427251 49427262 p3.(TGC)4 12 49443512 49443516 pl.(C)5

12 49427266 49427286 p3.(TGC)7 12 49443641 49443645 pl.(C)5

12 49427395 49427399 pl.(C)5 12 49443667 49443672 pl.(C)6

12 49427506 49427510 pl.(C)5 12 49443789 49443793 pl.(G)5

12 49427665 49427679 p3.(TGC)5 12 49444053 49444057 pl.(G)5

12 49427843 49427847 pl.(C)5 12 49444073 49444077 pl.(C)5

12 49427937 49427942 pl.(T)6 12 49444181 49444185 pl.(C)5

12 49428411 49428416 pl.(C)6 12 49444363 49444367 pl.(G)5

12 49431291 49431302 p3.(TGC)4 12 49444378 49444383 pl.(G)6

12 49431306 49431317 p3.(TGC)4 12 49444443 49444447 pl.(G)5

12 49431545 49431549 pl.(G)5 12 49444505 49444509 pl.(C)5

12 49431722 49431726 pl.(G)5 12 49444809 49444813 pl.(G)5

12 49431834 49431838 pl.(G)5 12 49444863 49444867 pl.(G)5

12 49431874 49431879 pl.(C)6 12 49444933 49444938 pl.(G)6

12 49432030 49432034 pl.(G)5 12 49444960 49444965 pl.(G)6

12 49432236 49432240 pl.(G)5 12 49444987 49444992 pl.(G)6

12 49432347 49432351 pl.(G)5 12 49445041 49445046 pl.(G)6

12 49432399 49432403 pl.(G)5 12 49445095 49445100 pl.(G)6

12 49432420 49432424 pl.(A)5 12 49445149 49445154 pl.(G)6

12 49432464 49432468 pl.(C)5 12 49445203 49445208 pl.(G)6

12 49433113 49433117 pl.(G)5 12 49445257 49445261 pl.(G)5

12 49433233 49433237 pl.(G)5 12 49445375 49445379 pl.(G)5

12 49433407 49433414 pl.(A)8 12 49445500 49445505 pl.(G)6

12 49433773 49433777 pl.(G)5 12 49445526 49445532 pl.(G)7

12 49433904 49433908 pl.(G)5 12 49445883 49445887 pl.(G)5

12 49433960 49433964 pl.(G)5 12 49445929 49445933 pl.(A)5

12 49434005 49434010 pl.(G)6 12 49445949 49445953 pl.(G)5

12 49434074 49434079 pl.(C)6 12 49446138 49446142 pl.(G)5

12 49434082 49434086 pl.(C)5 12 49446166 49446171 pl.(G)6

12 49434129 49434133 pl.(G)5 12 49446462 49446466 pl.(G)5

12 49434247 49434251 pl.(A)5 12 49446481 49446485 pl.(G)5

12 49434354 49434358 pl.(G)5 12 49447430 49447434 pl.(G)5

12 49434378 49434382 pl.(G)5 12 49447773 49447777 pl.(C)5

12 49434408 49434412 pl.(G)5 12 49448147 49448151 pl.(C)5

12 49434492 49434496 pl.(G)5 12 49448408 49448413 pl.(C)6

12 49434562 49434567 pl.(G)6 12 49448529 49448533 pl.(C)5

12 49434648 49434652 pl.(G)5 12 51173906 51173916 pl.(T)6(C)5

12 49434726 49434730 pl.(G)5 12 51189684 51189689 pl.(T)6

12 49434759 49434763 pl.(C)5 12 51203227 51203234 pl.(T)8

12 49434851 49434855 pl.(G)5 12 51203239 51203243 pl.(A)5

12 49434924 49434928 pl.(G)5 12 51207780 51207784 pl.(T)5

12 49434940 49434944 pl.(C)5 12 51208184 51208188 pl.(C)5

12 49434959 49434964 pl.(G)6 12 51208215 51208219 pl.(A)5

12 49435157 49435161 pl.(G)5 12 54332816 54332821 pl.(G)6

12 49435187 49435191 pl.(G)5 12 54333021 54333026 pl.(C)6

12 49435199 49435204 pl.(G)6 12 54333066 54333070 pl.(G)5

12 49435230 49435234 pl.(G)5 12 54367186 54367190 pl.(C)5

12 49435324 49435328 pl.(G)5 12 54367227 54367231 pl.(C)5

12 49435706 49435710 pl.(G)5 12 54367371 54367375 pl.(A)5

12 49436020 49436024 pl.(G)5 12 54367423 54367427 pl.(C)5

12 49436029 49436033 pl.(G)5 12 54367530 54367535 nl ϊΓ ή Chr Start End MS Chr Start End MS

12 54367559 54367563 pl.(G)5 12 69210596 69210601 pl.(T)6

12 54367575 54367579 pl.(C)5 12 69229771 69229778 pl.(T)8

12 54367702 54367706 pl.(C)5 12 69233090 69233096 pl.(C)7

12 56474039 56474043 pl.(C)5 12 69233240 69233246 pl.(A)7

12 56480326 56480330 pl.(G)5 12 69233489 69233493 pl.(A)5

12 56481363 56481368 pl.(C)6 12 71833843 71833847 pl.(C)5

12 56481662 56481666 pl.(G)5 12 71833921 71833925 pl.(G)5

12 56481794 56481799 pl.(T)6 12 71898385 71898391 pl.(C)7

12 56482392 56482396 pl.(A)5 12 71946884 71946888 pl.(C)5

12 56482422 56482426 pl.(G)5 12 71965286 71965290 pl.(T)5

12 56486818 56486823 pl.(T)6 12 71965330 71965334 pl.(T)5

12 56487278 56487282 pl.(G)5 12 71971691 71971697 pl.(T)7

12 56487586 56487590 pl.(G)5 12 71977559 71977563 pl.(C)5

12 56488248 56488252 pl.(C)5 12 71977713 71977718 pl.(T)6

12 56490962 56490967 pl.(G)6 12 71977724 71977728 pl.(T)5

12 56492628 56492632 pl.(G)5 12 71978363 71978367 pl.(A)5

12 56493620 56493629 p2.(AG)5 12 92537884 92537888 pl.(T)5

12 56493944 56493949 pl.(T)6 12 92539312 92539316 pl.(G)5

12 56494877 56494881 pl.(C)5 12 92539325 92539329 pl.(G)5

12 56495306 56495310 pl.(C)5 12 111856235 111856239 pl.(C)5

12 56495441 56495445 pl.(C)5 12 111856434 111856438 pl.(C)5

12 56495627 56495631 pl.(G)5 12 111856443 111856447 pl.(C)5

12 56495647 56495651 pl.(G)5 12 111856464 111856468 pl.(C)5

12 56495715 56495720 pl.(C)6 12 111885145 111885150 pl.(G)6

12 56495740 56495744 pl.(A)5 12 111885352 111885376 p5.(TGGGG)5

12 57107333 57107337 pl.(A)5 12 111885901 111885905 pl.(G)5

12 57910951 57910955 pl.(T)5 12 111885939 111885944 pl.(C)6

12 57911083 57911087 pl.(C)5 12 112204866 112204870 pl.(C)5

12 58143031 58143036 pl.(G)6 12 112227714 112227718 pl.(G)5

12 58143105 58143109 pl.(G)5 12 112229119 112229123 pl.(C)5

12 58145018 58145022 pl.(G)5 12 112229927 112229933 pl.(G)7

12 59267917 59267921 pl.(T)5 12 112235938 112235942 pl.(G)5

12 59268049 59268053 pl.(T)5 12 112235960 112235964 pl.(G)5

12 59268114 59268118 pl.(T)5 12 112884072 112884076 pl.(T)5

12 59268283 59268287 pl.(A)5 12 112884149 112884154 pl.(T)6

12 59270250 59270254 pl.(A)5 12 112890982 112890992 pl.(T)6(A)5

12 59271483 59271488 pl.(A)6 12 112891049 112891053 pl.(A)5

12 59271541 59271545 pl.(G)5 12 112910733 112910744 p4.(TTTC)3

12 59271619 59271623 pl.(A)5 12 112910811 112910815 pl.(A)5

12 59272767 59272771 pl.(C)5 12 112910817 112910821 pl.(A)5

12 59272792 59272797 pl.(G)6 12 112910829 112910833 pl.(A)5

12 59272862 59272866 pl.(G)5 12 112915443 112915447 pl.(T)5

12 59274556 59274561 pl.(T)6 12 112915697 112915701 pl.(A)5

12 59274689 59274693 pl.(A)5 12 112924351 112924355 pl.(G)5

12 59276679 59276683 pl.(A)5 12 121416697 121416701 pl.(C)5

12 59277377 59277381 pl.(A)5 12 121416709 121416713 pl.(G)5

12 59279645 59279650 pl.(T)6 12 121416763 121416767 pl.(G)5

12 59279691 59279697 pl.(A)7 12 121432118 121432125 pl.(C)8

12 59282621 59282630 pl.(C)5(A)5 12 121432191 121432195 pl.(C)5

12 59282718 59282722 pl.(T)5 12 121434164 121434168 pl.(C)5

12 65445175 65445179 pl.(T)5 12 121434356 121434365 pl.(G)5(C)5

12 65449910 65449914 pl.(A)5 12 121434367 121434372 pl.(C)6

12 65462692 65462698 pl.(A)7 12 121435461 121435465 pl.(C)5

12 65514341 65514345 pl.(T)5 12 121437279 121437283 pl.(C)5

12 65514813 65514817 pl.(G)5 12 121439034 121439039 pl.(G)6

12 66221835 66221839 pl.(A)5 12 121440235 121440239 pl.(C)5

12 66357072 66357076 pl.(G)5 12 122473237 122473241 pl.(A)5

12 69202230 69202234 pl.(C)5 12 122473252 122473257 pl.(A)6

12 69202972 69202979 pl.(T)8 12 122481782 122481786 pl.(C)5

12 69203080 69203084 pl.(T)5 12 122481828 122481832 nl ίΓ« Chr Start End MS Chr Start End MS

12 122492892 122492896 pl.(G)5 13 26975687 26975691 pl.(C)5

12 133209268 133209272 pl.(C)5 13 28537278 28537284 pl.(C)7

12 133209298 133209303 pl.(C)6 13 28537425 28537436 p3.(GCT)4

12 133209314 133209318 pl.(G)5 13 28543040 28543045 pl.(G)6

12 133210819 133210823 pl.(A)5 13 28588620 28588624 pl.(A)5

12 133210882 133210893 p3.(TCC)4 13 28589809 28589813 pl.(G)5

12 133210942 133210946 pl.(C)5 13 28597588 28597593 pl.(T)6

12 133218360 133218364 pl.(C)5 13 28599086 28599091 pl.(A)6

12 133219301 133219305 pl.(C)5 13 28601256 28601260 pl.(A)5

12 133219487 133219492 pl.(G)6 13 28601305 28601309 pl.(T)5

12 133220099 133220110 p2.(CA)6 13 28601359 28601363 pl.(A)5

12 133225574 133225578 pl.(G)5 13 28602330 28602334 pl.(C)5

12 133233794 133233799 pl.(T)6 13 28602421 28602425 pl.(T)5

12 133238184 133238189 pl.(A)6 13 28608439 28608443 pl.(T)5

12 133242026 133242030 pl.(T)5 13 28609814 28609823 pl.(A)10

12 133245024 133245030 pl.(G)7 13 28611433 28611437 pl.(A)5

12 133245435 133245439 pl.(C)5 13 28622509 28622513 pl.(A)5

12 133249274 133249278 pl.(C)5 13 28622588 28622593 pl.(A)6

12 133252024 133252028 pl.(C)5 13 28624317 28624321 pl.(T)5

12 133252326 133252331 pl.(A)6 13 28624327 28624331 pl.(T)5

12 133252728 133252732 pl.(G)5 13 28626686 28626690 pl.(C)5

12 133264011 133264015 pl.(C)5 13 28626770 28626774 pl.(T)5

12 133264017 133264022 pl.(C)6 13 28631536 28631540 pl.(A)5

12 133264053 133264057 pl.(G)5 13 28644741 28644746 pl.(A)6

13 20567378 20567389 p3.(GAT)4 13 28877347 28877351 pl.(G)5

13 20567394 20567398 pl.(T)5 13 28877508 28877519 p4.(AAAG)3

13 20567417 20567421 pl.(C)5 13 28880913 28880917 pl.(G)5

13 20567473 20567478 pl.(A)6 13 28886163 28886167 pl.(T)5

13 20567609 20567613 pl.(A)5 13 28897047 28897052 pl.(T)6

13 20567651 20567655 pl.(A)5 13 28901608 28901613 pl.(A)6

13 20567689 20567693 pl.(T)5 13 28903818 28903822 pl.(T)5

13 20568021 20568025 pl.(T)5 13 28903860 28903864 pl.(C)5

13 20576982 20576986 pl.(T)5 13 28959048 28959052 pl.(T)5

13 20577145 20577150 pl.(A)6 13 28964077 28964082 pl.(T)6

13 20577271 20577275 pl.(A)5 13 28964206 28964211 pl.(T)6

13 20580502 20580506 pl.(T)5 13 28980037 28980046 pl.(A)10

13 20580535 20580539 pl.(A)5 13 29001915 29001919 pl.(T)5

13 20593678 20593684 pl.(T)7 13 29002067 29002071 pl.(A)5

13 20605534 20605538 pl.(A)5 13 29005443 29005447 pl.(T)5

13 20610869 20610873 pl.(T)5 13 29012359 29012364 pl.(T)6

13 20611023 20611028 pl.(A)6 13 29041262 29041267 pl.(C)6

13 20625560 20625564 pl.(T)5 13 32890594 32890598 pl.(A)5

13 20632727 20632731 pl.(C)5 13 32890628 32890633 pl.(T)6

13 20633580 20633584 pl.(T)5 13 32890638 32890642 pl.(T)5

13 20635206 20635210 pl.(T)5 13 32900296 32900300 pl.(A)5

13 20635264 20635268 pl.(A)5 13 32900364 32900370 pl.(T)7

13 20640977 20640982 pl.(T)6 13 32900372 32900376 pl.(C)5

13 20641372 20641376 pl.(T)5 13 32905047 32905051 pl.(T)5

13 20657094 20657101 pl.(A)8 13 32905070 32905074 pl.(T)5

13 20657787 20657792 pl.(T)6 13 32905098 32905102 pl.(A)5

13 20657812 20657816 pl.(A)5 13 32906416 32906420 pl.(A)5

13 20659991 20659996 pl.(T)6 13 32906536 32906540 pl.(T)5

13 20660153 20660157 pl.(A)5 13 32906548 32906552 pl.(T)5

13 26828733 26828738 pl.(C)6 13 32906566 32906571 pl.(A)6

13 26828741 26828746 pl.(C)6 13 32906577 32906581 pl.(A)5

13 26828911 26828920 p2.(GT)5 13 32906603 32906609 pl.(A)7

13 26927863 26927874 p4.(TTTC)3 13 32906640 32906644 pl.(A)5

13 26975408 26975412 pl.(T)5 13 32906648 32906652 pl.(A)5

13 26975446 26975450 pl.(T)5 13 32906664 32906668 pl.(A)5

13 26975609 26975623 p3.(CAG)5 13 32906889 32906893 nl (A\ Chr Start End MS Chr Start End MS

13 32906916 32906927 p4.(AAAG)3 13 32929162 32929167 pl.(A)6

13 32907119 32907123 pl.(A)5 13 32929326 32929330 pl.(A)5

13 32907172 32907176 pl.(T)5 13 32929365 32929369 pl.(A)5

13 32907203 32907208 pl.(A)6 13 32930668 32930672 pl.(A)5

13 32907365 32907369 pl.(A)5 13 32931911 32931915 pl.(A)5

13 32907421 32907428 pl.(A)8 13 32931924 32931928 pl.(A)5

13 32907441 32907445 pl.(A)5 13 32937355 32937360 pl.(A)6

13 32910389 32910393 pl.(T)5 13 32937388 32937392 pl.(A)5

13 32910579 32910583 pl.(A)5 13 32937480 32937484 pl.(A)5

13 32910655 32910659 pl.(A)5 13 32953633 32953639 pl.(A)7

13 32910662 32910667 pl.(A)6 13 32953641 32953645 pl.(A)5

13 32910923 32910927 pl.(A)5 13 32954023 32954030 pl.(A)8

13 32910977 32910981 pl.(A)5 13 32954204 32954208 pl.(T)5

13 32911002 32911006 pl.(A)5 13 32954273 32954279 pl.(A)7

13 32911074 32911080 pl.(A)7 13 32968995 32968999 pl.(T)5

13 32911105 32911109 pl.(A)5 13 32969056 32969060 pl.(A)5

13 32911322 32911327 pl.(A)6 13 32972287 32972293 pl.(T)7

13 32911358 32911362 pl.(A)5 13 32972446 32972450 pl.(A)5

13 32911381 32911385 pl.(A)5 13 32972590 32972595 pl.(A)6

13 32911443 32911449 pl.(A)7 13 32972626 32972631 pl.(A)6

13 32911736 32911740 pl.(A)5 13 32972726 32972730 pl.(A)5

13 32912081 32912085 pl.(A)5 13 32972866 32972870 pl.(A)5

13 32912196 32912200 pl.(A)5 13 32972893 32972898 pl.(A)6

13 32912346 32912352 pl.(A)7 13 40174968 40174972 pl.(C)5

13 32912519 32912523 pl.(A)5 13 40175061 40175072 p3.(AGG)4

13 32912656 32912661 pl.(T)6 13 41133898 41133903 pl.(C)6

13 32912771 32912776 pl.(T)6 13 41134359 41134363 pl.(T)5

13 32912792 32912796 pl.(A)5 13 41134928 41134932 pl.(T)5

13 32913080 32913085 pl.(A)6 13 41239933 41239938 pl.(G)6

13 32913119 32913123 pl.(A)5 13 41240355 41240359 pl.(C)5

13 32913126 32913130 pl.(T)5 13 46701833 46701837 pl.(T)5

13 32913135 32913139 pl.(A)5 13 46721052 46721057 pl.(C)6

13 32913296 32913300 pl.(A)5 13 46728965 46728969 pl.(T)5

13 32913382 32913386 pl.(A)5 13 46732768 46732772 pl.(T)5

13 32913392 32913396 pl.(T)5 13 46732791 46732795 pl.(A)5

13 32913423 32913427 pl.(A)5 13 46733797 46733802 pl.(T)6

13 32913436 32913440 pl.(A)5 13 48878062 48878067 pl.(C)6

13 32913502 32913506 pl.(T)5 13 48878069 48878073 pl.(A)5

13 32913523 32913527 pl.(A)5 13 48878106 48878110 pl.(C)5

13 32913559 32913565 pl.(A)7 13 48878115 48878126 p3.(CCG)4

13 32913677 32913681 pl.(A)5 13 48878127 48878131 pl.(C)5

13 32913693 32913697 pl.(A)5 13 48881489 48881498 p2.(AG)5

13 32913784 32913789 pl.(A)6 13 48916721 48916726 pl.(T)6

13 32913837 32913843 pl.(A)7 13 48916753 48916757 pl.(A)5

13 32913850 32913854 pl.(T)5 13 48916834 48916838 pl.(A)5

13 32913953 32913957 pl.(A)5 13 48934141 48934149 pl.(T)9

13 32913959 32913963 pl.(A)5 13 48941616 48941621 pl.(T)6

13 32914070 32914075 pl.(A)6 13 48941669 48941673 pl.(A)5

13 32914138 32914142 pl.(A)5 13 48941696 48941700 pl.(T)5

13 32914251 32914255 pl.(T)5 13 48942687 48942691 pl.(A)5

13 32914422 32914426 pl.(T)5 13 49030368 49030373 pl.(A)6

13 32914617 32914621 pl.(A)5 13 49030479 49030484 pl.(A)6

13 32914801 32914805 pl.(A)5 13 49039329 49039333 pl.(T)5

13 32914860 32914865 pl.(A)6 13 49039341 49039345 pl.(C)5

13 32915054 32915058 pl.(A)5 13 49039484 49039488 pl.(A)5

13 32915062 32915066 pl.(A)5 13 49050933 49050938 pl.(A)6

13 32915089 32915093 pl.(T)5 13 49054125 49054129 pl.(T)5

13 32915250 32915254 pl.(T)5 13 103053835 103053839 pl.(T)5

13 32915302 32915306 pl.(A)5 13 103054032 103054036 pl.(A)5

13 32929096 32929100 pl.(A)5 13 103498619 103498623 nl ίΠ« Chr Start End MS Chr Start End MS

13 103504578 103504583 pl.(T)6 14 20781791 20781795 pl.(T)5

13 103504597 103504601 pl.(T)5 14 23777233 23777237 pl.(T)5

13 103506715 103506719 pl.(A)5 14 23777241 23777245 pl.(G)5

13 103508419 103508423 pl.(A)5 14 23777400 23777404 pl.(G)5

13 103508446 103508450 pl.(A)5 14 23778117 23778121 pl.(G)5

13 103510685 103510689 pl.(C)5 14 23778132 23778136 pl.(G)5

13 103513899 103513903 pl.(A)5 14 23778157 23778162 pl.(T)6

13 103513992 103513996 pl.(G)5 14 23778207 23778211 pl.(G)5

13 103514479 103514483 pl.(A)5 14 35873802 35873806 pl.(G)5

13 103518670 103518674 pl.(A)5 14 35873826 35873830 pl.(G)5

13 103519135 103519140 pl.(T)6 14 36986877 36986881 pl.(C)5

13 103519144 103519148 pl.(A)5 14 36986886 36986890 pl.(C)5

13 103524568 103524574 pl.(A)7 14 36986889 36986900 p3.(CCG)4

13 103524612 103524620 pl.(A)9 14 36987157 36987161 pl.(C)5

13 103524718 103524722 pl.(G)5 14 36988309 36988314 pl.(C)6

13 103527648 103527654 pl.(T)7 14 36988340 36988344 pl.(C)5

13 103527851 103527855 pl.(A)5 14 36988599 36988606 pl.(A)8

13 103527951 103527960 pl.(T)5(G)5 14 38060553 38060558 pl.(C)6

13 103528058 103528062 pl.(A)5 14 38060812 38060816 pl.(G)5

13 103528238 103528242 pl.(A)5 14 38060912 38060917 pl.(G)6

13 103528256 103528261 pl.(A)6 14 38060955 38060959 pl.(C)5

13 110434454 110434458 pl.(G)5 14 38060992 38060996 pl.(G)5

13 110434477 110434482 pl.(C)6 14 38061011 38061015 pl.(G)5

13 110434526 110434530 pl.(C)5 14 38061138 38061142 pl.(C)5

13 110434578 110434592 p3.(GCG)5 14 38061156 38061160 pl.(C)5

13 110434721 110434725 pl.(C)5 14 38061169 38061173 pl.(C)5

13 110434766 110434770 pl.(G)5 14 38061517 38061528 p3.(CGC)4

13 110434811 110434815 pl.(C)5 14 38061726 38061731 pl.(C)6

13 110434921 110434925 pl.(G)5 14 51202268 51202272 pl.(T)5

13 110434962 110434973 p3.(GGC)4 14 51202342 51202349 pl.(A)8

13 110434973 110434978 pl.(C)6 14 51204848 51204852 pl.(A)5

13 110435013 110435017 pl.(G)5 14 51204918 51204922 pl.(T)5

13 110435021 110435025 pl.(G)5 14 51204963 51204967 pl.(T)5

13 110435129 110435135 pl.(G)7 14 51211015 51211019 pl.(T)5

13 110435263 110435268 pl.(G)6 14 51211044 51211049 pl.(T)6

13 110435283 110435287 pl.(C)5 14 51214831 51214835 pl.(A)5

13 110435345 110435349 pl.(G)5 14 51219317 51219321 pl.(T)5

13 110435377 110435381 pl.(G)5 14 51219368 51219372 pl.(T)5

13 110435443 110435447 pl.(G)5 14 51219429 51219433 pl.(T)5

13 110435816 110435820 pl.(G)5 14 51219436 51219440 pl.(T)5

13 110435914 110435918 pl.(G)5 14 51223224 51223228 pl.(T)5

13 110435962 110435966 pl.(G)5 14 51223311 51223315 pl.(T)5

13 110436088 110436092 pl.(G)5 14 51223539 51223543 pl.(T)5

13 110436190 110436194 pl.(G)5 14 51224050 51224055 pl.(T)6

13 110436227 110436231 pl.(C)5 14 51224070 51224074 pl.(A)5

13 110436297 110436320 p3.(CGG)8 14 51224207 51224211 pl.(A)5

13 110436343 110436347 pl.(G)5 14 51224368 51224372 pl.(A)5

13 110436456 110436460 pl.(C)5 14 51224400 51224405 pl.(A)6

13 110436717 110436721 pl.(C)5 14 51225062 51225071 p2.(TC)5

13 110436791 110436805 p3.(CCG)5 14 51225341 51225346 pl.(T)6

13 110436815 110436819 pl.(G)5 14 51226868 51226873 pl.(T)6

13 110436925 110436929 pl.(G)5 14 51226953 51226957 pl.(T)5

13 110437133 110437137 pl.(C)5 14 51226973 51226977 pl.(T)5

13 110437233 110437237 pl.(G)5 14 51237150 51237154 pl.(T)5

13 110437402 110437407 pl.(G)6 14 51237214 51237223 p2.(CT)5

13 110437755 110437759 pl.(C)5 14 51237236 51237241 pl.(T)6

13 110438159 110438163 pl.(T)5 14 51237680 51237684 pl.(T)5

14 20779717 20779721 pl.(T)5 14 51239659 51239664 pl.(T)6

14 20779784 20779789 pl.(A)6 14 51239684 51239688 pl.(T)5

14 20779826 20779831 pl.(A)6 14 51239734 51239738 ni ms Chr Start End MS Chr Start End MS

14 51239752 51239757 pl.(A)6 14 92470084 92470088 pl.(T)5

14 56078944 56078948 pl.(A)5 14 92470243 92470247 pl.(T)5

14 56078953 56078957 pl.(A)5 14 92470472 92470476 pl.(T)5

14 56079108 56079113 pl.(A)6 14 92470813 92470817 pl.(T)5

14 56079187 56079192 pl.(A)6 14 92470894 92470899 pl.(T)6

14 56079277 56079281 pl.(A)5 14 92470971 92470975 pl.(T)5

14 56084825 56084830 pl.(A)6 14 92471338 92471342 pl.(A)5

14 56096688 56096699 p4.(AGAA)3 14 92471409 92471414 pl.(T)6

14 56113679 56113683 pl.(T)5 14 92471444 92471448 pl.(A)5

14 56113719 56113723 pl.(A)5 14 92471767 92471771 pl.(T)5

14 56114751 56114755 pl.(A)5 14 92471798 92471803 pl.(T)6

14 56115514 56115518 pl.(A)5 14 92471872 92471876 pl.(A)5

14 56119727 56119731 pl.(T)5 14 92471981 92471985 pl.(T)5

14 56122748 56122753 pl.(A)6 14 92472131 92472135 pl.(T)5

14 56126396 56126400 pl.(C)5 14 92472166 92472170 pl.(T)5

14 56130661 56130665 pl.(A)5 14 92472174 92472178 pl.(T)5

14 56130685 56130689 pl.(A)5 14 92472197 92472203 pl.(T)7

14 56130722 56130727 pl.(A)6 14 92472698 92472704 pl.(T)7

14 56137475 56137481 pl.(A)7 14 92472800 92472804 pl.(A)5

14 56138345 56138349 pl.(A)5 14 92477357 92477361 pl.(T)5

14 56142544 56142548 pl.(T)5 14 92477421 92477425 pl.(A)5

14 56145099 56145103 pl.(A)5 14 92482209 92482214 pl.(A)6

14 56146276 56146280 pl.(T)5 14 92487883 92487893 pl.(A)6(T)5

14 56150851 56150856 pl.(A)6 14 92491657 92491661 pl.(T)5

14 65543166 65543170 pl.(T)5 14 92491769 92491777 pl.(A)9

14 65543267 65543271 pl.(C)5 14 92505968 92505972 pl.(C)5

14 65544693 65544697 pl.(T)5 14 92506010 92506014 pl.(C)5

14 66975316 66975320 pl.(G)5 14 92506065 92506070 pl.(A)6

14 67389497 67389501 pl.(C)5 14 93263894 93263898 pl.(A)5

14 67389526 67389530 pl.(C)5 14 93264000 93264004 pl.(A)5

14 67555750 67555755 pl.(C)6 14 93264121 93264126 pl.(A)6

14 67579894 67579898 pl.(A)5 14 93264210 93264214 pl.(A)5

14 67610068 67610074 pl.(T)7 14 93273069 93273076 pl.(T)8

14 67610143 67610147 pl.(G)5 14 93275634 93275639 pl.(T)6

14 67610157 67610161 pl.(G)5 14 93275855 93275859 pl.(A)5

14 67626190 67626194 pl.(T)5 14 93282603 93282607 pl.(A)5

14 67631865 67631871 pl.(T)7 14 93286040 93286044 pl.(T)5

14 67631921 67631925 pl.(A)5 14 93299699 93299704 pl.(A)6

14 68292184 68292188 pl.(T)5 14 93301931 93301935 pl.(T)5

14 68301921 68301930 pl.(A)5(T)5 14 93303745 93303749 pl.(T)5

14 81554355 81554359 pl.(C)5 14 93303775 93303779 pl.(T)5

14 81609362 81609366 pl.(C)5 14 93305824 93305828 pl.(T)5

14 81609513 81609522 pl.(A)5(C)5 14 95556792 95556799 pl.(T)8

14 81609598 81609602 pl.(C)5 14 95556824 95556828 pl.(A)5

14 81609746 81609750 pl.(C)5 14 95557005 95557010 pl.(A)6

14 81610032 81610036 pl.(G)5 14 95557359 95557364 pl.(T)6

14 81610153 81610157 pl.(T)5 14 95557631 95557635 pl.(A)5

14 81610522 81610526 pl.(G)5 14 95557639 95557643 pl.(C)5

14 92436189 92436193 pl.(A)5 14 95560398 95560402 pl.(C)5

14 92441021 92441025 pl.(T)5 14 95562799 95562804 pl.(T)6

14 92441583 92441587 pl.(T)5 14 95562840 95562844 pl.(A)5

14 92442441 92442445 pl.(A)5 14 95562982 95562993 p3.(CTC)4

14 92460190 92460194 pl.(T)5 14 95569684 95569688 pl.(T)5

14 92460216 92460220 pl.(T)5 14 95569765 95569769 pl.(A)5

14 92460249 92460253 pl.(T)5 14 95570433 95570438 pl.(T)6

14 92461868 92461872 pl.(A)5 14 95572563 95572568 pl.(A)6

14 92465574 92465579 pl.(A)6 14 95573983 95573987 pl.(A)5

14 92466342 92466346 pl.(T)5 14 95574205 95574211 pl.(T)7

14 92469832 92469836 pl.(T)5 14 95574281 95574285 pl.(T)5

14 92469918 92469923 pl.(T)6 14 95579570 95579574 nl (A^ Chr Start End MS Chr Start End MS

14 95590568 95590572 pl.(A)5 15 40462833 40462837 pl.(A)5

14 95590628 95590632 pl.(T)5 15 40475980 40475984 pl.(T)5

14 95590875 95590879 pl.(A)5 15 40476036 40476040 pl.(A)5

14 95591010 95591017 pl.(A)8 15 40477353 40477357 pl.(T)5

14 95598841 95598846 pl.(T)6 15 40477435 40477439 pl.(T)5

14 95598876 95598880 pl.(T)5 15 40477506 40477511 pl.(C)6

14 95599820 95599824 pl.(T)5 15 40494781 40494785 pl.(T)5

14 96178662 96178666 pl.(G)5 15 40494803 40494807 pl.(C)5

14 99640549 99640553 pl.(T)5 15 40504777 40504781 pl.(T)5

14 99641206 99641210 pl.(C)5 15 40509789 40509793 pl.(T)5

14 99641679 99641683 pl.(G)5 15 40512758 40512762 pl.(T)5

14 99641914 99641918 pl.(G)5 15 40512872 40512876 pl.(T)5

14 99641932 99641936 pl.(G)5 15 40912893 40912898 pl.(T)6

14 99642214 99642218 pl.(G)5 15 40913048 40913053 pl.(A)6

14 99697775 99697779 pl.(G)5 15 40913062 40913066 pl.(T)5

14 99697857 99697861 pl.(G)5 15 40913119 40913123 pl.(A)5

14 99697901 99697906 pl.(A)6 15 40913289 40913293 pl.(A)5

14 99723872 99723876 pl.(G)5 15 40913467 40913471 pl.(T)5

14 99724016 99724020 pl.(A)5 15 40913550 40913554 pl.(T)5

14 99724030 99724034 pl.(C)5 15 40913635 40913639 pl.(G)5

14 102548790 102548794 pl.(A)5 15 40913810 40913814 pl.(A)5

14 102549380 102549385 pl.(T)6 15 40913955 40913959 pl.(T)5

14 102549430 102549436 pl.(T)7 15 40914006 40914010 pl.(A)5

14 102549450 102549454 pl.(T)5 15 40914353 40914357 pl.(A)5

14 102550137 102550141 pl.(T)5 15 40914593 40914597 pl.(A)5

14 102550211 102550216 pl.(T)6 15 40914879 40914883 pl.(A)5

14 102550324 102550330 pl.(A)7 15 40914903 40914908 pl.(A)6

14 102550810 102550814 pl.(T)5 15 40915030 40915034 pl.(A)5

14 102550895 102550899 pl.(A)5 15 40915589 40915593 pl.(A)5

14 102551161 102551178 p3.(TCT)6 15 40915657 40915661 pl.(A)5

14 102551258 102551262 pl.(T)5 15 40915672 40915677 pl.(A)6

14 102551264 102551268 pl.(T)5 15 40915709 40915713 pl.(A)5

14 102551625 102551629 pl.(A)5 15 40916044 40916049 pl.(A)6

14 102551635 102551639 pl.(A)5 15 40916100 40916104 pl.(A)5

14 102552121 102552125 pl.(C)5 15 40916265 40916269 pl.(A)5

14 102552470 102552475 pl.(A)6 15 40916445 40916449 pl.(A)5

14 102605734 102605738 pl.(G)5 15 40916692 40916696 pl.(G)5

14 105236710 105236714 pl.(G)5 15 40916822 40916827 pl.(A)6

14 105238778 105238782 pl.(C)5 15 40916972 40916977 pl.(A)6

14 105239313 105239317 pl.(A)5 15 40917160 40917164 pl.(A)5

14 105239385 105239389 pl.(C)5 15 40917173 40917177 pl.(T)5

14 105239591 105239595 pl.(G)5 15 40917332 40917336 pl.(A)5

14 105240253 105240257 pl.(C)5 15 40917381 40917385 pl.(T)5

14 105242073 105242084 p3.(CTC)4 15 40917419 40917423 pl.(T)5

15 34640379 34640383 pl.(G)5 15 40917690 40917694 pl.(A)5

15 34640439 34640444 pl.(G)6 15 40917724 40917728 pl.(A)5

15 34640680 34640684 pl.(A)5 15 40917741 40917746 pl.(A)6

15 34642894 34642898 pl.(G)5 15 40917759 40917770 p3.(AAG)4

15 34646683 34646688 pl.(C)6 15 40917785 40917791 pl.(A)7

15 34647271 34647275 pl.(A)5 15 40917796 40917801 pl.(A)6

15 34647838 34647842 pl.(G)5 15 40920269 40920273 pl.(T)5

15 34647845 34647849 pl.(G)5 15 40920324 40920329 pl.(A)6

15 34647969 34647973 pl.(C)5 15 40933097 40933105 pl.(T)9

15 34648286 34648290 pl.(G)5 15 40954465 40954469 pl.(T)5

15 34648377 34648381 pl.(C)5 15 40990947 40990951 pl.(T)5

15 34649080 34649084 pl.(C)5 15 40998365 40998369 pl.(T)5

15 34649123 34649127 pl.(A)5 15 41001215 41001220 pl.(T)6

15 34649306 34649310 pl.(A)5 15 41022126 41022131 pl.(A)6

15 34649312 34649316 pl.(A)5 15 41023386 41023390 pl.(T)5

15 40462330 40462334 pl.(T)5 15 41023399 41023403 nl (A^ Chr Start End MS Chr Start End MS

15 45847654 45847669 p4.(TTTA)4 15 91292663 91292667 pl.(A)5

15 45847739 45847744 pl.(A)6 15 91292769 91292773 pl.(A)5

15 45848143 45848147 pl.(T)5 15 91293056 91293061 pl.(A)6

15 55700942 55700947 pl.(A)6 15 91293075 91293080 pl.(T)6

15 55710625 55710629 pl.(T)5 15 91295090 91295101 p3.(TGA)4

15 57355941 57355945 pl.(T)5 15 91303965 91303969 pl.(T)5

15 57383979 57383983 pl.(C)5 15 91304060 91304064 pl.(T)5

15 57489984 57489990 pl.(A)7 15 91304139 91304147 pl.(A)9

15 57524477 57524481 pl.(T)5 15 91304286 91304300 p3.(TGA)5

15 57525061 57525065 pl.(T)5 15 91306286 91306290 pl.(T)5

15 57544619 57544623 pl.(A)5 15 91306294 91306299 pl.(A)6

15 57565386 57565390 pl.(A)5 15 91306395 91306399 pl.(T)5

15 57574630 57574634 pl.(C)5 15 91312651 91312659 pl.(T)9

15 57574691 57574695 pl.(A)5 15 91326044 91326049 pl.(T)6

15 57578878 57578882 pl.(A)5 15 91326101 91326105 pl.(A)5

15 66679650 66679655 pl.(C)6 15 91326110 91326114 pl.(A)5

15 66679726 66679730 pl.(C)5 15 91328318 91328322 pl.(T)5

15 66727506 66727510 pl.(G)5 15 91341407 91341411 pl.(T)5

15 66777509 66777513 pl.(C)5 15 91346764 91346768 pl.(A)5

15 66779599 66779603 pl.(T)5 15 91346826 91346835 pl.(T)5(A)5

15 66782062 66782067 pl.(A)6 15 91346959 91346963 pl.(T)5

15 74287226 74287231 pl.(C)6 15 91347433 91347438 pl.(A)6

15 74287236 74287240 pl.(C)5 15 91347440 91347444 pl.(A)5

15 74290338 74290342 pl.(C)5 15 91347484 91347489 pl.(A)6

15 74290349 74290353 pl.(C)5 15 91347533 91347537 pl.(T)5

15 74290537 74290541 pl.(T)5 15 91347557 91347561 pl.(T)5

15 74335425 74335429 pl.(C)5 15 91352430 91352434 pl.(A)5

15 74336739 74336743 pl.(G)5 15 91354569 91354573 pl.(A)5

15 74336986 74336990 pl.(C)5 15 91354604 91354608 pl.(A)5

15 74337151 74337156 pl.(G)6 15 91358331 91358335 pl.(G)5

15 74337203 74337207 pl.(C)5 15 99192755 99192778 pl.(T)24

15 74337355 74337359 pl.(G)5 15 99192851 99192855 pl.(G)5

15 88423489 88423498 pl.(C)5(T)5 15 99251109 99251114 pl.(G)6

15 88476295 88476299 pl.(G)5 15 99251129 99251133 pl.(A)5

15 88576130 88576134 pl.(G)5 15 99251216 99251220 pl.(C)5

15 88678391 88678395 pl.(T)5 15 99434695 99434706 p4.(TGCC)3

15 88678547 88678552 pl.(G)6 15 99440129 99440133 pl.(G)5

15 88678622 88678626 pl.(G)5 15 99442809 99442814 pl.(A)6

15 88680722 88680726 pl.(C)5 15 99454621 99454625 pl.(C)5

15 88680772 88680776 pl.(A)5 15 99467164 99467168 pl.(T)5

15 88726662 88726666 pl.(G)5 15 99473454 99473458 pl.(T)5

15 88799219 88799223 pl.(G)5 15 99500476 99500480 pl.(C)5

15 90627494 90627498 pl.(C)5 15 99500618 99500622 pl.(G)5

15 90628262 90628266 pl.(C)5 16 339452 339456 pl.(T)5

15 90628339 90628343 pl.(G)5 16 343564 343568 pl.(G)5

15 90630504 90630508 pl.(A)5 16 347093 347097 pl.(C)5

15 90630813 90630817 pl.(G)5 16 347748 347752 pl.(G)5

15 90631886 90631890 pl.(T)5 16 347983 347988 pl.(C)6

15 90631918 90631924 pl.(C)7 16 348180 348184 pl.(G)5

15 90634774 90634778 pl.(G)5 16 348211 348215 pl.(G)5

15 90645536 90645540 pl.(G)5 16 360055 360060 pl.(G)6

15 91136948 91136952 pl.(C)5 16 396234 396239 pl.(G)6

15 91136994 91136999 pl.(T)6 16 396792 396796 pl.(G)5

15 91147608 91147612 pl.(T)5 16 396955 396959 pl.(G)5

15 91150677 91150681 pl.(G)5 16 2100466 2100470 pl.(A)5

15 91161098 91161106 pl.(T)9 16 2104308 2104312 pl.(G)5

15 91168999 91169004 pl.(T)6 16 2105396 2105400 pl.(C)5

15 91181747 91181751 pl.(C)5 16 2110822 2110826 pl.(G)5

15 91292589 91292593 pl.(T)5 16 2112016 2112020 pl.(C)5

15 91292610 91292614 pl.(A)5 16 2112605 2112609 nl ίΠ« Chr Start End MS Chr Start End MS

16 2115544 2115548 pl.(C)5 16 3828057 3828061 pl.(C)5

16 2121821 2121825 pl.(C)5 16 3828121 3828125 pl.(T)5

16 2126529 2126533 pl.(C)5 16 3828136 3828140 pl.(T)5

16 2127615 2127620 pl.(C)6 16 3828186 3828190 pl.(A)5

16 2129112 2129116 pl.(A)5 16 3832688 3832692 pl.(G)5

16 2129400 2129404 pl.(G)5 16 3842008 3842012 pl.(T)5

16 2130165 2130169 pl.(G)5 16 3843434 3843438 pl.(T)5

16 2131772 2131776 pl.(C)5 16 3843553 3843557 pl.(T)5

16 2133752 2133756 pl.(C)5 16 3860693 3860697 pl.(G)5

16 2134569 2134574 pl.(C)6 16 3860788 3860793 pl.(A)6

16 2134978 2134982 pl.(C)5 16 3900661 3900665 pl.(G)5

16 2138147 2138151 pl.(G)5 16 3900703 3900707 pl.(G)5

16 2213961 2213966 pl.(G)6 16 3929821 3929825 pl.(C)5

16 2220615 2220620 pl.(C)6 16 9857003 9857007 pl.(T)5

16 2220714 2220728 p3.(GAG)5 16 9857075 9857079 pl.(G)5

16 2220740 2220744 pl.(G)5 16 9857365 9857369 pl.(G)5

16 2222314 2222319 pl.(C)6 16 9857380 9857386 pl.(T)7

16 2222334 2222338 pl.(C)5 16 9857428 9857432 pl.(A)5

16 2226259 2226263 pl.(C)5 16 9857702 9857706 pl.(G)5

16 3777751 3777755 pl.(C)5 16 9857917 9857921 pl.(C)5

16 3777803 3777807 pl.(G)5 16 9858533 9858537 pl.(A)5

16 3777817 3777821 pl.(G)5 16 9858693 9858697 pl.(T)5

16 3777898 3777903 pl.(G)6 16 9923281 9923285 pl.(T)5

16 3778099 3778103 pl.(G)5 16 9928017 9928021 pl.(A)5

16 3778193 3778197 pl.(G)5 16 9934970 9934974 pl.(A)5

16 3778207 3778211 pl.(C)5 16 9943668 9943672 pl.(G)5

16 3778282 3778286 pl.(G)5 16 10273880 10273884 pl.(C)5

16 3778303 3778314 p3.(GCT)4 16 10274173 10274178 pl.(G)6

16 3778377 3778381 pl.(C)5 16 10989215 10989219 pl.(C)5

16 3778401 3778412 p3.(TGC)4 16 10995900 10995905 pl.(C)6

16 3778440 3778454 p3.(TGC)5 16 10996050 10996054 pl.(G)5

16 3778549 3778553 pl.(G)5 16 10997576 10997580 pl.(C)5

16 3779057 3779061 pl.(G)5 16 10997614 10997618 pl.(C)5

16 3779100 3779104 pl.(G)5 16 10998613 10998617 pl.(C)5

16 3779136 3779147 p3.(TGC)4 16 11000726 11000730 pl.(G)5

16 3779193 3779197 pl.(G)5 16 11000926 11000930 pl.(G)5

16 3779205 3779209 pl.(G)5 16 11001305 11001311 pl.(C)7

16 3779211 3779217 pl.(G)7 16 11001500 11001504 pl.(G)5

16 3779258 3779263 pl.(G)6 16 11009445 11009449 pl.(C)5

16 3779331 3779335 pl.(G)5 16 11010287 11010291 pl.(C)5

16 3779369 3779373 pl.(G)5 16 11348750 11348754 pl.(G)5

16 3779604 3779608 pl.(C)5 16 11348846 11348850 pl.(C)5

16 3779755 3779759 pl.(G)5 16 11348998 11349002 pl.(A)5

16 3779810 3779814 pl.(C)5 16 11349090 11349094 pl.(C)5

16 3781402 3781406 pl.(G)5 16 11349186 11349190 pl.(G)5

16 3781421 3781426 pl.(G)6 16 11349228 11349232 pl.(G)5

16 3786071 3786075 pl.(T)5 16 11349377 11349381 pl.(G)5

16 3786697 3786701 pl.(T)5 16 11439367 11439371 pl.(G)5

16 3786734 3786739 pl.(T)6 16 11444490 11444494 pl.(T)5

16 3789591 3789596 pl.(G)6 16 11444668 11444672 pl.(A)5

16 3789629 3789634 pl.(A)6 16 12059171 12059175 pl.(T)5

16 3790459 3790463 pl.(A)5 16 12060144 12060148 pl.(T)5

16 3790496 3790500 pl.(A)5 16 12060189 12060193 pl.(A)5

16 3808053 3808065 pl.(A)13 16 12096835 12096839 pl.(T)5

16 3817721 3817727 pl.(T)7 16 12142216 12142222 pl.(T)7

16 3817917 3817921 pl.(A)5 16 12145684 12145698 pl.(T)15

16 3819310 3819314 pl.(G)5 16 12145715 12145719 pl.(A)5

16 3819360 3819365 pl.(A)6 16 12145733 12145737 pl.(A)5

16 3820641 3820645 pl.(G)5 16 12145802 12145806 pl.(A)5

16 3828047 3828051 pl.(G)5 16 14020409 14020413 nl ίΓ« Chr Start End MS Chr Start End MS

16 14020492 14020496 pl.(A)5 16 23647646 23647650 pl.(T)5

16 14020551 14020555 pl.(T)5 16 23652421 23652425 pl.(C)5

16 14020583 14020587 pl.(T)5 16 27441412 27441416 pl.(C)5

16 14021907 14021911 pl.(T)5 16 27454270 27454274 pl.(T)5

16 14022099 14022103 pl.(T)5 16 27454294 27454298 pl.(C)5

16 14024724 14024728 pl.(A)5 16 27455913 27455917 pl.(C)5

16 14026097 14026102 pl.(A)6 16 27457319 27457323 pl.(C)5

16 14026104 14026109 pl.(A)6 16 27460061 27460066 pl.(G)6

16 14026116 14026121 pl.(A)6 16 27460368 27460372 pl.(G)5

16 14028053 14028058 pl.(A)6 16 27460530 27460536 pl.(C)7

16 14028165 14028170 pl.(A)6 16 31191504 31191515 p4.(TTGC)3

16 14029202 14029206 pl.(C)5 16 31195645 31195649 pl.(C)5

16 14029245 14029249 pl.(A)5 16 31201632 31201643 p3.(GTG)4

16 14029251 14029256 pl.(A)6 16 31202139 31202143 pl.(G)5

16 14031703 14031707 pl.(A)5 16 31202283 31202287 pl.(G)5

16 14038582 14038586 pl.(A)5 16 31202376 31202380 pl.(G)5

16 14041458 14041462 pl.(T)5 16 50783635 50783639 pl.(A)5

16 14042012 14042016 pl.(A)5 16 50783668 50783673 pl.(T)6

16 14042034 14042038 pl.(A)5 16 50783808 50783812 pl.(A)5

16 14042196 14042200 pl.(A)5 16 50783825 50783829 pl.(A)5

16 15797783 15797790 pl.(T)8 16 50783949 50783953 pl.(A)5

16 15797788 15797799 p4.(TTTG)3 16 50784028 50784032 pl.(A)5

16 15797806 15797810 pl.(T)5 16 50785506 50785510 pl.(A)5

16 15811082 15811086 pl.(C)5 16 50785567 50785571 pl.(T)5

16 15812298 15812302 pl.(G)5 16 50813568 50813573 pl.(T)6

16 15815472 15815476 pl.(T)5 16 50815149 50815153 pl.(T)5

16 15820795 15820806 p3.(CTT)4 16 50816282 50816286 pl.(A)5

16 15826409 15826413 pl.(A)5 16 50816290 50816294 pl.(A)5

16 15831482 15831486 pl.(A)5 16 50816386 50816390 pl.(A)5

16 15832454 15832458 pl.(T)5 16 50820787 50820791 pl.(A)5

16 15832547 15832551 pl.(T)5 16 50820852 50820856 pl.(A)5

16 15834017 15834028 p3.(TCC)4 16 50825462 50825466 pl.(T)5

16 15835375 15835386 p3.(TCC)4 16 50825510 50825514 pl.(T)5

16 15839102 15839107 pl.(G)6 16 50825519 50825525 pl.(A)7

16 15870020 15870024 pl.(T)5 16 50827539 50827543 pl.(A)5

16 15931944 15931948 pl.(C)5 16 56832375 56832379 pl.(C)5

16 15932054 15932058 pl.(T)5 16 56852600 56852604 pl.(C)5

16 23614813 23614817 pl.(T)5 16 56862880 56862884 pl.(T)5

16 23625383 23625387 pl.(T)5 16 56871570 56871574 pl.(C)5

16 23625402 23625406 pl.(T)5 16 56872937 56872942 pl.(T)6

16 23632770 23632774 pl.(G)5 16 56966143 56966154 p3.(CCG)4

16 23632779 23632783 pl.(A)5 16 56969317 56969321 pl.(A)5

16 23637581 23637585 pl.(T)5 16 56969363 56969367 pl.(A)5

16 23641240 23641244 pl.(T)5 16 56973795 56973799 pl.(T)5

16 23641510 23641514 pl.(A)5 16 56974079 56974083 pl.(T)5

16 23641551 23641555 pl.(T)5 16 56974134 56974138 pl.(G)5

16 23641576 23641580 pl.(T)5 16 56977181 56977186 pl.(C)6

16 23641597 23641601 pl.(T)5 16 64981820 64981824 pl.(G)5

16 23641768 23641772 pl.(T)5 16 64981894 64981898 pl.(C)5

16 23646202 23646206 pl.(T)5 16 65005526 65005530 pl.(G)5

16 23646321 23646325 pl.(T)5 16 65006905 65006909 pl.(A)5

16 23646518 23646522 pl.(T)5 16 65016062 65016066 pl.(G)5

16 23646536 23646540 pl.(T)5 16 65022061 65022065 pl.(T)5

16 23646542 23646546 pl.(T)5 16 65022077 65022081 pl.(C)5

16 23646553 23646558 pl.(T)6 16 65022250 65022261 p3.(AGA)4

16 23646688 23646692 pl.(T)5 16 65026836 65026840 pl.(A)5

16 23646981 23646987 pl.(T)7 16 65032685 65032689 pl.(A)5

16 23647028 23647033 pl.(T)6 16 65038686 65038690 pl.(C)5

16 23647174 23647178 pl.(T)5 16 65038772 65038776 pl.(T)5

16 23647310 23647314 pl.(T)5 16 65087836 65087840 nl (A^ Chr Start End MS Chr Start End MS

16 65155906 65155910 pl.(C)5 16 89805312 89805316 pl.(T)5

16 67063280 67063291 p4.(CGGC)3 16 89805344 89805348 pl.(A)5

16 67063359 67063364 pl.(T)6 16 89805890 89805894 pl.(A)5

16 67063397 67063408 p4.(GGCG)3 16 89816314 89816318 pl.(A)5

16 67070530 67070534 pl.(T)5 16 89825051 89825055 pl.(C)5

16 67070578 67070583 pl.(T)6 16 89831345 89831354 p2.(AG)5

16 67644826 67644830 pl.(G)5 16 89836978 89836982 pl.(G)5

16 67644874 67644878 pl.(G)5 16 89858961 89858965 pl.(G)5

16 67645140 67645144 pl.(G)5 16 89869675 89869680 pl.(T)6

16 67645242 67645246 pl.(G)5 16 89869710 89869714 pl.(T)5

16 67645310 67645314 pl.(A)5 16 89869753 89869757 pl.(A)5

16 67645339 67645345 pl.(A)7 16 89874779 89874783 pl.(A)5

16 67645357 67645361 pl.(A)5 16 89874780 89874794 p5.(AAAAC)3

16 67645500 67645504 pl.(A)5 16 89877444 89877448 pl.(C)5

16 67645507 67645511 pl.(A)5 16 89880998 89881003 pl.(T)6

16 67646013 67646022 p2.(AC)5 16 89882372 89882376 pl.(T)5

16 67655481 67655485 pl.(A)5 16 89882974 89882978 pl.(C)5

16 67663291 67663295 pl.(T)5 17 1264432 1264436 pl.(A)5

16 67663351 67663355 pl.(G)5 17 1268176 1268180 pl.(T)5

16 67663393 67663397 pl.(A)5 17 1303327 1303333 pl.(C)7

16 67670718 67670722 pl.(C)5 17 5039922 5039926 pl.(G)5

16 67671655 67671661 pl.(A)7 17 5041562 5041566 pl.(C)5

16 67671723 67671727 pl.(C)5 17 5042701 5042705 pl.(T)5

16 68772188 68772192 pl.(C)5 17 5042861 5042865 pl.(G)5

16 68835613 68835617 pl.(T)5 17 5042875 5042879 pl.(C)5

16 68835781 68835786 pl.(C)6 17 5050397 5050401 pl.(A)5

16 68842439 68842443 pl.(A)5 17 5050423 5050427 pl.(T)5

16 68842456 68842460 pl.(A)5 17 5072157 5072162 pl.(T)6

16 68842662 68842666 pl.(C)5 17 5072211 5072215 pl.(G)5

16 68845694 68845698 pl.(A)5 17 5074903 5074907 pl.(G)5

16 68847286 68847290 pl.(C)5 17 5074927 5074931 pl.(A)5

16 68849545 68849549 pl.(C)5 17 5211975 5211986 pl.(T)7(C)5

16 68853333 68853337 pl.(G)5 17 5212019 5212024 pl.(A)6

16 68855967 68855971 pl.(C)5 17 5212036 5212040 pl.(T)5

16 68862139 68862143 pl.(C)5 17 5238634 5238638 pl.(A)5

16 68863543 68863548 pl.(T)6 17 5241301 5241305 pl.(T)5

16 68863643 68863647 pl.(C)5 17 5266262 5266266 pl.(A)5

16 79632685 79632689 pl.(A)5 17 5271654 5271660 pl.(T)7

16 79632907 79632911 pl.(T)5 17 5283649 5283653 pl.(T)5

16 79633069 79633074 pl.(C)6 17 5284676 5284681 pl.(T)6

16 79633076 79633080 pl.(C)5 17 5286554 5286558 pl.(T)5

16 79633587 79633591 pl.(G)5 17 7572885 7572889 pl.(G)5

16 79633594 79633598 pl.(G)5 17 7572963 7572968 pl.(T)6

16 79633623 79633627 pl.(G)5 17 7572991 7572995 pl.(T)5

16 79633642 79633646 pl.(C)5 17 7573944 7573949 pl.(C)6

16 79633699 79633703 pl.(T)5 17 7577036 7577040 pl.(G)5

16 79633806 79633829 p3.(GCC)8 17 7578398 7578402 pl.(G)5

16 88943420 88943424 pl.(G)5 17 7578475 7578479 pl.(G)5

16 88943690 88943694 pl.(G)5 17 7579420 7579424 pl.(G)5

16 88947117 88947121 pl.(C)5 17 7579471 7579476 pl.(G)6

16 88947900 88947904 pl.(G)5 17 7579585 7579589 pl.(G)5

16 88949178 88949182 pl.(G)5 17 7579875 7579879 pl.(G)5

16 88951484 88951488 pl.(G)5 17 8044444 8044455 p3.(TCC)4

16 88952431 88952435 pl.(G)5 17 8045990 8045994 pl.(C)5

16 88958773 88958777 pl.(G)5 17 8046624 8046628 pl.(G)5

16 88967899 88967903 pl.(G)5 17 8046664 8046668 pl.(C)5

16 88967931 88967937 pl.(G)7 17 8046676 8046680 pl.(G)5

16 88967945 88967949 pl.(C)5 17 8046936 8046940 pl.(G)5

16 88967968 88967972 pl.(G)5 17 8046957 8046961 pl.(G)5

16 88967982 88967987 pl.(G)6 17 8046970 8046974 nl ίΠ« Chr Start End MS Chr Start End MS

17 8047028 8047032 pl.(G)5 17 20135629 20135640 p3.(GGA)4

17 8047055 8047059 pl.(G)5 17 20135668 20135672 pl.(G)5

17 8047170 8047174 pl.(G)5 17 20149324 20149328 pl.(C)5

17 8049284 8049288 pl.(G)5 17 20150518 20150523 pl.(T)6

17 8049423 8049427 pl.(C)5 17 20150565 20150569 pl.(C)5

17 8049759 8049773 p3.(AGG)5 17 20156809 20156813 pl.(T)5

17 8050258 8050262 pl.(A)5 17 20160801 20160805 pl.(C)5

17 8050599 8050603 pl.(C)5 17 20160844 20160848 pl.(C)5

17 8050857 8050861 pl.(G)5 17 29422307 29422312 pl.(C)6

17 8050864 8050868 pl.(G)5 17 29482989 29482997 pl.(T)9

17 8050889 8050894 pl.(G)6 17 29483009 29483013 pl.(A)5

17 8051378 8051382 pl.(C)5 17 29486050 29486056 pl.(A)7

17 8051411 8051416 pl.(G)6 17 29486095 29486099 pl.(A)5

17 8051562 8051566 pl.(G)5 17 29496902 29496906 pl.(T)5

17 8053933 8053937 pl.(G)5 17 29509514 29509518 pl.(T)5

17 8053954 8053958 pl.(C)5 17 29528046 29528050 pl.(T)5

17 8053993 8053997 pl.(C)5 17 29528062 29528066 pl.(T)5

17 8054012 8054016 pl.(G)5 17 29533247 29533251 pl.(T)5

17 8108670 8108674 pl.(G)5 17 29546008 29546014 pl.(T)7

17 8110130 8110135 pl.(G)6 17 29552102 29552108 pl.(T)7

17 8110172 8110176 pl.(A)5 17 29552144 29552149 pl.(T)6

17 8110209 8110213 pl.(G)5 17 29553478 29553484 pl.(C)7

17 8113556 8113560 pl.(G)5 17 29556175 29556179 pl.(G)5

17 9820503 9820508 pl.(C)6 17 29556463 29556468 pl.(T)6

17 9820521 9820526 pl.(C)6 17 29557946 29557952 pl.(A)7

17 9823027 9823031 pl.(A)5 17 29560075 29560079 pl.(A)5

17 9846535 9846539 pl.(G)5 17 29562958 29562962 pl.(A)5

17 9862544 9862548 pl.(T)5 17 29575991 29575997 pl.(T)7

17 9923195 9923200 pl.(G)6 17 29576098 29576103 pl.(C)6

17 11998914 11998918 pl.(A)5 17 29585355 29585359 pl.(T)5

17 11998923 11998927 pl.(A)5 17 29585473 29585477 pl.(A)5

17 12044602 12044607 pl.(A)6 17 29587378 29587382 pl.(T)5

17 17117152 17117156 pl.(A)5 17 29587388 29587392 pl.(T)5

17 17118487 17118491 pl.(G)5 17 29592235 29592239 pl.(T)5

17 17119682 17119686 pl.(G)5 17 29592261 29592265 pl.(A)5

17 17119709 17119716 pl.(G)8 17 29592336 29592341 pl.(T)6

17 17129540 17129544 pl.(G)5 17 29652996 29653000 pl.(T)5

17 17131219 17131223 pl.(T)5 17 29654765 29654769 pl.(C)5

17 17131253 17131257 pl.(C)5 17 29654863 29654868 pl.(T)6

17 17131403 17131407 pl.(G)5 17 29657362 29657366 pl.(A)5

17 17942768 17942777 p2.(TG)5 17 29657480 29657484 pl.(T)5

17 17942804 17942808 pl.(G)5 17 29661845 29661851 pl.(T)7

17 17942910 17942914 pl.(C)5 17 29661917 29661921 pl.(T)5

17 17942971 17942982 p3.(GCG)4 17 29661997 29662001 pl.(A)5

17 17942997 17943002 pl.(C)6 17 29662025 29662029 pl.(A)5

17 17943015 17943019 pl.(G)5 17 29664535 29664544 p2.(GA)5

17 17943049 17943053 pl.(C)5 17 29664829 29664834 pl.(T)6

17 17943223 17943237 p5.(GCCGG)3 17 29670156 29670161 pl.(A)6

17 17957429 17957433 pl.(T)5 17 29676128 29676133 pl.(T)6

17 17957486 17957491 pl.(A)6 17 29676272 29676276 pl.(A)5

17 17962196 17962200 pl.(T)5 17 29683558 29683563 pl.(C)6

17 17968483 17968487 pl.(C)5 17 29685482 29685490 pl.(T)9

17 17968598 17968603 pl.(A)6 17 29701020 29701024 pl.(T)5

17 20000007 20000011 pl.(G)5 17 29701175 29701186 p4.(GCTT)3

17 20013796 20013800 pl.(G)5 17 29701189 29701194 pl.(T)6

17 20108263 20108270 pl.(A)8 17 30264243 30264248 pl.(G)6

17 20108745 20108749 pl.(A)5 17 30264290 30264294 pl.(G)5

17 20108912 20108916 pl.(A)5 17 30264296 30264300 pl.(G)5

17 20109003 20109007 pl.(A)5 17 30264326 30264330 pl.(G)5

17 20130808 20130812 pl.(A)5 17 30264341 30264345 nl ίΠ« Chr Start End MS Chr Start End MS

17 30264407 30264411 pl.(G)5 17 37627446 37627450 pl.(A)5

17 30264426 30264440 p3.(CCT)5 17 37627501 37627506 pl.(A)6

17 30264457 30264461 pl.(G)5 17 37627688 37627692 pl.(C)5

17 30315331 30315336 pl.(T)6 17 37627694 37627698 pl.(C)5

17 30320877 30320881 pl.(T)5 17 37627730 37627734 pl.(C)5

17 30321036 30321040 pl.(T)5 17 37627838 37627842 pl.(C)5

17 30321571 30321575 pl.(T)5 17 37627892 37627896 pl.(C)5

17 30321747 30321751 pl.(A)5 17 37646922 37646926 pl.(C)5

17 30322768 30322773 pl.(A)6 17 37646973 37646977 pl.(A)5

17 30325859 30325863 pl.(A)5 17 37646992 37646996 pl.(T)5

17 30325872 30325876 pl.(G)5 17 37648997 37649001 pl.(T)5

17 30326005 30326010 pl.(A)6 17 37649051 37649055 pl.(G)5

17 30326012 30326016 pl.(A)5 17 37657637 37657641 pl.(A)5

17 34144743 34144747 pl.(G)5 17 37672019 37672023 pl.(T)5

17 34151072 34151077 pl.(T)6 17 37680918 37680922 pl.(T)5

17 34151159 34151163 pl.(G)5 17 37680930 37680934 pl.(C)5

17 34161549 34161563 p5.(TTTTC)3 17 37686892 37686896 pl.(C)5

17 34163122 34163128 pl.(T)7 17 37686901 37686906 pl.(C)6

17 34163252 34163256 pl.(A)5 17 37686931 37686935 pl.(C)5

17 34165417 34165421 pl.(T)5 17 37686962 37686967 pl.(C)6

17 34165493 34165497 pl.(G)5 17 37687472 37687478 pl.(G)7

17 34169360 34169365 pl.(T)6 17 37687514 37687518 pl.(G)5

17 34171073 34171077 pl.(C)5 17 37687540 37687544 pl.(G)5

17 34171886 34171892 pl.(G)7 17 37856517 37856521 pl.(G)5

17 34171993 34171997 pl.(G)5 17 37856540 37856545 pl.(C)6

17 36864134 36864139 pl.(C)6 17 37864563 37864567 pl.(C)5

17 36868121 36868125 pl.(G)5 17 37865605 37865609 pl.(C)5

17 36868162 36868167 pl.(G)6 17 37866585 37866590 pl.(C)6

17 36868998 36869003 pl.(C)6 17 37868224 37868228 pl.(C)5

17 36871946 36871950 pl.(A)5 17 37873563 37873570 pl.(C)8

17 36872060 36872065 pl.(G)6 17 37879565 37879569 pl.(C)5

17 36872704 36872708 pl.(C)5 17 37879626 37879630 pl.(G)5

17 36872745 36872750 pl.(C)6 17 37880235 37880239 pl.(C)5

17 36872761 36872765 pl.(T)5 17 37881449 37881453 pl.(G)5

17 36873054 36873058 pl.(G)5 17 37882045 37882049 pl.(G)5

17 36873217 36873221 pl.(C)5 17 37882064 37882069 pl.(C)6

17 36873777 36873781 pl.(C)5 17 37882888 37882892 pl.(C)5

17 36874153 36874157 pl.(C)5 17 37883139 37883143 pl.(G)5

17 36875803 36875807 pl.(G)5 17 37883215 37883219 pl.(G)5

17 36876005 36876009 pl.(C)5 17 37883597 37883601 pl.(C)5

17 36876058 36876062 pl.(G)5 17 37883664 37883668 pl.(G)5

17 36880862 36880866 pl.(C)5 17 37883774 37883779 pl.(C)6

17 36880948 36880952 pl.(G)5 17 37883790 37883794 pl.(C)5

17 37070623 37070627 pl.(G)5 17 37883974 37883978 pl.(C)5

17 37070690 37070701 p3.(AGC)4 17 37884080 37884084 pl.(T)5

17 37074849 37074853 pl.(C)5 17 37884091 37884095 pl.(G)5

17 37075042 37075046 pl.(C)5 17 37884218 37884223 pl.(G)6

17 37618346 37618350 pl.(G)5 17 38487425 38487429 pl.(C)5

17 37618494 37618498 pl.(C)5 17 38487504 38487508 pl.(G)5

17 37618710 37618714 pl.(A)5 17 38487554 38487559 pl.(C)6

17 37618716 37618721 pl.(A)6 17 38504624 38504628 pl.(C)5

17 37618930 37618934 pl.(A)5 17 38508182 38508193 p3.(AAG)4

17 37618990 37618994 pl.(C)5 17 38508244 38508248 pl.(G)5

17 37619153 37619157 pl.(C)5 17 38508576 38508580 pl.(C)5

17 37627123 37627127 pl.(T)5 17 38510655 38510659 pl.(C)5

17 37627196 37627200 pl.(A)5 17 38510766 38510770 pl.(G)5

17 37627289 37627293 pl.(A)5 17 38511612 38511616 pl.(C)5

17 37627307 37627318 p3.(GCT)4 17 38512370 38512375 pl.(G)6

17 37627361 37627365 pl.(T)5 17 38512377 38512382 pl.(G)6

17 37627418 37627422 pl.(A)5 17 38512389 38512393 nl ίΠ« Chr Start End MS Chr Start End MS

17 38512402 38512408 pl.(C)7 17 41605867 41605871 pl.(G)5

17 38512567 38512571 pl.(C)5 17 41605882 41605886 pl.(G)5

17 38512607 38512611 pl.(G)5 17 41606496 41606500 pl.(C)5

17 38512754 38512758 pl.(G)5 17 41607554 41607558 pl.(G)5

17 38512832 38512836 pl.(C)5 17 41610084 41610088 pl.(C)5

17 38512886 38512891 pl.(C)6 17 41610229 41610233 pl.(G)5

17 38512911 38512915 pl.(G)5 17 41610251 41610255 pl.(C)5

17 38512928 38512933 pl.(G)6 17 41610701 41610707 pl.(G)7

17 38512936 38512940 pl.(C)5 17 41611358 41611362 pl.(G)5

17 38512991 38512995 pl.(T)5 17 41623025 41623029 pl.(G)5

17 38785043 38785048 pl.(T)6 17 41623042 41623046 pl.(G)5

17 38785153 38785157 pl.(C)5 17 47677765 47677769 pl.(G)5

17 38787185 38787191 pl.(A)7 17 47684696 47684700 pl.(A)5

17 38792169 38792175 pl.(T)7 17 47700209 47700213 pl.(G)5

17 38792285 38792289 pl.(T)5 17 48262813 48262818 pl.(G)6

17 38792313 38792317 pl.(G)5 17 48262926 48262930 pl.(G)5

17 38792680 38792684 pl.(T)5 17 48264249 48264253 pl.(G)5

17 38792782 38792786 pl.(A)5 17 48264275 48264280 pl.(G)6

17 38793793 38793797 pl.(G)5 17 48264413 48264417 pl.(G)5

17 40354405 40354409 pl.(G)5 17 48264476 48264480 pl.(G)5

17 40354436 40354440 pl.(C)5 17 48264491 48264495 pl.(G)5

17 40362447 40362453 pl.(T)7 17 48265247 48265251 pl.(G)5

17 40368127 40368131 pl.(A)5 17 48265329 48265333 pl.(G)5

17 40369187 40369191 pl.(A)5 17 48265964 48265968 pl.(G)5

17 40369241 40369245 pl.(T)5 17 48266153 48266157 pl.(C)5

17 40370236 40370243 pl.(G)8 17 48266161 48266176 p2.(AG)8

17 40375459 40375464 pl.(T)6 17 48266283 48266287 pl.(G)5

17 40379587 40379591 pl.(A)5 17 48266301 48266306 pl.(G)6

17 40379600 40379604 pl.(C)5 17 48266319 48266323 pl.(G)5

17 40379711 40379717 pl.(A)7 17 48266516 48266521 pl.(G)6

17 40467769 40467773 pl.(G)5 17 48266784 48266788 pl.(G)5

17 40468879 40468884 pl.(G)6 17 48266793 48266797 pl.(G)5

17 40475305 40475309 pl.(T)5 17 48266883 48266887 pl.(G)5

17 40476839 40476843 pl.(G)5 17 48267221 48267225 pl.(G)5

17 40476850 40476855 pl.(A)6 17 48267372 48267376 pl.(G)5

17 40476969 40476973 pl.(G)5 17 48267399 48267403 pl.(G)5

17 40481444 40481448 pl.(C)5 17 48267472 48267476 pl.(G)5

17 40485995 40485999 pl.(T)5 17 48267904 48267908 pl.(G)5

17 40491420 40491424 pl.(C)5 17 48269204 48269208 pl.(G)5

17 40491433 40491437 pl.(A)5 17 48269390 48269394 pl.(G)5

17 41197709 41197713 pl.(G)5 17 48270010 48270014 pl.(G)5

17 41215361 41215365 pl.(T)5 17 48270168 48270172 pl.(G)5

17 41228526 41228530 pl.(T)5 17 48271368 48271372 pl.(G)5

17 41234422 41234426 pl.(T)5 17 48271815 48271819 pl.(G)5

17 41234597 41234601 pl.(A)5 17 48272092 48272096 pl.(G)5

17 41242954 41242958 pl.(T)5 17 48272164 48272168 pl.(G)5

17 41244017 41244021 pl.(A)5 17 48272956 48272961 pl.(G)6

17 41244219 41244224 pl.(T)6 17 48273272 48273277 pl.(G)6

17 41244440 41244444 pl.(A)5 17 48273517 48273521 pl.(G)5

17 41244558 41244562 pl.(T)5 17 48273722 48273726 pl.(G)5

17 41244596 41244600 pl.(A)5 17 48274529 48274533 pl.(C)5

17 41245162 41245166 pl.(T)5 17 48274591 48274595 pl.(C)5

17 41245355 41245359 pl.(T)5 17 48276790 48276794 pl.(G)5

17 41245587 41245594 pl.(T)8 17 53342786 53342790 pl.(G)5

17 41245725 41245729 pl.(T)5 17 53342812 53342818 pl.(T)7

17 41245820 41245824 pl.(T)5 17 53342825 53342830 pl.(A)6

17 41245848 41245852 pl.(T)5 17 53342869 53342873 pl.(C)5

17 41246532 41246538 pl.(T)7 17 53342941 53342945 pl.(C)5

17 41247865 41247870 pl.(T)6 17 53345173 53345177 pl.(C)5

17 41256251 41256256 pl.(T)6 17 53345267 53345271 ni ms Chr Start End MS Chr Start End MS

17 53345288 53345293 pl.(C)6 17 59858268 59858273 pl.(T)6

17 53345355 53345359 pl.(C)5 17 59858292 59858296 pl.(T)5

17 53398248 53398252 pl.(T)5 17 59861645 59861649 pl.(A)5

17 55339499 55339506 pl.(T)8 17 59861666 59861670 pl.(A)5

17 56435079 56435083 pl.(G)5 17 59861749 59861754 pl.(T)6

17 56435094 56435098 pl.(A)5 17 59861759 59861763 pl.(T)5

17 56435161 56435167 pl.(C)7 17 59861776 59861780 pl.(A)5

17 56435205 56435209 pl.(T)5 17 59878817 59878821 pl.(A)5

17 56435408 56435412 pl.(G)5 17 59885829 59885833 pl.(T)5

17 56435458 56435462 pl.(T)5 17 59886114 59886118 pl.(G)5

17 56435615 56435619 pl.(G)5 17 59926603 59926608 pl.(T)6

17 56435669 56435673 pl.(C)5 17 59934561 59934565 pl.(T)5

17 56435815 56435819 pl.(G)5 17 59934595 59934599 pl.(A)5

17 56436028 56436032 pl.(G)5 17 59937205 59937209 pl.(T)5

17 56436189 56436194 pl.(A)6 17 62006838 62006842 pl.(G)5

17 56437531 56437535 pl.(G)5 17 62009560 62009571 p3.(AGC)4

17 56437619 56437623 pl.(A)5 17 62496298 62496302 pl.(T)5

17 56439919 56439923 pl.(G)5 17 62498570 62498574 pl.(T)5

17 56440643 56440647 pl.(G)5 17 62498610 62498614 pl.(A)5

17 56440773 56440777 pl.(G)5 17 62499407 62499411 pl.(T)5

17 56448298 56448303 pl.(G)6 17 62499421 62499425 pl.(A)5

17 57697479 57697483 pl.(C)5 17 62500358 62500362 pl.(A)5

17 57721627 57721632 pl.(T)6 17 62500830 62500834 pl.(A)5

17 57721719 57721723 pl.(A)5 17 62500874 62500878 pl.(T)5

17 57724752 57724756 pl.(T)5 17 62500969 62500976 pl.(A)8

17 57724777 57724781 pl.(T)5 17 63010537 63010541 pl.(T)5

17 57733327 57733331 pl.(T)5 17 63010693 63010697 pl.(A)5

17 57737894 57737898 pl.(T)5 17 63010865 63010870 pl.(T)6

17 57741350 57741355 pl.(A)6 17 63049740 63049744 pl.(G)5

17 57743453 57743459 pl.(T)7 17 63049855 63049859 pl.(A)5

17 57744312 57744316 pl.(T)5 17 63052468 63052477 p2.(CG)5

17 57750998 57751004 pl.(T)7 17 63052715 63052732 p3.(GCC)6

17 57752049 57752053 pl.(T)5 17 66511521 66511527 pl.(T)7

17 57752130 57752135 pl.(A)6 17 66511720 66511724 pl.(A)5

17 57752192 57752197 pl.(A)6 17 66520162 66520166 pl.(T)5

17 57754304 57754309 pl.(T)6 17 66523968 66523972 pl.(T)5

17 57758641 57758648 pl.(T)8 17 66523974 66523978 pl.(T)5

17 57759977 57759985 pl.(T)9 17 73774661 73774665 pl.(A)5

17 57760012 57760017 pl.(A)6 17 73775204 73775209 pl.(G)6

17 57760793 57760797 pl.(T)5 17 74732279 74732284 pl.(G)6

17 57761321 57761325 pl.(T)5 17 74732328 74732332 pl.(G)5

17 57762403 57762413 pl.(T)l l 17 74732908 74732912 pl.(C)5

17 57762481 57762485 pl.(A)5 17 74732956 74732961 pl.(G)6

17 57763011 57763015 pl.(T)5 17 74733223 74733228 pl.(G)6

17 57763024 57763029 pl.(A)6 17 75398133 75398137 pl.(T)5

17 59760685 59760689 pl.(T)5 17 75398318 75398322 pl.(C)5

17 59760731 59760735 pl.(T)5 17 75398563 75398567 pl.(C)5

17 59760764 59760768 pl.(T)5 17 75398615 75398619 pl.(C)5

17 59760894 59760898 pl.(A)5 17 75398666 75398670 pl.(C)5

17 59760967 59760973 pl.(T)7 17 75398668 75398682 p5.(CCCAG)3

17 59761147 59761152 pl.(T)6 17 75398749 75398753 pl.(C)5

17 59761414 59761425 p4.(TTTG)3 17 75478268 75478272 pl.(C)5

17 59761460 59761465 pl.(T)6 17 75484798 75484802 pl.(C)5

17 59763238 59763242 pl.(T)5 17 75488741 75488745 pl.(C)5

17 59763432 59763436 pl.(T)5 17 75495099 75495103 pl.(G)5

17 59763442 59763446 pl.(T)5 17 75495225 75495229 pl.(C)5

17 59763533 59763537 pl.(A)5 17 75495334 75495338 pl.(C)5

17 59821853 59821858 pl.(T)6 17 75495452 75495456 pl.(C)5

17 59821941 59821945 pl.(T)5 17 75495467 75495471 pl.(C)5

17 59857629 59857633 pl.(T)5 17 75495473 75495477 nl ίΓ« Chr Start End MS Chr Start End MS

17 75495523 75495527 pl.(A)5 17 78350086 78350092 pl.(T)7

17 75495548 75495552 pl.(C)5 17 78350674 78350678 pl.(T)5

17 75495557 75495561 pl.(C)5 17 78354713 78354717 pl.(C)5

17 76988740 76988744 pl.(A)5 17 78355338 78355342 pl.(C)5

17 76993149 76993153 pl.(C)5 17 78356768 78356774 pl.(T)7

17 76993313 76993317 pl.(T)5 17 78357681 78357685 pl.(A)5

17 76993418 76993422 pl.(G)5 17 78360206 78360210 pl.(A)5

17 76993428 76993432 pl.(G)5 17 78363955 78363959 pl.(C)5

17 76993495 76993500 pl.(G)6 17 78367137 78367141 pl.(T)5

17 76993507 76993511 pl.(G)5 17 78519367 78519371 pl.(T)5

17 76993581 76993585 pl.(G)5 17 78519409 78519413 pl.(C)5

17 76993593 76993597 pl.(G)5 17 78519415 78519419 pl.(C)5

17 76993634 76993639 pl.(C)6 17 78519421 78519425 pl.(C)5

17 78237521 78237525 pl.(C)5 17 78519468 78519472 pl.(G)5

17 78237566 78237570 pl.(C)5 17 78519523 78519527 pl.(A)5

17 78247117 78247121 pl.(G)5 17 78727867 78727871 pl.(A)5

17 78261617 78261621 pl.(A)5 17 78727961 78727965 pl.(C)5

17 78261638 78261642 pl.(A)5 17 78796094 78796098 pl.(C)5

17 78261800 78261804 pl.(C)5 17 78796934 78796939 pl.(T)6

17 78261868 78261872 pl.(C)5 17 78829315 78829319 pl.(T)5

17 78261986 78261990 pl.(G)5 17 78831583 78831587 pl.(C)5

17 78262019 78262024 pl.(C)6 17 78857290 78857295 pl.(C)6

17 78263501 78263505 pl.(A)5 17 78866568 78866572 pl.(C)5

17 78263581 78263585 pl.(A)5 17 78867528 78867532 pl.(C)5

17 78263597 78263603 pl.(A)7 17 78882599 78882608 p2.(TC)5

17 78269384 78269389 pl.(A)6 17 78896582 78896586 pl.(C)5

17 78269413 78269417 pl.(A)5 17 78897434 78897438 pl.(C)5

17 78269426 78269430 pl.(T)5 17 78936354 78936358 pl.(C)5

17 78269481 78269485 pl.(T)5 17 79937053 79937057 pl.(C)5

17 78269493 78269498 pl.(A)6 17 79953922 79953926 pl.(G)5

17 78286906 78286910 pl.(T)5 17 79954508 79954512 pl.(C)5

17 78292981 78292985 pl.(T)5 17 79954531 79954535 pl.(G)5

17 78302131 78302136 pl.(A)6 17 79954545 79954550 pl.(G)6

17 78307893 78307897 pl.(T)5 17 79967075 79967079 pl.(C)5

17 78307971 78307975 pl.(A)5 17 79969420 79969424 pl.(G)5

17 78310007 78310011 pl.(G)5 17 79969487 79969492 pl.(T)6

17 78310128 78310132 pl.(A)5 17 79970120 79970124 pl.(A)5

17 78313098 78313102 pl.(C)5 17 79974898 79974902 pl.(G)5

17 78313325 78313329 pl.(C)5 17 79974910 79974915 pl.(C)6

17 78314019 78314024 pl.(C)6 18 22669448 22669452 pl.(A)5

17 78316988 78316992 pl.(A)5 18 22804478 22804483 pl.(C)6

17 78319284 78319288 pl.(C)5 18 22804693 22804697 pl.(T)5

17 78319588 78319593 pl.(T)6 18 22804871 22804875 pl.(A)5

17 78319849 78319853 pl.(C)5 18 22805120 22805124 pl.(T)5

17 78320152 78320156 pl.(A)5 18 22805389 22805393 pl.(T)5

17 78320327 78320331 pl.(T)5 18 22805404 22805408 pl.(T)5

17 78320756 78320761 pl.(C)6 18 22805689 22805693 pl.(A)5

17 78320764 78320768 pl.(A)5 18 22805919 22805923 pl.(T)5

17 78320828 78320832 pl.(T)5 18 22806063 22806067 pl.(G)5

17 78321274 78321278 pl.(A)5 18 22806122 22806126 pl.(T)5

17 78321318 78321322 pl.(G)5 18 22807093 22807097 pl.(T)5

17 78321341 78321345 pl.(T)5 18 22902155 22902159 pl.(A)5

17 78321624 78321628 pl.(C)5 18 22932034 22932038 pl.(C)5

17 78324139 78324143 pl.(T)5 18 22932062 22932066 pl.(G)5

17 78324202 78324206 pl.(T)5 18 22932192 22932196 pl.(G)5

17 78328279 78328283 pl.(T)5 18 23615012 23615023 p3.(CTG)4

17 78343588 78343597 p2.(TC)5 18 23618627 23618631 pl.(A)5

17 78345719 78345724 pl.(A)6 18 23632818 23632822 pl.(A)5

17 78346883 78346887 pl.(G)5 18 23637543 23637547 pl.(A)5

17 78349570 78349575 pl.(C)6 18 23637600 23637604 nl ίΓ« Chr Start End MS Chr Start End MS

18 23637648 23637652 pl.(G)5 19 1207153 1207164 p3.(AAG)4

18 23670491 23670495 pl.(C)5 19 1218447 1218451 pl.(A)5

18 23670590 23670594 pl.(G)5 19 1221314 1221319 pl.(C)6

18 42281351 42281355 pl.(G)5 19 1226573 1226577 pl.(C)5

18 42281390 42281394 pl.(C)5 19 1611771 1611775 pl.(G)5

18 42281657 42281661 pl.(C)5 19 1615273 1615277 pl.(C)5

18 42281746 42281751 pl.(A)6 19 1615487 1615492 pl.(G)6

18 42281789 42281793 pl.(A)5 19 1615698 1615703 pl.(G)6

18 42529940 42529945 pl.(A)6 19 1619152 1619163 p4.(CTGG)3

18 42530278 42530282 pl.(C)5 19 1619792 1619796 pl.(C)5

18 42530308 42530312 pl.(A)5 19 1619821 1619825 pl.(G)5

18 42530320 42530325 pl.(A)6 19 1620979 1620984 pl.(G)6

18 42530560 42530566 pl.(A)7 19 1620992 1620996 pl.(G)5

18 42530729 42530733 pl.(C)5 19 1621901 1621905 pl.(G)5

18 42530977 42530981 pl.(C)5 19 1621972 1621977 pl.(G)6

18 42531055 42531059 pl.(A)5 19 1622147 1622151 pl.(C)5

18 42531328 42531332 pl.(A)5 19 1622183 1622187 pl.(G)5

18 42531388 42531392 pl.(C)5 19 1622325 1622329 pl.(G)5

18 42531514 42531518 pl.(C)5 19 1622346 1622350 pl.(G)5

18 42531699 42531703 pl.(T)5 19 1646432 1646446 p5.(GGGAG)3

18 42532259 42532263 pl.(T)5 19 2164138 2164142 pl.(C)5

18 42532374 42532378 pl.(A)5 19 2164171 2164180 p2.(CG)5

18 42532404 42532409 pl.(T)6 19 2164186 2164190 pl.(G)5

18 42532823 42532827 pl.(T)5 19 2164222 2164226 pl.(G)5

18 42533045 42533049 pl.(A)5 19 2189723 2189727 pl.(T)5

18 42618442 42618447 pl.(T)6 19 2191141 2191145 pl.(C)5

18 42643201 42643205 pl.(A)5 19 2194555 2194560 pl.(A)6

18 42643299 42643303 pl.(A)5 19 2210863 2210867 pl.(C)5

18 45372131 45372135 pl.(A)5 19 2211158 2211162 pl.(C)5

18 45391420 45391427 pl.(T)8 19 2211795 2211800 pl.(C)6

18 45394686 45394690 pl.(A)5 19 2213626 2213630 pl.(A)5

18 45394832 45394836 pl.(A)5 19 2220114 2220118 pl.(C)5

18 48573403 48573407 pl.(A)5 19 2220213 2220217 pl.(C)5

18 48573524 48573528 pl.(A)5 19 2222089 2222093 pl.(T)5

18 48573564 48573569 pl.(A)6 19 2222129 2222133 pl.(C)5

18 48575047 48575051 pl.(T)5 19 2222363 2222367 pl.(C)5

18 48575122 48575126 pl.(A)5 19 2222479 2222483 pl.(C)5

18 48584514 48584519 pl.(G)6 19 2223376 2223381 pl.(C)6

18 48584703 48584707 pl.(T)5 19 2225372 2225378 pl.(T)7

18 48602994 48602999 pl.(T)6 19 2225396 2225400 pl.(A)5

18 56348485 56348489 pl.(A)5 19 2225430 2225434 pl.(C)5

18 56348561 56348566 pl.(C)6 19 2226423 2226427 pl.(G)5

18 56400758 56400762 pl.(A)5 19 2226478 2226482 pl.(G)5

18 56411562 56411566 pl.(T)5 19 3094772 3094783 p3.(GCT)4

18 56412883 56412893 pl.(T)l l 19 3110140 3110144 pl.(C)5

18 56413013 56413017 pl.(A)5 19 3118934 3118939 pl.(G)6

18 56415067 56415071 pl.(A)5 19 3120980 3120984 pl.(C)5

18 56415083 56415087 pl.(T)5 19 4094499 4094503 pl.(G)5

18 60796001 60796005 pl.(G)5 19 4095412 4095416 pl.(G)5

18 60985465 60985469 pl.(C)5 19 4099215 4099220 pl.(G)6

18 60985666 60985670 pl.(G)5 19 4099312 4099317 pl.(G)6

18 60985768 60985772 pl.(G)5 19 4123888 4123899 p3.(CGG)4

18 60985776 60985785 pl.(C)5(G)5 19 4361796 4361800 pl.(G)5

18 60999042 60999046 pl.(T)5 19 4362619 4362623 pl.(G)5

18 61022426 61022430 pl.(T)5 19 4362641 4362645 pl.(C)5

18 61022537 61022541 pl.(A)5 19 4364123 4364127 pl.(G)5

19 680323 680328 pl.(G)6 19 6213029 6213033 pl.(G)5

19 680496 680500 pl.(G)5 19 6213336 6213341 pl.(G)6

19 1207065 1207069 pl.(G)5 19 6213427 6213433 pl.(G)7

19 1207077 1207081 pl.(G)5 19 6213728 6213734 nl (CM Chr Start End MS Chr Start End MS

19 6222187 6222191 pl.(T)5 19 11114006 11114011 pl.(T)6

19 6222272 6222289 p3.(AGG)6 19 11118576 11118587 p3.(AGG)4

19 6222406 6222410 pl.(G)5 19 11118633 11118644 p3.(AGA)4

19 6222412 6222416 pl.(G)5 19 11121216 11121220 pl.(G)5

19 6222418 6222422 pl.(G)5 19 11129671 11129675 pl.(C)5

19 6222424 6222428 pl.(G)5 19 11130296 11130300 pl.(C)5

19 6222438 6222442 pl.(G)5 19 11134182 11134186 pl.(G)5

19 6262243 6262247 pl.(T)5 19 11141498 11141503 pl.(G)6

19 6262305 6262310 pl.(G)6 19 11141541 11141545 pl.(T)5

19 6262324 6262328 pl.(A)5 19 11143959 11143963 pl.(C)5

19 10597273 10597277 pl.(A)5 19 11145716 11145730 p3.(GAG)5

19 10597303 10597307 pl.(T)5 19 13049479 13049483 pl.(C)5

19 10599929 10599933 pl.(G)5 19 13049937 13049941 pl.(C)5

19 10600005 10600009 pl.(C)5 19 13050364 13050368 pl.(G)5

19 10600425 10600430 pl.(C)6 19 13050970 13050974 pl.(G)5

19 10602320 10602324 pl.(C)5 19 13051347 13051352 pl.(C)6

19 10602354 10602358 pl.(G)5 19 13051439 13051443 pl.(C)5

19 10610631 10610635 pl.(C)5 19 13210215 13210219 pl.(G)5

19 10828903 10828907 pl.(G)5 19 13211729 13211733 pl.(G)5

19 10870401 10870407 pl.(C)7 19 13211774 13211778 pl.(G)5

19 10870480 10870484 pl.(A)5 19 13211824 13211829 pl.(G)6

19 10883166 10883170 pl.(T)5 19 13211867 13211871 pl.(G)5

19 10883184 10883188 pl.(A)5 19 13211891 13211895 pl.(G)5

19 10904475 10904479 pl.(G)5 19 13211914 13211918 pl.(G)5

19 10904538 10904543 pl.(C)6 19 15366368 15366372 pl.(G)5

19 10906780 10906784 pl.(A)5 19 15367010 15367014 pl.(T)5

19 10909155 10909159 pl.(C)5 19 15367902 15367906 pl.(G)5

19 10909173 10909177 pl.(C)5 19 15375495 15375499 pl.(G)5

19 10912957 10912961 pl.(C)5 19 15375536 15375540 pl.(G)5

19 10922933 10922937 pl.(C)5 19 15376235 15376239 pl.(G)5

19 10934453 10934459 pl.(C)7 19 15376248 15376254 pl.(G)7

19 10935777 10935781 pl.(C)5 19 15376262 15376266 pl.(G)5

19 10939898 10939902 pl.(C)5 19 15378305 15378310 pl.(T)6

19 10940839 10940844 pl.(C)6 19 15383768 15383772 pl.(G)5

19 10940852 10940856 pl.(C)5 19 15383774 15383779 pl.(G)6

19 10940882 10940888 pl.(C)7 19 15383856 15383860 pl.(C)5

19 10940905 10940909 pl.(G)5 19 16192832 16192836 pl.(A)5

19 10940930 10940934 pl.(C)5 19 17937615 17937619 pl.(C)5

19 10941025 10941030 pl.(C)6 19 17937647 17937651 pl.(G)5

19 10941038 10941042 pl.(C)5 19 17941420 17941424 pl.(G)5

19 10941661 10941665 pl.(C)5 19 17942212 17942223 p4.(GCGG)3

19 10941731 10941736 pl.(G)6 19 17942472 17942476 pl.(C)5

19 10941746 10941752 pl.(G)7 19 17943520 17943524 pl.(G)5

19 11096027 11096031 pl.(G)5 19 17943746 17943750 pl.(G)5

19 11096048 11096052 pl.(C)5 19 17945489 17945493 pl.(G)5

19 11096983 11096987 pl.(C)5 19 17945781 17945785 pl.(G)5

19 11097084 11097088 pl.(G)5 19 17945961 17945965 pl.(C)5

19 11097604 11097608 pl.(C)5 19 17946029 17946033 pl.(G)5

19 11097625 11097630 pl.(C)6 19 17946828 17946832 pl.(C)5

19 11098363 11098367 pl.(C)5 19 17950344 17950349 pl.(C)6

19 11098392 11098396 pl.(C)5 19 17950466 17950470 pl.(G)5

19 11098417 11098421 pl.(C)5 19 17951077 17951081 pl.(G)5

19 11098425 11098429 pl.(C)5 19 17951115 17951119 pl.(C)5

19 11098477 11098481 pl.(C)5 19 17951155 17951159 pl.(G)5

19 11098540 11098544 pl.(C)5 19 17953399 17953403 pl.(G)5

19 11107033 11107037 pl.(A)5 19 17953984 17953989 pl.(G)6

19 11107042 11107046 pl.(A)5 19 17954643 17954648 pl.(G)6

19 11107048 11107052 pl.(A)5 19 17955112 17955118 pl.(G)7

19 11113697 11113701 pl.(T)5 19 18266938 18266952 p5.(GGCCC)3

19 11113790 11113794 pl.(C)5 19 18266965 18266969 nl ίΓ« Chr Start End MS Chr Start End MS

19 18271271 18271275 pl.(C)5 19 33793253 33793258 pl.(G)6

19 18271331 18271335 pl.(C)5 19 33793280 33793284 pl.(G)5

19 18271722 18271726 pl.(C)5 19 33793321 33793325 pl.(G)5

19 18271957 18271961 pl.(C)5 19 40739717 40739727 pl.(G)5(A)6

19 18272767 18272771 pl.(C)5 19 40739811 40739815 pl.(G)5

19 18272855 18272859 pl.(C)5 19 40740960 40740964 pl.(G)5

19 18273005 18273009 pl.(C)5 19 40741245 40741250 pl.(C)6

19 18273026 18273031 pl.(C)6 19 40741967 40741971 pl.(C)5

19 18273105 18273110 pl.(G)6 19 40744816 40744820 pl.(C)5

19 18273319 18273323 pl.(G)5 19 40744883 40744887 pl.(G)5

19 18273770 18273774 pl.(C)5 19 40748501 40748505 pl.(G)5

19 18276957 18276961 pl.(C)5 19 40762855 40762860 pl.(G)6

19 18279340 18279344 pl.(A)5 19 41725248 41725252 pl.(C)5

19 18279523 18279528 pl.(C)6 19 41725254 41725258 pl.(C)5

19 18279888 18279892 pl.(C)5 19 41725374 41725378 pl.(C)5

19 18555523 18555527 pl.(C)5 19 41726645 41726650 pl.(C)6

19 18557106 18557112 pl.(G)7 19 41727836 41727840 pl.(C)5

19 18561309 18561313 pl.(G)5 19 41727868 41727872 pl.(C)5

19 18561489 18561493 pl.(G)5 19 41727909 41727913 pl.(C)5

19 18561563 18561567 pl.(G)5 19 41727936 41727940 pl.(C)5

19 18561580 18561584 pl.(G)5 19 41736918 41736922 pl.(G)5

19 18561595 18561599 pl.(G)5 19 41737092 41737096 pl.(C)5

19 18561752 18561756 pl.(G)5 19 41737179 41737183 pl.(C)5

19 18569046 18569050 pl.(C)5 19 41743896 41743901 pl.(C)6

19 18572536 18572540 pl.(C)5 19 41743933 41743939 pl.(C)7

19 18572589 18572593 pl.(G)5 19 41744385 41744390 pl.(C)6

19 18576644 18576648 pl.(G)5 19 41745116 41745120 pl.(G)5

19 18576713 18576717 pl.(G)5 19 41748777 41748781 pl.(C)5

19 18632881 18632885 pl.(C)5 19 41749512 41749518 pl.(C)7

19 18632889 18632893 pl.(C)5 19 41754521 41754525 pl.(C)5

19 18794474 18794497 p3.(GGA)8 19 41754638 41754643 pl.(C)6

19 18794643 18794647 pl.(G)5 19 41758740 41758745 pl.(G)6

19 18856626 18856630 pl.(C)5 19 41765621 41765625 pl.(C)5

19 18856634 18856638 pl.(C)5 19 41765647 41765652 pl.(C)6

19 18864360 18864364 pl.(A)5 19 42381381 42381385 pl.(G)5

19 18870879 18870884 pl.(G)6 19 42383118 42383122 pl.(G)5

19 18876263 18876267 pl.(C)5 19 42383209 42383213 pl.(C)5

19 18879460 18879464 pl.(C)5 19 42383281 42383285 pl.(G)5

19 18879471 18879475 pl.(C)5 19 42383610 42383615 pl.(C)6

19 18879514 18879518 pl.(C)5 19 42383633 42383637 pl.(G)5

19 18879546 18879550 pl.(C)5 19 42383729 42383733 pl.(C)5

19 18879554 18879560 pl.(C)7 19 42385070 42385074 pl.(C)5

19 18887974 18887978 pl.(C)5 19 42788840 42788845 pl.(C)6

19 18887993 18888000 pl.(C)8 19 42791229 42791233 pl.(C)5

19 18888096 18888100 pl.(C)5 19 42791268 42791272 pl.(C)5

19 19256495 19256500 pl.(G)6 19 42791282 42791286 pl.(G)5

19 19256727 19256736 pl.(C)5(G)5 19 42791339 42791344 pl.(C)6

19 19256769 19256775 pl.(G)7 19 42792124 42792128 pl.(G)5

19 19256799 19256803 pl.(G)5 19 42793141 42793145 pl.(G)5

19 19256826 19256830 pl.(C)5 19 42793444 42793448 pl.(C)5

19 19256837 19256841 pl.(G)5 19 42794441 42794446 pl.(C)6

19 19257564 19257568 pl.(C)5 19 42794460 42794464 pl.(C)5

19 19257630 19257634 pl.(G)5 19 42794469 42794473 pl.(C)5

19 19257847 19257851 pl.(G)5 19 42794627 42794631 pl.(C)5

19 19257861 19257865 pl.(G)5 19 42794637 42794641 pl.(C)5

19 19258538 19258542 pl.(C)5 19 42794643 42794647 pl.(C)5

19 19261529 19261535 pl.(T)7 19 42794655 42794659 pl.(G)5

19 30303876 30303880 pl.(T)5 19 42794820 42794824 pl.(C)5

19 30308412 30308416 pl.(A)5 19 42794869 42794873 pl.(C)5

19 30311698 30311702 pl.(A)5 19 42795075 42795079 nl ίΠ« Chr Start End MS Chr Start End MS

19 42795243 42795247 pl.(C)5 19 52714707 52714711 pl.(C)5

19 42795269 42795273 pl.(G)5 19 52715968 52715972 pl.(C)5

19 42795378 42795382 pl.(G)5 19 52716002 52716006 pl.(G)5

19 42795609 42795614 pl.(C)6 19 52725345 52725349 pl.(C)5

19 42795739 42795743 pl.(C)5 19 52729280 52729284 pl.(C)5

19 42795886 42795891 pl.(C)6 19 52729310 52729315 pl.(G)6

19 42796799 42796803 pl.(C)5 19 54079940 54079945 pl.(T)6

19 42796883 42796889 pl.(C)7 19 54079990 54079996 pl.(A)7

19 42797135 42797139 pl.(C)5 19 54080347 54080352 pl.(A)6

19 42797165 42797170 pl.(C)6 19 54080449 54080453 pl.(A)5

19 42797376 42797381 pl.(C)6 19 54611426 54611430 pl.(G)5

19 42797386 42797390 pl.(C)5 19 54611448 54611452 pl.(G)5

19 42797951 42797955 pl.(C)5 19 54611522 54611526 pl.(G)5

19 42798164 42798168 pl.(C)5 19 54611710 54611714 pl.(G)5

19 42798406 42798410 pl.(C)5 19 54647257 54647261 pl.(G)5

19 42798428 42798432 pl.(G)5 19 54651892 54651896 pl.(A)5

19 42799098 42799102 pl.(C)5 19 54651966 54651971 pl.(C)6

19 42799131 42799136 pl.(C)6 19 54652022 54652026 pl.(C)5

19 45252212 45252216 pl.(C)5 19 54652033 54652037 pl.(C)5

19 45252261 45252267 pl.(C)7 19 54652156 54652161 pl.(C)6

19 45252312 45252316 pl.(C)5 19 54652408 54652412 pl.(G)5

19 45254584 45254588 pl.(C)5 19 54652440 54652445 pl.(C)6

19 45259476 45259480 pl.(C)5 19 54652452 54652456 pl.(C)5

19 45259482 45259486 pl.(C)5 19 54653322 54653326 pl.(G)5

19 45259558 45259563 pl.(G)6 19 54653329 54653333 pl.(G)5

19 45261997 45262001 pl.(G)5 19 54653362 54653366 pl.(G)5

19 45262066 45262070 pl.(C)5 19 54656613 54656617 pl.(C)5

19 45262726 45262731 pl.(C)6 19 54656635 54656640 pl.(C)6

19 45262737 45262742 pl.(C)6 19 54656659 54656663 pl.(C)5

19 45262770 45262781 p4.(CTTC)3 19 54657445 54657449 pl.(C)5

19 45262843 45262848 pl.(C)6 19 54659036 54659040 pl.(C)5

19 45262873 45262877 pl.(G)5 19 54659168 54659172 pl.(C)5

19 45262880 45262886 pl.(G)7 19 54659175 54659179 pl.(C)5

19 45281211 45281215 pl.(G)5 19 54659190 54659194 pl.(C)5

19 45281290 45281294 pl.(C)5 20 31017156 31017160 pl.(A)5

19 45281309 45281313 pl.(C)5 20 31017747 31017758 p3.(CAG)4

19 45281399 45281403 pl.(G)5 20 31019113 31019117 pl.(A)5

19 45284229 45284233 pl.(G)5 20 31019437 31019442 pl.(T)6

19 45284269 45284273 pl.(C)5 20 31021277 31021282 pl.(A)6

19 45293254 45293258 pl.(C)5 20 31022224 31022230 pl.(T)7

19 45296724 45296728 pl.(C)5 20 31022297 31022301 pl.(C)5

19 45297485 45297489 pl.(C)5 20 31022442 31022449 pl.(G)8

19 45297503 45297508 pl.(C)6 20 31023046 31023050 pl.(C)5

19 45855584 45855588 pl.(C)5 20 31023983 31023988 pl.(A)6

19 45867598 45867602 pl.(G)5 20 31024426 31024430 pl.(T)5

19 45867672 45867677 pl.(C)6 20 31024510 31024514 pl.(T)5

19 45867808 45867813 pl.(G)6 20 31024637 31024642 pl.(G)6

19 45868419 45868423 pl.(G)5 20 36012536 36012545 p2.(TC)5

19 45871907 45871911 pl.(T)5 20 36012641 36012645 pl.(G)5

19 45873782 45873786 pl.(C)5 20 36012666 36012670 pl.(C)5

19 45916842 45916847 pl.(T)6 20 36012720 36012724 pl.(C)5

19 45916899 45916903 pl.(C)5 20 36014585 36014589 pl.(C)5

19 45922461 45922465 pl.(G)5 20 36022570 36022574 pl.(C)5

19 45926605 45926609 pl.(C)5 20 36030027 36030031 pl.(G)5

19 51376683 51376688 pl.(C)6 20 39316497 39316501 pl.(G)5

19 51376784 51376789 pl.(G)6 20 39317087 39317098 p3.(TGG)4

19 51377965 51377969 pl.(C)5 20 39658062 39658066 pl.(T)5

19 51378081 51378085 pl.(G)5 20 39704915 39704919 pl.(A)5

19 51378098 51378102 pl.(C)5 20 39706242 39706246 pl.(A)5

19 51381669 51381673 pl.(G)5 20 39725848 39725853 nl mfi Chr Start End MS Chr Start End MS

20 39725912 39725916 pl.(A)5 21 36206777 36206781 pl.(G)5

20 39725955 39725959 pl.(A)5 21 36421232 36421236 pl.(G)5

20 39728715 39728719 pl.(A)5 21 39755389 39755393 pl.(C)5

20 39741464 39741469 pl.(A)6 21 39755427 39755433 pl.(A)7

20 39742590 39742601 p4.(TTTC)3 21 39755554 39755559 pl.(G)6

20 39744012 39744016 pl.(T)5 21 39762972 39762976 pl.(A)5

20 39744063 39744067 pl.(T)5 21 39764347 39764352 pl.(G)6

20 39746897 39746901 pl.(A)5 21 39774562 39774576 p5.(ACAAA)3

20 43955925 43955929 pl.(G)5 21 39775416 39775420 pl.(G)5

20 43964533 43964537 pl.(G)5 21 39775477 39775481 pl.(G)5

20 43977016 43977020 pl.(G)5 21 39795373 39795377 pl.(G)5

20 52188261 52188271 pl.(T)6(C)5 21 39817381 39817385 pl.(G)5

20 52188288 52188294 pl.(T)7 21 42842590 42842595 pl.(C)6

20 52188387 52188391 pl.(T)5 21 42843818 42843822 pl.(T)5

20 52188400 52188409 pl.(A)10 21 42845287 42845291 pl.(G)5

20 52192548 52192552 pl.(T)5 21 42845355 42845359 pl.(C)5

20 52192737 52192741 pl.(T)5 21 42848552 42848556 pl.(A)5

20 52192818 52192822 pl.(C)5 21 42851110 42851115 pl.(T)6

20 52193078 52193082 pl.(T)5 21 42851199 42851203 pl.(A)5

20 52193226 52193230 pl.(C)5 21 42851212 42851217 pl.(A)6

20 52193248 52193252 pl.(T)5 21 42866377 42866381 pl.(G)5

20 52193420 52193425 pl.(T)6 21 44513126 44513139 pl.(T)6(A)8

20 52193453 52193457 pl.(T)5 21 44513198 44513202 pl.(A)5

20 52193489 52193493 pl.(T)5 21 44515638 44515642 pl.(A)5

20 52193554 52193558 pl.(A)5 21 44515807 44515812 pl.(A)6

20 52193620 52193625 pl.(A)6 21 44527612 44527623 p3.(CCG)4

20 52193636 52193640 pl.(T)5 22 19167754 19167760 pl.(A)7

20 52193687 52193691 pl.(T)5 22 19195739 19195743 pl.(A)5

20 52193728 52193732 pl.(T)5 22 19195776 19195780 pl.(T)5

20 52193812 52193816 pl.(T)5 22 19203775 19203779 pl.(A)5

20 52194917 52194921 pl.(A)5 22 19208924 19208928 pl.(C)5

20 52194966 52194970 pl.(T)5 22 19208953 19208957 pl.(G)5

20 52194983 52194987 pl.(T)5 22 19209481 19209486 pl.(T)6

20 52194998 52195002 pl.(A)5 22 19220690 19220694 pl.(T)5

20 52198642 52198648 pl.(T)7 22 19223226 19223230 pl.(T)5

20 52198816 52198820 pl.(C)5 22 19226837 19226842 pl.(A)6

20 52198848 52198852 pl.(T)5 22 19263362 19263368 pl.(A)7

20 52199202 52199208 pl.(T)7 22 19279181 19279195 p3.(CGG)5

20 54945199 54945203 pl.(C)5 22 19707424 19707428 pl.(C)5

20 54945602 54945606 pl.(A)5 22 19707962 19707966 pl.(C)5

20 54945677 54945681 pl.(G)5 22 19709156 19709160 pl.(C)5

20 54959326 54959331 pl.(T)6 22 19709245 19709249 pl.(G)5

20 54959341 54959345 pl.(T)5 22 21288188 21288192 pl.(A)5

20 57478614 57478618 pl.(A)5 22 23523205 23523209 pl.(C)5

20 57478757 57478762 pl.(C)6 22 23523395 23523399 pl.(C)5

20 57484205 57484209 pl.(T)5 22 23523564 23523568 pl.(G)5

20 57485378 57485382 pl.(T)5 22 23523586 23523591 pl.(C)6

20 57485893 57485897 pl.(C)5 22 23523784 23523788 pl.(A)5

20 60739192 60739196 pl.(C)5 22 23523816 23523820 pl.(G)5

20 60740566 60740571 pl.(G)6 22 23523832 23523836 pl.(C)5

20 62331943 62331947 pl.(C)5 22 23523903 23523907 pl.(C)5

20 62332057 62332061 pl.(G)5 22 23523952 23523956 pl.(C)5

21 34399229 34399233 pl.(T)5 22 23524000 23524004 pl.(G)5

21 34399276 34399280 pl.(G)5 22 23524097 23524102 pl.(C)6

21 34399702 34399706 pl.(G)5 22 23524294 23524299 pl.(C)6

21 34399986 34399991 pl.(G)6 22 23603670 23603674 pl.(C)5

21 34399993 34399997 pl.(G)5 22 23610586 23610590 pl.(C)5

21 34400017 34400021 pl.(G)5 22 23626208 23626212 pl.(G)5

21 36164486 36164490 pl.(G)5 22 23627310 23627314 pl.(C)5

21 36164839 36164843 pl.(G)5 22 23631814 23631820 nl (CM Chr Start End MS Chr Start End MS

22 24129357 24129368 p3.(ATG)4 22 30057270 30057274 pl.(C)5

22 24134057 24134063 pl.(A)7 22 30070939 30070943 pl.(G)5

22 24135859 24135864 pl.(C)6 22 30074321 30074325 pl.(C)5

22 24143260 24143264 pl.(C)5 22 30077585 30077589 pl.(A)5

22 28193075 28193079 pl.(G)5 22 31737529 31737535 pl.(T)7

22 28193164 28193168 pl.(C)5 22 31737674 31737678 pl.(A)5

22 28193233 28193237 pl.(G)5 22 31740553 31740557 pl.(G)5

22 28193333 28193337 pl.(G)5 22 31740735 31740739 pl.(C)5

22 28193474 28193478 pl.(C)5 22 31740856 31740861 pl.(G)6

22 28193492 28193496 pl.(C)5 22 31741056 31741061 pl.(G)6

22 28193499 28193503 pl.(C)5 22 31741089 31741093 pl.(G)5

22 28193569 28193573 pl.(C)5 22 31741290 31741294 pl.(C)5

22 28193623 28193627 pl.(C)5 22 31741323 31741327 pl.(C)5

22 28193690 28193694 pl.(T)5 22 31741341 31741345 pl.(C)5

22 28193719 28193723 pl.(C)5 22 31741482 31741486 pl.(T)5

22 28193772 28193776 pl.(G)5 22 31741597 31741601 pl.(C)5

22 28193792 28193796 pl.(C)5 22 36678673 36678684 p4.(TGTC)3

22 28194006 28194010 pl.(G)5 22 36678834 36678838 pl.(G)5

22 28194184 28194188 pl.(C)5 22 36684462 36684466 pl.(G)5

22 28194217 28194221 pl.(C)5 22 36688264 36688268 pl.(T)5

22 28194231 28194236 pl.(G)6 22 36689419 36689433 p3.(CCT)5

22 28194307 28194311 pl.(C)5 22 36690293 36690298 pl.(C)6

22 28194340 28194344 pl.(G)5 22 36694956 36694960 pl.(C)5

22 28194421 28194425 pl.(C)5 22 36696225 36696229 pl.(T)5

22 28194512 28194516 pl.(C)5 22 36696281 36696292 p3.(CTC)4

22 28194535 28194539 pl.(G)5 22 36696316 36696320 pl.(G)5

22 28194881 28194898 p3.(GCT)6 22 36696914 36696925 p3.(TCT)4

22 28194913 28194930 p3.(TGC)6 22 36696948 36696962 p3.(CTC)5

22 28194934 28194960 p3.(TGC)9 22 36708257 36708262 pl.(G)6

22 28195185 28195190 pl.(G)6 22 36714377 36714381 pl.(T)5

22 28195625 28195639 p3.(GCT)5 22 36737462 36737466 pl.(G)5

22 28195729 28195733 pl.(C)5 22 36745146 36745157 p4.(GGCT)3

22 28196140 28196144 pl.(C)5 22 36745238 36745242 pl.(T)5

22 28196185 28196189 pl.(C)5 22 38369476 38369481 pl.(G)6

22 28196195 28196199 pl.(G)5 22 38369496 38369500 pl.(C)5

22 28196286 28196291 pl.(C)6 22 38369708 38369712 pl.(G)5

22 28196356 28196360 pl.(G)5 22 38369803 38369807 pl.(G)5

22 28196398 28196408 pl.(G)5(C)6 22 38370110 38370114 pl.(C)5

22 28196539 28196544 pl.(G)6 22 38373905 38373909 pl.(G)5

22 28196549 28196553 pl.(G)5 22 38379676 38379690 p3.(CCG)5

22 29091793 29091797 pl.(G)5 22 38379796 38379800 pl.(C)5

22 29095849 29095853 pl.(A)5 22 39621797 39621802 pl.(G)6

22 29095914 29095918 pl.(C)5 22 39626106 39626111 pl.(C)6

22 29108014 29108018 pl.(A)5 22 39631876 39631880 pl.(C)5

22 29121096 29121100 pl.(T)5 22 39640023 39640027 pl.(C)5

22 29130434 29130438 pl.(G)5 22 40807460 40807464 pl.(G)5

22 29130719 29130723 pl.(A)5 22 40807477 40807482 pl.(G)6

22 29669714 29669722 pl.(T)9 22 40807617 40807622 pl.(G)6

22 29678431 29678435 pl.(G)5 22 40807757 40807768 p4.(AGGG)3

22 29684714 29684718 pl.(G)5 22 40807795 40807799 pl.(G)5

22 29693944 29693948 pl.(T)5 22 40807831 40807836 pl.(G)6

22 29694746 29694750 pl.(G)5 22 40814383 40814387 pl.(G)5

22 29695315 29695319 pl.(C)5 22 40814485 40814489 pl.(C)5

22 29695765 29695775 pl.(G)6(C)5 22 40814527 40814532 pl.(G)6

22 29695830 29695834 pl.(A)5 22 40814586 40814590 pl.(G)5

22 29999923 29999928 pl.(G)6 22 40814720 40814724 pl.(G)5

22 30050682 30050686 pl.(T)5 22 40814731 40814736 pl.(G)6

22 30050708 30050712 pl.(A)5 22 40814738 40814742 pl.(G)5

22 30051572 30051577 pl.(T)6 22 40814744 40814748 pl.(G)5

22 30057197 30057201 pl.(A)5 22 40814900 40814905 nl ϊΓ ή Chr Start End MS Chr Start End MS

22 40814932 40814936 pl.(G)5 22 41545921 41545925 pl.(C)5

22 40815026 40815030 pl.(G)5 22 41546023 41546027 pl.(C)5

22 40815071 40815075 pl.(G)5 22 41547821 41547828 pl.(T)8

22 40815086 40815091 pl.(G)6 22 41548269 41548273 pl.(A)5

22 40815269 40815273 pl.(G)5 22 41548348 41548352 pl.(A)5

22 40816542 40816548 pl.(G)7 22 41550985 41550995 pl.(T)l l

22 40816887 40816901 p3.(TGC)5 22 41556700 41556704 pl.(G)5

22 40816930 40816941 p3.(GCT)4 22 41566525 41566531 pl.(A)7

22 40816970 40816975 pl.(G)6 22 41568507 41568511 pl.(T)5

22 40816978 40816983 pl.(C)6 22 41569645 41569649 pl.(A)5

22 40817001 40817006 pl.(G)6 22 41569654 41569658 pl.(A)5

22 40819552 40819556 pl.(G)5 22 41569681 41569685 pl.(A)5

22 40819613 40819617 pl.(G)5 22 41572243 41572247 pl.(T)5

22 40820216 40820220 pl.(G)5 22 41572765 41572770 pl.(T)6

22 40820312 40820316 pl.(G)5 22 41572810 41572814 pl.(A)5

22 40827491 40827496 pl.(A)6 22 41573261 41573265 pl.(C)5

22 41489005 41489009 pl.(A)5 22 41573476 41573480 pl.(C)5

22 41513810 41513814 pl.(C)5 22 41573555 41573559 pl.(T)5

22 41521966 41521970 pl.(A)5 22 41573584 41573588 pl.(C)5

22 41522009 41522013 pl.(A)5 22 41573603 41573607 pl.(C)5

22 41525970 41525974 pl.(C)5 22 41573946 41573950 pl.(C)5

22 41525977 41525981 pl.(A)5 22 41574081 41574085 pl.(G)5

22 41527458 41527462 pl.(C)5 22 41574201 41574205 pl.(C)5

22 41533648 41533652 pl.(T)5 22 41574379 41574390 p3.(CAG)4

22 41536135 41536139 pl.(T)5 22 41574552 41574556 pl.(C)5

22 41542730 41542735 pl.(T)6 22 41574679 41574685 pl.(C)7

22 41543876 41543880 pl.(C)5 22 41574986 41574992 pl.(A)7

22 41545025 41545038 pl.(T)14 22 42526682 42526686 pl.(G)5

22 41545901 41545905 pl.(C)5

[00464] Patient DNA was sequenced by NGS using the 592-gene panel. See Tables 7-10. We examined the 7,317 target microsatellite loci and compared them to the reference genome hgl9 from the UCSC Genome Browser database (hgdownload.cse.ucsc.edu/goldenPath/hgl9/bigZips/). The number of microsatellite loci that were altered by somatic insertion or deletion was counted for each patient sample. Only insertions or deletions that increased or decreased the number of repeats were considered. A locus was not counted more than once even if it had multiple lengths of insertions or deletions. Thresholds were calibrated based on comparison of total number of altered loci per patient to MSI-FA results with the aim to maximize sensitivity while maintaining an appropriately high specificity, positive predictive value (PPV), and negative predictive value (NPV).

[00465] We calibrated our thresholds by comparing the total altered loci per patient by NGS to the PCR- based MSI FA results from 2, 189 cases that included 26 distinct cancer lineages, consisting mostly of colorectal (n = 1,193) and endometrial (n = 709) cases. See FIG. 32A. The figure shows analysis by PCR FA (y-axis) classified cases as MSS, MSI-low (MSI-L), or MSI-high (MSI-H), and NGS (x-axis) classified cases as MSS (<46 altered microsatellite loci/Mb) or MSI-H (>46 altered microsatellite loci/Mb). Cases include all cancer lineages (n = 2,189), colorectal adenocarcinoma (CRC; n = 1,193), and endometrial cancer (n = 708). Abbreviations in FIG. 32A: Mb, megabase; MSI-H, microsatellite high; MSI-L, microsatellite low: MSS, microsatellite stable. [00466] An appropriate threshold aims to provide acceptably high levels of sensitivity, specificity, and positive and negative predictive values across cancer types, while capturing most if not all MSI-H by FA cases of colorectal cancer. Based on this analysis, samples having 46 or more loci with insertions or deletions were considered MSI-H.

[00467] Total mutation burden

[00468] TMB was calculated based on the number of nonsynonymous somatic mutations identified by NGS, while excluding any known single nucleotide polymorphisms (SNPs) in dbSNP (version 137) or in the 1000 Genomes Project database (phase 3; www.internationalgenome.org/). [20] TMB is reported as mutations per Mb sequenced. The threshold for determining high TMB as greater than or equal to 17 mutations/megabase was established by comparing TMB with MSI by FA in CRC cases, based on reports of TMB having high concordance with MSI in CRC. [7,21]

[00469] PD-L1 IHC

[00470] IHC analysis was performed on slides of FFPE tumor samples using automated staining techniques. The procedures met the standards and requirements of the College of American Pathologists.

[00471] The primary antibody against PD-L1 was SP142 (Spring Bioscience, Pleasanton, CA), except for NSCLC tumors tested after January 2016. For NSCLC tumors tested after January 2016, the primary PD- Ll antibody clone was 22c3 (Dako, Santa Clara, CA). For the calculations in this Example, staining for both antibodies was considered positive if there was staining on > 1% of tumor cells.

[00472]Mismatch repair protein IHC

[00473] MMR protein expression was tested by IHC using antibody clones (MLHl, Ml antibody; MSH2, G2191129 antibody; MSH6, 44 antibody; PMS2, EPR3947 antibody (Ventana Medical Systems, Inc., Tucson, AZ)). The complete absence of protein expression (0+ in 100% of cells) was considered a loss of MMR, and thus dMMR.

[00474] Cancer types analyzed by PCR-FA and byMSI-NGS

[00475] Matched cases analyzed both by PCR-FA and by MSI-NGS included the following cancer types: bladder cancer (n = 3), breast carcinoma (n = 16), cervical cancer (n = 2), cholangiocarcinoma (n = 17), colorectal adenocarcinoma (n = 1193), endometrial cancer (n = 708), esophageal and esophagogastric junction carcinoma (n = 7), extrahepatic bile duct adenocarcinoma (n = 2), gastric adenocarcinoma (n = 10), gastrointestinal stromal tumors (n = 2), glioblastoma (n = 9), liver hepatocellular carcinoma (n = 8), lymphoma (n = 2), malignant solitary fibrous tumor of the pleura (n = 1), melanoma (n = 4),

neuroendocrine tumors (n = 10), none of these (n = 21), NSCLC (n = 5), other female genital tract malignancy (n = 12), ovarian surface epithelial carcinomas (n = 15), pancreatic adenocarcinoma (n = 44), prostatic adenocarcinoma (n = 1), small intestinal malignancies (n = 7), soft tissue tumors (n = 1), thyroid carcinoma (n = 1), uterine sarcoma (n = 87), and uveal melanoma (n = 1).

[00476] Cancer types analyzed by IHC and by MSI-NGS

[00477] Matched cases analyzed both by IHC and by MSI-NGS included the following cancer types: bladder cancer (n = 4), breast carcinoma (n = 18), cervical cancer (n = 1), cholangiocarcinoma (n = 21), colorectal adenocarcinoma (n = 925), endometrial cancer (n = 445), esophageal and esophagogastric junction carcinoma (n = 8), gastric adenocarcinoma (n = 15), gastrointestinal stromal tumors (n = 3), glioblastoma (n = 53), head and neck squamous cell carcinoma (n = 1), kidney cancer (n = 1), liver hepatocellular carcinoma (n = 12), low-grade glioma (n = 7), lymphoma (n = 3), melanoma (n = 2), neuroendocrine tumors (n = 10), none of these (n = 38), NSCLC (n = 6), other female genital tract malignancy (n = 3), ovarian surface epithelial carcinomas (n = 17), pancreatic adenocarcinoma (n = 318), prostatic adenocarcinoma (n = 2), small intestinal malignancies (n = 5), soft tissue tumors (n = 1), uterine sarcoma (n = 65), and uveal melanoma (n = 2).

[00478] Results

[00479] Matched MSI FA PCR and 592-gene NGS assays from 2, 189 cases (FIG. 32A and Table 17) were used to calibrate the MSI NGS assay to classify samples as MSI-H or microsatellite stable (MSS). A cutoff of >46 altered loci was chosen with with goal of optimizing the performance of the MSI-NGS test in CRC and endometrial cancers, which are cancer types for which MSI testing has traditionally had the highest clinical relevance. See FIG. 32A. Performance was maintained when this cutoff was used across all 2, 189 FA-matched cases that spanned 26 cancer types (sensitivity 95.8% [95% confidence interval (CI) 92.24, 98.08], specificity 99.4% [95% CI 98.94, 99.69], positive predictive value (PPV) 94.5% [95% CI 90.62, 97.14], and negative predictive value (NPV) 99.2% [95% CI, 98.75, 99.57]). For purposes of calculating the MSI NGS performance metrics, cases categorized as MSI-Low by FA were grouped with the MSS FA cohort. Since patients with MSI-L tumors are most often treated in a manner similar to patients with MSS tumors in the clinic, grouping MSI-L with MSS is reasonable.

Table 17: Classification of MSI by NGS compared with PCR fragment analysis for 2,189 matched cases

n = 709) 97.81)

MSI-H 123 8

[00480] Abbreviations in Table 17: CRC, colorectal cancer; FA, fragment analysis; MMR, mismatch repair; MSI-L, microsatellite instability-low; MSI-H, microsatellite instability-high; MSS, microsatellite stable; NGS, next generation sequencing; NPV, negative predictive value; PPV, positive predictive value.

[00481] An additional comparison involved 1,986 cases that were examined both by MSI-NGS and by IHC for MMR protein status. See Table 18. Cases with dMMR protein status were identified by IHC in 171 cases (8.6%), while NGS identified 156 cases (7.9%). Compared with IHC for MMR proteins, across 26 cancer types, NGS had a sensitivity of 87.1%, specificity of 99.6%, PPV of 95.5%, and NPV of 98.8%. Compared with IHC for MMR proteins, NGS of CRC cases had a sensitivity of 91.7%, specificity of 99.7%, PPV of 94.8%, and NPV of 99.4%.

Table 18: Classification of microsatellite instability by NGS compared with MMR by IHC

[00482] Abbreviations in Table 17: IHC, immunohistochemistry; MMR, mismatch repair; dMMR, deficient mismatch repair; MMR-P, mismatch repair proficient; MSI-H, microsatellite instability-high; MSS, microsatellite stable; NPV, negative predictive value; PPV, positive predictive value.

[00483] The highest percentage of MSI-H cases were endometrial cancer (18%), followed by gastric adenocarcinoma (9%), small intestinal malignancies (8%), and colorectal adenocarcinoma (6%). Cancer types with no MSI-H included melanoma (0 of 360 cases), bladder cancer (0 of 144), head and neck squamous carcinoma (0 of 118), low-grade glioma 90 of 107), gastrointestinal stromal cancers (0 of 65), and thymic cancer (0 of 28).

[00484] The relationship between TMB, MSI, and PD-L1 was explored by analyzing 11,348 cases that had results for all three assays. See FIG. 32B and Table 19. In this set, the overall rate of MSI-H was

3.0%. Overall high TMB was 7.7% and PD-L1 positivity was 25.4%. Among MSI-H cases, 70% were also high TMB (62.6% with TMB removed). Among high TMB cases, 27% were also MSI-H. Only 0.6% of the cases were positive for all three markers, whereas 69.5% of the cases were negative for all three. Of the total cohort, 26% of MSI-H cases were PD-Ll positive whereas 44% of TMB high cases were PD-Ll positive.

[00485] The overlap between the biomarkers TMB, MSI, and PD-Ll differed among cancer types. See FIGs. 32C-32I (FIG. 32C shows colorectal cancer (CRC); FIG. 32D shows endometrial cancer; FIG. 32E shows non-small cell lung cancer (NSCLC); FIG. 32F shows melanoma; FIG. 32G shows ovarian surface epithelial carcinoma; FIG. 32H shows neuroendocrine cancer; FIG. 321 shows cervical cancer) and Table 19. High TMB and MSI-H had 95% overlap for CRC, which was expected, since the TMB cutoff was based on CRC MSI-FA results. However, 57% of MSI-H endometrial cancer cases were also high TMB. Likewise, ovarian, neuroendocrine, and cervical cancers also had significant percentages of MSI-H cases that were not TMB high. In contrast, NSCLC and melanoma had few or no MSI-H cases, while still having a significant number of high TMB cases.

Table 19: Biomarkers by NGS across cancer types

adenocarcinoma

Cholangiocarcinoma 177 4 2.3 6 3.4 33 18.6 3 1.7 1 0.6 1 0.6 0 0.0 139 78.5

Cervical cancer 168 6 3.6 13 7.7 74 44.0 2 1.2 3 1.8 10 6.0 1 0.6 89 53.0

Kidney cancer 155 1 0.6 1 0.6 46 29.7 0 0.0 1 0.6 0 0.0 0 0.0 108 69.7

Bladder cancer 143 0 0.0 24 16.8 61 42.7 0 0.0 0 0.0 9 6.3 0 0.0 67 46.9

Uterine sarcoma 128 3 2.3 3 2.3 24 18.8 1 0.8 1 0.8 3 2.3 1 0.8 102 79.7

Head and neck 111 0 0.0 6 5.4 72 64.9 0 0.0 0 0.0 4 3.6 0 0.0 37 33.3 squamous

carcinoma

Low-grade glioma 95 0 0.0 1 1.1 7 7.4 0 0.0 0 0.0 0 0.0 0 0.0 87 91.6

Small cell lung 75 1 1.3 4 5.3 10 13.3 0 0.0 0 0.0 2 2.7 0 0.0 62 82.7 cancer

Liver hepatocellular 73 2 2.7 1 1.4 7 9.6 1 1.4 0 0.0 0 0.0 0 0.0 64 87.7 carcinoma

Small intestinal 72 6 8.3 6 8.3 12 16.7 5 6.9 1 1.4 1 1.4 1 1.4 54 75.0 malignancies

Other female genital 57 1 1.8 4 7.0 27 47.4 1 1.8 0 0.0 3 5.3 0 0.0 29 50.9 tract malignancies

Non-epithelial 56 1 1.8 0 0.0 4 7.1 0 0.0 0 0.0 0 0.0 0 0.0 51 91.1 ovarian cancer

Gastrointestinal 52 0 0.0 0 0.0 20 38.5 0 0.0 0 0.0 0 0.0 0 0.0 32 61.5 stromal tumors

(GIST)

Uveal melanoma 50 1 2.0 1 2.0 10 20.0 1 2.0 1 2.0 1 2.0 1 2.0 40 80.0

Retroperitoneal or 46 0 0.0 0 0.0 10 21.7 0 0.0 0 0.0 0 0.0 0 0.0 36 78.3 peritoneal sarcoma

Thyroid carcinoma 42 1 2.4 1 2.4 26 61.9 1 2.4 1 2.4 1 2.4 1 2.4 16 38.1

Extrahepatic bile 29 1 3.4 1 3.4 6 20.7 1 3.4 1 3.4 1 3.4 1 3.4 23 79.3 duct

adenocarcinoma

Lymphoma 27 0 0.0 2 7.4 16 59.3 0 0.0 0 0.0 2 7.4 0 0.0 11 40.7

Thymic carcinoma 26 0 0.0 1 3.8 18 69.2 0 0.0 0 0.0 1 3.8 0 0.0 8 30.8

Male genital tract 15 0 0.0 0 0.0 3 20.0 0 0.0 0 0.0 0 0.0 0 0.0 12 80.0 malignancy

Multiple myeloma 10 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 10 100.0

Retroperitoneal or 7 0 0.0 0 0.0 2 28.6 0 0.0 0 0.0 0 0.0 0 0.0 5 71.4 peritoneal

carcinoma

Merkel cell 6 0 0.0 2 33.3 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 66.7 carcinoma

Nodal diffuse large 5 0 0.0 0 0.0 2 40.0 0 0.0 0 0.0 0 0.0 0 0.0 3 60.0 B-cell lymphoma

Malignant solitary 3 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 3 100.0 fibrous tumor of the

pleura

Acute myeloid 1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 100.0 leukemia

Lung 1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 100.0 bronchioloalveolar

carcinoma

[00486] Certain cancer types showed interesting relationships regarding MSI and TMB. See FIG. 32 J, which show scatter plots comparing MSI as altered microsatellite (MS) loci determined by NGS to TMB per megabase for colorectal adenocarcinoma (panel i; n = 1267), endometrial cancer (panel ii; n = 667), NSCLC (panel iii; n = 964), and melanoma (panel iv; n = 175). The horizontal line indicates 46 altered MS and the vertical line indicates 17 mutations/Mb, which are the cutoff used to determine high status. In both CRC and endometrial cancer, the majority of MSI-H cases were also high in TMB. This pattern was not seen in two cancer types driven primarily by environmentally caused mutagenesis, NSCLC and melanoma. In NSCLC, 14.0% (264/1868) of cases were high TMB, but only 0.6% (12/1868) were MSI- H. Melanoma had no cases that were MSI-H, but 36.5% were high TMB (126/345).

[00487] Detailed patient characteristics and results for all samples used in this Example can be found in "Table 55 - Patient Characteristics and Test Results" of priority document U.S. Provisional Patent Serial No. 62/631,381, filed February 15, 2018, which application is incorporated by reference in its entirety, including without limitation Table 55 therein.

[00488] Discussion

[00489] MSI-H cancers are a genetically -defined subset of cancers with the potential for enhanced responsiveness to anti-PD-1 therapies and related therapies. [5-7] Determining MSI status across cancer types offers the opportunity to identify patients who are likely to respond to such treatments, while avoiding unnecessary toxicities for patients identified as unlikely to respond. In this Example, we developed a sensitive and specific MSI assay by NGS that is comparable to the existing gold standard of PCR FA methods without requiring matched samples from normal tissue.

[00490] The method was calibrated using 2,189 cases across 26 cancer types that had both MSI-FA and

592-gene NGS results. This number of matched samples between FA and NGS is a substantially larger calibration set that that used in another published NGS MSI method. [22] Previously published data using the MSI-NGS method described herein found MSI-H status present in 24 of 31 cancer types. [23]

Likewise, here we identified MSI-H in 23 of 26 cancer types. The detection of MSI-H cases in this extensive list of cancer types supports the concept that MSI is a generalized cancer phenotype. [3]

[00491] Notably, MSI-H cases that were not TMB-H or PD-L1 -positive occurred in significant percentages of ovarian (24%), neuroendocrine (57%), and cervical (33%) cancers. With the recent approval of pembrolizumab for MSI-H patients of any solid tumor type, this subset of patients now has a promising treatment that would not have been identified using either of the other two immunotherarjv biomarker assays. Given the lack of overlap of MSI and high TMB in several cancer types, these data suggest patient benefit by performing both TMB analysis and MSI-NGS and potentially other complementary tests, e.g., PD-L1 IHC.

[00492] This MSI-NGS assay has concordance with the FA method for CRC (100% sensitivity and 99.9% specificity) but slightly reduced agreement when looking across all cancer types (95.8% sensitivity and 99.9% specificity; PPV of 94.5%). As the FA test was developed for CRC, MSI-NGS discrepancies in non-CRC cancer types may be due to other loci being involved in these cancer types that are not measured by the FA method. Without being bound by theory, this raises the possibility that some of the FA PCR results could be false negatives, rather than the corresponding MSI-NGS results being false positives. For example, our NGS assay has broader microsatellite coverage and may be a better predictor of response than the FA assay, which is limited to 5 microsatellite sites.

[00493] The use of NGS to determine MSI status offers advantages over FA by PCR. Due to the large number of microsatellite regions analyzed, this method of NGS analysis of MSI does not require a sample of normal tissue for comparison. The comparison of a large number of microsatellite sequences to a reference human genome was able to provide a level of sensitivity comparable to that achieved using only a few microsatellites and comparing to a normal sample from the same patient. Thus, with this method, it is feasible to determine MSI status for patients who do not have available normal tissue or for whom it would be a burden to obtain. Coupling the calculation of MSI to data that are already generated by a broad NGS sequencing panel allows for MSI status to be determined efficiently for any patient who is already receiving broad NGS sequencing results, without adding the cost of an additional stand-alone test or consuming additional tumor tissue that could be used for other testing. Further, while FA by PCR was optimized to analyze CRC, [24] our NGS analysis of MSI is a pan-cancer method whose development was technically validated across 26 cancer types.

[00494] IHC testing for MMR protein is commonly performed on CRC and endometrial cancer cases to test for Lynch syndrome. Clinical evidence indicates that treatments with the PD-1 inhibitors

pembrolizumab and nivolumab both lead to favorable responses in patients with dMMR tumors. [5,7,18] Our NGS-MSI assay has 87.1% sensitivity for dMMR detection compared to MMR-IHC (see Table 18). However, the proteins measured by standard MMR-IHC (MLHl, MSH2, MSH6, and PMS2) are not equal in their contribution to the mismatch repair process. Previous research on endometrial carcinoma found that most MSI-H tumors had loss of MLHl and PMS2, with concordant loss of the MLH1/PMS2 heterodimer in 48% and with MSI-H in 97% of PSM2 -negative cases. [25] Without being bound by theory, there may be a subset of dMMR cases with relatively low microsatellite alterations, which are identified as MSS by NGS, that have lower rates of response to PD-1 inhibition compared with cases that are MSI-H and dMMR cases. This is supported by data indicating that the subset of dMMR CRC cases called MSS by FA were less likely to respond to nivolumab than MSI-H cases. [18] These data suggest potential benefit of both MSI-NGS and MMR-IHC, in cancer types where MMR-IHC loss is more common, to identify more patients with potential response. [00495] Current NCCN guidelines recommend MSI and MMR proficiency testing on patients with colon and endometrial cancer. Considering the landscape of the site-agnostic approval of pembrolizumab for patients with MSI-H cancers, the testing recommendation should now be expanded to include all patients with advanced solid tumors lacking satisfactory treatment options. The method of MSI-NGS presented in this Example addresses disadvantages of both FA and MMR-IHC, thus providing an improved platform to measure MSI status in all tumors. MSI-NGS can be added to other malignancy-specific molecular panels, requires no extra tissue, and has lower marginal cost when FA is considered as an add-on test that must be performed along with an NGS panel. With the evolution in cancer care toward molecularly-defined diagnoses, validation of NGS measurement of MSI status provides a mechanism for all cancer patients, regardless of malignancy, to achieve testing that can determine whether a potentially life-extending agent may be appropriate.

[00496] We also compared MSI with TMB. See, e.g., FIG. 32C. MSI is measured by NGS through counting insertions or deletions of 2-5 nucleotides in specific areas of the genome known to accumulate errors in microsatellites. In contrast, TMB was measured here by counting nonsynonymous mutations across the sequenced portion of the genome. Therefore, TMB can capture a wider range of mutational signatures because it covers the genome more broadly. Although most MSI-H cases are high TMB, the opposite is not true. Our cut-off for high TMB of >17 mutations/Mb is similar to the recently published cutoff values of > 13.8 and >20 mutations/Mb. [6,26] True biological differences in TML and MSI appear to exist in certain cancer types. For example, tumors driven primarily by environmentally caused mutations (e.g., NSCLC and melanoma) have a higher proportion of cases with high TMB vs MSI (FIG. 32C) compared to tumors that are not as strongly associated with environmental factors (e.g., smoking and sun exposure, respectively).

[00497] The 11,348 cases included in these comprehensive genomic analyses by NGS are generally from patients with advanced, refractory disease who lacked obvious treatment options. This could lead to some downward bias in the reported MSI frequencies, e.g., CRC MSI-H rates are lower in advanced disease than in the overall CRC population. [4] Thus, a larger percentage of patients may benefit from MSI-NGS testing than even suggested here.

[00498] In conclusion, we used a large patient database to develop a method to determine MSI status using NGS. The MSI-NGS test is applicable across cancer types and does not require matched normal samples, which is particularly beneficial for patients where such tissue is limited or not available. The investigation of the relationship among TMB, MSI, and PD-Ll revealed a population with MSI-H disease, but low TMB and no PD-Ll expression, thus expanding the pool of potential immunotherapy recipients. Without being bound by theory, the best option may be to measure all three to ensure that as many patients as possible benefit from these drugs.

[00499] References

[00500] 1. de la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol. 2010;28(20):3380-7. [00501] 2. Murphy KM, Zhang S, Geiger T, Hafez MJ, Bacher J, Berg KD, et al. Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn. 2006;8(3):305-l 1.

[00502] 3. Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016;22(11): 1342-50.

[00503] 4. Lee V, Murphy A, Le DT, Diaz LA, Jr. Mismatch repair deficiency and response to immune checkpoint blockade. The Oncologist. 2016;21(10): 1200-11.

[00504] 5. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-13.

[00505] 6. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med.

2017;23(6):703-13.

[00506] 7. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-20.

[00507] 8. Overman M, Kopetz S, McDermott R, Leach J, Lonardi S, Lenz H, et al. Nivolumab ± ipilimumab in treatment of patients with metastatic colorectal cancer with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J Clin Oncol. 2016;34:suppl; abstract 3501.

[00508] 9. Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, et al. Immune checkpoint Inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol. 2016;34(19):2206-11.

[00509] 10. Castro MP, Goldstein N. Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations. J Immunother Cancer. 2015;3:58.

[00510] 11. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230): 124-8.

[00511] 12. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031): 1909-20.

[00512] 13. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.

[00513] 14. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer

immunotherapy. Mol Cancer Ther. 2015; 14(4):847-56.

[00514] 15. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med.

2015;373(17): 1627-39. [00515] 16. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28.

[00516] 17. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Clin Cancer Res. 2014;20(19):5064-74.

[00517] 18. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability -high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017.

[00518] 19. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn. 2008; 10(4):301-7.

[00519] 20. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68-74.

[00520] 21. Stadler ZK, Battaglin F, Middha S, Hechtman JF, Tran C, Cercek A, et al. Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels. J Clin Oncol. 2016;34(18):2141-7.

[00521] 22. Hall MJ, Gowen K, Sanford EM, Elvin JA, Ali SM, Kaczmar J, et al. Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP). J Clin Oncol. 2017;34(suppl):abst 1523.

[00522] 23. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017.

[00523] 24. Bacher JW, Flanagan LA, Smalley RL, Nassif NA, Burgart LJ, Halberg RB, et al.

Development of a fluorescent multiplex assay for detection of MSI-high tumors. Dis Markers. 2004;20(4-

5):237-50.

[00524] 25. Modica I, Soslow RA, Black D, Tornos C, Kauff N, Shia J. Utility of

immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. Am J Surg Pathol. 2007;31(5):744-51.

[00525] 26. Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med.

2017;9(1):34.

[00526] The above references are denoted by bracketed numbers in the Example. Each of these references is incorporated by reference herein in its entirety.

[00527] Although preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims

CLAIMS WHAT IS CLAIMED IS:

1. A method of determining microsatellite instability (MSI) in a biological sample, comprising:

(a) obtaining a nucleic acid sequence of a plurality of microsatellite loci from the biological sample;

(b) determining the number of altered microsatellite loci based on the nucleic acid sequences obtained in step (a);

(c) comparing the number of altered microsatellite loci determined in step (b) to a threshold number; and

(d) identifying the biological sample as MSI-high if the number of altered microsatellite loci is greater than or equal to the threshold number.

2. The method of claim 1, wherein the biological sample comprises formalin-fixed paraffin- embedded (FFPE) tissue, fixed tissue, a core needle biopsy, a fine needle aspirate, unstained slides, fresh frozen (FF) tissue, formalin samples, tissue comprised in a solution that preserves nucleic acid or protein molecules, a fresh sample, a malignant fluid, a bodily fluid, a tumor sample, a tissue sample, or any combination thereof.

3. The method of claim 1 or 2, wherein the biological sample comprises cells from a solid tumor.

4. The method of claim 2 or 3, wherein the biological sample comprises a bodily fluid.

5. The method of any one of claims 2-4, wherein the bodily fluid comprises a malignant fluid, a pleural fluid, a peritoneal fluid, or any combination thereof.

6. The method of any one of claims 2-5, wherein the bodily fluid comprises peripheral blood, sera, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid, pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, tears, cyst fluid, pleural fluid, peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocyst cavity fluid, or umbilical cord blood.

7. The method of any preceding claim, wherein the nucleic acid sequence is obtained by sequencing genomic DNA.

8. The method of claim 7, wherein the sequencing comprises next generation sequencing

(NGS).

9. The method of any preceding claim, wherein the plurality of microsatellite loci comprises at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 2000, 3000, 4000, 5000, 6000, or 7000 loci.

10. The method of any preceding claim, wherein the plurality of microsatellite loci excludes: i) sex chromosome loci; ii) microsatellite loci in regions that typically have lower coverage depth relative to other genomic regions; iii) microsatellites with repeat unit lengths greater than 3, 4, 5, 6 or 7 nucleotides, preferably greater than 5 nucleotides; or iv) any combination of i)-iii).

11. The method of any preceding claim, wherein the members of the plurality of

microsatellite loci are selected from Table 16.

12. The method of claim 11, wherein the plurality of microsatellite loci comprises all loci in Table 16, wherein optionally the plurality of loci consists of all loci in Table 16.

13. The method of any one of claims 9-12, wherein each member of the plurality of microsatellite loci is located within the vicinity of a gene.

14. The method of claim 13, wherein each member of the plurality of microsatellite loci is located within the vicinity of a cancer gene.

15. The method of claim 14, wherein each member of the plurality of microsatellite loci is located within the vicinity of a cancer gene selected from Table 7, Table 8, Table 9, Table 10, or any combination thereof.

16. The method of any preceding claim, wherein determining the number of altered microsatellite loci in step (b) comprises comparing each nucleic acid sequence obtained in step (a) to a reference sequence for each microsatellite loci.

17. The method of any preceding claim, wherein determining the number of altered microsatellite loci comprises identifying insertions or deletions that increased or decreased the number of repeats in each microsatellite loci.

18. The method of claim 17, wherein the number of altered microsatellite loci only counts each altered loci once regardless of the number of insertions or deletions at that loci.

19. The method of any preceding claim, wherein the threshold number is calibrated based on comparison of the number of altered microsatellite loci per patient to MSI results obtained using a different laboratory technique on a same biological sample.

20. The method of claim 19, wherein the different laboratory technique comprises fragment analysis, immunohistochemistry of mismatch repair genes, sequencing of mismatch repair genes, immunohistochemistry of immunomodulators, or any combination thereof.

21. The method of claim 19 or claim 20, wherein the threshold number is determined using biological samples from at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, or 2000 cancer patients.

22. The method of any one of claims 19-21, wherein the samples represent cancers from at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 20, or 25 distinct cancer lineages.

23. The method of claim 22, wherein the distinct cancer lineages comprise cancers selected from colorectal adenocarcinoma, endometrial cancer, bladder cancer, breast carcinoma, cervical cancer, cholangiocarcinoma, esophageal and esophagogastric junction carcinoma, extrahepatic bile duct adenocarcinoma, gastric adenocarcinoma, gastrointestinal stromal tumors, glioblastoma, liver

hepatocellular carcinoma, lymphoma, malignant solitary fibrous tumor of the pleura, melanoma, neuroendocrine tumors, NSCLC, female genital tract malignancy, ovarian surface epithelial carcinomas, pancreatic adenocarcinoma, prostatic adenocarcinoma, small intestinal malignancies, soft tissue tumors, thyroid carcinoma, uterine sarcoma, uveal melanoma, and any combination thereof.

24. The method of claim 23, wherein the threshold number is calibrated across at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 20, or 25 distinct cancer lineages using sensitivity, specificity, positive predictive value, negative predictive value, or any combination thereof.

25. The method of any one of claims 19-24, wherein the threshold number is determined to provide high sensitivity to MSI-high as determined in colorectal cancer using the different laboratory technique, wherein optionally the different laboratory technique comprises fragment analysis.

26. The method of any preceding claim, wherein the threshold number is less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the number of members of the plurality of microsatellite loci; and the threshold number is greater than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the number of members of the plurality of microsatellite loci.

27. The method of claim 26, wherein the threshold number is between about 10% and about 0.1%, or between about 5% and about 0.2%, or between about 3% and about 0.3%, or between about 1% and about 0.4%, of the number of members of the plurality of microsatellite loci.

28. The method of any preceding claim, wherein the number of members of the plurality of microsatellite loci is greater than 7000 and the threshold number is > 40 and < 50, wherein optionally the threshold level is 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50.

29. The method of any preceding claim, wherein MSI-high is determined without assessing microsatellite loci in normal tissue.

30. The method of any preceding claim, further comprising identifying the biological sample as microsatellite stable (MSS) if the number of altered microsatellite loci is below the threshold number.

31. The method of any preceding claim, further comprising identifying the biological sample as MSI-low if the number of altered microsatellite loci in the sample is less than or equal to a lower threshold number.

32. The method of any preceding claim, further comprising determining a tumor mutation burden (TMB) for the biological sample.

33. The method of claim 32, wherein TMB is determined using the same laboratory analysis as MSI.

34. The method of claim 32 or claim 33, wherein TMB is determined by sequence analysis of a plurality of cancer genes selected from Table 7, Table 8, Table 9, Table 10, or any combination thereof.

35. The method of any one of claims 32-34, wherein TMB is determined using missense mutations that have not been previously identified as germline alterations.

36. The method of any one of claims 32-35, wherein TMB-High is determined by comparing a mutation rate to a TMB-High threshold, wherein TMB-High is defined as the mutation rate greater than or equal to the TMB-High threshold, and wherein optionally the mutation rate is expressed in units of mutations / megabase.

37. The method of claim 36, wherein the TMB-High threshold is determined by comparing TMB with MSI determined in colorectal cancer from a same sample.

38. The method of any one of claims 36-37, wherein the TMB-High threshold is greater than or equal to 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mutations / megabase of missense mutations, wherein optionally the TMB-High threshold is 17 mutations / megabase.

39. The method of any one of claims 32-38, wherein TMB-Low is determined by comparing a mutation rate to a TMB-Low threshold, wherein TMB-Low is defined as the mutation rate less than or equal to the TMB-Low threshold, and wherein optionally the mutation rate is expressed in units of mutations / megabase.

40. The method of claim 39, wherein the TMB-Low threshold is determined by comparing TMB with MSI determined in colorectal cancer from a same sample.

41. The method of any one of claims 39-40, wherein the TMB-Low threshold is less than or equal to 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mutations / megabase of missense mutations, wherein optionally the TMB-Low threshold is 6 mutations / megabase.

42. The method of any preceding claim, further comprising profiling MLH1, MSH2, MSH6, PMS2, PD-L1, or any combination thereof, in the biological sample.

43. The method of claim 42, wherein the profiling comprises determining: i) a protein expression level, wherein optionally the protein expression level is determined using IHC, flow cytometry or an immunoassay; ii) a nucleic acid sequence, wherein optionally the sequence is determined using next generation sequencing; iii) a promoter hypermethylation, wherein optionally the hypermethylation is determined using pyrosequencing; and iv) any combination thereof.

44. A method of identifying at least one therapy of potential benefit for an individual with cancer, the method comprising:

(a) obtaining the biological sample according to any one of claims 1-6 from the individual;

(b) generating a molecular profile by performing the method of any preceding claim on the biological sample; and

(c) identifying the therapy of potential benefit based on the molecular profile.

45. The method of claim 44, wherein generating the molecular profile comprises performing additional analysis on the biological sample according to Table 5, Table 6, Table 7, Table 8, Table 9, Table 10, or any combination thereof.

46. The method of claim 44 or claim 45, wherein generating the molecular profile comprises performing additional analysis on the biological sample to: i) determine a tumor mutation burden (TMB); ii) determine an expression level of MLH1; iii) determine an expression level of MSH2, determine an expression level of MSH6; iv) determine an expression level of PMS2; v) determine an expression level of PD-L1; vi) or any combination thereof.

47. The method of any one of claims 44-46, wherein the step of identifying comprises identifying potential benefit from an immune checkpoint inhibitor therapy when the biological sample is MSI-High.

48. The method of any one of claims 44-47, wherein the step of identifying comprises identifying potential benefit from an immune checkpoint inhibitor therapy when the biological sample is MSI-High, TMB -High, MLH1-, MSH2-, MSH6-, PMS2-, PD-L1+, or any combination thereof.

49. The method of any one of claims 44-47, wherein the step of identifying comprises identifying potential benefit from an immune checkpoint inhibitor therapy when the biological sample is MSI-High, TMB-High, PD-L1+, or any combination thereof.

50. The method of any one of claims 47-49, wherein the immune checkpoint inhibitor therapy is selected from ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, pidilizumab, AMP-224, AMP-514, PDR001, BMS-936559, or any combination thereof.

51. The method of any one of claims 44-50, further comprising identifying at least one therapy of potential lack of benefit based on the molecular profile, at least one clinical trial for the subject based on the molecular profile, or any combination thereof.

52. The method of any one of claims 44-51, wherein the subject has not previously been treated with the at least one therapy of potential benefit.

53. The method of any one of claims 44-52, wherein the cancer comprises a metastatic cancer, a recurrent cancer, or any combination thereof.

54. The method of any one of claims 44-53, wherein the cancer is refractory to a prior therapy.

55. The method of claim 54, wherein the prior therapy comprises the standard of care for the cancer.

56. The method of claim 54, wherein the cancer is refractory to all known standard of care therapies.

57. The method of any one of claims 44-53, wherein the subject has not previously been treated for the cancer.

58. The method of any one of claims 44-57, further comprising administering the at least one therapy of potential benefit to the individual.

59. The method of claim 58, wherein progression free survival (PFS), disease free survival (DFS), or lifespan is extended by the administration.

60. The method of any one of claims 44-59, wherein the cancer comprises an acute lymphoblastic leukemia; acute myeloid leukemia; adrenocortical carcinoma; AIDS-related cancer; AIDS- related lymphoma; anal cancer; appendix cancer; astrocytomas; atypical teratoid/rhabdoid tumor; basal cell carcinoma; bladder cancer; brain stem glioma; brain tumor, brain stem glioma, central nervous system atypical teratoid/rhabdoid tumor, central nervous system embryonal tumors, astrocytomas,

craniopharyngioma, ependymoblastoma, ependymoma, medulloblastoma, medulloepithelioma, pineal parenchymal tumors of intermediate differentiation, supratentorial primitive neuroectodermal tumors and pineoblastoma; breast cancer; bronchial tumors; Burkitt lymphoma; cancer of unknown primary site (CUP); carcinoid tumor; carcinoma of unknown primary site; central nervous system atypical teratoid/rhabdoid tumor; central nervous system embryonal tumors; cervical cancer; childhood cancers; chordoma; chronic lymphocytic leukemia; chronic myelogenous leukemia; chronic myeloproliferative disorders; colon cancer; colorectal cancer; craniopharyngioma; cutaneous T-cell lymphoma; endocrine pancreas islet cell tumors; endometrial cancer; ependymoblastoma; ependymoma; esophageal cancer; esthesioneuroblastoma; Ewing sarcoma; extracranial germ cell tumor; extragonadal germ cell tumor; extrahepatic bile duct cancer; gallbladder cancer; gastric (stomach) cancer; gastrointestinal carcinoid tumor; gastrointestinal stromal cell tumor; gastrointestinal stromal tumor (GIST); gestational trophoblastic tumor; glioma; hairy cell leukemia; head and neck cancer; heart cancer; Hodgkin lymphoma;

hypopharyngeal cancer; intraocular melanoma; islet cell tumors; Kaposi sarcoma; kidney cancer;

Langerhans cell histiocytosis; laryngeal cancer; lip cancer; liver cancer; malignant fibrous histiocytoma bone cancer; medulloblastoma; medulloepithelioma; melanoma; Merkel cell carcinoma; Merkel cell skin carcinoma; mesothelioma; metastatic squamous neck cancer with occult primary; mouth cancer; multiple endocrine neoplasia syndromes; multiple myeloma; multiple myeloma/plasma cell neoplasm; mycosis fungoides; myelodysplasia syndromes; myeloproliferative neoplasms; nasal cavity cancer; nasopharyngeal cancer; neuroblastoma; Non-Hodgkin lymphoma; nonmelanoma skin cancer; non-small cell lung cancer; oral cancer; oral cavity cancer; oropharyngeal cancer; osteosarcoma; other brain and spinal cord tumors; ovarian cancer; ovarian epithelial cancer; ovarian germ cell tumor; ovarian low malignant potential tumor; pancreatic cancer; papillomatosis; paranasal sinus cancer; parathyroid cancer; pelvic cancer; penile cancer; pharyngeal cancer; pineal parenchymal tumors of intermediate

differentiation; pineoblastoma; pituitary tumor; plasma cell neoplasm/multiple myeloma;

pleuropulmonary blastema; primary central nervous system (CNS) lymphoma; primary hepatocellular liver cancer; prostate cancer; rectal cancer; renal cancer; renal cell (kidney) cancer; renal cell cancer; respiratory tract cancer; retinoblastoma; rhabdomyosarcoma; salivary gland cancer; Sezary syndrome; small cell lung cancer; small intestine cancer; soft tissue sarcoma; squamous cell carcinoma; squamous neck cancer; stomach (gastric) cancer; supratentorial primitive neuroectodermal tumors; T-cell lymphoma; testicular cancer; throat cancer; thymic carcinoma; thymoma; thyroid cancer; transitional cell cancer; transitional cell cancer of the renal pelvis and ureter; trophoblastic tumor; ureter cancer; urethral cancer; uterine cancer; uterine sarcoma; vaginal cancer; vulvar cancer; Waldenstrom macroglobulinemia; or Wilm's tumor.

61. The method of any one of claims 44-59, wherein the cancer comprises an acute myeloid leukemia (AML), breast carcinoma, cholangiocarcinoma, colorectal adenocarcinoma, extrahepatic bile duct adenocarcinoma, female genital tract malignancy, gastric adenocarcinoma, gastroesophageal adenocarcinoma, gastrointestinal stromal tumor (GIST), glioblastoma, head and neck squamous carcinoma, leukemia, liver hepatocellular carcinoma, low grade glioma, lung bronchioloalveolar carcinoma (BAC), non-small cell lung cancer (NSCLC), lung small cell cancer (SCLC), lymphoma, male genital tract malignancy, malignant solitary fibrous tumor of the pleura (MSFT), melanoma, multiple myeloma, neuroendocrine tumor, nodal diffuse large B-cell lymphoma, non epithelial ovarian cancer (non-EOC), ovarian surface epithelial carcinoma, pancreatic adenocarcinoma, pituitary carcinomas, oligodendroglioma, prostatic adenocarcinoma, retroperitoneal or peritoneal carcinoma, retroperitoneal or peritoneal sarcoma, small intestinal malignancy, soft tissue tumor, thymic carcinoma, thyroid carcinoma, or uveal melanoma.

62. A method of generating a molecular profiling report comprising preparing a report comprising the generated molecular profile according to any one of claims 44-61.

63. The method of claim 62, wherein the report further comprises a list of the at least one therapy of potential benefit for the individual.

64. The method of claim 63, wherein the report further comprises a list of at least one therapy of potential lack of benefit for the individual.

65. The method of claim 63, wherein the report further comprises a list of at least one therapy of indeterminate benefit for the individual.

66. The method of claim 63, wherein the report further comprises identification of the at least one therapy as standard of care or not for the cancer lineage.

67. The method of claim 62, wherein the report further comprises a listing of biomarkers tested when generating the molecular profile, the type of testing performed for each biomarker, and results of the testing for each biomarker.

68. The method of claim 62, wherein the report further comprises a list of clinical trials for which the subject is indicated and/or eligible based on the molecular profile.

69. The method of claim 62, wherein the report further comprises a list of evidence supporting the identification of therapies as of potential benefit, potential lack of benefit, or indeterminate benefit based on the molecular profile.

70. The method of claim 62, wherein the report further comprises: 1) a list of biomarkers in the molecular profile; 2) a description of the molecular profile of the biomarkers as determined for the subject; 3) a therapy associated with at least one of the genes and/or gene products in the molecular profile; and 4) and an indication whether each therapy is of potential benefit, potential lack of benefit, or indeterminate benefit for treating the individual based on the molecular profile.

71. The method of claim 70, wherein the description of the molecular profile of the genes and/or gene products comprises the technique used to assess the gene and/or gene products and the results of the assessment.

72. The method of any of claims 62-71, wherein the report is computer generated.

73. The method of claim 72, wherein the report is a printed report or a computer file.

74. The method of claim 72, wherein the report is accessible via a web portal.

75. Use of a reagent in carrying out the method of any preceding claim.

76. Use of a reagent in the manufacture of a reagent or kit for carrying out the method of any of claims 1-74.

77. A kit comprising a reagent for carrying out the method of any of claims 1-74.

78. The use of any of claims 75-76 or kit of claim 77, wherein the reagent comprises at least one of a reagent for extracting nucleic acid from a sample, a reagent for performing ISH, a reagent for performing IHC, a reagent for performing PCR, a reagent for performing Sanger sequencing, a reagent for performing next generation sequencing, a probe set for performing next generation sequencing, a probe set for sequencing the plurality of microsatellite loci, a reagent for a DNA microarray, a reagent for performing pyrosequencing, a nucleic acid probe, a nucleic acid primer, an antibody, an aptamer, a reagent for performing bisulfite treatment of nucleic acid, and any combination thereof.

79. A report generated by the method of any of claims 62-74.

80. A computer system for generating the report of claim 79.

81. A system for identifying at least one therapy associated with a cancer in an individual, comprising:

(a) at least one host server;

(b) at least one user interface for accessing the at least one host server to access and input data;

(c) at least one processor for processing the inputted data;

(d) at least one memory coupled to the processor for storing the processed data and instructions for:

i. accessing an MSI status generated by the method of any of claims 1-74; and ii. identifying, based on the MSI status, at least one of: A) at least one therapy with potential benefit for treatment of the cancer; B) at least one therapy with potential lack of benefit for treatment of the cancer; and C) at least one therapy associated with a clinical trial; and

(e) at least one display for displaying the identified at least one of: A) at least one therapy with potential benefit for treatment of the cancer; B) at least one therapy with potential lack of benefit for treatment of the cancer; and C) at least one therapy associated with a clinical trial.

82. The system of claim 81, further comprising at least one memory coupled to the processor for storing the processed data and instructions for identifying, based on the generated molecular profile according to any one of claims 44-61, at least one of: A) at least one therapy with potential benefit for treatment of the cancer; B) at least one therapy with potential lack of benefit for treatment of the cancer; and C) at least one therapy associated with a clinical trial; and at least one display for display thereof.

83. The system of claim 81 or claim 82, further comprising at least one database comprising references for various biomarker states, data for drug/biomarker associations, or both.

84. The system of any one of claims 81-83, wherein the at least one display comprises a report of claim 79.